FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Ding, YN Wang, J Xie, ST Hsu, HC Mountz, J AF Ding, Yanna Wang, John Xie, Shutao Hsu, Hui-Chen Mountz, John TI Nuclear expression of CXCR5 is asscociated with expansion of spleen follicular T helper cells in autoimmune BXD2 mice SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract C1 [Ding, Yanna; Wang, John; Xie, Shutao; Hsu, Hui-Chen; Mountz, John] Univ Alabama Birmingham, Birmingham, AL USA. [Mountz, John] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD APR 1 PY 2010 VL 184 SU 1 MA 143.30 PG 1 WC Immunology SC Immunology GA V44OM UT WOS:000209758304165 ER PT J AU Fan, J Li, YH Xiang, M Billiar, T Wilson, M AF Fan, Jie Li, Yuehua Xiang, Meng Billiar, Timothy Wilson, Mark TI Hemorrhagic shock primes for IL-1 beta processing: role of upregulated TLR2 SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract C1 [Fan, Jie; Li, Yuehua; Xiang, Meng; Billiar, Timothy; Wilson, Mark] Univ Pittsburgh, Surg, Pittsburgh, PA USA. [Fan, Jie; Wilson, Mark] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD APR 1 PY 2010 VL 184 SU 1 MA 136.1 PG 1 WC Immunology SC Immunology GA V44OM UT WOS:000209758304004 ER PT J AU Li, H Wu, Q Yang, PA Wang, J Kolls, J Hsu, HC Mountz, J AF Li, Hao Wu, Qi Yang, PingAr Wang, John Kolls, Jay Hsu, Hui-chen Mountz, John TI Collaborative Effects of IL-17 and IL-23 in Deletion of Antigen Stimulated CD4+CD8+Double Positive Thymocytes SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract C1 [Li, Hao; Wu, Qi; Yang, PingAr; Wang, John; Hsu, Hui-chen; Mountz, John] Univ Alabama Birmingham, Birmingham, AL USA. [Kolls, Jay] Louisiana State Univ, Hlth Sci Ctr, Shreveport, LA 71105 USA. [Mountz, John] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD APR 1 PY 2010 VL 184 SU 1 MA 143.17 PG 1 WC Immunology SC Immunology GA V44OM UT WOS:000209758304155 ER PT J AU Lin, PY Sun, L Wierman, M Tekmal, R Pierce, A Daniel, B Curiel, T AF Lin, Pei-Yi Sun, Lishi Wierman, Margaret Tekmal, Rajeshwar Pierce, Anson Daniel, Benjamin Curiel, Tyler TI Sex-related differences in regulatory T cell function are estrogen and B7-H1 dependent SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract C1 [Lin, Pei-Yi; Sun, Lishi; Tekmal, Rajeshwar; Pierce, Anson; Daniel, Benjamin; Curiel, Tyler] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Wierman, Margaret] Univ Colorado, Aurora, CO USA. [Pierce, Anson] South Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD APR 1 PY 2010 VL 184 SU 1 MA 143.53 PG 1 WC Immunology SC Immunology GA V44OM UT WOS:000209758304159 ER PT J AU Stephen, T Wilson, B Laufer, T AF Stephen, Tom Wilson, Bridget Laufer, Terri TI Reorganizing the signaling molecules in CD4+T cells by TCR-MHC class II interactions in the thymic medulla prevents T cell hyperactivation SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract C1 [Stephen, Tom; Laufer, Terri] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. [Wilson, Bridget] Univ New Mexico, Dept Pathol, Albuquerque, NM 87131 USA. [Laufer, Terri] Philadelphia Vet Affairs Med Ctr, Dept Med, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD APR 1 PY 2010 VL 184 SU 1 MA 50.1 PG 1 WC Immunology SC Immunology GA V44OM UT WOS:000209758301115 ER PT J AU Chock, M Goreshi, R Keiser, E Werth, VP Chung, L Florentino, D AF Chock, M. Goreshi, R. Keiser, E. Werth, V. P. Chung, L. Florentino, D. TI Quantitative assessment of disease severity in dermatomyositis SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology CY MAY 05-08, 2010 CL Atlanta, GA SP Soc Investtigat Dermatol C1 [Chock, M.; Keiser, E.; Chung, L.; Florentino, D.] Stanford Univ, Stanford, CA 94305 USA. [Goreshi, R.; Werth, V. P.] Univ Penn, Philadelphia, PA 19104 USA. [Goreshi, R.; Werth, V. P.] Philadelphia VA Med Ctr, Philadelphia, PA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 2010 VL 130 SU 1 MA 299 BP S50 EP S50 PG 1 WC Dermatology SC Dermatology GA 580ND UT WOS:000276455100297 ER PT J AU Nabatian, A Bashir, MM Werth, V AF Nabatian, A. Bashir, M. M. Werth, V. P. TI Immunologic actions of glycosaminoglycans in cutaneous lupus erythematosus & dermatomyositis SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology CY MAY 05-08, 2010 CL Atlanta, GA SP Soc Investtigat Dermatol C1 [Nabatian, A.; Bashir, M. M.; Werth, V. P.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Nabatian, A.; Bashir, M. M.; Werth, V. P.] Univ Penn, Philadelphia, PA 19104 USA. [Nabatian, A.] UMDNJ, Robert Wood Johnson Med Sch, New Brunswick, NJ USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 2010 VL 130 SU 1 MA 044 BP S8 EP S8 PG 1 WC Dermatology SC Dermatology GA 580ND UT WOS:000276455100047 ER PT J AU Sharma, SD Katiyar, SK AF Sharma, S. D. Katiyar, S. K. TI Obesity exacerbates UVB radiation-induced inflammation and cell survival signals in UVB-irradiated mouse skin SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology CY MAY 05-08, 2010 CL Atlanta, GA SP Soc Investtigat Dermatol C1 [Sharma, S. D.; Katiyar, S. K.] Univ Alabama, Birmingham, AL USA. [Katiyar, S. K.] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 2010 VL 130 SU 1 MA 768 BP S128 EP S128 PG 1 WC Dermatology SC Dermatology GA 580ND UT WOS:000276455100766 ER PT J AU Vaid, M Nandakumar, V Elmets, CA Katiyar, SK AF Vaid, M. Nandakumar, V. Elmets, C. A. Katiyar, S. K. TI (-)-Epigallocatechin-3-gallate reactivates silenced tumor suppressor gene by modifying DNA methylation and histone acetylation patterns in human epidermoid carcinoma cells SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology CY MAY 05-08, 2010 CL Atlanta, GA SP Soc Investtigat Dermatol C1 [Vaid, M.; Nandakumar, V.; Elmets, C. A.; Katiyar, S. K.] Univ Alabama, Birmingham, AL USA. [Elmets, C. A.; Katiyar, S. K.] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 2010 VL 130 SU 1 MA 249 BP S42 EP S42 PG 1 WC Dermatology SC Dermatology GA 580ND UT WOS:000276455100248 ER PT J AU Varghese, SA Powell, TB Janech, MG Budisavljevic, MN Stanislaus, RC Almeida, JS Arthur, JM AF Varghese, Sanju A. Powell, Thomas B. Janech, Michael G. Budisavljevic, Milos N. Stanislaus, Romesh C. Almeida, Jonas S. Arthur, John M. TI Identification of Diagnostic Urinary Biomarkers for Acute Kidney Injury SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Article DE acute kidney injury; biomarkers; diagnosis; kidney; urine ID ACUTE-RENAL-FAILURE; BETA-2-GLYCOPROTEIN-1 APOLIPOPROTEIN-H; GELATINASE-ASSOCIATED LIPOCALIN; INTENSIVE-CARE-UNIT; FRACTIONAL EXCRETION; TUBULAR MALFUNCTION; GEL-ELECTROPHORESIS; MASS-SPECTROMETRY; PROTEOMICS; MOLECULE-1 AB Acute kidney injury (AKI) is an important cause of death among hospitalized patients. The 2 most common causes of AKI are acute tubular necrosis (ATN) and prerenal azotemia (PRA). Appropriate diagnosis of the disease is important but often difficult. We analyzed urine proteins by 2-dimensional gel electrophoresis from 38 patients with AKI. Patients were randomly assigned to a training set, an internal test set, or an external validation set. Spot abundances were analyzed by artificial neural networks to identify biomarkers that differentiate between ATN and PRA. When the trained neural network algorithm was tested against the training data, it identified the diagnosis for 16 of 18 patients in the training set and all 10 patients in the internal test set. The accuracy was validated in the novel external set of patients where conditions of 9 of 10 patients were correctly diagnosed including 5 of 5 with ATN and 4 of 5 with PRA. Plasma retinol-binding protein was identified in 1 spot and a fragment of albumin and plasma retinol-binding protein in the other. These proteins are candidate markers for diagnostic assays of AKI. C1 [Varghese, Sanju A.; Powell, Thomas B.; Janech, Michael G.; Budisavljevic, Milos N.; Arthur, John M.] Med Univ S Carolina, Dept Med, Div Nephrol, Charleston, SC 29425 USA. [Budisavljevic, Milos N.; Arthur, John M.] Ralph H Johnson VA Med Ctr, Dept Med, Charleston, SC USA. [Stanislaus, Romesh C.; Almeida, Jonas S.] Univ Texas MD Anderson Canc Ctr, Dept Biostat & Appl Math, Houston, TX 77030 USA. RP Arthur, JM (reprint author), Med Univ S Carolina, Dept Med, Div Nephrol, 96 Jonathan Lucas St,POB 250623, Charleston, SC 29425 USA. EM arthurj@musc.edu OI Janech, Michael/0000-0002-3202-4811 FU National Heart, Lung, and Blood Institute [R01DK080234]; National Institutes of Health [N01-HV-28181]; Department of Veterans Affairs FX Supported by R01DK080234 and with Federal funds as part of the NHLBI Proteomics Initiative from the National Heart, Lung, and Blood Institute, National Institutes of Health, under contract no. N01-HV-28181. Additional support for this project came from the Department of Veterans Affairs. NR 36 TC 7 Z9 7 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 EI 1708-8267 J9 J INVEST MED JI J. Invest. Med. PD APR PY 2010 VL 58 IS 4 BP 612 EP 620 PG 9 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 583ZL UT WOS:000276719600009 PM 20224435 ER PT J AU Sun, B Abadjian, L Rempel, H Calosing, C Rothlind, J Pulliam, L AF Sun, Bing Abadjian, Linda Rempel, Hans Calosing, Cyrus Rothlind, Johannes Pulliam, Lynn TI Peripheral biomarkers do not correlate with cognitive impairment in highly active antiretroviral therapy-treated subjects with human immunodeficiency virus type 1 infection SO JOURNAL OF NEUROVIROLOGY LA English DT Article ID CEREBRAL VOLUME LOSS; HIV-INFECTION; NEUROCOGNITIVE IMPAIRMENT; APOLIPOPROTEIN-E; AIDS DEMENTIA; VIRAL LOAD; ACTIVATION; PERFORMANCE; DYSFUNCTION; DISORDERS AB Neuropsychological (NP) impairments in human immunodeficiency virus (HIV)-infected individuals remain high despite the introduction of highly active antiretroviral therapy (HAART). We sought to determine whether or not a monocyte gene expression profile along with other peripheral factors would correlate with neuropsychological impairment among HIV-infected individuals. Forty-four HIV-1-seropositive subjects (HIV+) on HAART and 11 HIV-1-seronegative controls (HIV-) had NP testing and blood drawn for monocyte gene expression analysis. All HIV+ subjects were assessed for CD4 counts, apolipoprotein E (ApoE) genotype, viral load, and plasma lipopolysaccharide (LPS) and soluble CD14 (sCD14). NP scores were normalized to age, gender, and education. Twenty-five percent of HIV+ individuals showed abnormal NP testing results (> 1.5 SD below normal in two domains). HIV+ individuals had deficits in attention/working memory, verbal learning, and information processing speed compared to HIV- controls. There was no correlation between overall NP impairment and plasma viral load, level of education, age, ethnic diversity, sCD14, plasma LPS, CD4 cell count, ApoE genotype, or years of infection. However, greater years of infection had worse visual learning performance. sCD14 and CD4 nadir positively correlated with information processing speed and fine motor skills, respectively. LPS correlated with viral load but not cognitive impairment. Monocyte gene expression confirmed a chronic inflammatory profile that correlated with viral load but not cognition. No blood index or profile was associated with overall NP impairment.1 year) paraplegia (T1-T10) or tetraplegia (C4-C8). Methods: Blood samples were collected before and after the first and eighth sessions (2 sessions per week for 4 weeks) of FES exercise. Results: Platelet aggregation was inhibited by 20% after the first session and by 40% (P < 0.001) after the eighth session. Thrombin activity was unchanged after the first session (10.7 +/- 0.85 s to 10.43 +/- 0.56 s) and decreased after the eighth session (12.5 +/- 1.98 s to 11.1 +/- 1.7 s; P < 0.0003). Antithrombin III activity increased after the first (103.8% +/- 8.9% to 110% +/- 6.9%; P < 0.0008) and eighth sessions (107.8% +/- 12.1% to 120.4% +/- 13.1%; P < 0.0001). Cyclic adenosine monophosphate increased after the first (9.9% +/- 2.5% to 15.8% +/- 3%; P < 0.001) and eighth sessions (17.8% +/- 4.2% to 36.5% +/- 7.6%; P < 0.0001). After the eighth session, factors V and X increased significantly (88% +/- 27% to 103% +/- 23%, P < 0.0001; 100% +/- 40% to 105% +/- 7%, P < 0.01, respectively); factors VII and VIII and fibrinogen did not change significantly. A significant reduction in platelet activation/aggregation was demonstrated in response to FES-LCE. The decrease in thrombin level was caused by the simultaneous increase in antithrombin activity. Conclusion: These findings provide new insight into the potential protective effects of FES-LCE against the risk of cardiovascular disease. C1 [Kahn, Nighat N.] James J Peters VA Med Ctr, RR&D Ctr Excellence, Bronx, NY 10468 USA. [Kahn, Nighat N.; Feldman, Susan P.; Bauman, William A.] Mt Sinai Sch Med, New York, NY USA. RP Kahn, NN (reprint author), James J Peters VA Med Ctr, RR&D Ctr Excellence, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM nighat.kahn@va.gov NR 51 TC 3 Z9 3 U1 1 U2 2 PU AMER PARAPLEGIA SOC PI JACKSON HWIGHTS PA 75-20 ASTORIA BLVD, JACKSON HWIGHTS, NY 11370-1177 USA SN 1079-0268 J9 J SPINAL CORD MED JI J. Spinal Cord. Med. PD APR PY 2010 VL 33 IS 2 BP 150 EP 158 PG 9 WC Clinical Neurology SC Neurosciences & Neurology GA 595BG UT WOS:000277585100008 PM 20486534 ER PT J AU Gallun, FJ AF Gallun, Frederick J. TI Judgments of intensity for brief sequences SO JOURNAL OF THE ACOUSTICAL SOCIETY OF AMERICA LA English DT Article DE acoustic intensity; acoustic intensity measurement; acoustic noise; hearing ID AUDITORY ATTENTIONAL BLINK; WORKING-MEMORY; DISCRIMINATION; FREQUENCY; MASKING; LEVEL; TIME AB The ability to make intensity judgments for sequential stimuli was examined with an intensity-discrimination task involving three 50-ms noise bursts with non-overlapping frequency ranges. Targets (single bursts) presented in three-burst sequences were required to be as much as 5 dB more intense than targets presented as single bursts in isolation, especially for the later targets. Randomizing target position in the sequence did not reliably reduce performance, nor were thresholds for younger and older listeners reliably different. These increases in increment detection threshold are indications of a specific intensity-processing deficit for stimuli occurring later in a sequence. C1 Portland VA Med Ctr, VA RR&D Natl Ctr Rehabilitat Auditory Res, Portland, OR 97239 USA. RP Gallun, FJ (reprint author), Portland VA Med Ctr, VA RR&D Natl Ctr Rehabilitat Auditory Res, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM frederick.gallun@va.gov RI Gallun, Frederick/G-3792-2012 OI Gallun, Frederick/0000-0002-4145-2199 FU Department of Veterans Affairs; NIH FX This work was supported by the Department of Veterans Affairs and by the NIH. Stephen Fausti, Anna Diedesch, Michelle Molis, Marjorie Leek, Chris Mason, Virginia Best, Gerald Kidd, and Barbara Shinn-Cunningham provided helpful comments and guidance. Matthew Marble, Kelly Reavis, and Marc Caldwell helped with data collection. The greatest debt is to the participants. NR 18 TC 1 Z9 1 U1 0 U2 1 PU ACOUSTICAL SOC AMER AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0001-4966 J9 J ACOUST SOC AM JI J. Acoust. Soc. Am. PD APR PY 2010 VL 127 IS 4 BP EL166 EP EL171 DI 10.1121/1.3359815 PG 6 WC Acoustics; Audiology & Speech-Language Pathology SC Acoustics; Audiology & Speech-Language Pathology GA 580DC UT WOS:000276426100008 PM 20369985 ER PT J AU Ganz, DA Koretz, BK McCreath, HE Wenger, NS Roth, CP Bail, JK Reuben, DB AF Ganz, D. A. Koretz, B. K. McCreath, H. E. Wenger, N. S. Roth, C. P. Bail, J. K. Reuben, D. B. TI The Effect of Nurse Practitioner Co-Management on Quality of Care of Patients with Chronic Conditions in an Academic Geriatric Practice SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY MAY 12-15, 2010 CL Orlando, FL SP Amer Geriatr Soc C1 [Ganz, D. A.; Koretz, B. K.; McCreath, H. E.; Wenger, N. S.; Bail, J. K.; Reuben, D. B.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Ganz, D. A.] VA Greater Los Angeles Healthcare Syst, HSR&D Ctr Excellence, Los Angeles, CA USA. [Roth, C. P.] RAND Hlth, Santa Monica, CA USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2010 VL 58 SU 1 BP 8 EP 8 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 577TO UT WOS:000276247100021 ER PT J AU Sarkisian, C Trejo, L Wang, P Frank, J Weiner, B AF Sarkisian, C. Trejo, L. Wang, P. Frank, J. Weiner, B. TI Caminemos !: a randomized trial of a behavioral intervention to increase walking among older Latinos SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY MAY 12-15, 2010 CL Orlando, FL SP Amer Geriatr Soc C1 [Sarkisian, C.] GRECC, VA Greater Los Angeles, Los Angeles, CA USA. [Sarkisian, C.; Wang, P.; Frank, J.] Univ Calif Los Angeles, Div Geriatr, Los Angeles, CA 90024 USA. [Weiner, B.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA. [Trejo, L.] City Los Angeles, Dept Aging, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2010 VL 58 SU 1 BP 15 EP 15 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 577TO UT WOS:000276247100041 ER PT J AU Williams, BA Mehta, KM Cenzer, IS Walter, LC AF Williams, B. A. Mehta, K. M. Cenzer, I. Stijacic Walter, L. C. TI Wealth and the appropriate use of PSA screening among older men SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY MAY 12-15, 2010 CL Orlando, FL SP Amer Geriatr Soc C1 [Williams, B. A.; Mehta, K. M.; Cenzer, I. Stijacic; Walter, L. C.] UCSF, Div Geriatr, San Francisco, CA USA. [Williams, B. A.; Mehta, K. M.; Walter, L. C.] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2010 VL 58 SU 1 BP 15 EP 16 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 577TO UT WOS:000276247100042 ER PT J AU Ross, JS Reed, KC AF Ross, J. S. Reed, K. C. TI Intranasal Steroid Induced Psychosis In A Geriatric Patient SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY MAY 12-15, 2010 CL Orlando, FL SP Amer Geriatr Soc C1 [Ross, J. S.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Ross, J. S.; Reed, K. C.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2010 VL 58 SU 1 BP 19 EP 19 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 577TO UT WOS:000276247100051 ER PT J AU Manoff, S McFetridge, R Liss, C Marchese, R Raab, J Rueda, A Musher, D AF Manoff, S. McFetridge, R. Liss, C. Marchese, R. Raab, J. Rueda, A. Musher, D. TI Antibody Persistence 10 Years after 1st and 2nd Doses of 23-Valent Pneumococcal Polysaccharide Vaccine (PN23), and Immunogenicity and Safety of 2nd and 3rd Doses in Older Adults SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY MAY 12-15, 2010 CL Orlando, FL SP Amer Geriatr Soc C1 [Manoff, S.; McFetridge, R.; Liss, C.; Marchese, R.] Merck, N Wales, PA USA. [Raab, J.] PPD, Wayne, NJ USA. [Rueda, A.; Musher, D.] VA Med Ctr, Houston, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2010 VL 58 SU 1 BP 25 EP 26 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 577TO UT WOS:000276247100071 ER PT J AU Sanchez-Reilly, S Ross, J O'Donnell, L Lee, S Schillerstrom, J AF Sanchez-Reilly, S. Ross, J. O'Donnell, L. Lee, S. Schillerstrom, J. TI A Longitudinal Curriculum in Geriatric Palliative Care for Medical Students SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY MAY 12-15, 2010 CL Orlando, FL SP Amer Geriatr Soc C1 [Sanchez-Reilly, S.; Ross, J.; O'Donnell, L.; Schillerstrom, J.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Sanchez-Reilly, S.; Ross, J.; Lee, S.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2010 VL 58 SU 1 BP 44 EP 44 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 577TO UT WOS:000276247100126 ER PT J AU Horton, MS Pugh, M Lawrence, VA AF Horton, M. S. Pugh, M. Lawrence, V. A. TI Nonpharmacological Therapy for Insomnia in Elders: A Systematic SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY MAY 12-15, 2010 CL Orlando, FL SP Amer Geriatr Soc C1 [Horton, M. S.] Univ Texas Hlth Sci Ctr San Antonio, VA Univ, San Antonio, TX 78229 USA. [Pugh, M.; Lawrence, V. A.] S Texas Vet Hlth Care Syst, VERDICT REAP, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2010 VL 58 SU 1 BP 65 EP 65 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 577TO UT WOS:000276247100187 ER PT J AU Hsu, A Sudore, R Doughan, J Williams, B AF Hsu, A. Sudore, R. Doughan, J. Williams, B. TI When Caring Costs More. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY MAY 12-15, 2010 CL Orlando, FL SP Amer Geriatr Soc C1 [Hsu, A.; Sudore, R.; Williams, B.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Hsu, A.; Sudore, R.; Doughan, J.; Williams, B.] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2010 VL 58 SU 1 BP 78 EP 78 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 577TO UT WOS:000276247100224 ER PT J AU Pham, A Datta, S Weber, T Walter, L Colon-Emeric, C AF Pham, A. Datta, S. Weber, T. Walter, L. Colon-Emeric, C. TI Cost-effectiveness of Oral Bisphosphonates for Osteoporosis at Different Ages and Levels of Life Expectancy. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY MAY 12-15, 2010 CL Orlando, FL SP Amer Geriatr Soc C1 [Pham, A.; Weber, T.] Duke Univ, Med Ctr, Durham, NC USA. [Datta, S.] Duke Univ, Gen Internal Med, Durham, NC USA. [Datta, S.] Durham VA Med Ctr, Ctr Hlth Serv Res, Durham, NC USA. [Walter, L.] Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. [Colon-Emeric, C.] Durham VA Med Ctr, Geriatr Res Educ & Clin Ctr, Durham, NC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2010 VL 58 SU 1 BP 97 EP 98 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 577TO UT WOS:000276247100279 ER PT J AU Hirano, LA Anawalt, BD Shields, AT Matsumoto, AM AF Hirano, L. A. Anawalt, B. D. Shields, A. T. Matsumoto, A. M. TI Evaluation and Treatment of Osteoporosis in High Risk Veterans. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY MAY 12-15, 2010 CL Orlando, FL SP Amer Geriatr Soc C1 [Hirano, L. A.; Anawalt, B. D.; Shields, A. T.; Matsumoto, A. M.] Univ Washington, Seattle, WA 98195 USA. [Hirano, L. A.; Shields, A. T.; Matsumoto, A. M.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2010 VL 58 SU 1 BP 101 EP 102 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 577TO UT WOS:000276247100291 ER PT J AU Steinman, MA Fung, K Boscardin, J Heidenreich, PA AF Steinman, M. A. Fung, K. Boscardin, J. Heidenreich, P. A. TI Age and receipt of guideline-recommended care for heart failure: a nationwide study. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY MAY 12-15, 2010 CL Orlando, FL SP Amer Geriatr Soc C1 [Steinman, M. A.; Fung, K.; Boscardin, J.] San Francisco VA Med Ctr, San Francisco, CA USA. [Heidenreich, P. A.] VA Palo Alto Hlth Care Syst, Palo Alto, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2010 VL 58 SU 1 BP 113 EP 114 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 577TO UT WOS:000276247100326 ER PT J AU Jeffery, S Aspinall, SL Zhao, X Handler, SM Hanlon, JT AF Jeffery, S. Aspinall, S. L. Zhao, X. Handler, S. M. Hanlon, J. T. TI The Quality of Warfarin Prescribing and Monitoring in Veterans Affairs Nursing Homes. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY MAY 12-15, 2010 CL Orlando, FL SP Amer Geriatr Soc C1 [Jeffery, S.] VA Connecticut Healthcare Syst, Dept Pharm, West Haven, CT USA. [Aspinall, S. L.; Zhao, X.] VA Ctr Medicat Safety, Hines, IL USA. [Aspinall, S. L.; Zhao, X.] VA Pittsburgh Healthcare Syst, VA Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Handler, S. M.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Handler, S. M.; Hanlon, J. T.] Univ Pittsburgh, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2010 VL 58 SU 1 BP 114 EP 114 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 577TO UT WOS:000276247100328 ER PT J AU Dinescu, A Korc-Grodzicki, B Ross, JS AF Dinescu, A. Korc-Grodzicki, B. Ross, J. S. TI Discharge Location Disagreements and Re-hospitalization Risk among Frail, Elderly Adults. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY MAY 12-15, 2010 CL Orlando, FL SP Amer Geriatr Soc C1 [Dinescu, A.; Ross, J. S.] Mt Sinai Hosp, New York, NY 10029 USA. [Korc-Grodzicki, B.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Ross, J. S.] James J Peters VA Med Ctr, Bronx, NY USA. [Ross, J. S.] James J Peters VA Med Ctr, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2010 VL 58 SU 1 BP 115 EP 115 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 577TO UT WOS:000276247100331 ER PT J AU Dublin, S Anderson, ML Heckbert, SR Haneuse, SJ Crane, PK Breitner, JC McCormick, W Bowen, JD Teri, L McCurry, SM Larson, EB AF Dublin, S. Anderson, M. L. Heckbert, S. R. Haneuse, S. J. Crane, P. K. Breitner, J. C. McCormick, W. Bowen, J. D. Teri, L. McCurry, S. M. Larson, E. B. TI Atrial fibrillation and risk of incident dementia or Alzheimer's disease SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY MAY 12-15, 2010 CL Orlando, FL SP Amer Geriatr Soc C1 [Dublin, S.; Anderson, M. L.; Heckbert, S. R.; Haneuse, S. J.; McCurry, S. M.; Larson, E. B.] Grp Hlth Res Inst, Seattle, WA USA. [Dublin, S.; Heckbert, S. R.; Haneuse, S. J.; Crane, P. K.; Breitner, J. C.; McCormick, W.; Bowen, J. D.; Teri, L.; McCurry, S. M.; Larson, E. B.] Univ Washington, Seattle, WA 98195 USA. [Breitner, J. C.] VA Puget Sound, Seattle, WA USA. [Bowen, J. D.] Swedish Neurosci Inst, Seattle, WA USA. RI Crane, Paul/C-8623-2014 NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2010 VL 58 SU 1 BP 122 EP 123 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 577TO UT WOS:000276247100352 ER PT J AU Huang, A Brown, J Moore, E Walter, L Scholes, D Lin, F Fihn, S AF Huang, A. Brown, J. Moore, E. Walter, L. Scholes, D. Lin, F. Fihn, S. TI Clinical significance of postvoid residual volume in older women SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY MAY 12-15, 2010 CL Orlando, FL SP Amer Geriatr Soc C1 [Huang, A.; Brown, J.; Walter, L.; Lin, F.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Brown, J.; Walter, L.] SFVAMC, San Francisco, CA USA. [Moore, E.; Fihn, S.] Univ Washington, Seattle, WA 98195 USA. [Scholes, D.] Grp Hlth Res Inst, Seattle, WA USA. [Scholes, D.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2010 VL 58 SU 1 BP 123 EP 123 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 577TO UT WOS:000276247100354 ER PT J AU Means, A Martin, J Fiorentino, L Chung, C Josephson, K Jouldjian, S Alessi, C AF Means, A. Martin, J. Fiorentino, L. Chung, C. Josephson, K. Jouldjian, S. Alessi, C. TI Sleep Disorders Among Older Veterans Undergoing Inpatient Post-Acute Rehabilitation SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY MAY 12-15, 2010 CL Orlando, FL SP Amer Geriatr Soc C1 [Means, A.] Loyola Univ Chicago, Stritch Sch Med, Maywood, IL USA. [Martin, J.; Josephson, K.; Jouldjian, S.; Alessi, C.] VA Greater Los Angeles, GRECC, Los Angeles, CA USA. [Martin, J.; Fiorentino, L.; Chung, C.; Alessi, C.] Univ Calif Los Angeles, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2010 VL 58 SU 1 BP 127 EP 127 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 577TO UT WOS:000276247100366 ER PT J AU Michael, JT Abdel-Karim, IA AF Michael, J. T. Abdel-Karim, I. A. TI Tolerance of cancer drug trials in different geriatric populations. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY MAY 12-15, 2010 CL Orlando, FL SP Amer Geriatr Soc C1 [Michael, J. T.] Univ Texas Hlth Sci Ctr San Antonio, Sch Med, San Antonio, TX 78229 USA. [Abdel-Karim, I. A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Hematol & Med Oncol, San Antonio, TX 78229 USA. [Abdel-Karim, I. A.] S Texas Vet Hlth Care Syst, Hematol & Oncol, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2010 VL 58 SU 1 BP 144 EP 144 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 577TO UT WOS:000276247100416 ER PT J AU Key, C Lee, S Garza, M Sanchez-Reilly, SE AF Key, C. Lee, S. Garza, M. Sanchez-Reilly, S. E. TI Impact of a geriatric consultation on the prescription of potentially inappropriate medications and opioids in elderly patients. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY MAY 12-15, 2010 CL Orlando, FL SP Amer Geriatr Soc C1 [Key, C.; Garza, M.; Sanchez-Reilly, S. E.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX USA. [Key, C.; Lee, S.; Sanchez-Reilly, S. E.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2010 VL 58 SU 1 BP 170 EP 170 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 577TO UT WOS:000276247100492 ER PT J AU Wenger, NS Roth, CP Martin, DC Nickels, LD Mach, J Ganz, DA AF Wenger, N. S. Roth, C. P. Martin, D. C. Nickels, L. D. Mach, J. Ganz, D. A. TI Quality of Care Provided in a Special Needs Plan Using a Nurse Care Manager Model. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY MAY 12-15, 2010 CL Orlando, FL SP Amer Geriatr Soc C1 [Wenger, N. S.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Wenger, N. S.; Roth, C. P.; Ganz, D. A.] RAND Hlth, Santa Monica, CA USA. [Ganz, D. A.] VA Greater Los Angeles Healthcare Syst, HSR&D Ctr Excellence, Los Angeles, CA USA. [Mach, J.] XL Hlth, Baltimore, MD USA. [Martin, D. C.; Nickels, L. D.] Ovations, UnitedHlth Grp, Minneapolis, MN USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2010 VL 58 SU 1 BP 175 EP 175 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 577TO UT WOS:000276247100505 ER PT J AU Lin, JC Bang, J Moore, AA AF Lin, J. C. Bang, J. Moore, A. A. TI Drinking Patterns and Development of Functional Limitations Among Older Adults. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY MAY 12-15, 2010 CL Orlando, FL SP Amer Geriatr Soc C1 [Lin, J. C.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Lin, J. C.; Moore, A. A.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Moore, A. A.] Univ Calif Los Angeles, Integrated Subst Abuse Programs, Los Angeles, CA 90095 USA. [Bang, J.] Mayo Clin, Rochester, MN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2010 VL 58 SU 1 BP 180 EP 180 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 577TO UT WOS:000276247100520 ER PT J AU Davila, AE Garza, M Lee, S Ross, JS Sanchez-Reilly, S AF Davila, A. E. Garza, M. Lee, S. Ross, J. S. Sanchez-Reilly, S. TI Effectiveness of a Geriatric Palliative Care Consult on Pain and Geriatric Syndromes. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY MAY 12-15, 2010 CL Orlando, FL SP Amer Geriatr Soc C1 [Davila, A. E.; Garza, M.; Ross, J. S.; Sanchez-Reilly, S.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Garza, M.; Lee, S.; Ross, J. S.; Sanchez-Reilly, S.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2010 VL 58 SU 1 BP 185 EP 186 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 577TO UT WOS:000276247100536 ER PT J AU Gestuvo, M Lindenberger, E AF Gestuvo, M. Lindenberger, E. TI Skin Hazards of Hospitalization Beyond Pressure Ulcers. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY MAY 12-15, 2010 CL Orlando, FL SP Amer Geriatr Soc C1 [Gestuvo, M.] Mt Sinai Sch Med, New York, NY USA. [Lindenberger, E.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2010 VL 58 SU 1 BP 196 EP 196 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 577TO UT WOS:000276247100567 ER PT J AU Patel, NK Copeland, LA Parchman, ML Lawrence, VA AF Patel, N. K. Copeland, L. A. Parchman, M. L. Lawrence, V. A. TI Physical activity, functioning and length of stay in older diabetes patients SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY MAY 12-15, 2010 CL Orlando, FL SP Amer Geriatr Soc C1 [Patel, N. K.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Copeland, L. A.; Parchman, M. L.; Lawrence, V. A.] Dept Vet Affairs, VERDICT Res, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2010 VL 58 SU 1 BP 226 EP 226 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 577TO UT WOS:000276247100657 ER PT J AU Bowling, B Sawlyer, P Allman, RM AF Bowling, B. Sawlyer, P. Allman, R. M. TI Anemia and Functional Decline in Community-Dwelling Older Adults with Chronic Kidney Disease SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY MAY 12-15, 2010 CL Orlando, FL SP Amer Geriatr Soc C1 [Bowling, B.; Sawlyer, P.; Allman, R. M.] Univ Alabama, Birmingham, AL USA. [Bowling, B.; Allman, R. M.] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2010 VL 58 SU 1 BP 234 EP 234 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 577TO UT WOS:000276247100681 ER PT J AU Nyaggah, E Roberts, CK Greenberg, G Hahn, TJ Lee, CC AF Nyaggah, E. Roberts, C. K. Greenberg, G. Hahn, T. J. Lee, C. C. TI Is physical activity in older men associated with serum testosterone and sex hormone-binding globulin levels? SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY MAY 12-15, 2010 CL Orlando, FL SP Amer Geriatr Soc C1 [Nyaggah, E.; Greenberg, G.; Hahn, T. J.; Lee, C. C.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Roberts, C. K.] Univ Calif Los Angeles, Dept Physiol Sci Epidemiol, Los Angeles, CA USA. [Roberts, C. K.] Univ Calif Los Angeles, Ctr Metab Dis Prevent, Los Angeles, CA USA. [Greenberg, G.; Hahn, T. J.; Lee, C. C.] Vet Affairs Greater Los Angeles Healthcare Syst, Internal Med GRECC, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2010 VL 58 SU 1 BP 236 EP 236 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 577TO UT WOS:000276247100686 ER PT J AU Andrews, C Sanchez-Reilly, S Lee, S Ross, J AF Andrews, C. Sanchez-Reilly, S. Lee, S. Ross, J. TI Advance Directives Among Older Adults Seen In Geriatric Palliative Care And Internal Medicine Clinics SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY MAY 12-15, 2010 CL Orlando, FL SP Amer Geriatr Soc C1 [Andrews, C.; Sanchez-Reilly, S.; Ross, J.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Sanchez-Reilly, S.; Lee, S.; Ross, J.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2010 VL 58 SU 1 BP 240 EP 240 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 577TO UT WOS:000276247100698 ER PT J AU Jennings, LA Auerbach, AD Maselli, J Pekow, PS Lindenauer, PK Lee, SJ AF Jennings, Lee A. Auerbach, Andrew D. Maselli, Judith Pekow, Penelope S. Lindenauer, Peter K. Lee, Sei J. TI Missed Opportunities for Osteoporosis Treatment in Patients Hospitalized for Hip Fracture SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article; Proceedings Paper CT 32nd Annual National Meeting of the Society-for-General-Internal-Medicine CY MAY 13-16, 2009 CL Miami, FL SP Soc Gen Internal Med (SGIM) DE osteoporosis; hip fracture; calcium; vitamin D ID RANDOMIZED CONTROLLED-TRIAL; MAJOR NONCARDIAC SURGERY; BONE-MINERAL DENSITY; SUBSEQUENT FRACTURE; FRAGILITY FRACTURE; PREVENT FRACTURES; ZOLEDRONIC ACID; MORTALITY; MEN; MANAGEMENT AB OBJECTIVES Although osteoporosis treatment can dramatically reduce fracture risk, rates of treatment after hip fracture remain low. In-hospital initiation of recommended medications has improved outcomes in heart disease; hospitalization for hip fracture may represent a similar opportunity for improvement. The objective of this study was to examine rates of in-hospital treatment with a combination of calcium and vitamin D (Cal+D) and antiresorptive or bone-forming medications in patients hospitalized for hip fractures DESIGN Observational cohort. SETTING Three hundred eighteen hospitals in the United States. PARTICIPANTS Fifty-one thousand three hundred forty-six patients aged 65 and older hospitalized for osteoporotic hip fracture. MEASUREMENTS In-hospital administration of Cal+D and antiresorptive or bone-forming medications. RESULTS Three thousand four hundred five patients (6.6%) received Cal+D anytime after a procedure to correct femoral fracture; 3,763 patients (7.3%) received antiresorptive or bone-forming medications. Only 1,023 patients (2.0%) were prescribed ideal therapy, receiving Cal+D and an antiresorptive or bone-forming medication. Treatment rates remained low across virtually all patient-, provider-, and hospital-level characteristics. The strongest predictor of treatment with Cal+D was the receipt of an antiresorptive or bone-forming medication (adjusted odds ratio=5.50, 95% confidence interval=4.84-6.25), but only 27.2% of patients who received these medications also received Cal+D. CONCLUSION Rates of in-hospital initiation of osteoporosis treatment for patients with hip fracture are low and may represent an opportunity to improve care. C1 [Jennings, Lee A.] Univ Calif San Francisco, Dept Med, San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Auerbach, Andrew D.; Maselli, Judith] Univ Calif San Francisco, Div Hosp Med, San Francisco, CA 94121 USA. [Pekow, Penelope S.; Lindenauer, Peter K.] Tufts Univ, Sch Med, Baystate Med Ctr, Ctr Qual & Safety Res, Boston, MA 02111 USA. [Pekow, Penelope S.; Lindenauer, Peter K.] Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA. [Lee, Sei J.] San Francisco VA Med Ctr, Div Geriatr, San Francisco, CA USA. RP Jennings, LA (reprint author), Univ Calif San Francisco, Dept Med, San Francisco VA Med Ctr, 4150 Clement St,Bldg 203,Rm 1A-87, San Francisco, CA 94121 USA. EM lee.jennings@ucsf.edu FU NCRR NIH HHS [KL2 RR024130, KL2 RR024130-048738, KL2RR024130, KL2 RR024130-04]; NHLBI NIH HHS [R01 HL086473-03, 5R01HL086473, R01 HL086473]; NIA NIH HHS [L30 AG030755-02, R21 AG026668-02, L30 AG030755, R21 AG026668, 5R21AG026668] NR 48 TC 55 Z9 59 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2010 VL 58 IS 4 BP 650 EP 657 DI 10.1111/j.1532-5415.2010.02769.x PG 8 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 577TN UT WOS:000276247000004 PM 20398147 ER PT J AU Shah, SA Spinale, FG Ikonomidis, JS Stroud, RE Chang, EI Reed, CE AF Shah, Sonam A. Spinale, Francis G. Ikonomidis, John S. Stroud, Robert E. Chang, Eileen I. Reed, Carolyn E. TI Differential matrix metalloproteinase levels in adenocarcinoma and squamous cell carcinoma of the lung SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY LA English DT Article; Proceedings Paper CT 89th Annual Meeting of the American-Association-for-Thoracic-Surgery CY MAY 09-13, 2009 CL Boston, MA SP Amer Assoc Thorac Surg ID CANCER PATIENTS; TISSUE INHIBITOR; PLASMA MATRIX-METALLOPROTEINASE-9; VENTRICULAR MYOCARDIUM; COLORECTAL-CANCER; MESSENGER-RNA; PHASE-III; EXPRESSION; PROGNOSIS; SURVIVAL AB Objective: The matrix metalloproteinases (MMPs) have been implicated in the aggressive course of non-small cell lung cancer (NSCLC). However, there are a large number of MMP subtypes with diverse proteolytic substrates and different induction pathways. This study tested the hypothesis that a differential MMP profile would exist between NSCLC and normal lung and that MMP patterns would differ between NSCLC histologic types. Methods: NSCLC samples and remote normal samples were obtained from patients with stage I or II NSCLC with either squamous cell (n = 22) or adenocarcinoma (n = 19) histologic characteristics. Absolute concentrations for each of the MMP subclasses were determined by a calibrated and validated multiplex suspension array: collagenases (MMP-1, -8, and -13), gelatinases (MMP-2 and -9), lysins (MMP-2 and -7), and elastase (MMP-12). Results: Overall, MMP levels were significantly increased in NSCLC compared with normal. For example, MMP-1 and MMP-7 increased by approximately 10-fold in NSCLC (P < .05). Moreover, a different MMP portfolio was observed between NSCLC histologic types. For example MMP-1, -8, -9, and -12 increased by more than 4-fold in squamous cell versus adenocarcinoma (P < .05). In those patients who had recurrence within 3 years of resection, 3-fold higher levels of MMP-8 and -9 were observed (P < .05). Conclusion: Increased levels of a number of MMP types occur with NSCLC, but the MMP profile was distinctly different between histologic types and in those patients with recurrence. These different MMP profiles may be important in the mechanistic basis for the natural history of different NSCLC types, as well as identifying potential prognostic and therapeutic targets. (J Thorac Cardiovasc Surg 2010; 139: 984-90) C1 [Reed, Carolyn E.] MUSC, Dept Surg, Div Cardiothorac Surg, Charleston, SC 29425 USA. Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Reed, CE (reprint author), MUSC, Dept Surg, Div Cardiothorac Surg, 25 Courtenay Dr, Charleston, SC 29425 USA. EM reedce@musc.edu OI Chang, Eileen/0000-0002-3444-7260 FU NHLBI NIH HHS [R01 HL059165, R01 HL059165-11, HL81691, HL59165] NR 39 TC 13 Z9 13 U1 1 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5223 J9 J THORAC CARDIOV SUR JI J. Thorac. Cardiovasc. Surg. PD APR PY 2010 VL 139 IS 4 BP 984 EP 990 DI 10.1016/j.jtcvs.2009.12.016 PG 7 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 572GG UT WOS:000275815000025 PM 20304142 ER PT J AU Gold, KJ DeMonner, SM Lantz, PM Hayward, RA AF Gold, Katherine J. DeMonner, Sonya M. Lantz, Paula M. Hayward, Rodney A. TI Prematurity and Low Birth Weight as Potential Mediators of Higher Stillbirth Risk in Mixed Black/White Race Couples SO JOURNAL OF WOMENS HEALTH LA English DT Article ID FETAL-DEATH CERTIFICATES; UNITED-STATES; PERINATAL-MORTALITY; ETHNIC-DIFFERENCES; INFANT-MORTALITY; DISPARITY; VALIDITY; OUTCOMES; TRENDS AB Objective: Although births of multiracial and multiethnic infants are becoming more common in the United States, little is known about birth outcomes and risks for adverse events. We evaluated risk of fetal death for mixed race couples compared with same race couples and examined the role of prematurity and low birth weight as potential mediating risk factors. Methods: We performed a retrospective cohort analysis using data from the 1998-2002 California Birth Cohort to evaluate the odds of fetal death, low birth weight, and prematurity for couples with a mother and father who were categorized as either being of same or different racial groups. Risk of prematurity (birth prior to 37 weeks gestation) and low birth weight (<2500 g) were also tested to see if the model could explain variations among groups. Results: The analysis included approximately 1.6 million live births and 1749 stillbirths. In the unadjusted model, compared with two white parents, black/black and black/white couples had a significantly higher risk of fetal death. When all demographic, social, biological, genetic, congenital, and procedural risk factors except gestational age and birth weight were included, the odds ratios (OR) were all still significant. Black/black couples had the highest level of risk (OR 2.11, CI 1.77-2.51), followed by black mother/white father couples (OR 2.01, CI 1.16-3.48), and white mother/black father couples (OR 1.84, CI 1.33-2.54). Virtually all of the higher risk of fetal death was explainable by higher rates of low birth weight and prematurity. Conclusions: Mixed race black and white couples face higher odds of prematurity and low birth weight, which appear to contribute to the substantially higher demonstrated risk for stillbirth. There are likely additional unmeasured factors that influence birth outcomes for mixed race couples. C1 [Gold, Katherine J.] Univ Michigan, Dept Obstet & Gynecol, Dept Family Med, Ann Arbor, MI 48104 USA. [DeMonner, Sonya M.; Hayward, Rodney A.] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48104 USA. [DeMonner, Sonya M.; Hayward, Rodney A.] US Dept Vet Affairs, HSR&D Ctr Excellence, Ann Arbor, MI USA. [DeMonner, Sonya M.; Hayward, Rodney A.] Univ Michigan, Robert Wood Johnson Fdn Clin Scholars Program, Ann Arbor, MI 48104 USA. [Lantz, Paula M.; Hayward, Rodney A.] Univ Michigan, Sch Publ Hlth, Dept Hlth Management & Policy, Ann Arbor, MI 48104 USA. [Lantz, Paula M.] Univ Michigan, Inst Social Res, Ann Arbor, MI 48104 USA. RP Gold, KJ (reprint author), Univ Michigan, Dept Obstet & Gynecol, Dept Family Med, 1018 Fuller St, Ann Arbor, MI 48104 USA. EM ktgold@umich.edu FU Robert Wood Johnson Clinical Scholars Program FX Salary funding for K.J.G. and funding to purchase the original dataset were provided by the Robert Wood Johnson Clinical Scholars Program. NR 29 TC 10 Z9 10 U1 0 U2 2 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 J9 J WOMENS HEALTH JI J. Womens Health PD APR PY 2010 VL 19 IS 4 BP 767 EP 773 DI 10.1089/jwh.2009.1561 PG 7 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 587XS UT WOS:000277030400017 PM 20235877 ER PT J AU Sifri, CD Sun, HY Cacciarelli, TV Wispelwey, B Pruett, TL Singh, N AF Sifri, Costi D. Sun, Hsin-Yun Cacciarelli, Thomas V. Wispelwey, Brian Pruett, Timothy L. Singh, Nina TI Pretransplant Cryptococcosis and Outcome After Liver Transplantation SO LIVER TRANSPLANTATION LA English DT Article ID CALCINEURIN-INHIBITOR AGENTS; NEOFORMANS INFECTION; ACTIVATED MACROPHAGES; DRUG-INTERACTIONS; RENAL-ALLOGRAFT; IFN-GAMMA; RECIPIENTS; PULMONARY; MICE; INTERLEUKIN-4 AB The posttransplant outcomes and optimal management of patients with end-stage liver disease who develop cryptococcosis prior to transplantation have not been defined. We discuss these issues in the context of successful liver transplantation and pretransplant cryptococcal disease. Our report suggests that liver transplantation may be cautiously considered under the umbrella of fluconazole therapy in patients with end-stage liver disease and pretransplant cryptococcosis, provided that disease control is achieved with adequate treatment before transplantation. Liver Transpl 16:499-502, 2010. (C) 2010 AASLD. C1 [Sifri, Costi D.; Wispelwey, Brian; Pruett, Timothy L.] Univ Virginia, Charlottesville, VA USA. [Sun, Hsin-Yun; Cacciarelli, Thomas V.; Singh, Nina] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Sun, Hsin-Yun] Natl Taiwan Univ, Coll Med, Dept Internal Med, Natl Taiwan Univ Hosp, Taipei, Taiwan. [Cacciarelli, Thomas V.; Singh, Nina] Univ Pittsburgh, Pittsburgh, PA USA. RP Singh, N (reprint author), Vet Adm Med Ctr, Infect Dis Sect, Univ Dr C, Pittsburgh, PA 15240 USA. EM nis5@pitt.edu OI SUN, HSIN-YUN/0000-0003-0074-7721 NR 31 TC 6 Z9 6 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1527-6465 J9 LIVER TRANSPLANT JI Liver Transplant. PD APR PY 2010 VL 16 IS 4 BP 499 EP 502 DI 10.1002/lt.22024 PG 4 WC Gastroenterology & Hepatology; Surgery; Transplantation SC Gastroenterology & Hepatology; Surgery; Transplantation GA 582BN UT WOS:000276570300015 PM 20373460 ER PT J AU Caplan, L Pittman, CB Zeringue, AL Scherrer, JF Wehmeier, KR Cunningham, FE Eisen, SA McDonald, JR AF Caplan, Liron Pittman, Cory B. Zeringue, Angelique L. Scherrer, Jeffrey F. Wehmeier, Kent R. Cunningham, Francesca E. Eisen, Seth A. McDonald, Jay R. TI An Observational Study of Musculoskeletal Pain Among Patients Receiving Bisphosphonate Therapy SO MAYO CLINIC PROCEEDINGS LA English DT Article ID GLUCOCORTICOID-INDUCED OSTEOPOROSIS; POSTMENOPAUSAL OSTEOPOROSIS; ZOLEDRONIC ACID; PRACTICE PATTERNS; PAGETS-DISEASE; RISEDRONATE; PREVENTION; BONE; PERSISTENCE; ALENDRONATE AB OBJECTIVE. To seek evidence for the association of bisphosphonate use with diffuse musculoskeletal pain (MSKP) in a large national cohort, controlling for conditions associated with MSKP. PATIENTS AND METHODS This retrospective cohort study enrolled all US veterans aged 65 years or older with a vertebral or hip fracture who were treated for at least 1 year between October 1, 1998, and September 30, 2006 (N=26,545). All International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnostic codes, demographics, and pharmaceutical data were obtained from national databases. A composite end point, based on ICD-9-CM codes compatible with diffuse MSKP, was constructed. The primary outcome was time until MSKP. We performed regression analysis using the Cox proportional hazards model, controlling for age, sex, race, alcoholism, depression, anxiety, smoking, recent 3-hydroxy-3-methylglutaryi coenzyme A reductase inhibitor (statin) use, rheumatic disease, and comorbidity score. RESULTS The univariate regression identified an association of bisphosphonate exposure and MSKP (hazard ratio, 1.22; 95% confidence interval, 1.04-1.44). In the multivariate regression, however, patients prescribed a bisphosphonate were not more likely to be assigned an ICD-9-CM code compatible with diffuse MSKP (hazard ratio. 1.10; 95% confidence interval, 0.93-1.30). Consistent with prior studies, we found that female sex, depression, anxiety, comorbidity score, and the presence of a rheumatic disease were all associated with a greater risk of a diagnosis of diffuse MSKP. There was no demonstrable association with statin exposure. CONCLUSION Bisphosphonate use was not associated with a statistically higher rate of MSKP in this cohort. Individual patients may rarely report MSKP while taking bisphosphonates; however, for our studied cohort. incident MSKP does not appear to explain bisphosphonate discontinuation rates C1 [Caplan, Liron] Univ Colorado, Dept Med, Denver Vet Affairs Med Ctr, Denver, CO 80045 USA. [Pittman, Cory B.] Mercy Arthrit & Osteoporosis Ctr, Urbandale, IA USA. [Zeringue, Angelique L.; McDonald, Jay R.] Washington Univ, Sch Med, Dept Med, St Louis Vet Affairs Med Ctr, St Louis, MO 63110 USA. [Scherrer, Jeffrey F.] Washington Univ, Sch Med, Dept Psychiat, St Louis Vet Affairs Med Ctr, St Louis, MO 63110 USA. [Wehmeier, Kent R.] Univ Florida, Dept Med, Coll Med Jacksonville, Jacksonville, FL USA. [Cunningham, Francesca E.] Vet Affairs Pharm Benefits Management, Hines, IL USA. [Eisen, Seth A.] Vet Affairs Hlth Serv Res & Dev, Washington, DC USA. RP Caplan, L (reprint author), Univ Colorado, Dept Med, Denver Vet Affairs Med Ctr, POB 6511,B115, Denver, CO 80045 USA. RI Zeringue, Angelique/I-1755-2012 FU US Department of Veterans Affairs [IAF 06-026-2]; National Institutes of Health [KL2RR024994]; VA Health Services Research & Development (HSRD) FX Funding support for this research was provided by the US Department of Veterans Affairs (VA) Merit Review Grant IAF 06-026-2 Dr McDonald is supported in part by National Institutes of Health grant KL2RR024994 Dr Caplan is supported by a VA Health Services Research & Development (HSR&D) grant, however, the funding sources had no role in the study design, in the collection, analysis, and interpretation of data, in the writing of the report, or in the decision to submit the manuscript for publication NR 27 TC 10 Z9 10 U1 1 U2 4 PU MAYO CLINIC PROCEEDINGS PI ROCHESTER PA 660 SIEBENS BLDG MAYO CLINIC, ROCHESTER, MN 55905 USA SN 0025-6196 J9 MAYO CLIN PROC JI Mayo Clin. Proc. PD APR PY 2010 VL 85 IS 4 BP 341 EP 348 DI 10.4065/mcp.2009.0492 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 578ZZ UT WOS:000276337100005 PM 20231335 ER PT J AU Dunlap, LJ Zarkin, GA Bray, JW Mills, M Kivlahan, DR McKay, JR Latham, P Tonigan, JS AF Dunlap, Laura J. Zarkin, Gary A. Bray, Jeremy W. Mills, Michael Kivlahan, Daniel R. McKay, James R. Latham, Patricia Tonigan, J. Scott TI Revisiting the Cost-Effectiveness of the COMBINE Study for Alcohol Dependent Patients The Patient Perspective SO MEDICAL CARE LA English DT Article DE alcohol treatment; cost-effectiveness; patient costs ID EFFECTIVENESS ACCEPTABILITY CURVES; COMBINED PHARMACOTHERAPIES; BEHAVIORAL INTERVENTIONS; DRUG-TREATMENT; FORM 90; TIME; RELIABILITY; SEEKING; CANCER; TRIAL AB Objective: Most cost and cost-effectiveness studies of substance abuse treatments focus on the costs to the provider/payer. Although this perspective is important, the costs incurred by patients should also be considered when evaluating treatment. This article presents estimates of patients' costs associated with the Combined Pharmacotherapies and Behavioral Interventions (COMBINE) alcohol treatments and evaluates the treatments' cost-effectiveness from the patient perspective. Study Design: A prospective cost-effectiveness study of patients in COMBINE, a randomized controlled clinical trial of 9 alternative alcohol treatment regimens involving 1383 patients with diagnoses of primary alcohol dependence across 11 US clinic sites. We followed a microcosting approach that allowed estimation of patients' costs for specific COMBINE treatment activities. The primary clinical outcomes from COMBINE are used as indicators of treatment effectiveness. Results: The average total patient time devoted to treatment ranged from about 30 hours to 46 hours. Time spent traveling to and from treatment sessions and participation in self-help meetings accounted for the largest portion of patient time costs. The cost-effectiveness results indicate that 6 of the 9 treatments were economically dominated and only 3 treatments are potentially cost-effective depending on patient's willingness to pay for the considered outcomes: medical management (MM) + placebo, MM + naltrexone, and MM + naltrexone + acamprosate. Conclusions: Few studies consider the patient's perspective in estimating costs and cost-effectiveness even though these costs may have a substantial impact on a patient's treatment choice, ability to access treatment, or treatment adherence. For this study, the choice of the most cost-effective treatment depends on the value placed on the outcomes by the patient, and the conclusions drawn by the patient may differ from that of the provider/payer. C1 [Dunlap, Laura J.; Zarkin, Gary A.; Bray, Jeremy W.; Mills, Michael] RTI Int, Res Triangle Pk, NC USA. [Kivlahan, Daniel R.] Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [McKay, James R.] Univ Penn, Dept Psychiat, Ctr Continuum Care, Philadelphia, PA 19104 USA. [McKay, James R.] Univ Penn, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. [Latham, Patricia] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Tonigan, J. Scott] Univ New Mexico, Ctr Alchoholism Subst Abuse & Addict, Albuquerque, NM 87131 USA. RP Dunlap, LJ (reprint author), RTI Int, 6110 Execut Blvd,Suite 902, Rockville, MD 20852 USA. EM ljd@rti.org FU National Institute on Alcohol Abuse and Alcoholism [1-R01-AA12788] FX This study was supported by grant 1-R01-AA12788 from the National Institute on Alcohol Abuse and Alcoholism. NR 29 TC 8 Z9 8 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD APR PY 2010 VL 48 IS 4 BP 306 EP 313 DI 10.1097/MLR.0b013e3181ca3d40 PG 8 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 582ZE UT WOS:000276639300004 PM 20355261 ER PT J AU Yadav, V Marracci, GH Munar, MY Cherala, G Stuber, LE Alvarez, L Shinto, L Koop, DR Bourdette, DN AF Yadav, Vijayshree Marracci, Gail H. Munar, Myrna Y. Cherala, Ganesh Stuber, Lauren E. Alvarez, Lilia Shinto, Lynne Koop, Dennis R. Bourdette, Dennis N. TI Pharmacokinetic study of lipoic acid in multiple sclerosis: comparing mice and human pharmacokinetic parameters SO MULTIPLE SCLEROSIS JOURNAL LA English DT Article DE Multiple sclerosis; lipoic acid; pharmacokinetics; experimental autoimmune encephalomyelitis; anti-oxidants; dietary supplements ID EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; PLACEBO-CONTROLLED TRIAL; SYMPTOMATIC DIABETIC POLYNEUROPATHY; STIMULATES CAMP PRODUCTION; BURNING MOUTH SYNDROME; CONTROLLED PHASE IIB; T-CELL MIGRATION; DOUBLE-BLIND; THIOCTIC ACID; HEALTHY-VOLUNTEERS AB Lipoic acid is a natural anti-oxidant available as an oral supplement from a number of different manufacturers. Lipoic acid administered subcutaneously is an effective therapy for murine experimental autoimmune encephalomyelitis, a model of multiple sclerosis. The aim of this study was to compare serum lipoic acid levels with oral dosing in patients with multiple sclerosis with serum levels in mice receiving subcutaneous doses of lipoic acid. We performed serum pharmacokinetic studies in patients with multiple sclerosis after a single oral dose of 1200 mg lipoic acid. Patients received one of the three different racemic formulations randomly: tablet (Formulation A) and capsules (Formulations B and C). Mice pharmacokinetic studies were performed with three different subcutaneous doses (20, 50 and 100 mg/kg racemic lipoic acid). The pharmacokinetic parameters included Maximum Serum Concentrations (C(max) in mu g/ml) and area under the curve (0-infinity) (AUC(0-infinity) in mu g*min/ml). We found mean C(max) and AUC(0-infinity) in patients with multiple sclerosis as follows: group A (N=7) 3.8 +/- 2.6 and 443.1 +/- 283.9; group B (N=8) 9.9 +/- 4.5 and 745.2 +/- 308.7 and group C (N=8) 10.3 +/- 3.8 and 848.8 +/- 360.5, respectively. Mean C(max) and AUC(0-infinity) in the mice were: 100 mg/kg lipoic acid: 30.9 +/- 2.9 and 998 +/- 245; 50 mg/kg lipoic acid: 7.6 +/- 1.4 and 223 +/- 20; 20 mg/kg lipoic acid: 2.7 +/- 0.7 and 119 +/- 33. We conclude that patients taking 1200 mg of lipoic acid from two of the three oral formulations achieved serum C(max) and AUC levels comparable to that observed in mice receiving 50 mg/kg subcutaneous dose of lipoic acid, which is a highly therapeutic dose in experimental autoimmune encephalomyelitis. A dose of 1200 mg oral lipoic acid can achieve therapeutic serum levels in patients with multiple sclerosis. C1 [Yadav, Vijayshree; Marracci, Gail H.; Stuber, Lauren E.; Alvarez, Lilia; Shinto, Lynne; Bourdette, Dennis N.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA. [Marracci, Gail H.; Bourdette, Dennis N.] Portland VA Med Ctr, Portland, OR USA. [Koop, Dennis R.] Oregon Hlth & Sci Univ, Dept Physiol & Pharmacol, Portland, OR 97239 USA. [Munar, Myrna Y.; Cherala, Ganesh] Oregon Hlth & Sci Univ, Oregon State Univ, Portland, OR 97239 USA. RP Yadav, V (reprint author), Oregon Hlth & Sci Univ, Dept Neurol, Mail Code L 226,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM yadavv@ohsu.edu FU National Center of Complementary and Alternative medicine, Oregon Clinical and Translational Research Institute (OCTRI) [K23 AT003258]; National Center for Research Resources (NCRR) [UL1 RR024140]; National Institutes of Health (NIH); Biomedical Laboratory Research & Development Service, Department of Veterans Affairs; Laura Fund for Innovation in MS Research; Nancy Davis Center Without Walls FX Grant number K23 AT003258 from National Center of Complementary and Alternative medicine, Oregon Clinical and Translational Research Institute (OCTRI), grant number UL1 RR024140 from the National Center for Research Resources (NCRR), components of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research, and the Biomedical Laboratory Research & Development Service, Department of Veterans Affairs, the Laura Fund for Innovation in MS Research and the Nancy Davis Center Without Walls. We thank Pure Encapsulations (R) and Vital Nutrients (R) for donating their LA formulation products. NR 49 TC 14 Z9 15 U1 2 U2 4 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1352-4585 J9 MULT SCLER J JI Mult. Scler. J. PD APR PY 2010 VL 16 IS 4 BP 387 EP 397 DI 10.1177/1352458509359722 PG 11 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 581NI UT WOS:000276530000002 PM 20150394 ER PT J AU Velez, JCQ Janech, MG AF Velez, Juan Carlos Q. Janech, Michael G. TI A case of lactic acidosis induced by linezolid SO NATURE REVIEWS NEPHROLOGY LA English DT Article ID MITOCHONDRIAL PROTEIN-SYNTHESIS; OXAZOLIDINONE ANTIBIOTICS; SEROTONIN SYNDROME; INHIBITION; INFECTIONS; PHARMACOKINETICS; HEMODIALYSIS; RECIPIENT; TOXICITY; RIBOSOME AB Background. A 36-year-old African American man with end-stage renal disease on chronic maintenance hemodialysis was transferred first from a hospital to a long-term acute care facility for advanced care then to the intensive care unit of our university hospital with unexplained abdominal pain, nausea, hypotension, altered mental status and anion gap metabolic acidosis. Subsequent review of the patient's medication list revealed that the he had been on linezolid for 6 weeks for the treatment of vancomycin-resistant Enterococcus fecalis bacteremia. Investigations. Medical history, physical examination, laboratory tests, CT imaging of the thorax, abdomen and pelvis and PCR-based tests to determine the presence of polymorphisms in the 16S ribosomal RNA gene. Diagnosis. Lactic acidosis associated with prolonged exposure to linezolid. Management. Discontinuation of linezolid. C1 [Velez, Juan Carlos Q.] Med Univ S Carolina, Dept Med, Div Nephrol, Charleston, SC 29425 USA. [Janech, Michael G.] Ralph H Johnson VA Med Ctr, Med & Res Serv, Charleston, SC 29403 USA. RP Velez, JCQ (reprint author), Med Univ S Carolina, Dept Med, Div Nephrol, 96 Jonathan Lucas St,Clin Sci Bldg,Room 829, Charleston, SC 29425 USA. EM velezj@musc.edu RI Velez, Juan Carlos/N-3782-2016 OI Janech, Michael/0000-0002-3202-4811 FU NIH NIDDK; Veterans Affairs CDA-2 Career Development Award; Nephcure Foundation FX The research work of Dr J. C. Q. Velez is supported by a NIH NIDDK K08 Career Development Award. The research work of Dr M. G. Janech is supported by a Veterans Affairs CDA-2 Career Development Award and the Nephcure Foundation. NR 36 TC 11 Z9 13 U1 2 U2 4 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1759-5061 J9 NAT REV NEPHROL JI Nat. Rev. Nephrol. PD APR PY 2010 VL 6 IS 4 BP 236 EP 242 DI 10.1038/nrneph.2010.20 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA 575EF UT WOS:000276048800009 PM 20348931 ER PT J AU Canalejo, A Canalejo, R Rodriguez, ME Martinez-Moreno, JM Felsenfeld, AJ Rodriguez, M Almaden, Y AF Canalejo, Antonio Canalejo, Rocio Encarnacion Rodriguez, M. Martinez-Moreno, Julio M. Felsenfeld, Arnold J. Rodriguez, Mariano Almaden, Yolanda TI Development of parathyroid gland hyperplasia without uremia: role of dietary calcium and phosphate SO NEPHROLOGY DIALYSIS TRANSPLANTATION LA English DT Article DE calcium-sensing receptor; dietary calcium; dietary phosphate; parathyroid cell proliferation; vitamin D receptor ID SENSING RECEPTOR EXPRESSION; CHRONIC-RENAL-FAILURE; VITAMIN-D-RECEPTOR; SECONDARY HYPERPARATHYROIDISM; CELL-PROLIFERATION; TGF-ALPHA; PHOSPHORUS RESTRICTION; GENE-EXPRESSION; DOWN-REGULATION; RATS AB Background. Many experimental studies have demonstrated that parathyroid cell proliferation is induced by uremia and further aggravated by hypocalcemia, phosphorus retention and vitamin D deficiency. However, these factors may also promote parathyroid growth without uremia. In the present study, we examined the onset and progression of parathyroid hyperplasia regardless of the uremic setting, a situation that might occur soon during the early renal disease. Thus, the novelty of this work resides in the close examination of the time course for the expected changes in proliferation rates and their association with parathyroid hormone (PTH) release in normal rats under the physiological demands of a high-phosphate diet (HPD) or a low-calcium diet (LCD). Methods. We evaluated the functional response of the parathyroid glands in normal rats to different physiological demands an HPD 0.6% Ca, 1.2% P) and LCD 0.2% Ca, 0.6% P) and compared it with that of uremic rats. Furthermore, we also evaluated the time course for the reversal of high-P and low-Ca-induced parathyroid cell growth and PTH upon normalization of dietary Ca and P intake (0.6% Ca, 0.6% P). Proliferation was Measured by flow cytometry and calcium receptor (CaR) and vitamin D receptor (VDR) expression were assessed by qRT-PCR. Results. The pattern in the development of parathyroid hyperplasia by the two dietary models was different. The HPD produced a stronger stimulus than the number of proliferating cells doubled after only 1 day, while the LCD required 5 days to induce an increase; the elevated calcitriol might be a mitigating factor. The increase in cell proliferation was accompanied by a transient down-regulation of VDR expression (higher in the HPD); the expression of CaR was not affected by either diet. Cell proliferation and VDR mRNA levels were restored to control values by Day 15; it is as though the gland had attained a sufficient level of hyperplasia to respond to the PTH challenge. Compared to normal rats, the response of uremic rats to the HPD showed sustained and much higher rates of PTH secretion and cell proliferation and sustained down-regulation of both VDR mRNA and CaR mRNA. Finally, the recovery from the HPD or LCD to a control diet resulted in a rapid restoration of PTH values (1 to 2 days), but the reduction in cell proliferation was delayed (3 to 5 days). Conclusions. Regardless of uremia, a physiological demand to increase the PTH secretion driven either by a high P or a low Ca intake is able to induce a different pattern of parathyroid hyperplasia, which might be aggravated by the down-regulation of VDR expression. The recovery from the HPD or LCD to a control diet results in a more rapid reduction in PTH than in cell proliferation. C1 [Canalejo, Antonio] Univ Huelva, Dept Environm Biol & Publ Hlth, Huelva, Spain. [Canalejo, Rocio; Encarnacion Rodriguez, M.; Martinez-Moreno, Julio M.; Rodriguez, Mariano; Almaden, Yolanda] Hosp Univ Reina Sofia, Serv Nephrol, Unit Invest, Cordoba, Spain. [Felsenfeld, Arnold J.] W Los Angeles VA Med Ctr, Dept Med, Los Angeles, CA USA. [Felsenfeld, Arnold J.] Univ Calif Los Angeles, Los Angeles, CA USA. RP Canalejo, A (reprint author), Univ Huelva, Dept Environm Biol & Publ Hlth, Huelva, Spain. EM antonio.canalejo@dbasp.uhu.es RI Rodriguez, teresa/H-5452-2011; Canalejo, Antonio/L-8407-2014 OI Canalejo, Antonio/0000-0003-2098-8960; Rodriguez, Mariano/0000-0002-9380-6614 FU Group CTS-179; Fundacion Nefrologica; Consejeria de Salud de Is Junta de Andalucia [PI0025/2007]; Fundacion Progreso y Salud; Consejeria de Salud; Junta de Andalucia; FIS; Ministerio de Sanidad de Espana; [PI07-0287]; [PI07-0315] FX The work reported here was supported by Government Grants PI07-0287 and PI07-0315, Group CTS-179, Fundacion Nefrologica, Fundacion Hospital Reina Sofia-CajaSur and research grant PI0025/2007 from Consejeria de Salud de Is Junta de Andalucia. Y.A. is a senior researcher supported by the Fundacion Progreso y Salud, Consejeria de Salud, Junta de Andalucia. R.C. and M.E.R. are pre-doctoral fellows supported by Junta de Andalucia and FIS, Ministerio de Sanidad de Espana, respectively. NR 40 TC 4 Z9 4 U1 1 U2 2 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0931-0509 EI 1460-2385 J9 NEPHROL DIAL TRANSPL JI Nephrol. Dial. Transplant. PD APR PY 2010 VL 25 IS 4 BP 1087 EP 1097 DI 10.1093/ndt/gfp616 PG 11 WC Transplantation; Urology & Nephrology SC Transplantation; Urology & Nephrology GA 591DO UT WOS:000277279400014 PM 19934096 ER PT J AU Gazdzinski, S Millin, R Kaiser, LG Durazzo, TC Mueller, SG Weiner, MW Meyerhoff, DJ AF Gazdzinski, Stefan Millin, Rachel Kaiser, Lana G. Durazzo, Timothy C. Mueller, Susanne G. Weiner, Michael W. Meyerhoff, Dieter J. TI BMI and Neuronal Integrity in Healthy, Cognitively Normal Elderly: A Proton Magnetic Resonance Spectroscopy Study SO OBESITY LA English DT Article ID BODY-MASS INDEX; NORMAL HUMAN BRAIN; IN-VIVO; CENTRAL OBESITY; ALZHEIMERS-DISEASE; N-ACETYLASPARTATE; INCIDENT DEMENTIA; ADULTS; RISK; METABOLISM AB Recent studies associated excess body weight with brain structural alterations, poorer cognitive function, and lower prefrontal glucose metabolism. We found that higher BMI was related to lower concentrations of N-acetyl-aspartate (NAA, a marker of neuronal integrity) in a healthy middle-aged cohort, especially in frontal lobe. Here, we evaluated whether NAA was also associated with BMI in a healthy elderly cohort. We used 4 Tesla proton magnetic resonance spectroscopy ((1)H MRS) data from 23 healthy, cognitively normal elderly participants (69.4 +/- 6.9 years; 12 females) and measured concentrations of NAA, glutamate (Glu, involved in cellular metabolism), choline-containing compounds (Cho, involved in membrane metabolism), and creatine (Cr, involved in high-energy metabolism) in anterior (ACC) and posterior cingulate cortices (PCC). After adjustment for age, greater BMI was related to lower NAA/Cr and NAA/Cho ratios (beta < -0.56, P < 0.008) and lower Glu/Cr and Glu/Cho ratios (beta < -0.46, P < 0.02) in ACC. These associations were not significant in PCC (beta > -0.36, P > 0.09). The existence of an association between NAA and BMI in ACC but not in PCC is consistent with our previous study in healthy middle-aged individuals and with reports of lower frontal glucose metabolism in young healthy individuals with elevated BMI. Taken together, these results provide evidence that elevated BMI is associated with neuronal abnormalities mostly in frontal brain regions that subserve higher cognitive functions and impulse control. Future studies need to evaluate whether these metabolite abnormalities are involved in the development and maintenance of weight problems. C1 [Gazdzinski, Stefan; Millin, Rachel; Kaiser, Lana G.; Durazzo, Timothy C.; Mueller, Susanne G.; Weiner, Michael W.; Meyerhoff, Dieter J.] San Francisco Vet Adm Med Ctr, CIND, San Francisco, CA USA. [Kaiser, Lana G.; Durazzo, Timothy C.; Mueller, Susanne G.; Weiner, Michael W.; Meyerhoff, Dieter J.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA. [Weiner, Michael W.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Weiner, Michael W.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [Weiner, Michael W.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. RP Gazdzinski, S (reprint author), San Francisco Vet Adm Med Ctr, CIND, San Francisco, CA USA. EM Stefan.Gazdzinski@yahoo.com FU [AA10788]; [AG010897]; [AG12435] FX The study was supported by AA10788 (D.J.M.), AG010897 (M. W. W.), and AG12435 (M. W. W.). This material is the result of work supported with resources and the use of facilities at the Radiology Research Service of the Veterans Administration Medical Center in San Francisco. We thank Jeffrey Kasten, Kristen Peek, and Sky Raptentsetsang of the Center for Imaging of Neurodegenerative Diseases for data acquisition and processing. We extend our gratitude to Dr Lustig of the University of California San Francisco for critical review of this manuscript. NR 39 TC 33 Z9 33 U1 1 U2 6 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1930-7381 J9 OBESITY JI Obesity PD APR PY 2010 VL 18 IS 4 BP 743 EP 748 DI 10.1038/oby.2009.325 PG 6 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA 583HR UT WOS:000276665200016 PM 19816410 ER PT J AU Thompson, GR Patel, PK Kirkpatrick, WR Westbrook, SD Berg, D Erlandsen, J Redding, SW Patterson, TF AF Thompson, George R., III Patel, Payal K. Kirkpatrick, William R. Westbrook, Steven D. Berg, Deborah Erlandsen, Josh Redding, Spencer W. Patterson, Thomas F. TI Oropharyngeal candidiasis in the era of antiretroviral therapy SO ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTOLOGY LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-INFECTED PATIENTS; FLUCONAZOLE-RESISTANT CANDIDA; IN-VITRO SUSCEPTIBILITY; ESOPHAGEAL CANDIDIASIS; DOUBLE-BLIND; REFRACTORY OROPHARYNGEAL; ORAL CANDIDIASIS; 1,3-BETA-D-GLUCAN SYNTHASE; CASPOFUNGIN RESISTANCE AB Oropharyngeal candidiasis (OPC) remains a common problem in the HIV-infected population despite the availability of antiretroviral therapy (ART). Although Candida albicans is the most frequently implicated pathogen, other Candida species also may cause infection. The emergence of antifungal resistance within these causative yeasts, especially in patients with recurrent oropharyngeal infection or with long-term use of antifungal therapies, requires a working knowledge of alternative antifungal agents. Identification of the infecting organism and antifungal susceptibility testing enhances the ability of clinicians to prescribe appropriate antifungal therapy. Characterization of the responsible mechanisms has improved our understanding of the development of antifungal resistance and could enhance the management of these infections. Immune reconstitution has been shown to reduce rates of OPC, but few studies have evaluated the current impact of ART on the epidemiology of OPC and antifungal resistance in these patients. Preliminary results from an ongoing clinical study showed that in patients with advanced AIDS, oral yeast colonization was extensive, occurring in 81.1% of the 122 patients studied, and symptomatic infection occurred in one-third. In addition, resistant yeasts were still common, occurring in 25.3% of patients colonized with yeasts or with symptomatic infection. Thus, OPC remains a significant infection in advanced AIDS, even with ART. Current knowledge of the epidemiology, pathogenesis, clinical presentation, treatment, and mechanisms of antifungal resistance observed in OPC are important in managing patients with this infection and are the focus of this review. (Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010; 109: 488-495) C1 [Thompson, George R., III; Patel, Payal K.; Kirkpatrick, William R.; Berg, Deborah; Erlandsen, Josh; Patterson, Thomas F.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Infect Dis, San Antonio, TX 78229 USA. [Thompson, George R., III; Westbrook, Steven D.; Redding, Spencer W.] Univ Texas Hlth Sci Ctr San Antonio, Dept Dent Diagnost Sci, San Antonio, TX 78229 USA. [Westbrook, Steven D.; Redding, Spencer W.; Patterson, Thomas F.] S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. RP Thompson, GR (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Internal Med, Div Infect Dis, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM thompsong2@uthscsa.edu OI Patel, Payal/0000-0001-8666-7313 FU Basilea; Merck; Pfizer; Schering-Plough; Astellas; National Institute of Health [5RO1DE018096] FX G. R. T. has served as a consultant for Basilea. T. F. P. has received research support from Basilea, Merck, Pfizer, and Schering-Plough, has received speaking fees from Merck and Pfizer, and is a consultant for Basilea, Merck, Nektar, Pfizer, and Toyama. S. W. R. has received research support from Pfizer, Schering-Plough, and Astellas.; Supported in part by a National Institute of Health research grant to T. F. P. (5RO1DE018096). NR 63 TC 42 Z9 43 U1 0 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 1079-2104 EI 1528-395X J9 ORAL SURG ORAL MED O JI Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. PD APR PY 2010 VL 109 IS 4 BP 488 EP 495 DI 10.1016/j.tripleo.2009.11.026 PG 8 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 571IT UT WOS:000275746200002 PM 20156694 ER PT J AU Friedlander, AH Sung, EC Chung, EM Garrett, NR AF Friedlander, Arthur H. Sung, Eric C. Chung, Evelyn M. Garrett, Neal R. TI Radiographic quantification of chronic dental infection and its relationship to the atherosclerotic process in the carotid arteries SO ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTOLOGY LA English DT Article ID INTIMA-MEDIA THICKNESS; PERIODONTAL-DISEASE; CARDIOVASCULAR-DISEASE; ATHEROMATOUS PLAQUES; GENDER-DIFFERENCES; ENDOTHELIAL-CELLS; HEART-DISEASE; TOOTH LOSS; CORONARY; RISK AB Background. Atherosclerosis may be initiated/accelerated by chronic dental infection (CDI). Noninvasively visualizing the carotid arteries is an accepted surrogate marker for determining coronary artery atherosclerosis (CAA). We hypothesized that 36 individuals with radiographic carotid atheromas would have more radiographic CDI than risk-matched individuals without atheromas. Methods. We determined the arithmetic sum of individuals' periapical and furcal lesions, pericoronitis sites, carious roots, teeth with pulpal caries, and vertical bony defects (> 4 mm). Results. Individuals with atheromas had a significantly (P < .01) greater mean score of 15.5 +/- 10.4 compared with control subjects (7.9 +/- 8.1). Similarly significant (P < .05) was the difference in the mean numbers of mesial and distal vertical bony defects in the atheroma group (4.1 +/- 3.9 and 4.8 +/- 3.8, respectively) compared with control subjects (1.6 +/- 2.4 and 1.8 +/- 2.7, respectively). Conclusions. Individuals with atheromas on their radiographs (and high probability of CAA) had significantly greater amounts of CDI than individuals without atheromas. (Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010; 109: 615-621) C1 [Friedlander, Arthur H.] Univ Calif Los Angeles, Med Ctr, Hosp Dent Serv, Los Angeles, CA 90024 USA. [Garrett, Neal R.] Univ Calif Los Angeles, Sch Dent, Weintraub Ctr Reconstruct Biotechnol, Los Angeles, CA 90024 USA. RP Friedlander, AH (reprint author), VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM arthur.friedlander@med.va.gov NR 47 TC 9 Z9 9 U1 0 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 1079-2104 J9 ORAL SURG ORAL MED O JI Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. PD APR PY 2010 VL 109 IS 4 BP 615 EP 621 DI 10.1016/j.tripleo.2009.10.036 PG 7 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 571IT UT WOS:000275746200019 PM 20097109 ER PT J AU Hui, HX Tang, YMG Zhu, LJ Khoury, N Hui, Z Wang, KY Perfetti, R Go, VLW AF Hui, Hongxiang Tang, Yongming G. Zhu, Lunjian Khoury, Nasif Hui, Zhe Wang, Kevin Yuqi Perfetti, Ricardo Go, Vay Liang W. TI Glucagon Like Peptide-1-Directed Human Embryonic Stem Cells Differentiation Into Insulin-Producing Cells Via Hedgehog, cAMP, and PI3K Pathways SO PANCREAS LA English DT Article DE glucagonlike peptide-1 (GLP-1); embryonic stem cells; signal pathways ID IN-VITRO DIFFERENTIATION; PANCREAS DEVELOPMENT; PROTEIN-KINASE; REGULATED EXPRESSION; SIGNALING PATHWAYS; RESPONSE ELEMENT; SECRETING CELLS; GENE-EXPRESSION; SONIC HEDGEHOG; BONE-MARROW AB Objectives: That glucagonlike peptide-1 (GLP-1) induces differentiation of primate embryonic stem (ES) cells into insulin-producing cells has been reported by several groups and also confirmed with our observations. Methods: To further elucidate the process in detail and the signaling pathways involved in this differentiation, we induced human ES cells HUES1 differentiated into insulin secretion cells by GLP-1 treatment. Results: A time-dependent pattern of down expression of the stem cell markers (human telomerase reverse transcriptase and octamer-4), and the appearance of multiple A-cell-specific proteins (insulin, glucokinase, glucose transporter, type 2, and islet duodenal homeobox 1) and hedgehog signal molecules (Indian hedgehog, sonic hedgehog, and hedgehog receptor, patched) have been identified. Cotreatment with hedgehog signal inhibitor cytopamine was able to block this differentiation, providing evidence of the involvement of the hedgehog signaling pathway in GLP-1-induced differentiation. We also observed increased transcripts of the transcription factors of activator protein 1, serum response element-1, DNA-binding transcription factors, and cAMP response element in GLP-1-induced ES cell differentiation. Inhibition profile by its specific inhibitors indicated that the cyclic adenosine monophosphate and phosphatidylinositol-3-kinase pathways, but not the mitogen-activated protein kinase pathway, were required for the induced differentiation of ES cells. Conclusions: These data support that GLP-1 directs human ES cell differentiation into insulin-producing cells via hedgehog, cyclic adenosine monophosphate, and phosphatidylinositol-3-kinase pathways. C1 [Hui, Hongxiang; Hui, Zhe; Wang, Kevin Yuqi; Go, Vay Liang W.] Univ Calif Los Angeles, David Geffen Sch Med, Ctr Excellence Pancreat Dis, Los Angeles, CA 90024 USA. [Hui, Hongxiang] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA USA. [Hui, Hongxiang; Zhu, Lunjian; Khoury, Nasif; Perfetti, Ricardo] Cedars Sinai Med Ctr, Div Endocrinol & Diabet, Los Angeles, CA 90048 USA. [Hui, Hongxiang; Tang, Yongming G.] Nanfang Med Univ, Int Ctr Metab Dis, Guangzhou, Guangdong, Peoples R China. [Tang, Yongming G.] Cedars Sinai Med Ctr, Div Med Genet, Los Angeles, CA 90048 USA. RP Hui, HX (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Ctr Excellence Pancreat Dis, Los Angeles, CA 90024 USA. EM huihongx@gmail.com FU National Institutes of Health [PO1AT003960]; Hirshberg Foundation for Pancreatic Cancer Research FX This work was partially supported by the National Institutes of Health funding of the UCLA Center of Excellence in Pancreatic Diseases (PO1AT003960) and the Hirshberg Foundation for Pancreatic Cancer Research. NR 55 TC 12 Z9 16 U1 2 U2 9 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0885-3177 J9 PANCREAS JI Pancreas PD APR PY 2010 VL 39 IS 3 BP 315 EP 322 DI 10.1097/MPA.0b013e3181bc30dd PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 573YY UT WOS:000275955500005 PM 19924023 ER PT J AU Osborn, CY Egede, LE AF Osborn, Chandra Y. Egede, Leonard E. TI Validation of an Information-Motivation-Behavioral Skills model of diabetes self-care (IMB-DSC) SO PATIENT EDUCATION AND COUNSELING LA English DT Article DE Diabetes; Self-care; Behavior change; Social support; Motivation ID BLOOD-GLUCOSE CONTROL; COMPLICATIONS; MANAGEMENT; ADHERENCE; EDUCATION; SAMPLE; RISK AB Objective: Comprehensive behavior change frameworks are needed to provide guidance for the design, implementation, and evaluation of diabetes self-care programs in diverse populations. We applied the Information-Motivation-Behavioral Skills (IMB) model, a well-validated, comprehensive health behavior change framework, to diabetes self-care. Methods: Patients with diabetes were recruited from an outpatient clinic. Information gathered pertained to demographics, diabetes knowledge (information); diabetes fatalism (personal motivation); social support (social motivation); and diabetes self-care (behavior). Hemoglobin MC values were extracted from the patient medical record. Structural equation models tested the IMB framework. Results: More diabetes knowledge (r = 0.22 p < 0.05), less fatalistic attitudes (r = 0.20, p < 0.05), and more social support (r = 0.27, p < 0.01) were independent, direct predictors of diabetes self-care behavior; and through behavior, were related to glycemic control (r = 0.20, p <0.05). Conclusions: Consistent with the IMB model, having more information (more diabetes knowledge), personal motivation (less fatalistic attitudes), and social motivation (more social support) was associated with behavior: and behavior was the sole predictor of glycemic control. Practice implications: The IMB model is an appropriate, comprehensive health behavior change framework for diabetes self-care. The findings indicate that in addition to knowledge, diabetes education programs should target personal and social motivation to effect behavior change. (C) 2009 Elsevier Ireland Ltd. All rights reserved. C1 [Egede, Leonard E.] Med Univ S Carolina, Ctr Hlth Dispar Res, Charleston, SC 29425 USA. [Osborn, Chandra Y.] Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37212 USA. [Osborn, Chandra Y.] Vanderbilt Univ, Sch Med, Diabet Res & Training Ctr, Vanderbilt Eskind Diabet Ctr, Nashville, TN 37212 USA. [Osborn, Chandra Y.] Univ Connecticut, Ctr Hlth Intervent & Prevent, Storrs, CT USA. [Egede, Leonard E.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Egede, Leonard E.] Ralph H Johnson VA Med Ctr, Ctr Dis Prevent & Hlth Intervent Div Populat, Charleston, SC USA. RP Egede, LE (reprint author), Med Univ S Carolina, Ctr Hlth Dispar Res, 135 Rutledge Ave,Room 280H, Charleston, SC 29425 USA. EM egedel@musc.edu FU NIDDK [P60DK020593] FX Dr. Osborn is supported by a Minority Supplement Award (NIDDK P60DK020593). NR 31 TC 39 Z9 41 U1 1 U2 16 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0738-3991 J9 PATIENT EDUC COUNS JI Patient Educ. Couns. PD APR PY 2010 VL 79 IS 1 BP 49 EP 54 DI 10.1016/j.pec.2009.07.016 PG 6 WC Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary SC Public, Environmental & Occupational Health; Social Sciences - Other Topics GA 583RW UT WOS:000276698200009 PM 19699601 ER PT J AU Li, M Balamuthusamy, S Khan, AM Maderdrut, JL Simon, EE Batuman, V AF Li, Min Balamuthusamy, Saravanan Khan, Altaf M. Maderdrut, Jerome L. Simon, Eric E. Batuman, Vecihi TI Pituitary adenylate cyclase-activating polypeptide ameliorates cisplatin-induced acute kidney injury SO PEPTIDES LA English DT Article DE Apoptosis; Cancer chemotherapy; Inflammation; p53; Renoprotection ID ACUTE-RENAL-FAILURE; VASOACTIVE-INTESTINAL-PEPTIDE; TUBULE EPITHELIAL-CELLS; TUMOR-SUPPRESSOR P53; 4 SPLICE VARIANTS; INDUCED APOPTOSIS; EXTRACELLULAR-MATRIX; MULTIPLE-MYELOMA; IN-VIVO; CANCER CELLS AB Cisplatin nephrotoxicity involves DNA damage, proinflammatory responses and apoptosis/necrosis of renal proximal tubular epithelial cells. Pituitary adenylate cyclase-activating polypeptide (PACAP) has been shown to protect kidneys from ischemic injury and light chain-induced damage by modulating inflammation. Confluent monolayer of HK-2 human renal cells were exposed to 50 mu M cisplatin in the presence or absence of either PACAP38 or p53 siRNA. Mice injected with cisplatin were also treated with PACAP38 daily for 3 days. The damage to HK-2 cells caused by cisplatin involved the activation of p53, caspase-7, and poly (ADP-ribose) polymerase-1 (PARP-1). PACAP38 prevented the decrease in the apurinic/apyrimidinic endonuclease-1 by suppressing p53 activation and blocked the cleavage of caspase-7 and PARP-1 in cisplatin-exposed cells. PACAP also markedly inhibited cisplatin-induced apoptotic tubule cell death. Exposure to cisplatin significantly suppressed the expression of fibronectin and collagens I and IV, and altered the integrin repertoire of human renal tubule cells, while PACAP partially reversed the reduction of fibronectin, collagen IV, and the integrin subunits in cells exposed to cisplatin. Experiments with PACAP receptor antagonists and siRNA silencing of p53 showed that the renoprotection with PACAP was mediated by the PAC(1) receptor and through both p53-dependent and independent suppression of apoptosis. PACAP was renoprotective in vivo and prevented the rise in blood urea nitrogen and creatinine in mice treated with cisplatin. These results suggest that p53 plays a pivotal role in decreased integrin-mediated extracellular matrix component expression in cisplatin-induced tubule cell apoptosis, and reveal a novel aspect of PACAP-mediated renoprotection. (C) 2009 Elsevier Inc. All rights reserved. C1 [Li, Min; Balamuthusamy, Saravanan; Khan, Altaf M.; Simon, Eric E.; Batuman, Vecihi] Tulane Univ, Sch Med, Dept Med, Sect Nephrol & Hypertens, New Orleans, LA 70112 USA. [Maderdrut, Jerome L.] Tulane Univ, Sch Med, Dept Med, Peptide Res Lab, New Orleans, LA 70112 USA. [Simon, Eric E.; Batuman, Vecihi] US Dept Vet Affairs, SE Louisiana Vet Hlth Care Syst, New Orleans, LA 70161 USA. RP Li, M (reprint author), Tulane Univ, Sch Med, Dept Med, Sect Nephrol & Hypertens, 1430 Tulane Ave,SL-45, New Orleans, LA 70112 USA. EM minlee@tulane.edu OI Batuman, Vecihi/0000-0002-1800-9009 FU Louisiana Board of Regents [013RCEEP-07]; Rudolph Matas Memorial Fund; Louisiana Cancer Research Consortium; Dialysis Clinic, Inc.; Arimura Foundation FX This work was supported in part by grant 013RCEEP-07 from the Research Commercialization and Educational Enhancement Program of the Louisiana Board of Regents, the Rudolph Matas Memorial Fund, the Louisiana Cancer Research Consortium, the Dialysis Clinic, Inc., and the Arimura Foundation. NR 62 TC 14 Z9 14 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-9781 J9 PEPTIDES JI Peptides PD APR PY 2010 VL 31 IS 4 BP 592 EP 602 DI 10.1016/j.peptides.2009.12.018 PG 11 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy SC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy GA 586FE UT WOS:000276887600011 PM 20034524 ER PT J AU Simms, LJ Yufik, T Gros, DF AF Simms, Leonard J. Yufik, Tom Gros, Daniel F. TI Incremental Validity of Positive and Negative Valence in Predicting Personality Disorder SO PERSONALITY DISORDERS-THEORY RESEARCH AND TREATMENT LA English DT Article DE Big Five model; Big Seven model; personality disorder; dimensional models AB The Big Seven model of personality includes five dimensions similar to the Big Five model as well as two evaluative dimensions Positive Valence (PV) and Negative Valence (NV)-which reflect extremely positive and negative person descriptors, respectively. Recent theory and research have suggested that PV and NV predict significant variance in personality disorder (PD) above that predicted by the Big Five, but firm conclusions have not been possible because previous studies have been limited to only single measures of PV, NV, and the Big Five traits. In the present study, we replicated and extended previous findings using three markers of all key constructs including PV, NV, and the Big Five in a diverse sample of 338 undergraduates. Results of hierarchical multiple regression analyses revealed that PV incrementally predicted Narcissistic and Histrionic PDs above the Big Five and that NV nonspecifically incremented the prediction of most PDs. Implications for dimensional models of personality pathology are discussed. C1 [Simms, Leonard J.; Yufik, Tom] SUNY Buffalo, Dept Psychol, Buffalo, NY 14260 USA. [Gros, Daniel F.] Ralph H Johnson Vet Adm Med Ctr, Charleston, SC USA. [Gros, Daniel F.] Med Univ S Carolina, Charleston, SC USA. RP Simms, LJ (reprint author), SUNY Buffalo, Dept Psychol, Pk Hall 218, Buffalo, NY 14260 USA. EM ljsimms@buffalo.edu FU NIMH NIH HHS [R01 MH080086, R01 MH080086-01A2, 1R01MH080086] NR 38 TC 6 Z9 6 U1 0 U2 1 PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 1949-2715 J9 PERSONAL DISORD JI Personal. Disord. PD APR PY 2010 VL 1 IS 2 BP 77 EP 86 DI 10.1037/a0019752 PG 10 WC Psychology, Clinical SC Psychology GA V27OH UT WOS:000208622000001 PM 20730038 ER PT J AU Sox, HC Helfand, M Grimshaw, J Dickersin, K Tovey, D Knottnerus, JA Tugwell, P AF Sox, Harold C. Helfand, Mark Grimshaw, Jeremy Dickersin, Kay Tovey, David Knottnerus, J. Andre Tugwell, Peter TI Comparative Effectiveness Research: Challenges for Medical Journals SO PLOS MEDICINE LA English DT Editorial Material C1 [Sox, Harold C.] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dartmouth Inst, Hanover, NH 03756 USA. [Helfand, Mark] Portland VA Med Ctr, Portland, OR USA. [Helfand, Mark] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA. [Grimshaw, Jeremy] Ottawa Hosp Res Inst, Clin Epidemiol Program, Ottawa, ON, Canada. [Dickersin, Kay] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Tovey, David] Cochrane Lib, London, England. [Knottnerus, J. Andre] Univ Maastricht, Dept Gen Practice, Maastricht, Netherlands. [Tugwell, Peter] Univ Ottawa, Dept Med, Ottawa, ON, Canada. [Tugwell, Peter] Univ Ottawa, Dept Epidemiol & Community Med, Ottawa, ON, Canada. RP Sox, HC (reprint author), Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dartmouth Inst, Hanover, NH 03756 USA. EM helfand@ohsu.edu RI Marusic, Ana/E-7683-2013; Knottnerus, Johannes/A-3829-2009 OI Marusic, Ana/0000-0001-6272-0917; Peiperl, Laurence/0000-0003-1237-4846; Tugwell, Peter/0000-0001-5062-0556 NR 7 TC 14 Z9 14 U1 0 U2 0 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1549-1277 J9 PLOS MED JI PLos Med. PD APR PY 2010 VL 7 IS 4 AR e1000269 DI 10.1371/journal.pmed.1000269 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 590PO UT WOS:000277239500001 PM 20436963 ER PT J AU Spilman, P Podlutskaya, N Hart, MJ Debnath, J Gorostiza, O Bredesen, D Richardson, A Strong, R Galvan, V AF Spilman, Patricia Podlutskaya, Natalia Hart, Matthew J. Debnath, Jayanta Gorostiza, Olivia Bredesen, Dale Richardson, Arlan Strong, Randy Galvan, Veronica TI Inhibition of mTOR by Rapamycin Abolishes Cognitive Deficits and Reduces Amyloid-beta Levels in a Mouse Model of Alzheimer's Disease SO PLOS ONE LA English DT Article ID PROTEIN TRANSGENIC MICE; LIFE-SPAN; MAMMALIAN PROTEIN; PLAQUE-FORMATION; ALPHA-SYNUCLEIN; AUTOPHAGY; PATHWAY; YEAST; TOR; INDUCTION AB Background: Reduced TOR signaling has been shown to significantly increase lifespan in a variety of organisms [1,2,3,4]. It was recently demonstrated that long-term treatment with rapamycin, an inhibitor of the mTOR pathway[5], or ablation of the mTOR target p70S6K[6] extends lifespan in mice, possibly by delaying aging. Whether inhibition of the mTOR pathway would delay or prevent age-associated disease such as AD remained to be determined. Methodology/Principal Findings: We used rapamycin administration and behavioral tools in a mouse model of AD as well as standard biochemical and immunohistochemical measures in brain tissue to provide answers for this question. Here we show that long-term inhibition of mTOR by rapamycin prevented AD-like cognitive deficits and lowered levels of A beta(42), a major toxic species in AD[7], in the PDAPP transgenic mouse model. These data indicate that inhibition of the mTOR pathway can reduce A beta(42) levels in vivo and block or delay AD in mice. As expected from the inhibition of mTOR, autophagy was increased in neurons of rapamycin-treated transgenic, but not in non-transgenic, PDAPP mice, suggesting that the reduction in A beta and the improvement in cognitive function are due in part to increased autophagy, possibly as a response to high levels of A beta. Conclusions/Significance: Our data suggest that inhibition of mTOR by rapamycin, an intervention that extends lifespan in mice, can slow or block AD progression in a transgenic mouse model of the disease. Rapamycin, already used in clinical settings, may be a potentially effective therapeutic agent for the treatment of AD. C1 [Spilman, Patricia; Gorostiza, Olivia; Bredesen, Dale] Buck Inst Age Res, Novato, CA USA. [Podlutskaya, Natalia; Galvan, Veronica] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78229 USA. [Podlutskaya, Natalia; Richardson, Arlan; Strong, Randy; Galvan, Veronica] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. [Strong, Randy] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA. [Richardson, Arlan; Strong, Randy] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. [Hart, Matthew J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Mol Med, San Antonio, TX 78229 USA. [Richardson, Arlan; Strong, Randy] S Texas Vet Hlth Care Syst, Ctr Geriatr Res Educ & Clin, San Antonio, TX USA. [Richardson, Arlan; Strong, Randy] S Texas Vet Hlth Care Syst, Res Serv, San Antonio, TX USA. [Debnath, Jayanta] Univ Calif San Francisco, Dept Pathol, San Francisco, CA USA. RP Spilman, P (reprint author), Buck Inst Age Res, Novato, CA USA. EM galvanv@uthscsa.edu FU Alzheimer's Association [NIRG-DDC-120433]; NIA Interventions Testing Center [U01AG022307]; San Antonio Nathan Shock Aging Center [P30AG-13319]; Research and Development Service of the Department of Veterans Affairs FX This work was supported by NIRG-DDC-120433 from the Alzheimer's Association to V. G. and by the NIA Interventions Testing Center (U01AG022307) to R. S. The authors also recognize the support of the San Antonio Nathan Shock Aging Center (P30AG-13319, A.R.) and the VA Neurodegeneration Research Center (REAP) from the Research and Development Service of the Department of Veterans Affairs (A.R., R.S.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 50 TC 338 Z9 360 U1 9 U2 62 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD APR 1 PY 2010 VL 5 IS 3 AR e9979 DI 10.1371/journal.pone.0009979 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 580AG UT WOS:000276418200050 PM 20376313 ER PT J AU Maguen, S Cohen, G Cohen, BE Lawhon, GD Marmar, CR Seal, KH AF Maguen, Shira Cohen, Greg Cohen, Beth E. Lawhon, G. Dawn Marmar, Charles R. Seal, Karen H. TI The Role of Psychologists in the Care of Iraq and Afghanistan Veterans in Primary Care Settings SO PROFESSIONAL PSYCHOLOGY-RESEARCH AND PRACTICE LA English DT Article DE integrated care; veterans; mental health; post-traumatic stress disorder; health care ID POSTTRAUMATIC-STRESS-DISORDER; RANDOMIZED CONTROLLED-TRIAL; MENTAL-HEALTH-SERVICES; STEPPED COLLABORATIVE CARE; TRAUMATIC BRAIN-INJURY; AFFAIRS PRIMARY-CARE; UNITED-STATES; DEPRESSION; OUTCOMES; MANAGEMENT AB Although military personnel serving in Iraq and Afghanistan are at high risk of developing mental health problems, many report significant barriers to care and few seek help. Integrated primary care is a comprehensive model of health care that aims to improve access to care and provides a framework to assess and meet the complex psychiatric needs of newly returning veterans by embedding mental health specialists within primary care. We describe the role of psychologists in a Department of Veterans Affairs (VA) integrated primary care clinic that serves veterans of Iraq and Afghanistan. Psychologists based in primary care can assist veterans with reintegration to civilian life by providing rapid mental health assessment, normalizing readjustment concerns, planning for veterans safety, implementing brief interventions within primary care. facilitating transition to additional mental health care, and informing veterans of other available psychosocial services. A case example demonstrating the psychologist's role highlights the benefits of an integrated care model. Implications of employing this model include reduction of symptoms and impairment by reducing stigma and barriers to seeking mental health care, increased motivation to engage ill treatment, and implementation of early interventions. This model may also be beneficial in the civilian health care sector with groups that are at high risk for mental health problems, yet experience barriers to care. particularly stigma. C1 [Maguen, Shira; Cohen, Greg; Cohen, Beth E.; Lawhon, G. Dawn; Marmar, Charles R.; Seal, Karen H.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Marmar, Charles R.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. RP Maguen, S (reprint author), San Francisco VA Med Ctr, 4150 Clement St 116-P, San Francisco, CA 94121 USA. EM shira.maguen@va.gov NR 37 TC 9 Z9 9 U1 3 U2 11 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0735-7028 J9 PROF PSYCHOL-RES PR JI Prof. Psychol.-Res. Pract. PD APR PY 2010 VL 41 IS 2 BP 135 EP 142 DI 10.1037/a0018835 PG 8 WC Psychology, Multidisciplinary SC Psychology GA 586EY UT WOS:000276886800007 ER PT J AU Lemke, SP Schaefer, JA AF Lemke, Sonne P. Schaefer, Jeanne A. TI Recent Changes in the Prevalence of Psychiatric Disorders Among VA Nursing Home Residents SO PSYCHIATRIC SERVICES LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; PRIMARY-CARE CLINICS; MENTAL-ILLNESS; UNITED-STATES; SERVICE USE; HEALTH; VETERANS; TRENDS; AGE; EPIDEMIOLOGY AB Objective: This study identified recent changes in the prevalence of psychiatric disorders among Department of Veterans Affairs (VA) nursing home residents. Methods: Psychiatric diagnoses in administrative data-bases were summarized for nursing home residents in 1998, 2002, and 2006. Census prevalence rates were compared with findings from earlier VA nursing home surveys. Prevalence rates were compared for age groups and birth cohorts of VA nursing home admissions in 1998 (N=27,734) and 2006 (N=32,543). Results: Among residents in the census samples, prevalence rates for dementia and schizophrenia fluctuated moderately from 1990 to 2006, depression prevalence increased sharply, alcohol use disorder prevalence declined, and drug use disorder prevalence increased. Among 1998 and 2006 admissions, dementia prevalence increased for most birth cohorts but declined for most age groups (35% to 32% overall). Depression prevalence increased for all age groups and birth cohorts (27% to 37% overall), as did posttraumatic stress disorder prevalence (5% to 12% overall). Serious mental illness prevalence increased among the oldest residents and birth cohorts (19% to 22% overall). Alcohol use disorder prevalence declined for all birth cohorts and most age groups (18% to 16% overall), but drug use disorder prevalence increased substantially for younger age groups (6% to 9% overall). Conclusions: Examining differences in prevalence between birth cohorts and age groups can clarify trends in nursing home resident characteristics and improve projections of their future needs. (Psychiatric Services 61: 356-363, 2010) C1 [Lemke, Sonne P.; Schaefer, Jeanne A.] Ctr Hlth Care Evaluat, Palo Alto Hlth Care Syst, US Dept Vet Affairs, Menlo Pk, CA 94025 USA. RP Lemke, SP (reprint author), Ctr Hlth Care Evaluat, Palo Alto Hlth Care Syst, US Dept Vet Affairs, 795 Willow Rd, Menlo Pk, CA 94025 USA. EM sonne.lemke@va.gov FU Department of Veterans Affairs [IIR 03-243]; Veterans Health Administration; Office of Research and Development Health Services Research and Development Service (HSRD) FX This research was supported in part by grant IIR 03-243 from the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development Health Services Research and Development Service (HSR&D). The findings and conclusions are those of the authors and do not necessarily represent those of the Department of Veterans Affairs or HSR&D. The authors thank Kathy Fung, M. S., and Kirsten Unger-Hu, M. S., for their valuable contributions to data management and analyses. NR 24 TC 8 Z9 8 U1 0 U2 2 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD APR PY 2010 VL 61 IS 4 BP 356 EP 363 PG 8 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 577WH UT WOS:000276254200006 PM 20360274 ER PT J AU Harris, AHS Kivlahan, DR Bowe, T Humphreys, KN AF Harris, Alex H. S. Kivlahan, Daniel R. Bowe, Thomas Humphreys, Keith N. TI Pharmacotherapy of Alcohol Use Disorders in the Veterans Health Administration SO PSYCHIATRIC SERVICES LA English DT Article ID NATIONAL EPIDEMIOLOGIC SURVEY; ADDICTION TREATMENT CENTERS; SUBSTANCE-USE DISORDERS; TREAT ALCOHOLISM; NALTREXONE; DEPENDENCE; ADOPTION; MEDICATIONS; PREVALENCE; TRIALS AB Objective: Acamprosate, oral and long-acting injectable naltrexone, and disulfiram are approved for treatment of alcohol dependence. Their availability and consideration of their use in treatment are now standards of high-quality care. This study determined rates of medication initiation among Veterans Health Administration (VHA) patients. Methods: VHA pharmacy and administrative data were used to identify patients with alcohol use disorder diagnoses in fiscal years (FY) 2006 and 2007 and the proportion (nationally and by facility) who received each medication. Patient characteristics associated with receipt were also examined. Results: Among more than a quarter-million patients with alcohol use disorder diagnoses, the percentage receiving any of the medications increased from 2.8% in FY 2006 to 3.0% in FY 2007. Receipt of these medications was more likely among patients who received specialty addiction care, those with alcohol dependence (compared with abuse), those younger than 55 years, and females. In the patient subgroups examined, the largest proportion to receive any of the medications was 11.6%. Across 128 VHA facilities, rates of use among patients in the sample who had received past-year specialty addiction treatment ranged from 0% to 20.5%; rates ranged from 0% to 4.3% among those with no specialty treatment. Patient preferences and medical contraindications could not be determined from the data. Conclusions: Findings suggest the need to better understand systemwide variation in use of these medications and their use as a rough proxy for availability and consideration of pharmacotherapy-a standard of care with strong organizational support. (Psychiatric Services 61:392-398, 2010) C1 [Harris, Alex H. S.; Bowe, Thomas; Humphreys, Keith N.] US Dept Vet Affairs, VA Palo Alto Hlth Care Syst, Ctr Hlth Care Evaluat, Menlo Pk, CA 94025 USA. [Harris, Alex H. S.; Bowe, Thomas; Humphreys, Keith N.] Stanford Univ, Sch Med, Menlo Pk, CA USA. [Kivlahan, Daniel R.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Kivlahan, Daniel R.] Univ Washington, Sch Med, Seattle, WA USA. RP Harris, AHS (reprint author), US Dept Vet Affairs, VA Palo Alto Hlth Care Syst, Ctr Hlth Care Evaluat, 795 Willow Rd,MC152, Menlo Pk, CA 94025 USA. EM alexander.harris2@va.gov FU VA Office of Research and Development, Health Services Research and Development Service [MRP-05-168-1] FX This study was funded in part by grant MRP-05-168-1 from the VA Office of Research and Development, Health Services Research and Development Service. The authors thank David Oslin, M. D., for his helpful comments and suggestions. The views expressed herein are not necessarily those of the Department of Veteran Affairs. NR 32 TC 36 Z9 36 U1 3 U2 4 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD APR PY 2010 VL 61 IS 4 BP 392 EP 398 PG 7 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 577WH UT WOS:000276254200011 PM 20360279 ER PT J AU Hunt, J Eisenberg, D Kilbourne, AM AF Hunt, Justin Eisenberg, Daniel Kilbourne, Amy M. TI Consequences of Receipt of a Psychiatric Diagnosis for Completion of College SO PSYCHIATRIC SERVICES LA English DT Article ID EDUCATIONAL-ATTAINMENT; ALCOHOL-CONSUMPTION; BIPOLAR-I; PSYCHOSOCIAL DISABILITY; UNIVERSITY-STUDENTS; MENTAL-HEALTH; DISORDERS; DEPRESSION; POPULATION; PREVALENCE AB Objective: The purpose of this study was to evaluate the independent associations between DSM-IV psychiatric disorders and the failure to complete college among college entrants. Methods: Data were from the 2001-2002 National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). The sample included 15,800 adults, aged 22 years and older, who at least entered college. Diagnoses were made with the NESARC survey instrument, the Alcohol Use Disorder and Associated Disability Interview Schedule-DSM-IV Version. The large sample permitted analysis of multiple psychiatric disorders in the same multivariable logistic regression models. Given the frequent comorbidity of these disorders, this approach is an important step toward disentangling the independent roles of disorders in postsecondary educational outcomes. Results: Evaluation of the independent associations between specific psychiatric disorders and postsecondary educational attainment showed that five diagnoses were positively and significantly associated with the failure to graduate from college. Four were axis I diagnoses: bipolar I disorder, marijuana use disorder, amphetamine use disorder, and cocaine use disorder. One was an axis II diagnosis: antisocial personality disorder. Conclusions: This study provides new data on DSM-IV diagnoses associated with the failure to complete postsecondary education. The findings suggest that psychiatric factors play a significant role in college academic performance, and the benefits of prevention, detection, and treatment of psychiatric illness may therefore include higher college graduation rates. (Psychiatric Services 61:399-404, 2010) C1 [Hunt, Justin] Univ Arkansas Med Sci, Dept Psychiat & Behav Sci, Little Rock, AR 72205 USA. [Eisenberg, Daniel] Univ Michigan, Sch Publ Hlth, Dept Hlth Policy & Management, Ann Arbor, MI 48109 USA. [Kilbourne, Amy M.] Univ Michigan, Sch Med, Dept Psychiat, Ann Arbor, MI 48109 USA. [Kilbourne, Amy M.] US Dept Vet Affairs, Hlth Serv Res & Dev, Serious Mental Illness Treatment Res & Evaluat Ct, Ann Arbor, MI USA. RP Hunt, J (reprint author), Univ Arkansas Med Sci, Dept Psychiat & Behav Sci, 4301 W Markham St,755, Little Rock, AR 72205 USA. EM huntjustinb@uams.edu FU Robert Wood Johnson Foundation FX The Robert Wood Johnson Foundation provided salary support (two-year research fellowship for Dr. Hunt) through its Clinical Scholars Program. NR 44 TC 23 Z9 23 U1 2 U2 11 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD APR PY 2010 VL 61 IS 4 BP 399 EP 404 PG 6 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 577WH UT WOS:000276254200012 PM 20360280 ER PT J AU Salzer, MS Palmer, SC Kaplan, K Brusilovskiy, E Ten Have, T Hampshire, M Metz, J Coyne, JC AF Salzer, Mark S. Palmer, Steven C. Kaplan, Katy Brusilovskiy, Eugene Ten Have, Thomas Hampshire, Maggie Metz, James Coyne, James C. TI A randomized, controlled study of Internet peer-to-peer interactions among women newly diagnosed with breast cancer SO PSYCHO-ONCOLOGY LA English DT Article DE Internet; peer support; breast cancer; well-being ID SUPPORT GROUPS; INSIGHTFUL DISCLOSURE; INSTRUMENT; THERAPY; IMPACT AB Objective: Peer-to-peer interactions are associated with enhanced psychosocial adjustment among women with breast cancer. Millions of women with cancer and others with various health conditions use the Internet to establish peer relationships, usually without professional moderation. This paper reports findings from the first randomized, controlled study of the benefits of these types of Internet-based peer interactions. Methods: This pilot study involved seventy-eight women who were recently diagnosed with breast cancer. Participants were randomly assigned to either an Internet peer support condition or Internet-based educational control condition. Data were gathered at baseline and 4- and 12-months. Primary outcomes of interest were psychological distress and quality of life. Results: Contrary to hypotheses, participants in the Internet peer support condition tended to do worse over time on primary outcome measures. There were no differences between groups on secondary outcomes of perceived social support, self-efficacy, or hope. Paradoxically, many women in the Internet peer support condition actively participated and reported high levels of satisfaction, suggesting some self-perceived benefits. Conclusions: These results suggest that Internet based peer-to-peer interactions may not necessarily be universally beneficial despite the positive experiences reported by many participants. Further research is needed to understand the magnitude of this effect with a larger sample. Moreover, these results raise questions about the need to understand the comparative effectiveness of Internet-based communications by group structure (i.e., unstructured/structured; unmoderated/moderated) and the effect of content (i.e., expression of fear/anxiety, insightful disclosures, etc.) on outcomes. Copyright (C) 2009 John Wiley & Sons, Ltd. C1 [Salzer, Mark S.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Salzer, Mark S.] Philadelphia VA Med Ctr, Philadelphia, PA USA. RP Salzer, MS (reprint author), Univ Penn, Dept Psychiat, 3535 Market St,3rd Floor CMHPSR, Philadelphia, PA 19104 USA. EM Mark.Solzer@uphs.upenn.edu FU National Cancer Institute [1R21CA098888-01A1] FX The study was supported by a study funded by the National Cancer Institute (Salzer, P. I.: 1R21CA098888-01A1). NR 20 TC 43 Z9 43 U1 1 U2 11 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 1057-9249 J9 PSYCHO-ONCOLOGY JI Psycho-Oncol. PD APR PY 2010 VL 19 IS 4 BP 441 EP 446 DI 10.1002/pon.1586 PG 6 WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences, Biomedical SC Oncology; Psychology; Biomedical Social Sciences GA 585CF UT WOS:000276801200013 PM 19484712 ER PT J AU Li, XB Ricci, R Large, CH Anderson, B Nahas, Z Bohning, DE George, MS AF Li, Xingbao Ricci, Raffaella Large, Charles H. Anderson, Berry Nahas, Ziad Bohning, Daryl E. George, Mark S. TI Interleaved transcranial magnetic stimulation and fMRI suggests that lamotrigine and valproic acid have different effects on corticolimbic activity SO PSYCHOPHARMACOLOGY LA English DT Article DE Transcranial magnetic stimulation; Neuroimaging; Motor cortex; Corticolimbic system; Lamotrigine; Valproic acid; fMRI; Anticonvulsant ID ANTERIOR CINGULATE CORTEX; CORTICAL EXCITABILITY; ANTIEPILEPTIC DRUGS; BIPOLAR DISORDER; MOTOR CORTEX; FUNCTIONAL CONNECTIVITY; BOLD-FMRI; TMS; MECHANISMS; MOOD AB Combined transcranial magnetic stimulation (TMS) and functional magnetic resonance imaging (fMRI) can be used to study anticonvulsant drugs. A previous study showed that lamotrigine (LTG) inhibited brain activation induced when TMS was applied over motor cortex, whereas it increased activation induced by TMS applied over prefrontal cortex. The present double-blind, placebo-controlled, crossover study in 30 healthy subjects again combined TMS and fMRI to test whether the effects seen previously with LTG would be confirmed and to compare these with a second anticonvulsant drug, valproic acid (VPA). Statistical parametric mapping analysis showed that both LTG and VPA, compared to placebo, inhibited TMS-induced activation of the motor cortex. In contrast, when TMS was applied over prefrontal cortex, LTG increased the activation of limbic regions, confirming previous results; VPA had no effect. We conclude that LTG and VPA have similar inhibitory effects on motor circuits, but differing effects on the prefrontal corticolimbic system. The study demonstrates that a combination of TMS and fMRI techniques may be useful in the study of the effects of neuroactive drugs on specific brain circuits. C1 [Li, Xingbao; Ricci, Raffaella; Anderson, Berry; Nahas, Ziad; George, Mark S.] Med Univ S Carolina, Dept Psychiat, Brain Stimulat Lab, Charleston, SC 29425 USA. [Li, Xingbao; Bohning, Daryl E.; George, Mark S.] Med Univ S Carolina, Ctr Adv Imaging Res, Charleston, SC 29425 USA. [Large, Charles H.] GlaxoSmithKline SpA, Med Res Ctr, Verona, Italy. [George, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Li, XB (reprint author), Med Univ S Carolina, Dept Psychiat, Brain Stimulat Lab, 502N,67 President St, Charleston, SC 29425 USA. EM lixi@musc.edu OI Ricci, Raffaella/0000-0003-3422-2552 FU GlaxoSmithKline; Center for Advanced Imaging Research and Brain Stimulation Laboratory infrastructure and resources FX This study was funded primarily by an unrestricted research grant from GlaxoSmithKline to Dr. George, as well as from Center for Advanced Imaging Research and Brain Stimulation Laboratory infrastructure and resources. CHL is a full-time employee of GlaxoSmithKline S. p. A. None of the other authors has equity or financial conflicts. Drs. Li and George had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. NR 45 TC 8 Z9 8 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0033-3158 J9 PSYCHOPHARMACOLOGY JI Psychopharmacology PD APR PY 2010 VL 209 IS 3 BP 233 EP 244 DI 10.1007/s00213-010-1786-y PG 12 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 572AM UT WOS:000275798400003 PM 20195575 ER PT J AU Nuechterlein, KH Green, MF Kern, RS AF Nuechterlein, Keith H. Green, Michael F. Kern, Robert S. TI RECENT ADVANCES IN TRANSLATING AND CULTURALLY ADAPTING THE MATRICS CONSENSUS COGNITIVE BATTERY FOR INTERNATIONAL USE SO SCHIZOPHRENIA RESEARCH LA English DT Meeting Abstract CT 2nd Conference of the Schizophrenia-International-Research-Society (SIRS) CY APR 10-14, 2010 CL Florence, ITALY SP Schizophrenia Int Res Soc C1 [Nuechterlein, Keith H.; Green, Michael F.; Kern, Robert S.] Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA USA. [Nuechterlein, Keith H.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA USA. [Green, Michael F.; Kern, Robert S.] VA Greater Angeles Healthcare Syst, MIRECC, VISN 22, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD APR PY 2010 VL 117 IS 2-3 SI SI BP 329 EP 330 DI 10.1016/j.schres.2010.02.564 PG 2 WC Psychiatry SC Psychiatry GA 586TR UT WOS:000276936800566 ER PT J AU Genevsky, A Fisher, M Garrett, CT Cook, C Vinogradov, S AF Genevsky, Alexander Fisher, Melissa Garrett, Coleman T. Cook, Colleen Vinogradov, Sophia TI INCREASED SERUM BDNF INDUCED BY COGNITIVE TRAINING IN SCHIZOPHRENIA IS NEGATIVELY ASSOCIATED WITH BASELINE SAA SO SCHIZOPHRENIA RESEARCH LA English DT Meeting Abstract CT 2nd Conference of the Schizophrenia-International-Research-Society (SIRS) CY APR 10-14, 2010 CL Florence, ITALY SP Schizophrenia Int Res Soc C1 [Genevsky, Alexander; Fisher, Melissa; Garrett, Coleman T.; Cook, Colleen; Vinogradov, Sophia] San Francisco VA Med Ctr, San Francisco, CA USA. [Genevsky, Alexander; Fisher, Melissa; Garrett, Coleman T.; Cook, Colleen; Vinogradov, Sophia] Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD APR PY 2010 VL 117 IS 2-3 SI SI BP 368 EP 368 DI 10.1016/j.schres.2010.02.653 PG 1 WC Psychiatry SC Psychiatry GA 586TR UT WOS:000276936801023 ER PT J AU Keefe, R Vinogradov, S Medalia, A Buckley, P Caroff, S D'Souza, D Harvey, P Graham, K Marder, S Miller, D Olson, S Patel, J Velligan, D Walker, T Haim, A Stroup, S AF Keefe, Richard Vinogradov, Sophia Medalia, Alice Buckley, Peter Caroff, Stanley D'Souza, Deepak Harvey, Phillip Graham, Karen Marder, Steve Miller, Del Olson, Steve Patel, Jayendra Velligan, Dawn Walker, Trina Haim, Adam Stroup, Scott TI FEASIBILITY STUDY OF MULTI-SITE COGNITIVE REMEDIATION IN THE SCHIZOPHRENIA TRIALS NETWORK (CRSTN) SO SCHIZOPHRENIA RESEARCH LA English DT Meeting Abstract CT 2nd Conference of the Schizophrenia-International-Research-Society (SIRS) CY APR 10-14, 2010 CL Florence, ITALY SP Schizophrenia Int Res Soc C1 [Keefe, Richard; Walker, Trina] Duke Univ, Med Ctr, Durham, NC USA. [Vinogradov, Sophia] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Medalia, Alice; Stroup, Scott] Columbia Univ, Coll Phys & Surg, New York, NY USA. [Buckley, Peter] Med Coll Georgia, Augusta, GA 30912 USA. [Caroff, Stanley] Univ Penn, Sch Med, Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. [D'Souza, Deepak] Yale Univ, Sch Med, New Haven, CT USA. [Harvey, Phillip] Emory Univ, Sch Med, Atlanta, GA 30322 USA. [Graham, Karen] Univ N Carolina, Chapel Hill, NC USA. [Marder, Steve] Univ Calif Los Angeles, Semel Inst, Los Angeles, CA USA. [Marder, Steve] VA Desert Pacific Mental Illness Res Educ & Clin, Los Angeles, CA USA. [Miller, Del] Univ Iowa, Carver Coll Med, Iowa City, IA USA. [Olson, Steve] Univ Minnesota, Minneapolis, MN USA. [Patel, Jayendra] Univ Massachusetts, Sch Med, Worcester, MA 01605 USA. [Velligan, Dawn] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Haim, Adam] NIMH, Bethesda, MD 20892 USA. NR 0 TC 3 Z9 3 U1 0 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD APR PY 2010 VL 117 IS 2-3 SI SI BP 394 EP 394 PG 1 WC Psychiatry SC Psychiatry GA 586TR UT WOS:000276936801081 ER PT J AU Richards, K Sawyer, AM AF Richards, Kathy Sawyer, Amy M. TI What We Don't Know about Sleep-Related Breathing Disorders in the Elderly SO SLEEP LA English DT Editorial Material ID WORKING-MEMORY; INTERMITTENT HYPOXIA; APNEA; BRAIN; CONSEQUENCES; IMPAIRMENT; ACTIVATION; DISEASE C1 [Richards, Kathy] Univ Penn, Sch Nursing, John A Hartford Ctr Geriatr Nursing Excellence, Philadelphia, PA 19104 USA. [Richards, Kathy] Univ Penn, Sch Nursing, Ctr Integrat Sci Aging, Philadelphia, PA 19104 USA. [Richards, Kathy] Madlyn & Leonard Abramson Ctr Jewish Life, Polisher Res Inst, N Wales, PA USA. [Sawyer, Amy M.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Richards, K (reprint author), Univ Penn, Sch Nursing, John A Hartford Ctr Geriatr Nursing Excellence, Claire M Fagin Hall,418 Curie Blvd,Room 311, Philadelphia, PA 19104 USA. EM kathyr@nursing.upenn.edu FU NINR NIH HHS [K99 NR011173] NR 20 TC 1 Z9 1 U1 0 U2 3 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PD APR 1 PY 2010 VL 33 IS 4 BP 423 EP 425 PG 3 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 581IJ UT WOS:000276515500004 PM 20394310 ER PT J AU Mandava, P Kalkonde, YV Rochat, RH Kent, TA AF Mandava, Pitchaiah Kalkonde, Yogeshwar V. Rochat, Ryan H. Kent, Thomas A. TI A Matching Algorithm to Address Imbalances in Study Populations Application to the National Institute of Neurological Diseases and Stroke Recombinant Tissue Plasminogen Activator Acute Stroke Trial SO STROKE LA English DT Article DE acute treatment; acute stroke; cerebrovascular accident; matching; nearest neighbor ID ACUTE ISCHEMIC-STROKE; NINDS; REANALYSIS; SCORE AB Background and Purpose-Outcome from stroke is highly dependent on baseline conditions. Patients with stroke have a wide range of severities, ages, and etiologies and it has proven difficult to achieve randomization of key variables in clinical trials. We present a new post hoc approach to achieve balance among selected variables. To illustrate the approach, we rebalanced the National Institute of Neurological Diseases and Stroke Recombinant Tissue Plasminogen Activator trial, in which the contribution of baseline imbalances continues to be debated. Methods-We selected baseline stroke severity (National Institutes of Health Stroke Scale), age, and glucose as matching criteria. The closest matched placebo and treated subjects were identified based on nearness to each other in 3-dimensional Euclidean space. Matching was performed within the quintiles of National Institutes of Health Stroke Scale that have been previously used to assess balance. Subjects who could not be matched were eliminated. Outcomes were assessed using the original specified National Institute of Neurological Diseases and Stroke trial measures. Results-We successfully matched the 2 arms resulting in nearly identical baseline characteristics and distribution among quintiles. Despite fewer subjects after outlier elimination, the primary outcome measures remained significantly improved. After rebalancing, the magnitude of benefit was reduced by 13% to 23%. Benefit was apparent mostly in the large vessel occlusion subtype. Conclusion-This study demonstrated the feasibility of rebalancing individual subjects within a randomized trial. After rebalancing and outlier elimination, recombinant tissue plasminogen activator continued to demonstrate improved outcome. That the apparent treatment effect was reduced suggests that imbalances contributed to the magnitude of the original National Institute of Neurological Diseases and Stroke outcomes. This method could in theory be applied to any data set to find matched subjects for outcome or other analyses. (Stroke. 2010; 41: 765-770.) C1 [Mandava, Pitchaiah] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA. Baylor Coll Med, VA Med Ctr, Stroke Program, Houston, TX 77030 USA. RP Mandava, P (reprint author), Baylor Coll Med, Dept Neurol, 2002 Holcombe Blvd 127, Houston, TX 77030 USA. EM pmandava@bcm.tmc.edu RI Mandava, Pitchaiah/B-6046-2013 OI Mandava, Pitchaiah/0000-0003-4957-4518; Kent, Thomas/0000-0002-9877-7584 NR 28 TC 15 Z9 15 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD APR PY 2010 VL 41 IS 4 BP 765 EP 770 DI 10.1161/STROKEAHA.109.574103 PG 6 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 575XU UT WOS:000276106100038 PM 20167911 ER PT J AU Chen, W Zhang, G Marvizon, JCG AF Chen, W. Zhang, G. Marvizon, J. C. G. TI NMDA RECEPTORS IN PRIMARY AFFERENTS REQUIRE PHOSPHORYLATION BY Src FAMILY KINASES TO INDUCE SUBSTANCE P RELEASE IN THE RAT SPINAL CORD SO NEUROSCIENCE LA English DT Article DE C-fiber; dorsal horn; internalization; nociceptor; neurokinin-1 receptor; protein tyrosine phosphatase ID METHYL-D-ASPARTATE; DORSAL-ROOT GANGLIA; PRIMARY SENSORY NEURONS; NEUROKININ-1 RECEPTOR; NR2B SUBUNIT; SYNAPTIC-TRANSMISSION; GABA(B) RECEPTORS; HORN NEURONS; LAMINA-I; PROJECTION NEURONS AB The function of N-methyl-D-aspartate (NMDA) receptors in primary afferents remains controversial, in particular regarding their ability to evoke substance P release in the spinal cord. The objective of this study was, first, to confirm that substance P release evoked by NMDA is mediated by NMDA receptors in primary afferent terminals. Second, we investigated whether these NMDA receptors are inactivated in some conditions, which would explain why their effect on substance P release was not observed in some studies. Substance P release was induced in spinal cord slices and measured as neurokinin 1 (NK1) receptor internalization in lamina I neurons. NMDA (combined with D-serine) induced NK1 receptor internalization with a half of the effective concentration (EC(50)) of 258 nM. NMDA-induced NK1 receptor internalization was abolished by the NK1 receptor antagonist L-703,606, confirming that is was caused by substance P release, by NMDA receptor antagonists (MK1801 and ifenprodil), showing that it was mediated by NMDA receptors containing the NR2B subunit, and by preincubating the slices with capsaicin, showing that the substance P release was from primary afferents. However, it was not affected by lidocaine and omega-conotoxin MVIIA, which block Na(+) channels and voltage-dependent Ca(2+) channels, respectively. Therefore, NMDA-induced substance P release does not require firing of primary afferents or the opening of Ca(2+) channels, which is consistent with the idea that NMDA receptors induce substance P directly by letting Ca(2+) into primary afferent terminals. Importantly, NMDA-induced substance P release was eliminated by preincubating the slices for 1 h with the Src family kinase inhibitors PP1 and dasatinib, and was substantially increased by the protein tyrosine phosphatase inhibitor BVT948. In contrast, PP1 did not affect NK1 receptor internalization induced by capsaicin. These results show that tyrosine-phosphorylation of these NMDA receptors is regulated by the opposite actions of Src family kinases and protein tyrosine phosphatases, and is required to induce substance P release. Published by Elsevier Ltd on behalf of IBRO. C1 [Marvizon, J. C. G.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Chen, W.; Zhang, G.; Marvizon, J. C. G.] Univ Calif Los Angeles, David Geffen Sch Med, Ctr Neurobiol Stress, CURE Digest Dis Res Ctr,Div Digest Dis,Dept Med, Los Angeles, CA 90095 USA. RP Marvizon, JCG (reprint author), VA Greater Los Angeles Healthcare Syst, Bldg 115,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM marvizon@ucla.edu FU Rehabilitation Research and Development Service, Department of Veteran Affairs [B47661] FX Supported by grant B47661 from the Rehabilitation Research and Development Service, Department of Veteran Affairs to J.C.M. NR 72 TC 13 Z9 13 U1 0 U2 1 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4522 J9 NEUROSCIENCE JI Neuroscience PD MAR 31 PY 2010 VL 166 IS 3 BP 924 EP 934 DI 10.1016/j.neuroscience.2010.01.009 PG 11 WC Neurosciences SC Neurosciences & Neurology GA 582LD UT WOS:000276597900018 PM 20074620 ER PT J AU Zile, MR Gaasch, WH Anand, IS Haass, M Little, WC Miller, AB Lopez-Sendon, J Teerlink, JR White, M McMurray, JJ Komajda, M McKelvie, R Ptaszynska, A Hetzel, SJ Massie, BM Carson, PE AF Zile, Michael R. Gaasch, William H. Anand, Inder S. Haass, Markus Little, William C. Miller, Alan B. Lopez-Sendon, Jose Teerlink, John R. White, Michel McMurray, John J. Komajda, Michel McKelvie, Robert Ptaszynska, Agata Hetzel, Scott J. Massie, Barry M. Carson, Peter E. CA I-Preserve Investigators TI Mode of Death in Patients With Heart Failure and a Preserved Ejection Fraction Results From the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) Trial SO CIRCULATION LA English DT Article DE heart failure; cardiac death; death, sudden; irbesartan; ventricular ejection fraction ID CARDIAC-RESYNCHRONIZATION THERAPY; SYSTOLIC FUNCTION; LEFT-VENTRICLE; CLINICAL CHARACTERISTICS; ISOSORBIDE DINITRATE; VASODILATOR THERAPY; MORTALITY; MORBIDITY; ENALAPRIL; CARVEDILOL AB Background-The mode of death has been well characterized in patients with heart failure and a reduced ejection fraction; however, less is known about the mode of death in patients with heart failure and a preserved ejection fraction (HFPEF). The purpose of this study was to examine the mode of death in patients with HFPEF enrolled in the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial and to determine whether irbesartan altered the distribution of mode of death in HFPEF. Methods and Results-All deaths were reviewed by a clinical end-point committee, and the mode of death was assigned by consensus of the members. The annual mortality rate was 5.2% in the I-Preserve trial. There were no significant differences in mortality rate between the placebo and irbesartan groups. The mode of death was cardiovascular in 60% (including 26% sudden, 14% heart failure, 5% myocardial infarction, and 9% stroke), noncardiovascular in 30%, and unknown in 10%. There were no differences in the distribution of mode-specific mortality rates between placebo and irbesartan. Conclusions-Sixty percent of the deaths in patients with HFPEF were cardiovascular, with sudden death and heart failure death being the most common. Treatment with irbesartan did not affect overall mortality or the distribution of mode-specific mortality rates. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT00095238. (Circulation. 2010; 121: 1393-1405.) C1 [Zile, Michael R.] Med Univ S Carolina, Dept Med, Div Cardiol, Charleston, SC 29425 USA. [Zile, Michael R.] RHJ Dept Vet Affairs Med Ctr, Charleston, SC USA. [Gaasch, William H.] Lahey Clin Fdn, Burlington, MA USA. [Anand, Inder S.] Univ Minnesota, Minneapolis, MN USA. [Anand, Inder S.] VA Med Ctr, Minneapolis, MN USA. [Haass, Markus] Theresienkrankenhaus, Mannheim, Germany. Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA. [Miller, Alan B.] Univ Florida Shands Jacksonville, Jacksonville, FL USA. [Lopez-Sendon, Jose] Hosp Univ La Paz, Madrid, Spain. [Teerlink, John R.; Massie, Barry M.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Teerlink, John R.; Massie, Barry M.] San Francisco VA Med Ctr, San Francisco, CA USA. [White, Michel] Montreal Heart Inst, Montreal, PQ H1T 1C8, Canada. [McMurray, John J.] Univ Glasgow, Glasgow Cardiovasc Res Ctr, British Heart Fdn, Glasgow, Lanark, Scotland. [Komajda, Michel] Univ Paris, Pitie Salpetriere Hosp, F-75252 Paris, France. [McKelvie, Robert] McMaster Univ, Hamilton, ON, Canada. [Ptaszynska, Agata] Bristol Myers Squibb Co, Princeton, NJ USA. [Hetzel, Scott J.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI 53706 USA. [Carson, Peter E.] Georgetown Univ, Washington, DC USA. [Carson, Peter E.] Washington VAMC, Washington, DC USA. RP Zile, MR (reprint author), Med Univ S Carolina, Dept Med, Div Cardiol, Ashley River Towers,25 Courtenay Dr,Room 7067, Charleston, SC 29425 USA. EM zilem@musc.edu RI Max, Mad/E-5238-2010; Teerlink, John/D-2986-2012 OI Max, Mad/0000-0001-6966-6829; Liang, Chang-seng/0000-0002-0328-0277; mcmurray, john/0000-0002-6317-3975 FU Bristol-Myers Squibb; Sanofi-Aventis FX The I-Preserve Trial was funded by Bristol-Myers Squibb and Sanofi-Aventis. NR 62 TC 135 Z9 139 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD MAR 30 PY 2010 VL 121 IS 12 BP 1393 EP 1405 DI 10.1161/CIRCULATIONAHA.109.909614 PG 13 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 575RD UT WOS:000276084400004 PM 20231531 ER PT J AU Yates, MA Li, Y Chlebeck, P Proctor, T Vandenbark, AA Offner, H AF Yates, M. A. Li, Y. Chlebeck, P. Proctor, T. Vandenbark, A. A. Offner, H. TI Progesterone treatment reduces disease severity and increases IL-10 in experimental autoimmune encephalomyelitis SO JOURNAL OF NEUROIMMUNOLOGY LA English DT Article DE Progesterone; Estrogen; EAE; Multiple sclerosis; B cells ID CENTRAL-NERVOUS-SYSTEM; CD8(+) T-CELLS; MULTIPLE-SCLEROSIS; DENDRITIC CELLS; ALPHA PRODUCTION; SPINAL-CORD; B-CELLS; ESTROGEN; MICE; EXPRESSION AB Ovarian hormones, including progesterone, are known to have immunomodulatory and neuroprotective effects which may alter the disease course of experimental autoimmune encephalomyelitis (EAE). In the current study, we examined the treatment potential of progesterone beginning at the onset of EAE symptoms. Progesterone treated animals showed reduced peak disease scores and cumulative disease indices, and decreased inflammatory cytokine secretion (IL-2 and IL-17). In addition, increased production of IL-10 was accompanied by increased numbers of CD19+ cells and an increase in CD8+ cells. Decreased chemokine and chemokine receptor expression in the spinal cord also contributed to decreased lesions in the spinal cord. (C) 2010 Elsevier B.V. All rights reserved. C1 [Yates, M. A.; Li, Y.; Chlebeck, P.; Proctor, T.; Vandenbark, A. A.; Offner, H.] Portland VA Med Ctr, Portland, OR USA. [Yates, M. A.; Li, Y.; Vandenbark, A. A.; Offner, H.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Vandenbark, A. A.] Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA. [Offner, H.] Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97201 USA. RP Offner, H (reprint author), Portland VA Med Ctr, R&D 31,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM offnerva@ohsu.edu FU National Multiple Sclerosis Society Postdoctoral Fellowship [FG1832-A-1]; National Multiple Sclerosis Society [RG3405-B-5]; NIH [NS45445, NS49210]; Biomedical Laboratory R&D Service, Department of Veterans Affairs FX Dr. Yates is a Postdoctoral Fellow of the National Multiple Sclerosis Society, and this work was supported in part by National Multiple Sclerosis Society Postdoctoral Fellowship FG1832-A-1, National Multiple Sclerosis Society grant RG3405-B-5, NIH grants NS45445, and NS49210, and the Biomedical Laboratory R&D Service, Department of Veterans Affairs. NR 40 TC 47 Z9 47 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-5728 J9 J NEUROIMMUNOL JI J. Neuroimmunol. PD MAR 30 PY 2010 VL 220 IS 1-2 BP 136 EP 139 DI 10.1016/j.jneuroim.2010.01.013 PG 4 WC Immunology; Neurosciences SC Immunology; Neurosciences & Neurology GA 580SL UT WOS:000276469900019 PM 20153059 ER PT J AU Maron, DJ Boden, WE O'Rourke, RA Hartigan, PM Calfas, KJ Mancini, GBJ Spertus, JA Dada, M Kostuk, WJ Knudtson, M Harris, CL Sedlis, SP Zoble, RG Title, LM Gosselin, G Nawaz, S Gau, GT Blaustein, AS Bates, ER Shaw, LJ Berman, DS Chaitman, BR Weintraub, WS Teo, KK AF Maron, David J. Boden, William E. O'Rourke, Robert A. Hartigan, Pamela M. Calfas, Karen J. Mancini, G. B. John Spertus, John A. Dada, Marcin Kostuk, William J. Knudtson, Merril Harris, Crystal L. Sedlis, Steven P. Zoble, Robert G. Title, Lawrence M. Gosselin, Gilbert Nawaz, Shah Gau, Gerald T. Blaustein, Alvin S. Bates, Eric R. Shaw, Leslee J. Berman, Daniel S. Chaitman, Bernard R. Weintraub, William S. Teo, Koon K. CA COURAGE Trial Res Grp TI Intensive Multifactorial Intervention for Stable Coronary Artery Disease Optimal Medical Therapy in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) Trial SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Article DE coronary disease; medical therapy; risk factors; secondary prevention ID CONVERTING ENZYME-INHIBITORS; ACUTE MYOCARDIAL-INFARCTION; QUALITY-OF-LIFE; RANDOMIZED-TRIALS; SECONDARY PREVENTION; GLUCOSE CONTROL; HEART-DISEASE; DIET-HEART; TASK-FORCE; METAANALYSIS AB Objectives This paper describes the medical therapy used in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial and its effect on risk factors. Background Most cardiovascular clinical trials test a single intervention. The COURAGE trial tested multiple lifestyle and pharmacologic interventions (optimal medical therapy) with or without percutaneous coronary intervention in patients with stable coronary disease. Methods All patients, regardless of treatment assignment, received equivalent lifestyle and pharmacologic interventions for secondary prevention. Most medications were provided at no cost. Therapy was administered by nurse case managers according to protocols designed to achieve predefined lifestyle and risk factor goals. Results The patients (n = 2,287) were followed for 4.6 years. There were no significant differences between treatment groups in proportion of patients achieving therapeutic goals. The proportion of smokers decreased from 23% to 19% (p = 0.025), those who reported <7% of calories from saturated fat increased from 46% to 80% (p < 0.001), and those who walked >= 150 min/week increased from 58% to 66% (p < 0.001). Body mass index increased from 28.8 +/- 0.13 kg/m(2) to 29.3 +/- 0.23 kg/m(2) (p < 0.001). Appropriate medication use increased from pre-randomization to 5 years as follows: antiplatelets 87% to 96%; beta-blockers 69% to 85%; renin-angiotensin-aldosterone system inhibitors 46% to 72%; and statins 64% to 93%. Systolic blood pressure decreased from a median of 131 +/- 0.49 mm Hg to 123 +/- 0.88 mm Hg. Low-density lipoprotein cholesterol decreased from a median of 101 +/- 0.83 mg/dl to 72 +/- 0.88 mg/dl. Conclusions Secondary prevention was applied equally and intensively to both treatment groups in the COURAGE trial by nurse case managers with treatment protocols and resulted in significant improvement in risk factors. Optimal medical therapy in the COURAGE trial provides an effective model for secondary prevention among patients with chronic coronary disease. (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation; NCT00007657) (J Am Coll Cardiol 2010; 55: 1348-58) (C) 2010 by the American College of Cardiology Foundation C1 [Maron, David J.] Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37212 USA. [Maron, David J.] Vanderbilt Univ, Sch Med, Dept Emergency Med, Nashville, TN 37212 USA. [Boden, William E.] SUNY Buffalo, Buffalo, NY 14260 USA. [Boden, William E.] Buffalo Gen Hosp, Buffalo, NY 14203 USA. [O'Rourke, Robert A.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Hartigan, Pamela M.] VA Cooperat Studies Program, Coordinating Ctr, West Haven, CT USA. [Calfas, Karen J.] Univ Calif San Diego, San Diego, CA 92103 USA. [Mancini, G. B. John] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada. [Spertus, John A.] Univ Missouri, Mid Amer Heart Inst, Kansas City, MO 64110 USA. [Kostuk, William J.] London Hlth Sci Ctr, London, ON, Canada. [Dada, Marcin] Hartford Hosp, Hartford, CT 06115 USA. [Knudtson, Merril] Libin Cardiovasc Inst Alberta, Edmonton, AB, Canada. [Harris, Crystal L.] VA Cooperat Studies Program, Albuquerque, NM USA. [Sedlis, Steven P.] NYU, Sch Med, New York, NY USA. [Sedlis, Steven P.] Vet Affairs New York Harbor Hlth Care Syst, New York, NY USA. [Zoble, Robert G.] James A Haley Vet Adm Med Ctr, Tampa, FL 33612 USA. [Title, Lawrence M.] Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada. [Gosselin, Gilbert] Montreal Heart Inst, Montreal, PQ H1T 1C8, Canada. [Nawaz, Shah] Sudbury Reg Hosp, Sudbury, ON, Canada. [Gau, Gerald T.] Mayo Clin, Rochester, MN USA. [Blaustein, Alvin S.] Michael E DeBakey VA Med Ctr, Houston, TX USA. [Bates, Eric R.] Univ Michigan, Med Ctr, Ann Arbor, MI USA. [Shaw, Leslee J.] Emory Univ, Atlanta, GA 30322 USA. [Berman, Daniel S.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Chaitman, Bernard R.] St Louis Univ, St Louis, MO 63103 USA. [Weintraub, William S.] Christiana Care Hlth Syst, Newark, DE USA. [Teo, Koon K.] McMaster Univ, Med Ctr, Hamilton, ON, Canada. RP Maron, DJ (reprint author), Vanderbilt Heart & Vasc Inst, 1215 21st Ave S,MCE 5th Floor S Tower, Nashville, TN 37232 USA. EM david.maron@vanderbilt.edu OI Sedlis, Steven/0000-0002-8194-8017 FU Merck; Abbott Laboratories; Amgen; Roche Diagnostics; Lilly; CV Therapeutics; Bristol-Myers Squibb; Astellas Healthcare; Sanofi-Aventis; Boehringer Ingelheim FX Dr. Boden has received consulting fees and lecture fees from Kos Pharmaceuticals, PDL BioPharma, Pfizer, CV Therapeutics, and Sanofi-Aventis and grant support from Merck and Abbott Laboratories. Dr. O'Rourke has received consulting fees from King Pharmaceuticals, Lilly, and CV Therapeutics. Dr. Calfas has been a stockholder of SanTech, Inc. a company founded in cooperation with San Diego State University and exclusively licensed to disseminate the PACE materials. Dr. Mancini has received honoraria from Merck, GlaxoSmithKline, Sanofi-Aventis, AstraZeneca and Abbott. Dr. Spertus has received consulting fees from Amgen and United Healthcare and grant support from Amgen, Roche Diagnostics, and Lilly (and in the past, consulting fees and grant support from CV Therapeutics and has been owner of the copyright for the Seattle Angina Questionnaire, the Peripheral Artery Questionnaire, and the Kansas City Cardiomyopathy Questionnaire). Dr. Bates has received consulting fees from Sanofi-Aventis and AstraZeneca and lecture fees from Sanofi-Aventis. Dr. Shaw has received grant support from Bristol-Myers Squibb and Astellas Healthcare. Dr. Berman has received consulting fees, lecture fees, and grant support from Bristol-Myers Squibb and software royalties from Cedars Sinai Medical Center. Dr. Chaitman has received consulting fees from CV Therapeutics, Roche, Merck, Lilly, Sanofi-Aventis, Forest; lecture fees from CV Therapeutics; and research grants from Roche and CV Therapeutics. Dr. Weintraub has received consulting fees from Sanofi-Aventis and Bristol-Myers Squibb and grant support from Sanofi-Aventis. Dr. Teo has received grant support from Boehringer Ingelheim. NR 50 TC 50 Z9 52 U1 1 U2 14 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD MAR 30 PY 2010 VL 55 IS 13 BP 1348 EP 1358 DI 10.1016/j.jacc.2009.10.062 PG 11 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 573CL UT WOS:000275885900009 PM 20338496 ER PT J AU Cornier, MA Salzberg, AK Endly, DC Bessesen, DH Tregellas, JR AF Cornier, Marc-Andre Salzberg, Andrea K. Endly, Dawnielle C. Bessesen, Daniel H. Tregellas, Jason R. TI Sex-based differences in the behavioral and neuronal responses to food SO PHYSIOLOGY & BEHAVIOR LA English DT Article DE fMRI; Neuroimaging; Obesity; Food intake; Gender; Appetite ID REDUCED-OBESE INDIVIDUALS; BODY-WEIGHT; GENDER-DIFFERENCES; BRAIN ACTIVATION; OVARIECTOMIZED RATS; ESTRADIOL DECREASES; DIETARY RESTRAINT; PREFRONTAL CORTEX; ENERGY-BALANCE; FEMALE RATS AB Sex-based differences in food intake related behaviors have been observed previously. The objective of this study was to examine sex-based differences in the behavioral and neuronal responses to food. 22 women and 21 men were studied. After 6 days of controlled eucaloric feeding, ad libitum energy intake (El) was measured for 3 days. Appetite ratings using visual analog scales were obtained before and after each meal. Functional magnetic resonance imaging was performed in the overnight fasted state on the last day of eucaloric feeding while subjects were presented visual stimuli of food and neutral non-food objects. While hunger and prospective consumption were not different between sexes, women had higher post-meal satiety ratings and dietary restraint than men. Images of hedonic foods resulted in significantly greater activation of lateral and dorsolateral prefrontal cortex (DLPFC) and parietal cortex in women as compared to men. No brain regions were more activated in men as compared to women. Men increased their El during the ad libitum diet phase. While measures of appetite or feeding behaviors did not correlate with either neuronal activation or subsequent El. DLPFC activation in response to hedonic foods was negatively correlated with El. In summary, greater prefrontal neuronal responses to food cues in women may suggest increased cognitive processing related to executive function, such as planning, guidance or evaluation of behavior. Finally, increased DLPFC activation, perhaps relating to inhibitory cognitive control in response to food cues may be a better predictor of food intake than behavioral measures. (C) 2010 Elsevier Inc. All rights reserved. C1 [Cornier, Marc-Andre; Salzberg, Andrea K.; Endly, Dawnielle C.; Bessesen, Daniel H.] Univ Colorado Denver, Div Endocrinol Diabet & Metab, Dept Med, Aurora, CO 80045 USA. [Tregellas, Jason R.] Univ Colorado Denver, Dept Psychiat, Aurora, CO 80045 USA. [Cornier, Marc-Andre; Bessesen, Daniel H.] Denver Hlth Med Ctr, Dept Med, Denver, CO 80204 USA. [Tregellas, Jason R.] Denver VA Med Ctr, Res Serv, Denver, CO 80220 USA. RP Cornier, MA (reprint author), Univ Colorado Denver, Div Endocrinol Diabet & Metab, Dept Med, Mail Stop 8106,12801 E 17th Ave,Room 7103, Aurora, CO 80045 USA. EM marc.cornier@ucdenver.edu RI Tregellas, Jason/J-3637-2015 FU NIH/NCRR Colorado CTSI [UL1 RR025780]; NIH/NIDDK Clinical Nutrition Research Unit [DK48520]; NIH/NCRR [RR016185] FX We acknowledge and thank Debra Singel and Yiping Du for their assistance with the fMRI studies. We also thank the dietary services and metabolic kitchen of the University of Colorado Denver CTRC. This publication was supported by NIH/NCRR Colorado CTSI grant number UL1 RR025780, NIH/NIDDK Clinical Nutrition Research Unit grant number DK48520, and NIH/NCRR grant number RR016185. Its contents are the authors' sole responsibility and do not necessarily represent official NIH views. NR 53 TC 77 Z9 77 U1 6 U2 25 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0031-9384 J9 PHYSIOL BEHAV JI Physiol. Behav. PD MAR 30 PY 2010 VL 99 IS 4 BP 538 EP 543 DI 10.1016/j.physbeh.2010.01.008 PG 6 WC Psychology, Biological; Behavioral Sciences SC Psychology; Behavioral Sciences GA 576KQ UT WOS:000276143700018 PM 20096712 ER PT J AU Egede, LE Strom, JL Durkalski, VL Mauldin, PD Moran, WP AF Egede, Leonard E. Strom, Joni L. Durkalski, Valerie L. Mauldin, Patrick D. Moran, William P. TI Rationale and design: telephone-delivered behavioral skills interventions for Blacks with type 2 diabetes SO TRIALS LA English DT Article ID FUNCTIONAL HEALTH LITERACY; URBAN AFRICAN-AMERICANS; PRIMARY-CARE PROVIDERS; PHYSICAL-ACTIVITY; SELF-MANAGEMENT; UNITED-STATES; PSYCHOMETRIC PROPERTIES; CLINICAL INERTIA; GLYCEMIC CONTROL; QUESTIONNAIRE AB Background: African Americans with Type 2 diabetes (T2DM) have higher prevalence of diabetes, poorer metabolic control, and greater risk for complications and death compared to American Whites. Poor outcomes in African Americans with T2DM can be attributed to patient, provider, and health systems level factors. Provider and health system factors account for <10% of variance in major diabetes outcomes including hemoglobin A1c (HbA1c), lipid control, and resource use. Key differences appear to be at the patient level. Of the patient level factors, consistent differences between African Americans and American Whites with T2DM have been found in diabetes knowledge, self-management skills, empowerment, and perceived control. A variety of interventions to improve diabetes self-management have been tested including: 1) knowledge interventions; 2) lifestyle interventions; 3) skills training interventions; and 4) patient activation and empowerment interventions. Most of these interventions have been tested individually, but rarely have they been tested in combination, especially among African Americans who have the greatest burden of diabetes related complications. This study provides a unique opportunity to address this gap in the literature. Methods/Design: We describe an ongoing four-year randomized clinical trial, using a 2 x 2 factorial design, which will test the efficacy of separate and combined telephone-delivered, diabetes knowledge/information and motivation/behavioral skills training interventions in high risk African Americans with poorly controlled T2DM (HbA1c = 9%). Two-hundred thirty-two (232) male and female African-American participants, 18 years of age or older and with an HbA1c = 9%, will be randomized into one of four groups for 12-weeks of phone interventions: (1) an education group, (2) a motivation/skills group, (3) a combined group or (4) a usual care/general health education group. Participants will be followed for 12-months to ascertain the effect of the interventions on glycemic control. Our primary hypothesis is that among African Americans with poorly controlled T2DM, patients randomized to the combined diabetes knowledge/information and motivation/behavioral skills training intervention will have significantly greater reduction in HbA1c at 12 months of follow-up compared to the usual care/general health education group. Discussion: Results from this study will provide important insight into how best to deliver diabetes education and skills training in ethnic minorities and whether combined knowledge/information and motivation/behavioral skills training is superior to the usual method of delivering diabetes education for African Americans with poorly controlled T2DM. C1 [Egede, Leonard E.; Mauldin, Patrick D.] Ctr Dis Prevent & Hlth Intervent Diverse Populat, Ralph H Johnson VAMC, Charleston, SC USA. [Egede, Leonard E.; Strom, Joni L.; Moran, William P.] Med Univ S Carolina, Div Gen Internal Med & Geriatr, Charleston, SC 29425 USA. [Egede, Leonard E.; Strom, Joni L.; Mauldin, Patrick D.; Moran, William P.] Med Univ S Carolina, Ctr Hlth Dispar Res, Charleston, SC 29425 USA. [Durkalski, Valerie L.] Med Univ S Carolina, Div Biostat & Epidemiol, Charleston, SC 29425 USA. [Mauldin, Patrick D.] Med Univ S Carolina, Dept Clin Pharm & Outcome Sci, Charleston, SC 29425 USA. RP Egede, LE (reprint author), Ctr Dis Prevent & Hlth Intervent Diverse Populat, Ralph H Johnson VAMC, Charleston, SC USA. EM egedel@musc.edu FU National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [R01DK081121-01A1] FX The study is funded by grant # R01DK081121-01A1 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). NR 48 TC 4 Z9 4 U1 1 U2 8 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1745-6215 J9 TRIALS JI Trials PD MAR 29 PY 2010 VL 11 AR 35 DI 10.1186/1745-6215-11-35 PG 11 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 584MF UT WOS:000276755400001 PM 20350322 ER PT J AU Rieckmann, T Fuller, BE Saedi, GA McCarty, D AF Rieckmann, Traci Fuller, Bret E. Saedi, Goal Auzeen McCarty, Dennis TI Adoption of practice guidelines and assessment tools in substance abuse treatment SO SUBSTANCE ABUSE TREATMENT PREVENTION AND POLICY LA English DT Article ID DIFFUSION; BELIEFS; STAFF AB Background: The gap between research and practice limits utilization of relevant, progressive and empirically validated strategies in substance abuse treatment. Methods: Participants included substance abuse treatment programs from the Northeastern United States. Structural equation models were constructed with agency level data to explore two outcome variables: adoption of practice guidelines and assessment tools at two points in time; models also included organizational, staffing and service variables. Results: In 1997, managed care involvement and provision of primary care services had the strongest association with increased use of assessment tools, which, along with provision of counseling services, were associated with a greater use of practice guidelines. In 2001, managed care involvement, counseling services and being a stand-alone drug treatment agency were associated with a greater use of assessment tools, which was in turn related to an increase in the use of practice guidelines. Conclusions: This study provides managers, clinicians and policy-makers with a framework for understanding factors related to the adoption of new technologies in substance abuse treatment. C1 [Rieckmann, Traci; McCarty, Dennis] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97239 USA. [Fuller, Bret E.] Portland VA Med Ctr, Portland, OR 97239 USA. [Saedi, Goal Auzeen] Univ Notre Dame, Dept Psychol, Notre Dame, IN 46556 USA. RP Rieckmann, T (reprint author), Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, 3181 SW Sam Jackson Pk Rd,Mailcode CB669, Portland, OR 97239 USA. EM rieckman@ohsu.edu FU NIAAA NIH HHS [R01 AA011363-05, R01 AA011363, R01-AA11363]; NIDA NIH HHS [K23 DA021225, U10 DA013036] NR 38 TC 2 Z9 2 U1 1 U2 2 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1747-597X J9 SUBST ABUSE TREAT PR JI Subst/ Abus. Treatment Prev. Pol. PD MAR 26 PY 2010 VL 5 AR 4 DI 10.1186/1747-597X-5-4 PG 9 WC Substance Abuse SC Substance Abuse GA 593BL UT WOS:000277426500001 PM 20346158 ER PT J AU Ross, JS Normand, SLT Wang, Y Ko, DT Chen, J Drye, EE Keenan, PS Lichtman, JH Bueno, H Schreiner, GC Krumholz, HM AF Ross, Joseph S. Normand, Sharon-Lise T. Wang, Yun Ko, Dennis T. Chen, Jersey Drye, Elizabeth E. Keenan, Patricia S. Lichtman, Judith H. Bueno, Hector Schreiner, Geoffrey C. Krumholz, Harlan M. TI Hospital Volume and 30-Day Mortality for Three Common Medical Conditions SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID ACUTE MYOCARDIAL-INFARCTION; HEALTH-CARE; QUALITY; MODEL; RATES; TIME AB BACKGROUND The association between hospital volume and the death rate for patients who are hospitalized for acute myocardial infarction, heart failure, or pneumonia remains unclear. It is also not known whether a volume threshold for such an association exists. METHODS We conducted cross-sectional analyses of data from Medicare administrative claims for all fee-for-service beneficiaries who were hospitalized between 2004 and 2006 in acute care hospitals in the United States for acute myocardial infarction, heart failure, or pneumonia. Using hierarchical logistic-regression models for each condition, we estimated the change in the odds of death within 30 days associated with an increase of 100 patients in the annual hospital volume. Analyses were adjusted for patients' risk factors and hospital characteristics. Bootstrapping procedures were used to estimate 95% confidence intervals to identify the condition-specific volume thresholds above which an increased volume was not associated with reduced mortality. RESULTS There were 734,972 hospitalizations for acute myocardial infarction in 4128 hospitals, 1,324,287 for heart failure in 4679 hospitals, and 1,418,252 for pneumonia in 4673 hospitals. An increased hospital volume was associated with reduced 30-day mortality for all conditions (P<0.001 for all comparisons). For each condition, the association between volume and outcome was attenuated as the hospital's volume increased. For acute myocardial infarction, once the annual volume reached 610 patients ( 95% confidence interval [CI], 539 to 679), an increase in the hospital volume by 100 patients was no longer significantly associated with reduced odds of death. The volume threshold was 500 patients ( 95% CI, 433 to 566) for heart failure and 210 patients ( 95% CI, 142 to 284) for pneumonia. CONCLUSIONS Admission to higher-volume hospitals was associated with a reduction in mortality for acute myocardial infarction, heart failure, and pneumonia, although there was a volume threshold above which an increased condition-specific hospital volume was no longer significantly associated with reduced mortality. C1 [Ross, Joseph S.] Mt Sinai Sch Med, New York, NY 10029 USA. [Ross, Joseph S.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. [Normand, Sharon-Lise T.] Harvard Univ, Sch Med, Boston, MA USA. [Normand, Sharon-Lise T.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Wang, Yun; Chen, Jersey; Drye, Elizabeth E.; Schreiner, Geoffrey C.; Krumholz, Harlan M.] Yale New Haven Med Ctr, New Haven, CT 06504 USA. [Wang, Yun; Chen, Jersey; Lichtman, Judith H.; Krumholz, Harlan M.] Yale Univ, Sch Med, New Haven, CT USA. [Ko, Dennis T.] Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada. [Ko, Dennis T.] Inst Clin Evaluat Sci, Toronto, ON, Canada. [Bueno, Hector] Hosp Gen Univ Gregorio Maranon, Madrid, Spain. RP Ross, JS (reprint author), Mt Sinai Sch Med, 1 Gustave L Levy Pl,Box 1070, New York, NY 10029 USA. EM joseph.ross@mssm.edu RI Max, Mad/E-5238-2010; BUENO, HECTOR/I-3910-2015 OI Max, Mad/0000-0001-6966-6829; BUENO, HECTOR/0000-0003-0277-7596; Ko, Dennis/0000-0001-6840-8051 FU CMS [HHSM-500-2005-CO001C]; National Institute on Aging [K08 AG032886]; American Federation for Aging Research; Fondo de Investigaciones Sanitarias, Instituto de Salud Carlos III, Madrid [BA08/90010] FX Supported by a contract (HHSM-500-2005-CO001C) with the CMS, by a grant (K08 AG032886, to Dr. Ross) from the National Institute on Aging, by the American Federation for Aging Research through the Paul B. Beeson Career Development Award Program, and by a grant (BA08/90010, to Dr. Bueno) from the Fondo de Investigaciones Sanitarias, Instituto de Salud Carlos III, Madrid. NR 22 TC 127 Z9 130 U1 1 U2 15 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD MAR 25 PY 2010 VL 362 IS 12 BP 1110 EP 1118 DI 10.1056/NEJMsa0907130 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA 573FU UT WOS:000275894600008 PM 20335587 ER PT J AU Ix, JH de Boer, IH Wassel, CL Criqui, MH Shlipak, MG Whooley, MA AF Ix, Joachim H. de Boer, Ian H. Wassel, Christina L. Criqui, Michael H. Shlipak, Michael G. Whooley, Mary A. TI Urinary Creatinine Excretion Rate and Mortality in Persons With Coronary Artery Disease The Heart and Soul Study SO CIRCULATION LA English DT Article DE cardiovascular diseases; creatinine; muscles; mortality ID CARDIOVASCULAR-DISEASE; MUSCLE MASS; CYSTATIN-C; RESISTANCE EXERCISE; CLINICAL-CARDIOLOGY; SEDENTARY MEN; ASSOCIATION; INDIVIDUALS; METABOLISM; VARIABILITY AB Background-In persons with coronary artery disease, low body mass index is associated with greater mortality; however, it is uncertain whether low muscle mass is a risk factor for mortality in this setting. Methods and Results-In this study, 903 individuals with coronary artery disease provided 24-hour urine collections. We measured urine creatinine and volume and calculated creatinine excretion rate, a marker of muscle mass. Cox proportional-hazards models evaluated the association of creatinine excretion rate with mortality risk. Over a median follow-up of 6.0 years, 232 participants (26%) died. Compared with the highest sex-specific creatinine excretion rate tertile, the lowest tertile (<1068 mg/d in men, <766 mg/d in women) was associated with >2-fold risk of mortality (hazard ratio, 2.30; 95% confidence interval, 1.51 to 3.51) in models adjusted for age, sex, race, cystatin C-based estimated glomerular filtration rate, body mass index, traditional cardiovascular disease risk factors, and C-reactive protein levels. The association was essentially unaltered with further adjustment for physical fitness, left ventricular mass, left ventricular ejection fraction, or fasting insulin and glucose levels. Conclusions-Lower creatinine excretion rate is strongly associated with mortality in outpatients with coronary artery disease, independently of conventional measures of body composition, kidney function, and traditional coronary artery disease risk factors. Future studies should determine whether low creatinine excretion rate may be a modifiable risk factor for mortality among persons with coronary artery disease, potentially through resistive exercise training or nutrition interventions. (Circulation. 2010; 121: 1295-1303.) C1 [Ix, Joachim H.] Univ Calif San Diego, Dept Med, Div Nephrol, San Diego, CA 92161 USA. [Ix, Joachim H.; Wassel, Christina L.; Criqui, Michael H.] Univ Calif San Diego, Dept Family & Prevent Med, Div Prevent Med, San Diego, CA 92161 USA. [Criqui, Michael H.] Univ Calif San Diego, Dept Med, Div Cardiol, San Diego, CA 92161 USA. [Ix, Joachim H.] Vet Affairs San Diego Healthcare Syst, Nephrol Sect, San Diego, CA 92161 USA. [de Boer, Ian H.] Univ Washington, Dept Med, Div Nephrol, Seattle, WA 98195 USA. [de Boer, Ian H.] Univ Washington, Dept Med, Kidney Res Inst, Seattle, WA USA. [Shlipak, Michael G.; Whooley, Mary A.] San Francisco VA Med Ctr, Gen Internal Med Sect, San Francisco, CA USA. [Shlipak, Michael G.; Whooley, Mary A.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Shlipak, Michael G.; Whooley, Mary A.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. RP Ix, JH (reprint author), Univ Calif San Diego, Dept Med, Div Nephrol & Hypertens, 3350 La Jolla Village Dr,Mail Code 111-H, San Diego, CA 92161 USA. EM joeix@ucsd.edu FU American Heart Association; National Heart Lung and Blood Institute (NHLBI) [R01HL096851, R01 HL079235]; Department of Veterans Epidemiology; Department of Veterans Affairs Health Services Research and Development service; American Federation for Aging Research; Robert Wood Johnson Foundation; Ischemia Research and Education Foundation; American Diabetes Association; National Institutes on Aging; National Institutes on Diabetes Digestive and Kidney Diseases; Department of Defense FX This study was supported by grants from the American Heart Association (Fellow-to-Faculty Transition) and the National Heart Lung and Blood Institute (NHLBI: R01HL096851) to Dr Ix. The Heart and Soul Study was supported by the Department of Veterans Epidemiology Merit Review Program, the Department of Veterans Affairs Health Services Research and Development service, the NHLBI (R01 HL079235), the American Federation for Aging Research (Paul Beeson Scholars Program), the Robert Wood Johnson Foundation (Generalist Physician Faculty Scholars Program), and the Ischemia Research and Education Foundation. The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.; Dr Ix reports receiving grant support from the NHLBI, the American Heart Association, and the American Diabetes Association. Drs Wassel and Criqui report receiving grants from the NHLBI. Dr Shlipak reports receiving grant support from the American Heart Association, NHLBI, National Institutes on Aging, and National Institutes on Diabetes Digestive and Kidney Diseases. Dr Whooley reports receiving grants from the NHLBI, Veterans Affairs, and Department of Defense. Dr de Boer reports no conflicts. NR 33 TC 52 Z9 53 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD MAR 23 PY 2010 VL 121 IS 11 BP 1295 EP 1303 DI 10.1161/CIRCULATIONAHA.109.924266 PG 9 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 572VW UT WOS:000275863200005 PM 20212276 ER PT J AU Fernandes, F Ansari, IUH Striker, R AF Fernandes, Fiona Ansari, Israr-ul H. Striker, Rob TI Cyclosporine Inhibits a Direct Interaction between Cyclophilins and Hepatitis C NS5A SO PLOS ONE LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; IN-VITRO; RNA-POLYMERASE; CELL-CULTURE; REPLICATION; PROTEIN; GENOME; BINDING; STRAIN; DOMAIN AB Background: Hepatitis C Virus (HCV) infection is a leading indication for liver transplantation. HCV infection reoccurs almost universally post transplant, decreasing both graft longevity and patient survival. The immunosuppressant, cyclosporine A (CsA) has potent anti-HCV activity towards both HCV replicons and the genotype 2a cell culture infectious virus. Previously, we isolated mutations in the 1bN replicon with less sensitivity to CsA that mapped to both NS5A and NS5B regions of the virus. Mutations in NS5A alone conferred decreased CsA susceptibility regardless of NS5B mutations. Methodology/Principal Findings: We examined the mechanisms by which NS5A mutations contribute to CsA resistance and if they are strain dependent. Using in vitro mutagenesis, the amino acid position 321 mutation of NS5A was restored to the wild-type tyrosine residue conferring partial CsA susceptibility on the mutant replicon. The 321 mutation also alters CsA susceptibility of the JFH cell culture virus. Additionally, we demonstrated a novel CsA-sensitive interaction between NS5A and both cyclophilin A and B. Both the mutant NS5A and wild type NS5A bind cyclophilin in vitro. The NS5A: cyclophilin interaction requires both the NS5A region identified by the resistance mutants and cyclophilin catalytic residues. In cell culture, NS5A from CsA resistant mutant has an enhanced interaction with cyclophilin B. Additionally; NS5B facilitates a stronger binding of mutant NS5A to endogenous cyclophilin B than wild-type in cell culture. Conclusions/Significance: Collectively, this data suggests direct interactions between cyclophilins and NS5A are critical to understand for optimal use of cyclophilin inhibitors in anti-HCV therapy. C1 [Fernandes, Fiona; Ansari, Israr-ul H.; Striker, Rob] Univ Wisconsin, Dept Med, Madison, WI USA. [Striker, Rob] Univ Wisconsin Hosp & Clin, William S Middleton Mem Vet Adm Hosp, Madison, WI 53792 USA. RP Fernandes, F (reprint author), SUNY Stony Brook, Dept Microbiol & Mol Genet, Stony Brook, NY 11794 USA. EM tstriker@wisc.edu FU American Cancer Society Research Scholar [07-077-01]; Office of Research and Development; Biomedical Laboratory R&D Service, Department of Veterans Affairs; University of Wisconsin Institute for Clinical and Translational Research; NIH Clinical and Translational Science [1UL1RR025011] FX This research was supported by the American Cancer Society Research Scholar Grant (07-077-01) to R. S., by the Office of Research and Development, Biomedical Laboratory R&D Service, Department of Veterans Affairs, and by the University of Wisconsin Institute for Clinical and Translational Research, funded through an NIH Clinical and Translational Science Award, grant number 1UL1RR025011. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 38 TC 57 Z9 57 U1 0 U2 1 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 23 PY 2010 VL 5 IS 3 AR e9815 DI 10.1371/journal.pone.0009815 PG 11 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 573FS UT WOS:000275894400017 PM 20352119 ER PT J AU Fishman, J Ten Have, T Casarett, D AF Fishman, Jessica Ten Have, Thomas Casarett, David TI Cancer and the Media How Does the News Report on Treatment and Outcomes? SO ARCHIVES OF INTERNAL MEDICINE LA English DT Review ID BREAST-CANCER; NURSING-HOMES; CARE; COVERAGE; LIFE; DEATH; PAIN; END; CREDIBILITY; MANAGEMENT AB Background: Cancer receives a great deal of news media attention. Although approximately half of all US patients with cancer die of their illness or of related complications, it is unknown whether reports in the news media reflect this reality. Methods: To determine how cancer news coverage repot-is about cancer care and outcornes, we conducted a content analysis of US cancer news reporting in 8 large-readership newspapers and 5 national magazines. Trained coders determined the proportion of articles reporting about cancer survival, cancer death and dying, aggressive cancer treatment, cancer treatment failure, adverse events of cancer treatment, and end-of-life palliative or hospice care. Results: Of 436 articles about cancer, 140 (32.1%; 95% confidence interval [CI], 28%-37%) focused Oil survival and only 33 (7.6 %; 5%-.1.0%) focused on death and dying (p<.001, chi(2) test). Only 57 articles (13.1%; 10%-17%) reported that aggressive cancer treatments can fail, and 131. (30.0%; 26%-35%) reported that aggressive treatments can result in adverse events. Although most articles (249 of 436 [57.1%]; 95% CI, 52%-62%) discussed aggressive treatments exclusively, almost none (2 of 436; [0.5%]; 0%-2%) discussed end-of-life palliative or hospice care exclusively (P <.001, chi(2) test), and only a few (11 of 436 [2.5%]; 1%-6%) discussed aggressive treatment, and end-of-life care. Conclusions: News reports about cancer frequently discuss aggressive treatment and survival but rarely discuss treatment failure, adverse events, end-of-life care, or death. These portrayals of cancer care in the news media may give patients an inappropriately optimistic view of cancer treatment, outcomes, and prognosis. C1 [Fishman, Jessica; Ten Have, Thomas] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Fishman, Jessica] Univ Penn, Annenberg Sch Commun, Philadelphia, PA 19104 USA. [Casarett, David] Univ Penn, VA Ctr Hlth Equ Res & Promot, Philadelphia, PA 19104 USA. [Casarett, David] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Fishman, Jessica; Ten Have, Thomas; Casarett, David] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. RP Fishman, J (reprint author), Univ Penn, Ctr Clin Epidemiol & Biostat, 711 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM fishman1@mail.med.upenn.edu FU NCI NIH HHS [P20 CA095856, 5P50CA095856-05] NR 49 TC 16 Z9 16 U1 1 U2 10 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD MAR 22 PY 2010 VL 170 IS 6 BP 515 EP 518 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA 571QB UT WOS:000275768400002 PM 20233800 ER PT J AU Slatore, CG Chien, JW Au, DH Satia, JA White, E AF Slatore, Christopher G. Chien, Jason W. Au, David H. Satia, Jessie A. White, Emily TI Lung Cancer and Hormone Replacement Therapy: Association in the Vitamins and Lifestyle Study SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID FOOD FREQUENCY QUESTIONNAIRE; GROWTH-FACTOR RECEPTOR; ESTROGEN-RECEPTOR; REPRODUCTIVE FACTORS; BETA-CAROTENE; WOMEN; RISK; SMOKING; COHORT; EPIDEMIOLOGY AB Purpose Lung cancer is the leading cause of cancer-related mortality among women. The role of hormone replacement therapy (HRT) in lung cancer development is unclear. Patients and Methods We evaluated a prospective cohort of 36,588 peri-and postmenopausal women aged 50 to 76 years from Washington State recruited in 2000 to 2002 (Vitamins and Lifestyle [VITAL] Study). Lung cancer cases (n = 344) were identified through the Seattle-Puget Sound Surveillance, Epidemiology, and End Results cancer registry during 6 years of follow-up. Hazard ratios (HRs) associated with use and duration of specific HRT formulations were calculated for total incident lung cancer, specific morphologies, and cancer by stage at diagnosis. Results After adjusting for smoking, age, and other potential confounders, there was an increased risk of incident lung cancer associated with increasing duration of estrogen plus progestin (E + P) use (HR = 1.27 for E + P use 1 to 9 years, 95% CI, 0.91 to 1.78; and HR = 1.48 for E + P use >= 10 years, 95% CI, 1.03 to 2.12; P for trend = . 03). There was no association with duration of unopposed estrogen use. Duration of E + P use was associated with an advanced stage at diagnosis (P for trend = .03). Conclusion Use of E + P increased the risk of incident lung cancer in a duration-dependent manner, with an approximate 50% increased risk for use of 10 years or longer. These findings may be helpful for informing women of their risk of developing lung cancer and delineating important pathways involved in hormone metabolism and lung cancer. C1 [Slatore, Christopher G.] Portland VA Med Ctr, Portland, OR 97239 USA. Oregon Hlth & Sci Univ, Div Pulm & Crit Care Med, Portland, OR 97201 USA. Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA. Fred Hutchinson Canc Res Ctr, Canc Prevent Program, Seattle, WA 98104 USA. Univ Washington, Div Pulm & Crit Care, Seattle, WA 98195 USA. Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA. Univ N Carolina, Dept Nutr, Chapel Hill, NC USA. Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA. RP Slatore, CG (reprint author), Portland VA Med Ctr, 3710 SW US Vet Hosp Rd,R&D 66, Portland, OR 97239 USA. EM slatore@ohsu.edu OI Slatore, Christopher/0000-0003-0958-8122 FU CHEST Foundation of the American College of Chest Physicians; LUNGevity Foundation; National Institutes of Health [CA130328, CA74846, CA96556, CA119683]; Department of Veterans Affairs; Portland Veterans Affairs Medical Center, Portland, OR; Veterans Affairs Puget Sound Health Care System, Seattle, WA FX Supported by the CHEST Foundation of the American College of Chest Physicians and the LUNGevity Foundation to C. G. S. This work was also supported by the National Institutes of Health (Grant No. CA130328 to C.G.S., CA74846 to E.W., and CA96556 and CA119683 to J.S.). C.G.S. and D.H.A. were supported by the Department of Veterans Affairs. This study is the result of work supported by resources from the Portland Veterans Affairs Medical Center, Portland, OR, and Veterans Affairs Puget Sound Health Care System, Seattle, WA. NR 49 TC 52 Z9 56 U1 0 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAR 20 PY 2010 VL 28 IS 9 BP 1540 EP 1546 DI 10.1200/JCO.2009.25.9739 PG 7 WC Oncology SC Oncology GA 572IR UT WOS:000275824600017 PM 20159813 ER PT J AU Sun, W Jin, JF Xu, RJ Hu, W Szulc, ZM Bielawski, J Obeid, LM Mao, CG AF Sun, Wei Jin, Junfei Xu, Ruijuan Hu, Wei Szulc, Zdzislaw M. Bielawski, Jacek Obeid, Lina M. Mao, Cungui TI Substrate Specificity, Membrane Topology, and Activity Regulation of Human Alkaline Ceramidase 2 (ACER2) SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID PERFORMANCE LIQUID-CHROMATOGRAPHY; MITOCHONDRIAL CERAMIDASE; SACCHAROMYCES-CEREVISIAE; MOLECULAR-CLONING; ACID CERAMIDASE; GOLGI-APPARATUS; SPHINGOSINE; DISEASE; ENZYME; CELLS AB Human alkaline ceramidase 2 (ACER2) plays an important role in cellular responses by regulating the hydrolysis of ceramides in cells. Here we report its biochemical characterization, membrane topology, and activity regulation. Recombinant ACER2 was expressed in yeast mutant cells (Delta ypc1 Delta ydc1) that lack endogenous ceramidase activity, and microsomes from ACER2-expressiong yeast cells were used to biochemically characterize ACER2. ACER2 catalyzed the hydrolysis of various ceramides and followed Michaelis-Menten kinetics. ACER2 required Ca(2+) for both its in vitro and cellular activities. ACER2 has 7 putative transmembrane domains, and its amino (N) and carboxyl (C) termini were found to be oriented in the lumen of the Golgi complex and cytosol, respectively. ACER2 mutant (ACER2 Delta N36) lacking the N-terminal tail (the first 36 amino acid residues) exhibited undetectable activity and was mislocalized to the endoplasmic reticulum, suggesting that the N-terminal tail is necessary for both ACER2 activity and Golgi localization. ACER2 mutant (ACER2 Delta N13) lacking the first 13 residues was also mislocalized to the endoplasmic reticulum although it retained ceramidase activity. Overexpression of ACER2, ACER2 Delta N13, but not ACER2 Delta N36 increased the release of sphingosine 1-phosphate from cells, suggesting that its mislocalization does not affect the ability of ACER2 to regulate sphingosine 1-phosphate secretion. However, overexpression of ACER2 but not ACER2 Delta N13 or ACER2 Delta N36 inhibited the glycosylation of integrin beta 1 subunit and Lamp1, suggesting that its mistargeting abolishes the ability of ACER2 to regulation protein glycosylation. These data suggest that ACER2 has broad substrate specificity and requires Ca(2+) for its activity and that ACER2 has the cytosolic C terminus and luminal N terminus, which are essential for its activity, correct cellular localization, and regulation for protein glycosylation. C1 [Sun, Wei; Jin, Junfei; Xu, Ruijuan; Hu, Wei; Obeid, Lina M.; Mao, Cungui] Med Univ S Carolina, Dept Med, Div Gen Internal Med, Charleston, SC 29425 USA. [Szulc, Zdzislaw M.; Bielawski, Jacek; Obeid, Lina M.; Mao, Cungui] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. [Obeid, Lina M.] Med Univ S Carolina, Ralph H Johnson Vet Affairs Hosp, Charleston, SC 29425 USA. RP Mao, CG (reprint author), Med Univ S Carolina, Dept Med, Div Gen Internal Med, 114 Doughty St,Rm 646,STB,POB 250779, Charleston, SC 29425 USA. EM maoc@musc.edu OI obeid, lina/0000-0002-0734-0847 FU National Institutes of Health [R01CA104834]; Veterans Affairs Merit award FX This work was supported, in whole or in part, by National Institutes of Health Grant R01CA104834 (to C. M.) and a Veterans Affairs Merit award (to L.M.O.). NR 27 TC 22 Z9 25 U1 0 U2 2 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD MAR 19 PY 2010 VL 285 IS 12 BP 8995 EP 9007 DI 10.1074/jbc.M109.069203 PG 13 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 568VZ UT WOS:000275553700051 PM 20089856 ER PT J AU Kim, SH Fraser, PE Westaway, D George-Hyslop, PHS Ehrlich, ME Gandy, S AF Kim, Soong Ho Fraser, Paul E. Westaway, David George-Hyslop, Peter H. St. Ehrlich, Michelle E. Gandy, Sam TI Group II Metabotropic Glutamate Receptor Stimulation Triggers Production and Release of Alzheimer's Amyloid beta(42) from Isolated Intact Nerve Terminals SO JOURNAL OF NEUROSCIENCE LA English DT Article ID LONG-TERM POTENTIATION; PRECURSOR PROTEIN; TRANSGENIC MICE; IN-VIVO; SYNAPTIC PLASTICITY; CEREBRAL-CORTEX; DISEASE; ACTIVATION; PEPTIDE; KINASE AB Aberrant accumulation of amyloid beta (A beta) oligomers may underlie the cognitive failure of Alzheimer's disease (AD). All species of A beta peptides are produced physiologically during normal brain activity. Therefore, elucidation of mechanisms that interconnect excitatory glutamatergic neurotransmission, synaptic amyloid precursor protein (APP) processing and production of its metabolite, A beta, may reveal synapse-specific strategies for suppressing the pathological accumulation of A beta oligomers and fibrils that characterize AD. To study synaptic APP processing, we used isolated intact nerve terminals (cortical synaptoneurosomes) from TgCRND8 mice, which express a human APP with familial AD mutations. Potassium chloride depolarization caused sustained release from synaptoneurosomes of A beta(42) as well as A beta(40), and appeared to coactivate alpha-, beta-and gamma-secretases, which are known to generate a family of released peptides, including A beta(40) and A beta(42). Stimulation of postsynaptic group I metabotropic glutamate receptor (mGluRs) with DHPG (3,5-dihydroxyphenylglycine) induced a rapid accumulation of APP C-terminal fragments (CTFs) in the synaptoneurosomes, a family of membrane-bound intermediates generated from APP metabolized by alpha- and beta-secretases. Following stimulation with the group II mGluR agonist DCG-IV, levels of APP CTFs in the synaptoneurosomes initially increased but then returned to baseline by 10 min after stimulation. This APP CTF degradation phase was accompanied by sustained accumulation of A beta(42) in the releasate, which was blocked by the group IImGluR antagonist LY341495. These data suggest that group IImGluR may trigger synaptic activation of all three secretases and that suppression of group II mGluR signaling may be a therapeutic strategy for selectively reducing synaptic generation of A beta(42). C1 [Kim, Soong Ho; Ehrlich, Michelle E.; Gandy, Sam] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA. [Gandy, Sam] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. [Ehrlich, Michelle E.] Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA. [Fraser, Paul E.; George-Hyslop, Peter H. St.] Univ Toronto, Ctr Res Neurodegenerat Dis, Dept Med Biophys, Toronto, ON M5S 1A1, Canada. [Fraser, Paul E.; George-Hyslop, Peter H. St.] Univ Toronto, Ctr Res Neurodegenerat Dis, Dept Med Neurol, Toronto, ON M5S 1A1, Canada. [Westaway, David] Univ Alberta, Ctr Prions & Prot Folding Dis, Edmonton, AB T6G 2M8, Canada. [George-Hyslop, Peter H. St.] Univ Cambridge, Dept Clin Neurosci, Cambridge CB2 0XY, England. [Gandy, Sam] James J Peters Vet Affairs Med Ctr, Bronx, NY 10468 USA. RP Gandy, S (reprint author), Mt Sinai Sch Med, Dept Neurol, 1 Gustave L Levy Pl,Box 1137, New York, NY 10029 USA. EM samuel.gandy@mssm.edu FU National Institutes of Health [AG10491]; Cure Alzheimer's Fund; Canadian Institutes of Health Research; Alzheimer Society of Ontario; Alberta Prion Research Institute; Canada Foundation for Innovation; Howard Hughes Medical Institute; Wellcome Trust FX This work was supported by National Institutes of Health Grant AG10491, Cure Alzheimer's Fund, Canadian Institutes of Health Research, the Alzheimer Society of Ontario, the Alberta Prion Research Institute, the Canada Foundation for Innovation, Howard Hughes Medical Institute, and The Wellcome Trust. We thank Loren Khan-Vaughan and Justine Bonet for assistance with mouse colony management. NR 51 TC 45 Z9 46 U1 0 U2 3 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD MAR 17 PY 2010 VL 30 IS 11 BP 3870 EP 3875 DI 10.1523/JNEUROSCI.4717-09.2010 PG 6 WC Neurosciences SC Neurosciences & Neurology GA 571BT UT WOS:000275724800003 PM 20237257 ER PT J AU Halpern, SD Raz, A Kohn, R Rey, M Asch, DA Reese, P AF Halpern, Scott D. Raz, Amelie Kohn, Rachel Rey, Michael Asch, David A. Reese, Peter TI Regulated Payments for Living Kidney Donation: An Empirical Assessment of the Ethical Concerns SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID ORGAN DONATION; CONJOINT-ANALYSIS; HEALTH-CARE; CONFIDENCE-INTERVALS; COST-EFFECTIVENESS; CLINICAL-TRIALS; DONORS; INCENTIVES; TRANSPLANTATION; CONSEQUENCES AB Background: Although regulated payments to encourage living kidney donation could reduce morbidity and mortality among patients waiting for a kidney transplant, doing so raises several ethical concerns. Objective: To determine the extent to which the 3 main concerns with paying kidney donors might manifest if a regulated market were created. Design: Cross-sectional study of participants' willingness to donate a kidney in 12 scenarios. Setting: Regional rail and urban trolley lines in Philadelphia County, Philadelphia, Pennsylvania. Participants: Of 550 potential participants, 409 completed the questionnaire (response rate, 74.4%); 342 of these participants were medically eligible to donate. Intervention: Across scenarios, researchers experimentally manipulated the amount of money that participants would receive, the participants' risk for subsequently developing kidney failure themselves, and who would receive the donated kidney. Measurements: The researchers determined whether payment represents an undue inducement by evaluating participants' sensitivity to risk in relation to the payment offered or an unjust inducement by evaluating participants' sensitivity to payment as a function of their annual income. The researchers also evaluated whether introducing payment would hinder altruistic donations by comparing participants' willingness to donate altruistically before versus after the introduction of payments. Results: Generalized estimating equation models revealed that participants' willingness to donate increased significantly as their risk for kidney failure decreased, as the payment offered increased, and when the kidney recipient was a family member rather than a patient on a public waiting list (P < 0.001 for each). No statistical interactions were identified between payment and risk (odds ratio, 1.00 [95% CI, 0.96 to 1.03]) or between payment and income (odds ratio, 1.01 [CI, 0.99 to 1.03]). The proximity of these estimates to 1.0 and narrowness of the CIs suggest that payment is neither an undue nor an unjust inducement, respectively. Alerting participants to the possibility of payment did not alter their willingness to donate for altruistic reasons (P = 0.40). Limitation: Choices revealed in hypothetical scenarios may not reflect real-world behaviors. Conclusion: Theoretical concerns about paying persons for living kidney donation are not corroborated by empirical evidence. A real-world test of regulated payments for kidney donation is needed to definitively show whether payment provides a viable and ethical method to increase the supply of kidneys available for transplantation. C1 [Halpern, Scott D.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Halpern, SD (reprint author), Univ Penn, Sch Med, 724 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM scott.halpern@uphs.upenn.edu OI Asch, David/0000-0002-7970-286X FU Greenwall Foundation Faculty Scholar Award in Bioethics; National Institutes of Health [K23-078688-01]; University of Pennsylvania Center for Bioethics FX By a Greenwall Foundation Faculty Scholar Award in Bioethics (Dr. Halpern), the National Institutes of Health (Dr. Reese; grant K23-078688-01), and internships from the University of Pennsylvania Center for Bioethics (Ms. Raz, Ms. Kohn, and Mr. Rey). NR 43 TC 28 Z9 28 U1 1 U2 11 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD MAR 16 PY 2010 VL 152 IS 6 BP 358 EP + DI 10.7326/0003-4819-152-6-201003160-00005 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA 573IF UT WOS:000275905200003 PM 20231566 ER PT J AU Westreich, D Cole, SR Tien, PC Chmiel, JS Kingsley, L Funk, MJ Anastos, K Jacobson, LP AF Westreich, Daniel Cole, Stephen R. Tien, Phyllis C. Chmiel, Joan S. Kingsley, Lawrence Funk, Michele Jonsson Anastos, Kathryn Jacobson, Lisa P. TI Time Scale and Adjusted Survival Curves for Marginal Structural Cox Models SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Article DE acquired immunodeficiency syndrome; antiretroviral therapy; highly active; bias (epidemiology); causal inference; confounding factors (epidemiology); proportional hazards model; survival curve; survival time ID ACTIVE ANTIRETROVIRAL THERAPY; HUMAN-IMMUNODEFICIENCY-VIRUS; INVERSE PROBABILITY WEIGHTS; LOGISTIC-REGRESSION; CAUSAL INFERENCE; HIV; AIDS; MORTALITY; CHOICE; DEATH AB Typical applications of marginal structural time-to-event (e.g., Cox) models have used time on study as the time scale. Here, the authors illustrate use of time on treatment as an alternative time scale. In addition, a method is provided for estimating Kaplan-Meier-type survival curves for marginal structural models. For illustration, the authors estimate the total effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome (AIDS) or death in 1,498 US men and women infected with human immunodeficiency virus and followed for 6,556 person-years between 1995 and 2002; 323 incident cases of clinical AIDS and 59 deaths occurred. Of the remaining 1,116 participants, 77% were still under observation at the end of follow-up. By using time on study, the hazard ratio for AIDS or death comparing always with never using highly active antiretroviral therapy from the marginal structural model was 0.52 (95% confidence interval: 0.35, 0.76). By using time on treatment, the analogous hazard ratio was 0.44 (95% confidence interval: 0.32, 0.60). In time-to-event analyses, the choice of time scale may have a meaningful impact on estimates of association and precision. In the present example, use of time on treatment yielded a hazard ratio further from the null and more precise than use of time on study as the time scale. C1 [Westreich, Daniel; Cole, Stephen R.; Funk, Michele Jonsson] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA. [Tien, Phyllis C.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Tien, Phyllis C.] San Francisco VA Med Ctr, San Francisco, CA USA. [Chmiel, Joan S.] Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Chicago, IL 60611 USA. [Kingsley, Lawrence] Univ Pittsburgh, Dept Infect Dis & Microbiol, Pittsburgh, PA USA. [Anastos, Kathryn] Montefiore Med Ctr, Bronx, NY 10467 USA. [Anastos, Kathryn] Albert Einstein Coll Med, Bronx, NY 10467 USA. [Jacobson, Lisa P.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. RP Cole, SR (reprint author), McGavran Greenberg Hall,CB7435, Chapel Hill, NC 27599 USA. EM cole@unc.edu RI Jonsson Funk, Michele/F-6885-2011 OI Jonsson Funk, Michele/0000-0002-3756-7540 FU National Institute of Allergy and Infectious Diseases, National Institutes of Health [T32-AI-07001, R03-AI-071763, R01-AA-01759, UO1-AI-35004, UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UO1-AI-34993, UO1-AI-42590]; National Cancer Institute; National Heart, Lung, and Blood Institute [UO1-AI-35042, 5-MO1-RR-00722, UO1-AI-35043, UO1-AI-37984, UO1-AI-35039, UO1-AI-35040, UO1-AI-37613, UO1-AI-35041]; National Institute of Child Health and Human Development [UO1-HD-32632]; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Center for Research Resources [UL1 RR024131] FX This work was supported by the National Institute of Allergy and Infectious Diseases, National Institutes of Health (grant T32-AI-07001 to D. W.; R03-AI-071763 and R01-AA-01759 to S. R. C.). Data in this article were collected by the Multicenter AIDS Cohort Study (MACS) funded by the National Institute of Allergy and Infectious Diseases, with additional supplemental funding from the National Cancer Institute and the National Heart, Lung, and Blood Institute (UO1-AI-35042, 5-MO1-RR-00722 (GCRC), UO1-AI-35043, UO1-AI-37984, UO1-AI-35039, UO1-AI-35040, UO1-AI-37613, UO1-AI-35041). Data in this article were also collected by the Women's Interagency HIV Study Collaborative Study Group funded by the National Institute of Allergy and Infectious Diseases (UO1-AI-35004, UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UO1-AI-34993, and UO1-AI-42590) and by the National Institute of Child Health and Human Development (UO1-HD-32632). The Women's Interagency HIV Study is jointly funded by the National Cancer Institute, the National Institute on Drug Abuse, and the National Institute on Deafness and Other Communication Disorders. Funding is also provided by the National Center for Research Resources (UCSF-CTSI grant UL1 RR024131). NR 41 TC 26 Z9 26 U1 0 U2 8 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD MAR 15 PY 2010 VL 171 IS 6 BP 691 EP 700 DI 10.1093/aje/kwp418 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 568ZJ UT WOS:000275565100009 PM 20139124 ER PT J AU Mularski, RA Campbell, ML Asch, SM Reeve, BB Basch, E Maxwell, TL Hoverman, JR Cuny, J Clauser, SB Snyder, C Seow, H Wu, AW Dy, S AF Mularski, Richard A. Campbell, Margaret L. Asch, Steven M. Reeve, Bryce B. Basch, Ethan Maxwell, Terri L. Hoverman, J. Russell Cuny, Joanne Clauser, Steve B. Snyder, Claire Seow, Hsien Wu, Albert W. Dy, Sydney TI A Review of Quality of Care Evaluation for the Palliation of Dyspnea SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Article DE dyspnea; quality of health care; quality indicators; health care; assessment ID CLINICAL METHODS; LIFE CARE; DISEASE; BREATHLESSNESS; QUESTIONNAIRE; END; INDICATORS; CANCER; DESCRIPTORS; SHORTNESS AB Assessment and management of dyspnea has emerged as a priority topic for quality evaluation and improvement. Evaluating dyspnea quality of care requires valid, reliable, and responsive measures of the care provided to patients across settings and diseases. As part of an Agency for Healthcare Research and Quality Symposium, we reviewed quality of care measures for dyspnea by compiling quality measures identified in systematic searches and reviews. Systematic reviews identified only three existing quality measurement sets that included quality measures for dyspnea care. The existing dyspnea quality measures reported by retrospective evaluations of care assess only four aspects: dyspnea assessment within 48 hours of hospital admission, use of objective scales to rate dyspnea severity, identification of management plans, and evidence of dyspnea reduction. To begin to improve care, clinicians need to assess and regularly document patient's experiences of dyspnea. There is no consensus on how dyspnea should be characterized for quality measurement, and although over 40 tools exist to assess dyspnea, no rating scale or instrument is ideal for palliative care. The panel recommended that dyspnea assessment should include a measure of intensity and some inquiry into the associated bother or distress experienced by the patient. A simple question into the presence or absence of dyspnea would be unlikely to help guide therapy, as complete relief of dyspnea in advanced disease would not be anticipated. Additional knowledge gaps include standards for clinical dyspnea care, assessment in the cognitively impaired, and evaluation of effectiveness of dyspnea care for patients with advanced disease. C1 [Mularski, Richard A.] Oregon Hlth & Sci Univ, Ctr Hlth Res, Portland, OR 97227 USA. [Campbell, Margaret L.] Wayne State Univ, Detroit Receiving Hosp Ctr Hlth Res, Detroit, MI USA. [Asch, Steven M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90095 USA. [Reeve, Bryce B.; Clauser, Steve B.] NCI, Outcomes Res Branch, Appl Res Program, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA. [Basch, Ethan] Mem Sloan Kettering Canc Ctr, Hlth Outcomes Grp, New York, NY 10021 USA. [Maxwell, Terri L.] ExcelleRx Inc, Philadelphia, PA USA. [Hoverman, J. Russell] Texas Oncol, Dallas, TX USA. [Cuny, Joanne] Univ HealthSyst Consortium, Oak Brook, IL USA. [Snyder, Claire; Dy, Sydney] Johns Hopkins Sch Publ Hlth, Dept Hlth Policy & Management, Johns Hopkins Sch Med, Div Gen Internal Med, Baltimore, MD USA. [Seow, Hsien] McMaster Univ, Dept Oncol, Hamilton, ON, Canada. RP Mularski, RA (reprint author), Oregon Hlth & Sci Univ, Ctr Hlth Res, 3800 N Interstate,WIN 1060, Portland, OR 97227 USA. EM Richard.A.Mularski@kpchr.org OI Campbell, Margaret/0000-0003-4517-690X FU Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services [290-2005-00341]; Spiration, Inc.; Novartis; Amgen; Wyeth Pharmaceuticals; United Healthcare FX Supported by Contract No. 290-2005-00341 from the Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services as part of the Developing Evidence to Inform Decisions about Effectiveness (DEcIDE) program. The Symposium on Developing a Framework to Assess Cancer Quality Indicators for End-of-Life Care was held in Baltimore, MD on April 28, 2008. The authors of this manuscript are responsible for its content. Statements in the manuscript should not be construed as endorsement by the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services.; R.A.M. received 850,001-$100,000 from Spiration, Inc., and 850,001-8100,001 from Novartis in industry-sponsored grants. M.L.C. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. S.M.A. received more than 8100,001 from Amgen in grants. B.B.R. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. E.B. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. T.L.M. is a full-time employee of excelleRx, Inc., and received S10,001-850,000 from Wyeth Pharmaceuticals in industry-sponsored grants for database analysis related to constipation prevalence at the end of life. J.R.H. received $1,001-85,000 from United Healthcare in advisory board fees. j.C. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. S.B.C. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. C.S. does not have a financial relationship with a commercial I. entity that has an interest in the subject of this manuscript. H.S. does not NR 50 TC 20 Z9 20 U1 2 U2 4 PU AMER THORACIC SOC PI NEW YORK PA 1740 BROADWAY, NEW YORK, NY 10019-4374 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD MAR 15 PY 2010 VL 181 IS 6 BP 534 EP 538 DI 10.1164/rccm.200903-0462PP PG 5 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 632RX UT WOS:000280446500005 PM 20056904 ER PT J AU El Jamali, A Valente, AJ Clark, RA AF El Jamali, Amina Valente, Anthony J. Clark, Robert A. TI Regulation of phagocyte NADPH oxidase by hydrogen peroxide through a Ca2+/c-Abl signaling pathway SO FREE RADICAL BIOLOGY AND MEDICINE LA English DT Article DE NADPH oxidase; NOX2; Neutrophil; Superoxide; Hydrogen peroxide; Signaling; c-Abl, Calcium; Free radicals ID ABL TYROSINE KINASE; NEUTROPHIL RESPIRATORY BURST; SMOOTH-MUSCLE-CELLS; C-DELTA; OXIDATIVE STRESS; GROWTH-FACTOR; HEMATOPOIETIC-CELLS; CALCIUM IONOPHORE; HUMAN MONOCYTES; MYC EXPRESSION AB The importance of H2O2 as a cellular signaling molecule has been demonstrated in a number of cell types and pathways. Here we explore a positive feedback mechanism of H2O2-mediated regulation of the phagocyte respiratory burst NADPH oxidase (NOX2). H2O2 induced a dose-dependent stimulation of superoxide production in human neutrophils, as well as in K562 leukemia cells overexpressing NOX2 system components. Stimulation was abrogated by the addition of catalase, the extracellular Ca2+ chelator BAPTA, the T-type Ca2+ channel inhibitor mibefradil, the PKC delta inhibitor rottlerin, or the c-Abl nonreceptor tyrosine kinase inhibitor imatinib mesylate or by overexpression of a dominant-negative form of c-Abl. H2O2 induced phosphorylation of tyrosine 311 on PKC delta and this activating phosphorylation was blocked by treatment with rottlerin, imatinib mesylate, or BAPTA. Rac GTPase activation in response to H2O2 was abrogated by BAPTA, imatinib mesylate, or rottlerin. In conclusion, H2O2 stimulates NOX2-mediated superoxide generation in neutrophils and K562/NOX2 cells via a signaling pathway involving Ca2+ influx and c-Abl tyrosine kinase acting upstream of PKC delta. This positive feedback regulatory pathway has important implications for amplifying the innate immune response and contributing to oxidative stress in inflammatory disorders. (c) 2009 Elsevier Inc. All rights reserved. C1 [El Jamali, Amina] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX 78229 USA. RP El Jamali, A (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. EM AkoulouzeBik@uthscsa.edu FU National Institutes of Health [R01-Al020866, T32 HL07446, P30-CA054174, P30-AG013319, P01-AG019316]; Department of Veterans Affairs FX This work was supported by grants from the National Institutes of Health (R01-Al020866 and T32 HL07446) and the Department of Veterans Affairs. The confocal microscopy studies were performed in the University of Texas Health Science Center Institutional Optical Imaging Facility, which is supported by NIH Grants P30-CA054174 (Cancer Therapy and Research Center), P30-AG013319 (Nathan Shock Center), and P01-AG019316 (Aging, Oxidative Stress and Cell Death). The authors thank Alain Virion and Yves Gorin for helpful discussion and critical review of the manuscript, Victoria Frohlich for expert guidance on the confocal microscope image acquisition and analysis, John Cornell for insightful advice on statistical analysis, and Maria Gamez and Doran Pearson for expert technical assistance. Dr. Clark is a scientific cofounder member of the Scientific Advisory Board and equity holder in GenKyoTex SA, a Swiss biotechnology start-up company with a primary goal of developing clinically useful inhibitors of the NOX family of NADPH oxidases. No other competing financial interests exist. NR 62 TC 19 Z9 19 U1 1 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0891-5849 J9 FREE RADICAL BIO MED JI Free Radic. Biol. Med. PD MAR 15 PY 2010 VL 48 IS 6 BP 798 EP 810 DI 10.1016/j.freeradbiomed.2009.12.018 PG 13 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA 561WS UT WOS:000275011400006 PM 20043988 ER PT J AU Zolopa, AR Berger, DS Lampiris, H Zhong, LJ Chuck, SL Enejosa, JV Kearney, BP Cheng, AK AF Zolopa, Andrew R. Berger, Daniel S. Lampiris, Harry Zhong, Lijie Chuck, Steven L. Enejosa, Jeffrey V. Kearney, Brian P. Cheng, Andrew K. TI Activity of Elvitegravir, a Once-Daily Integrase Inhibitor, against Resistant HIV Type 1: Results of a Phase 2, Randomized, Controlled, Dose-Ranging Clinical Trial SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID IMMUNODEFICIENCY-VIRUS TYPE-1; EXPERIENCED HIV-1-INFECTED PATIENTS; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; TMC125 ETRAVIRINE; RALTEGRAVIR; INFECTION; EFFICACY; SAFETY; RITONAVIR AB Background. This phase 2, randomized, active-controlled, 48-week study assessed the noninferiority of the human immunodeficiency virus (HIV) integrase inhibitor elvitegravir to comparator ritonavir-boosted protease inhibitor (CPI/r) in treatment-experienced subjects. Methods. Subjects had HIV RNA levels >= 1000 copies/mL and >= 1 protease resistance mutation. Subjects received nucleoside or nucleotide reverse-transcriptase inhibitors (NRTIs) with or without T-20 and either CPI/r or once- daily elvitegravir at a dose of 20 mg, 50 mg, or 125 mg (blinded to dose) with ritonavir. After week 8, the independent data monitoring committee stopped the elvitegravir 20 mg arm and allowed subjects in the elvitegravir 50 mg and 125 mg arms to add protease inhibitors. The primary end point was the time-weighted average change from baseline in HIV RNA level through week 24 (DAVG(24)). Results. A total of 278 subjects with a median of 11 protease and 3 thymidine analog mutations were randomized and treated. One-half of subjects received NRTIs without expected antiviral activity. Compared with the DAVG(24) for the CPI/r arm (-1.19 log(10) copies/mL), the elvitegravir 50 mg arm was noninferior (-1.44 log(10) copies/mL), and the elvitegravir 125 mg arm was superior (-1.66 log(10) copies/mL; P = . 021). Efficacy was impacted by activity of background agents. There was no relationship between elvitegravir dosage and adverse events. Conclusions. Elvitegravir was well-tolerated and produced rapid virologic suppression that was durable with active background therapy. C1 [Zolopa, Andrew R.] Stanford Univ, Div Infect Dis & Geog Med, Stanford, CA 94305 USA. [Lampiris, Harry] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Lampiris, Harry] San Francisco VA Med Ctr, San Francisco, CA USA. [Zhong, Lijie; Chuck, Steven L.; Enejosa, Jeffrey V.; Kearney, Brian P.; Cheng, Andrew K.] Gilead Sci Inc, Foster City, CA 94404 USA. [Berger, Daniel S.] Northstar Med Ctr, Chicago, IL USA. RP Zolopa, AR (reprint author), Stanford Univ, Div Infect Dis & Geog Med, 300 Pasteur Dr,Rm S-156,Grant Bldg, Stanford, CA 94305 USA. EM azolopa@stanford.edu FU Gilead Sciences FX Potential conflicts of interest: A.Z. has received grant support from Gilead Sciences and is on the National Advisory Board for Gilead Sciences; D.B. has received compensation for conducting clinical trials sponsored by Gilead Sciences and is a stockholder; H.L. has received grant support from Gilead Sciences; L.Z., S.C., J.E., B.K., and A.C. are employees and stockholders of Gilead Sciences.; Financial support: Gilead Sciences. NR 14 TC 80 Z9 81 U1 0 U2 4 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD MAR 15 PY 2010 VL 201 IS 6 BP 814 EP 822 DI 10.1086/650698 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 557JH UT WOS:000274664900004 PM 20146631 ER PT J AU Kovacs, A Karim, R Mack, WJ Xu, JA Chen, Z Operskalski, E Frederick, T Landay, A Voris, J Spencer, L Young, MA Tien, PC Augenbraun, M Strickler, HD Al-Harthi, L AF Kovacs, Andrea Karim, Roksana Mack, Wendy J. Xu, Jiaao Chen, Zhi Operskalski, Eva Frederick, Toni Landay, Alan Voris, John Spencer, La Shonda Young, Mary A. Tien, Phyllis C. Augenbraun, Michael Strickler, Howard D. Al-Harthi, Lena TI Activation of CD8 T Cells Predicts Progression of HIV Infection in Women Coinfected with Hepatitis C Virus SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY; CENTRAL-NERVOUS-SYSTEM; IMMUNE ACTIVATION; DISEASE PROGRESSION; MICROBIAL TRANSLOCATION; LYMPHOCYTE-ACTIVATION; CLINICAL PROGRESSION; BACTERIAL PNEUMONIA; VIRAL LOAD AB Background. Because activation of T cells is associated with human immunodeficiency virus (HIV) pathogenesis, CD4 and CD8 activation levels in patients coinfected with HIV and hepatitis C virus (HCV) may explain conflicting reports regarding effects of HCV on HIV disease progression. Methods. Kaplan-Meier and multivariate Cox regression models were used to study the risk of incident clinical AIDS and AIDS-related deaths among 813 HCV-negative women with HIV infection, 87 HCV-positive nonviremic women with HIV coinfection, and 407 HCV-positive viremic women with HIV coinfection (median follow-up time, 5.2 years). For 592 women, the percentages of activated CD4 and CD8 T cells expressing HLA-DR (DR) and/or CD38 were evaluated. Results. HCV-positive viremic women had a statistically significantly higher percentage of activated CD8 T cells (P<.001) and a statistically significantly higher incidence of AIDS compared with HCV-negative women (P<.001 [log-rank test]). The AIDS risk was greater among HCV-positive viremic women in the highest tertile compared with the lowest tertile (>43% vs <26%) of CD8(+)CD38(+)DR(+) T cells (hazard ratio, 2.94 [95% confidence interval, 1.50-5.77]; P<.001). This difference was not observed in the HCV-negative women (hazard ratio, 1.87 [95% confidence interval, 0.80-4.35]; P = .16). In contrast, CD4 activation predicted AIDS in both groups similarly. Increased percentages of CD8(+)CD38(-)DR(+), CD4(+)CD38(-)DR(-), and CD8(+)CD38(-)DR(-) T cells were associated with a 160% decreased risk of AIDS for HCV-positive viremic women and HCV-negative women. Conclusion. HCV-positive viremic women with HIV coinfection who have high levels of T cell activation may have increased risk of AIDS. Earlier treatment of HIV and HCV infection may be beneficial. C1 [Kovacs, Andrea] Univ So Calif, Maternal Child & Adolescent Ctr Infect Dis & Viro, Keck Sch Med, HRA 300, Los Angeles, CA 90033 USA. [Karim, Roksana; Mack, Wendy J.] Univ So Calif, Dept Prevent Med, Keck Sch Med, Los Angeles, CA 90033 USA. [Tien, Phyllis C.; Al-Harthi, Lena] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Tien, Phyllis C.; Al-Harthi, Lena] San Francisco VA Med Ctr, San Francisco, CA USA. [Landay, Alan; Voris, John] Rush Univ, Dept Immunol & Microbiol, Med Ctr, Chicago, IL 60612 USA. [Young, Mary A.] Georgetown Univ, Div Infect Dis, Washington, DC USA. [Augenbraun, Michael] Suny Downstate Coll Med, Dept Med, Brooklyn, NY USA. [Strickler, Howard D.] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA. RP Kovacs, A (reprint author), Univ So Calif, Maternal Child & Adolescent Ctr Infect Dis & Viro, Keck Sch Med, HRA 300, 1640 Marengo St, Los Angeles, CA 90033 USA. EM akovacs@usc.edu FU National Institute of Allergy and Infectious Diseases [R01-A1052065-04, R01-AI057006]; Eunice Kennedy Shriver National Institute of Child Health and Human Development [U01-HD-32632]; National Cancer Institute; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Center for Research Resources [UL1 RR024131]; [U01-AI-35004]; [U01-AI-31834]; [U01-AI-34994]; [U01-AI-34989]; [U01-AI-34993]; [U01-AI-42590]; [K23 AI-66943] FX Financial support: National Institute of Allergy and Infectious Diseases (grant R01-A1052065-04 to A. K.; grant R01-AI057006 to H. S.; grants U01-AI-35004, U01-AI-31834, U01-AI-34994, U01-AI-34989, U01-AI-34993, and U01-AI-42590 to the Women's Interagency HIV Study [WIHS]; and grant K23 AI-66943 to P. C. T.); Eunice Kennedy Shriver National Institute of Child Health and Human Development (grant U01-HD-32632 to the WIHS); National Cancer Institute; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Center for Research Resources (UCSF-CTSI grant UL1 RR024131). NR 50 TC 48 Z9 50 U1 0 U2 1 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD MAR 15 PY 2010 VL 201 IS 6 BP 823 EP 834 DI 10.1086/650997 PG 12 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 557JH UT WOS:000274664900005 PM 20151840 ER PT J AU Kennerson, ML Nicholson, GA Kaler, SG Kowalski, B Mercer, JFB Tang, JR Llanos, RM Chu, SN Takata, RI Speck-Martins, CE Baets, J Almeida-Souza, L Fischer, D Timmerman, V Taylor, PE Scherer, SS Ferguson, TA Bird, TD De Jonghe, P Feely, SME Shy, ME Garbern, JY AF Kennerson, Marina L. Nicholson, Garth A. Kaler, Stephen G. Kowalski, Bartosz Mercer, Julian F. B. Tang, Jingrong Llanos, Roxana M. Chu, Shannon Takata, Reinaldo I. Speck-Martins, Carlos E. Baets, Jonathan Almeida-Souza, Leonardo Fischer, Dirk Timmerman, Vincent Taylor, Philip E. Scherer, Steven S. Ferguson, Toby A. Bird, Thomas D. De Jonghe, Peter Feely, Shawna M. E. Shy, Michael E. Garbern, James Y. TI Missense Mutations in the Copper Transporter Gene ATP7A Cause X-Linked Distal Hereditary Motor Neuropathy SO AMERICAN JOURNAL OF HUMAN GENETICS LA English DT Article ID SPINAL MUSCULAR-ATROPHY; OCCIPITAL-HORN-SYNDROME; MARIE-TOOTH-DISEASE; MENKES-DISEASE; NEURON DISEASE; CANDIDATE GENE; DEFICIENCY MYELONEUROPATHY; WILSON-DISEASE; PROTEIN; TRAFFICKING AB Distal hereditary motor neuropathies comprise a clinically and genetically heterogeneous group of disorders. We recently mapped an X-linked form of this condition to chromosome Xq13.1-q21 in two large unrelated families. The region of genetic linkage included ATP7A, which encodes a copper-transporting P-type ATPase mutated in patients with Menkes disease, a severe infantile-onset neurodegenerative condition. We identified two unique ATP7A missense mutations (p.P1386S and p.T9941) in males with distal motor neuropathy in two families. These molecular alterations impact highly conserved amino acids in the carboxyl half of ATP7A and do not directly involve the copper transporter's known critical functional domains. Studies of p.P1386S revealed normal ATP7A mRNA and protein levels, a defect in ATP7A trafficking, and partial rescue of a S. cerevisiae copper transport knockout. Although ATP7A mutations are typically associated with severe Menkes disease or its milder allelic variant, occipital horn syndrome, we demonstrate here that certain missense mutations at this locus can cause a syndrome restricted to progressive distal motor neuropathy without overt signs of systemic copper deficiency. This previously unrecognized genotype-phenotype correlation suggests an important role of the ATP7A copper transporter in motor-neuron maintenance and function. C1 [Kennerson, Marina L.; Nicholson, Garth A.; Kowalski, Bartosz; Chu, Shannon] Univ Sydney, ANZAC Res Inst, Northcott Neurosci Lab, Concord, Australia. [Kennerson, Marina L.; Nicholson, Garth A.] Concord Hosp, Mol Med Lab, Concord, Australia. [Kaler, Stephen G.; Tang, Jingrong] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Unit Human Copper Metab, Program Mol Med, NIH, Bethesda, MD USA. [Mercer, Julian F. B.; Llanos, Roxana M.; Taylor, Philip E.] Deakin Univ, Sch Life & Environm Sci, Ctr Cellular & Mol Biol, Burwood, Australia. [Takata, Reinaldo I.; Speck-Martins, Carlos E.] Sarah Network Rehabil Hosp, Brasilia, DF, Brazil. [Baets, Jonathan; Almeida-Souza, Leonardo; Timmerman, Vincent; De Jonghe, Peter] Flanders Inst Biotechnol, Dept Mol Genet, Antwerp, Belgium. [Baets, Jonathan; Almeida-Souza, Leonardo; Timmerman, Vincent; De Jonghe, Peter] Univ Antwerp, B-2020 Antwerp, Belgium. [Fischer, Dirk] Univ Basel Hosp, Dept Neurol, CH-4031 Basel, Switzerland. [Fischer, Dirk] Univ Childrens Hosp Basel, Dept Neuropediat, Basel, Switzerland. [Scherer, Steven S.; Ferguson, Toby A.] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA. [Bird, Thomas D.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA. [Bird, Thomas D.] Univ Washington, Sch Med, Dept Med Genet, Seattle, WA USA. [Bird, Thomas D.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Feely, Shawna M. E.; Shy, Michael E.; Garbern, James Y.] Wayne State Univ, Sch Med, Dept Neurol, Detroit, MI 48201 USA. [Feely, Shawna M. E.; Shy, Michael E.; Garbern, James Y.] Wayne State Univ, Sch Med, Ctr Mol Med & Genet, Detroit, MI 48201 USA. RP Kennerson, ML (reprint author), Univ Sydney, ANZAC Res Inst, Northcott Neurosci Lab, Concord, Australia. EM marinak@anzac.edu.au RI Almeida-Souza, Leonardo/C-3437-2011; Kennerson, Marina/B-5058-2014 FU Motor Neuron Disease Research Institute of Australia; National Health and Medical Research Council of Australia; Intramural Research program of the National Institute of Child Health and Human Development; Methusalem project of the University of Antwerp; Fund for Scientific Research (FWO-Flanders); Medical Foundation Queen Elisabeth (GSKE); Interuniversity Attraction Poles program [P6/43]; Belgian Federal Science Policy Office (BELSPO) FX We thank the patients and family members for their participation in this study. We thank Rabia Chaudhry and Alison Blake for their assistance with Cell Cultures and Jose Centeno for fibroblast copper measurements. This work was supported by grants from the Motor Neuron Disease Research Institute of Australia, the National Health and Medical Research Council of Australia, the Intramural Research program of the National Institute of Child Health and Human Development, the Methusalem project of the University of Antwerp, the Fund for Scientific Research (FWO-Flanders), the Medical Foundation Queen Elisabeth (GSKE), and the Interuniversity Attraction Poles program (P6/43) of the Belgian Federal Science Policy Office (BELSPO). J.B. and L.S. are Supported by PhD fellowships of the FWO-Flanders and the University of Antwerp, respectively. We thank Professor David Handelsman for his useful constructive comments on the manuscript. NR 47 TC 81 Z9 83 U1 0 U2 4 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 0002-9297 J9 AM J HUM GENET JI Am. J. Hum. Genet. PD MAR 12 PY 2010 VL 86 IS 3 BP 343 EP 352 DI 10.1016/j.ajhg.2010.01.027 PG 10 WC Genetics & Heredity SC Genetics & Heredity GA 570LG UT WOS:000275678800006 PM 20170900 ER PT J AU Hu, W Xu, RJ Sun, W Szulc, ZM Bielawski, J Obeid, LM Mao, CG AF Hu, Wei Xu, Ruijuan Sun, Wei Szulc, Zdzislaw M. Bielawski, Jacek Obeid, Lina M. Mao, Cungui TI Alkaline Ceramidase 3 (ACER3) Hydrolyzes Unsaturated Long-chain Ceramides, and Its Down-regulation Inhibits Both Cell Proliferation and Apoptosis SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID PERFORMANCE LIQUID-CHROMATOGRAPHY; MOLECULAR-CLONING; ACID CERAMIDASE; FUNCTIONAL-CHARACTERIZATION; MITOCHONDRIAL CERAMIDASE; SACCHAROMYCES-CEREVISIAE; FARBER-DISEASE; CANCER CELLS; SPHINGOSINE; GENERATION AB Ceramides with different fatty acyl chains may vary in their physiological or pathological roles; however, it remains unclear how cellular levels of individual ceramide species are regulated. Here, we demonstrate that our previously cloned human alkaline ceramidase 3 (ACER3) specifically controls the hydrolysis of ceramides carrying unsaturated long acyl chains, unsaturated long-chain (ULC) ceramides. In vitro, ACER3 only hydrolyzed C(18:1)-, C(20:1)-, C(20:4)-ceramides, dihydroceramides, and phytoceramides. In cells, ACER3 overexpression decreased C(18:1)- and C(20:1)-ceramides and dihydroceramides, whereas ACER3 knockdown by RNA interference had the opposite effect, suggesting that ACER3 controls the catabolism of ULC ceramides and dihydroceramides. ACER3 knockdown inhibited cell proliferation and up-regulated the cyclin-dependent kinase inhibitor p21(CIP1/WAF1). Blocking p21(CIP1/WAF1) up-regulation attenuated the inhibitory effect of ACER3 knockdown on cell proliferation, suggesting that ACER3 knockdown inhibits cell proliferation because of p21(CIP1/WAF1) up-regulation. ACER3 knockdown inhibited cell apoptosis in response to serum deprivation. ACER3 knockdown up-regulated the expression of the alkaline ceramidase 2 (ACER2), and the ACER2 up-regulation decreased non-ULC ceramide species while increasing both sphingosine and its phosphate. Collectively, these data suggest that ACER3 catalyzes the hydrolysis of ULC ceramides and dihydroceramides and that ACER3 coordinates with ACER2 to regulate cell proliferation and survival. C1 [Mao, Cungui] Med Univ S Carolina, Div Gen Internal Med, Dept Med, Charleston, SC 29425 USA. [Szulc, Zdzislaw M.; Bielawski, Jacek; Obeid, Lina M.; Mao, Cungui] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. [Obeid, Lina M.] Ralph H Johnson Vet Affairs Hosp, Charleston, SC 29425 USA. RP Mao, CG (reprint author), Med Univ S Carolina, Div Gen Internal Med, Dept Med, 114 Doughty St,Rm 646,STB,POB 250779, Charleston, SC 29425 USA. EM maoc@musc.edu OI obeid, lina/0000-0002-0734-0847 FU National Institutes of Health [P20RR017677, R01CA104834, R01GM062887]; Veterans Affairs Merit award FX This work was supported, in whole or in part, by National Institutes of Health Grants P20RR017677 (to C.M.), R01CA104834 (to C.M.), and R01GM062887 (to L.M.O.). This work was also supported by a Veterans Affairs Merit award (to L.M.O.). NR 42 TC 32 Z9 33 U1 0 U2 2 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD MAR 12 PY 2010 VL 285 IS 11 BP 7964 EP 7976 DI 10.1074/jbc.M109.063586 PG 13 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 567AE UT WOS:000275413800014 PM 20068046 ER PT J AU Lee, BY Wiringa, AE Bailey, RR Lewis, GJ Feura, J Muder, RR AF Lee, Bruce Y. Wiringa, Ann E. Bailey, Rachel R. Lewis, G. Jonathan Feura, Jared Muder, Robert R. TI Staphylococcus aureus vaccine for orthopedic patients: An economic model and analysis SO VACCINE LA English DT Article DE Staphylococcus aureus; Vaccine; Orthopedic surgery; Economics; Computer simulation ID POLYSACCHARIDE CONJUGATE VACCINE; QUALITY-OF-LIFE; PASSIVE-IMMUNIZATION; TOTAL HIP; MRSA; INFECTIONS; SURGERY; UTILITY; IMMUNOTHERAPY; ARTHROPLASTY AB To evaluate the potential economic value of a Staphylococcus aureus vaccine for pre-operative orthopedic surgery patients, we developed an economic computer simulation model. At MRSA colonization rates as low as 1%, a $50 vaccine was cost-effective [<=$50,000 per quality-adjusted life year (QALY) saved] at vaccine efficacy >= 30%, and a $100 vaccine at vaccine efficacy >= 70%. High MASA prevalence (>= 25%) could justify a vaccine price as high as $1000. Our results suggest that a S. aureus vaccine for the pre-operative orthopedic population would be very cost-effective over a wide range of MASA prevalence and vaccine efficacies and costs. (C) 2010 Elsevier Ltd. All rights reserved. C1 [Lee, Bruce Y.] Univ Pittsburgh, Publ Hlth Computat & Operat Res PHICOR, Sect Decis Sci & Clin Syst Modeling, Pittsburgh, PA 15213 USA. [Lee, Bruce Y.; Wiringa, Ann E.; Bailey, Rachel R.; Lewis, G. Jonathan; Feura, Jared] Univ Pittsburgh, Dept Biomed Informat, Pittsburgh, PA 15213 USA. [Lee, Bruce Y.; Wiringa, Ann E.; Bailey, Rachel R.; Lewis, G. Jonathan; Feura, Jared] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15213 USA. [Muder, Robert R.] Univ Pittsburgh, Div Infect Dis, VA Pittsburgh Hlth Syst, Pittsburgh, PA 15213 USA. RP Lee, BY (reprint author), Univ Pittsburgh, Publ Hlth Computat & Operat Res PHICOR, Sect Decis Sci & Clin Syst Modeling, 200 Meyran Ave,Suite 200, Pittsburgh, PA 15213 USA. EM BYL1@pitt.edu OI Slayton, Rachel/0000-0003-4699-8040 FU National Institute of General Medical Sciences Models of Infectious Disease Agent Study (MIDAS) [1U54GM088491-0109] FX Supported by the National Institute of General Medical Sciences Models of Infectious Disease Agent Study (MIDAS) through grant 1U54GM088491-0109. The funder had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 42 TC 15 Z9 15 U1 0 U2 1 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD MAR 11 PY 2010 VL 28 IS 12 BP 2465 EP 2471 DI 10.1016/j.vaccine.2009.12.075 PG 7 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 576HN UT WOS:000276135200015 PM 20064479 ER PT J AU Heinlen, LD McClain, MT Ritterhouse, LL Bruner, BF Edgerton, CC Keith, MP James, JA Harley, JB AF Heinlen, Latisha D. McClain, Micah T. Ritterhouse, Lauren L. Bruner, Benjamin F. Edgerton, Colin C. Keith, Michael P. James, Judith A. Harley, John B. TI 60 kD Ro and nRNP A Frequently Initiate Human Lupus Autoimmunity SO PLOS ONE LA English DT Article ID ANTI-SM ANTIBODIES; CLINICAL-SIGNIFICANCE; PEPTIDE IMMUNIZATION; HUMORAL AUTOIMMUNITY; SURFACE-STRUCTURES; REVISED CRITERIA; ERYTHEMATOSUS; AUTOANTIBODIES; DIAGNOSIS; NEPHRITIS AB Systemic lupus erythematosus (SLE) is a clinically heterogeneous, humoral autoimmune disorder. The unifying feature among SLE patients is the production of large quantities of autoantibodies. Serum samples from 129 patients collected before the onset of SLE and while in the United States military were evaluated for early pre-clinical serologic events. The first available positive serum sample frequently already contained multiple autoantibody specificities (65%). However, in 34 SLE patients the earliest pre-clinical serum sample positive for any detectable common autoantibody bound only a single autoantigen, most commonly 60 kD Ro (29%), nRNP A (24%), anti-phospholipids (18%) or rheumatoid factor (15%). We identified several recurrent patterns of autoantibody onset using these pre-diagnostic samples. In the serum samples available, anti-nRNP A appeared before or simultaneously with anti-nRNP 70 K in 96% of the patients who had both autoantibodies at diagnosis. Anti-60 kD Ro antibodies appeared before or simultaneously with anti-La (98%) or anti-52 kD Ro (95%). The autoantibody response in SLE patients begins simply, often binding a single specific autoantigen years before disease onset, followed by epitope spreading to additional autoantigenic specificities that are accrued in recurring patterns. C1 [Heinlen, Latisha D.; McClain, Micah T.; Ritterhouse, Lauren L.; Bruner, Benjamin F.; James, Judith A.] Oklahoma Med Res Fdn, Dept Clin Immunol, Oklahoma City, OK 73104 USA. [Heinlen, Latisha D.; Ritterhouse, Lauren L.; James, Judith A.; Harley, John B.] Univ Oklahoma, Hlth Sci Ctr, Dept Internal Med, Oklahoma City, OK USA. [Heinlen, Latisha D.; Ritterhouse, Lauren L.; James, Judith A.; Harley, John B.] Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK USA. [Edgerton, Colin C.] Walter Reed Army Med Ctr, Washington, DC 20307 USA. [Keith, Michael P.] Natl Naval Med Ctr, Bethesda, MD USA. [Harley, John B.] US Dept Vet Affairs, Oklahoma City, OK USA. [Harley, John B.] Oklahoma Med Res Fdn, Dept Arthrit & Immunol, Oklahoma City, OK 73104 USA. RP Heinlen, LD (reprint author), Oklahoma Med Res Fdn, Dept Clin Immunol, 825 NE 13th St, Oklahoma City, OK 73104 USA. EM harley@omrf.org FU National Institutes of Health [AI31584, AR48045, AR49084, AR45084, AR45451, RR15577, AR48940, RR20143, AI62629, AI50350]; Kirkland Scholar Awards; United States Department of Veterans Affairs; Lou Kerr Chair in Biomedical Research FX This work was supported in part by grants from the National Institutes of Health (AI31584, AR48045, AR49084, AR45084, AR45451, RR15577, AR48940, RR20143, AI62629, AI50350), Kirkland Scholar Awards (JBH and JAJ) and the United States Department of Veterans Affairs. This work was also supported in part by the Lou Kerr Chair in Biomedical Research to JAJ. Bio-Rad provided the ANA test kits and selected the laboratory as a beta-test site for their commercial bead based assay. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 39 TC 22 Z9 22 U1 1 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 10 PY 2010 VL 5 IS 3 AR e9599 DI 10.1371/journal.pone.0009599 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 565XE UT WOS:000275328800012 PM 20224770 ER PT J AU Nautiyal, A Chaukiyal, P AF Nautiyal, Amit Chaukiyal, Pooja TI Second neoplasm: 31-year latency after childhood leukemia SO CANADIAN MEDICAL ASSOCIATION JOURNAL LA English DT Editorial Material ID CANCER SURVIVOR C1 [Nautiyal, Amit] Univ Pittsburgh, Dept Med, Pittsburgh, PA 15260 USA. [Chaukiyal, Pooja] Vet Affairs Pittsburgh Hlth Care Syst, Dept Med, Pittsburgh, PA USA. RP Nautiyal, A (reprint author), Univ Pittsburgh, Dept Med, Pittsburgh, PA 15260 USA. NR 4 TC 0 Z9 0 U1 0 U2 0 PU CMA-CANADIAN MEDICAL ASSOC PI OTTAWA PA 1867 ALTA VISTA DR, OTTAWA, ONTARIO K1G 3Y6, CANADA SN 0820-3946 J9 CAN MED ASSOC J JI Can. Med. Assoc. J. PD MAR 9 PY 2010 VL 182 IS 4 BP E185 EP E185 DI 10.1503/cmaj.090562 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 560RO UT WOS:000274920000022 PM 20026628 ER PT J AU Chen, J Krumholz, HM Wang, Y Curtis, JP Rathore, SS Ross, JS Normand, SLT Schreiner, GC Mulvey, G Nallamothu, BK AF Chen, Jersey Krumholz, Harlan M. Wang, Yun Curtis, Jeptha P. Rathore, Saif S. Ross, Joseph S. Normand, Sharon-Lise T. Schreiner, Geoffrey C. Mulvey, Gregory Nallamothu, Brahmajee K. TI Differences in Patient Survival After Acute Myocardial Infarction by Hospital Capability of Performing Percutaneous Coronary Intervention SO ARCHIVES OF INTERNAL MEDICINE LA English DT Article ID SITE CARDIAC-CATHETERIZATION; PRIMARY ANGIOPLASTY; OUTCOMES; CARE; REGIONALIZATION; FACILITIES; THROMBOLYSIS; CENTERS; IMPACT; TRIAL AB Background: There are increasing calls for regionalization of acute myocardial infarction ( AMI) care in the United States to hospitals with the capacity to perform percutaneous coronary intervention (PCI). Whether regionalization will improve outcomes depends in part on the magnitude of existing differences in outcomes between PCI and non-PCI hospitals within the same health care region. Methods: A 100% sample of claims from Medicare fee-for-service beneficiaries 65 years or older hospitalized for AMI between January 1, 2004, and December 31, 2006, was used to calculate hospital-level, 30-day risk-standardized mortality rates (RSMRs). The RSMRs between PCI and local non-PCI hospitals were compared within local health care regions defined by hospital referral regions (HRRs). Results: A total of 523 119 AMI patients was admitted to 1382 PCI hospitals, and 194 909 AMI patients were admitted to 2491 non-PCI hospitals in 295 HRRs with at least 1 PCI and 1 non-PCI hospital. Although PCI hospitals had lower RSMRs than non-PCI hospitals ( mean, 16.1% vs 16.9%; P < .001), considerable overlap was seen in RSMRs between non-PCI and PCI hospitals within the same HRR. In 80 HRRs, the RSMRs at the best-performing PCI hospital were lower than those at local non-PCI hospitals by 3% or more. Among the remaining HRRs, the RSMRs at the best-performing PCI hospital were lower by 1.5% to 3.0% in 104 HRRs and by greater than 0 to 1.5% in 74 HRRs. In 37 HRRs, the RSMRs at the best-performing PCI hospital were no better or were higher than at local non-PCI hospitals. Conclusions: The magnitude of benefit from comprehensively regionalizing AMI care to PCI hospitals appears to vary greatly across HRRs. These findings support a tailored regionalization policy that targets areas with the greatest outcome differences between PCI and local non-PCI hospitals. C1 [Chen, Jersey] Yale Univ, Sch Med, Dept Internal Med, Cardiol Sect,Div Cardiol, New Haven, CT 06520 USA. [Chen, Jersey; Krumholz, Harlan M.; Wang, Yun; Curtis, Jeptha P.; Schreiner, Geoffrey C.; Mulvey, Gregory] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, New Haven, CT 06504 USA. [Ross, Joseph S.] Mt Sinai Sch Med, Div Geriatr & Palliat Med, New York, NY USA. [Ross, Joseph S.] James P Peters Vet Adm Med Ctr, Hlth Serv Res & Dev Res Enhancement Program, Bronx, NY USA. [Ross, Joseph S.] James P Peters Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA. [Normand, Sharon-Lise T.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA. [Normand, Sharon-Lise T.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Nallamothu, Brahmajee K.] Univ Michigan, Vet Affairs Ann Arbor Hlth Serv Res & Dev Ctr Exc, Ann Arbor, MI USA. [Nallamothu, Brahmajee K.] Univ Michigan, Dept Internal Med, Div Cardiovasc Med, Ann Arbor, MI 48109 USA. RP Chen, J (reprint author), Yale Univ, Sch Med, Dept Internal Med, Cardiol Sect,Div Cardiol, 333 Cedar St,POB 208017, New Haven, CT 06520 USA. EM jersey.chen@yale.edu FU NIA NIH HHS [K08 AG032886, K08 AG032886-02] NR 20 TC 12 Z9 12 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD MAR 8 PY 2010 VL 170 IS 5 BP 433 EP 439 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 565PU UT WOS:000275307300007 PM 20212179 ER PT J AU Ramanathan, L Hu, SX Frautschy, SA Siegel, JM AF Ramanathan, Lalini Hu, Shuxin Frautschy, Sally A. Siegel, Jerome M. TI Short-term total sleep deprivation in the rat increases antioxidant responses in multiple brain regions without impairing spontaneous alternation behavior SO BEHAVIOURAL BRAIN RESEARCH LA English DT Article DE Total sleep deprivation; Y maze; Metabolic activity; Antioxidant responses; Rat ID GLUTATHIONE DEPLETION; SUPEROXIDE-DISMUTASE; PARADOXICAL SLEEP; OXIDATIVE STRESS; SPATIAL MEMORY; HIPPOCAMPUS; DECREASES; ENZYMES; MICE; FRAGMENTATION AB Total sleep deprivation (TSD) induces a broad spectrum of cognitive, behavioral and cellular changes. We previously reported that long term (5-11 days) TSD in the rat, by the disk-over-water method, decreases the activity of the antioxidant enzyme superoxide dismutase (SOD) in the brainstem and hippocampus. To gain insight into the mechanisms causing cognitive impairment, here we explore the early associations between metabolic activity, antioxidant responses and working memory (one form of cognitive impairment). Specifically we investigated the impact of short-term (6h) TSD, by gentle handling, on the levels of the endogenous antioxidant, total glutathione (GSHt), and the activities of the antioxidative enzymes, SOD and glutathione peroxidase (GPx). Short-term TSD had no significant impact on SOD activity, but increased GSHt levels in the rat cortex, brainstem and basal forebrain, and GPx activity in the rat hippocampus and cerebellum. We also observed increased activity of hexokinase, (HK), the rate limiting enzyme of glucose metabolism, in the rat cortex and hypothalamus. We further showed that 6 h of TSD leads to increased exploratory behavior to a new environment, without impairing spontaneous alternation behavior (SAB) in the Y maze. We conclude that acute (6 h) sleep loss may trigger compensatory mechanisms (like increased antioxidant responses) that prevent initial deterioration in working memory. Published by Elsevier B.V. C1 [Ramanathan, Lalini; Siegel, Jerome M.] Greater Los Angeles Hlth Care Syst, Neurobiol Res 151A3, North Hills, CA USA. [Ramanathan, Lalini; Siegel, Jerome M.] Univ Calif Los Angeles, Dept Psychiat & Behav Sci, Los Angeles, CA 90024 USA. [Hu, Shuxin; Frautschy, Sally A.] Greater Los Angeles Hlth Care Syst, Geriatr Res & Educ Clin Ctr 151A3, North Hills, CA USA. [Hu, Shuxin; Frautschy, Sally A.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. [Frautschy, Sally A.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA. RP Siegel, JM (reprint author), VA GLAHS Sepulveda, Neurobiol Res 151A3,16111 Plummer St, North Hills, CA 91343 USA. EM jsiegel@ucla.edu RI Sanguansri, Luz/B-6630-2011 OI Sanguansri, Luz/0000-0003-1908-7604 FU Department of Veteran Affairs [HL-060296, HL-41370, MH-64109] FX This research was supported by grants HL-060296, HL-41370 and MH-64109 and by the Medical Research Services of the Department of Veteran Affairs. NR 31 TC 17 Z9 22 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0166-4328 J9 BEHAV BRAIN RES JI Behav. Brain Res. PD MAR 5 PY 2010 VL 207 IS 2 BP 305 EP 309 DI 10.1016/j.bbr.2009.10.014 PG 5 WC Behavioral Sciences; Neurosciences SC Behavioral Sciences; Neurosciences & Neurology GA 558RC UT WOS:000274761800009 PM 19850085 ER PT J AU Mengshol, JA Golden-Mason, L Arikawa, T Smith, M Niki, T McWilliams, R Randall, JA McMahan, R Zimmerman, MA Rangachari, M Dobrinskikh, E Busson, P Polyak, SJ Hirashima, M Rosen, HR AF Mengshol, John A. Golden-Mason, Lucy Arikawa, Tomohiro Smith, Maxwell Niki, Toshiro McWilliams, Ryan Randall, Jessica A. McMahan, Rachel Zimmerman, Michael A. Rangachari, Manu Dobrinskikh, Evgenia Busson, Pierre Polyak, Stephen J. Hirashima, Mitsuomi Rosen, Hugo R. TI A Crucial Role for Kupffer Cell-Derived Galectin-9 in Regulation of T Cell Immunity in Hepatitis C Infection SO PLOS ONE LA English DT Article ID VIRUS-INFECTION; LIVER-INJURY; HEPATOCELLULAR-CARCINOMA; GLYCAN INTERACTIONS; CD127 EXPRESSION; HCV INFECTION; LYMPHOCYTES; TOLERANCE; TIM-3; APOPTOSIS AB Approximately 200 million people throughout the world are infected with hepatitis C virus (HCV). One of the most striking features of HCV infection is its high propensity to establish persistence (similar to 70-80%) and progressive liver injury. Galectins are evolutionarily conserved glycan-binding proteins with diverse roles in innate and adaptive immune responses. Here, we demonstrate that galectin-9, the natural ligand for the T cell immunoglobulin domain and mucin domain protein 3 (Tim-3), circulates at very high levels in the serum and its hepatic expression (particularly on Kupffer cells) is significantly increased in patients with chronic HCV as compared to normal controls. Galectin-9 production from monocytes and macrophages is induced by IFN-gamma, which has been shown to be elevated in chronic HCV infection. In turn, galectin-9 induces proinflammatory cytokines in liver-derived and peripheral mononuclear cells; galectin-9 also induces anti-inflammatory cytokines from peripheral but not hepatic mononuclear cells. Galectin-9 results in expansion of CD4(+) CD25(+) FoxP3(+) CD127(low) regulatory T cells, contraction of CD4+ effector T cells, and apoptosis of HCV-specific CTLs. In conclusion, galectin-9 production by Kupffer cells links the innate and adaptive immune response, providing a potential novel immunotherapeutic target in this common viral infection. C1 [Mengshol, John A.; Golden-Mason, Lucy; McWilliams, Ryan; Randall, Jessica A.; McMahan, Rachel; Dobrinskikh, Evgenia; Rosen, Hugo R.] Univ Colorado, Sch Med, Dept Med, Div Gastroenterol & Hepatol, Aurora, CO USA. [Mengshol, John A.; Rosen, Hugo R.] Denver Vet Affairs Med Ctr, Denver, CO USA. [Golden-Mason, Lucy; Rosen, Hugo R.] Univ Colorado, Sch Med, Div Clin Immunol, Denver, CO USA. [Golden-Mason, Lucy; Rosen, Hugo R.] Natl Jewish Hosp, Denver, CO USA. [Smith, Maxwell] Univ Colorado, Sch Med, Dept Pathol, Denver, CO 80262 USA. [Arikawa, Tomohiro; Hirashima, Mitsuomi] Kagawa Med Univ, Dept Immunol & Immunopathol, Kagawa, Japan. [Niki, Toshiro] GalPharma, Kagawa, Japan. [Zimmerman, Michael A.] Univ Colorado, Sch Med, Div Transplant Surg, Aurora, CO USA. [Rangachari, Manu] Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Neurol Dis, Boston, MA 02115 USA. [Busson, Pierre] Inst Cancerol Gustave Roussy, Villejuif, France. [Polyak, Stephen J.] Univ Washington, Div Lab Med, Seattle, WA 98195 USA. RP Mengshol, JA (reprint author), Univ Colorado, Sch Med, Dept Med, Div Gastroenterol & Hepatol, Aurora, CO USA. EM Hugo.Rosen@ucdenver.edu RI Polyak, Stephen/B-5743-2011 FU National Institutes of Health (NIH) [RO1 DK060590, U19 A 1066328-01] FX This research is supported by National Institutes of Health (NIH) grants RO1 DK060590 and U19 A 1066328-01 (HCV center grant) to HRR. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Dr Niki from Galpharma provided antibodies. NR 52 TC 89 Z9 96 U1 0 U2 5 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 4 PY 2010 VL 5 IS 3 AR e9504 DI 10.1371/journal.pone.0009504 PG 12 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 564EW UT WOS:000275197100005 PM 20209097 ER PT J AU Yao, JK Dougherty, GG Reddy, RD Keshavan, MS Montrose, DM Matson, WR McEvoy, J Kaddurah-Daouk, R AF Yao, Jeffrey K. Dougherty, George G., Jr. Reddy, Ravinder D. Keshavan, Matcheri S. Montrose, Debra M. Matson, Wayne R. McEvoy, Joseph Kaddurah-Daouk, Rima TI Homeostatic Imbalance of Purine Catabolism in First-Episode Neuroleptic-Naive Patients with Schizophrenia SO PLOS ONE LA English DT Article ID SERUM URIC-ACID; PERFORMANCE LIQUID-CHROMATOGRAPHY; IMPAIRED GLUTATHIONE SYNTHESIS; MULTIPLE-SCLEROSIS PATIENTS; PLASMA ANTIOXIDANTS; PARKINSONS-DISEASE; OXIDATIVE STRESS; RISK-FACTOR; SYSTEM; BRAIN AB Background: Purine catabolism may be an unappreciated, but important component of the homeostatic response of mitochondria to oxidant stress. Accumulating evidence suggests a pivotal role of oxidative stress in schizophrenia pathology. Methodology/Principal Findings: Using high-pressure liquid chromatography coupled with a coulometric multi-electrode array system, we compared 6 purine metabolites simultaneously in plasma between first-episode neuroleptic-naive patients with schizophrenia (FENNS, n = 25) and healthy controls (HC, n = 30), as well as between FENNS at baseline (BL) and 4 weeks (4w) after antipsychotic treatment. Significantly higher levels of xanthosine (Xant) and lower levels of guanine (G) were seen in both patient groups compared to HC subjects. Moreover, the ratios of G/guanosine (Gr), uric acid (UA)/Gr, and UA/Xant were significantly lower, whereas the ratio of Xant/G was significantly higher in FENNS-BL than in HC. Such changes remained in FENNS-4w with exception that the ratio of UA/Gr was normalized. All 3 groups had significant correlations between G and UA, and Xan and hypoxanthine (Hx). By contrast, correlations of UA with each of Xan and Hx, and the correlation of Xan with Gr were all quite significant for the HC but not for the FENNS. Finally, correlations of Gr with each of UA and G were significant for both HC and FENNS-BL but not for the FENNS-4w. Conclusions/Significance: During purine catabolism, both conversions of Gr to G and of Xant to Xan are reversible. Decreased ratios of product to precursor suggested a shift favorable to Xant production from Xan, resulting in decreased UA levels in the FENNS. Specifically, the reduced UA/Gr ratio was nearly normalized after 4 weeks of antipsychotic treatment. In addition, there are tightly correlated precursor and product relationships within purine pathways; although some of these correlations persist across disease or medication status, others appear to be lost among FENNS. Taken together, these results suggest that the potential for steady formation of antioxidant UA from purine catabolism is altered early in the course of illness. C1 [Yao, Jeffrey K.; Dougherty, George G., Jr.; Reddy, Ravinder D.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Yao, Jeffrey K.; Dougherty, George G., Jr.; Reddy, Ravinder D.; Keshavan, Matcheri S.; Montrose, Debra M.] Univ Pittsburgh, Western Psychiat Inst & Clin, Med Ctr, Dept Psychiat, Pittsburgh, PA 15213 USA. [Yao, Jeffrey K.] Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Pittsburgh, PA 15213 USA. [Keshavan, Matcheri S.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Keshavan, Matcheri S.] Harvard Univ, Boston, MA 02115 USA. [Matson, Wayne R.] Bedford VA Med Ctr, Bedford, MA USA. [McEvoy, Joseph; Kaddurah-Daouk, Rima] Duke Univ, Med Ctr, Durham, NC USA. RP Yao, JK (reprint author), VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. EM jkyao@pitt.edu FU Department of Veterans Affairs (VA); Veterans Health Administration; Office of Research and Development; Biomedical Laboratory Research Development; VA Pittsburgh Healthcare System; National Institute of Health [MH58141, MH64118, MH45203, R24 GM078233, c UL1 RR024153]; NIH/NCRR/GCRC [M01 RR00056]; Metabolomics Research Network (RKD); Stanley Medical Research Institute (RKD); National Alliance for Research on Schizophrenia and Affective Disorders (RKD) FX This material is based upon work supported in part by the grants from the Department of Veterans Affairs (VA), Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research & Development [Merit Reviews (JKY) and Senior Research Career Scientist Award (JKY)], VA Pittsburgh Healthcare System (JKY, GGD, RDR), National Institute of Health [MH58141 (JKY), MH64118 (RDR), MH45203 (MSK), R24 GM078233 (RKD), c UL1 RR024153 and NIH/NCRR/GCRC Grant M01 RR00056], Metabolomics Research Network (RKD); Stanley Medical Research Institute (RKD), and National Alliance for Research on Schizophrenia and Affective Disorders (RKD). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 83 TC 31 Z9 31 U1 0 U2 6 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 3 PY 2010 VL 5 IS 3 AR e9508 DI 10.1371/journal.pone.0009508 PG 14 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 562OZ UT WOS:000275063400014 PM 20209081 ER PT J AU Goldstein, N Carlson, M Livote, E Kutner, JS AF Goldstein, Nathan Carlson, Melissa Livote, Elayne Kutner, Jean S. TI Brief Communication: Management of Implantable Cardioverter-Defibrillators in Hospice: A Nationwide Survey SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID OF-LIFE; CARE; END AB Background: Communication about the deactivation of implantable cardioverter-defibrillators (ICDs) in patients near the end of life is rare. Objective: To determine whether hospices are admitting patients with ICDs, whether such patients are receiving shocks, and how hospices manage ICDs. Design: Cross-sectional survey. Setting: Randomly selected hospice facilities. Participants: 900 hospices, 414 of which responded fully. Measurements: Frequency of admission of patients with ICDs, frequency with which patients received shocks, existence of ICD deactivation policies, and frequency of deactivation. Results: 97% of hospices admitted patients with ICDs, and 58% reported that in the past year, a patient had been shocked. Only 10% of hospices had a policy that addressed deactivation. On average, 42% (95% CI, 37% to 48%) of patients with ICDs had the shocking function deactivated. Limitation: The study relied on the knowledge of hospice administrators. Conclusion: Hospices are admitting patients with ICDs, and patients are being shocked at the end of life. Ensuring that hospices have policies in place to address deactivation may improve the care for patients with these devices. The authors provide a sample deactivation policy (available at www.annals.org). C1 [Goldstein, Nathan] Mt Sinai Sch Med, Dept Geriatr, New York, NY 10029 USA. James J Peters Vet Affairs Med Ctr, Bronx, NY USA. Univ Colorado, Denver Sch Med, Aurora, CO USA. RP Goldstein, N (reprint author), Mt Sinai Sch Med, Dept Geriatr, Box 1070,1 Gustave Levy Pl, New York, NY 10029 USA. EM Nathan.Goldstein@mssm.edu FU National Institute of Aging [K23 AG025933K07AG030337-01A2]; National Institute of Nursing Research [1K99NR010495-01] FX By the National Institute of Aging, grants K23 AG025933 (Dr. Goldstein) and K07AG030337-01A2 (Dr. Kutner), and the National Institute of Nursing Research, grant 1K99NR010495-01 (Dr. Carlson). NR 14 TC 57 Z9 57 U1 0 U2 0 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD MAR 2 PY 2010 VL 152 IS 5 BP 296 EP W94 DI 10.7326/0003-4819-152-5-201003020-00007 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA 565XJ UT WOS:000275329600004 PM 20194235 ER PT J AU Vetter, ML Iqbal, N Dalton-Bakes, C Volger, S Wadden, TA AF Vetter, Marion L. Iqbal, Nayyar Dalton-Bakes, Cornelia Volger, Sheri Wadden, Thomas A. TI Long-Term Effects of Low-Carbohydrate Versus Low-Fat Diets in Obese Persons SO ANNALS OF INTERNAL MEDICINE LA English DT Letter ID WEIGHT-LOSS DIETS C1 [Vetter, Marion L.] Hosp Univ Penn, Philadelphia, PA 19104 USA. [Iqbal, Nayyar; Dalton-Bakes, Cornelia] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. [Volger, Sheri; Wadden, Thomas A.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. RP Vetter, ML (reprint author), Hosp Univ Penn, 3400 Spruce St, Philadelphia, PA 19104 USA. OI volger, sheri/0000-0002-1689-1173 NR 3 TC 6 Z9 6 U1 0 U2 3 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD MAR 2 PY 2010 VL 152 IS 5 BP 334 EP 335 DI 10.7326/0003-4819-152-5-201003020-00020 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 565XJ UT WOS:000275329600016 PM 20194246 ER PT J AU Vandebroek, I Balick, MJ Ososki, A Kronenberg, F Yukes, J Wade, C Jimenez, F Peguero, B Castillo, D AF Vandebroek, Ina Balick, Michael J. Ososki, Andreana Kronenberg, Fredi Yukes, Jolene Wade, Christine Jimenez, Francisco Peguero, Brigido Castillo, Daisy TI The importance of botellas and other plant mixtures in Dominican traditional medicine SO JOURNAL OF ETHNOPHARMACOLOGY LA English DT Article DE Ethnobotany; Ethnomedicine; Plant mixtures; Herbal remedies; Dominican Republic; Migrants; New York City; Caribbean; Botella; Cultural keystone practice ID NEW-YORK-CITY; WOMENS HEALTH CONDITIONS; LATINO HEALERS; BOTANICAS; ETHNOBOTANY AB Ethnopharmacological relevance: Plant mixtures are understudied in ethnobotanical research. Aim of the study: To investigate the importance of plant mixtures (remedies consisting of at least two plants) in Dominican traditional medicine. Materials and methods: A Spanish language questionnaire was administered to 174 Dominicans living in New York City (NYC) and 145 Dominicans living in the Dominican Republic (DR), including lay persons (who self-medicate with plants) and specialists (traditional healers). Plants were identified through specimens purchased in NYC botanica shops and Latino grocery shops, and from voucher collections. Results: The percentage of mixtures as compared to single plants in plant use reports varied between 32 and 41%, depending on the geographic location (NYC or DR) and participant status (lay person or specialist). Respiratory conditions, reproductive health and genitourinary conditions were the main categories for which Dominicans use plant mixtures. Lay persons reported significantly more mixtures prepared as teas, mainly used in NYC to treat respiratory conditions. Specialists mentioned significantly more botellas (bottled herbal mixtures), used most frequently in the DR to treat reproductive health and genitourinary conditions. Cluster analysis demonstrated that different plant species are used to treat respiratory conditions as compared to reproductive health and genitourinary conditions. Interview participants believed that combining plants in mixtures increases their potency and versatility as medicines. Conclusions: The present study demonstrates the importance and complexity of plant mixtures in Dominican traditional medicine and the variation in its practices influenced by migration from the DR to NYC, shedding new lighten the foundations of a particular ethnomedical system. (C) 2009 Elsevier Ireland Ltd. All rights reserved. C1 [Vandebroek, Ina; Balick, Michael J.; Kronenberg, Fredi; Yukes, Jolene] New York Bot Garden, Inst Econ Bot, Bronx, NY 10458 USA. [Ososki, Andreana] San Francisco VA Med Ctr, San Francisco, CA USA. [Wade, Christine] CUNY, Off Inst Res & Assessment, New York, NY 10021 USA. [Jimenez, Francisco; Peguero, Brigido; Castillo, Daisy] Jardin Bot Nacl Dr Rafael Ma Moscoso, Dept Bot, Santo Domingo, Dominican Rep. RP Vandebroek, I (reprint author), New York Bot Garden, Inst Econ Bot, 2900 So Blvd, Bronx, NY 10458 USA. EM ivandebroek@nybg.org FU National Institutes of Health/National Center for Complementary and Alternative Medicine [5 R21 AT 001889-02] FX The authors wish to thank Dominican interview participants in New York City and the Dominican Republic for generously sharing their knowledge about traditional medicine. This project was supported by a grant from the National Institutes of Health/National Center for Complementary and Alternative Medicine (PI: Dr. Michael J. Balick, Grant # 5 R21 AT 001889-02). Hannah Stevens, MA., Manager of the NYBG GIS laboratory is kindly thanked for elaborating maps of the study sites. Irina Adam took the picture of the Dominican botella. We are indebted to interns and research assistants at the Institute of Economic Botany of The New York Botanical Garden who collaborated in this project (Gabriela Alvarez, Frans Beltran, Levenia Duran, Daniel Kulakowski, Greta Meyers, Saneddy Quezada, Sam Stein, Margaret Terrero) and volunteers (Yadira Arias, Tomas Diaz, Ashley Duval, Claudia Remes). We would also like to thank Dr. Linda Cushman, Ms. Iris De Castro, Dr. Flor Henderson, Rafael Lantigua MD, Dr. Milciades Mejia, Ms. Miriam Mejia, and Lionel Robineau MD for their help with the project. NR 33 TC 26 Z9 26 U1 1 U2 9 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0378-8741 J9 J ETHNOPHARMACOL JI J. Ethnopharmacol. PD MAR 2 PY 2010 VL 128 IS 1 BP 20 EP 41 DI 10.1016/j.jep.2009.12.013 PG 22 WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary Medicine; Pharmacology & Pharmacy SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary Medicine GA 574RI UT WOS:000276010000003 PM 20006697 ER PT J AU Maloney, JD Maloney, JD AF Maloney, James D. Maloney, James D., III TI Vegetation Size Marker for Extraction Technique? SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Editorial Material DE lead extraction; percutaneous endocarditis; intracardiac vegetations ID INFECTIVE ENDOCARDITIS; PACEMAKER ENDOCARDITIS; SURGICAL EXTRACTION; LEAD EXTRACTION; MANAGEMENT; DIAGNOSIS; RISK C1 [Maloney, James D.] Heartland Spine & Specialty Hosp, Cardiovasc Serv, Overland Pk, KS USA. [Maloney, James D., III] Univ Wisconsin, Dept Cardiothorac Surg, Madison, WI USA. [Maloney, James D., III] Univ Wisconsin Hosp & Clin, William S Middleton Mem Vet Adm Hosp, Thorac Surg Sect, Madison, WI 53792 USA. RP Maloney, JD (reprint author), Carondelet Heart Inst, 1000 Carondelet Dr, Kansas City, MO 64114 USA. EM jdmepmd@aol.com; jdmepmd@aol.com NR 20 TC 2 Z9 2 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD MAR 2 PY 2010 VL 55 IS 9 BP 895 EP 897 DI 10.1016/j.jacc.2009.11.035 PG 3 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 559XS UT WOS:000274865100008 PM 20185040 ER PT J AU Cohen, CI Kasckow, J Jeste, DV Vahia, I AF Cohen, Carl I. Kasckow, John Jeste, Dilip V. Vahia, Ipsit TI SUICIDAL BEHAVIOR IN THE OLDER PATIENT WITH SCHIZOPHRENIA SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-of-Geriatric-Psychiatry CY MAR 05-08, 2010 CL Savannah, GA SP Amer Assoc Geriat Psychiat C1 [Kasckow, John] VA Pittsburgh Hlth Care Syst, Pittsburgh, PA USA. [Jeste, Dilip V.; Vahia, Ipsit] Univ Calif San Diego, San Diego, CA 92103 USA. [Cohen, Carl I.] Suny Downstate Med Ctr, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1064-7481 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2010 VL 18 IS 3 SU 1 BP S42 EP S43 PG 2 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 753PB UT WOS:000289790800051 ER PT J AU Mavandadi, S Sayers, SL Oslin, DW AF Mavandadi, Shahrzad Sayers, Steven L. Oslin, David W. TI Social Exchanges and Suicide Ideation among Older Veterans with Behavioral Health Issues SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-of-Geriatric-Psychiatry CY MAR 05-08, 2010 CL Savannah, GA SP Amer Assoc Geriat Psychiat C1 [Mavandadi, Shahrzad; Sayers, Steven L.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Oslin, David W.] Univ Penn, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1064-7481 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2010 VL 18 IS 3 SU 1 BP S56 EP S56 PG 1 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 753PB UT WOS:000289790800055 ER PT J AU Peskind, ER Li, G Millard, S Chi, PB Sokal, I Yu, CE Bekris, LM Raskind, M Galasko, D Montine, TJ AF Peskind, Elaine R. Li, Gail Millard, Steven Chi, Peter B. Sokal, Izabela Yu, Chang-En Bekris, Lynn M. Raskind, Murray Galasko, Douglas Montine, Thomas J. TI Age-related Decline in Cognitive Function is Associated with Cerebrospinal Fluid Concentration of Brain-Derived Neurotrophic Factor SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-of-Geriatric-Psychiatry CY MAR 05-08, 2010 CL Savannah, GA SP Amer Assoc Geriat Psychiat C1 [Peskind, Elaine R.; Li, Gail; Millard, Steven; Raskind, Murray] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Chi, Peter B.; Sokal, Izabela; Yu, Chang-En; Bekris, Lynn M.; Montine, Thomas J.] Univ Washington, Seattle, WA 98195 USA. [Galasko, Douglas] Univ Calif San Diego, San Diego, CA 92103 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1064-7481 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2010 VL 18 IS 3 SU 1 BP S70 EP S71 PG 2 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 753PB UT WOS:000289790800078 ER PT J AU Raskind, M Wang, LY Wilkinson, CW Li, G Sikkema, CL Millard, S Hanscom, B Galasko, D Peskind, ER AF Raskind, Murray Wang, Lucy Y. Wilkinson, Charles W. Li, Gail Sikkema, Carl L. Millard, Steven Hanscom, Brett Galasko, Douglas Peskind, Elaine R. TI Cerebrospinal Fluid Norepinephrine is Inversely Related to Aspects of Cognition in Brain Aging SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-of-Geriatric-Psychiatry CY MAR 05-08, 2010 CL Savannah, GA SP Amer Assoc Geriat Psychiat C1 [Raskind, Murray; Wang, Lucy Y.; Wilkinson, Charles W.; Li, Gail; Sikkema, Carl L.; Millard, Steven; Peskind, Elaine R.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Hanscom, Brett] Univ Washington, Seattle, WA 98195 USA. [Galasko, Douglas] Univ Calif San Diego, San Diego, CA 92103 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1064-7481 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2010 VL 18 IS 3 SU 1 BP S70 EP S70 PG 1 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 753PB UT WOS:000289790800077 ER PT J AU Sultzer, D Melrose, R Campa, OM Achamallah, N Harwood, D Brody, A Walston, A Mandelkern, M AF Sultzer, David Melrose, Rebecca Campa, Olivia M. Achamallah, Natalie Harwood, Dylan Brody, Arthur Walston, Amy Mandelkern, Mark TI Cholinergic Receptor Imaging in Alzheimer's Disease: Method and Early Results SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-of-Geriatric-Psychiatry CY MAR 05-08, 2010 CL Savannah, GA SP Amer Assoc Geriat Psychiat C1 [Melrose, Rebecca; Campa, Olivia M.; Achamallah, Natalie; Harwood, Dylan; Brody, Arthur; Walston, Amy] VA Greater Los Angeles Healthcare Syst, Psychiat Serv, Los Angeles, CA USA. [Mandelkern, Mark] VA Greater Los Angeles Healthcare Syst, Nucl Med Serv, Los Angeles, CA USA. [Sultzer, David] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1064-7481 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2010 VL 18 IS 3 SU 1 BP S71 EP S72 PG 2 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 753PB UT WOS:000289790800079 ER PT J AU Pakhomova, ON Taylor, AB Becker, A Holloway, SP Kannan, TR Baseman, JB Hart, PJ AF Pakhomova, Olga N. Taylor, Alexander B. Becker, Argentina Holloway, Stephen P. Kannan, T. R. Baseman, Joel B. Hart, P. John TI Crystallization of community-acquired respiratory distress syndrome toxin from Mycoplasma pneumoniae SO ACTA CRYSTALLOGRAPHICA SECTION F-STRUCTURAL BIOLOGY AND CRYSTALLIZATION COMMUNICATIONS LA English DT Article ID CHRONIC ASTHMA; IDENTIFICATION; PERTUSSIS; PROTEIN AB Community-acquired respiratory distress syndrome toxin (CARDS TX) is a 591-amino-acid protein with ADP-ribosyltransferase and vacuolating activities that damages the cells lining the respiratory tracts of patients infected with the bacterial pathogen Mycoplasma pneumoniae. Crystals of CARDS TX were grown in space group C2, with unit-cell parameters a = 191.4, b = 107.4, c = 222.1 angstrom, beta = 90.6 degrees. A complete 2.2 angstrom data set was obtained from a single CARDS TX crystal. C1 [Pakhomova, Olga N.; Taylor, Alexander B.; Becker, Argentina; Holloway, Stephen P.; Hart, P. John] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA. [Pakhomova, Olga N.; Taylor, Alexander B.; Holloway, Stephen P.; Hart, P. John] Univ Texas Hlth Sci Ctr San Antonio, Xray Crystallog Core Lab, San Antonio, TX 78229 USA. [Kannan, T. R.; Baseman, Joel B.] Univ Texas Hlth Sci Ctr San Antonio, Dept Microbiol & Immunol, San Antonio, TX 78229 USA. [Hart, P. John] S Texas Vet Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Dept Vet Affairs, San Antonio, TX 78229 USA. RP Hart, PJ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA. EM pjhart@biochem.uthscsa.edu FU Robert A. Welch Foundation [AQ-1399]; IH [U19 AI070412]; Kleberg Foundation FX This work was supported by the Robert A. Welch Foundation Grant AQ-1399 (to PJH), by IH grant U19 AI070412 (to JBB) and by the Kleberg Foundation (to JBB). NR 20 TC 2 Z9 2 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1744-3091 J9 ACTA CRYSTALLOGR F JI Acta Crystallogr. F-Struct. Biol. Cryst. Commun. PD MAR PY 2010 VL 66 BP 294 EP 296 DI 10.1107/S1744309110000114 PN 3 PG 3 WC Biochemical Research Methods; Biochemistry & Molecular Biology; Biophysics; Crystallography SC Biochemistry & Molecular Biology; Biophysics; Crystallography GA 562ND UT WOS:000275057700019 PM 20208164 ER PT J AU Barnes, DE Covinsky, KE Whitmer, RA Kuller, LH Lopez, OL Yaffe, K AF Barnes, Deborah E. Covinsky, Kenneth E. Whitmer, Rachel A. Kuller, Lewis H. Lopez, Oscar L. Yaffe, Kristine TI Commentary on "Developing a national strategy to prevent dementia: Leon Thal Symposium 2009." Dementia risk indices: A framework for identifying individuals with a high dementia risk SO ALZHEIMERS & DEMENTIA LA English DT Article ID CARDIOVASCULAR HEALTH COGNITION; OLDER-ADULTS; PROGNOSTIC INDEX; BREAST-CANCER; VALIDATION; PREDICTION; SCORE; MORTALITY C1 [Barnes, Deborah E.] Univ Calif San Francisco, San Francisco VA Med Ctr, Dept Psychiat, San Francisco, CA 94121 USA. [Covinsky, Kenneth E.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94121 USA. [Whitmer, Rachel A.] Kaiser Div Res, Oakland, CA USA. [Kuller, Lewis H.; Lopez, Oscar L.] Univ Pittsburgh, Pittsburgh, PA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94121 USA. RP Barnes, DE (reprint author), Univ Calif San Francisco, San Francisco VA Med Ctr, Dept Psychiat, 4150 Clement St,151R, San Francisco, CA 94121 USA. EM deborah.bames@ucsf.edu FU National Heart, Lung, and Blood Institute [N01-HC-85079, N01-HC-85086, N01-HC-35129, N01 HC-15103, N01 HC-55222, N01-HC-75150, N01-HC-45133, U01 HL080295]; National Institute on Aging [AG15928]; National Institute of Neurological Disorders and Stroke; National Institutes of Health [K01 AG024069]; Alzheimer's Association [IIRG-06-27306]; NIH/NCRR UCSF-CTSI [UL1 RR024131] FX The Cardiovascular Health Study (CHS) was supported by contract numbers N01-HC-85079 through N01-HC-85086, N01-HC-35129, N01 HC-15103, N01 HC-55222, N01-HC-75150, N01-HC-45133, grant number U01 HL080295 from the National Heart, Lung, and Blood Institute, and grant AG15928 from the National Institute on Aging with additional contribution from the National Institute of Neurological Disorders and Stroke. A full list of principal CHS investigators and institutions can be found at http://www.chs-nhlbi.org/pi.htm. Dr Barnes is funded through a K01 Career Development Award (K01 AG024069) from the National Institutes of Health and an Alzheimer's Association award (IIRG-06-27306). This project also was supported by NIH/NCRR UCSF-CTSI Grant Number UL1 RR024131. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. NR 21 TC 18 Z9 18 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1552-5260 J9 ALZHEIMERS DEMENT JI Alzheimers. Dement. PD MAR PY 2010 VL 6 IS 2 BP 138 EP 141 DI 10.1016/j.jalz.2010.01.005 PG 4 WC Clinical Neurology SC Neurosciences & Neurology GA 582DR UT WOS:000276576400009 PM 20298975 ER PT J AU Laine, L Spiegel, B Rostom, A Moayyedi, P Kuipers, EJ Bardou, M Sung, J Barkun, AN AF Laine, Loren Spiegel, Brennan Rostom, Alaa Moayyedi, Paul Kuipers, Ernst J. Bardou, Marc Sung, Joseph Barkun, Alan N. TI Methodology for Randomized Trials of Patients With Nonvariceal Upper Gastrointestinal Bleeding: Recommendations From an International Consensus Conference SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Review ID ENDOSCOPIC THERAPY; PEPTIC-ULCER; HEMORRHAGE; MULTICENTER; PANTOPRAZOLE; PREVENTION; INFUSION; BLOOD AB The aim of this document is to provide a methodological framework for the design, performance, analysis, interpretation, and communication of randomized trials that assess management of patients with nonvariceal upper gastrointestinal bleeding. Literature searches were performed and an iterative process with electronic and face-to-face meetings was used to achieve consensus among panel members as part of an International Consensus Conference on Nonvariceal Upper Gastrointestinal Bleeding. Recommendations of the panel include the following. Randomized trials must explicitly state their primary hypothesis. A nonmanipulable randomization schedule with concealed allocation should be used. Stratification (e.g., for age and stigmata of hemorrhage) may be considered, especially in smaller studies. The patient and personnel providing care or recording information should be blinded. Inclusion criteria should be overt bleeding with endoscopy performed within 24 h or less. One type of lesion (e.g., ulcer) should be studied with stigmata to be included predefined. Use of placebo/no therapy vs. active controls depends on current standard practice. Standardizing study and key non-study interventions should ensure uniform provision of interventions. Criteria for repeat endoscopy and subsequent interventions should be predefined. The primary end point should be further bleeding (persistent and recurrent bleeding) with primary assessment at 7 days; mortality, with primary assessment at 30 days, would be appropriate in very large trials. Sample size calculation based on assumptions regarding primary end point results with regard to study intervention and control must be provided, and all patients enrolled must be accounted for. In general, the primary population for analysis is all patients randomized, although a per-protocol population may be used if this is the more conservative approach (e.g., equivalence study). C1 [Laine, Loren] Univ So Calif, Div Gastrointestinal & Liver Dis, Keck Sch Med, Los Angeles, CA 90033 USA. [Spiegel, Brennan] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Spiegel, Brennan] VA Greater Los Angeles Healthcare Syst, Div Digest Dis, Los Angeles, CA USA. [Rostom, Alaa] Univ Calgary, Div Gastroenterol, Calgary, AB, Canada. [Moayyedi, Paul] McMaster Univ, Med Ctr, Div Gastroenterol, Hamilton, ON, Canada. [Kuipers, Ernst J.] Erasmus MC Univ Med Ctr, Dept Gastroenterol & Hepatol, Rotterdam, Netherlands. [Kuipers, Ernst J.] Erasmus MC Univ Med Ctr, Dept Internal Med, Rotterdam, Netherlands. [Bardou, Marc] CHU Dijon, Ctr Invest Clin, Dijon, France. [Sung, Joseph] Chinese Univ Hong Kong, Inst Digest Dis, Shatin, Hong Kong, Peoples R China. [Barkun, Alan N.] McGill Univ, Div Gastroenterol, Montreal, PQ, Canada. RP Laine, L (reprint author), Univ So Calif, Div Gastrointestinal & Liver Dis, Keck Sch Med, 2025 Zonal Ave, Los Angeles, CA 90033 USA. EM llaine@usc.edu RI Hossain, Sarah /C-7332-2009; Moayyedi, Paul/M-6178-2014 OI Hossain, Sarah /0000-0003-1355-0979; Moayyedi, Paul/0000-0002-3616-9292 FU Canadian Association of Gastroenterology; European Association for Gastroenterology and Endoscopy; Asian Pacific Society of Digestive Endoscopy; Canadian Institutes of Health Research, Institute of Diabetes, Metabolism and Nutrition; AstaZeneca Molndal; Abbott Canada; Olympus Canada FX This work was supported by the Canadian Association of Gastroenterology; the European Association for Gastroenterology and Endoscopy; the Asian Pacific Society of Digestive Endoscopy; the Canadian Institutes of Health Research, Institute of Diabetes, Metabolism and Nutrition; and arm's length contributions to the above sponsoring societies from AstaZeneca Molndal, Abbott Canada, and Olympus Canada. NR 29 TC 19 Z9 20 U1 0 U2 3 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD MAR PY 2010 VL 105 IS 3 BP 540 EP 550 DI 10.1038/ajg.2009.702 PG 11 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 567PE UT WOS:000275458300012 PM 20029415 ER PT J AU Weigelt, JA Lipsky, BA Tabak, YP Derby, KG Kim, M Gupta, V AF Weigelt, John A. Lipsky, Benjamin A. Tabak, Ying P. Derby, Karen G. Kim, Myoung Gupta, Vikas TI Surgical site infections: Causative pathogens and associated outcomes SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Article DE Surgical site infection; outcomes research; methicillin-resistant Staphylococcus aureus; hospital mortality; hospital length of stay; hospital costs ID RESISTANT STAPHYLOCOCCUS-AUREUS; ECONOMIC OUTCOMES; UNITED-STATES; SURVEILLANCE; PREVENTION; HOSPITALS; IMPACT; MORTALITY; DISCHARGE; SURGERY AB Background: Surgical site infections (SSIs) are associated with substantial morbidity, mortality, and cost. Few studies have examined the causative pathogens, mortality, and economic burden among patients rehospitalized for SSIs. Methods: From 2003 to 2007, 8302 patients were readmitted to 97 US hospitals with a culture-confirmed SSI. We analyzed the causative pathogens and their associations with in-hospital mortality, length of stay (LOS), and cost. Results: The proportion of methicillin-resistant Staphylococcus aureus (MRSA) significantly increased among culture-positive SSI patients during the study period (16.1% to 20.6%, respectively, P<.0001). MRSA (compared with other) infections had higher raw mortality rates (1.4% vs 0.8%, respectively, P=.03), longer LOS (median, 6 vs 5 days, respectively, P<.0001), and higher hospital costs ($7036 vs $6134, respectively, P<.0001). The MRSA infection risk-adjusted attributable LOS increase was 0.93 days (95% confidence interval [CI]: 0.65-1.21; P<.0001), and cost increase was $1157 (95% CI: $641-$1644; P<.0001). Other significant independent risk factors increasing cost and LOS included illness severity, transfer from another health care facility, previous admission (<30 days), and other polymicrobial infections (P<.05). Conclusion: SSIs caused by MRSA increased significantly and were independently associated with economic burden. Admission illness severity, transfer from another health care setting, and recent hospitalization were associated with higher mortality, increased LOS, and cost. C1 [Weigelt, John A.] Med Coll Wisconsin, Dept Surg, Div Trauma Crit Care, Milwaukee, WI 53226 USA. [Lipsky, Benjamin A.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Lipsky, Benjamin A.] Univ Washington, Seattle, WA 98195 USA. [Tabak, Ying P.; Derby, Karen G.; Gupta, Vikas] Cardinal Hlth Clin Res Serv, Marlborough, MA USA. [Kim, Myoung] Ortho McNeil Janssen Sci Affairs LLC, Raritan, NJ USA. RP Weigelt, JA (reprint author), Med Coll Wisconsin, Dept Surg, Div Trauma Crit Care, 9200 W Wisconsin Ave, Milwaukee, WI 53226 USA. EM jweigelt@mcw.edu OI Lipsky, Benjamin A./0000-0001-9886-5114 FU OMJUS FX Dr. Weigelt is an advisory board member, on the speaker's bureau, received research support from OMJUS; Dr. Lipsky is an advisory board member and has received research support from OMJUS; Dr. Kim is a current employee of OMJUS; Ms. Derby and Drs. Tabak and Gupta are currently employees of Cardinal Health, Inc. Dr. Lipsky is an employee of the US Government. This paper does not represent the views of the US Government. NR 24 TC 45 Z9 49 U1 0 U2 4 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD MAR PY 2010 VL 38 IS 2 BP 112 EP 120 DI 10.1016/j.ajic.2009.06.010 PG 9 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 559WR UT WOS:000274859500005 PM 19889474 ER PT J AU Johansen, KL Finkelstein, FO Revicki, DA Gitlin, M Evans, C Mayne, TJ AF Johansen, Kirsten L. Finkelstein, Fredric O. Revicki, Dennis A. Gitlin, Matthew Evans, Christopher Mayne, Tracy J. TI Systematic Review and Meta-analysis of Exercise Tolerance and Physical Functioning in Dialysis Patients Treated With Erythropoiesis-Stimulating Agents SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Review DE Chronic kidney disease; erythropoiesis-stimulating agents; epoetin alfa; exercise tolerance; quality of life ID QUALITY-OF-LIFE; RECOMBINANT-HUMAN-ERYTHROPOIETIN; ANEMIC HEMODIALYSIS-PATIENTS; SICKNESS IMPACT PROFILE; CHRONIC KIDNEY-DISEASE; CORONARY-ARTERY DISEASE; CHRONIC HEART-FAILURE; CHRONIC-RENAL-FAILURE; HEALTH-STATUS MEASURE; MAINTENANCE HEMODIALYSIS AB Background: The role of erythropoiesis-stimulating agents (ESAs) in treating the anemia of chronic kidney disease has been reevaluated in view of recent studies suggesting that the use of these agents may be associated with increased morbidity and mortality. This potential increased risk needs to be weighed against the potential benefit of ESAs in improving various aspects of health-related quality of life, in particular, exercise tolerance and physical functioning. Study Design: A systematic review and meta-analysis of exercise tolerance and physical functioning. Setting & Participants: Adults on maintenance dialysis therapy. Selection Criteria for Studies: Outcomes measured before and after ESA treatment were required. Studies of physical function were required to include at least 25 participants. Intervention: Treatment with any ESA. Outcomes: Exercise tolerance measured using VO2peak (oxygen consumption per minute at the peak workload during the test), duration of exercise, or 6-minute walk distance or physical functioning assessed using >= 1 patient-or clinician-reported outcome measure that included a physical function domain. Results: 28 articles met criteria for inclusion for evaluation of exercise tolerance, and 14 articles, for physical function. Meta-analysis showed a 23.8% increase in VO2peak from before to after erythropoietin therapy initiation (15 studies) and a nonsignificant 8.2% increase comparing a higher with a lower hemoglobin target (3 studies). For physical functioning, 4 studies met criteria for inclusion in the meta-analysis: there was a 10.5% increase in Karnofsky score from before to after erythropoietin therapy initiation. Limitations: Many studies of exercise tolerance did not include control groups. A wide variety of instruments was used to assess physical function. Conclusions: Partial correction of anemia through ESA treatment has a consistent and positive impact on VO2peak. ESA treatment improves patient-and clinician-assessed physical functioning. Am J Kidney Dis 55: 535-548. (C) 2010 by the National Kidney Foundation, Inc. C1 [Johansen, Kirsten L.] Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Finkelstein, Fredric O.] Yale Univ, Hosp St Raphael, New Haven, CT USA. [Revicki, Dennis A.] United BioSource Corp, Bethesda, MD USA. [Gitlin, Matthew; Mayne, Tracy J.] Amgen Inc, Thousand Oaks, CA USA. [Evans, Christopher] Mapi Values, Boston, MA USA. RP Johansen, KL (reprint author), Univ Calif San Francisco, San Francisco VA Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA. EM kirsten.johansen@ucsf.edu FU Amgen Inc. FX This study was conceived by employees of Amgen Inc, which markets ESAs; Dr Gitlin is an employee of Amgen Inc. Dr Mayne formerly was an employee of Amgen Inc. Drs Johansen and Finkelstein have received research support from Amgen Inc. Dr Revicki and his employer United Biosource Corp, as well as Dr Evans and his employer MapiValues, have received consulting fees and research support from Amgen Inc. NR 70 TC 35 Z9 37 U1 3 U2 10 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 EI 1523-6838 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD MAR PY 2010 VL 55 IS 3 BP 535 EP 548 DI 10.1053/j.ajkd.2009.12.018 PG 14 WC Urology & Nephrology SC Urology & Nephrology GA 563DW UT WOS:000275109000017 PM 20133033 ER PT J AU Jolly, SE Burrows, NR Chen, SC Li, SY Jurkovitz, CT Narva, AS Norris, KC Shlipak, MG AF Jolly, Stacey E. Burrows, Nilka Rios Chen, Shu-Cheng Li, Suying Jurkovitz, Claudine T. Narva, Andrew S. Norris, Keith C. Shlipak, Michael G. TI Racial and Ethnic Differences in Albuminuria in Individuals With Estimated GFR Greater Than 60 mL/min/1.73 m(2): Results From the Kidney Early Evaluation Program (KEEP) SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Article DE Albuminuria; health disparities; Kidney Early Evaluation Program (KEEP); screening ID GLOMERULAR-FILTRATION-RATE; SERUM CREATININE VALUES; RENAL-DISEASE; NONDIABETIC INDIVIDUALS; CARDIOVASCULAR EVENTS; GENERAL-POPULATION; AMERICAN-INDIANS; NATIONAL-HEALTH; HEART-FAILURE; UNITED-STATES AB Background: Albuminuria is an important marker for chronic kidney disease and progression to end-stage renal disease in the general population; understanding racial and ethnic differences can help inform efforts to reduce health disparities. We sought to estimate independent associations of race/ethnicity with albuminuria to determine whether observed differences were attributable to known kidney disease risk factors. Methods: This cross-sectional study included 64,161 Kidney Early Evaluation Program (KEEP) participants, 2000-2008, with estimated glomerular filtration rate >= 60 mL/min/1.73 m(2), not on regular dialysis therapy, and without a previous kidney transplant. Albuminuria (urine albumin-creatinine ratio >= 30 mg/g) was examined by self-reported race and ethnicity. Covariates were age, sex, educational level, body mass index, diabetes status or glucose level, hypertension status or blood pressure measurement, smoking status, health insurance status, and geographic region. Results: Albuminuria prevalences were 8% (n = 2,303) in whites, 11% (n = 2,310) in African Americans, 9% (n = 730) in Hispanics, 10% (n = 381) in Asians, and 15% (n = 344) in American Indians/ Alaska Natives. Compared with whites, odds of albuminuria were higher for all groups after multivariate adjustment. Odds were highest for American Indians/Alaska Natives (adjusted OR, 1.93; 95% CI, 1.70-2.20), then Asians (adjusted OR, 1.42; 95% CI, 1.26-1.61), African Americans (adjusted OR, 1.38; 95% CI, 1.29-1.47), and Hispanics (adjusted OR, 1.19; 95% CI, 1.08-1.31). Conclusions: In the KEEP study population, albuminuria prevalence was higher in African Americans, Hispanics, Asians, and American Indians/Alaska Natives than in non-Hispanic whites, suggesting a need for screening for early detection of kidney damage, especially in people at increased risk, in the community primary care setting. Am J Kidney Dis 55(S2):S15-S22. (c) 2010 by the National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved. C1 [Jolly, Stacey E.] Cleveland Clin, Inst Med, Cleveland, OH 44195 USA. [Burrows, Nilka Rios] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA USA. [Chen, Shu-Cheng; Li, Suying] Minneapolis Med Res Fdn Inc, Chron Dis Res Grp, Minneapolis, MN USA. [Jurkovitz, Claudine T.] Christiana Care Hlth Syst, Ctr Outcomes Res, Newark, DE USA. [Narva, Andrew S.] NIDDK, Bethesda, MD USA. [Norris, Keith C.] Charles R Drew Univ Med & Sci, Dept Internal Med, Los Angeles, CA 90059 USA. [Shlipak, Michael G.] Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. RP Jolly, SE (reprint author), Cleveland Clin, Inst Med, 9500 Euclid Ave,G10, Cleveland, OH 44195 USA. EM jollys@ccf.org FU National Kidney Foundation Inc; Amgen; Abbott; Novartis; Siemens; Genentech; Genzyme; Nephroceuticals; Pfizer; LifeScan; Suplena; National Institute of Diabetes and Digestive and Kidney Diseases [R01 DK 066488] FX The KEEP is a program of the National Kidney Foundation Inc and is supported by Amgen, Abbott, Novartis, Siemens, Genentech, Genzyme, Nephroceuticals, Pfizer, LifeScan, and Suplena. Dr Shlipak's work was supported by the American Heart Association Established Investigator Award and R01 DK 066488 from the National Institute of Diabetes and Digestive and Kidney Diseases. NR 41 TC 18 Z9 19 U1 0 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD MAR PY 2010 VL 55 IS 3 SU 2 BP S15 EP S22 DI 10.1053/j.ajkd.2009.09.034 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA 559WU UT WOS:000274859800003 PM 20172444 ER PT J AU Copeland, LA Berg, GD Johnson, DM Bauer, RL AF Copeland, Laurel A. Berg, Gregory D. Johnson, Donna M. Bauer, Richard L. TI An Intervention for VA Patients With Congestive Heart Failure SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Article ID PROPENSITY SCORE; READMISSION; POPULATION; CARDIOMYOPATHY; MANAGEMENT; MORTALITY; ADMISSION; OUTCOMES; RISK; CARE AB Objective: To assess the effect of a telephone intervention to improve quality of life among patients with congestive heart failure (CHF). Study Design: Prospective randomized study. Methods: Single-site recruitment of 458 patients using Veterans Health Administration care into a randomized controlled trial with a 1-year pre-intervention data collection period and a 1-year intervention and follow-up period. To compensate for imbalanced study groups, propensity scores were included in adjusted models of quality of life, satisfaction with care, inpatient utilization, survival, and costs of care. Results: Patients aged 45 to 95 years participated in the study; 22% were of Hispanic race/ethnicity, and 7% were African American. All but 5 were male, consistent with the older population among veterans. At baseline, 40% were in Goldman Specific Activity Scale class I, 42% were in class III, 6% were in class II or IV, and 12% were unclassified. Patients scored a mean (SD) of 14 (1.5) points below the norm on the physical component score. After the yearlong intervention, no differences in clinical outcomes were noted between the intervention group and the control group. The CHF-related costs were higher for the intervention group, as were overall costs that included the cost of the intervention. Intervention group patients reported better compliance with weight monitoring and exercise recommendations. Conclusions: A risk-stratified intervention for patients with CHF resulted in potential behavioral improvements but no survival benefit. A high-cost high-intensity intervention may be required to improve survival for patients with CHF. Inclusion of the costs of interventions is recommended for future researchers. (Am J Manag Care. 2010; 16(3): 158-165) C1 [Copeland, Laurel A.; Bauer, Richard L.] S Texas Vet Hlth Care Syst, Dept Vet Affairs, VERDICT Res Ctr, San Antonio, TX 78229 USA. [Copeland, Laurel A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Bauer, Richard L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Berg, Gregory D.; Johnson, Donna M.] McKesson Corp, Broomfield, CO USA. RP Copeland, LA (reprint author), S Texas Vet Hlth Care Syst, Dept Vet Affairs, VERDICT Res Ctr, 7400 Merton Minter 11C6, San Antonio, TX 78229 USA. EM laurel.copeland@va.gov OI Copeland, Laurel/0000-0002-9478-0209 FU Veterans Health Administration, Health Services Research and Development; Office of the Chief of Staff and the VERDICT Research Center, South Texas Veterans Health Care System; McKesson Corporation; Veterans Health Administration [MRP-05-145, IIR-05-326] FX This study was supported by the Veterans Health Administration, Health Services Research and Development Program; by the Office of the Chief of Staff and the VERDICT Research Center, South Texas Veterans Health Care System; and by the McKesson Corporation, which developed the intervention tested.; Dr Copeland was supported by Health Services Research and Development Program career development grants MRP-05-145 and IIR-05-326 from the Veterans Health Administration. NR 28 TC 12 Z9 12 U1 0 U2 3 PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC PI PLAINSBORO PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD MAR PY 2010 VL 16 IS 3 BP 158 EP 165 PG 8 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 567XY UT WOS:000275483400001 PM 20225911 ER PT J AU Pevnick, JM Asch, SM Adams, JL Mattke, S Patel, MH Ettner, SL Bell, DS AF Pevnick, Joshua M. Asch, Steven M. Adams, John L. Mattke, Soeren Patel, Mihir H. Ettner, Susan L. Bell, Douglas S. TI Adoption and Use of Stand-Alone Electronic Prescribing in a Health Plan-Sponsored Initiative SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Article ID MEDICAL-RECORDS; PHYSICIANS; CARE; QUALITY; ERRORS AB Objectives: To quantify rates of stand-alone e-prescribing (SEP) adoption and use among primary care physicians (PCPs) participating in a SEP initiative and to determine which physician and patient characteristics were associated with higher rates of each. Study Design: Using records from an insurer-led SEP initiative, we compared the characteristics of 297 PCPs who adopted SEP through the initiative with the characteristics of 1892 eligible PCPs who did not. Among 297 adopters, we studied the extent of SEP use. Methods: Dependent variables included each physician's adoption of SEP and his or her e-prescribing use ratio (the ratio of electronic prescriptions to pharmacy claims in the same period). Independent variables included characteristics of PCPs (specialty, practice size, and prescribing volume) and their patients (patient age, sex, race/ethnicity, and household income). Results: Solo practitioners, pediatricians, and physicians with more patients from predominantly African American zip codes were under-represented among SEP adopters. The mean (SD) e-prescribing use ratio among adopters was 0.23 (0.28). Twenty percent of physicians maintained e-prescribing use ratios above 0.50. Available physician characteristics explained little of the variance in use, but physicians in smaller practices had greater use (P = .02). Conclusions: Certain categories of physicians may need more tailored incentives to adopt SEP. On average, adopters used the SEP system for only about one-quarter of their prescriptions. Some adopters achieved high levels of SEP use, and further research is needed to elucidate the factors that enabled this. (Am J Manag Care. 2010; 16(3): 182-189) C1 [Pevnick, Joshua M.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Pevnick, Joshua M.; Asch, Steven M.] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA. [Asch, Steven M.; Adams, John L.; Bell, Douglas S.] RAND Hlth, Santa Monica, CA USA. [Mattke, Soeren] RAND Hlth, Boston, MA USA. [Patel, Mihir H.] Horizon Blue Cross Blue Shield New Jersey, Newark, NJ USA. [Asch, Steven M.; Ettner, Susan L.; Bell, Douglas S.] Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA USA. RP Pevnick, JM (reprint author), Cedars Sinai Med Ctr, 8700 Beverly Blvd,Rm B113, Los Angeles, CA 90048 USA. EM jpevnick@gmail.com RI Bell, Douglas/G-6702-2013 OI Bell, Douglas/0000-0002-5063-8294 FU Agency for Healthcare Research and Quality [1U18HS016391-01]; Department of Veterans Affairs FX This project was funded by grant 1U18HS016391-01 from the Agency for Healthcare Research and Quality as part of a larger set of e-prescribing pilot studies. This work was also supported by a health services research and development fellowship from the Department of Veterans Affairs (Dr Pevnick). NR 22 TC 11 Z9 11 U1 1 U2 2 PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC PI PLAINSBORO PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD MAR PY 2010 VL 16 IS 3 BP 182 EP 189 PG 8 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 567XY UT WOS:000275483400003 PM 20225913 ER PT J AU Bekris, LM Galloway, NM Montine, TJ Schellenberg, GD Yu, CE AF Bekris, Lynn M. Galloway, Nichole M. Montine, Thomas J. Schellenberg, Gerard D. Yu, Chang-En TI APOE mRNA and Protein Expression in Postmortem Brain Are Modulated by an Extended Haplotype Structure SO AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS LA English DT Article DE Alzheimer's disease; APOE; post-mortem brain; TOMM40 ID APOLIPOPROTEIN-E GENE; AMYLOID PRECURSOR PROTEIN; ONSET ALZHEIMERS-DISEASE; TRANSGENIC MICE; E GENOTYPE; MITOCHONDRIAL DYSFUNCTION; PROMOTER POLYMORPHISMS; LINKAGE DISEQUILIBRIUM; ALLELIC EXPRESSION; REGULATORY REGION AB Currently the epsilon 4 allele of the apolipoprotein E gene (APOE) is the strongest genetic risk factor for late onset Alzheimer's disease (AD). However, inheritance of the APOE epsilon 4 allele is not necessary or sufficient for the development of AD. Genetic evidence suggests that multiple loci in a 70 kb region surrounding APOE are associated with AD risk. Even though these loci could represent surrogate markers in linkage disequilibrium with APOE epsilon 4 allele, they could also contribute biological effects independent of the APOE epsilon 4 allele. Our previous study identified multiple SNPs upstream from APOE that are associated with cerebrospinal fluid apoE levels, suggesting that a haplotype structure proximal to APOE can influence apoE expression. In this study, we examined apoE expression in human post-mortem brain (PMB), and constructed chromosome-phase-separated haplotypes of the APOE proximal region to evaluate their effect on PMB apoE expression. ApoE protein expression was found to differ among AD brain regions and to differ between AD and control hippocampus. in addition, an extended APOE proximal haplotype structure, spanning from the TOMM40 gene to the APOE promoter, may modulate apoE expression in a brain region-specific manner and may influence AD disease status. In conclusion, this haplotype-phenotype analysis of apoE expression in PMB suggests that either; (1) the cis-regulation of APOE expression levels extends far upstream of the APOE promoter or (2) an APOE epsilon 4 allele independent mechanism involving the TOMM40 gene plays a role in the risk of AD. (C) 2009 Wiley-Liss, Inc. C1 [Bekris, Lynn M.; Galloway, Nichole M.; Yu, Chang-En] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Bekris, Lynn M.; Yu, Chang-En] Univ Washington, Dept Med, Seattle, WA USA. [Montine, Thomas J.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA. [Schellenberg, Gerard D.] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA. RP Bekris, LM (reprint author), 1660 S Colombian Way,Box 358280 GRECC S182B, Seattle, WA 98108 USA. EM lbekris@u.washington.edu FU Veterans Affairs Biomedical Laboratory Research Development Merit Review; National Institutes of Health [P50 AG00536] FX Grant sponsor: Veterans Affairs Biomedical Laboratory Research Development Merit Review; Grant sponsor: National Institutes of Health; Grant Number: P50 AG00536. NR 48 TC 32 Z9 32 U1 0 U2 6 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1552-4841 J9 AM J MED GENET B JI Am. J. Med. Genet. B PD MAR PY 2010 VL 153B IS 2 BP 409 EP 417 DI 10.1002/ajmg.b.30993 PG 9 WC Genetics & Heredity; Psychiatry SC Genetics & Heredity; Psychiatry GA 566NI UT WOS:000275377900006 PM 19554612 ER PT J AU Holland, R Meyers, D Hildebrand, C Bridges, AJ Roach, MA Vogelman, B AF Holland, Robert Meyers, David Hildebrand, Christopher Bridges, Alan J. Roach, Mary A. Vogelman, Bennett TI Creating Champions for Health Care Quality and Safety SO AMERICAN JOURNAL OF MEDICAL QUALITY LA English DT Article DE systems-based learning; quality improvement; patient safety; graduate medical education; health care quality ID IMPROVEMENT; MEDICINE; PERFORMANCE; COMPETENCE; EDUCATION AB Patient safety and quality of care are public concerns that demand personal responsibility at all levels of the health care organization. Senior residents in our graduate medical education program took responsibility for a capstone quality improvement project designed to transform them into champions for health care quality. Residents (n = 26) participated alone or in pairs in a 1-month faculty-mentored rotation at the Veterans Administration Hospital during the 2007-2008 academic year. They completed a Web-based curriculum, identified a quality-of-care issue, applied Plan-Do-Study-Act cycles, authored a report, and engaged colleagues in their innovations during a department-wide presentation. Results indicated that residents demonstrated significantly enhanced knowledge and attitudes about patient safety and quality improvement and provided consistently positive faculty and rotation evaluations. In addition, residents generated 20 quality improvement project proposals with a 50% rate of hospital-wide implementation, leading to meaningful changes in the systems that affect patient care. C1 [Holland, Robert; Meyers, David; Hildebrand, Christopher; Bridges, Alan J.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA. [Roach, Mary A.; Vogelman, Bennett] Univ Wisconsin, Madison Sch Med & Publ Hlth, Madison, WI USA. RP Holland, R (reprint author), William S Middleton Mem Vet Adm Med Ctr, 2500 Overlook Terrace, Madison, WI 53705 USA. EM Robert.Holland@va.gov FU Medical Education and Research Committee (MERC) of the University of Wisconsin-Madison School of Medicine and Public Health FX The authors disclosed receipt of the following financial support for the research and/or authorship of this article: Completion of this article was made possible by a grant from the Medical Education and Research Committee (MERC) of the University of Wisconsin-Madison School of Medicine and Public Health as well as by the support of the Education Innovation Project of the Residency Review Committee for Internal Medicine, of which we are a participating residency. NR 18 TC 12 Z9 12 U1 1 U2 6 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1062-8606 J9 AM J MED QUAL JI Am. J. Med. Qual. PD MAR-APR PY 2010 VL 25 IS 2 BP 102 EP 108 DI 10.1177/1062860609352108 PG 7 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 566KZ UT WOS:000275370400004 PM 19966115 ER PT J AU Singh, H Thomas, EJ Sittig, DF Wilson, L Espadas, D Khan, MM Petersen, LA AF Singh, Hardeep Thomas, Eric J. Sittig, Dean F. Wilson, Lindsey Espadas, Donna Khan, Myrna M. Petersen, Laura A. TI Notification of Abnormal Lab Test Results in an Electronic Medical Record: Do Any Safety Concerns Remain? SO AMERICAN JOURNAL OF MEDICINE LA English DT Article DE Abnormal diagnostic test results; Communication; Diagnostic errors; Electronic medical records; Health information technology; Patient follow-up; Patient safety; Primary care ID INFORMATION-TECHNOLOGY; FOLLOW-UP; COMMUNICATION; ERRORS; DIAGNOSIS AB BACKGROUND: Follow-up of abnormal outpatient laboratory test results is a major patient safety concern. Electronic medical records can potentially address this concern through automated notification. We examined whether automated notifications of abnormal laboratory results (alerts) in an integrated electronic medical record resulted in timely follow-up actions. METHODS: We studied 4 alerts: hemoglobin Alc >= 15%, positive hepatitis C antibody, prostate-specific antigen >= 15 ng/mL and thyroid-stimulating hormone >= 15 mlU/L. An alert tracking system determined whether the alert was acknowledged (ie, provider clicked on and opened the message) within 2 weeks of transmission;. acknowledged alerts were considered read. Within 30 days of result transmission, record review and provider contact determined follow-up actions (eg. patient contact, treatment). Multivariable logistic regression models analyzed predictors for lack of timely follow-up. RESULTS: Between May and December 2008, 78,158 tests (hemoglobin Ale, hepatitis C antibody, thyroid- stimulating hormone, and prostate-specific antigen) were performed, of which 1163 (1.48%) were transmitted as alerts; 10.2% of these (119/1163) were unacknowledged. Timely follow-up was lacking in 79 (6.8%), and was statistically not different for acknowledged and unacknowledged alerts (6.4% vs 10.1 %; P = .13). Of 1163 alerts, 202 (17.4%) arose from unnecessarily ordered (redundant) tests. Alerts for a new versus known diagnosis were more likely to lack timely follow-up (odds ratio 7.35; 95% confidence interval, 4.16-12.97), whereas alerts related to redundant tests were less likely to lack timely follow-up (odds ratio 0.24; 95% confidence interval, 0.07-0.84). CONCLUSIONS: Safety concerns related to timely patient follow-up remain despite automated notification of non-life-threatening abnormal laboratory results in the outpatient setting, Published by, Elsevier Inc. . The American Journal of Medicine (2010) 123, 238-244 C1 [Singh, Hardeep; Wilson, Lindsey; Espadas, Donna; Khan, Myrna M.; Petersen, Laura A.] Baylor Coll Med, Houston VA Hlth Serv Res & Dev Ctr Excellence, Ctr Inquiry Improve Outpatient Safety Effect Elec, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Singh, Hardeep; Wilson, Lindsey; Espadas, Donna; Khan, Myrna M.; Petersen, Laura A.] Baylor Coll Med, Sect Hlth Serv Res, Dept Med, Houston, TX 77030 USA. [Thomas, Eric J.] Univ Texas Houston, Div Gen Med, Dept Med,Univ Texas Med Sch Houston, Mem Hermann Ctr Healthcare Qual & Safety, Houston, TX USA. [Sittig, Dean F.] Univ Texas Sch Hlth Informat Sci, Houston, TX USA. [Sittig, Dean F.] UT Mem Hermann Ctr Healthcare Qual & Safety, Houston, TX USA. RP Singh, H (reprint author), VA Med Ctr 152, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM hardeeps@bcm.tmc.edu FU NIH [K23CA125585]; VA National Center of Patient Safety; Agency for Health Care Research and Quality Health Services Research Demonstration and Dissemination [R18 HS17244-02]; Houston VA Health Set-vices Research & Development Center of Excellence [HFP90-020] FX The study was supported by an NIH K23 career development award (K23CA125585) to Dr. Singh, the VA National Center of Patient Safety, Agency for Health Care Research and Quality Health Services Research Demonstration and Dissemination Grant (R18 HS17244-02) to Dr. Thomas, and in part by the Houston VA Health Set-vices Research & Development Center of Excellence (HFP90-020). These sources had no role in the design and conduct of the study: collection, management. analysis. and interpretation of the data: and preparation, review, or approval of the manuscript. NR 26 TC 53 Z9 53 U1 3 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9343 J9 AM J MED JI Am. J. Med. PD MAR PY 2010 VL 123 IS 3 BP 238 EP 244 DI 10.1016/j.amjmed.2009.07.027 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 572EE UT WOS:000275809400013 PM 20193832 ER PT J AU Choi, AI Hernandez, GT Rodriguez, RA O'Hare, AM AF Choi, Andy I. Hernandez, German T. Rodriguez, Rudolph A. O'Hare, Ann M. TI Influence of Hispanic Ethnicity and Diabetic End-stage Renal Disease Reply SO AMERICAN JOURNAL OF MEDICINE LA English DT Letter C1 [Choi, Andy I.] Univ Calif San Francisco, Dept Med, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. [Hernandez, German T.] Texas Tech Univ, Hlth Sci Ctr, Dept Med, Paul L Foster Sch Med, El Paso, TX USA. [Rodriguez, Rudolph A.; O'Hare, Ann M.] Univ Washington, Dept Med, VA Puget Sound Healthcare Syst, Seattle, WA USA. RP Choi, AI (reprint author), Univ Calif San Francisco, Dept Med, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. NR 2 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9343 J9 AM J MED JI Am. J. Med. PD MAR PY 2010 VL 123 IS 3 BP E21 EP E21 DI 10.1016/j.amjmed.2009.11.002 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 572EE UT WOS:000275809400031 ER PT J AU Daniel, E Thorne, JE Newcomb, CW Pujari, SS Kacmaz, RO Levy-Clarke, GA Nussenblatt, RB Rosenbaum, JT Suhler, EB Foster, CS Jabs, DA Kempen, JH AF Daniel, Ebenezer Thorne, Jennifer E. Newcomb, Craig W. Pujari, Siddharth S. Kacmaz, R. Oktay Levy-Clarke, Grace A. Nussenblatt, Robert B. Rosenbaum, James T. Suhler, Eric B. Foster, C. Stephen Jabs, Douglas A. Kempen, John H. TI Mycophenolate Mofetil for Ocular Inflammation SO AMERICAN JOURNAL OF OPHTHALMOLOGY LA English DT Article ID EYE DISEASE; IMMUNOSUPPRESSIVE THERAPY; UVEITIS; AGENT; DRUGS AB PURPOSE: To evaluate mycophenolate mofetil as a single noncorticosteroid immunosuppressive treatment for noninfectious ocular inflammatory diseases. DESIGN: Retrospective cohort study. METHODS: Characteristics of patients with noninfectious ocular inflammation treated with mycophenolate mofetil at 4 subspecialty clinics from 1995 to 2007 were abstracted by expert reviewers in a standardized chart review of every eye at every visit. Main outcomes measured were control of inflammation, corticosteroid-sparing effects, and discontinuation of mycophenolate mofetil (including the reasons for discontinuation). Survival analysis was used to estimate the incidence of outcomes, and to identify risk factors for each. RESULTS: Among 236 patients (397 eyes) treated with mycophenolate mofetil monotherapy, 20.3%, 11.9%, and 39.8% had anterior uveitis, intermediate uveitis, and posterior uveitis or panuveitis respectively; 14% had scleritis; 7.6% had mucous membrane pemphigoid; and 6.4% had other ocular inflammatory diseases. By Kaplan-Meier estimation, complete control of inflammation-sustained over consecutive visits spanning at least 28 days-was achieved in 53% and 73% of patients within 6 months and 1 year respectively. Systemic corticosteroid dosage was reduced to 10 mg of prednisone or less, while maintaining sustained control of inflammation, in 41% and 55% of patients in 6 months and 1 year respectively. Twelve percent of patients discontinued mycophenolate mofetil within the first year because of side effects of therapy. CONCLUSIONS: Given sufficient time, mycophenolate mofetil was effective in managing ocular inflammation in approximately half of the treated patients. Treatment, limiting side effects were observed in 12% of patients and typically were reversible. (Am J Ophthalmol 2010;149: 423-432. (C) 2010 by Elsevier Inc. All rights reserved.) C1 [Kempen, John H.] Univ Penn, Dept Ophthalmol, Ctr Prevent Ophthalmol & Biostat, Sch Med, Philadelphia, PA 19104 USA. [Daniel, Ebenezer] Univ Penn, Sch Med, Fundus Photograph Reading Ctr, Philadelphia, PA 19104 USA. [Newcomb, Craig W.; Jabs, Douglas A.] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Newcomb, Craig W.; Kempen, John H.] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Thorne, Jennifer E.] Johns Hopkins Univ, Dept Ophthalmol, Baltimore, MD USA. [Thorne, Jennifer E.] Johns Hopkins Univ, Dept Epidemiol, Baltimore, MD USA. [Pujari, Siddharth S.; Kacmaz, R. Oktay; Foster, C. Stephen] Massachusetts Eye Res & Surg Inst, Cambridge, MA USA. [Levy-Clarke, Grace A.] St Lukes Cataract & Laser Inst, Dept Ophthalmol, Tarpon Springs, FL USA. [Levy-Clarke, Grace A.; Nussenblatt, Robert B.] NEI, Immunol Lab, Bethesda, MD 20892 USA. [Rosenbaum, James T.; Suhler, Eric B.] Oregon Hlth & Sci Univ, Dept Ophthalmol, Portland, OR 97201 USA. [Rosenbaum, James T.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA. [Suhler, Eric B.] Portland VA Med Ctr, Portland, OR USA. [Foster, C. Stephen] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA. [Kacmaz, R. Oktay; Jabs, Douglas A.] Mt Sinai Sch Med, Dept Ophthalmol, New York, NY USA. [Jabs, Douglas A.] Mt Sinai Sch Med, Dept Med, New York, NY USA. RP Kempen, JH (reprint author), Univ Penn, Dept Ophthalmol, Ctr Prevent Ophthalmol & Biostat, Sch Med, 3535 Market St,Suite 700, Philadelphia, PA 19104 USA. EM john.kempen@uphs.upenn.edu OI Daniel, Ebenezer/0000-0002-2027-2316 FU NEI NIH HHS [EY014943, R01 EY014943, R01 EY014943-05, R56 EY014943] NR 27 TC 78 Z9 82 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9394 J9 AM J OPHTHALMOL JI Am. J. Ophthalmol. PD MAR PY 2010 VL 149 IS 3 BP 423 EP 432 DI 10.1016/j.ajo.2009.09.026 PG 10 WC Ophthalmology SC Ophthalmology GA 565MD UT WOS:000275296400011 PM 20042178 ER PT J AU Baker, AM Klein, RL Haeri, S Moss, KL Boggess, KA AF Baker, Arthur M. Klein, Richard L. Haeri, Sina Moss, Kevin L. Boggess, Kim A. TI Association of Midgestational Paraoxonase 1 Activity with Pregnancies Complicated by Preeclampsia SO AMERICAN JOURNAL OF PERINATOLOGY LA English DT Article DE Lipid dysfunction; oxidative stress; paraoxonase; preeclampsia ID DEPENDENT DIABETES-MELLITUS; SERUM PARAOXONASE; ANTIOXIDANT; WOMEN; ARYLESTERASE; COHORT; RISK AB The antioxidant enzyme paraoxonase 1 is a marker of oxidative stress and has been implicated in the pathogenesis of preeclampsia. Our objective was to determine if an association exists between low paraoxonase 1 activity at midgestation and the development of preeclampsia. We conducted a case-control study of 50 women with preeclampsia and 101 women with uncomplicated term deliveries. Maternal serum collected at 15 to 20 weeks was used to measure paraoxonase 1 activity using two substrates: paraoxon and phenylacetate (arylesterase activity). The groups did not differ with respect to maternal demographics. Paraoxonase 1 activity (paraoxon) was significantly higher in women with preeclampsia compared with controls (19.4 +/- 9.4 versus 15.6 +/- 8.0 change in absorbance per minute (dA/min), p = 0.009). When stratified by disease severity, paraoxonase 1 activity (paraoxon) was highest in women with severe preeclampsia (21.6 +/- 9.1 versus 15.6 +/- 8.0 dA/min, p = 0.002). We observed a trend toward higher arylesterase activity in women with preeclampsia compared with controls (0.343 +/- 0.07 versus 0.323 +/- 0.06 dA/min, p = 0.06). Midgestational paraoxonase 1 activity is higher in women with preeclampsia before clinical signs of the disease are present. Prospective studies are needed to determine the significance of paraoxonase 1 in the pathogenesis of preeclampsia. C1 [Baker, Arthur M.; Haeri, Sina; Boggess, Kim A.] Univ N Carolina, Dept Obstet & Gynecol, Div Maternal Fetal Med, Chapel Hill, NC 27599 USA. [Klein, Richard L.] Med Univ S Carolina, Dept Med, Div Endocrinol Metab & Med Genet, Charleston, SC 29425 USA. [Klein, Richard L.] Ralph H Johnson Dept Vet Affairs Med Ctr, Res Serv, Charleston, SC USA. [Moss, Kevin L.] Univ N Carolina, Dept Dent, Chapel Hill, NC 27599 USA. RP Baker, AM (reprint author), Univ N Carolina, Dept Obstet & Gynecol, Div Maternal Fetal Med, 3010 Old Clin Bldg,CB 7516, Chapel Hill, NC 27599 USA. EM abaker2@med.unc.edu FU University of North Carolina; Department of Veterans' Affairs FX This work was supported by a grant from The University of North Carolina Medical Alumni Endowment Fund (A. M. B.) and funding from a Department of Veterans' Affairs MERIT award (R. L. K.). The authors gratefully acknowledge the technical assistance of Ms. Andrea Semler. NR 25 TC 5 Z9 7 U1 0 U2 0 PU THIEME MEDICAL PUBL INC PI NEW YORK PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA SN 0735-1631 J9 AM J PERINAT JI Am. J. Perinatol. PD MAR PY 2010 VL 27 IS 3 BP 205 EP 210 DI 10.1055/s-0029-1236438 PG 6 WC Obstetrics & Gynecology; Pediatrics SC Obstetrics & Gynecology; Pediatrics GA 557JI UT WOS:000274665000004 PM 19685420 ER PT J AU Atkinson, GJ Lee, MY Mehta, MK AF Atkinson, George J. Lee, Michael Y. Mehta, Madhu K. TI Heterotopic Ossification in the Residual Lower Limb in an Adult Nontraumatic Amputee Patient SO AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION LA English DT Article DE Amputation; Ossification; Heterotopic; Adult; Rehabilitation ID BONE; OVERGROWTH; AMPUTATION AB Atkinson GJ, Lee MY, Mehta MK: Heterotopic ossification in the residual lower limb in an adult nontraumatic amputee patient. Am J Phys Med Rehabil 2010;89:245-248. Heterotopic ossification usually occurs in association with various neurologic injuries, trauma, and burns. There have been few reports in the literature of heterotopic bone formation at the distal residual limb in the adult amputee population. All previous cases with a documented cause have involved traumatic amputations. An adult diabetic patient who underwent left below-the-knee amputation for progressive Charcot foot is presented. The patient began to experience residual limb pain and decline in functional mobility 4-5 mos after surgery. Radiographs demonstrated heterotopic bone around the distal tibial and fibular remnant with extension into adjacent soft tissue. Triple-phase bone scan testing and tissue biopsy verified active heterotopic ossification. The patient was treated with etidronate and eventually was able to ambulate with a prosthesis on a regular basis. This case demonstrates that heterotopic ossification may occur and be a source of residual limb pain in the adult nontraumatic amputee population. C1 [Atkinson, George J.; Lee, Michael Y.; Mehta, Madhu K.] Univ N Carolina, Sch Med, Dept Phys Med & Rehabil, Chapel Hill, NC USA. RP Atkinson, GJ (reprint author), S Texas Vet Hlth Care Syst, Dept Phys Med & Rehabil, 1629 Treasure Hills Blvd,Suite B-5, Harlingen, TX 78550 USA. NR 12 TC 5 Z9 5 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0894-9115 J9 AM J PHYS MED REHAB JI Am. J. Phys. Med. Rehabil. PD MAR PY 2010 VL 89 IS 3 BP 245 EP 248 DI 10.1097/PHM.0b013e3181c5657c PG 4 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 569WM UT WOS:000275633500009 PM 19966560 ER PT J AU Liu, JR Wu, XX Franklin, JL Messina, JL Hill, HS Moellering, DR Walton, RG Martin, M Garvey, WT AF Liu, Jiarong Wu, Xuxia Franklin, John L. Messina, Joseph L. Hill, Helliner S. Moellering, Douglas R. Walton, R. Grace Martin, Mitchell Garvey, W. Timothy TI Mammalian Tribbles homolog 3 impairs insulin action in skeletal muscle: role in glucose-induced insulin resistance SO AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM LA English DT Article DE glucose toxicity; type 2 diabetes; insulin signaling ID FUNCTIONAL Q84R POLYMORPHISM; ACTIVATED PROTEIN-KINASE; METABOLIC SYNDROME; CELL-DEATH; GLUT4 TRANSLOCATION; SIGNAL-TRANSDUCTION; 3T3-L1 ADIPOCYTES; TRANSPORT SYSTEM; LIPID-METABOLISM; TRB3 EXPRESSION AB Liu J, Wu X, Franklin JL, Messina JL, Hill HS, Moellering DR, Walton RG, Martin M, Garvey WT. Mammalian Tribbles homolog 3 impairs insulin action in skeletal muscle: role in glucose-induced insulin resistance. Am J Physiol Endocrinol Metab 298: E565-E576, 2010. First published December 8, 2009; doi:10.1152/ajpendo. 00467.2009.-Tribbles homolog 3 (TRIB3) was found to inhibit insulin-stimulated Akt phosphorylation and modulate gluconeogenesis in rodent liver. Currently, we examined a role for TRIB3 in skeletal muscle insulin resistance. Ten insulin-sensitive, ten insulin-resistant, and ten untreated type 2 diabetic (T2DM) patients were metabolically characterized by hyperinsulinemic euglycemic glucose clamps, and biopsies of vastus lateralis were obtained. Skeletal muscle samples were also collected from rodent models including streptozotocin (STZ)-induced diabetic rats, db/db mice, and Zucker fatty rats. Finally, L6 muscle cells were used to examine regulation of TRIB3 by glucose, and stable cell lines hyperexpressing TRIB3 were generated to identify mechanisms underlying TRIB3-induced insulin resistance. We found that 1) skeletal muscle TRIB3 protein levels are significantly elevated in T2DM patients; 2) muscle TRIB3 protein content is inversely correlated with glucose disposal rates and positively correlated with fasting glucose; 3) skeletal muscle TRIB3 protein levels are increased in STZ-diabetic rats, db/db mice, and Zucker fatty rats; 4) stable TRIB3 hyperexpression in muscle cells blocks insulin-stimulated glucose transport and glucose transporter 4 (GLUT4) translocation and impairs phosphorylation of Akt, ERK, and insulin receptor substrate-1 in insulin signal transduction; and 5) TRIB3 mRNA and protein levels are increased by high glucose concentrations, as well as by glucose deprivation in muscle cells. These data identify TRIB3 induction as a novel molecular mechanism in human insulin resistance and diabetes. TRIB3 acts as a nutrient sensor and could mediate the component of insulin resistance attributable to hyperglycemia (i.e., glucose toxicity) in diabetes. C1 [Wu, Xuxia; Hill, Helliner S.; Moellering, Douglas R.; Walton, R. Grace; Garvey, W. Timothy] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA. [Messina, Joseph L.; Garvey, W. Timothy] Univ Alabama Birmingham, Birmingham Vet Affairs Med Ctr, Birmingham, AL 35294 USA. [Liu, Jiarong; Franklin, John L.; Messina, Joseph L.] Univ Alabama Birmingham, Dept Pathol, Div Mol & Cellular Pathol, Birmingham, AL 35294 USA. [Martin, Mitchell] Hoffmann La Roche Inc, Dept Res Informat Genet & Gen, Preclin Res & Dev, Nutley, NJ 07110 USA. RP Wu, XX (reprint author), Univ Alabama Birmingham, Dept Nutr Sci, 1675 Univ Blvd, Birmingham, AL 35294 USA. EM xuxiawu@uab.edu FU National Institute of Diabetes and Digestive and Kidney Diseases [DK-038764, DK-083562, DK-62071]; National Heart, Lung, and Blood Institute [HL-055782]; American Heart Association; Department of Defense [W81XWH-0510387]; Merit Review Program of the Department of Veterans Affairs; University of Alabama at Birmingham (UAB) Center for Clinical and Translational Science [UL1 RR025777]; UAB Clinical Nutrition Research Unit [P30-DK56336]; UAB Diabetes Research and Training Center [P60-DK079626] FX This work was supported by National Institute of Diabetes and Digestive and Kidney Diseases Grants DK-038764, DK-083562, and DK-62071 and National Heart, Lung, and Blood Institute Grant HL-055782, American Heart Association Beginning Grant-in-Aid (to X. Wu), the Department of Defense (W81XWH-0510387), and the Merit Review Program of the Department of Veterans Affairs (to W. T. Garvey and J. L. Messina). We also gratefully acknowledge the support of the University of Alabama at Birmingham (UAB) Center for Clinical and Translational Science (UL1 RR025777), the UAB Clinical Nutrition Research Unit (P30-DK56336), and the UAB Diabetes Research and Training Center (P60-DK079626). NR 66 TC 32 Z9 35 U1 1 U2 5 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1849 EI 1522-1555 J9 AM J PHYSIOL-ENDOC M JI Am. J. Physiol.-Endocrinol. Metab. PD MAR PY 2010 VL 298 IS 3 BP E565 EP E576 DI 10.1152/ajpendo.00467.2009 PG 12 WC Endocrinology & Metabolism; Physiology SC Endocrinology & Metabolism; Physiology GA 557YA UT WOS:000274705200020 PM 19996382 ER PT J AU Woods, SS Jaen, CR AF Woods, Susan Swartz Jaen, Carlos Roberto TI Increasing Consumer Demand for Tobacco Treatments Ten Design Recommendations for Clinicians and Healthcare Systems SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID SMOKING-CESSATION TREATMENTS; DEPENDENCE TREATMENT; PUBLIC-HEALTH; UNITED-STATES; PATIENT; SATISFACTION; SMOKERS; PHYSICIANS; BEHAVIORS; SERVICES AB Health professionals play an important role in addressing patient tobacco use in clinical settings. While there is clear evidence that identifying tobacco use and assisting smokers in quitting affects outcomes, challenges to improve routine, clinician-delivered tobacco intervention persist. The Consumer Demand Initiative has identified simple design principles to increase consumers' use of proven tobacco treatments. Applying these design strategies to activities across the healthcare system, we articulate ten recommendations that can be implemented in the context of most clinical systems where most clinicians work. The recommendations are: (1) reframe the definition of success, (2) portray proven treatments as the best care, (3) redesign the 5A's of tobacco intervention, (4) be ready to deliver the right treatment at the right time, (5) move tobacco from the social history to the problem list, (6) use words as therapy and language that makes sense, (7) fit tobacco treatment into clinical team workflows, (8) embed tobacco treatment into health information technology, (9) make every encounter an opportunity to intervene, and (10) end social disparities for tobacco users. Clinical systems need to change to improve tobacco treatment implementation. The consumer- and clinician-centered recommendations provide a roadmap that focuses on increasing clinician performance through greater understanding of the clinician's role in helping tobacco users, highlighting the value of evidence-based tobacco treatments, employing shared decision-making skills, and integrating routine tobacco treatment into clinical system routines. (Am J Prev Med 2010;38(3S):S385-S392) Published by Elsevier Inc. on behalf of American journal of Preventive Medicine C1 [Woods, Susan Swartz] Portland VA Med Ctr, Portland, OR 97239 USA. [Woods, Susan Swartz] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Jaen, Carlos Roberto] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. RP Woods, SS (reprint author), Portland VA Med Ctr, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM woodssus@ohsu.edu NR 50 TC 4 Z9 4 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD MAR PY 2010 VL 38 IS 3 SU 3 BP S385 EP S392 DI 10.1016/j.amepre.2009.12.003 PG 8 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 566OX UT WOS:000275383200013 PM 20176312 ER PT J AU Mortensen, EM Garcia, S Leykum, L Nakashima, B Restrepo, MI Anzueto, A AF Mortensen, Eric M. Garcia, Sean Leykum, Luci Nakashima, Brandy Restrepo, Marcos I. Anzueto, Antonio TI Association of Hypoglycemia With Mortality for Subjects Hospitalized With Pneumonia SO AMERICAN JOURNAL OF THE MEDICAL SCIENCES LA English DT Article DE Pneumonia; Hypoglycemia; Mortality ID COMMUNITY-ACQUIRED PNEUMONIA; ELDERLY-PATIENTS; GLUCOSE; SEPSIS; SEVERITY; OUTCOMES AB Background: Previous research has shown that hypoglycemia is associated with worse outcomes for the elderly, in sepsis, and in children with pneumonia. The purpose of this study was to examine whether hypoglycemia (<70 mg/dL) is associated with increased 30-day mortality, after adjusting for potential confounders, for adults hospitalized with pneumonia. Methods: A retrospective cohort study conducted at 2 tertiary teaching hospitals. Eligible subjects were admitted with a diagnosis of, and had a chest x-ray consistent with, community-acquired pneumonia. Our primary analysis was a multivariable logistic regression with the dependent variable of 30-day mortality and with independent variable of hypoglycemia, diabetes, severity of illness determined using the pneumonia severity index, and pneumonia-related processes of care. Results: Data were abstracted on 787 subjects at the 2 hospitals. Mortality was 8.1% at 30 days. At presentation, 55% of subjects were at low risk, 33% were at moderate risk, and 12% were at high risk. In our cohort, 2.8% (n = 22) had hypoglycemia at presentation. Unadjusted mortality for those who were hypoglycemic was 27.3% versus 8.6% for those who were not (P = 0.0003). In the multivariable analysis, hypoglycemia (odds ratio: 4.1, 95% confidence interval: 1.4-11.7) was significantly associated with 30-day mortality. Conclusions: After adjusting for severity of illness and other potential confounders, hypoglycemia is significantly associated with 30-day mortality for patients hospitalized with pneumonia. Patients with hypoglycemia should be placed in closely monitored settings even when by pneumonia specific risk systems they would normally be discharged. C1 [Mortensen, Eric M.; Garcia, Sean; Leykum, Luci; Restrepo, Marcos I.; Anzueto, Antonio] ALMD UTHSCSA, S Texas Vet Hlth Care Syst, VERDICT Res Program, Med Serv,Audie L Murphy Div, San Antonio, TX 78229 USA. [Mortensen, Eric M.] Univ Texas Hlth Sci Ctr San Antonio, Div Gen Internal Med, San Antonio, TX 78229 USA. [Restrepo, Marcos I.; Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, Div Pulm Crit Care Med, San Antonio, TX 78229 USA. [Garcia, Sean; Leykum, Luci] Univ Texas Hlth Sci Ctr San Antonio, Hosp Med, San Antonio, TX 78229 USA. RP Mortensen, EM (reprint author), ALMD UTHSCSA, S Texas Vet Hlth Care Syst, VERDICT Res Program, Med Serv,Audie L Murphy Div, 7400 Merton Minter Blvd 11C6, San Antonio, TX 78229 USA. EM mortensene@uthscsa.edu RI Restrepo, Marcos/H-4442-2014 OI Mortensen, Eric/0000-0002-3880-5563 FU Department of Veteran Affairs; Howard Hughes Medical Institute [00378-001]; NHLBI [NO1-HR-16153]; CTSA [KL2 RR025766] FX This study was supported by a Department of Veteran Affairs Veterans Integrated Service Network 17 new faculty grant and a Howard Hughes Medical Institute faculty-start up grant 00378-001 (EMM); in part, by the NHLBI grant NO1-HR-16153 (to AA); by a Department of Veteran Affairs Veterans Integrated Service Network 17 new faculty grant and a CTSA Award Number KL2 RR025766 (to MIR); and supported with resources and the use of facilities at the South Texas Veterans Health Care System. NR 22 TC 5 Z9 5 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0002-9629 J9 AM J MED SCI JI Am. J. Med. Sci. PD MAR PY 2010 VL 339 IS 3 BP 239 EP 243 DI 10.1097/MAJ.0b013e3181ca43fe PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA 567CD UT WOS:000275419000009 PM 20220334 ER PT J AU Gray, KM Watson, NL Carpenter, MJ LaRowe, SD AF Gray, Kevin M. Watson, Noreen L. Carpenter, Matthew J. LaRowe, Steven D. TI N-Acetylcysteine (NAC) in Young Marijuana Users: An Open-Label Pilot Study SO AMERICAN JOURNAL ON ADDICTIONS LA English DT Letter ID DOUBLE-BLIND; DEPENDENCE; PLACEBO C1 [Gray, Kevin M.; Watson, Noreen L.; Carpenter, Matthew J.; LaRowe, Steven D.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Carpenter, Matthew J.] Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA. [LaRowe, Steven D.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Gray, KM (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, 67 President St,POB 250861, Charleston, SC 29425 USA. EM graykm@musc.edu OI LaRowe, Steven/0000-0002-7664-2451 FU NCRR NIH HHS [M01 RR001070-31, M01 RR01070, M01 RR001070]; NIDA NIH HHS [K12 DA000357, K12 DA000357-09, K23 DA020482, K23 DA020482-03, R01 DA026777, R01 DA026777-01] NR 10 TC 45 Z9 47 U1 0 U2 3 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1055-0496 J9 AM J ADDICTION JI Am. J. Addict. PD MAR-APR PY 2010 VL 19 IS 2 BP 187 EP 189 DI 10.1111/j.1521-0391.2009.00027.x PG 3 WC Substance Abuse SC Substance Abuse GA 556VJ UT WOS:000274621100011 PM 20163391 ER PT J AU Reust, DL Reeves, ST Abernathy, JH Dixon, JA Gaillard, WF Mukherjee, R Koval, CN Stroud, RE Spinale, FG AF Reust, Daryl L. Reeves, Scott T. Abernathy, James H., III Dixon, Jennifer A. Gaillard, William F., II Mukherjee, Rupak Koval, Christine N. Stroud, Robert E. Spinale, Francis G. TI Temporally and Regionally Disparate Differences in Plasmin Activity by Tranexamic Acid SO ANESTHESIA AND ANALGESIA LA English DT Article ID EPSILON-AMINOCAPROIC ACID; CARDIAC-SURGERY; CARDIOPULMONARY BYPASS; BLOOD-TRANSFUSION; RENAL-FAILURE; REPERFUSION; FIBRINOLYSIS; METAANALYSIS; THROMBOSIS; INHIBITOR AB BACKGROUND: A major complication associated with cardiac surgery is excessive and prolonged bleeding in the perioperative period. Improving coagulation by inhibiting fibrinolysis, primarily through inhibition of plasmin activity (PLact) with antifibrinolytics such as tranexamic acid (TXA), has been a pharmacological mainstay in cardiac surgical patients. Despite its almost ubiquitous use, the temporal and regional modulation of PLact profiles by TXA remains unexplored. Accordingly, we developed a fluorogenic-microdialysis system to measure in vivo dynamic changes in PLact after TXA administration in a large animal model. METHODS: Pigs (25-35 kg) were randomly assigned to receive TXA (30 mg/kg, diluted into 50 mL normal saline; n = 9) or vehicle (50 mL normal saline; n = 7). Microdialysis probes were placed in the liver, myocardium, kidney, and quadriceps muscle compartments. The microdialysate infusion contained a validated plasmin-specific fluorogenic peptide. The fluorescence emission (standard fluorogenic units [SFU]) of the interstitial fluid collected from the microdialysis probes, which directly reflects PLact, was determined at steady-state baseline and 30, 60, 90, and 120 min after TXA/vehicle infusion. Plasma PLact was determined at the same time points using the same fluorogenic substrate approach. RESULTS: TXA reduced plasma PLact at 30 min after infusion by >110 SFU compared with vehicle values (P < 0.05). Specifically, there was a decrease in liver PLact at 90 and 120 min after TXA infusion of >150 SFU (P < 0.05) and 175 SFU (P < 0.05), respectively. The decrease in liver PLact occurred 60 min after the maximal decrease in plasma PLact. In contrast, kidney, heart, and quadriceps PLact transiently increased followed by an overall decrease at 120 min. CONCLUSIONS: Using a large animal model and in vivo microdialysis measurements of PLact, the unique findings from this study were 2-fold. First, TXA induced temporally distinct PLact profiles within the plasma and selected interstitial compartments. Second, TXA caused region-specific changes in PLact profiles. These temporal and regional differences in the effects of TXA may have important therapeutic considerations when managing fibrinolysis in the perioperative period. (Anesth Analg 2010; 110: 694-701) C1 [Spinale, Francis G.] Med Univ S Carolina, Dept Cardiothorac Surg, Div Cardiothorac Surg, Charleston, SC 29403 USA. [Reust, Daryl L.; Reeves, Scott T.; Abernathy, James H., III] Med Univ S Carolina, Dept Anesthesiol & Perioperat Med, Charleston, SC 29403 USA. [Dixon, Jennifer A.; Gaillard, William F., II; Mukherjee, Rupak; Koval, Christine N.; Stroud, Robert E.; Spinale, Francis G.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Spinale, FG (reprint author), Med Univ S Carolina, Dept Cardiothorac Surg, Div Cardiothorac Surg, Strom Thurmond Res Bldg,114 Doughty St,Room 625, Charleston, SC 29403 USA. EM wilburnm@musc.edu FU NIH [HL059165, HL078650]; Veterans' Affairs Health Administration FX Supported in part by NIH grants HL059165 and HL078650 and a Merit Award form the Veterans' Affairs Health Administration. NR 32 TC 6 Z9 6 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0003-2999 J9 ANESTH ANALG JI Anesth. Analg. PD MAR PY 2010 VL 110 IS 3 BP 694 EP 701 DI 10.1213/ANE.0b013e3181c7eb27 PG 8 WC Anesthesiology SC Anesthesiology GA 563MS UT WOS:000275137200012 PM 20185649 ER PT J AU Givrad, TK Maarek, JMI Moore, WH Holschneider, DP AF Givrad, Tina K. Maarek, Jean-Michel I. Moore, William H. Holschneider, Daniel P. TI Powering an Implantable Minipump with a Multi-layered Printed Circuit Coil for Drug Infusion Applications in Rodents SO ANNALS OF BIOMEDICAL ENGINEERING LA English DT Article DE Electromagnetic field; Class-E oscillator; Infusion pump; Printed coil; Radio frequency identification device ID CHALLENGE; RATS AB We report the use of a multi-layer printed coil circuit for powering (36-94 mW) an implantable microbolus infusion pump (MIP) that can be activated remotely for use in drug infusion in nontethered, freely moving small animals. This implantable device provides a unique experimental tool with applications in the fields of animal behavior, pharmacology, physiology, and functional brain imaging. Two different designs are described: a battery-less pump usable when the animal is inside a home-cage surrounded by a primary inductive coil and a pump powered by a rechargeable battery that can be used for studies outside the home-cage. The use of printed coils for powering of small devices by inductive power transfer presents significant advantages over similar approaches using hand-wound coils in terms of ease of manufacturing and uniformity of design. The high efficiency of a class-E oscillator allowed powering of the minipumps without the need for close physical contact of the primary and secondary coils, as is currently the case for most devices powered by inductive power transfer. C1 [Givrad, Tina K.; Maarek, Jean-Michel I.] Univ So Calif, Dept Biomed Engn, Los Angeles, CA 90089 USA. [Moore, William H.] Univ So Calif, Alfred E Mann Inst, Los Angeles, CA 90089 USA. [Holschneider, Daniel P.] Univ So Calif, Dept Psychiat, Los Angeles, CA 90089 USA. [Holschneider, Daniel P.] Univ So Calif, Dept Neurol, Los Angeles, CA 90089 USA. [Holschneider, Daniel P.] Univ So Calif, Dept Cell & Neurobiol, Los Angeles, CA 90089 USA. [Holschneider, Daniel P.] Univ So Calif, Dept Biomed Engn, Los Angeles, CA 90089 USA. [Holschneider, Daniel P.] Greater Los Angeles VA Med Ctr, Los Angeles, CA 90073 USA. RP Givrad, TK (reprint author), Univ So Calif, Dept Biomed Engn, 1042 Downey Way 140, Los Angeles, CA 90089 USA. EM givrad@usc.edu FU NIBIB [1 RO1 NS050171] FX Supported by the NIBIB (1 RO1 NS050171). We would like to thank Drs. Jun Yang, Zhou Wang and Theodore Sadler and Ms. Yumei Guo for their contributions NR 15 TC 8 Z9 8 U1 1 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0090-6964 J9 ANN BIOMED ENG JI Ann. Biomed. Eng. PD MAR PY 2010 VL 38 IS 3 BP 707 EP 713 DI 10.1007/s10439-009-9876-x PG 7 WC Engineering, Biomedical SC Engineering GA 571JA UT WOS:000275746900015 PM 20033778 ER PT J AU Ahuja, SS AF Ahuja, Seema S. TI Quantification of plaque volume by micro-CT techniques SO ANNALS OF CLINICAL AND LABORATORY SCIENCE LA English DT Meeting Abstract C1 [Ahuja, Seema S.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Ahuja, Seema S.] S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ASSOC CLINICAL SCIENTISTS PI MIDDLEBURY PA PO BOX 1287, MIDDLEBURY, VT 05753 USA SN 0091-7370 J9 ANN CLIN LAB SCI JI Ann. Clin. Lab. Sci. PD SPR PY 2010 VL 40 IS 2 MA 25 BP 192 EP 192 PG 1 WC Medical Laboratory Technology SC Medical Laboratory Technology GA 588CC UT WOS:000277043100039 ER PT J AU Raval, MV Bilimoria, KY Bentrem, DJ Stewart, AK Winchester, DP Ko, CY Reynolds, M AF Raval, Mehul V. Bilimoria, Karl Y. Bentrem, David J. Stewart, Andrew K. Winchester, David P. Ko, Clifford Y. Reynolds, Marleta TI Nodal Evaluation in Wilms' Tumors Analysis of the National Cancer Data Base SO ANNALS OF SURGERY LA English DT Article ID UNITED-STATES; QUALITY ASSESSMENT; COLON-CANCER; PROGNOSIS; CHILDREN; METASTASES; MANAGEMENT; SURVIVAL; STUDY-5; CARE AB Objective: We used a large US clinical cancer registry to assess nodal evaluation performance in children with Wilms' Tumors (WT), to determined factors associated with nodal evaluation, and to define the prognostic importance of nodal status. Summary Background Data: Lymph node assessment remains a part of accurate staging and helps determine therapy for patients with WT. Lack of nodal assessment has been noted but not well studied. Methods: Patients (0-18 years) with WT from the National Cancer Data Base (1985-2001) were assessed for nodal evaluation. Logistic regression was used to identify factors associated with the likelihood of lymph node evaluation. Survival was estimated using the Kaplan-Meier method. Cox regression was used to estimate the risk of mortality. Results: Of 3593 patients, 1510 (42%) had no lymph nodes evaluated by pathology and reported to the National Cancer Data Base. Of 2083 patients who had lymph nodes assessed, 535 (25.7%) had positive nodes. Patients age 2 years or younger, with larger tumor size, and treated at a higher volume center were more likely to have nodes assessed (P < 0.01). Patients who had nodes evaluated had a better 5-year survival compared with those who did not have nodes evaluated (92.2% vs. 88.1%, P < 0.001). In Cox regression, nodal metastases (P < 0.001; HR: 2.2, CI: 1.6-3.0) were associated with increased risk of death after adjusting for patient, tumor, and hospital characteristics. Conclusions: Many patients do not have lymph nodes evaluated during WT resection. Opportunities exist for improved staging and possibly survival in patients with WT through better nodal assessment. C1 [Raval, Mehul V.; Bilimoria, Karl Y.; Stewart, Andrew K.; Winchester, David P.; Ko, Clifford Y.] Amer Coll Surg, Canc Programs, Div Res & Optimal Patient Care, Chicago, IL USA. [Raval, Mehul V.; Reynolds, Marleta] Childrens Mem Hosp, Div Pediat Surg, Chicago, IL 60614 USA. [Raval, Mehul V.; Bilimoria, Karl Y.; Bentrem, David J.] Northwestern Univ, Feinberg Sch Med, Dept Surg, Div Gastrointestinal & Oncol Surg, Chicago, IL 60611 USA. [Bentrem, David J.] Jesse Brown VA Med Ctr, Chicago, IL USA. [Winchester, David P.] N Shore Univ Hlth Syst, Dept Surg, Evanston, IL USA. [Ko, Clifford Y.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA. [Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Raval, MV (reprint author), 633 N St Clair St,22nd Floor, Chicago, IL 60611 USA. EM m-raval@md.northwestern.edu OI Raval, Mehul/0000-0002-1527-2661 FU John Gray Research Fellowship; Daniel F. and Ada L. Rice Foundation; Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service; American College of Surgeons, Commission on Cancer; American Cancer Society FX Supported by the John Gray Research Fellowship and the Daniel F. and Ada L. Rice Foundation (to M. V. R.), a career development award from the Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service (D.J.B.). The National Cancer Data Base is supported by the American College of Surgeons, Commission on Cancer, and the American Cancer Society. NR 45 TC 13 Z9 13 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0003-4932 EI 1528-1140 J9 ANN SURG JI Ann. Surg. PD MAR PY 2010 VL 251 IS 3 BP 559 EP 565 DI 10.1097/SLA.0b013e3181cc95d7 PG 7 WC Surgery SC Surgery GA 562OD UT WOS:000275060800028 PM 20083995 ER PT J AU Wiederhold, NP Najvar, LK Bocanegra, R Graybill, JR Patterson, TF AF Wiederhold, Nathan P. Najvar, Laura K. Bocanegra, Rosie Graybill, John R. Patterson, Thomas F. TI Efficacy of Posaconazole as Treatment and Prophylaxis against Fusarium solani SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID CELL TRANSPLANT RECIPIENTS; IN-VITRO ACTIVITIES; ORAL POSACONAZOLE; INVASIVE ASPERGILLOSIS; HEMATOLOGIC MALIGNANCY; AMPHOTERICIN-B; PHARMACOKINETICS; VORICONAZOLE; TRIAZOLES; INFECTION AB Invasive fusariosis is a highly aggressive fungal infection associated with high mortality in heavily immunocompromised patients. Although posaconazole is efficacious as salvage therapy against infections caused by Fusarium species, concerns remain regarding this agent in the setting of reduced potency. To evaluate the efficacy of posaconazole as treatment or prophylaxis against invasive fusariosis caused by Fusarium solani, we utilized a neutropenic murine model of disseminated disease. ICR mice were administered escalating doses of posaconazole (6.25, 12.5, 25, or 50 mg/kg of body weight twice daily [BID]) by oral gavage beginning 2 days prior to inoculation in the prophylaxis studies or beginning 12 h after inoculation as treatment. Therapy was continued until day 9 postinoculation, and animals were monitored off therapy until day 15 for survival. Fungal burden was assessed as CFU in the kidneys. A clear dose-response relationship was observed, as the highest dose of posaconazole (50 mg/kg) was the most effective in prolonging survival and reducing tissue fungal burden both as prophylaxis and as treatment. This dose response was associated with high posaconazole serum concentrations as measured by bioassay. However, the extent of efficacy was also dependent on the infecting inoculum, as greater increases in survival and reductions in fungal burden were observed with the lower inocula tested. In this model high dosages of posaconazole were effective as treatment and prophylaxis against disseminated fusariosis caused by F. solani. C1 [Wiederhold, Nathan P.; Najvar, Laura K.; Bocanegra, Rosie; Graybill, John R.; Patterson, Thomas F.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Wiederhold, Nathan P.] Univ Texas Austin, Coll Pharm, Austin, TX 78712 USA. [Najvar, Laura K.; Bocanegra, Rosie; Graybill, John R.; Patterson, Thomas F.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Wiederhold, NP (reprint author), Univ Texas Hlth Sci Ctr San Antonio, PERC 6220,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM wiederholdn@uthscsa.edu OI Wiederhold, Nathan/0000-0002-2225-5122 FU Schering-Plough, Inc.; Schering-Plough; Pfizer; Merck; Basilea; CyDex; Nektar Therapeutics FX This study was funded by Schering-Plough, Inc.; N. P. W. has received research support from Schering-Plough, Pfizer, Merck, Basilea, and CyDex. T. F. P. has received research support from Merck, Basilea, Pfizer, Schering-Plough, and Nektar Therapeutics; has received speaker fees from Merck and Pfizer; and has served as a consultant for Basilea, Merck, Pfizer, and Toyama. NR 22 TC 11 Z9 11 U1 0 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD MAR PY 2010 VL 54 IS 3 BP 1055 EP 1059 DI 10.1128/AAC.01445-09 PG 5 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA 558HY UT WOS:000274733300012 PM 20065054 ER PT J AU Hussein, MRA Al Bshabshe, AA Dalati, T AF Hussein, Mahmoud Rezk A. Al Bshabshe, Ali A. Dalati, Taufik TI Leukemia Cutis: Case Report and Review of Literature SO APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY LA English DT Review DE leukemia; skin; myeloperoxidase ID SECTIONS AB Leukemias are neoplasms of hematolymphoid cells that predominantly involve the peripheral blood. Cutaneous involvement (leukemia cutis) occurs in chronic myeloid leukemia, chronic lymphocytic leukemia, and in monocytic leukemia. Here, we report a case of a 49-year-old female patient known to have chronic myeloid leukemia presented with multiple cutaneous lesions. The clinicopathologic features were presented and the relevant literature was discussed. C1 [Hussein, Mahmoud Rezk A.; Al Bshabshe, Ali A.; Dalati, Taufik] Asir Cent Hosp, Dept Pathol & Med, Abha, Saudi Arabia. [Hussein, Mahmoud Rezk A.] Univ Wisconsin, Sch Med, Madison, WI USA. [Hussein, Mahmoud Rezk A.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Hussein, MRA (reprint author), Assiut Univ, Fac Med, Dept Pathol, Assiut, Egypt. EM mrcpath17@gmail.com NR 5 TC 5 Z9 5 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1062-3345 J9 APPL IMMUNOHISTO M M JI Appl. Immunohistochem. PD MAR PY 2010 VL 18 IS 2 BP 190 EP 191 DI 10.1097/PAI.0b013e3181bfbcdc PG 2 WC Anatomy & Morphology; Medical Laboratory Technology; Pathology SC Anatomy & Morphology; Medical Laboratory Technology; Pathology GA 563UI UT WOS:000275160000014 PM 19956066 ER PT J AU Gupta, SR Agnani, S Tehrani, S Yeh, S Lauer, AK Suhler, EB AF Gupta, Seema R. Agnani, Shivali Tehrani, Shandiz Yeh, Steven Lauer, Andreas K. Suhler, Eric B. TI Endogenous Streptococcus agalactiae (Group B Streptococcus) Endophthalmitis as a Presenting Sign of Precursor T-Cell Lymphoblastic Leukemia SO ARCHIVES OF OPHTHALMOLOGY LA English DT Letter ID BACTERIAL ENDOPHTHALMITIS C1 [Gupta, Seema R.; Agnani, Shivali; Tehrani, Shandiz; Yeh, Steven; Lauer, Andreas K.; Suhler, Eric B.] Oregon Hlth & Sci Univ, Casey Eye Inst, Dept Ophthalmol, Portland, OR 97239 USA. [Suhler, Eric B.] Portland VA Med Ctr, Portland, OR USA. RP Suhler, EB (reprint author), Oregon Hlth & Sci Univ, Casey Eye Inst, Dept Ophthalmol, 3375 SW Terwilliger Blvd, Portland, OR 97239 USA. EM suhlere@ohsu.edu NR 4 TC 2 Z9 2 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9950 J9 ARCH OPHTHALMOL-CHIC JI Arch. Ophthalmol. PD MAR PY 2010 VL 128 IS 3 BP 384 EP 385 PG 3 WC Ophthalmology SC Ophthalmology GA 565QC UT WOS:000275308100023 PM 20212217 ER PT J AU Hula, WD Doyle, PJ Hula, SNA AF Hula, William D. Doyle, Patrick J. Hula, Shannon N. Austermann TI Patient-Reported Cognitive and Communicative Functioning: 1 Construct or 2? SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE Communication disorders; Patient outcomes assessment; Rehabilitation; Stroke ID FIT STATISTICS; ITEM BANKS; SCALE; STROKE; RELIABILITY; VALIDITY; OUTCOMES; SCORE; UNIDIMENSIONALITY; DIMENSIONALITY AB Hula WD, Doyle PJ, Austermann Hula SN. Patient-reported cognitive and communicative functioning: 1 construct or 2? Arch Phys Med Rehabil 2010;91:400-6. Objectives: To examine the dimensionality of scales for measuring patient-reported cognitive and communicative functioning in a sample of stroke survivors and to evaluate the consequences for measurement of treating them as a single, undifferentiated construct. Design: Secondary analysis of existing cross-sectional data. Setting: Data were collected in outpatient rehabilitation clinics and in the community. Participants: Unilateral stroke survivors (N=316) 3 months or more postonset referred for participation in research. Interventions: Not applicable. Main Outcome Measures: The Burden of Stroke Scale cognition and communication domain scales were evaluated by using confirmatory factor analysis. Rasch analysis, and tests of differential item functioning (DIF). To evaluate the impact of multidimensionality on the measurement of individual patients, separately estimated cognition and communication scores were compared. Combined and separately estimated scores were also examined for responsiveness to group differences in the presence of cognitive and communicative impairment. Results: Factor analysis and Rasch model fit analyses equivocally supported the unidimensionality of the item pool. DIF analyses between participants with right versus left hemisphere stroke suggested multidimensionality. Scaling cognition and communication items separately resulted in different person scores for a significant number of patients and greater responsiveness to group differences. Conclusions: Patient-reported scales assessing communication along with more general cognitive activities may possess an internal structure that is inconsistent with a unidimensional measurement model with potential negative consequences for measurement. C1 [Hula, William D.; Doyle, Patrick J.; Hula, Shannon N. Austermann] VA Pittsburgh Healthcare Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA 15206 USA. [Hula, William D.; Doyle, Patrick J.] Univ Pittsburgh, Dept Commun Sci & Disorders, Pittsburgh, PA USA. RP Hula, WD (reprint author), VA Pittsburgh Healthcare Syst, Ctr Geriatr Res Educ & Clin, 7180 Highland Dr,132A-H, Pittsburgh, PA 15206 USA. EM William.Hula@va.gov FU Veterans Affairs Rehabilitation Research and Development (VA RRD); Veterans Affairs Rehabilitation Research and Development [C2386R]; [C6210M] FX Supported by the Veterans Affairs Rehabilitation Research and Development (VA RR&D) Career Development Award (grant no. C6210M) and the Veterans Affairs Rehabilitation Research and Development Merit Review Award (grant no. C2386R). NR 41 TC 3 Z9 3 U1 2 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD MAR PY 2010 VL 91 IS 3 BP 400 EP 406 DI 10.1016/j.apmr.2009.11.013 PG 7 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 592YM UT WOS:000277417900012 PM 20298831 ER PT J AU Betjemann, RS Johnson, EP Barnard, H Boada, R Filley, CM Filipek, PA Willcutt, EG DeFries, JC Pennington, BF AF Betjemann, Rebecca S. Johnson, Erin Phinney Barnard, Holly Boada, Richard Filley, Christopher M. Filipek, Pauline A. Willcutt, Erik G. DeFries, John C. Pennington, Bruce F. TI Genetic Covariation Between Brain Volumes and IQ, Reading Performance, and Processing Speed SO BEHAVIOR GENETICS LA English DT Article DE Twin design; MRI; Brain volume; Intelligence; Processing speed; Reading ID ENVIRONMENTAL-INFLUENCES; WORKING-MEMORY; PHONOLOGICAL AWARENESS; INSPECTION TIME; HUMAN NEOCORTEX; WHITE-MATTER; INTELLIGENCE; VARIABILITY; DISABILITY; MRI AB Although there has been much interest in the relation between brain size and cognition, few studies have investigated this relation within a genetic framework and fewer still in non-adult samples. We analyzed the genetic and environmental covariance between structural MRI data from four brain regions (total brain volume, neocortex, white matter, and prefrontal cortex), and four cognitive measures (verbal IQ (VIQ), performance IQ (PIQ), reading ability, and processing speed), in a sample of 41 MZ twin pairs and 30 same-sex DZ twin pairs (mean age at cognitive test = 11.4 years; mean age at scan = 15.4 years). Multivariate Cholesky decompositions were performed with each brain volume measure entered first, followed by the four cognitive measures. Consistent with previous research, each brain and cognitive measure was found to be significantly heritable. The novel finding was the significant genetic but not environmental covariance between brain volumes and cognitive measures. Specifically, PIQ shared significant common genetic variance with all four measures of brain volume (r (g) = .58-.82). In contrast, VIQ shared significant genetic influence with neocortex volume only (r (g) = .58). Processing speed was significant with total brain volume (r (g) = .79), neocortex (r (g) = .64), and white matter (r (g) = .89), but not prefrontal cortex. The only brain measure to share genetic influence with reading was total brain volume (r (g) = .32), which also shared genetic influences with processing speed. C1 [Betjemann, Rebecca S.] Regis Univ, Dept Psychol, Denver, CO 80221 USA. [Johnson, Erin Phinney; Barnard, Holly; Boada, Richard; Pennington, Bruce F.] Univ Denver, Denver, CO USA. [Boada, Richard; Filley, Christopher M.] Univ Colorado, Denver Sch Med, Denver, CO 80202 USA. [Filley, Christopher M.] Denver Vet Affairs Med Ctr, Denver, CO USA. [Filipek, Pauline A.] Univ Texas Hlth Sci Ctr Houston, Houston, TX USA. [Willcutt, Erik G.; DeFries, John C.] Univ Colorado, Boulder, CO 80309 USA. RP Betjemann, RS (reprint author), Regis Univ, Dept Psychol, D-12,3333 Regis Blvd, Denver, CO 80221 USA. EM rbetjema@regis.edu FU NIMH [T32 MH016880-25]; NIH [HD027802] FX Initial work on this paper was done when R. Betjemann was a postdoctoral trainee at the Institute for Behavioral Genetics, University of Colorado, Boulder, CO. This training was funded by NIMH training grant T32 MH016880-25. This project was also funded by NIH grant HD027802 to the Colorado Learning Disabilities Research Center, of which B. Pennington, J. DeFries, and E. Willcutt are Co-PIs. NR 61 TC 14 Z9 14 U1 1 U2 13 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0001-8244 J9 BEHAV GENET JI Behav. Genet. PD MAR PY 2010 VL 40 IS 2 SI SI BP 135 EP 145 DI 10.1007/s10519-009-9328-2 PG 11 WC Behavioral Sciences; Genetics & Heredity; Psychology, Multidisciplinary SC Behavioral Sciences; Genetics & Heredity; Psychology GA 561GM UT WOS:000274964000004 PM 20072853 ER PT J AU Nakamae, H Storer, BE Storb, R Storek, J Chauncey, TR Pulsipher, MA Petersen, FB Wade, JC Maris, MB Bruno, B Panse, J Petersdorf, E Woolfrey, A Maloney, DG Sandmaier, BM AF Nakamae, Hirohisa Storer, Barry E. Storb, Rainer Storek, Jan Chauncey, Thomas R. Pulsipher, Michael A. Petersen, Finn B. Wade, James C. Maris, Michael B. Bruno, Benedetto Panse, Jens Petersdorf, Effie Woolfrey, Ann Maloney, David G. Sandmaier, Brenda M. TI Low-Dose Total Body Irradiation and Fludarabine Conditioning for HLA Class I-Mismatched Donor Stem Cell Transplantation and Immunologic Recovery in Patients with Hematologic Malignancies: A Multicenter Trial SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Article DE Nonmyeloablative allogeneic hematopoietic stem cell transplantation; HLA-class I mismatched donor; Low-dose total body irradiation; Fludarabine ID VERSUS-HOST-DISEASE; BONE-MARROW-TRANSPLANTATION; MATCHED UNRELATED DONORS; PERIPHERAL-BLOOD; SOMATIC MUTATION; B-CELLS; LEUKEMIA; ALLELES; RECONSTITUTION; PROPHYLAXIS AB HLA-mismatched grafts are a viable alternative source for patients without HLA-matched donors receiving ablative hematopoietic cell transplantation (HCT), although their use in reduced intensity conditioning (RIC) or nonmyeloablative (NMA) conditioning HCT has been not well established. Here, we extended HCT to recipients of HLA class I-mismatched grafts to investigate whether NMA conditioning can establish stable donor engraftment. Fifty-nine patients were conditioned with fludarabine (Flu) 90 mg/m(2) and 2 Gy total body irradiation (TBI), followed by immunosuppression with cyclosporine (CsA) 5.0 mg/kg twice a day and mycophenolate mofetil (MMF) 15 mg/kg 3 times a day for transplantation of granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood stern cells (PBSCs) from related (n = 5) or unrelated donors (n = 54) with I antigen +/- I allele HLA class I mismatch or 2 HLA class I allele mismatches. Sustained donor engraftment was observed in 95% of the evaluable patients. The incidence of grade II-IV acute and extensive chronic graft-versus-host disease (aGVHD, cGVHD) was 69% and 41%, respectively. The cumulative probability of nonrelapse mortality (NRM) was 47% at 2 years. Two-year overall and progression-free survival (OS, PFS) was 29% and 28%, respectively. NMA conditioning with Flu and low-dose TBI, followed by HCT using HLA class I-mismatched donors leads to successful engraftment and long-term survival; however, the high incidence of aGVHD and NRM needs to be addressed by alternate GVHD prophylaxis regimens. Biol Blood Marrow Transplant 16: 384-394 (2010) (C) 2010 American Society for Blood and Marrow Transplantation C1 [Nakamae, Hirohisa; Storer, Barry E.; Storb, Rainer; Storek, Jan; Chauncey, Thomas R.; Petersdorf, Effie; Woolfrey, Ann; Maloney, David G.; Sandmaier, Brenda M.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA. [Storer, Barry E.; Storb, Rainer; Chauncey, Thomas R.; Petersdorf, Effie; Woolfrey, Ann; Maloney, David G.; Sandmaier, Brenda M.] Univ Washington, Sch Med, Seattle, WA USA. [Storek, Jan] Univ Calgary, Calgary, AB, Canada. [Chauncey, Thomas R.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Pulsipher, Michael A.] Univ Utah, Salt Lake City, UT USA. [Petersen, Finn B.] Intermt Blood & Marrow Transplant Program, Salt Lake City, UT USA. [Wade, James C.] Med Coll Wisconsin, Milwaukee, WI 53226 USA. [Maris, Michael B.] Rocky Mt Blood & Marrow Transplantat, Denver, CO USA. [Bruno, Benedetto] Univ Turin, Turin, Italy. [Panse, Jens] Univ Hamburg, Hamburg, Germany. RP Sandmaier, BM (reprint author), Fred Hutchinson Canc Res Ctr, Div Clin Res, 1100 Fairview Ave N,Mail Stop D1-100,POB 19024, Seattle, WA 98109 USA. EM bsandmai@fhcrc.org FU National Cancer Institute [CA 18029, CA15704]; National Heart, Lung, and Blood Institute [HL36444]; Berlex, Inc; Graduate School of Medicine, Osaka City University, Osaka, Japan; Canada Research Chairs Program; Alberta Heritage Foundation for Medical Research; Regione Piemonte: Ricerca Finalizzata [2005, 2006, 2007] FX This study was supported by grants from the National Cancer Institute (CA 18029 and CA15704) and from the National Heart, Lung, and Blood Institute (HL36444) and also by a research grant from Berlex, Inc. Hirohisa Nakamae is funded by the Graduate School of Medicine, Osaka City University, Osaka, Japan. Jan Storek is funded by the Canada Research Chairs Program and Alberta Heritage Foundation for Medical Research. Benedetto Bruno is funded by Regione Piemonte: Ricerca Finalizzata 2005, 2006, and 2007. The authors thank research nurses Michelle Bouvier and Hsien-Tzu Chen, data manager Gresford Thomas, and trial coordinator Jennifer Freese for their invaluable help in making this study possible. We also thank Mohamed L Sorror, MD, for providing the HCT-CI scores; Mika Nakamae, MD, for reviewing data; Helen Crawford, Bonnie Larson, and Sue Carbonneau for manuscript preparation; and the transplant teams, physicians, nurses, and support personnel for their care of the patients in this study. NR 50 TC 20 Z9 22 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD MAR PY 2010 VL 16 IS 3 BP 384 EP 394 DI 10.1016/j.bbmt.2009.11.004 PG 11 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA 584DO UT WOS:000276730800011 PM 19900571 ER PT J AU Ogdie, A Li, J Dai, L Paessler, ME Yu, X Diaz-Torne, C Akmatov, M Schumacher, HR Pessler, F AF Ogdie, A. Li, J. Dai, L. Paessler, M. E. Yu, X. Diaz-Torne, C. Akmatov, M. Schumacher, H. R. Pessler, F. TI Identification of broadly discriminatory tissue biomarkers of synovitis with binary and multicategory receiver operating characteristic analysis SO BIOMARKERS LA English DT Article DE Computational biology; gene expression; growth factors/cytokines/inflammatory mediators ID WAR-VETERANS-ILLNESS; RHEUMATOID-ARTHRITIS; SEPTIC ARTHRITIS; LABORATORY TESTS; JOINT PAIN; ROC CURVE; ARTHROPATHIES; ANGIOGENESIS; BIOPSY AB Immunohistochemical synovial tissue biomarkers are used increasingly to classify arthropathies, study their pathogenesis, and to measure disease activity in clinical trials. We have used receiver operating characteristic (ROC) analysis to quantify the discriminatory abilities of markers for common inflammatory cells (subintimal CD15, CD68, CD3, CD20, CD38, and lining CD68), proliferating cells (Ki-67) and blood vessels (von Willebrand factor, vWF) among inflammatory (chronic septic arthritis, early arthritis and rheumatoid arthritis (RA)) and degenerative arthropathies (osteoarthritis (OA) and orthopedic arthropathies) and normal synovium. Six of the eight markers distinguished accurately between RA and the degenerative arthropathies (area under the curve (AUC) 0.91-0.97), whereas subintimal CD68 (AUC 0.92) and Ki-67 (AUC 0.87) distinguished best between OA and normal synovium. Fold differences in mean expression correlated only modestly with AUCs (r(2) = 0.44). Multicategory ROC analysis ranked Ki-67, subintimal CD68, and CD15 as discriminating best among all six sample groups, and thus identified them as the most broadly applicable markers. C1 [Akmatov, M.; Pessler, F.] Helmholtz Ctr Infect Res, D-38124 Braunschweig, Germany. [Ogdie, A.; Schumacher, H. R.] Univ Penn, Sch Med, Div Rheumatol, Philadelphia, PA 19104 USA. [Li, J.] Natl Univ Singapore, Dept Stat & Appl Probabil, Singapore 117548, Singapore. [Dai, L.] Sun Yat Sen Univ, Affiliated Hosp 2, Guangzhou 510275, Guangdong, Peoples R China. [Diaz-Torne, C.] Hosp Santa Creu & Sant Pau, Barcelona, Spain. [Paessler, M. E.] Childrens Hosp Philadelphia, Dept Pathol, Philadelphia, PA 19104 USA. [Yu, X.] Tradit Chinese Med Western Med Hosp, Cangzhou, Hebei, Peoples R China. [Dai, L.; Yu, X.; Diaz-Torne, C.; Schumacher, H. R.] Philadelphia VA Med Ctr, Div Rheumatol, Philadelphia, PA USA. [Pessler, F.] Tech Univ Dresden, Klin & Poliklin Kinder & Jugendmed, Dresden, Germany. RP Pessler, F (reprint author), Helmholtz Ctr Infect Res, Inhoffenstr 7, D-38124 Braunschweig, Germany. EM frank.pessler@helmholtz-hzi.de RI Li, Jialiang/B-9132-2014 OI Li, Jialiang/0000-0002-9704-4135; Ogdie, Alexis/0000-0002-4639-0775; Cesar, Diaz-Torne/0000-0001-6275-7699 FU National Institutes of Health [T32-CA 09140]; American College of Rheumatology/Research and Education Foundation; German Federal Ministry for Education and Science [SGP 08/A01] FX We thank Gilda Clayburne for expert technical assistance, Irene Loglisci, Roxann Thompson, Valice Matthews and John Romano (Philadelphia VA Medical Center, Department of Pathology) for help with histology, Lan X. Chen (Presbyterian Hospital, Philadelphia, PA) for helpful discussion and Angela Rosen-Wolff (University Children's Hospital, Technical University of Dresden, Germany) for helpful discussion and a critical reading of the manuscript. Support is gratefully acknowledged through National Institutes of Health Training Grant T32-CA 09140, a 2007-8 American College of Rheumatology/Research and Education Foundation Amgen Pediatric Rheumatology Research Award, and International Collaboration Seed Grant SGP 08/A01 from the German Federal Ministry for Education and Science (all to F. P.). The study was approved by the institutional review boards of the Philadelphia VA Medical Center, the University of Pennsylvania and the 2nd Affiliated Hospital of Sun Yat-sen University (Guangzhou, China). NR 23 TC 11 Z9 11 U1 0 U2 1 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1354-750X J9 BIOMARKERS JI Biomarkers PD MAR PY 2010 VL 15 IS 2 BP 183 EP 190 DI 10.3109/13547500903411095 PG 8 WC Biotechnology & Applied Microbiology; Toxicology SC Biotechnology & Applied Microbiology; Toxicology GA 612OA UT WOS:000278907900011 PM 19916737 ER PT J AU Wang, HJ Zhou, XH AF Wang, Huixia Judy Zhou, Xiao-Hua TI Estimation of the retransformed conditional mean in health care cost studies SO BIOMETRIKA LA English DT Article DE Conditional mean; Heteroscedastic regression model; Medical cost; Quantile regression; Skewed data; Two-part model ID QUANTILE RATIO ESTIMATION; REGRESSION QUANTILES; RISK ADJUSTMENT; 2-PART MODEL; HETEROSCEDASTICITY; EXPENDITURES; ADO AB We propose a new approach for analyzing skewed and heteroscedastic health care cost data through regression of the conditional quantiles of the transformed cost. Using the appealing equivariance property of quantiles to monotone transformations, we propose a distribution-free estimator of the conditional mean cost on the original scale. The proposed method is extended to a two-part heteroscedastic model to account for zero costs commonly seen in health care cost studies. Simulation studies indicate that the proposed estimator has competitive and more robust performance than existing estimators in various heteroscedastic models. C1 [Wang, Huixia Judy] N Carolina State Univ, Dept Stat, Raleigh, NC 27695 USA. [Zhou, Xiao-Hua] Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv, Res & Dev Ctr Excellence, Seattle, WA 98101 USA. RP Wang, HJ (reprint author), N Carolina State Univ, Dept Stat, Raleigh, NC 27695 USA. EM wang@stat.ncsu.edu; azhou@u.washington.edu NR 22 TC 7 Z9 7 U1 0 U2 5 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0006-3444 EI 1464-3510 J9 BIOMETRIKA JI Biometrika PD MAR PY 2010 VL 97 IS 1 BP 147 EP 158 DI 10.1093/biomet/asp072 PG 12 WC Biology; Mathematical & Computational Biology; Statistics & Probability SC Life Sciences & Biomedicine - Other Topics; Mathematical & Computational Biology; Mathematics GA 558WA UT WOS:000274778000011 ER PT J AU Wiren, KM Semirale, AA Hashimoto, JG Zhang, XW AF Wiren, Kristine M. Semirale, Anthony A. Hashimoto, Joel G. Zhang, Xiao-Wei TI Signaling pathways implicated in androgen regulation of endocortical bone SO BONE LA English DT Article DE Androgen; Androgen receptor; Osteoblast; Bone formation; BMP; TGF-beta ID GROWTH-FACTOR-BETA; DIFFERENTIATION IN-VITRO; MESENCHYMAL STEM-CELLS; OSTEOBLAST DIFFERENTIATION; ADRENAL ANDROGENS; OSTEOSARCOMA CELLS; HYPOGONADAL MEN; MALE-MICE; RECEPTOR; EXPRESSION AB Periosteal expansion is a recognized response to androgen exposure during bone development and in profoundly hypogonadal adults. However, androgen also suppresses endocortical bone formation, indicating that its effects on bone are dichotomous and envelope-specific. In fact, enhanced androgen signaling has been shown to have dramatic detrimental effects on whole bone biomechanical properties in two different transgenic models with skeletally targeted androgen receptor (AR) overexpression. As the mechanisms underlying this response are uncharacterized, we compared patterns of gene expression in periosteum-free cortical bone samples derived from AR-overexpressing transgenic male mice and their wild-type counterparts. We then assessed direct androgen effects in both wild-type and AR-overexpressing osteoblasts in primary culture. Among Major Signaling pathways associated with bone formation, focused quantitative RT-PCR (qPCR) array-based analysis of endocortical bone gene expression from wild-type vs. transgenic males identified the transforming growth factor-beta (TGF-beta) superfamily and bone morphogenetic protein (BMP) signaling as significantly altered by androgen in vivo. Bioinformatic analyses indicated proliferation, osteoblast differentiation and mineralization as major biological processes affected. Consistent with the in vivo array data and bioinformatic analyses, inhibition of differentiation observed with androgen exposure was reduced by exogenous BMP2 treatment of AR-overexpressing cultures to stimulate BMP signaling, confirming array pathway analysis. In addition, nonaromatizable dihydrotestosterone (DHT) inhibited osteoblast proliferation, differentiation and several indices of mineralization, including mineral accumulation and mineralized nodule formation in primary cultures from both wild-type and AR-transgenic mice. These findings identify a molecular mechanism based on altered BMP signaling that contributes to androgen inhibition of osteoblast differentiation and mineralization. Such detrimental effects of androgen on osteoblast function May underlie the generally disappointing results of androgen therapy. Published by Elsevier Inc. C1 [Wiren, Kristine M.; Semirale, Anthony A.; Hashimoto, Joel G.; Zhang, Xiao-Wei] Portland VA Med Ctr, Bone & Mineral Res Unit, Portland, OR 97239 USA. [Wiren, Kristine M.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97239 USA. [Wiren, Kristine M.; Semirale, Anthony A.; Hashimoto, Joel G.; Zhang, Xiao-Wei] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97239 USA. RP Wiren, KM (reprint author), Portland VA Med Ctr, Bone & Mineral Res Unit, P3 R&D39,3710 SW Vet Hosp Rd, Portland, OR 97239 USA. EM wirenk@ohsu.edu OI Wiren, Kristine/0000-0002-6159-4450 FU United States Army Research Acquisition Activity Award [W81XWH-05-1-0086]; National Institute of Diabetes, Digestive Kidney Disease [R01 DK067541] FX The authors would like to thank Dr. Robert Majeska (City College of New York) for helpful comments in the preparation of the manuscript. This publication was made possible by grants from the United States Army Research Acquisition Activity Award No. W81XWH-05-1-0086 (KMW) and the National Institute of Diabetes, Digestive & Kidney Disease R01 DK067541 (KMW). The information contained in this publication does not necessarily reflect the position or the policy of the government, and no official endorsement should be inferred. All work was performed in facilities provided by the Department of Veterans Affairs. NR 56 TC 10 Z9 10 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 8756-3282 EI 1873-2763 J9 BONE JI Bone PD MAR PY 2010 VL 46 IS 3 BP 710 EP 723 DI 10.1016/j.bone.2009.10.039 PG 14 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 564WJ UT WOS:000275248600019 PM 19895913 ER PT J AU Hong, Z Shi, M Chung, KA Quinn, JF Peskind, ER Galasko, D Jankovic, J Zabetian, CP Leverenz, JB Baird, G Montine, TJ Hancock, AM Hwang, H Pan, C Bradner, J Kang, UJ Jensen, PH Zhang, J AF Hong, Zhen Shi, Min Chung, Kathryn A. Quinn, Joseph F. Peskind, Elaine R. Galasko, Douglas Jankovic, Joseph Zabetian, Cyrus P. Leverenz, James B. Baird, Geoffrey Montine, Thomas J. Hancock, Aneeka M. Hwang, Hyejin Pan, Catherine Bradner, Joshua Kang, Un J. Jensen, Poul H. Zhang, Jing TI DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease SO BRAIN LA English DT Article DE cerebrospinal fluid; Parkinson's disease; biomarker; DJ-1; alpha-synuclein ID HUMAN PLASMA; ELISA; MITOCHONDRIA; PROGRESSION; DISORDERS; DEMENTIA; COMPLEX; PROTEIN; MARKER AB Biomarkers are urgently needed for the diagnosis and monitoring of disease progression in Parkinson's disease. Both DJ-1 and alpha-synuclein, two proteins critically involved in Parkinson's disease pathogenesis, have been tested as disease biomarkers in several recent studies with inconsistent results. These have been largely due to variation in the protein species detected by different antibodies, limited numbers of patients in some studies, or inadequate control of several important variables. In this study, the nature of DJ-1 and alpha-synuclein in human cerebrospinal fluid was studied by a combination of western blotting, gel filtration and mass spectrometry. Sensitive and quantitative Luminex assays detecting most, if not all, species of DJ-1 and alpha-synuclein in human cerebrospinal fluid were established. Cerebrospinal fluid concentrations of DJ-1 and alpha-synuclein from 117 patients with Parkinson's disease, 132 healthy individuals and 50 patients with Alzheimer's disease were analysed using newly developed, highly sensitive Luminex technology while controlling for several major confounders. A total of 299 individuals and 389 samples were analysed. The results showed that cerebrospinal fluid DJ-1 and alpha-synuclein levels were dependent on age and influenced by the extent of blood contamination in cerebrospinal fluid. Both DJ-1 and alpha-synuclein levels were decreased in Parkinson's patients versus controls or Alzheimer's patients when blood contamination was controlled for. In the population aged >= 65 years, when cut-off values of 40 and 0.5 ng/ml were chosen for DJ-1 and alpha-synuclein, respectively, the sensitivity and specificity for patients with Parkinson's disease versus controls were 90 and 70% for DJ-1, and 92 and 58% for alpha-synuclein. A combination of the two markers did not enhance the test performance. There was no association between DJ-1 or alpha-synuclein and the severity of Parkinson's disease. Taken together, this represents the largest scale study for DJ-1 or alpha-synuclein in human cerebrospinal fluid so far, while using newly established sensitive Luminex assays, with controls for multiple variables. We have demonstrated that total DJ-1 and alpha-synuclein in human cerebrospinal fluid are helpful diagnostic markers for Parkinson's disease, if variables such as blood contamination and age are taken into consideration. C1 [Hong, Zhen; Shi, Min; Montine, Thomas J.; Hancock, Aneeka M.; Hwang, Hyejin; Pan, Catherine; Bradner, Joshua; Zhang, Jing] Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98104 USA. [Hong, Zhen] Sichuan Univ, Dept Neurol, W China Med Sch, Chengdu 610064, Sichuan, Peoples R China. [Chung, Kathryn A.; Quinn, Joseph F.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Peskind, Elaine R.; Leverenz, James B.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98104 USA. [Peskind, Elaine R.; Zabetian, Cyrus P.; Leverenz, James B.] Vet Affairs Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, Seattle, WA USA. [Galasko, Douglas] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA. [Jankovic, Joseph] Baylor Coll Med, Dept Neurol, Parkinsons Dis Ctr, Houston, TX 77030 USA. [Jankovic, Joseph] Baylor Coll Med, Dept Neurol, Movement Disorders Clin, Houston, TX 77030 USA. [Zabetian, Cyrus P.; Leverenz, James B.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98104 USA. [Baird, Geoffrey] Univ Washington, Sch Med, Dept Lab Med, Seattle, WA 98104 USA. [Kang, Un J.] Univ Chicago, Dept Neurol, Chicago, IL 60637 USA. [Jensen, Poul H.] Univ Aarhus, Dept Med Biochem, Aarhus, Denmark. RP Zhang, J (reprint author), Univ Washington, Sch Med, Dept Pathol, HMC Box 359635,325 9th Ave, Seattle, WA 98104 USA. EM zhangj@uw.edu RI Shi, Min/G-6165-2012 OI Shi, Min/0000-0002-6901-2558 FU National Institutes of Health [ES004696, NS057567, AG025327, AG033398, NS060252, NS062684, AG05136, AG08017, AG08671, UL1 RR025014- 01]; Dana Foundation; Michael J. Fox Foundation; The Friends of Alzheimer's Research; Alzheimer's Association of Western and Central Washington; Department of Veterans Affairs FX National Institutes of Health grants (ES004696, NS057567, AG025327, AG033398, NS060252, NS062684, AG05136, AG08017, AG08671 and UL1 RR025014- 01); Dana Foundation; The Michael J. Fox Foundation; The Friends of Alzheimer's Research; The Alzheimer's Association of Western and Central Washington; The Department of Veterans Affairs. NR 33 TC 251 Z9 259 U1 6 U2 43 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0006-8950 J9 BRAIN JI Brain PD MAR PY 2010 VL 133 BP 713 EP 726 DI 10.1093/brain/awq008 PN 3 PG 14 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 575DI UT WOS:000276046000009 PM 20157014 ER PT J AU Yun, RJ Krystal, JH Mathalon, DH AF Yun, Richard J. Krystal, John H. Mathalon, Daniel H. TI Working Memory Overload: Fronto-Limbic Interactions and Effects on Subsequent Working Memory Function SO BRAIN IMAGING AND BEHAVIOR LA English DT Article DE Functional magnetic resonance imaging; Dorsolateral prefrontal cortex; Amygdala; Working memory; Emotional-cognitive interaction ID PREFRONTAL CORTEX; VOLUNTARY SUPPRESSION; EMOTIONAL MODULATION; COGNITIVE CONTROL; TASK-PERFORMANCE; MENTAL FATIGUE; AMYGDALA; FMRI; DEPRESSION; PATHWAYS AB The human working memory system provides an experimentally useful model for examination of neural overload effects on subsequent functioning of the overloaded system. This study employed functional magnetic resonance imaging in conjunction with a parametric working memory task to characterize the behavioral and neural effects of cognitive overload on subsequent cognitive performance, with particular attention to cognitive-limbic interactions. Overloading the working memory system was associated with varying degrees of subsequent decline in performance accuracy and reduced activation of brain regions central to both task performance and suppression of negative affect. The degree of performance decline was independently predicted by three separate factors operating during the overload condition: the degree of task failure, the degree of amygdala activation, and the degree of inverse coupling between the amygdala and dorsolateral prefrontal cortex. These findings suggest that vulnerability to overload effects in cognitive functioning may be mediated by reduced amygdala suppression and subsequent amygdala-prefrontal interaction. C1 [Yun, Richard J.; Krystal, John H.] Yale Univ, Dept Psychiat, New Haven, CT 06520 USA. [Yun, Richard J.; Krystal, John H.] VA Connecticut Healthcare Syst, Psychiat Serv, West Haven, CT USA. [Mathalon, Daniel H.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Mathalon, Daniel H.] San Francisco VA Med Ctr, Psychiat Serv, San Francisco, CA USA. RP Yun, RJ (reprint author), Yale Univ, Dept Psychiat, New Haven, CT 06520 USA. EM richard.yun@yale.edu OI Mathalon, Daniel/0000-0001-6090-4974 FU NIH [T32 MH19126, T32 MH19961]; Department of Veterans Affairs; Robert L. McNeil, Jr. Fellowship in Clinical Pharmacology FX This work was supported by NIH T32 MH19126 and T32 MH19961, the Department of Veterans Affairs, and a Robert L. McNeil, Jr. Fellowship in Clinical Pharmacology. The authors declare that they have no competing financial interests. NR 39 TC 16 Z9 16 U1 4 U2 11 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1931-7557 J9 BRAIN IMAGING BEHAV JI Brain Imaging Behav. PD MAR PY 2010 VL 4 IS 1 BP 96 EP 108 DI 10.1007/s11682-010-9089-9 PG 13 WC Neuroimaging SC Neurosciences & Neurology GA 583DK UT WOS:000276652900009 PM 20503117 ER PT J AU Tsuang, D Larson, EB Li, G Shofer, JB Montine, KS Thompson, ML Sonnen, JA Crane, PK Leverenz, JB Montine, TJ AF Tsuang, Debby Larson, Eric B. Li, Ge Shofer, Jane B. Montine, Kathleen S. Thompson, Mary Lou Sonnen, Joshua A. Crane, Paul K. Leverenz, James B. Montine, Thomas J. TI Association Between Lifetime Cigarette Smoking and Lewy Body Accumulation SO BRAIN PATHOLOGY LA English DT Article DE Alzheimer's disease; Lewy body; smoking; neuropathology ID PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; CLINICAL-DIAGNOSIS; DEMENTIA; RISK; PATHOLOGY; CONSORTIUM; COHORT; HEALTH AB Cigarette smoking has been associated repeatedly in observational studies with decreased risk of Parkinson's disease (PD), but its relationship to the risk of dementia or Alzheimer's disease (AD) is inconsistent. All of these studies have used clinical diagnoses of disease. We tested the hypothesis that lifetime cigarette use might be associated with reduced risk of neuropathologic changes of Lewy-related pathology (LRP) in multiple brain regions or with reduced risk of consensus neuropathologic changes of AD in a prospective community-based study of brain aging and dementia, the Adult Changes in Thought (ACT) study. We observed that heavy lifetime cigarette smoking (> 50 pack years) was associated with significantly reduced relative risk (RR) for LRP, but not AD-type pathologic changes, after correcting for selection bias, and with significantly reduced frequency of LRP in the substantia nigra. These findings are the first of which we are aware to associate reduced LRP in human brain with any exposure, and substantiate observational studies that have associated cigarette smoking with reduced risk of PD. Although cigarette smoking is too toxic to suggest as a treatment, if confirmed, these findings may guide future therapeutic strategies that attempt to suppress LRP in human brain by other means. C1 [Montine, Kathleen S.; Sonnen, Joshua A.; Montine, Thomas J.] Univ Washington, Dept Pathol, Seattle, WA 98104 USA. [Tsuang, Debby; Li, Ge; Shofer, Jane B.; Leverenz, James B.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98104 USA. [Larson, Eric B.; Crane, Paul K.] Univ Washington, Dept Internal Med, Seattle, WA 98104 USA. [Thompson, Mary Lou] Univ Washington, Dept Biostat, Seattle, WA 98104 USA. [Leverenz, James B.] Univ Washington, Dept Neurol, Seattle, WA 98104 USA. [Larson, Eric B.] Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA. [Tsuang, Debby; Li, Ge; Leverenz, James B.] VA Puget Sound Hlth Care Syst, Mental Illness Ctr, Seattle, WA USA. [Leverenz, James B.] VA Puget Sound Hlth Care Syst, Parkinsons Dis Res Educ & Clin Ctr, Seattle, WA USA. RP Montine, TJ (reprint author), Univ Washington, Dept Pathol, Box 359791,325 9th Ave, Seattle, WA 98104 USA. EM tmontine@u.washington.edu RI Crane, Paul/C-8623-2014; Sonnen, 37382016/H-3738-2016; Tsuang, Debby/L-7234-2016 OI Sonnen, 37382016/0000-0001-9267-8705; Tsuang, Debby/0000-0002-4716-1894; Crane, Paul/0000-0003-4278-7465 FU National Institutes of Health [AG05136, AG06781, AG023801, AG000258]; Nancy and Buster Alvord Endowment; VA Puget Sound Health Care System, Seattle, Washington FX This work was supported by grants from the National Institutes of Health (AG05136, AG06781, AG023801 and AG000258) and the Nancy and Buster Alvord Endowment. This material is also the result of work supported by resources from the VA Puget Sound Health Care System, Seattle, Washington. The authors declare that they have no conflict of interest with this work. NR 24 TC 13 Z9 13 U1 0 U2 4 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1015-6305 J9 BRAIN PATHOL JI Brain Pathol. PD MAR PY 2010 VL 20 IS 2 BP 412 EP 418 DI 10.1111/j.1750-3639.2009.00296.x PG 7 WC Clinical Neurology; Neurosciences; Pathology SC Neurosciences & Neurology; Pathology GA 551WE UT WOS:000274242400013 PM 19531100 ER PT J AU Hof, PR Elder, GA AF Hof, Patrick R. Elder, Gregory A. TI Introduction to the special issue of Brain Structure and Function on transgenic modeling of neurodegenerative disorders SO BRAIN STRUCTURE & FUNCTION LA English DT Editorial Material C1 [Hof, Patrick R.] Mt Sinai Sch Med, Dept Neurosci, New York, NY 10029 USA. [Hof, Patrick R.] Mt Sinai Sch Med, Dept Geriatr & Palliat Care, New York, NY 10029 USA. [Hof, Patrick R.] Mt Sinai Sch Med, Computat Neurobiol & Imaging Ctr, New York, NY 10029 USA. [Elder, Gregory A.] James J Peters Dept Vet Affairs Med Ctr, Neurol Serv, Bronx, NY 10468 USA. [Elder, Gregory A.] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. [Elder, Gregory A.] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA. RP Hof, PR (reprint author), Mt Sinai Sch Med, Dept Neurosci, 1 Gustave L Levy Pl, New York, NY 10029 USA. EM patrick.hof@mssm.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 1863-2653 J9 BRAIN STRUCT FUNCT JI Brain Struct. Funct. PD MAR PY 2010 VL 214 IS 2-3 BP 89 EP 90 DI 10.1007/s00429-010-0243-3 PG 2 WC Anatomy & Morphology; Neurosciences SC Anatomy & Morphology; Neurosciences & Neurology GA 576EK UT WOS:000276126900001 PM 20169361 ER PT J AU Sosa, MAG De Gasperi, R Elder, GA AF Sosa, Miguel A. Gama De Gasperi, Rita Elder, Gregory A. TI Animal transgenesis: an overview SO BRAIN STRUCTURE & FUNCTION LA English DT Review DE Conditional gene inactivation; Gene targeting; Inducible transgene expression; Pronuclear injection; Transgenic animal ID EMBRYONIC STEM-CELLS; SITE-SPECIFIC RECOMBINATION; SLEEPING-BEAUTY TRANSPOSON; MEDIATED GENE-TRANSFER; INTRACYTOPLASMIC SPERM INJECTION; VERTEBRATE FUNCTIONAL GENOMICS; YEAST ARTIFICIAL CHROMOSOME; ZINC-FINGER NUCLEASES; MAMMALIAN-CELLS; RNA INTERFERENCE AB Transgenic animals are extensively used to study in vivo gene function as well as to model human diseases. The technology for producing transgenic animals exists for a variety of vertebrate and invertebrate species. The mouse is the most utilized organism for research in neurodegenerative diseases. The most commonly used techniques for producing transgenic mice involves either the pronuclear injection of transgenes into fertilized oocytes or embryonic stem cell-mediated gene targeting. Embryonic stem cell technology has been most often used to produce null mutants (gene knockouts) but may also be used to introduce subtle genetic modifications down to the level of making single nucleotide changes in endogenous mouse genes. Methods are also available for inducing conditional gene knockouts as well as inducible control of transgene expression. Here, we review the main strategies for introducing genetic modifications into the mouse, as well as in other vertebrate and invertebrate species. We also review a number of recent methodologies for the production of transgenic animals including retrovirus-mediated gene transfer, RNAi-mediated gene knockdown and somatic cell mutagenesis combined with nuclear transfer, methods that may be more broadly applicable to species where both pronuclear injection and ES cell technology have proven less practical. C1 [Sosa, Miguel A. Gama; De Gasperi, Rita] James J Peters Dept Vet Affairs Med Ctr, Res & Dev Serv, Bronx, NY 10468 USA. [Sosa, Miguel A. Gama; De Gasperi, Rita; Elder, Gregory A.] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. [Elder, Gregory A.] James J Peters Dept Vet Affairs Med Ctr, Neurol Serv, Bronx, NY 10468 USA. [Elder, Gregory A.] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA. RP Sosa, MAG (reprint author), James J Peters Dept Vet Affairs Med Ctr, Res & Dev Serv, Res & Dev 3F-20,130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM miguel.gama-sosa@mssm.edu FU National Institute on Aging [AG02219, AG05138, AG20139, AG029361]; Alzheimer's Association [IIRG-07-57318]; Department of Veterans Affairs [1I01BX000342] FX Work in the authors' laboratories has been supported by the National Institute on Aging (grants AG02219, AG05138, AG20139, and AG029361), the Alzheimer's Association (IIRG-07-57318), and a Merit Award from the Department of Veterans Affairs (1I01BX000342). NR 227 TC 62 Z9 64 U1 0 U2 40 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 1863-2653 EI 1863-2661 J9 BRAIN STRUCT FUNCT JI Brain Struct. Funct. PD MAR PY 2010 VL 214 IS 2-3 BP 91 EP 109 DI 10.1007/s00429-009-0230-8 PG 19 WC Anatomy & Morphology; Neurosciences SC Anatomy & Morphology; Neurosciences & Neurology GA 576EK UT WOS:000276126900002 ER PT J AU Elder, GA Sosa, MAG De Gasperi, R Dickstein, DL Hof, PR AF Elder, Gregory A. Sosa, Miguel A. Gama De Gasperi, Rita Dickstein, Dara L. Hof, Patrick R. TI Presenilin transgenic mice as models of Alzheimer's disease SO BRAIN STRUCTURE & FUNCTION LA English DT Review DE Alzheimer's disease; Familial Alzheimer's disease; Hippocampal neurogenesis; Presenilin-1; Presenilin-2; Transgenic mice ID AMYLOID-PRECURSOR-PROTEIN; LONG-TERM POTENTIATION; KNOCK-IN MICE; FOREBRAIN-SPECIFIC PRESENILIN-1; CONDITIONAL DOUBLE-KNOCKOUT; MUTANT HUMAN PRESENILIN-1; NEURAL PROGENITOR CELLS; SYNAPTIC PLASTICITY; MOUSE MODEL; ADULT MICE AB Mutations in presenilin-1 (PS1) and presenilin-2 (PS2) cause familial Alzheimer's disease (FAD). Presenilins influence multiple molecular pathways and are best known for their role in the gamma-secretase cleavage of type I transmembrane proteins including the amyloid precursor protein (APP). PS1 and PS2 FAD mutant transgenic mice have been generated using a variety of promoters. PS1-associated FAD mutations have also been knocked into the endogenous mouse gene. PS FAD mutant mice consistently show elevations of A beta 42 with little if any effect on A beta 40. When crossed with plaque forming APP FAD mutant lines, the PS1 FAD mutants cause earlier and more extensive plaque deposition. Although single transgenic PS1 or PS2 mice do not form plaques, they exhibit a number of pathological features including age-related neuronal and synaptic loss as well as vascular pathology. They also exhibit increased susceptibility to excitotoxic injury most likely on the basis of exaggerated calcium release from the endoplasmic reticulum. Electrophysiologically long-term potentiation in the hippocampus is increased in young PS1 FAD mutant mice but this effect appears to be lost with aging. In most studies neurogenesis in the adult hippocampus is also impaired by PS1 FAD mutants. Mice in which PS1 has been conditionally knocked out in adult forebrain on a PS2 null background (PS1/2 cDKO) develop a striking neurodegeneration that mimics AD neuropathology in being associated with neuronal and synaptic loss, astrogliosis and hyperphosphorylation of tau, although it is not accompanied by plaque deposits. The relevance of PS transgenic mice as models of AD is discussed. C1 [Elder, Gregory A.] James J Peters Dept Vet Affairs Med Ctr, Neurol Serv, Bronx, NY 10468 USA. [Elder, Gregory A.; Sosa, Miguel A. Gama; De Gasperi, Rita] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. [Elder, Gregory A.] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA. [Sosa, Miguel A. Gama; De Gasperi, Rita] James J Peters Dept Vet Affairs Med Ctr, Res & Dev Serv, Bronx, NY 10468 USA. [Dickstein, Dara L.; Hof, Patrick R.] Mt Sinai Sch Med, Dept Neurosci, New York, NY 10029 USA. [Dickstein, Dara L.; Hof, Patrick R.] Mt Sinai Sch Med, Computat Neurobiol & Imaging Ctr, New York, NY 10029 USA. [Hof, Patrick R.] Mt Sinai Sch Med, Dept Geriatr & Palliat Care, New York, NY 10029 USA. RP Elder, GA (reprint author), James J Peters Dept Vet Affairs Med Ctr, Neurol Serv, 3E16,130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM gregory.elder@mssm.edu RI Dickstein, Dara/F-3036-2013 FU National Institute on Aging [AG02219, AG05138, AG20139, AG029361]; Alzheimer's Association [IIRG-07-57318]; Department of Veterans Affairs [1I01BX000342] FX Work in the authors' laboratories has been supported by the National Institute on Aging ( grants AG02219, AG05138, AG20139, and AG029361), the Alzheimer's Association (IIRG-07-57318) and a Merit Award from the Department of Veterans Affairs (1I01BX000342). NR 138 TC 26 Z9 29 U1 3 U2 15 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 1863-2653 J9 BRAIN STRUCT FUNCT JI Brain Struct. Funct. PD MAR PY 2010 VL 214 IS 2-3 BP 127 EP 143 DI 10.1007/s00429-009-0227-3 PG 17 WC Anatomy & Morphology; Neurosciences SC Anatomy & Morphology; Neurosciences & Neurology GA 576EK UT WOS:000276126900004 PM 19921519 ER PT J AU Yassaee, M Fiorentino, D Okawa, J Taylor, L Coley, C Troxel, AB Werth, VP AF Yassaee, M. Fiorentino, D. Okawa, J. Taylor, L. Coley, C. Troxel, A. B. Werth, V. P. TI Modification of the Cutaneous Dermatomyositis Disease Area and Severity Index, an outcome instrument SO BRITISH JOURNAL OF DERMATOLOGY LA English DT Article DE dermatomyositis; outcome measures ID LUPUS-ERYTHEMATOSUS; DERMATOLOGY AB Background Validated outcome measures in dermatology help standardize and improve patient care. A scoring system of skin disease severity in dermatomyositis known as the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) has been developed. Objectives To simplify and improve the tool for clinical research and care, we modified the CDASI and validated the new version, v2. Methods The original CDASI has four activity and two damage measures. The modified CDASI has three activity and two damage measures. The skin disease of 20 patients with dermatomyositis was evaluated by the same dermatologist using both the original and the modified CDASI. Global validation measures were implemented to assess overall skin disease state, skin disease activity and skin damage. Spearman's rho (r(sp)), adjusted for multiple observations on subjects, was used to determine the relationship between the two versions of the CDASI and their correlation with the physician global measures (PGMs). Results The total score and activity and damage subscores of the original and the modified CDASI correlated perfectly with each other (r(sp) = 0 99, 1 00, 1 00). The PGM-overall skin scale correlated with the total scores (r(sp) = 0 72, r(sp) = 0 76) and activity subscores (r(sp) = 0 68, r(sp) = 0 63) but not with the damage subscores (r(sp) = 0 14, r(sp) = 0 15) of the original and the modified CDASI, respectively. However, the PGM-activity and PGM-damage scales correlated with the activity (r(sp) = 0 76, r(sp) = 0 75) and damage subscores (r(sp) = 0 90, r(sp) = 0 90), respectively, of the original and the modified CDASI. Conclusions The modified CDASI is perfectly correlated with the original CDASI. It has equally good concurrent validity with the PGM-overall skin and PGM-activity scales. The CDASI subscores have equally good concurrent validity with the PGM-activity and PGM-damage scales. We suggest that PGMs of skin disease activity and damage should be assessed separately for greater specificity. The modified CDASI is a refined and equally as useful outcome measure. C1 [Yassaee, M.; Okawa, J.; Werth, V. P.] Univ Penn, Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. [Yassaee, M.; Werth, V. P.] Univ Penn, Sch Med, Dept Dermatol, Philadelphia, PA 19104 USA. [Fiorentino, D.] Stanford Univ, Dept Dermatol, Stanford, CA 94305 USA. [Taylor, L.; Coley, C.; Troxel, A. B.] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. RP Werth, VP (reprint author), Univ Penn, Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. EM werth@mail.med.upenn.edu OI Fiorentino, David/0000-0001-7951-3674; Troxel, Andrea/0000-0002-1393-3075 FU Department of Veterans Health Administration, Office of Research Development, Biomedical Laboratory Research and Development; National Institutes of Health [K24-AR 02207] FX This study was supported in part by a Merit Review Grant from the Department of Veterans Health Administration, Office of Research Development, Biomedical Laboratory Research and Development and by the National Institutes of Health (NIH K24-AR 02207) to V. P. W. NR 8 TC 19 Z9 21 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0007-0963 J9 BRIT J DERMATOL JI Br. J. Dermatol. PD MAR PY 2010 VL 162 IS 3 BP 669 EP 673 DI 10.1111/j.1365-2133.2009.09521.x PG 5 WC Dermatology SC Dermatology GA 555XR UT WOS:000274550600031 PM 19863510 ER PT J AU Knight, CS Tallaj, JA Rayburn, BK Pamboukian, SV Bourge, R Kirklin, JK McGiffin, D Litovsky, SH AF Knight, Carrie S. Tallaj, Jose A. Rayburn, Barry K. Pamboukian, Salpy V. Bourge, Robert Kirklin, James K. McGiffin, David Litovsky, Silvio H. TI Bradycardia and syncope as a presentation of cardiac allograft rejection involving the conducting system SO CARDIOVASCULAR PATHOLOGY LA English DT Article DE Bradycardia; Heart transplant; Rejection; Conducting system ID HEART-TRANSPLANTATION AB Post-heart transplantation bradycardic syncope and arrest could be clue to preferential rejection of the conduction system. We present six heart transplant patients with this presentation, two of whom died. The autopsy of one of those patients demonstrated severe rejection of the conduction system, with only mild rejection throughout the rest of the myocardium. We postulate that aggressive therapy for rejection and pacemaker placement may result in improved survival in heart transplant recipients with this clinical presentation. Published by Elsevier Inc. C1 [Knight, Carrie S.; Litovsky, Silvio H.] Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA. [Tallaj, Jose A.; Rayburn, Barry K.; Pamboukian, Salpy V.; Bourge, Robert] Univ Alabama, Dept Med, Birmingham, AL 35294 USA. [Tallaj, Jose A.] Birmingham VA Med Ctr, Birmingham, AL USA. [Kirklin, James K.; McGiffin, David] Univ Alabama, Dept Surg, Birmingham, AL 35294 USA. RP Tallaj, JA (reprint author), THT 338,1900 Univ Blvd, Birmingham, AL 35294 USA. EM jtallaj@uab.edu NR 9 TC 4 Z9 4 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-8807 J9 CARDIOVASC PATHOL JI Cardiovasc. Pathol. PD MAR-APR PY 2010 VL 19 IS 2 BP 117 EP 120 DI 10.1016/j.carpath.2008.10.006 PG 4 WC Cardiac & Cardiovascular Systems; Pathology SC Cardiovascular System & Cardiology; Pathology GA 610PN UT WOS:000278745800006 PM 19144548 ER PT J AU Restrepo, MI Mortensen, EM Rello, J Brody, J Anzueto, A AF Restrepo, Marcos I. Mortensen, Eric M. Rello, Jordi Brody, Jennifer Anzueto, Antonio TI Late Admission to the ICU in Patients With Community-Acquired Pneumonia Is Associated With Higher Mortality SO CHEST LA English DT Article ID INTENSIVE-CARE-UNIT; PREDICTION RULE; PNEUMOCOCCAL PNEUMONIA; ANTIMICROBIAL THERAPY; SEVERITY; VALIDATION; EPIDEMIOLOGY; PROGNOSIS; GUIDELINES; MANAGEMENT AB Background: Limited data are available on the impact of time to ICU admission and outcomes for patients with severe community acquired pneumonia (CAP). Our objective was to examine the association of time to ICU admission and 30-day mortality in patients with severe CAP. Methods: A retrospective cohort study of 161 ICU subjects with CAP (by International Classification of Diseases, 9th edition, codes) was conducted over a 3-year period at two tertiary teaching hospitals. Timing of the ICU admission was dichotomized into early ICU admission (EICUA, direct admission or within 24 h) and late ICU admission (LICUA, >= day 2). A multivariable analysis using Cox proportional hazard model was created with the primary outcome of 30-day mortality (dependent measure) and the American Thoracic Society (ATS) severity adjustment criteria and time to ICU admission as the independent measures. Results: Eighty-eight percent (n = 142) were EICUA patients compared with 12% (n = 19) LICUA patients. Groups were similar with respect to age, gender, comorbidities, clinical parameters, CAP-related process of care measures, and need for mechanical ventilation. LICUA patients had lower rates of ATS severity criteria at presentation (26.3% vs 53.5%; P = .03). LICUA patients (47.4%) had a higher 30-day mortality compared with EICUA (23.2%) patients (P = .02), which remained after adjusting in tire multivariable analysis (hazard ratio 2.6; 95% Cl, 1.2-5.5; P = .02). Conclusion: Patients with severe CAP with a late ICU admission have increased 30-day mortality after adjustment for illness severity. Further research should evaluate the risk factors associated and their impact on clinical outcomes in patients admitted late to the ICU. CHEST 2010; 137(3):552-557 C1 [Restrepo, Marcos I.] S Texas Vet Hlth Care Syst, ALMD, Vet Evidence Based Res Disseminat & Implementat C, San Antonio, TX 78229 USA. [Restrepo, Marcos I.; Mortensen, Eric M.; Anzueto, Antonio] S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX 78229 USA. [Mortensen, Eric M.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Gen Med, San Antonio, TX 78229 USA. [Restrepo, Marcos I.; Brody, Jennifer; Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, Div Pulm & Crit Care Med, San Antonio, TX 78229 USA. [Rello, Jordi] Hosp Univ Tarragona Joan XXIII, Serv Med Intens, Tarragona, Spain. [Rello, Jordi] CIBERES, Tarragona, Spain. [Rello, Jordi] Univ Rovira & Virgili, Tarragona, Spain. RP Restrepo, MI (reprint author), S Texas Vet Hlth Care Syst, ALMD, Vet Evidence Based Res Disseminat & Implementat C, 11C6,7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM restrepom@uthscsa.edu RI Restrepo, Marcos/H-4442-2014 OI Rello, Jordi/0000-0003-0676-6210; Mortensen, Eric/0000-0002-3880-5563 FU GlaxoSmithKline; Pfizer; Lilly Pharma FX The authors have reported to CHEST the following conflicts of interest: Dr. Restrepo has served on the speakers bureaus of Ortho-McNeil-Janssen, Johnson & Johnson, Pfizer, Covidien, and BAR D, Inc., and on the advisory boards for Ortho-McNeil-Janssen and Johnson & Johnson. Dr Anzueto has served on the speakers bureaus of Pfizer, Boehringer Ingelheim, GlaxoSmithKline, Astra Zeneca, Ortho-McNeil-Janssen, Johnson & Johnson, Bayer-Schering Pharma, and Schering-Plough; on the advisory board of GlaxoSmithKline, Boehringer Ingelheim, Bayer Schering Pharma, Schering-Plough, and Pfizer; and is the principal investigator on research grants that were awarded to the University of Texas Health Science Center at San Antonio by GlaxoSmithKline, Pfizer and Lilly Pharma. Drs Mortensen, Rello, and Brody have reported no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article. NR 28 TC 67 Z9 75 U1 0 U2 5 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA SN 0012-3692 J9 CHEST JI Chest PD MAR PY 2010 VL 137 IS 3 BP 552 EP 557 DI 10.1378/chest.09-1547 PG 6 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 567WC UT WOS:000275477100010 PM 19880910 ER PT J AU Deo, R Sotoodehnia, N Katz, R Sarnak, MJ Fried, LF Chonchol, M Kestenbaum, B Psaty, BM Siscovick, DS Shlipak, MG AF Deo, Rajat Sotoodehnia, Nona Katz, Ronit Sarnak, Mark J. Fried, Linda F. Chonchol, Michel Kestenbaum, Bryan Psaty, Bruce M. Siscovick, David S. Shlipak, Michael G. TI Cystatin C and Sudden Cardiac Death Risk in the Elderly SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES LA English DT Article DE cystatin C; kidney; sudden cardiac death; epidemiology ID CHRONIC KIDNEY-DISEASE; LEFT-VENTRICULAR HYPERTROPHY; CORONARY-HEART-DISEASE; STAGE RENAL-DISEASE; UNITED-STATES; CARDIOVASCULAR-DISEASE; HEMODIALYSIS-PATIENTS; SERUM CREATININE; WOMEN; DYSFUNCTION AB Background-Recent studies have demonstrated an association between moderate kidney dysfunction and sudden cardiac death in people with cardiovascular disease. Methods and Results-The study was a longitudinal analysis among 4465 participants from the Cardiovascular Health Study without prevalent cardiovascular disease at baseline. Cystatin C and creatinine were measured from baseline sera. Sudden cardiac death (SCD) was defined as a sudden pulseless condition from a cardiac origin in a previously stable individual that occurred out of the hospital or in the emergency room. The association between cystatin C tertiles and SCD was determined with multivariate Cox proportional hazards. A similar analysis compared SCD incidence across creatinine-based estimated glomerular filtration rate (eGFR) tertiles. Over a median follow-up of 11.2 years, 91 adjudicated SCD events occurred. The annual incidence of SCD events increased across cystatin C tertiles: 10 events per 10 000 person years in tertile 1, 25 events per 10 000 person years in tertile 2, and 32 events per 10 000 person-years in the highest cystatin C tertile. These associations persisted after multivariate adjustment: hazards ratio=2.72; 95% confidence interval, 1.44 to 5.16 in tertile 2 and hazards ratio=2.67; 95% confidence interval, 1.33 to 5.35 in tertile 3. After multivariate adjustment, the rate of SCD also increased in a linear distribution across creatinine-based eGFR tertiles: 15 events per 10 000 person-years in tertile 1, 22 events per 10 000 person-years in tertile 2, and 27 events per 10 000 person-years in tertile 3. No significant associations, however, remained between creatinine-based eGFR and SCD after multivariable adjustment. Conclusions-Impaired kidney function, as measured by cystatin C, has an independent association with SCD risk among elderly persons without clinical cardiovascular disease. (Circ Cardiovasc Qual Outcomes. 2010; 3: 159-164.) C1 [Deo, Rajat] Univ Penn, Div Cardiol, Philadelphia, PA 19104 USA. [Sotoodehnia, Nona] Univ Washington, Div Cardiol, Seattle, WA 98195 USA. [Katz, Ronit] Univ Washington, Collaborat Hlth Studies Coordinating Ctr, Seattle, WA 98195 USA. [Sarnak, Mark J.] Tufts Med Ctr, Div Nephrol, Boston, MA USA. [Fried, Linda F.] Univ Pittsburgh, Sch Med, Renal Electrolyte Div, Pittsburgh, PA USA. VA Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA USA. [Chonchol, Michel] Univ Colorado, Hlth Sci Ctr, Div Renal Dis & Hypertens, Denver, CO USA. [Kestenbaum, Bryan] Univ Washington, Div Nephrol, Seattle, WA 98195 USA. [Psaty, Bruce M.; Siscovick, David S.] Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA USA. [Psaty, Bruce M.; Siscovick, David S.] Univ Washington, Dept Epidemiol, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA. [Psaty, Bruce M.; Siscovick, David S.] Univ Washington, Dept Hlth Serv, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA. Ctr Hlth Studies, Grp Hlth, Seattle, WA USA. [Shlipak, Michael G.] Vet Affairs Med Ctr, Gen Internal Med Sect, San Francisco, CA 94121 USA. Univ Calif San Francisco, Dept Med, San Francisco, CA USA. Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. RP Deo, R (reprint author), Univ Penn, Div Cardiol, 3400 Spruce St,9 Founders Cardiol, Philadelphia, PA 19104 USA. EM Rajat.Deo@uphs.upenn.edu FU National Heart, Lung, and Blood Institute; National Institute of Neurological Disorders and Stroke [R01 AG027002]; [N01-HC-85079]; [N01-HC-85086]; [N01-HC-35129]; [N01-HC-15103]; [N01-HC-55222]; [N01-HC-75150]; [N01-HC-45133]; [U01 HL080295] FX This study was supported by contract Nos. N01-HC-85079 through N01-HC-85086, N01-HC-35129, N01-HC-15103, N01-HC-55222, N01-HC-75150, N01-HC-45133, grant No. U01 HL080295 from the National Heart, Lung, and Blood Institute, with additional contribution from the National Institute of Neurological Disorders and Stroke and R01 AG027002. A full list of principal CHS investigators and institutions can be found at http://www.chs-nhlbi.org/pi.htm. NR 43 TC 39 Z9 39 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1941-7713 J9 CIRC-CARDIOVASC QUAL JI Circ.-Cardiovasc. Qual. Outcomes PD MAR PY 2010 VL 3 IS 2 BP 159 EP 164 DI 10.1161/CIRCOUTCOMES.109.875369 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 575PT UT WOS:000276080200009 PM 20233980 ER PT J AU Felker, GM Pang, PS Adams, KF Cleland, JGF Cotter, G Dickstein, K Filippatos, GS Fonarow, GC Greenberg, BH Hernandez, AF Khan, S Komajda, M Konstam, MA Liu, PP Maggioni, AP Massie, BM McMurray, JJ Mehra, M Metra, M O'Connell, J O'Connor, CM Pina, IL Ponikowski, P Sabbah, HN Teerlink, JR Udelson, JE Yancy, CW Zannad, F Gheorghiade, M AF Felker, G. Michael Pang, Peter S. Adams, Kirkwood F. Cleland, John G. F. Cotter, Gad Dickstein, Kenneth Filippatos, Gerasimos S. Fonarow, Gregg C. Greenberg, Barry H. Hernandez, Adrian F. Khan, Sadiya Komajda, Michel Konstam, Marvin A. Liu, Peter P. Maggioni, Aldo P. Massie, Barry M. McMurray, John J. Mehra, Mandeep Metra, Marco O'Connell, John O'Connor, Christopher M. Pina, Ileana L. Ponikowski, Piotr Sabbah, Hani N. Teerlink, John R. Udelson, James E. Yancy, Clyde W. Zannad, Faiez Gheorghiade, Mihai CA Int AHFS Working Grp TI Clinical Trials of Pharmacological Therapies in Acute Heart Failure Syndromes Lessons Learned and Directions Forward SO CIRCULATION-HEART FAILURE LA English DT Article DE heart failure; patients; trials; acute heart failure ID WORSENING RENAL-FUNCTION; IN-HOSPITAL MORTALITY; RANDOMIZED CONTROLLED-TRIALS; CARDIAC TROPONIN-I; END-POINTS; MYOCARDIAL-INFARCTION; RISK STRATIFICATION; FLUID ACCUMULATION; PROGNOSTIC VALUE; OUTCOMES C1 [Gheorghiade, Mihai] Northwestern Univ, Ctr Cardiovasc Qual & Outcomes, Feinberg Sch Med, Dept Med, Chicago, IL 60611 USA. [Felker, G. Michael] Duke Clin Res Inst Durham, Durham, NC USA. [Pang, Peter S.] Northwestern Univ, Ctr Cardiovasc Qual & Outcomes, Feinberg Sch Med, Dept Emergency Med, Chicago, IL 60611 USA. [Adams, Kirkwood F.] Univ N Carolina, Sch Med, Dept Med, Chapel Hill, NC USA. [Adams, Kirkwood F.] Univ N Carolina, Sch Med, Dept Radiol, Chapel Hill, NC 27514 USA. [Cleland, John G. F.] Univ Hull, Dept Cardiol, Castle Hill Hosp, Kingston Upon Hull, Yorks, England. [Cotter, Gad] Momentum Res Inc, Durham, NC USA. Stavanger Univ Hosp, Stavanger, Norway. [Dickstein, Kenneth] Univ Bergen, Inst Internal Med, Bergen, Norway. [Filippatos, Gerasimos S.] Univ Athens, Hosp Attikon, Athens, Greece. [Fonarow, Gregg C.] David Geffen UCLA, Med Ctr, Ahmanson UCLA Cardiomyopathy Ctr, Los Angeles, CA USA. [Greenberg, Barry H.] Univ Calif San Diego, San Diego, CA 92103 USA. [Hernandez, Adrian F.] Duke Univ, Sch Med, Duke Clin Res Inst, Durham, NC USA. [Komajda, Michel] Univ Paris 06, AP HP, Paris, France. [Konstam, Marvin A.] Tufts Med Ctr, Ctr Cardiovasc, Boston, MA USA. [Konstam, Marvin A.] Tufts Univ, Sch Med, Boston, MA 02111 USA. [Liu, Peter P.] Univ Toronto, Toronto Gen Hosp, Inst Circulatory & Resp Hlth, Canadian Inst Hlth, Toronto, ON M5S 1A1, Canada. [Maggioni, Aldo P.] ANMCO Res Ctr, Florence, Italy. [Massie, Barry M.] Univ Calif San Francisco, Div Cardiol, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA. [McMurray, John J.] Univ Glasgow, BHF Cardiovasc Res Ctr, Glasgow, Lanark, Scotland. [Mehra, Mandeep] Univ Maryland, Sch Med, Baltimore, MD 21201 USA. [Metra, Marco] Univ & Civil Hosp Brescia, Dept Expt & Appl Med, Brescia, Italy. [O'Connell, John] Feinberg Sch Med, Div Cardiol, Chicago, IL USA. [O'Connor, Christopher M.] Duke Univ, Med Ctr, Duke Heart Ctr, Div Clin Pharmacol, Durham, NC 27710 USA. [Pina, Ileana L.] Case Western Reserve Univ, Cleveland, OH 44106 USA. [Ponikowski, Piotr] Med Univ, Fac Hlth Sci, Clin Mil Hosp, Katowice, Poland. [Sabbah, Hani N.] Henry Ford Hosp, Dept Med, Detroit, MI 48202 USA. [Teerlink, John R.] Vet Affairs Med Ctr, San Francisco, CA 94121 USA. [Udelson, James E.] Tufts Med Ctr, Div Cardiol, Boston, MA USA. [Yancy, Clyde W.] Baylor Heart & Vasc Inst, Dallas, TX USA. [Zannad, Faiez] Nancy Univ, Dept Cardiol, Nancy, France. RP Gheorghiade, M (reprint author), Northwestern Univ, Ctr Cardiovasc Qual & Outcomes, Feinberg Sch Med, Dept Med, 645 N Michigan Ave,Suite 1006, Chicago, IL 60611 USA. EM m-gheorghiade@northwestern.edu RI Teerlink, John/D-2986-2012; Lainscak, Mitja/F-3237-2015; Ponikowski, Piotr/O-6454-2015; Hernandez, Adrian F./A-7818-2016 OI Ponikowski, Piotr/0000-0002-3391-7064; Mehra, Mandeep/0000-0001-8683-7044; Hernandez, Adrian F./0000-0003-3387-9616; Cleland, John/0000-0002-1471-7016; Metra, Marco/0000-0001-6691-8568; mcmurray, john/0000-0002-6317-3975; Maggioni, Aldo Pietro/0000-0003-2764-6779 NR 69 TC 84 Z9 88 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1941-3289 J9 CIRC-HEART FAIL JI Circ.-Heart Fail. PD MAR PY 2010 VL 3 IS 2 BP 314 EP 325 DI 10.1161/CIRCHEARTFAILURE.109.893222 PG 12 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 570EQ UT WOS:000275655400021 PM 20233993 ER PT J AU Dixon, JA Spinale, FG AF Dixon, Jennifer A. Spinale, Francis G. TI Response to Letter Regarding Article "Large Animal Models of Heart Failure: A Critical Link in the Translation of Basic Science to Clinical Practice" SO CIRCULATION-HEART FAILURE LA English DT Letter ID CORONARY MICROEMBOLIZATION; SHEEP C1 [Dixon, Jennifer A.; Spinale, Francis G.] Med Univ S Carolina, Div Cardiothorac Surg, Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29425 USA. RP Dixon, JA (reprint author), Med Univ S Carolina, Div Cardiothorac Surg, Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29425 USA. EM wilburnm@musc.edu NR 5 TC 0 Z9 0 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1941-3289 J9 CIRC-HEART FAIL JI Circ.-Heart Fail. PD MAR PY 2010 VL 3 IS 2 BP E4 EP E4 DI 10.1161/CIRCHEARTFAILURE.109.934430 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 570EQ UT WOS:000275655400027 ER PT J AU Treger, R Pirouz, S Kamangar, N Corry, D AF Treger, Richard Pirouz, Shahriar Kamangar, Nader Corry, Dalila TI Agreement between Central Venous and Arterial Blood Gas Measurements in the Intensive Care Unit SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID DIABETIC-KETOACIDOSIS; VALUES; PH; BICARBONATE; PREDICTION; FAILURE; DISEASE; PCO(2) AB Background and objectives: Venous blood gas (VBG) analysis is a safer procedure than arterial blood gas (ABC) analysis and may be an alternative for determining acid-base status. The objective of this study was to examine the agreement between ABC and central VBG samples for all commonly used parameters in a medical intensive care unit (ICU) population. Design, setting, participants, & measurements: We performed a single-center, prospective trial to assess the agreement between arterial and central VBG measurements in a medical ICU. Adult patients who were admitted to the ICU and required both a central venous line and an arterial line were enrolled. When an ABC was performed, a central venous sample was obtained to examine the agreement among the pH, PCO(2), and bicarbonate. Data comparing central and peripheral VBG values were also obtained. Results: The mean arterial minus venous difference for pH, PCO(2), and bicarbonate was 0.027, -3.8, and -0.80, respectively. Bland-Altman plots for agreement of pH, PCO(2), and bicarbonate showed 95% limits of agreement of -0.028 to 0.081, -1.2.3 to 4.8, and -4.0 to 2.4, respectively. Regression equations were derived to predict arterial values from venous values as follows: Arterial pH = -0.307 + 1.05 x venous pH, arterial PCO(2) = 0.805 + 0.936 x venous PCO(2), and arterial bicarbonate = 0.513 + 0.945 x venous bicarbonate. The mean central minus peripheral differences for pH, PCO(2), and bicarbonate were not clinically important. Conclusions: Peripheral or central venous PH, PCO(2), and bicarbonate can replace their arterial equivalents in many clinical contexts encountered in the ICU. C1 [Treger, Richard] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Nephrol, Los Angeles, CA USA. [Treger, Richard] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Emergency Med, Los Angeles, CA USA. [Corry, Dalila] Olive View UCLA Med Ctr, Dept Nephrol, Sylmar, CA 91342 USA. [Pirouz, Shahriar] Olive View UCLA Med Ctr, Dept Internal Med, Sylmar, CA 91342 USA. [Kamangar, Nader] Olive View UCLA Med Ctr, Dept Pulm Crit Care, Sylmar, CA 91342 USA. [Treger, Richard; Pirouz, Shahriar; Kamangar, Nader; Corry, Dalila] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Treger, R (reprint author), W Los Angeles Vet Affairs Med Ctr, 11301 Wilshire Blvd,W111A, Los Angeles, CA 90073 USA. EM richard.treger@va.gov FU Olive-View-UCLA Education and Research Institute FX This project was supported by a seed grant from the Olive-View-UCLA Education and Research Institute. NR 16 TC 25 Z9 28 U1 0 U2 1 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD MAR PY 2010 VL 5 IS 3 BP 390 EP 394 DI 10.2215/CJN.00330109 PG 5 WC Urology & Nephrology SC Urology & Nephrology GA 565WB UT WOS:000275325000002 PM 20019117 ER PT J AU Al-Shahrouri, HZ Ramirez, P Fanti, P Abboud, H Lorenzo, C Haffner, S AF Al-Shahrouri, H. Z. Ramirez, P. Fanti, P. Abboud, H. Lorenzo, C. Haffner, S. TI NMR identifies atherogenic lipoprotein abnormalities in early diabetic nephropathy that are unrecognized by conventional analysis SO CLINICAL NEPHROLOGY LA English DT Article DE diabetic nephropathy; atherogenic lipids; albuminuria ID CHRONIC KIDNEY-DISEASE; NUCLEAR-MAGNETIC-RESONANCE; INSULIN-RESISTANCE ATHEROSCLEROSIS; FATAL MYOCARDIAL-INFARCTION; CARDIOVASCULAR EVENTS; DENSITY LIPOPROTEINS; APOLIPOPROTEIN-B; PARTICLE-SIZE; A-I; RISK AB Lipoprotein abnormalities are likely contributors to the high risk of cardiovascular disease in the chronic kidney disease (CKD) population, although information is limited. Specifically, little is known about lipoprotein abnormalities during the early stages of diabetic kidney disease. The aim of this study was to investigate the relationship between lipoproteins and early manifestations of CKD in the 517 Type 2 diabetes mellitus (T2DM) patients who participated in the Insulin Resistance Atherosclerosis Study ( IRAS). Methods: Lipoprotein abnormalities were measured by conventional lipid analysis, nuclear magnetic resonance (NMR) spectroscopy, gel gradient electrophoresis (GE), immunoprecipitation (IP), and ELISA. We grouped the cases into albumin to creatinine ratio (ACR) and estimated glomerular filtration rate (eGFR) quartiles. Results: In the conventional lipid analysis, triglycerides (TG) correlated directly with ACR and inversely with eGFR quartiles (p = 0.01), while LDL, HDL cholesterol did not correlate with change in ACR or eGFR. ACR was directly associated with apoB, total VLDL, medium VLDL, IDL and small LDL particle concentrations (p <= 0.03), and inversely with large LDL particles (p = 0.01) and LDL size (p = 0.008). Estimated GFR quartiles were inversely associated with total VLDL, small VLDL, IDL, and medium HDL particles (p <= 0.01). Conclusion: In subjects with T2DM, mild albuminuria and reduction in eGFR were associated with numerous atherogenic lipoprotein abnormalities that were detected by the combination of NMR spectroscopy, gel gradient electrophoresis, immunoprecipitation and ELISA but not by the standard clinical lipid analysis. C1 [Al-Shahrouri, H. Z.; Ramirez, P.; Fanti, P.; Abboud, H.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Clin Nephrol, San Antonio, TX 78229 USA. [Lorenzo, C.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Clin Epidemiol, San Antonio, TX 78229 USA. [Haffner, S.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Al-Shahrouri, HZ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Nephrol, Mail Code 7882,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM alshahrouri@uthscsa.edu FU National Heart, Lung, and Blood Institute [HL-47887, HL-47889, HL-47890, HL-47892, HL-47902]; NCRR GCRC [M01 RR431, M01 RR01346] FX This work was supported by National Heart, Lung, and Blood Institute Grants HL-47887, HL-47889, HL-47890, HL-47892, HL-47902 and the General Clinical Research Centers Program (NCRR GCRC, M01 RR431, M01 RR01346). NR 37 TC 5 Z9 5 U1 0 U2 0 PU DUSTRI-VERLAG DR KARL FEISTLE PI DEISENHOFEN-MUENCHEN PA BAHNHOFSTRASSE 9 POSTFACH 49, D-82032 DEISENHOFEN-MUENCHEN, GERMANY SN 0301-0430 J9 CLIN NEPHROL JI Clin. Nephrol. PD MAR PY 2010 VL 73 IS 3 BP 180 EP 189 PG 10 WC Urology & Nephrology SC Urology & Nephrology GA 563KM UT WOS:000275130800002 PM 20178716 ER PT J AU Locke, C Mceuen, J Felder, R Radcliffe, L Barrett, T Stevens, B Lesselroth, B Pope, D AF Locke, Christy Mceuen, Judy Felder, Robert Radcliffe, Leann Barrett, Thomas Stevens, Brent Lesselroth, Blake Pope, Diana TI Adherence, Safety, and Effectiveness of a Paper Versus Electronic Insulin Infusion Protocol in Acute Care SO CLINICAL NURSE SPECIALIST LA English DT Meeting Abstract C1 [Locke, Christy; Mceuen, Judy; Felder, Robert; Radcliffe, Leann; Barrett, Thomas; Stevens, Brent; Lesselroth, Blake; Pope, Diana] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0887-6274 J9 CLIN NURSE SPEC JI Clin. Nurse Spec. PD MAR-APR PY 2010 VL 24 IS 2 BP 88 EP 89 PG 2 WC Nursing SC Nursing GA 570QP UT WOS:000275693300014 ER PT J AU Richardson, J Tjoelker, R AF Richardson, Jenny Tjoelker, Rita TI Beyond the Bundle: The Value of the Clinical Nurse Specialists in Continuing Evidence-Based Practice Changes SO CLINICAL NURSE SPECIALIST LA English DT Meeting Abstract C1 [Richardson, Jenny; Tjoelker, Rita] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0887-6274 J9 CLIN NURSE SPEC JI Clin. Nurse Spec. PD MAR-APR PY 2010 VL 24 IS 2 BP 89 EP 89 PG 1 WC Nursing SC Nursing GA 570QP UT WOS:000275693300017 ER PT J AU Busch, AH Brenk, T AF Busch, Ann Herbage Brenk, Thomas TI Clinical Nurse Specialist Influencing Local to National Systems: Electronic Transplant Referral SO CLINICAL NURSE SPECIALIST LA English DT Meeting Abstract C1 [Busch, Ann Herbage; Brenk, Thomas] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0887-6274 J9 CLIN NURSE SPEC JI Clin. Nurse Spec. PD MAR-APR PY 2010 VL 24 IS 2 BP 91 EP 91 PG 1 WC Nursing SC Nursing GA 570QP UT WOS:000275693300023 ER PT J AU Valdez, CR Richardson, J Schrader, J AF Valdez, Christine R. Richardson, Jenny Schrader, Jennifer TI Evaluation of an Interdisciplinary Educational Program SO CLINICAL NURSE SPECIALIST LA English DT Meeting Abstract C1 [Valdez, Christine R.; Richardson, Jenny; Schrader, Jennifer] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0887-6274 J9 CLIN NURSE SPEC JI Clin. Nurse Spec. PD MAR-APR PY 2010 VL 24 IS 2 BP 95 EP 95 PG 1 WC Nursing SC Nursing GA 570QP UT WOS:000275693300035 ER PT J AU Atherton, S Busch, A Church, V Cole, JA Halmquist, J Locke, C Patten, S Richardson, J Tjoelker, R Valdez, C Vogeley, C AF Atherton, Sherri Busch, Ann Church, Victoria Cole, June Ann Halmquist, Jennifer Locke, Christy Patten, Stephen Richardson, Jenny Tjoelker, Rita Valdez, Christine Vogeley, Cathryn TI Finding the Clinical Nurse Specialist Voice and Articulating Value SO CLINICAL NURSE SPECIALIST LA English DT Meeting Abstract C1 [Atherton, Sherri; Busch, Ann; Church, Victoria; Cole, June Ann; Halmquist, Jennifer; Locke, Christy; Patten, Stephen; Richardson, Jenny; Tjoelker, Rita; Valdez, Christine; Vogeley, Cathryn] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0887-6274 J9 CLIN NURSE SPEC JI Clin. Nurse Spec. PD MAR-APR PY 2010 VL 24 IS 2 BP 96 EP 96 PG 1 WC Nursing SC Nursing GA 570QP UT WOS:000275693300038 ER PT J AU Patten, S AF Patten, Stephen TI Partnerships Between Hospitals and Schools of Nursing SO CLINICAL NURSE SPECIALIST LA English DT Meeting Abstract C1 [Patten, Stephen] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0887-6274 J9 CLIN NURSE SPEC JI Clin. Nurse Spec. PD MAR-APR PY 2010 VL 24 IS 2 BP 99 EP 99 PG 1 WC Nursing SC Nursing GA 570QP UT WOS:000275693300048 ER PT J AU Fehringer, EV Mikuls, TR Michaud, KD Henderson, WG O'Dell, JR AF Fehringer, Edward V. Mikuls, Ted R. Michaud, Kaleb D. Henderson, William G. O'Dell, James R. TI Shoulder Arthroplasties have Fewer Complications than Hip or Knee Arthroplasties in US Veterans SO CLINICAL ORTHOPAEDICS AND RELATED RESEARCH LA English DT Article ID SURGICAL CARE; RISK ADJUSTMENT; OUTCOMES; OSTEOARTHRITIS; QUALITY AB Total shoulder arthroplasties (TSA) are being performed more commonly for treatment of arthritis, although fewer than either hip (THA) or knee (TKA) arthroplasties. Total shoulder arthroplasty also provides general health improvements that are comparable to THA. One study suggests TSAs are associated with lower morbidity and mortality than THAs and TKAs. To confirm and extend that study, we therefore examined the association of patient characteristics (sociodemographics, comorbid illness, and other risk factors) with 30-day complications for patients undergoing TSAs, THAs, or TKAs. We used data from the Veterans Administration (VA) National Surgical Quality Improvement Program (NSQIP) for fiscal years 1999 to 2006. Sociodemographics, comorbidities, health behaviors, operative factors, and complications (mortality, return to the operating room, readmission within 14 days, cardiovascular events, and infections) were available for 10,407 THAs, 23,042 TKAs, and 793 TSAs. Sociodemographic features were comparable among groups. The mean operative time was greater for TSAs (3.0 hours) than for TKAs (2.2 hours) and THAs (2.4 hours). The 30-day mortality rates were 1.2%, 1.1%, and 0.4% for THAs, TKAs, and TSAs, respectively. The corresponding postoperative complication rates were 7.6%, 6.8%, and 2.8%. Adjusting for multiple risk factors, complications, readmissions, and postoperative stays were less for TSAs versus THAs and TKAs. In a VA population, TSAs required more operative time but resulted in shorter stays, fewer complications, and fewer readmissions than THAs and TKAs. Level of Evidence: Level III, therapeutic study. See the Guidelines for Authors for a complete description of levels of evidence. C1 [Fehringer, Edward V.] Univ Nebraska Med Ctr, Dept Orthopaed Surg & Rehabil, Omaha, NE 68198 USA. [Fehringer, Edward V.; Mikuls, Ted R.; Michaud, Kaleb D.; O'Dell, James R.] NAORC, Omaha, NE USA. [Henderson, William G.] Univ Colorado, Hlth Outcomes Program, UCD, AMC, Denver, CO 80202 USA. [Henderson, William G.] Denver VA Med Ctr, Denver, CO USA. RP Fehringer, EV (reprint author), Univ Nebraska Med Ctr, Dept Orthopaed Surg & Rehabil, 981080 Nebraska Med Ctr, Omaha, NE 68198 USA. EM evfehringer@unmc.edu NR 16 TC 26 Z9 26 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0009-921X J9 CLIN ORTHOP RELAT R JI Clin. Orthop. Rel. Res. PD MAR PY 2010 VL 468 IS 3 BP 717 EP 722 DI 10.1007/s11999-009-0996-2 PG 6 WC Orthopedics; Surgery SC Orthopedics; Surgery GA 558HM UT WOS:000274731700011 PM 19626383 ER PT J AU Chang, MH Fung, HB AF Chang, Mei H. Fung, Horatio B. TI Besifloxacin: A Topical Fluoroquinolone for the Treatment of Bacterial Conjunctivitis SO CLINICAL THERAPEUTICS LA English DT Review DE besifloxacin; bacterial conjunctivitis; ophthalmic fluoroquinolones ID OPHTHALMIC SUSPENSION 0.6-PERCENT; ANTIMICROBIAL AGENT; ESCHERICHIA-COLI; SAFETY; PHARMACOKINETICS; INFECTIONS; RESISTANCE; EFFICACY AB Background: Besifloxacin is a topical ophthalmic fluoroquinolone that was approved by the US Food and Drug Administration (FDA) in May 2009 for the treatment of bacterial conjunctivitis caused by susceptible bacterial strains. Objective: This article provides an overview of the pharmacology, clinical efficacy, and tolerability of ophthalmic besifloxacin when used for the treatment of bacterial conjunctivitis. Methods: Relevant reports pertaining to the pharmacology, efficacy, and tolerability of besifloxacin were identified through a search of MEDLINE (1985 December 2009) and International Pharmaceutical Abstracts (1985 December 2009) using the terms besifloxacin, BOL-303224-A, ophthalmic fluoroquinolones, and bacterial conjunctivitis. Additional publications were identified by reviewing the reference lists of identified articles and searching the FDA Web site. Results: Besifloxacin has potent in vitro inhibitory activity against most common ocular bacterial pathogens (MIC(90) values generally <= 4 mu g/mL), including Staphylococcus aureus, Streptococcus pneumoniae, and Haemophilus influenzae. In an ocular pharmacokinetic study in 64 healthy volunteers, the C(max) in tears (mean [SD], 610 [540] mu g/mL) was reached 10 minutes after a single ocular instillation of besifloxacin; concentrations >= 1.6 mu g/g of tear were sustained for at least 24 hours; and the elimination tin. was similar to 3.4 hours. In a study in 24 patients with a clinical diagnosis of bilateral bacterial conjunctivitis, systemic exposure (C(max)) after administration of besifloxacin ophthalmic suspension 3 times daily for 5 days was <0.5 ng/mL. In 2 randomized, double-masked, vehicle-controlled clinical trials, besifloxacin ophthalmic suspension was well tolerated and significantly more efficacious than vehicle in achieving clinical resolution (73.3% vs 43.1%, respectively, in one of the studies [P < 0.001]; 45.2% vs 33.0% in the other [P = 0.008]) and microbial eradication (88.3% vs 60.3% [P < 0.001] and 91.5% vs 59.7% [P < 0.001], respectively). In a randomized, double-masked, parallel-group, noninferiority trial comparing besifloxacin ophthalmic suspension 0.6% with moxifloxacin ophthalmic solution 0.5%, besifloxacin was found to be noninferior to moxifloxacin (predefined cutoff for noninferiority = 15), with no significant differences in rates of clinical resolution (58.3% and 59.4%, respectively; 95% CI, -9.48 to 7.29) or microbial eradication (93.3% and 91.1%; 95% CI, -2.44 to 6.74). Besifloxacin was generally well tolerated in these clinical trials, with the most common >= 1.5%) ocular adverse events being nonspecific conjunctivitis (2.6%), blurred vision (2.1%), bacterial conjunctivitis (1.8%), and eye pain (1.5%). The recommended dose of besifloxacin is 1 drop in the affected eye(s) 3 times daily (4-12 hours apart) for 7 days. Conclusion: Besifloxacin ophthalmic suspension 0.6% appeared to be well tolerated in the populations studied and was efficacious in the treatment of bacterial conjunctivitis caused by susceptible isolates. (Clin Then 2010;32:454-471) (C) 2010 Excerpta Medica Inc. C1 [Chang, Mei H.; Fung, Horatio B.] James J Peters Vet Affairs Med Ctr, Serv Pharm, Bronx, NY 10468 USA. RP Fung, HB (reprint author), James J Peters Vet Affairs Med Ctr, Serv Pharm, 130 W Kings Bridge Rd 119, Bronx, NY 10468 USA. EM horatio.fung@va.gov NR 32 TC 7 Z9 8 U1 0 U2 2 PU ELSEVIER PI BRIDGEWATER PA 685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA SN 0149-2918 J9 CLIN THER JI Clin. Ther. PD MAR PY 2010 VL 32 IS 3 BP 454 EP 471 DI 10.1016/j.clinthera.2010.03.013 PG 18 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 582XB UT WOS:000276632600004 PM 20399984 ER PT J AU Nelson, JE Puntillo, KA Pronovost, PJ Walker, AS McAdam, JL Ilaoa, D Penrod, J AF Nelson, Judith E. Puntillo, Kathleen A. Pronovost, Peter J. Walker, Amy S. McAdam, Jennifer L. Ilaoa, Debra Penrod, Joan TI In their own words: Patients and families define high-quality palliative care in the intensive care unit SO CRITICAL CARE MEDICINE LA English DT Article DE intensive care; critical care; palliative care; quality assessment; health care; quality indicators; qualitative research ID OF-LIFE CARE; CRITICALLY-ILL; CONTROLLED-TRIAL; VISITING POLICY; MEDICAL-CARE; HEALTH-CARE; END; ICU; PAIN; MEMBERS AB Objective: Although the majority of hospital deaths occur in the intensive care unit and virtually all critically ill patients and their families have palliative needs, we know little about how patients and families, the most important "stakeholders," define high-quality intensive care unit palliative care. We conducted this study to obtain their views on important domains of this care. Design: Qualitative study using focus groups facilitated by a single physician. Setting: A 20-bed general intensive care unit in a 382-bed community hospital in Oklahoma; 24-bed medical-surgical intensive care unit in a 377-bed tertiary, university hospital in urban California; and eight-bed medical intensive care unit in a 311-bed Veterans' Affairs hospital in a northeastern city. Patients: Randomly-selected patients with intensive care unit length of stay >= 5 days in 2007 to 2008 who survived the intensive care unit, families of survivors, and families of patients who died in the intensive care unit. Interventions: None. Measurements and Main Results: Focus group facilitator used open-ended questions and scripted probes from a written guide. Three investigators independently coded meeting transcripts, achieving consensus on themes. From 48 subjects (15 patients, 33 family members) in nine focus groups across three sites, a shared definition of high-quality intensive care unit palliative care emerged: timely, clear, and compassionate communication by clinicians; clinical decision-making focused on patients' preferences, goals, and values; patient care maintaining comfort, dignity, and personhood; and family care with open access and proximity to patients, interdisciplinary support in the intensive care unit, and bereavement care for families of patients who died. Participants also endorsed specific processes to operationalize the care they considered important. Conclusions: Efforts to improve intensive care unit palliative care quality should focus on domains and processes that are most valued by critically ill patients and their families, among whom we found broad agreement in a diverse sample. Measures of quality and effective interventions exist to improve care in domains that are important to intensive care unit patients and families. (Crit Care Med 2010; 38: 808-818) C1 [Nelson, Judith E.; Walker, Amy S.] Mt Sinai Sch Med, Div Pulm Crit Care & Sleep Med, New York, NY 10029 USA. [Nelson, Judith E.] Mt Sinai Sch Med, Hertzberg Palliat Care Inst, New York, NY USA. [Puntillo, Kathleen A.; McAdam, Jennifer L.] Univ Calif San Francisco, Dept Physiol Nursing, Crit Care Trauma Program, San Francisco, CA 94143 USA. [Pronovost, Peter J.] Johns Hopkins Univ, Sch Med, Dept Anesthesiol Crit Care Med Nursing & Surg, Baltimore, MD USA. [Pronovost, Peter J.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA. [McAdam, Jennifer L.] Dominican Univ Calif, Dept Nursing, San Rafael, CA USA. [Ilaoa, Debra] Norman Reg Hosp, Palliat Care Serv, Norman, OK USA. [Penrod, Joan] James J Peters VA Med Ctr, Ctr Study Hlth Care Syst & Sites Care, Bronx, NY USA. [Penrod, Joan] Mt Sinai Sch Med, Dept Geriatr & Adult Dev, New York, NY USA. RP Nelson, JE (reprint author), Mt Sinai Sch Med, Div Pulm Crit Care & Sleep Med, New York, NY 10029 USA. EM judith.nelson@mssm.edu FU National Institute on Aging (NIA) [R21-AG029955, K02-AG024476]; Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service [REA 08-260] FX This work was supported by R21-AG029955 from the National Institute on Aging (NIA). Dr. Nelson received an Independent Scientist Award from NIA, K02-AG024476. Dr. Penrod was supported by the Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service (project no. REA 08-260). Dr. Nelson and Dr. Pronovost served as consultants to the Voluntary Hospital Association, Inc., a national cooperative of not-for-profit, community-based hospitals, for development of ICU palliative care quality indicators. NR 50 TC 91 Z9 94 U1 4 U2 13 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0090-3493 J9 CRIT CARE MED JI Crit. Care Med. PD MAR PY 2010 VL 38 IS 3 BP 808 EP 818 DI 10.1097/CCM.0b013e3181c5887c PG 11 WC Critical Care Medicine SC General & Internal Medicine GA 565CI UT WOS:000275266200010 PM 20198726 ER PT J AU Roy, M Mahmood, N Rosendorff, C AF Roy, Monisankar Mahmood, Noman Rosendorff, Clive TI Evidence for Aggressive Blood Pressure-Lowering Goals in Patients with Coronary Artery Disease SO CURRENT ATHEROSCLEROSIS REPORTS LA English DT Article DE BP goals; Coronary artery disease; Hypertension; Blood pressure; J curve ID ISOLATED SYSTOLIC HYPERTENSION; LEFT-VENTRICULAR HYPERTROPHY; CARDIOVASCULAR-DISEASE; RANDOMIZED-TRIAL; HEART-DISEASE; ACTIVE TREATMENT; MORTALITY; RISK; FLOW; ATHEROSCLEROSIS AB Lowering blood pressure (BP) reduces the risk of major cardiovascular mortality and morbidity. Current consensus targets for BP reduction are less than 140/90 mm Hg in uncomplicated hypertension and less than 130/80 mm Hg in those patients with diabetes, chronic kidney disease, and coronary artery disease or in those who are at high risk for developing coronary artery disease (defined as a Framingham risk score of a parts per thousand yen 10%). There is solid epidemiologic evidence for lower BP targets, supported by some clinical studies with surrogate end points. On the other hand, there are meager data from clinical trials using hard end points, and there is a concern that overly aggressive BP lowering, especially of diastolic BP, may impair coronary perfusion, particularly in patients with left ventricular hypertrophy and/or coronary artery disease. This review evaluates the evidence for the benefit of lower BP targets in hypertension management. C1 [Roy, Monisankar; Mahmood, Noman; Rosendorff, Clive] Mt Sinai Sch Med, James J Peters VA Med Ctr, Bronx, NY 10468 USA. RP Rosendorff, C (reprint author), Mt Sinai Sch Med, James J Peters VA Med Ctr, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM monisankar.roy@va.gov; noman.mahmood@va.gov; clive.rosendorff@va.gov NR 40 TC 5 Z9 5 U1 0 U2 0 PU CURRENT MEDICINE GROUP PI PHILADELPHIA PA 400 MARKET STREET, STE 700, PHILADELPHIA, PA 19106 USA SN 1523-3804 J9 CURR ATHEROSCLER REP JI Curr. Atherosclerol. Rep. PD MAR PY 2010 VL 12 IS 2 BP 134 EP 139 DI 10.1007/s11883-010-0094-7 PG 6 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 583DW UT WOS:000276654300008 PM 20425249 ER PT J AU Soni, RK Weisbord, SD Unruh, ML AF Soni, Ritu K. Weisbord, Steven D. Unruh, Mark L. TI Health-related quality of life outcomes in chronic kidney disease SO CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION LA English DT Review DE anemia; chronic kidney disease; frailty; hypertension; quality of life; symptom burden ID CHRONIC RENAL-INSUFFICIENCY; ANEMIA CORRECTION; DIALYSIS PATIENTS; AFRICAN-AMERICAN; EPOETIN-ALPHA; HYPERTENSIVE PATIENTS; HEMOGLOBIN TARGET; NATIONAL-HEALTH; OLDER-ADULTS; FRAILTY AB Purpose of review Patients with chronic kidney disease (CKD) endure compromised health-related quality of life (HRQOL). Although the link between HRQOL and increased mortality in patients with end-stage renal disease (ESRD) is well documented, less is known about the relationship between CKD and HRQOL. This article reviews the recent evidence on HRQOL, its correlates and proposed intervention strategies to improve HRQOL in CKD. Recent findings A growing body of literature indicates that various comorbid conditions related to CKD play a substantial role in impaired HRQOL in CKD. Hypertension, both a cause and complication of CKD, negatively affects HRQOL due to associated comorbidities, side effects from antihypertensive medications and awareness of the diagnosis. Anemia has been associated with HRQOL, but concerns about the safety of erythropoietin-stimulating agents (ESAs) have led to more conservative anemia treatment. Frailty, symptom burden and depression are also major contributory factors to HRQOL in CKD. Summary Certain determinants of HRQOL in CKD, namely anemia and depression, are treatable. Early identification and correction may improve overall well being of patients. Clinical trials are required to demonstrate whether treatment interventions benefit HRQOL in this high-risk population. Furthermore, whether integration of HRQOL assessment into routine clinical practice will improve HRQOL outcomes remains to be determined. C1 [Weisbord, Steven D.; Unruh, Mark L.] Univ Pittsburgh, Sch Med, Renal Electrolyte Div, Med Ctr, Pittsburgh, PA 15213 USA. [Weisbord, Steven D.] VA Pittsburgh Healthcare Syst, Med Specialty Serv Line, Renal Sect, Pittsburgh, PA USA. [Weisbord, Steven D.] Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. RP Unruh, ML (reprint author), Univ Pittsburgh, Sch Med, Renal Electrolyte Div, Med Ctr, 200 Lothrop St,PUH C-1111, Pittsburgh, PA 15213 USA. EM unruh@pitt.edu FU NIDDK NIH HHS [K23 DK066006-05, DK66006, DK77785, K23 DK066006, R01 DK077785, R01 DK077785-04] NR 59 TC 44 Z9 46 U1 2 U2 13 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1062-4821 J9 CURR OPIN NEPHROL HY JI Curr. Opin. Nephrol. Hypertens. PD MAR PY 2010 VL 19 IS 2 BP 153 EP 159 DI 10.1097/MNH.0b013e328335f939 PG 7 WC Urology & Nephrology; Peripheral Vascular Disease SC Urology & Nephrology; Cardiovascular System & Cardiology GA 562OU UT WOS:000275062900005 PM 20051850 ER PT J AU Carlozzi, NE Horner, MD Kose, S Yamanaka, K Mishory, A Mu, Q Nahas, Z Wells, SA George, MS AF Carlozzi, Noelle E. Horner, Michael David Kose, Samet Yamanaka, Kaori Mishory, Alexander Mu, Qiwen Nahas, Ziad Wells, Sarah A. George, Mark S. TI Personality and Reaction Time after Sleep Deprivation SO CURRENT PSYCHOLOGY LA English DT Article DE Cognition; Personality; Reaction time; Sleep deprivation; State personality variables; Trait personality variables; Experiment ID PERFORMANCE; TASK AB The relationship between reaction time and both state and trait personality variables was investigated in 37 participants after 30 h of sleep deprivation. Regression analyses suggested that endorsement of greater Novelty Seeking, anger/hostility, and depression/dejection, and less confusion, was associated with greater reaction time declines on one Multi-Attribute Task Battery index after sleep deprivation. Further, greater Novelty Seeking and depression/dejection, and less vigor/activity, was associated with greater reaction time declines after sleep deprivation on another Multi-Attribute Task Battery index. Additional correlational analyses indicated that better reaction times were associated with greater Novelty Seeking and lower anger/hostility prior to sleep deprivation, and less confusion/bewilderment following sleep deprivation. Findings suggest that both state and trait personality variables are associated with reaction time performance following sleep deprivation. C1 [Carlozzi, Noelle E.] Kessler Fdn, Res Ctr, Outcomes & Assessment Lab, W Orange, NJ 07052 USA. [Horner, Michael David] Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC USA. [Horner, Michael David; George, Mark S.] Med Univ S Carolina, Charleston, SC 29425 USA. [Kose, Samet; Mishory, Alexander; Mu, Qiwen; Nahas, Ziad; Wells, Sarah A.; George, Mark S.] Brain Stimulat Lab, Charleston, SC USA. [Kose, Samet; Mishory, Alexander; Mu, Qiwen; Nahas, Ziad; Wells, Sarah A.; George, Mark S.] Ctr Adv Imaging Res, Charleston, SC USA. [Carlozzi, Noelle E.] Univ Med & Dent New Jersey, Newark, NJ 07103 USA. [Kose, Samet] Vanderbilt Univ, Dept Psychiat, Nashville, TN USA. [Yamanaka, Kaori] Showa Univ, Sch Med, Dept Neuropsychiat, Tokyo 142, Japan. RP Carlozzi, NE (reprint author), Kessler Fdn, Res Ctr, Outcomes & Assessment Lab, 1199 Pleasant Valley Way, W Orange, NJ 07052 USA. EM ncarlozzi@kesslerfoundation.org NR 20 TC 0 Z9 0 U1 5 U2 7 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1046-1310 J9 CURR PSYCHOL JI Curr. Psychol. PD MAR PY 2010 VL 29 IS 1 BP 24 EP 33 DI 10.1007/s12144-009-9068-8 PG 10 WC Psychology, Multidisciplinary SC Psychology GA 555FX UT WOS:000274495000003 ER PT J AU Stone, RA Rao, RH Sevick, MA Cheng, CR Hough, LJ Macpherson, DS Franko, CM Anglin, RA Obrosky, DS DeRubertis, FR AF Stone, Roslyn A. Rao, R. Harsha Sevick, Mary Ann Cheng, Chunrong Hough, Linda J. Macpherson, David S. Franko, Carol M. Anglin, Rebecca A. Obrosky, D. Scott DeRubertis, Frederick R. TI Active Care Management Supported by Home Telemonitoring in Veterans With Type 2 Diabetes The DiaTel randomized controlled trial SO DIABETES CARE LA English DT Article ID BLOOD-GLUCOSE CONTROL; GLYCEMIC CONTROL; COMPLICATIONS; INSULIN; METAANALYSIS; THERAPY; COSTS AB OBJECTIVE - We compared the short-term efficacy of home telemonitoring coupled with active medication management by a nurse practitioner with a monthly care coordination telephone call on glycemic control in veterans with type 2 diabetes and entry A1C >= 7.5%. RESEARCH DESIGN AND METHODS - Veterans who received primary care at the VA Pittsburgh Healthcare System from June 2004 to December 2005, who were taking oral hypoglycemic agents and/or insulin for >= 1 year, and who had A1C >= 7.5% at enrollment were randomly assigned to either active care management with home telemonitoring (ACM+HT group, n = 73) or a monthly care coordination telephone call (CC group, n = 77). Both groups received monthly calls for diabetes education and self-management review. ACM+HT group participants transmitted blood glucose, blood pressure, and weight to a nurse practitioner using the Viterion 100 TeleHealth Monitor; the nurse practitioner adjusted medications for glucose, blood pressure, and lipid control based on established American Diabetes Association targets. Measures were obtained at baseline, 3-month, and 6-month visits. RESULTS - Baseline characteristics were similar in both groups, with mean A1C of 9.4% (CC group) and 9.6% (ACM+HT group). Compared with the CC group, the ACM+HT group demonstrated significantly larger decreases in A1C at 3 months (1.7 vs. 0.7%) and 6 months (1.7 vs. 0.8%; P < 0.001 for each), with most improvement occurring by 3 months. CONCLUSIONS - Compared with the CC group, the ACM + HT group demonstrated significantly greater reductions in A1C by 3 and 6 months. However, both interventions improved glycemic control in primary care patients with previously inadequate control. C1 [Rao, R. Harsha; Anglin, Rebecca A.; DeRubertis, Frederick R.] VA Pittsburgh Healthcare Syst, Med Specialty Serv Line, Pittsburgh, PA USA. [Stone, Roslyn A.; Cheng, Chunrong] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA. [Stone, Roslyn A.; Sevick, Mary Ann; Cheng, Chunrong] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Rao, R. Harsha; Sevick, Mary Ann; Macpherson, David S.; Obrosky, D. Scott; DeRubertis, Frederick R.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA USA. [Sevick, Mary Ann; Franko, Carol M.] VA Pittsburgh Healthcare Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA. [Sevick, Mary Ann] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Behav & Community Hlth Sci, Pittsburgh, PA USA. [Hough, Linda J.] Vet Res Fdn Pittsburgh, Pittsburgh, PA USA. [Macpherson, David S.] VISN 4 Healthcare Network, Pittsburgh, PA USA. RP DeRubertis, FR (reprint author), VA Pittsburgh Healthcare Syst, Med Specialty Serv Line, Pittsburgh, PA USA. EM frederick.derubertis@va.gov FU U.S. Air Force [W81XWH-04-2-0030] FX This work was supported by award W81XWH-04-2-0030 from the U.S. Air Force, administered by the U.S. Army Medical Research Acquisition Activity, Fort Detrick, Maryland, and by resources and the use of facilities at the VAPHS. NR 24 TC 75 Z9 78 U1 2 U2 10 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 EI 1935-5548 J9 DIABETES CARE JI Diabetes Care PD MAR PY 2010 VL 33 IS 3 BP 478 EP 484 DI 10.2337/dc09-1012 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 568YO UT WOS:000275562700005 PM 20009091 ER PT J AU Sosenko, JM Palmer, JP Rafkin, LE Krischer, JP Cuthbertson, D Greenbaum, CJ Eisenbarth, G Skyler, JS AF Sosenko, Jay M. Palmer, Jerry P. Rafkin, Lisa E. Krischer, Jeffrey P. Cuthbertson, David Greenbaum, Carla J. Eisenbarth, George Skyler, Jay S. CA Diabet Prevention Trial-Type TI Trends of Earlier and Later Responses of C-peptide to Oral Glucose Challenges With Progression to Type 1 Diabetes in Diabetes Prevention Trial-Type 1 Participants SO DIABETES CARE LA English DT Article ID INSULIN-RESPONSE; TRIAL-TYPE-1; PREDICTION; TOLERANCE AB OBJECTIVE - We studied the C-peptide response to oral glucose with progression to type I diabetes in Diabetes Prevention Trial-Type 1 (DPT-1) participants. RESEARCH DESIGN AND METHODS - Among 504 DPT-1 participants <15 years of age, longitudinal analyses were performed in 36 progressors and 80 nonprogressors. Progressors had oral glucose tolerance tests (OGTTs) at baseline and every 6 months from 2.0 to 0.5 years before diagnosis; nonprogressors had OGTTs over similar intervals before their last Visit. Sixty-six progressors and 192 nonprogressors were also studied proximal to and at diagnosis. RESULTS - The 30-0 min C-peptide difference from OGTTs performed 2.0 years before diagnosis in progressors was lower than the 30-0 min C-peptide difference from OGTTs performed 2.0 years before the last visit in nonprogressors(P < 0.01) and remained lower overtime. The 90-60 min C-peptide difference was positive at every OGTT before diagnosis in progressors, whereas it was negative at every OGTT before the last Visit in nonprogressors (P < 0.01 at 2.0 years). The percentage whose peak C-peptide occurred at 120 min was higher in progressors at 2.0 years (P < 0.05); this persisted over time (P < 0.001 at 0.5 years). However, the peak C-peptide levels were only significantly lower at 0.5 years in progressors (P < 0.01). The timing of the peak C-peptide predicted type 1 diabetes (P < 0.001); peak C-peptide levels were less predictive (P < 0.05). CONCLUSIONS - A decreased early C-peptide response to oral glucose and an increased later response occur at least 2 years before the diagnosis of type 1 diabetes. C1 [Sosenko, Jay M.; Rafkin, Lisa E.; Skyler, Jay S.] Univ Miami, Div Endocrinol, Miami, FL USA. [Palmer, Jerry P.] Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Palmer, Jerry P.] Univ Washington, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA. [Krischer, Jeffrey P.] Univ S Florida, Div Informat & Biostat, Tampa, FL USA. [Cuthbertson, David] Univ S Florida, Pediat Epidemiol Ctr, Tampa, FL USA. [Greenbaum, Carla J.] Benaroya Res Inst Virginia Mason, Seattle, WA USA. [Eisenbarth, George] Univ Colorado, HLA DNA Lab, Aurora, CO USA. RP Sosenko, JM (reprint author), Univ Miami, Div Endocrinol, Miami, FL USA. EM jsosenko@med.miami.edu RI Skyler, Jay/F-4211-2016 FU NIDDK NIH HHS [U01 DK061034] NR 12 TC 20 Z9 20 U1 0 U2 2 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD MAR PY 2010 VL 33 IS 3 BP 620 EP 625 DI 10.2337/dc09-1770 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 568YO UT WOS:000275562700033 PM 20032282 ER PT J AU Egede, LE Osborn, CY AF Egede, Leonard E. Osborn, Chandra Y. TI Role of Motivation in the Relationship Between Depression, Self-care, and Glycemic Control in Adults With Type 2 Diabetes SO DIABETES EDUCATOR LA English DT Article ID FUNCTIONAL DISABILITY; COMORBID DEPRESSION; MAJOR DEPRESSION; METAANALYSIS; INDIVIDUALS; PREVALENCE; ADHERENCE; SYMPTOMS; QUESTIONNAIRE; ASSOCIATION AB Purpose The mechanism by which depression influences health outcomes in persons with diabetes is uncertain. The purpose of this study was to test whether depression is related to self-care behavior via social motivation and indirectly related to glycemic control via self-care behavior. Methods Patients with diabetes were recruited from an outpatient clinic. Information gathered pertained to demographics, depression, and diabetes knowledge (information); diabetes fatalism (personal motivation); social support (social motivation); and diabetes self-care (behavior). Hemoglobin A IC values were extracted from the patient medical record. Structural equation models tested the predicted pathways. Results Higher levels of depressive symptoms were significantly related to having less social support and decreased performance of diabetes self-care behavior. In addition, when depressive symptoms were included in the model, fatalistic attitudes were no longer associated with behavioral performance. Conclusions Among adults with diabetes, depression impedes the adoption of effective self-management behaviors (including physical activity, appropriate dietary behavior, foot care, and appropriate self-monitoring of blood glucose behavior) through a decrease in social motivation. C1 [Egede, Leonard E.] Med Univ S Carolina, Ctr Hlth Dispar Res, Charleston, SC 29425 USA. [Egede, Leonard E.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Egede, Leonard E.] Ralph H Johnson VA Med Ctr, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Charleston, SC USA. [Osborn, Chandra Y.] Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37212 USA. [Osborn, Chandra Y.] Vanderbilt Univ, Sch Med, Vanderbilt Eskind Diabet Ctr, Diabet Res & Training Ctr, Nashville, TN 37212 USA. RP Egede, LE (reprint author), Med Univ S Carolina, Ctr Hlth Dispar Res, 135 Rutledge Ave,Room 280H, Charleston, SC 29425 USA. EM egedel@musc.edu FU Diversity Supplement Award (NIDDK) [P60 DK020593] FX Dr Osborn is supported by a Diversity Supplement Award (NIDDK P60 DK020593). NR 33 TC 39 Z9 42 U1 4 U2 14 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0145-7217 J9 DIABETES EDUCATOR JI Diabetes Educ. PD MAR-APR PY 2010 VL 36 IS 2 BP 276 EP 283 DI 10.1177/0145721710361389 PG 8 WC Endocrinology & Metabolism; Public, Environmental & Occupational Health SC Endocrinology & Metabolism; Public, Environmental & Occupational Health GA 577ZG UT WOS:000276262000008 PM 20179250 ER PT J AU Egede, LE Ellis, C AF Egede, Leonard E. Ellis, Charles TI Diabetes and depression: Global perspectives SO DIABETES RESEARCH AND CLINICAL PRACTICE LA English DT Article DE Diabetes; Depression; Health care; Health outcomes; Global perspective ID PLACEBO-CONTROLLED TRIAL; CORONARY-HEART-DISEASE; POOR GLYCEMIC CONTROL; MENTAL-HEALTH SURVEYS; QUALITY-OF-LIFE; PRIMARY-CARE; COMORBID DEPRESSION; RISK-FACTOR; SELF-CARE; MEDICATION ADHERENCE AB Background: Diabetes and depression are highly prevalent conditions and have significant impact on health outcomes. This study reviewed the literature on the prevalence, burden of illness, morbidity, mortality, and cost of comorbid depression in people with diabetes as well as the evidence on effective treatments. Methods: Systematic review of the literature on the relationship between diabetes and depression was performed. A comprehensive search of the literature was performed on Medline from 1966 to 2009. Studies that examined the association between diabetes and depression were reviewed. A formal meta-analysis was not performed because of the broad area covered and the heterogeneity of the studies. Instead, a qualitative aggregation of studies was performed. Results: Diabetes and depression are debilitating conditions that are associated with significant morbidity, mortality, and healthcare costs. Coexisting depression in people with diabetes is associated with decreased adherence to treatment, poor metabolic control, higher complication rates, decreased quality of life, increased healthcare use and cost, increased disability and lost productivity, and increased risk of death. Conclusion: The coexistence of diabetes and depression is associated with significant morbidity, mortality, and increased healthcare cost. Coordinated strategies for clinical care are necessary to improve clinical outcomes and reduce the burden of illness. (C) 2010 Elsevier Ireland Ltd. All rights reserved. C1 [Egede, Leonard E.] Med Univ S Carolina, Ctr Hlth Dispar Res, Dept Med, Charleston, SC 29425 USA. [Egede, Leonard E.; Ellis, Charles] Ralph H Johnson VA Med Ctr, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Charleston, SC USA. [Ellis, Charles] Med Univ S Carolina, Dept Hlth Profess, Charleston, SC 29425 USA. RP Egede, LE (reprint author), Med Univ S Carolina, Ctr Hlth Dispar Res, Dept Med, 135 Rutledge Ave,Room 280H, Charleston, SC 29425 USA. EM egedel@musc.edu FU NIDDK NIH HHS [R01 DK081121, R01 DK081121-01A1, R01 DK081121-02, R01 DK081121-03] NR 85 TC 157 Z9 171 U1 11 U2 31 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0168-8227 J9 DIABETES RES CLIN PR JI Diabetes Res. Clin. Pract. PD MAR PY 2010 VL 87 IS 3 BP 302 EP 312 DI 10.1016/j.diabres.2010.01.024 PG 11 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 580KH UT WOS:000276446600002 PM 20181405 ER PT J AU Restrepo, MI Vasquez, EM Echeyerri, C Fiebelkorn, KR Anstead, GM AF Restrepo, Marcos I. Vasquez, E. Martin Echeyerri, Carolina Fiebelkorn, Kristin R. Anstead, Gregory M. TI Fibrin ring granulomas in Rickettsia typhi infection SO DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE LA English DT Article DE Rickettsia typhi; Murine typhus; Fever of unknown origin; Fibrin ring granuloma ID BONE-MARROW; Q-FEVER; MURINE TYPHUS; HEPATITIS-A; LIVER; PATIENT; DISEASE AB We describe a 71-year-old man hospitalized for fever and productive cough. Laboratory investigation showed anemia, thrombocytopenia, elevated transaminases, hyponatremia, and hypoalbuminemia. Computerized tomography of the abdomen, thorax, and sinuses, echocardiography, and a gallium scan did not reveal the source of the fever. The patient remained febrile despite courses of piperacillin tazobactam/azithromycin and ceftriaxone/vancomycin. A bone marrow biopsy showed fibrin ring granulomas, and 2 rickettsial serologic panels were positive for Rickettsia typhi infection and negative for Q fever. The patient was given doxycycline, and the fever resolved within 48 h. We propose that fibrin ring granulomas also occur in murine typhus. (C) 2010 Published by Elsevier Inc. C1 [Anstead, Gregory M.] Univ Texas Hlth Sci Ctr San Antonio, Div Infect Dis, Dept Med, San Antonio, TX 78229 USA. [Anstead, Gregory M.] S Texas Vet Healthcare Syst, Dept Med, San Antonio, TX 78229 USA. [Fiebelkorn, Kristin R.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [Vasquez, E. Martin; Echeyerri, Carolina] Hosp Pablo Tobon Uribe, Medellin, Colombia. [Restrepo, Marcos I.] Univ Texas Hlth Sci Ctr San Antonio, Div Pulm, Dept Med, San Antonio, TX 78229 USA. [Restrepo, Marcos I.] S Texas Vet Hlth Care Syst, Vet Evidence Res Disseminat & Implementat Ctr VER, San Antonio, TX 78229 USA. RP Anstead, GM (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Div Infect Dis, Dept Med, San Antonio, TX 78229 USA. EM anstead@uthscsa.edu RI Restrepo, Marcos/H-4442-2014 NR 30 TC 7 Z9 7 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0732-8893 EI 1879-0070 J9 DIAGN MICR INFEC DIS JI Diagn. Microbiol. Infect. Dis. PD MAR PY 2010 VL 66 IS 3 BP 322 EP 325 DI 10.1016/j.diagmicrobio.2009.10.019 PG 4 WC Infectious Diseases; Microbiology SC Infectious Diseases; Microbiology GA 594YJ UT WOS:000277577000014 PM 20071129 ER PT J AU Zhu, A Kaneshiro, M Kaunitz, JD AF Zhu, Amy Kaneshiro, Marc Kaunitz, Jonathan D. TI Evaluation and Treatment of Iron Deficiency Anemia: A Gastroenterological Perspective SO DIGESTIVE DISEASES AND SCIENCES LA English DT Review DE Clinical diagnosis; Micronutrient deficiencies; Red cell indices; Ferritin ID INFLAMMATORY-BOWEL-DISEASE; UPPER GASTROINTESTINAL-TRACT; RANDOMIZED CONTROLLED-TRIAL; RESTLESS LEGS SYNDROME; INTRAVENOUS IRON; SERUM FERRITIN; ORAL IRON; PREMENOPAUSAL WOMEN; CELIAC-DISEASE; CAPSULE-ENDOSCOPY AB A substantial volume of the consultations requested of gastroenterologists are directed towards the evaluation of anemia. Since iron deficiency anemia often arises from bleeding gastrointestinal lesions, many of which are malignant, establishment of a firm diagnosis usually obligates an endoscopic evaluation. Although the laboratory tests used to make the diagnosis have not changed in many decades, their interpretation has, and this is possibly due to the availability of extensive testing in key populations. We provide data supporting the use of the serum ferritin as the sole useful measure of iron stores, setting the lower limit at 100 mu g/l for some populations in order to increase the sensitivity of the test. Trends of the commonly obtained red cell indices, mean corpuscular volume, and the red cell distribution width can provide valuable diagnostic information. Once the diagnosis is established, upper and lower gastrointestinal endoscopy is usually indicated. Nevertheless, in many cases a gastrointestinal source is not found after routine evaluation. Additional studies, including repeat upper and lower endoscopy and often investigation of the small intestine may thus be required. Although oral iron is inexpensive and usually effective, there are many gastrointestinal conditions that warrant treatment of iron deficiency with intravenous iron. C1 [Kaunitz, Jonathan D.] W Los Angeles VA Med Ctr, Los Angeles, CA 90073 USA. [Zhu, Amy; Kaneshiro, Marc; Kaunitz, Jonathan D.] Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA. [Zhu, Amy; Kaneshiro, Marc] Cedars Sinai VA Residency Program, Los Angeles, CA USA. [Kaunitz, Jonathan D.] Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA. [Kaunitz, Jonathan D.] Brentwood Biomed Res Inst, Los Angeles, CA 90073 USA. RP Kaunitz, JD (reprint author), W Los Angeles VA Med Ctr, Bldg 114,Suite 217,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM jake@ucla.edu FU Department of Medicine, West Los Angeles VA Medical Center; Cedars-VA Residency Program FX This work was supported by the Department of Medicine, West Los Angeles VA Medical Center and the Cedars-VA Residency Program. We would like to thank Jenifer Kugler for her expert editorial assistance. NR 89 TC 41 Z9 45 U1 0 U2 13 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0163-2116 J9 DIGEST DIS SCI JI Dig. Dis. Sci. PD MAR PY 2010 VL 55 IS 3 BP 548 EP 559 DI 10.1007/s10620-009-1108-6 PG 12 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 556UD UT WOS:000274617500002 PM 20108038 ER PT J AU Wu, Y Zhao, WD Zhao, JB Zhang, YF Qin, WP Pan, JP Bauman, WA Blitzer, RD Cardozo, C AF Wu, Yong Zhao, Weidong Zhao, Jingbo Zhang, Yuanfei Qin, Weiping Pan, Jiangping Bauman, William A. Blitzer, Robert D. Cardozo, Christopher TI REDD1 Is a Major Target of Testosterone Action in Preventing Dexamethasone-Induced Muscle Loss SO ENDOCRINOLOGY LA English DT Article ID FOXO TRANSCRIPTION FACTORS; SKELETAL-MUSCLE; PROTEIN-SYNTHESIS; MAMMALIAN TARGET; ANABOLIC-STEROIDS; RAPAMYCIN PATHWAY; UBIQUITIN LIGASES; ATROPHY INVOLVE; EXPRESSION; CELLS AB Glucocorticoids are a well-recognized and common cause of muscle atrophy that can be prevented by testosterone. However, the molecular mechanisms underlying such protection have not been described. Thus, the global effects of testosterone on dexamethasone-induced changes in gene expression were evaluated in rat gastrocnemius muscle using DNA microarrays. Gene expression was analyzed after 7-d administration of dexamethasone, dexamethasone plus testosterone, or vehicle. Dexamethasone changed expression of 876 probe sets by at least 2-fold. Among these, 474 probe sets were changed by at least 2-fold in the opposite direction in the dexamethasone plus testosterone group (genes in opposition). Major biological themes represented by genes in opposition included IGF-I signaling, myogenesis and muscle development, and cell cycle progression. Testosterone completely prevented the 22-fold increase in expression of the mammalian target of rapamycin (mTOR) inhibitor regulated in development and DNA damage responses 1 (REDD1), and attenuated dexamethasone induced increased expression of eIF4E binding protein 1, Forkhead box O1, and the p85 regulatory subunit of the IGF-I receptor but prevented decreased expression of IRS-1. Testosterone attenuated increases in REDD1 protein in skeletal muscle and L6 myoblasts and prevented dephosphorylation of p70S6kinase at them TOR-dependentsite Thr389 in L6 myoblast cells. Effects of testosterone on REDD1 mRNA levels occurred within 1h, required the androgen receptor, were blocked by bicalutamide, and were due to inhibition of transcriptional activation of REDD1 by dexamethasone. These data suggest that testosterone blocks dexamethasone-induced changes in expression of REDD1 and other genes that collectively would otherwise down-regulate mTOR activity and hence also down-regulate protein synthesis. (Endocrinology 151: 1050-1059, 2010) C1 [Wu, Yong; Zhao, Weidong; Zhao, Jingbo; Zhang, Yuanfei; Qin, Weiping; Pan, Jiangping; Bauman, William A.; Cardozo, Christopher] James J Peters VA Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, Bronx, NY 10468 USA. [Qin, Weiping; Bauman, William A.; Cardozo, Christopher] Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA. [Blitzer, Robert D.] Mt Sinai Sch Med, Dept Pharmacol & Syst Therapeut, New York, NY 10029 USA. RP Cardozo, C (reprint author), James J Peters VA Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, 953 So Blvd, Bronx, NY 10468 USA. EM Chris.Cardozo@mssm.edu FU Veterans Health Administration, Rehabilitation Research and Development Service [B4162C, B3347K, B3522R]; National Institutes of Health [GM054508] FX This work was supported by the Veterans Health Administration, Rehabilitation Research and Development Service (Grant B4162C to W.A.B., and B3347K and B3522R to C.C.). R.D.B. was supported by National Institutes of Health Grant GM054508. NR 52 TC 27 Z9 27 U1 0 U2 1 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0013-7227 J9 ENDOCRINOLOGY JI Endocrinology PD MAR PY 2010 VL 151 IS 3 BP 1050 EP 1059 DI 10.1210/en.2009-0530 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 558AF UT WOS:000274711600025 PM 20032058 ER PT J AU Pramuka, M Hendrickson, R Van Cott, AC AF Pramuka, Michael Hendrickson, Rick Van Cott, Anne C. TI Survey results of Internet and computer usage in veterans with epilepsy SO EPILEPSY & BEHAVIOR LA English DT Article DE Computer access; Self-management; Access to care; Internet; Veterans ID MANAGEMENT; PROGRAM; THERAPY AB After our study of a self-management intervention for epilepsy [1], we gathered data on Internet use and computer availability to assess the feasibility of computer-based interventions in a veteran population. Veterans were asked to complete an anonymous questionnaire that gathered information regarding seizures/epilepsy in addition to demographic data, Internet use, computer availability, and interest in distance education regarding epilepsy. Three hundred twenty-four VA neurology clinic patients completed the survey. One hundred twenty-six self-reported a medical diagnosis of epilepsy and constituted the epilepsy/seizure group. For this group of veterans, the need for remote/distance-based interventions was validated given the majority of veterans traveled long distances (>2 hours). Only 51% of the epilepsy/seizure group had access to the Internet, and less than half (42%) expressed an interest in getting information on epilepsy self-management on their computer, suggesting that Web-based interventions may not be an optimal method for a self-management intervention in this population. Published by Elsevier Inc. C1 [Pramuka, Michael; Hendrickson, Rick; Van Cott, Anne C.] Univ Pittsburgh, Pittsburgh, PA USA. [Van Cott, Anne C.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Van Cott, AC (reprint author), MDP, Div Neurol, 111N-U VAPHS,Univ Dr C, Pittsburgh, PA 15240 USA. EM Anne.VanCott@va.gov FU Centers for Disease Control and Prevention FX The authors acknowledge the financial and administrative support of the Epilepsy Program of the Centers for Disease Control and Prevention and, in particular, Ms. Rosemarie Kobau, MPH. We are grateful for the support in survey collection, data entry, and study administration provided by Ms. Vivian Brice, R.N. NR 10 TC 9 Z9 9 U1 0 U2 3 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1525-5050 J9 EPILEPSY BEHAV JI Epilepsy Behav. PD MAR PY 2010 VL 17 IS 3 BP 366 EP 368 DI 10.1016/j.yebeh.2009.11.016 PG 3 WC Behavioral Sciences; Clinical Neurology; Psychiatry SC Behavioral Sciences; Neurosciences & Neurology; Psychiatry GA 574YK UT WOS:000276029900010 PM 20116339 ER PT J AU Tan, AU Hoffman, B Rosas, SE AF Tan, Ainah U. Hoffman, Brenda Rosas, Sylvia E. TI PATIENT PERCEPTION OF RISK FACTORS ASSOCIATED WITH CHRONIC KIDNEY DISEASE MORBIDITY AND MORTALITY SO ETHNICITY & DISEASE LA English DT Article DE Chronic Kidney Disease; Patient Knowledge; Patient Perception; Race Differences; Survey ID UNITED-STATES; CARE; EDUCATION; CKD; POPULATION; GUIDELINES; PHYSICIANS; AWARENESS; HEALTH AB Background: Educational interventions aimed at empowering patients are successful in chronic disease management. The purpose of this study was to assess patient knowledge of risk factors and complications associated with chronic kidney disease (CKD). Methods: We determined the perception of risk factors for CKD and its complications in 229 participants with a diagnosis of CKD stage 3 and 4 who completed an anonymous questionnaire. We evaluated predictors of better knowledge as measured by total correct responses using linear regression. Results: The majority (89.1%) but not all of participants were aware of their diagnosis of CKD. Almost a third (31.5%) of patients that were aware of a diagnosis of CKD did not know their serum creatinine level compared to only 15.4% of participants with diabetes who did not know their last serum glucose level. Most participants identified hypertension (92.1%) and diabetes (86%) as risk factors for CKD, but male sex (59%) and African American race (71.6%) were selected less frequently. While glucose, proteinuria and blood pressure control were commonly associated by participants as known methods to slow progression of CKD, smoking control (79.5%) and use of renin-angiotensin system inhibitors (63.8%) were less known. After adjustment for sociodemographic factors, younger age and presence of a college degree were the only independent predictors of knowledge of CKD risk factors. Conclusions: Access to CKD education needs to be tailored to the health literacy status of each patient. Educational interventional research studies are needed in early-stage CKD to determine impact on clinical outcomes. (Ethn Dis. 2010;20:106-110) C1 Univ Penn Hlth Syst, Dept Med, Renal Electrolyte & Hypertens Div, Philadelphia, PA USA. [Rosas, Sylvia E.] Philadelphia VA Med Ctr, Philadelphia, PA USA. RP Rosas, SE (reprint author), 1st Floor Founders,3400 Spruce St, Philadelphia, PA 19104 USA. EM Sylvia.rosas@uphs.upenn.edu RI Rosas, Sylvia/D-1106-2009 NR 22 TC 9 Z9 10 U1 0 U2 2 PU INT SOC HYPERTENSION BLACKS-ISHIB PI ATLANTA PA 100 AUBURN AVE NE STE 401, ATLANTA, GA 30303-2527 USA SN 1049-510X J9 ETHNIC DIS JI Ethn. Dis. PD SPR PY 2010 VL 20 IS 2 BP 106 EP 110 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 598EJ UT WOS:000277815700004 PM 20503888 ER PT J AU Short, EB Kose, S Mu, QW Borckardt, J Newberg, A George, MS Kozel, FA AF Short, E. Baron Kose, Samet Mu, Qiwen Borckardt, Jeffery Newberg, Andrew George, Mark S. Kozel, F. Andrew TI Regional Brain Activation During Meditation Shows Time and Practice Effects: An Exploratory FMRI Study SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE LA English DT Article DE anterior cingulate cortex; attention; dorsal lateral prefrontal cortex; functional MRI; meditation; time courses ID ANTERIOR CINGULATE CORTEX; WORKING-MEMORY; SLEEP-DEPRIVATION; PREFRONTAL CORTEX; TIBETAN-BUDDHIST; ATTENTION; SELECTION AB Meditation involves attentional regulation and may lead to increased activity in brain regions associated with attention such as dorsal lateral prefrontal cortex (DLPFC) and anterior cingulate cortex (ACC). Using functional magnetic resonance imaging, we examined whether DLPFC and ACC were activated during meditation. Subjects who meditate were recruited and scanned on a 3.0 Tesla scanner. Subjects meditated for four sessions of 12 min and performed four sessions of a 6 min control task. Individual and group t-maps were generated of overall meditation response versus control response and late meditation response versus early meditation response for each subject and time courses were plotted. For the overall group (n 13), and using an overall brain analysis, there were no statistically significant regional activations of interest using conservative thresholds. A region of interest analysis of the entire group time courses of DLPFC and ACC were statistically more active throughout meditation in comparison to the control task. Moreover, dividing the cohort into short (n 8) and long-term (n 5) practitioners (10 years) revealed that the time courses of long-term practitioners had significantly more consistent and sustained activation in the DLPFC and the ACC during meditation versus control in comparison to short-term practitioners. The regional brain activations in the more practised subjects may correlate with better sustained attention and attentional error monitoring. In summary, brain regions associated with attention vary over the time of a meditation session and may differ between long- and short-term meditation practitioners. C1 [Short, E. Baron] Med Univ S Carolina, Brain Stimulat Lab, Inst Psychiat, Charleston, SC 29425 USA. [Short, E. Baron; Kose, Samet; George, Mark S.; Kozel, F. Andrew] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Newberg, Andrew] Univ Penn, Med Ctr, Div Nucl Med, Philadelphia, PA 19104 USA. [George, Mark S.; Kozel, F. Andrew] Med Univ S Carolina, Ctr Adv Imaging Res, Charleston, SC 29425 USA. [Kozel, F. Andrew] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. RP Short, EB (reprint author), Med Univ S Carolina, Brain Stimulat Lab, Inst Psychiat, 67 President St,3North, Charleston, SC 29425 USA. EM shorteb@musc.edu RI Kozel, Frank/I-5366-2012 OI Newberg, Andrew/0000-0001-8230-1752 FU Center for Advanced Imaging Research (CAIR); University Research Committee at MUSC FX Grant support was received from a grant in kind from the Center for Advanced Imaging Research (CAIR) and the University Research Committee at MUSC. Subject participation support was received from the Charleston Tibetan Society and the Charleston Zen Center. NR 27 TC 33 Z9 33 U1 8 U2 21 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1741-427X J9 EVID-BASED COMPL ALT JI Evid.-based Complement Altern. Med. PD MAR PY 2010 VL 7 IS 1 BP 121 EP 127 DI 10.1093/ecam/nem163 PG 7 WC Integrative & Complementary Medicine SC Integrative & Complementary Medicine GA 553DE UT WOS:000274344700016 ER PT J AU Sonpavde, G Palapattu, GS AF Sonpavde, Guru Palapattu, Ganesh S. TI Neoadjuvant therapy preceding prostatectomy for prostate cancer: rationale and current trials SO EXPERT REVIEW OF ANTICANCER THERAPY LA English DT Review DE androgen-deprivation therapy; biologic agents; chemotherapy; neoadjuvant therapy; prostate cancer ID PHASE-II TRIAL; RANDOMIZED CONTROLLED-TRIAL; RADICAL PROSTATECTOMY; HIGH-RISK; HORMONAL-THERAPY; BREAST-CANCER; CHEMOHORMONAL THERAPY; ADJUVANT RADIOTHERAPY; ANDROGEN DEPRIVATION; RADIATION-THERAPY AB Neoadjuvant therapy improves outcomes for a number of malignancies and provides intermediate pathologic outcomes, which correlate with long-term outcomes. Neoadjuvant androgen-deprivation therapy, alone or with docetaxel chemotherapy, preceding prostatectomy for localized prostate cancer is feasible and demonstrates pathologic activity, but evidence for improved long-term outcomes is lacking. Data in support of the further exploration of neoadjuvant therapy for localized prostate cancer preceding prostatectomy are reviewed. Ongoing randomized trials are elucidating the impact of neoadjuvant androgen deprivation combined with docetaxel chemotherapy on pathologic and long-term outcomes. The correlation of pathologic and biologic outcomes with long-term outcomes in this setting is unknown. The neoadjuvant therapy approach followed by prostatectomy is feasible with a wide array of agents and provides a paradigm for evaluating the activity, and mechanism of action and resistance to new treatments. This promising modality may aid the rapid development of novel therapeutic agents. A multidisciplinary approach involving oncologists, urologists and pathologists is critical to the success of this model. C1 [Sonpavde, Guru] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Sonpavde, Guru] Sect Med Oncol, Dept Med, Webster, TX 77598 USA. [Palapattu, Ganesh S.] Methodist Hosp, Dept Urol, Houston, TX 77030 USA. RP Sonpavde, G (reprint author), 501 Med Ctr Blvd, Webster, TX 77598 USA. EM guru.sonpavde@usoncology.com; gpalapattu@tmhs.org FU BMS; Pfizer; Novartis; Astrazeneca; Cytogen FX Guru Sonpavde is a member of the speakers' bureau for Sanofi-Aventis, Wyeth, Pfizer and Novartis. He has received research support from BMS, Pfizer, Novartis, Astrazeneca and Cytogen. Guru Sonpavde is also on the advisory board for Celgene, Pfizer, Halozyme, Novartis and BMS. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. NR 75 TC 4 Z9 4 U1 0 U2 0 PU EXPERT REVIEWS PI LONDON PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB, ENGLAND SN 1473-7140 J9 EXPERT REV ANTICANC JI Expert Rev. Anticancer Ther PD MAR PY 2010 VL 10 IS 3 BP 439 EP 450 DI 10.1586/ERA.10.17 PG 12 WC Oncology SC Oncology GA 571VO UT WOS:000275784200020 PM 20214524 ER PT J AU Salmon, AB Richardson, A Perez, VI AF Salmon, Adam B. Richardson, Arlan Perez, Viviana I. TI Update on the oxidative stress theory of aging: Does oxidative stress play a role in aging or healthy aging? SO FREE RADICAL BIOLOGY AND MEDICINE LA English DT Review DE Oxidative stress; Aging; Disease; Life span; Health span; Free radicals ID EXTRACELLULAR-SUPEROXIDE-DISMUTASE; AMES DWARF MICE; METHIONINE-SULFOXIDE-REDUCTASE; NAKED MOLE-RAT; FREE-RADICAL PRODUCTION; LONGEST-LIVING RODENT; GLUTATHIONE-PEROXIDASE PROTECTS; AMYOTROPHIC-LATERAL-SCLEROSIS; ADULT DROSOPHILA-MELANOGASTER; TRANSGENIC MOUSE MODEL AB The oxidative stress theory of aging predicts that manipulations that alter oxidative stress/damage will alter aging. The gold standard for determining whether aging is altered is life span, i.e., does altering oxidative stress/damage change life span? Mice with genetic manipulations in their antioxidant defense system designed to directly address this prediction have, with few exceptions, shown no change in life span. However, when these transgenic/knockout mice are tested using models that develop various types of age-related pathology, they show alterations in progression and/or severity of pathology as predicted by the oxidative stress theory: increased oxidative stress accelerates pathology and reduced oxidative stress retards pathology. These contradictory observations might mean that (a) oxidative stress plays a very limited, if any, role in aging but a major role in health span and/or (b) the role that oxidative stress plays in aging depends on environment. In environments with minimal stress, as expected under optimal husbandry, oxidative damage plays little role in aging. However, under chronic stress, including pathological phenotypes that diminish optimal health, oxidative stress/damage plays a major role in aging. Under these conditions, enhanced antioxidant defenses exert an "antiaging" action, leading to changes in life span, age-related pathology, and physiological function as predicted by the oxidative stress theory of aging. (C) 2009 Elsevier Inc. All rights reserved. C1 [Salmon, Adam B.; Richardson, Arlan; Perez, Viviana I.] Univ Texas Hlth Sci Ctr San Antonio, Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. [Richardson, Arlan; Perez, Viviana I.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. [Richardson, Arlan] S Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78229 USA. RP Salmon, AB (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. EM salmona@uthscsa.edu FU NIH [T32AG021890-05, R01AG015908, R01AG023843, P01AG19316, P01AG020591, R37AG026557]; American Federation for Aging Research Senior Postdoctoral; Department of Veterans Affairs; San Antonio Nathan Shock Center of Excellence in the Basic Biology of Aging FX This work was supported by NIH Training Grant T32AG021890-05; NIH Grants R01AG015908, R01AG023843, P01AG19316, P01AG020591, and R37AG026557; an American Federation for Aging Research Senior Postdoctoral Grant; the Department of Veterans Affairs (Merit Grants and a Research Enhancement Award Program); and the San Antonio Nathan Shock Center of Excellence in the Basic Biology of Aging. NR 218 TC 170 Z9 175 U1 2 U2 79 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0891-5849 EI 1873-4596 J9 FREE RADICAL BIO MED JI Free Radic. Biol. Med. PD MAR 1 PY 2010 VL 48 IS 5 BP 642 EP 655 DI 10.1016/j.freeradbiomed.2009.12.015 PG 14 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA 555IN UT WOS:000274503100002 PM 20036736 ER PT J AU Young, BA Von Korff, M Heckbert, SR Ludman, EJ Rutter, C Lin, EHB Ciechanowski, PS Oliver, M Williams, L Himmelfarb, J Katon, WJ AF Young, Bessie A. Von Korff, Michael Heckbert, Susan R. Ludman, Evette J. Rutter, Carolyn Lin, Elizabeth H. B. Ciechanowski, Paul S. Oliver, Malia Williams, Lisa Himmelfarb, Jonathan Katon, Wayne J. TI Association of major depression and mortality in Stage 5 diabetic chronic kidney disease SO GENERAL HOSPITAL PSYCHIATRY LA English DT Article DE Depression; Diabetes; Mortality; Chronic kidney disease; ESRD ID GLOMERULAR-FILTRATION-RATE; RENAL-DISEASE; HEMODIALYSIS-PATIENTS; DIALYSIS PATIENTS; UNITED-STATES; PSYCHOLOGICAL-FACTORS; SERUM CREATININE; PRIMARY-CARE; SELF-CARE; RISK AB Objectives: Depression is the most common psychiatric disorder in patients with chronic kidney disease (CKD). We sought to determine the association of major depression with mortality among diabetic patients with late stage CKD. Method: The Pathways Study is a longitudinal, prospective cohort study initiated to determine the impact of depression on outcomes among primary care diabetic patients. Subjects were followed from 2001 until 2007 for a mean duration of 4.4 years. Major depression, identified by the Patient Health Questionnaire-9, was the primary exposure of interest. Stage 5 CKD was determined by dialysis codes and estimated glomerular filtration rate (<15 ml/min). An adjusted Cox proportional hazards multivariable model was used to determine the association of baseline major depression with mortality. Results: Of the 4128 enrolled subjects, 110 were identified with stage 5 CKD at baseline. Of those, 34 (22.1%) had major depression. Over a period of 5 years, major depression was associated with 2.95-fold greater risk of death (95% CI=1.24-7.02) compared to those with no or few depressive symptoms. Conclusion: Major depression at baseline was associated with a 2.95-fold greater risk of mortality among stage 5 CKD diabetic patients. Given the high mortality risk, further testing of targeted depression interventions should be considered in this population. Published by Elsevier Inc. C1 [Young, Bessie A.] Vet Affairs Puget Sound Hlth Care Syst, Epidemiol Res & Informat Ctr, Seattle, WA 98101 USA. [Young, Bessie A.; Himmelfarb, Jonathan] Univ Washington, Div Nephrol, Kidney Res Inst, Seattle, WA 98195 USA. [Young, Bessie A.; Williams, Lisa] Vet Affairs Puget Sound Hlth Care Syst, Primary & Specialty Care, Seattle, WA USA. [Von Korff, Michael; Ludman, Evette J.; Rutter, Carolyn; Lin, Elizabeth H. B.; Oliver, Malia] Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA USA. [Heckbert, Susan R.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Heckbert, Susan R.] Univ Washington, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA. [Ciechanowski, Paul S.; Katon, Wayne J.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. RP Young, BA (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Epidemiol Res & Informat Ctr, Seattle, WA 98101 USA. EM youngb@u.washington.edu FU NIDDK NIH HHS [R01 DK079745] NR 42 TC 34 Z9 34 U1 0 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0163-8343 J9 GEN HOSP PSYCHIAT JI Gen. Hosp. Psych. PD MAR-APR PY 2010 VL 32 IS 2 BP 119 EP 124 DI 10.1016/j.genhosppsych.2009.11.018 PG 6 WC Psychiatry SC Psychiatry GA 578KX UT WOS:000276293500001 PM 20302984 ER PT J AU Mamtani, M Anaya, JM He, W Ahuja, SK AF Mamtani, M. Anaya, J-M He, W. Ahuja, S. K. TI Association of copy number variation in the FCGR3B gene with risk of autoimmune diseases SO GENES AND IMMUNITY LA English DT Article DE copy number variation (CNV); FCGR3B; CCL3L1; systemic lupus erythematosus; Sjogren's syndrome ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; CONTAINING SEGMENTAL DUPLICATIONS; SJOGRENS-SYNDROME; IMMUNE-COMPLEXES; HUMAN GENOME; SUSCEPTIBILITY; CCL3L1; POLYMORPHISMS; GLOMERULONEPHRITIS; CLASSIFICATION AB Copy number variation (CNV) in the human genome is an important determinant of susceptibility to autoimmune diseases. Many autoimmune diseases share similar clinical and pathogenic features. Thus, CNVs of genes involved in immunity may serve as shared determinants of multiple autoimmune diseases. Here, we determined the association between CNV in the gene encoding FCGR3B with the risk of developing autoimmune diseases and whether the observed associations are modified by the CNV in CCL3L1 (CC chemokine ligand 3-like 1), a gene encoding a potent chemokine. In a cross-sectional study of 774 subjects, we estimated FCGR3B and CCL3L1 gene copy number in 146, 158 and 61 subjects with systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and primary Sjogren's syndrome (SS), respectively, and 409 healthy controls. The median gene dose of FCGR3B in the study population was two. FCGR3B copy number < or >2 was associated with an increased risk of SLE and primary SS but not RA. This association was mostly evident in subjects who also had two copies of CCL3L1. Thus, our data suggest that epistatic interactions between CNV of FCGR3B and CCL3L1, two immune response genes, may influence phenotypically related autoimmune diseases. Genes and Immunity (2010) 11, 155-160; doi:10.1038/gene.2009.71; published online 10 September 2009 C1 [Mamtani, M.; He, W.; Ahuja, S. K.] Univ Texas Hlth Sci Ctr San Antonio, S Texas Vet Hlth Care Syst, Vet Adm Ctr AIDS & HIV Infect 1, San Antonio, TX 78229 USA. [Mamtani, M.; He, W.; Ahuja, S. K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Anaya, J-M] Univ Nacl Rosario, Sch Med, Ctr Autoimmune Dis Res CREA, Corp Invest Biol, Medellin, Colombia. [Ahuja, S. K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Microbiol & Immunol, San Antonio, TX 78229 USA. [Ahuja, S. K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA. RP Ahuja, SK (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med Microbiol & Immunol, 7703 Floyd Curl Dr,Room 5-009R DTL, San Antonio, TX 78229 USA. EM ahujas@uthscsa.edu RI Anaya, Juan-Manuel/J-1960-2016 OI Anaya, Juan-Manuel/0000-0002-6444-1249; Universidad del Rosario, Biblioteca/0000-0003-3491-9392 FU Voelcker Fund Scholar Award; Max and Minnie Tomerlin Voelcker Fund; Elizabeth Glaser Scientist Award; Burroughs Wellcome Clinical Scientist Award in Translational Research; Doris Duke Distinguished Clinical Scientist Award; Rosario University, Bogota, Colombia FX We thank Robert A Clark and George Crawford for their institutional support; Jill King and Adriana Benavides for their help with the bioinformatics for designing the primers and probe. We thank the reviewers of this study for their critical review that greatly helped in improving our paper. This work was supported by the Voelcker Fund Scholar Award to Dr Sunil Ahuja from the Max and Minnie Tomerlin Voelcker Fund. SKA is also a recipient of the Elizabeth Glaser Scientist Award, the Burroughs Wellcome Clinical Scientist Award in Translational Research and the Doris Duke Distinguished Clinical Scientist Award. This work was also supported in part by the Rosario University, Bogota, Colombia. NR 40 TC 48 Z9 51 U1 0 U2 7 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1466-4879 J9 GENES IMMUN JI Genes Immun. PD MAR PY 2010 VL 11 IS 2 BP 155 EP 160 DI 10.1038/gene.2009.71 PG 6 WC Genetics & Heredity; Immunology SC Genetics & Heredity; Immunology GA 563XF UT WOS:000275169900006 PM 19741716 ER PT J AU Svenson, JL Chike-Harris, K Amria, MY Nowling, TK AF Svenson, J. L. Chike-Harris, K. Amria, M. Y. Nowling, T. K. TI The mouse and human Fli1 genes are similarly regulated by Ets factors in T cells SO GENES AND IMMUNITY LA English DT Article DE Fli1; Ets; gene expression; transcription factors; lymphocytes; lupus ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; MURINE LEUKEMIA-VIRUS; TRANSCRIPTION FACTORS; ENDOTHELIAL-CELLS; RENAL-DISEASE; EXPRESSION; FAMILY; PROMOTER; MEMBER; ERYTHROLEUKEMIA AB Fli1 is a member of the Ets family of transcription factors and is preferentially expressed in hematopoietic cell lineages. Its expression level is linked to the pathogenesis of lupus. In this study, we identified mechanisms involved in the transcriptional regulation of the mouse and human Fli1 promoters. We show that the Fli1 promoter is upregulated by Ets factors Ets1, Ets2, Fli1 and Elf1 either alone or in combination with GATA factors, but is inhibited by Tel. In vitro binding studies show that Elf1, Tel and Fli1 in T cells bind the three Ets-binding sites in the murine Fli1 proximal promoter. We identified transcription factor-binding sites in the human Fli1 promoter region that function in T cells in a similar manner to those in the mouse promoter. Furthermore, we show similar binding of Ets factors to the endogenous mouse and human Fli1 promoters in T cells and knocking down Ets1 results in an upregulation of Fli1 expression. Together, these results suggest that the human and mouse genes are regulated similarly and that Ets1 may be important in preventing the overexpression of Fli1 in T cells. This report lays the groundwork for identifying targets for manipulating Fli1 expression as a possible therapeutic approach. Genes and Immunity (2010) 11, 161- 172; doi: 10.1038/gene.2009.73; published online 15 October 2009 C1 [Svenson, J. L.; Chike-Harris, K.; Amria, M. Y.; Nowling, T. K.] Med Univ S Carolina, Childrens Res Inst, Dept Med, Div Rheumatol, Charleston, SC 29425 USA. [Nowling, T. K.] Ralph H Johnson VAMC, Res Serv, Charleston, SC USA. RP Nowling, TK (reprint author), Med Univ S Carolina, Childrens Res Inst, Dept Med, Div Rheumatol, MSC 637,CSB,Ste 912,96 Jonathon Lucas St, Charleston, SC 29425 USA. EM nowling@musc.edu FU NIH [DK072306, AR053376] FX This work was supported by NIH grants DK072306 and AR053376. The authors thank Dr Angie Rizzino, Dr Dennis Watson and Dr Maria Trojanowska for their kind gifts of Ets and GATA expression vectors. A special thanks also goes to Dr Gary Gilkeson for critical reading of the paper and providing valuable comments. NR 29 TC 16 Z9 16 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1466-4879 J9 GENES IMMUN JI Genes Immun. PD MAR PY 2010 VL 11 IS 2 BP 161 EP 172 DI 10.1038/gene.2009.73 PG 12 WC Genetics & Heredity; Immunology SC Genetics & Heredity; Immunology GA 563XF UT WOS:000275169900007 PM 19829305 ER PT J AU Tang, KS Suh, SW Alano, CC Shao, ZJ Hunt, WT Swanson, RA Anderson, CM AF Tang, Kim San Suh, Sang Won Alano, Conrad C. Shao, Zongjun Hunt, Waylon T. Swanson, Raymond A. Anderson, Christopher M. TI Astrocytic Poly(ADP-ribose) Polymerase-1 Activation Leads to Bioenergetic Depletion and Inhibition of Glutamate Uptake Capacity SO GLIA LA English DT Article DE DNA damage; excitotoxicity; NAD(+); ATP depletion; astrocyte-neuron communication ID DNA STRAND BREAKS; BRAIN-INJURY; CELL-DEATH; CEREBRAL-ISCHEMIA; NEURONAL DEATH; ENERGY-METABOLISM; TRANSPORTER GLT-1; NAD(+) DEPLETION; GENE DISRUPTION; FOCAL ISCHEMIA AB Poly(ADP-ribose) polymerase-1 (PARP-1) is a ubiquitous nuclear enzyme involved in genomic stability. Excessive oxidative DNA strand breaks lead to PARP-1-induced depletion of cellular NAD(+), glycolytic rate, ATP levels, and eventual cell death. Glutamate neurotransmission is tightly controlled by ATP-dependent astrocytic glutamate transporters, and thus we hypothesized that astrocytic PARP-1 activation by DNA damage leads to bioenergetic depletion and compromised glutamate uptake. PARP-1 activation by the DNA alkylating agent, N-methyl-N'-nitro-N-nitrosoguanidine (MNNG), caused a significant reduction of cultured cortical astrocyte survival (EC(50) = 78.2 +/- 2.7 mu M). HPLC revealed MNNG-induced time-dependent reductions in NAD(+) (98%, 4 h), ATP (71%, 4 h), ADP (63%, 4 h), and AMP (66%, 4 h). The maximal [(3)H]glutamate uptake rate (V(max)) also declined in a manner that corresponded temporally with ATP depletion, falling from 19.3 +/- 2.8 in control cells to 2.1 +/- 0.8 nmol/min/mg protein 4 h post-MNNG. Both bioenergetic depletion and loss of glutamate uptake capacity were attenuated by genetic deletion of PARP-1, directly indicating PARP-1 involvement, and by adding exogenous NAD+ (10 mM). In mixed neurons/astrocyte cultures, MNNG neurotoxicity was partially mediated by extracellular glutamate and was reduced by co-culture with PARP-1(-/-) astrocytes, suggesting that impairment of astrocytic glutamate uptake by PARP-1 can raise glutamate levels sufficiently to have receptor-mediated effects at neighboring neurons. Taken together, these experiments showed that PARP-1 activation leads to depletion of the total adenine nucleotide pool in astrocytes and severe reduction in neuroprotective glutamate uptake capacity. (C) 2009 Wiley-Liss, Inc. C1 [Tang, Kim San; Shao, Zongjun; Hunt, Waylon T.; Anderson, Christopher M.] St Boniface Gen Hosp, Res Ctr, Div Neurodegenerat Disorders, Winnipeg, MB R2H 2A6, Canada. [Tang, Kim San; Shao, Zongjun; Hunt, Waylon T.; Anderson, Christopher M.] Univ Manitoba, Dept Pharmacol & Therapeut, Winnipeg, MB, Canada. [Suh, Sang Won] Hallym Univ, Coll Med, Dept Physiol, Chunchon, South Korea. [Suh, Sang Won; Alano, Conrad C.; Swanson, Raymond A.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [Suh, Sang Won; Alano, Conrad C.; Swanson, Raymond A.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Anderson, CM (reprint author), St Boniface Gen Hosp, Res Ctr, Div Neurodegenerat Disorders, 351 Tache Ave,R4046, Winnipeg, MB R2H 2A6, Canada. EM canderson@sbrc.ca RI Anderson, Chris/J-7081-2014 OI Swanson, Raymond/0000-0002-3664-5359; Anderson, Christopher/0000-0003-0678-3002 FU Canadian Institutes of Health Research [MOP68829]; Heart and Stroke Foundation; Canadian Stroke Network; AstraZeneca FX Grant sponsor: Canadian Institutes of Health Research; Grant number: MOP68829. K.S.T. received a Focus on Stroke Research Fellowship from the CIHR, Heart and Stroke Foundation, Canadian Stroke Network, and AstraZeneca. C.M.A. received salary support from the Heart and Stroke Foundation of Canada. NR 65 TC 11 Z9 13 U1 0 U2 1 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0894-1491 J9 GLIA JI Glia PD MAR PY 2010 VL 58 IS 4 BP 446 EP 457 DI 10.1002/glia.20936 PG 12 WC Neurosciences SC Neurosciences & Neurology GA 550YZ UT WOS:000274172500007 PM 19795500 ER PT J AU Hoff, G Dominitz, JA AF Hoff, Geir Dominitz, Jason A. TI Contrasting US and European approaches to colorectal cancer screening: which is best? SO GUT LA English DT Article ID FECAL-OCCULT-BLOOD; RANDOMIZED CONTROLLED-TRIAL; AVERAGE-RISK POPULATION; BASE-LINE FINDINGS; UNITED-STATES; FLEXIBLE SIGMOIDOSCOPY; ASYMPTOMATIC ADULTS; COLONOSCOPIC POLYPECTOMY; ADENOMA DETECTION; AMERICAN-COLLEGE AB In the recent 1-2 decades, we have seen a considerable development in colorectal cancer (CRC) screening modalities and programme implementation, but major challenges remain. While CRC is still the second leading cause of cancer death in both the USA and Europe, there are limited data on the efficacy and effectiveness of all screening modalities except for the faecal occult blood test (FOBT). Newer screening tests, such as faecal immunochemical tests, molecular markers and CT colonography are being introduced and variably adopted, though overall rates of screening are suboptimal. Professional societies and governmental bodies have endorsed screening, though recommended approaches are quite variable, which may help to explain the great variation in screening practices. Unfortunately, quality assurance programmes are underutilised. Comparing the USA and Europe there may be more variation in CRC screening recommendation and practice within each continent than between them, but there seems to be a stronger emphasis on programmatic screening in Europe, facilitating quality assurance. The much debated need for randomised trials as new screening modalities emerge could be more easily handled if running screening programmes are regarded as natural platforms for testing out and evaluating presumed improvements in the service-including new emerging screening modalities. C1 [Hoff, Geir] Telemark Hosp, Dept Med, NO-3710 Skien, Norway. [Dominitz, Jason A.] Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Dominitz, Jason A.] Univ Washington, Dept Med, Div Gastroenterol, Seattle, WA USA. RP Hoff, G (reprint author), Telemark Hosp, Dept Med, NO-3710 Skien, Norway. EM hofg@online.no OI Dominitz, Jason/0000-0002-8070-7086 FU VA Puget Sound Health Care System; Department of Veterans Affairs; American Society for Gastrointestinal Endoscopy Career Development Award FX This material is based upon work supported by the VA Puget Sound Health Care System, Department of Veterans Affairs. JAD is supported by an American Society for Gastrointestinal Endoscopy Career Development Award. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs. NR 87 TC 37 Z9 39 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0017-5749 J9 GUT JI Gut PD MAR PY 2010 VL 59 IS 3 BP 407 EP 414 DI 10.1136/gut.2009.192948 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 564XQ UT WOS:000275252400027 PM 20207645 ER PT J AU Doane, LD Kremen, WS Eaves, LJ Eisen, SA Hauger, R Hellhammer, D Levine, S Lupien, S Lyons, MJ Mendoza, S Prom-Wormley, E Xian, H York, TP Franz, CE Jacobson, KC AF Doane, Leah D. Kremen, William S. Eaves, Lindon J. Eisen, Seth A. Hauger, Richard Hellhammer, Dirk Levine, Seymour Lupien, Sonia Lyons, Michael J. Mendoza, Sally Prom-Wormley, Elizabeth Xian, Hong York, Timothy P. Franz, Carol E. Jacobson, Kristen C. TI Associations Between Jet Lag and Cortisol Diurnal Rhythms After Domestic Travel SO HEALTH PSYCHOLOGY LA English DT Article DE jet lag; cortisol diumal rhythms; travel ID CIRCADIAN-RHYTHMS; PERFORMANCE; STRESS; TIME; RESPONSES; EASTWARD; FLIGHT; TWIN; AGE AB Objective: Millions of adults in the United States travel abruptly across time zones each year. Nevertheless, the impact of traveling over relatively short distances (across 3 or fewer time zones) on diurnal patterning of typical physiological response patterns has yet to be studied in a large, epidemiological sample. Design: The current research focuses on 764 middle-aged men comparing variations in diurnal cortisol regulation based on number of time zones traveled eastward or westward the day before. Main Outcome Measure: Participants provided samples of salivary cortisol at waking, 30-min postwaking, 10 a.m., 3 p.m., and bedtime. Results: Eastward travel was associated with a steeper salivary cortisol awakening response (p < .01) and lower peak (PEAK) levels of salivary cortisol the next morning (p < .05). Westward travel was associated with lower peak levels of cortisol the next morning (p < .05). Effect sizes for these differences ranged from Cohen's d = .29 to .47. Differences were not present for 2 days in their home environment. Conclusions: The results provide evidence that traveling across time zones is associated with diurnal cortisol regulation and should be studied further to understand the subsequent impacts on health and well-being in large national samples. C1 [Doane, Leah D.; Jacobson, Kristen C.] Univ Chicago, Dept Psychiat & Behav Neurosci, Chicago, IL 60637 USA. [Kremen, William S.; Hauger, Richard; Franz, Carol E.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. [Kremen, William S.] Univ Calif San Diego, Ctr Behav Genom, San Diego, CA 92103 USA. [Kremen, William S.; Hauger, Richard] VA San Diego Healthcare Syst, San Diego, CA USA. [Eaves, Lindon J.; Prom-Wormley, Elizabeth; York, Timothy P.] Virginia Commonwealth Univ, Virginia Inst Behav & Psychiat Genet, Richmond, VA 23284 USA. [Eisen, Seth A.] US Dept Vet Affairs, Washington, DC USA. [Eisen, Seth A.; Xian, Hong] Washington Univ, Dept Internal Med, St Louis, MO 63130 USA. [Eisen, Seth A.] Washington Univ, Dept Psychiat, St Louis, MO 63130 USA. [Hellhammer, Dirk] Univ Trier, Dept Psychobiol, D-54286 Trier, Germany. [Levine, Seymour; Mendoza, Sally] Univ Calif Davis, Dept Psychol, Davis, CA 95616 USA. [Lupien, Sonia] Univ Montreal, Ctr Studies Human Stress, Ctr Rech Fernand Seguin, Montreal, PQ H3C 3J7, Canada. [Lyons, Michael J.] Boston Univ, Dept Psychol, Boston, MA 02215 USA. [Xian, Hong] St Louis VA Med Ctr, St Louis, MO USA. RP Doane, LD (reprint author), Inst Policy Res, 2040 Sheridan Rd, Evanston, IL 60208 USA. EM l-doane@northwestern.edu RI Lyons, Michael/B-6119-2011; Jacobson, Kristen/D-2064-2009; Hellhammer, Dirk/F-1888-2013 OI Prom-Wormley, Elizabeth/0000-0001-9230-9723; Lyons, Michael/0000-0001-6516-9219 FU NIA NIH HHS [R01 AG022381-05, R01 AG018384, R01 AG018384-06A2, R01 AG018386, R01 AG018386-06A2, R01 AG022381, R01 AG022982, R01 AG022982-01A1] NR 39 TC 12 Z9 12 U1 1 U2 7 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0278-6133 EI 1930-7810 J9 HEALTH PSYCHOL JI Health Psychol. PD MAR PY 2010 VL 29 IS 2 BP 117 EP 123 DI 10.1037/a0017865 PG 7 WC Psychology, Clinical; Psychology SC Psychology GA 576HT UT WOS:000276135800003 PM 20230083 ER PT J AU Fowler, CG Chiasson, KB Leslie, TH Thomas, D Beasley, TM Kemnitz, JW Weindruch, R AF Fowler, Cynthia G. Chiasson, Kirstin Beach Leslie, Tami Hanson Thomas, Denise Beasley, T. Mark Kemnitz, Joseph W. Weindruch, Richard TI Auditory function in rhesus monkeys: Effects of aging and caloric restriction in the Wisconsin monkeys five years later SO HEARING RESEARCH LA English DT Article DE Hearing; Aging; Presbycusis; Age-related hearing loss; Monkeys; Otoacoustic emissions (OAE); Caloric restriction (diet restriction); Auditory brainstem response (ABR) ID PRODUCT OTOACOUSTIC EMISSIONS; UNIVERSITY-OF-WISCONSIN; DIETARY RESTRICTION; MACACA-MULATTA; HEARING-LOSS; COCHLEAR PATHOLOGY; EVOKED-RESPONSE; AGE; PRESBYCUSIS; THRESHOLDS AB Caloric restriction (CR) slows aging in many species and protects some animals from age-related hearing loss (ARHL), but the effect on humans is not yet known. Because rhesus monkeys are long-lived primates that are phylogenically closer to humans than other research animals are, they provide a better model for studying the effects of CR in aging and ARHL Subjects were from the pool of 55 rhesus monkeys aged 15-28 years who had been in the Wisconsin study on CR and aging for 8-13.5 years. Distortion product otoacoustic emissions (DPOAE) with 12 frequencies from 2211 to 8837 Hz and auditory brainstem response (ABR) thresholds from clicks and 8, 16, and 32 kHz tone bursts were obtained. DPOAE levels declined linearly at approximately 1 dB/year, but that rate doubled for the highest frequencies in the oldest monkeys. There were no interactions for diet condition or sex. ABR thresholds to clicks and tone bursts showed increases with aging. Borderline significance was shown for diet in the thresholds at 8 kHz stimuli, with monkeys on caloric restriction having lower thresholds. Because the rhesus monkeys have a maximum longevity of 40 years, the full benefits of CR may not yet be realized. (C) 2010 Elsevier B.V. All rights reserved. C1 [Fowler, Cynthia G.] Univ Wisconsin, Dept Commun Disorders, Madison, WI 53706 USA. [Chiasson, Kirstin Beach] Nationwide Childrens Hosp, Columbus, OH 43205 USA. [Leslie, Tami Hanson] Greater Milwaukee Otolaryngol LLC, Greenfield, WI 53220 USA. [Thomas, Denise] Childrens Mem Hosp, Chicago, IL 60614 USA. [Beasley, T. Mark] Univ Alabama Birmingham, Dept Biostat, Sch Publ Hlth, Birmingham, AL 35294 USA. [Kemnitz, Joseph W.] Univ Wisconsin, Wisconsin Natl Primate Res Ctr, Dept Physiol, Madison, WI 53715 USA. [Weindruch, Richard] Univ Wisconsin, Dept Med, William S Middleton Mem Vet Hosp, Madison, WI 53705 USA. RP Fowler, CG (reprint author), Univ Wisconsin, Dept Commun Disorders, 1975 Willow Dr, Madison, WI 53706 USA. EM cgfowler@wisc.edu; Kirstin.Chiasson@nationwidechildrens.org; tamil@gmodocs.com; DThomas@childrensmemorial.org; mbeasley@ms.soph.uab.edu; kemnitz@primate.wisc.edu; rhweindr@wisc.edu FU NIH [P01 AG11915]; National Primate Research Center [RR000167] FX This work was supported in part by NIH P01 AG11915. The Wisconsin National Primate Research Center is supported in part by NIH Grant RR000167. The authors would like to thank Scott Baum for assistance with the animals, and two anonymous reviewers for comments on an earlier version of this paper. Portions of these data were presented at the International Evoked Response Audiometry Study Group, Havana, Cuba, 2005. NR 40 TC 18 Z9 18 U1 0 U2 5 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0378-5955 EI 1878-5891 J9 HEARING RES JI Hear. Res. PD MAR PY 2010 VL 261 IS 1-2 BP 75 EP 81 DI 10.1016/j.heares.2010.01.006 PG 7 WC Audiology & Speech-Language Pathology; Neurosciences; Otorhinolaryngology SC Audiology & Speech-Language Pathology; Neurosciences & Neurology; Otorhinolaryngology GA 577AV UT WOS:000276193200011 PM 20079820 ER PT J AU Belperio, PS Mole, LA Boothroyd, DB Backus, LI AF Belperio, P. S. Mole, L. A. Boothroyd, D. B. Backus, L. I. TI Trends in uptake of recently approved antiretrovirals within a national healthcare system SO HIV MEDICINE LA English DT Article DE antiretrovirals; HIV/AIDS; protease inhibitor; uptake; VA healthcare system ID HIV DISEASE; THERAPY; SPECIALIZATION; ADOPTION; CLINICS; ACCESS; AIDS AB Objective The aim of the study was to describe Veterans Healthcare Administration (VHA) system-wide uptake of three HIV protease inhibitors: atazanavir, darunavir and tipranavir. Methods This retrospective cohort study evaluated VHA uptake of three target antiretrovirals and lopinavir/ritonavir in each complete 90-day quarter since approval to December 2007 using VHA HIV Clinical Case Registry data. We assessed uptake using number of new prescriptions, number of providers and facilities prescribing target agents, provider type, clinic type, facility size and location within four US regions. Results Overall, 6551 HIV-infected veterans received target antiretrovirals. Uptake was generally greatest within the first year after Food and Drug Administration (FDA) approval, and then slightly declined and plateaued. Geographically, early adoption of new antiretroviral drugs tended to occur in the Western USA, as evidenced by comparison of uptake patterns of new antiretrovirals to use of all antiretroviral agents. A small percentage of prescribers of all antiretrovirals were responsible for new prescriptions for target medications, particularly for darunavir and tipranavir. Providers at almost 50% of VHA facilities were prescribing these agents within the first year. Conclusions Uptake of new antiretrovirals in the VHA generally reflected overall prescribing of all antiretrovirals, suggesting a lack of VHA impediments to new antiretrovirals in the healthcare system. Some regional variation in uptake among the targeted antiretrovirals occurred over time but tended to resolve after the first several months. Providers responsible for early prescribing of the target medications were limited to a fraction of providers who tended to be physicians who practised in infectious disease (ID) clinics at medium-sized facilities. C1 [Belperio, P. S.; Mole, L. A.; Boothroyd, D. B.; Backus, L. I.] Ctr Qual Management Publ Hlth, Dept Vet Affairs, Palo Alto, CA USA. RP Belperio, PS (reprint author), VA Greater Los Angeles Healthcare Syst, Infect Dis Sect 111F, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM pamela.belperio@va.gov NR 22 TC 2 Z9 2 U1 0 U2 2 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1464-2662 J9 HIV MED JI HIV Med. PD MAR PY 2010 VL 11 IS 3 BP 209 EP 215 DI 10.1111/j.1468-1293.2009.00764.x PG 7 WC Infectious Diseases SC Infectious Diseases GA 551IL UT WOS:000274200600007 PM 19863620 ER PT J AU Sabbaghian, MS Ranaudo, J Zeng, L Alongi, AP Perez-Perez, G Shamamian, P AF Sabbaghian, M. Shirin Ranaudo, Jeffrey Zeng, Lin Alongi, Alexandra P. Perez-Perez, Guillermo Shamamian, Peter TI Identification of Helicobacter spp. in bile and gallbladder tissue of patients with symptomatic gallbladder disease SO HPB LA English DT Article; Proceedings Paper CT 8th Congress of the European-Hepato-Pancreato-Biliary-Association CY JUN 18-20, 2009 CL Athens, GREECE SP European Hepato Pancreato Biliary Assoc DE Helicobacter; gallstones; gallbladder; cholecystitis ID CHOLESTEROL GALLSTONE FORMATION; PYLORI INFECTION; CHRONIC CHOLECYSTITIS; CAGA(+) STRAINS; GASTRIC CARDIA; DNA; RISK; RESPONSES; IMMUNE; MUCOSA AB Background: This experimental study was designed to determine if Helicobacter spp. contribute to benign gallbladder disease using polymerase chain reaction (PCR) methods. Methods: Patients with benign gallbladder disease scheduled for elective cholecystectomy at New York University Langone Medical Center were recruited from February to May 2008. Bile, gallbladder tissue and gallstones were collected. DNA was isolated from these specimens and amplified via PCR using C97F and C98R primers specific for Helicobacter spp. Appropriate positive and negative controls were used. Products were analysed with agarose gel electrophoresis, sequenced and results aligned using SEQUENCHER. Plasma was collected for detection of anti-Helicobacter pylori antibodies via enzyme-linked immunosorbent assay. Results: Of 36 patients, 12 patients' bile and/or tissue were positive for Helicobacter spp. by PCR. Species were most homologous with H. pylori, although other Helicobacter spp. were suggested. Six of 12 patients demonstrated anti-Helicobacter antibodies in plasma, suggesting that the remaining six might have demonstrated other species besides H. pylori. Four of six plasma samples with anti-Helicobacter antibodies were anti-CagA (cytotoxin associated gene) negative. Discussion: Helicobacter spp. can be detected in bile and gallbladder tissue of patients with benign gallbladder disease. The contribution of these bacteria to the pathophysiology of gallbladder disease and gallstone formation requires further study. C1 [Shamamian, Peter] Ralph H Johnson Vet Affairs Med Ctr, Surg Serv 112, Dept Surg, Charleston, SC 29401 USA. [Sabbaghian, M. Shirin; Ranaudo, Jeffrey; Zeng, Lin; Alongi, Alexandra P.] NYU, Dept Surg, Langone Med Ctr, New York, NY 10016 USA. [Perez-Perez, Guillermo] NYU, Sch Med, Dept Med, New York, NY USA. [Shamamian, Peter] Med Univ S Carolina, Charleston, SC 29425 USA. RP Shamamian, P (reprint author), Ralph H Johnson Vet Affairs Med Ctr, Surg Serv 112, Dept Surg, 109 Bee St, Charleston, SC 29401 USA. EM shamamia@musc.edu OI Perez Perez, Guillermo /0000-0002-0131-5798 NR 27 TC 3 Z9 3 U1 0 U2 1 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1365-182X J9 HPB JI HPB PD MAR PY 2010 VL 12 IS 2 BP 129 EP 133 DI 10.1111/j.1477-2574.2009.00148.x PG 5 WC Gastroenterology & Hepatology; Surgery SC Gastroenterology & Hepatology; Surgery GA 709JW UT WOS:000286435300008 PM 20495657 ER PT J AU Sonnenberg, A AF Sonnenberg, Amnon TI Age Distribution of IBD Hospitalization SO INFLAMMATORY BOWEL DISEASES LA English DT Article DE birth cohort; environmental risk factors; epidemiology of inflammatory bowel disease; hospital statistics; age effects; time trends ID INFLAMMATORY-BOWEL-DISEASE; CROHNS-DISEASE; ULCERATIVE-COLITIS; UNITED-STATES; TIME TRENDS; EPIDEMIOLOGY; PREVALENCE; MORTALITY; POPULATION; COUNTY AB Background and Aims: The ages of patients with Crohn's disease (CD) and ulcerative colitis (UC) are characterized by a bimodal distribution. The present study used hospital statistics to compare the age distribution of inflammatory bowel disease (IBD) among different countries. Methods: Hospital statistics from the period 1994 to 2007 were obtained through special requests to the national statistical offices of 9 European countries. Hospitalization was expressed as age- and sex-specific rates per 10,000 living people. Results: Hospitalization rates of different countries varied between 1.2 and 4.3 discharges per 10,000 for CD and between 0.7 and 4.7 discharges per 10.000 for UC. Countries with high CD rates were associated with similarly high UC rates (r = 0.955, P < 0.0001). In all countries alike, the age-distribution of CD hospitalization was characterized by a large peak in younger patients followed by a small peak in older patients. UC hospitalization was characterized by a small peak in younger patients followed by a large peak in older patients. Conclusions: The bimodal age distribution of IBD hospitalization can be explained in terms of varying exposure to 2 separate environmental risk factors that affected consecutive age groups differently over the course of the 20th century. C1 [Sonnenberg, Amnon] Portland VA Med Ctr, Portland, OR 97239 USA. [Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. RP Sonnenberg, A (reprint author), Portland VA Med Ctr, P3-GI,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM sonnenbe@ohsu.edu NR 22 TC 20 Z9 22 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1078-0998 J9 INFLAMM BOWEL DIS JI Inflamm. Bowel Dis. PD MAR PY 2010 VL 16 IS 3 BP 452 EP 457 DI 10.1002/ibd.21058 PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 576GX UT WOS:000276133600016 PM 19714765 ER PT J AU Sonnenberg, A AF Sonnenberg, Amnon TI Similar Geographic Variations of Mortality and Hospitalization Associated with IBD and Clostridium difficile Colitis SO INFLAMMATORY BOWEL DISEASES LA English DT Article DE environmental risk factors; epidemiology of IBD; geographic variation; hospital statistics; mortality from IBD ID INFLAMMATORY-BOWEL-DISEASE; UNITED-STATES; INFECTIONS; COHORT; IMPACT; STOOL AB Background: Superinfection with Clostridium difficile can aggravate the symptoms of preexisting inflammatory bowel disease (IBD). The study served to assess whether the geographic variation of IBD within the United States might be influenced by C. difficile infection. Methods: Hospitalization data of the Healthcare Cost and Utilization Project (HCUP) from 2001-2006 and mortality data from 1979-2005 of the US were analyzed by individual states. Hospitalization and mortality associated with Crohn's disease (CD), ulcerative colitis (UC), and C. difficile colitis were correlated with each other, using weighted least square linear regression with the population size of individual states as weight. Results: Among the hospitalization rates, there were strong correlations between both types of IBD, as well as each type of IBD with C. difficile colitis. Similarly, among the mortality rates there were strong correlations between both types of IBD, as well as each type of IBD with C. difficile colitis. Lastly, each type of hospitalization rate was also strongly correlated with each type of mortality rate. In general, hospitalization and mortality associated with IBD tended to be frequent in many of the northern states and infrequent in the Southwest and several southern states. Conclusions: The similarity in the geographic distribution of the 3 diseases could indicate the influence of C. difficile colitis in shaping the geographic patterns of IBD. It could also indicate that shared environmental risk factors influence the occurrence of IBD, as well as C. difficile colitis. C1 [Sonnenberg, Amnon] Portland VA Med Ctr, Portland, OR 97239 USA. [Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. RP Sonnenberg, A (reprint author), Portland VA Med Ctr, P3-GI,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM sonnenbe@ohsu.edu NR 19 TC 13 Z9 13 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1078-0998 J9 INFLAMM BOWEL DIS JI Inflamm. Bowel Dis. PD MAR PY 2010 VL 16 IS 3 BP 487 EP 493 DI 10.1002/ibd.21054 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 576GX UT WOS:000276133600022 PM 19637331 ER PT J AU Polsky, D Marcus, SC Werner, RM AF Polsky, Daniel Marcus, Steven C. Werner, Rachel M. TI Malpractice Premiums and the Supply of Obstetricians SO INQUIRY-THE JOURNAL OF HEALTH CARE ORGANIZATION PROVISION AND FINANCING LA English DT Article ID INSURANCE; CRISIS; LIABILITY; CARE; REFORMS; CAPS AB Using longitudinal data on practicing obstetricians from 1998 to 2004 derived from Pennsylvania, Florida, and New York hospital discharge data, this study finds that rising malpractice premiums are associated with an increased rate of exit and a reduced rate of entry for obstetricians. In Pennsylvania and Florida, where premiums rose by an average of 20% per year for four years, the combined effect of more exits and fewer entries was associated with a decline in obstetrical labor supply of 80 physicians, or 5.3% of the supply of obstetricians. C1 [Polsky, Daniel; Werner, Rachel M.] Univ Penn, Div Gen Internal Med, Sch Med, Philadelphia, PA 19104 USA. [Polsky, Daniel] Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA. [Marcus, Steven C.] Univ Penn, Sch Social Policy & Practice, Philadelphia, PA 19104 USA. [Werner, Rachel M.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. RP Polsky, D (reprint author), Univ Penn, Div Gen Internal Med, Sch Med, Blockley Hall,Rm 1204,423 Guardian Dr, Philadelphia, PA 19104 USA. EM polsky@mail.med.upenn.edu NR 27 TC 5 Z9 5 U1 1 U2 1 PU BLUE CROSS BLUE SHIELD ASSOC PI ROCHESTER PA 150 EAST MAIN ST, ROCHESTER, NY 14647 USA SN 0046-9580 J9 INQUIRY-J HEALTH CAR JI Inquiry-J. Health Care Organ. Provis. Financ. PD SPR PY 2010 VL 47 IS 1 BP 48 EP 61 DI 10.5034/inquiryjrnl_47.01.48 PG 14 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 595VA UT WOS:000277640300005 PM 20464954 ER PT J AU Einstein, DR Del Pin, F Jiao, XM Kuprat, AP Carson, JP Kunzelman, KS Cochran, RP Guccione, JM Ratcliffe, MB AF Einstein, Daniel R. Del Pin, Facundo Jiao, Xiangmin Kuprat, Andrew P. Carson, James P. Kunzelman, Karyn S. Cochran, Richard P. Guccione, Julius M. Ratcliffe, Mark B. TI Fluid-structure interactions of the mitral valve and left heart: Comprehensive strategies, past, present and future SO INTERNATIONAL JOURNAL FOR NUMERICAL METHODS IN BIOMEDICAL ENGINEERING LA English DT Article DE biofluid-structure interactions; ischemic mitral regurgitation; imaging-based finite element models ID FINITE-ELEMENT-METHOD; LEFT-VENTRICULAR WALL; IN-VITRO QUANTIFICATION; AORTIC-VALVE; PAPILLARY-MUSCLE; SHEAR-STRESS; ENDOTHELIAL-CELLS; COMPUTATIONAL ANALYSIS; MYOCARDIAL-INFARCTION; INCOMPRESSIBLE FLOWS AB The remodeling that occurs after a posterolateral myocardial infarction can alter mitral valve function by creating conformational abnormalities in the mitral annulus and in the posteromedial papillary muscle, leading to mitral regurgitation (MR). It is generally assumed that this remodeling is caused by a volume load and is mediated by an increase in diastolic wall stress. Thus, MR can be both the cause and effect of an abnormal cardiac stress environment. Computational modeling of ischemic MR and its surgical correction is attractive because it enables an examination of whether a given intervention addresses the correction of regurgitation (fluid-flow) at the cost of abnormal tissue stress. This is significant because the negative effects of an increased wall stress due to the intervention will only be evident over time. However, a meaningful fluid structure interaction (FSI) model of the left heart is not trivial; it requires a careful characterization of the in vivo cardiac geometry, the tissue parameterization through inverse analysis, a robust coupled solver that handles collapsing Lagrangian interfaces, the automatic grid-generation algorithms that are capable of accurately discretizing the cardiac geometry, the innovations in image analysis, the competent and efficient constitutive models and an understanding of the spatial organization of tissue microstructure. In this paper, we profile our work toward a comprehensive FSI model of the left heart by reviewing our early work, presenting our current work and laying out our future work in four broad categories: data collection, geometry, FSI and validation. Copyright (C) 2009 John Wiley & Sons, Ltd. C1 [Einstein, Daniel R.; Kuprat, Andrew P.; Carson, James P.] Pacific NW Natl Lab, Richland, WA 99352 USA. [Del Pin, Facundo] Livermore Software Technol Corp, Livermore, CA USA. [Jiao, Xiangmin] SUNY Stony Brook, Dept Appl Math & Stat, Stony Brook, NY 11794 USA. [Kunzelman, Karyn S.] Univ Maine, Dept Mech Engn, Orono, ME 04469 USA. [Cochran, Richard P.] Cent Maine Heart & Vasc Inst, Lewiston, ME USA. [Guccione, Julius M.; Ratcliffe, Mark B.] San Francisco VA Med Ctr, Dept Surg, San Francisco, CA USA. RP Einstein, DR (reprint author), Pacific NW Natl Lab, Richland, WA 99352 USA. EM daniel.einstein@pnl.gov OI Kuprat, Andrew/0000-0003-4159-918X; Jiao, Xiangmin/0000-0002-7111-9813 FU National Heart and Blood Institute [5R01HL077921-03, 1R01HL084431-01A1, 1RO1-HL073598-01A] FX Contract/grant sponsor: National Heart and Blood Institute; contract/grant numbers: 5R01HL077921-03, 1R01HL084431-01A1, 1RO1-HL073598-01A NR 120 TC 35 Z9 36 U1 2 U2 15 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 2040-7939 J9 INT J NUMER METH BIO JI Int. J. Numer. Meth. Biomed. PD MAR-APR PY 2010 VL 26 IS 3-4 SI SI BP 348 EP 380 DI 10.1002/cnm.1280 PG 33 WC Engineering, Biomedical; Mathematical & Computational Biology; Mathematics, Interdisciplinary Applications SC Engineering; Mathematical & Computational Biology; Mathematics GA 586HR UT WOS:000276897700007 PM 20454531 ER PT J AU Cruess, DG Localio, AR Platt, AB Brensinger, CM Christie, JD Gross, R Parker, CS Price, M Metlay, JP Cohen, A Newcomb, CW Strom, BL Kimmel, SE AF Cruess, Dean G. Localio, A. Russell Platt, Alec B. Brensinger, Colleen M. Christie, Jason D. Gross, Robert Parker, Catherine S. Price, Maureen Metlay, Joshua P. Cohen, Abigail Newcomb, Craig W. Strom, Brian L. Kimmel, Stephen E. TI Patient Attitudinal and Behavioral Factors Associated with Warfarin Non-adherence at Outpatient Anticoagulation Clinics SO INTERNATIONAL JOURNAL OF BEHAVIORAL MEDICINE LA English DT Article DE Warfarin adherence; Patient factors; MBMD; MEMS ID ACTIVE ANTIRETROVIRAL THERAPY; NONRHEUMATIC ATRIAL-FIBRILLATION; HIV-POSITIVE MEN; RISK-FACTORS; PSYCHOSOCIAL FACTORS; IN-RANGE; ANTIHYPERTENSIVE THERAPY; BLEEDING COMPLICATIONS; ANTITHROMBOTIC THERAPY; MEDICATION ADHERENCE AB Warfarin is an anticoagulant effective in preventing stroke, but it has a narrow therapeutic range requiring optimal adherence to achieve the most favorable effects. The goal of this study was to examine specific patient factors that might help explain warfarin non-adherence at outpatient anticoagulation clinics. In a prospective cohort study of 156 adults, we utilized logistic regression analyses to examine the relationship between the five Treatment Prognostics scales from the Millon Behavioral Medicine Diagnostic (MBMD), as well as three additional MBMD scales (Depression, Future Pessimism, and Social Isolation), and daily warfarin non-adherence assessed using electronic medication event monitoring systems caps over a median of 139 days. Four of the five Treatment Prognostic scales and greater social isolation were associated with warfarin non-adherence. When controlling for pertinent demographic and medical variables, the Information Discomfort scale remained significantly associated with warfarin non-adherence over time. Although several factors were related to warfarin non-adherence, patients reporting a lack of receptivity to details regarding their medical illness seemed most at risk for warfarin non-adherence. This information might aid in the development of interventions to enhance warfarin adherence and perhaps reduce adverse medical events. C1 [Cruess, Dean G.] Univ Connecticut, Dept Psychol, Storrs, CT 06269 USA. [Platt, Alec B.; Christie, Jason D.; Gross, Robert; Metlay, Joshua P.; Strom, Brian L.; Kimmel, Stephen E.] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA. [Localio, A. Russell; Platt, Alec B.; Brensinger, Colleen M.; Christie, Jason D.; Gross, Robert; Parker, Catherine S.; Price, Maureen; Metlay, Joshua P.; Cohen, Abigail; Newcomb, Craig W.; Strom, Brian L.; Kimmel, Stephen E.] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Localio, A. Russell; Platt, Alec B.; Brensinger, Colleen M.; Christie, Jason D.; Gross, Robert; Parker, Catherine S.; Price, Maureen; Metlay, Joshua P.; Cohen, Abigail; Newcomb, Craig W.; Strom, Brian L.; Kimmel, Stephen E.] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Metlay, Joshua P.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Cruess, DG (reprint author), Univ Connecticut, Dept Psychol, 406 Babbidge Rd,Unit 1020, Storrs, CT 06269 USA. EM Dean.Cruess@uconn.edu RI Cohen, Abigail/K-9180-2013 OI Cohen, Abigail/0000-0002-7425-7218 FU AHRQ HHS [P01 HS011530, P01-HS11530]; NHLBI NIH HHS [R01 HL066176, K24 HL070936, K24HL070936, R01 HL066176-01, R01-HL66176, T32 HL007891] NR 58 TC 25 Z9 25 U1 1 U2 14 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1070-5503 J9 INT J BEHAV MED JI Int. J. Behav. Med. PD MAR PY 2010 VL 17 IS 1 BP 33 EP 42 DI 10.1007/s12529-009-9052-6 PG 10 WC Psychology, Clinical SC Psychology GA 552LV UT WOS:000274293100004 PM 19579066 ER PT J AU Manoff, S McFetride, R Liss, C Marchese, R Rabb, J Rueda, A Musher, D AF Manoff, S. McFetride, R. Liss, C. Marchese, R. Rabb, J. Rueda, A. Musher, D. TI Antibody persistence 10 years after 1st and 2nd doses of 23-valent pneumococcal polysaccharide vaccine (PN23), and immunogenicity and safety of 2nd and 3rd doses in older adults SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES LA English DT Meeting Abstract C1 [Manoff, S.; McFetride, R.; Liss, C.; Marchese, R.] Merck, N Wales, PA USA. [Rabb, J.] PPD Vaccines & Biol, Wayne, PA USA. [Rueda, A.; Musher, D.] Baylor Coll Med, Houston, TX 77030 USA. [Rueda, A.; Musher, D.] VA Med Ctr, Houston, TX USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1201-9712 J9 INT J INFECT DIS JI Int. J. Infect. Dis. PD MAR PY 2010 VL 14 SU 1 BP E454 EP E454 DI 10.1016/j.ijid.2010.02.627 PG 1 WC Infectious Diseases SC Infectious Diseases GA 578MQ UT WOS:000276298201587 ER PT J AU Richardson, LK Amstadter, AB Kilpatrick, DG Gaboury, MT Tran, TL Trung, LT Tam, NT Tuan, T Buoi, LT Ha, TT Thach, TD Acierno, R AF Richardson, Lisa K. Amstadter, Ananda B. Kilpatrick, Dean G. Gaboury, Mario T. Trinh Luong Tran Lam Tu Trung Nguyen Thanh Tam Tran Tuan La Thi Buoi Tran Thu Ha Tran Duc Thach Acierno, Ron TI ESTIMATING MENTAL DISTRESS IN VIETNAM: THE USE OF THE SRQ-20 SO INTERNATIONAL JOURNAL OF SOCIAL PSYCHIATRY LA English DT Article DE community estimate; mental distress; mental health; Self Reporting Questionnaire 20; SRQ-20; Vietnam ID COMORBIDITY SURVEY REPLICATION; DSM-IV DISORDERS; HEALTH; PREVALENCE; COUNTRIES AB Background: Community-based estimates of psychopathology prevalence in developing countries such as Vietnam, are needed to reduce presumed significant burden of poor mental health. Aims: This study derived population-based prevalence estimates of mental distress, as measured by the SRQ-20, in a community sample of 4,981 adults living in Vietnam. This study also examined correlates of mental distress based on SRQ-20 caseness indications. Risk and protective factors were identified in terms of their unique contribution to caseness. Results: Using a cut-off of 7/8, 19.2% of the sample was considered to be a probable case (n = 954), with females endorsing more items than males. Marital status and employment status were not associated with mental health distress. Higher wealth, endorsing religious affiliation, and self-reports of good health were associated with lower SRQ-20 scores. Age and being female were associated with higher SRQ-20 scores. Conclusions: A single item was as adequate a measure of wealth as multi-item rating scales. Our estimate of mental distress using the SRQ-20 is much greater than that of other studies, and in contrast to western prevalence studies, age was not a protective factor in this study. The SRQ-20 is a brief, cost-effective and reasonably valid measure of both community and individual mental distress. C1 [Amstadter, Ananda B.; Kilpatrick, Dean G.; Acierno, Ron] Med Univ S Carolina, Charleston, SC 29425 USA. [Acierno, Ron] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. [Tran Tuan; La Thi Buoi; Tran Thu Ha; Tran Duc Thach] Res & Training Ctr Community Dev, Hanoi, Vietnam. [Nguyen Thanh Tam] Vietnam Vet Amer Fdn, Washington, DC USA. [Lam Tu Trung] Da Nang Mental Hlth Hosp, Da Nang, Vietnam. [Trinh Luong Tran] Hlth Dept Da Nang City, Da Nang, Vietnam. [Gaboury, Mario T.] Univ New Haven, Dept Criminal Justice, West Haven, CT USA. [Gaboury, Mario T.] Univ New Haven, Oskar Schindler Humanities Fdn, West Haven, CT USA. [Richardson, Lisa K.] Murdoch Univ, Perth, WA, Australia. RP Acierno, R (reprint author), Med Univ S Carolina, Charleston, SC 29425 USA. EM acierno@musc.edu RI Tran, Thach/H-7734-2014 OI Tran, Thach/0000-0002-4686-8601 NR 17 TC 10 Z9 10 U1 0 U2 1 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0020-7640 J9 INT J SOC PSYCHIATR JI Int. J. Soc. Psychiatr. PD MAR PY 2010 VL 56 IS 2 BP 133 EP 142 DI 10.1177/0020764008099554 PG 10 WC Psychiatry SC Psychiatry GA 564QU UT WOS:000275232000003 PM 20207676 ER PT J AU Wilkosz, PA Seltman, HJ Devlin, B Weamer, EA Lopez, OL DeKosky, ST Sweet, RA AF Wilkosz, Patricia A. Seltman, Howard J. Devlin, Bernie Weamer, Elise A. Lopez, Oscar L. DeKosky, Steven T. Sweet, Robert A. TI Trajectories of cognitive decline in Alzheimer's disease SO INTERNATIONAL PSYCHOGERIATRICS LA English DT Article DE late-onset Alzheimer disease (LOAD); psychosis; cognitive neuropsychology in dementia; assessment of cognitive disorders/dementia; APOE epsilon 4 ID EPSILON-4 ALLELE; DEMENTIA; RISK; PSYCHOSIS; CONSORTIUM; CLINICIAN; DIAGNOSIS; MODELS; ONSET; AGE AB Background: Late-onset Alzheimer disease (LOAD) is a clinically heterogeneous complex disease defined by progressively disabling cognitive impairment. Psychotic symptoms which affect approximately one-half of LOAD subjects have been associated with more rapid cognitive decline. However, the variety of cognitive trajectories in LOAD, and their correlates, have not been well defined. We therefore used latent class modeling to characterize trajectories of cognitive and behavioral decline in a cohort of AD subjects. Methods: 201 Caucasian subjects with possible or probable Alzheimer's disease (AD) were evaluated for cognitive and psychotic symptoms at regular intervals for up to 13.5 years. Cognitive symptoms were evaluated serially with the Mini-mental State Examination (MMSE), and psychotic symptoms were rated using the CERAD behavioral rating scale (CBRS). Analyses undertaken were latent class mixture models of quadratic trajectories including a random intercept with initial MMSE score, age, gender, education, and APOE epsilon 4 count modeled as concomitant variables. In a secondary analysis, psychosis status was also included. Results: AD subjects showed six trajectories with significantly different courses and rates of cognitive decline. The concomitant variables included in the best latent class trajectory model were initial MMSE and age. Greater burden of psychotic symptoms increased the probability of following a trajectory of more rapid cognitive decline in all age and initial MMSE groups. APOE epsilon 4 was not associated with any trajectory Conclusion: Trajectory modeling of longitudinal cognitive and behavioral data may provide enhanced resolution of phenotypic variation in AD. C1 [Wilkosz, Patricia A.; Devlin, Bernie; Weamer, Elise A.; Lopez, Oscar L.; DeKosky, Steven T.; Sweet, Robert A.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15213 USA. [Weamer, Elise A.; Lopez, Oscar L.; DeKosky, Steven T.; Sweet, Robert A.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15213 USA. [Seltman, Howard J.] Carnegie Mellon Univ, Dept Stat, Pittsburgh, PA 15213 USA. [Sweet, Robert A.] VA Pittsburgh Healthcare Syst, VISN MIRECC 4, Pittsburgh, PA USA. RP Sweet, RA (reprint author), Univ Pittsburgh, Dept Psychiat, Biomed Sci Tower,Rm W-1645,3811 OHara St, Pittsburgh, PA 15213 USA. EM sweetra@upmc.edu OI Seltman, Howard/0000-0002-7543-3578 FU National Institute of Aging [AG027224, AG005133] FX This study was supported in part by research grants AG027224 and AG005133 from the National Institute of Aging. The authors wish to thank Mr. James Emanuel for formatting the manuscript and the staff of the Alzheimer Disease Research and Clinic at the University of Pittsburgh. We also wish to thank the two anonymous reviewers for many helpful suggestions. NR 34 TC 47 Z9 48 U1 3 U2 7 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1041-6102 J9 INT PSYCHOGERIATR JI Int. Psychogeriatr. PD MAR PY 2010 VL 22 IS 2 BP 281 EP 290 DI 10.1017/S1041610209991001 PG 10 WC Psychology, Clinical; Geriatrics & Gerontology; Gerontology; Psychiatry; Psychology SC Psychology; Geriatrics & Gerontology; Psychiatry GA 563LF UT WOS:000275132800013 PM 19781112 ER PT J AU Williams, EC Peytremann-Bridevaux, I Fan, VS Bryson, CL Blough, DK Kivlahan, DR Bradley, KA AF Williams, Emily C. Peytremann-Bridevaux, Isabelle Fan, Vincent S. Bryson, Chris L. Blough, David K. Kivlahan, Daniel R. Bradley, Katharine A. TI The Association Between Alcohol Screening Scores and Health Status in Male Veterans SO JOURNAL OF ADDICTION MEDICINE LA English DT Article DE alcohol screening; alcohol misuse; self-reported health status; health-related quality of life ID QUALITY-OF-LIFE; PRIMARY-CARE PATIENTS; POSTTRAUMATIC-STRESS-DISORDER; ALL-CAUSE MORTALITY; SUBJECTIVE HEALTH; OLDER-ADULTS; CONSUMPTION PATTERNS; MENTAL-HEALTH; AUDIT-C; DRINKING AB Objectives: Alcohol use is associated with self-reported health status. However, little is known about the concurrent association between alcohol screening scores and patient perception of health. We evaluated this association in a sample of primarily older male veterans. Methods: This secondary, cross-sectional analysis included male general medicine outpatients from 7 VA medical centers who returned mailed questionnaires. Screening scores from the Alcohol Use Disorders Identification Test Consumption (AUDIT-C) questionnaire were divided into 6 categories (0, 1-3, 4-5, 6-7, 8-9, and 10-12). Outcomes included scores on the 8 subscales and 2 component scores of the 36-item Short Form Health Survey (SF-36). Unadjusted and adjusted linear regression models were fit to characterize the association between AUDIT-C categories and SF-36 scores. Models were adjusted for demographic characteristics, smoking, and site-both alone and in combination with 14 self-reported comorbid conditions. Results: Male respondents (n = 24,531; mean age = 63.6 years) represented 69% of those surveyed with the SF-36. After adjustment, a quadratic (inverted U-shaped) relationship was demonstrated between AUDIT-C categories and all SF-36 scores such that patients with AUDIT-C scores 4-5 or 6-7 reported the highest health status, and patients with AUDIT-C scores 0, 8-9, and >= 10 reported the lowest health status. Conclusions: Across all measures of health status, patients with the most severe alcohol misuse had significantly poorer health status than those who screened positive for alcohol misuse at mild or moderate levels of severity. The relatively good health status reported by patients with mild-moderate alcohol misuse might interfere with clinicians' acceptance and adoption of guidelines recommending that they counsel these patients about their drinking. C1 [Williams, Emily C.; Fan, Vincent S.; Bryson, Chris L.; Kivlahan, Daniel R.; Bradley, Katharine A.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA 98101 USA. [Fan, Vincent S.; Bryson, Chris L.; Bradley, Katharine A.] VA Puget Sound Hlth Care Syst, Primary & Specialty Med Care Serv, Seattle, WA 98101 USA. [Williams, Emily C.; Kivlahan, Daniel R.; Bradley, Katharine A.] VA Puget Sound Hlth Care Syst, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA 98101 USA. [Bryson, Chris L.; Bradley, Katharine A.] Univ Washington, Dept Med, Seattle, WA USA. [Kivlahan, Daniel R.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Fan, Vincent S.] Univ Washington, Dept Pulm & Crit Care, Seattle, WA 98195 USA. [Williams, Emily C.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Blough, David K.] Univ Washington, Dept Pharm, Seattle, WA 98195 USA. [Peytremann-Bridevaux, Isabelle] Univ Lausanne, Inst Social & Prevent Med, Lausanne, Switzerland. Ctr Hosp Vaudois, Lausanne, Switzerland. RP Williams, EC (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM emily.williams3@va.gov FU VA HSRD IIR [IAC 05-206-1]; VA Career Development Awards [RCD 02-170-2, RCD 03-177]; VA HSRD [SDR96-002, IIR99-376] FX Supported by VA HSR&D IIR Grant IAC 05-206-1, VA Career Development Awards RCD 02-170-2 (to V. S. F.) and RCD 03-177 (to C. L. B.) and the VA Ambulatory Care Quality Improvement Project (ACQUIP) was funded by VA HSR&D Grants SDR96-002 and IIR99-376. NR 74 TC 23 Z9 23 U1 3 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1932-0620 J9 J ADDICT MED JI J. Addict. Med. PD MAR PY 2010 VL 4 IS 1 BP 27 EP 37 DI 10.1097/ADM.0b013e3181a196b5 PG 11 WC Substance Abuse SC Substance Abuse GA 642OR UT WOS:000281226000004 PM 21769021 ER PT J AU Goldman, M Suh, JJ Lynch, KG Szucs, R Ross, J Xie, H O'Brien, CP Oslin, DW AF Goldman, Marina Suh, Jesse J. Lynch, Kevin G. Szucs, Regina Ross, Jennifer Xie, Hu O'Brien, Charles P. Oslin, David W. TI Identifying Risk Factors for Marijuana Use Among Veterans Affairs Patients SO JOURNAL OF ADDICTION MEDICINE LA English DT Article DE veterans; cannabis; screening; primary care ID HEAVY CANNABIS USERS; PRIMARY-CARE; SUBSTANCE USE; COST-EFFECTIVENESS; CELL CARCINOMA; UNITED-STATES; USE DISORDERS; TOBACCO; SMOKING; HEALTH AB Objectives: Cannabis is the most widely used drug in the United States, and its use carries negative health consequences; however, universal screening for cannabis use is cumbersome. If data commonly collected in the primary care setting (eg, use of alcohol, smoking status, and depression symptoms) could predict cannabis use, then providers can implement targeted marijuana screening in high-risk groups. Methods: We reviewed Behavioral Health Laboratory data collected between 2003 and 2006 from 5512 patients referred by Veterans Affairs primary care clinics for potential mental health needs. Logistic regression was used to determine the predictors of past year marijuana use. Results: A total of 11.5% of the sample reported using marijuana in the past year. Age, gender, other drug use, presence of alcohol use disorders, smoking status, depressive disorders, posttraumatic stress disorder, anxiety disorders, and psychotic symptoms, individually, were associated with the patients' use of marijuana during the past year. When controlling for age, race, and gender in a logistic regression analyses, only other drug use, alcohol use disorder, and smoking status were linked to past year marijuana use. Patients were 5.4 (95% confidence interval [CI] 4.3-6.7) times more likely to have used marijuana during the past year if they used another illicit drug during the past year. Those with alcohol use disorder diagnosis or current smokers were 2.3 (95% CI 1.9-2.8) and 1.5 times (95% CI 1.3-1.7), respectively, more likely to have used marijuana during the past year. Receiver operating characteristic curve (area under curve = 0.79) represents good sensitivity and specificity of the model, correctly classifying 88.4% of the past year marijuana users. Conclusion: Identifying patients at high risk for cannabis use may facilitate targeted screening and provision of interventions in primary care. Patients who screen positive for cigarette use, alcohol abuse or dependence, or have evidence of other illicit drug use could be considered for cannabis screening. C1 [Goldman, Marina; Suh, Jesse J.; Szucs, Regina; Xie, Hu; O'Brien, Charles P.; Oslin, David W.] Univ Penn, Dept Psychiat, Sch Med, Philadelphia, PA 19104 USA. [Suh, Jesse J.; Ross, Jennifer; O'Brien, Charles P.; Oslin, David W.] Vet Affairs Med Ctr VAMC Philadelphia, Philadelphia, PA USA. VISN 4 Mental Illness Res Educ & Clin Ctr MIRECC, Philadelphia, PA USA. RP Goldman, M (reprint author), Univ Penn, Dept Psychiat, Sch Med, 3900 Chestnut St, Philadelphia, PA 19104 USA. EM Goldman_M@mail.TRC.Upenn.edu FU Philadelphia Veterans Affairs Medical Center; VISN 4 Mental Illness Research, Education and Clinical Center (MIRECC); National Institute on Drug Abuse [T32-DA-07241] FX Supported, in part, by grants from the Philadelphia Veterans Affairs Medical Center and VISN 4 Mental Illness Research, Education and Clinical Center (MIRECC), and the National Institute on Drug Abuse (T32-DA-07241). NR 42 TC 5 Z9 5 U1 7 U2 9 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1932-0620 J9 J ADDICT MED JI J. Addict. Med. PD MAR PY 2010 VL 4 IS 1 BP 47 EP 51 DI 10.1097/ADM.0b013e3181b18782 PG 5 WC Substance Abuse SC Substance Abuse GA 642OR UT WOS:000281226000006 PM 21625378 ER PT J AU Skoner, D Gentile, D Bush, R Fasano, MB McLaughlin, A Esch, RE AF Skoner, David Gentile, Deborah Bush, Robert Fasano, Mary Beth McLaughlin, Anne Esch, Robert E. TI Sublingual immunotherapy in patients with allergic rhinoconjunctivitis caused by ragweed pollen SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Article DE Allergic rhinoconjunctivitis; maximum tolerable dose; medication score; subcutaneous immunotherapy; sublingual immunotherapy; symptom score ID CLINICAL-TRIALS; PEDIATRIC-PATIENTS; RHINITIS; EFFICACY; GRASS; ASTHMA; METAANALYSIS; RESPONSES; CHILDREN; FUTURE AB Background: Specific allergen immunotherapy is most often delivered subcutaneously, but sublingual immunotherapy may confer greater benefit in terms of tolerability and safety, accessibility, and improved antigen delivery. Objective: This randomized, double-blind, placebo-controlled trial was conducted to identify a safe and effective maintenance dose range of sublingual standardized glycerinated short ragweed pollen extract in adults with ragweed-induced rhinoconjunctivitis. Methods: In May 2006, a total of 115 patients with ragweed-induced rhinoconjunctivitis were randomly allocated to placebo (n = 40), medium-dose extract (4.8 mu g Amb a 1/d; n = 39), or high-dose extract (48 mu g Amb a 1/d; n = 36). In a 1-day (rush) dose-escalation regimen, ragweed pollen extract was administered sublingually in incremental doses until maximum tolerable or scheduled dose was reached and then maintained during the ragweed pollen season. Patient diaries were used to monitor nasal and ocular symptoms and medication. The primary endpoint was symptom score. Results: Both active treatment groups achieved a 15% reduction in total rhinoconjunctivitis symptom scores compared with placebo during the entire ragweed pollen season, but the difference was not statistically significant (P > .10) However, in an analysis of covariance correcting for preseasonal symptoms, both mean daily symptom scores (0.19 +/- 1.16 vs 1.00 +/- 2.30) and medication scores (0.0003 +/- 1.64 vs 0.63 +/- 1.06) for the entire pollen season were significantly reduced in the high-dose versus placebo groups, respectively (P <= .05). Ragweed-specific IgG, IgG(4), and IgA antibodies were increased after treatment in the medium- and high-dose groups and not the placebo group. Frequency of adverse events was similar between, the placebo and treatment groups, but oral-mucosal adverse events occurred more often with treatment. Conclusion: Standardized glycerinated short ragweed pollen extract administered sublingually at maintenance doses of 4.8 to 48 mu g Amb a 1/d was safe and can induce favorable clinical and immunologic changes in ragweed-sensitive subjects. However, additional trials are needed to establish efficacy. (J Allergy Clin Immunol 2010;125:660-6.) C1 [Skoner, David; Gentile, Deborah] Drexel Univ, Coll Med, Allegheny Gen Hosp, Pittsburgh, PA 15212 USA. [Bush, Robert] Univ Wisconsin, Sch Med & Publ Hlth, William S Middleton Mem Vet Adm Hosp, Madison, WI 53706 USA. [Fasano, Mary Beth] Univ Iowa, Hosp & Clin, Iowa City, IA 52242 USA. [McLaughlin, Anne] Welborn Clin Res Ctr, Evansville, IN USA. [Esch, Robert E.] Greer Labs Inc, Lenoir, NC USA. RP Skoner, D (reprint author), Drexel Univ, Coll Med, Allegheny Gen Hosp, 320 EN Ave, Pittsburgh, PA 15212 USA. EM dskoner@wpahs.org FU Greer Laboratories, Inc; Novartis Pharmaceuticals Corp; Schering Plough; Greer Laboratories; NIH; Lev Pharmaceuticals; Merck; Pharming; GlaxoSmithKline; Map Pharmaceuticals FX Editorial support was funded by Greer Laboratories, Inc.; Disclosure of potential conflict of interest: D. Skoner is on the speakers' bureau for AstraZeneca, GlaxoSmithKline, Merck. Inc, and Novartis Pharmaceutical Corp; receives research support from Novartis Pharmaceuticals Corp, and Schering Plough; and is a consultant for Merck, Inc. D. Gentile receives research support from Greer Laboratories. R. Bush invests in TEVA Pharmaceuticals and receives research support from the NIH and Greer Laboratories. M. B. Fasano receives research support from Greer Laboratories, Lev Pharmaceuticals, and CSL-Behring and is on the Board of Directors for ABAI. A. McLaughlin receives research support from Greer, Lev Pharmaceuticals, Merck, Pharming, GlaxoSmithKline, Novartis, and Map Pharmaceuticals and receives speakers' honoraria from Merck, Schering. GlaxoSmithKline, AstraZeneca, and Sanofi-Aventis. R. E. Esch is employed by Greer Laboratories. NR 35 TC 49 Z9 49 U1 0 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD MAR PY 2010 VL 125 IS 3 BP 660 EP 666 DI 10.1016/j.jaci.2009.12.931 PG 7 WC Allergy; Immunology SC Allergy; Immunology GA 573BK UT WOS:000275883200023 PM 20153030 ER PT J AU Roth, MY Lin, K Amory, JK Matsumoto, AM Anawalt, BD Snyder, CN Kalhorn, TF Bremner, WJ Page, ST AF Roth, M. Y. Lin, K. Amory, J. K. Matsumoto, A. M. Anawalt, B. D. Snyder, C. N. Kalhorn, T. F. Bremner, W. J. Page, S. T. TI Serum LH Correlates Highly With Intratesticular Steroid Levels in Normal Men SO JOURNAL OF ANDROLOGY LA English DT Article DE Contraception; hormone; infertility; testis ID HUMAN TESTIS; TESTOSTERONE CONCENTRATIONS; ANDROGEN MICROENVIRONMENT; GONADOTROPIN SUPPRESSION; MASS-SPECTROMETRY; SPERMATOGENESIS; FINASTERIDE; DIHYDROTESTOSTERONE; MAINTENANCE; DUTASTERIDE AB Sex steroids are essential for spermatogenesis; however, normal intratesticular concentrations of these hormones in man have not been extensively studied. To improve our understanding of intratesticular hormone concentrations, we performed bilateral testicular aspirations in a group of normal men, determined sex steroid concentrations within each testis, and compared these levels to serum hormone concentrations. Ten healthy human subjects aged 20-49 underwent bilateral testicular aspirations. Intratesticular hormone concentrations of testosterone, dihydrotestosterone (DHT), and estradiol were measured using liquid chromatography tandem mass spectrometry. Intratesticular testosterone concentrations ranged from 119 to 1251 ng/mL, with a mean of 635 +/- 368 ng/mL. Intratesticular estradiol ranged from 0.41 to 3.9 ng/mL, with a mean of 2.4 +/- 1.3 ng/mL. Intratesticular DHT ranged from 1.1 to 7.9 ng/mL, with a mean of 3.5 +/- 3.2 ng/mL. Intratesticular testosterone and estradiol concentrations correlated highly with serum luteinizing hormone (LH; r = 0.87 and r = 0.70 respectively, P < .01). Intratesticular testosterone correlated highly with serum testosterone. Moreover, a significant correlation between the right and left testes was observed for testosterone (r = 0.82, P = .003), but not for estradiol or DHT. Intratesticular hormone concentrations can be safely assessed by testicular aspiration. Intratesticular testosterone and estradiol correlate highly with serum LH concentrations, and variation in serum LH accounts for most of the variation in intratesticular testosterone among men. In addition, intratesticular testosterone is highly correlated between testes in a given individual. Direct measurement of intratesticular testosterone will improve our understanding of the relationship between intratesticular sex steroids and spermatogenesis, and may have implications for the development of male hormonal contraception. C1 [Roth, M. Y.; Lin, K.; Amory, J. K.; Matsumoto, A. M.; Anawalt, B. D.; Bremner, W. J.; Page, S. T.] Univ Washington, Dept Internal Med, Seattle, WA 98195 USA. [Roth, M. Y.; Amory, J. K.; Matsumoto, A. M.; Anawalt, B. D.; Snyder, C. N.; Bremner, W. J.; Page, S. T.] Univ Washington, Ctr Res Reprod & Contracept, Seattle, WA 98195 USA. [Lin, K.] Univ Washington, Dept Obstet & Gynecol, Seattle, WA 98195 USA. [Kalhorn, T. F.] Univ Washington, Dept Med Chem, Seattle, WA 98195 USA. [Matsumoto, A. M.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. RP Roth, MY (reprint author), Univ Washington, Dept Internal Med, 1959 NE Pacific St,Box 357138, Seattle, WA 98195 USA. EM mylang@u.washington.edu FU National Institute of Child Health and Human Development [U54-HD-12629, U54 HD-42454, K23 HD45386]; Training in Reproductive Biology [5 T32 HD007453]; Department of Veterans Affairs; National Institute of Aging, a Division of the National Institute of Health [K23 AG027238] FX Supported by the National Institute of Child Health and Human Development through cooperative agreements U54-HD-12629 and U54 HD-42454 as part of the specialized Cooperative Centers Program in Reproductive Research and the Cooperative Contraceptive Research Centers Program. M.Y.R. is supported by Training in Reproductive Biology grant 5 T32 HD007453. A.M.M. is supported by the Department of Veterans Affairs. J.K.A. is supported, in part, by the National Institute of Child Health and Human Development, through grant K23 HD45386. S.T.P. is supported by the National Institute of Aging, a Division of the National Institute of Health, by grant K23 AG027238. NR 28 TC 18 Z9 18 U1 0 U2 3 PU AMER SOC ANDROLOGY, INC PI LAWRENCE PA C/O ALLEN PRESS, INC PO BOX 368, LAWRENCE, KS 66044 USA SN 0196-3635 EI 1939-4640 J9 J ANDROL JI J. Androl. PD MAR-APR PY 2010 VL 31 IS 2 BP 138 EP 145 DI 10.2164/jandrol.109.008391 PG 8 WC Andrology SC Endocrinology & Metabolism GA 573NH UT WOS:000275920100007 PM 19779211 ER PT J AU Matsumoto, AM AF Matsumoto, Alvin M. TI Testosterone and the Aging Male SO JOURNAL OF ANDROLOGY LA English DT Meeting Abstract CT 35th Annual Meeting of the American-Society-of-Andrology CY APR 10-13, 2010 CL Houston, TX SP Amer Soc Androl C1 [Matsumoto, Alvin M.] Univ Washington, VA Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA 98195 USA. [Matsumoto, Alvin M.] Univ Washington, Dept Med, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC ANDROLOGY, INC PI LAWRENCE PA C/O ALLEN PRESS, INC PO BOX 368, LAWRENCE, KS 66044 USA SN 0196-3635 J9 J ANDROL JI J. Androl. PD MAR-APR PY 2010 SU S BP 26 EP 26 PG 1 WC Andrology SC Endocrinology & Metabolism GA 573NK UT WOS:000275920400018 ER PT J AU Ladenson, PW McCarren, M Morkin, E Edson, RG Shih, MC Warren, SR Barnhill, JG Churby, L Thai, H O'Brien, T Anand, I Warner, A Hattler, B Dunlap, M Erikson, J Goldman, S AF Ladenson, P. W. McCarren, M. Morkin, E. Edson, R. G. Shih, Mei-Chiung Warren, S. R. Barnhill, J. G. Churby, L. Thai, H. O'Brien, T. Anand, I. Warner, A. Hattler, B. Dunlap, M. Erikson, J. Goldman, S. TI Effects of the Thyromimetic Agent Diiodothyropropionic Acid on Body Weight, Body Mass Index, and Serum Lipoproteins: A Pilot Prospective, Randomized, Controlled Study SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID THYROID-HORMONE; HEART-FAILURE; HYPERTHYROIDISM; CHOLESTEROL; HYPOTHYROIDISM AB Context: Widespread thyroid hormone actions offer the possibility of developing selective thyromimetic analogs with salutary metabolic properties. Consequently, effects of diiodothyropropionic acid (DITPA) on body weight, serum lipoproteins, and bone metabolism markers were studied in a prospective, controlled, double-blind 24-wk trial, which was primarily designed to assess treatment of stable chronic heart failure. Design: Eighty-six patients (aged 66 +/- 11 yr, mean +/- SD) were randomized (1: 2) to placebo or an escalating DITPA dose (90 to 180, 270, and 360 mg/d)over 8 wk until serum TSH was less than 0.02 mU/liter. Patients were studied at 2, 4, 6, 8, 16, and 24 wk and after 4 wk off study drug. Only 21 DITPA-treated and 27 placebo patients completed the full 24 wk of therapy. Results: DITPA therapy lowered serum TSH levels and, to a lesser extent, serum T(3) and T(4), but there were no differences in clinical manifestations of thyrotoxicosis or hypothyroidism. Serum total and low density lipoprotein cholesterol levels both decreased on DITPA; there was a transient decrease in triglycerides and no change in high-density lipoprotein cholesterol. DITPA therapy was associated with significant reduction in body weight, 12.5 lb at 24 wk. Increases in serum osteocalcin, N-telopeptide, and deoxypyridinoline levels were consistent with increased bone turnover on DITPA. Conclusion: This investigation of DITPA actions demonstrated its efficacy in reducing body weight and lowering total and low-density lipoprotein cholesterol levels. However, DITPA's adverse effects at doses used resulted in a high dropout rate and potentially dangerous skeletal actions were observed. (J Clin Endocrinol Metab 95: 1349-1354, 2010) C1 [Ladenson, P. W.] Johns Hopkins Med Inst, Baltimore, MD 21287 USA. [McCarren, M.] Hines Vet Affairs Pharm Benefits Management, Hines, IL 60141 USA. [Morkin, E.; Thai, H.; Goldman, S.] Univ Arizona, Hlth Sci Ctr, Phoenix, AZ 85004 USA. [Edson, R. G.; Shih, Mei-Chiung; Churby, L.] Vet Affairs Palo Alto Hlth Care Syst, Vet Affairs Cooperat Studies Program, Coordinating Ctr, Palo Alto, CA 94304 USA. Clin Res Pharm Coordinating Ctr, Vet Affairs Cooperat Studies Program, Albuquerque, NM 87131 USA. [Warren, S. R.; Barnhill, J. G.] Univ New Mexico, Albuquerque, NM 87131 USA. Charleston Vet Affairs Med Ctr, Charleston, SC 29403 USA. [O'Brien, T.] Med Univ S Carolina, Charleston, SC 29403 USA. [Dunlap, M.] Case Western Reserve Univ, Cleveland, OH 44106 USA. Cleveland Vet Affairs Med Ctr, Cleveland, OH 44106 USA. [Hattler, B.] Univ Colorado, Denver, CO 80262 USA. Denver Vet Affairs Med Ctr, Denver, CO 80262 USA. [Anand, I.] Univ Minnesota, Minneapolis, MN 55455 USA. Minneapolis Vet Affairs Med Ctr, Minneapolis, MN 55455 USA. [Erikson, J.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. San Antonio Vet Affairs Med Ctr, San Antonio, TX 78229 USA. [Thai, H.; Goldman, S.] So Arizona Vet Affairs Hlth Care Syst, Tucson, AZ 85723 USA. [Shih, Mei-Chiung] Stanford Univ, Stanford, CA 94305 USA. [Warner, A.] Univ Calif Los Angeles, Los Angeles, CA 90095 USA. Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90095 USA. RP Ladenson, PW (reprint author), Johns Hopkins Univ, Dept Endocrinol & Metab, 1830 E Monument St,Suite 333, Baltimore, MD 21287 USA. EM ladenson@jhmi.edu FU Department of Veterans Affairs Office of Research and Development FX This work was supported by the Cooperative Studies Program of the Department of Veterans Affairs Office of Research and Development. NR 19 TC 27 Z9 29 U1 1 U2 2 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD MAR PY 2010 VL 95 IS 3 BP 1349 EP 1354 DI 10.1210/jc.2009-1209 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 564FA UT WOS:000275197500045 PM 20080837 ER PT J AU Cooperberg, MR Broering, JM Carroll, PR AF Cooperberg, Matthew R. Broering, Jeanette M. Carroll, Peter R. TI Time Trends and Local Variation in Primary Treatment of Localized Prostate Cancer SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; QUALITY-OF-LIFE; UNITED-STATES; RADICAL PROSTATECTOMY; MANAGEMENT; INTERVENTION; THERAPY; CAPSURE; MEN AB Purpose In the absence of high-level evidence or clinical guidelines supporting any given active treatment approach over another for localized prostate cancer, clinician and patient preferences may lead to substantial variation in treatment use. Methods Data were analyzed from 36 clinical sites that contributed data to the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) registry. Distribution of primary treatment use was measured over time. Prostate cancer risk was assessed using the D'Amico risk groups and the Cancer of the Prostate Risk Assessment (CAPRA) score. Descriptive analyses were performed, and a hierarchical model was constructed that controlled for year of diagnosis, cancer risk variables, and other patient factors to estimate the proportion of variation in primary treatment selection explicable by practice site. Results Among 11,892 men analyzed, 6.8% elected surveillance, 49.9% prostatectomy, 11.6% external-beam radiation, 13.3% brachytherapy, 4.0% cryoablation, and 14.4% androgen deprivation monotherapy. Prostate cancer risk drives treatment selection, but the data suggest both overtreatment of low-risk disease and undertreatment of high-risk disease. The former trend appears to be improving over time, while the latter is worsening. Treatment varies with age, comorbidity, and socioeconomic status. However, treatment patterns vary markedly across clinical sites, and this variation is not explained by case-mix variability or known patient factors. Practice site explains a proportion of this variation ranging from 13% for androgen deprivation monotherapy to 74% for cryoablation. Conclusion Substantial variation exists in management of localized prostate cancer that is not explained by measurable factors. A critical need exists for high-quality comparative effectiveness research in localized prostate cancer to help guide treatment decision making. J Clin Oncol 28: 1117-1123. (C) 2010 by American Society of Clinical Oncology C1 [Cooperberg, Matthew R.] Univ Calif San Francisco, Dept Urol, San Francisco, CA 94143 USA. San Francisco VA Med Ctr, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA. RP Cooperberg, MR (reprint author), Univ Calif San Francisco, Dept Urol, Box 1695,1600 Divisadero St,A 607, San Francisco, CA 94143 USA. EM mcooperberg@urology.ucsf.edu RI Cooperberg, Matthew/G-6249-2017 OI Cooperberg, Matthew/0000-0003-4339-6685 FU Department of Urology, University of California, San Francisco; National Institutes of Health/National Cancer Institute, University of California, San Francisco [P50CA89520] FX Support for CaPSURE is provided in part by Abbott Labs, Abbott Park, IL; by the Department of Urology, University of California, San Francisco; and by Special Program of Research Excellence (SPORE) Grant No. P50CA89520 from the National Institutes of Health/National Cancer Institute, University of California, San Francisco. NR 25 TC 461 Z9 472 U1 1 U2 19 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAR 1 PY 2010 VL 28 IS 7 BP 1117 EP 1123 DI 10.1200/JCO.2009.26.0133 PG 7 WC Oncology SC Oncology GA 560HG UT WOS:000274892500009 PM 20124165 ER PT J AU Corrigan, JD Selassie, AW Orman, JA AF Corrigan, John D. Selassie, Anbesaw W. Orman, Jean A. (Langlois) TI The Epidemiology of Traumatic Brain Injury SO JOURNAL OF HEAD TRAUMA REHABILITATION LA English DT Article DE craniocerebral trauma; epidemiology; traumatic brain injury ID TBI IDENTIFICATION METHOD; LONG-TERM DISABILITY; BIRTH COHORT; HEAD-INJURY; UNITED-STATES; PSYCHIATRIC-SYMPTOMS; NORTHERN FINLAND; SUBSTANCE-ABUSE; HOMELESS MEN; YOUNG-ADULTS AB Objective: To describe the most recent estimates of the incidence and prevalence of traumatic brain injury (TBI) and review current issues related to measurement and use of these data. Design: State of the science literature for the United States and abroad was analyzed and issues were identified for (1) incidence of TBI, (2) prevalence of lifetime history of TBI, and (3) incidence and prevalence of disability associated with TBI. Results: The most recent estimates indicate that each year 235 000 Americans are hospitalized for nonfatal TBI, 1.1 million are treated in emergency departments, and 50 000 die. The northern Finland birth cohort found that 3.8% of the population had experienced at least 1 hospitalization due to TBI by 35 years of age. The Christchurch New Zealand birth cohort found that by 25 years of age 31.6% of the population had experienced at least 1 TBI, requiring medical attention (hospitalization, emergency department, or physician office). An estimated 43.3% of Americans have residual disability 1 year after injury. The most recent estimate of the prevalence of US civilian residents living with disability following hospitalization with TBI is 3.2 million. Conclusion: Estimates of the incidence and prevalence of TBI are based on varying sources of data, methods of calculation, and assumptions. Informed users should be cognizant of the limitations of these estimates when determining their applicability. C1 [Corrigan, John D.] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA. [Selassie, Anbesaw W.] Med Univ S Carolina, Dept Biostat Bioinformat & Epidemiol, Charleston, SC 29425 USA. [Orman, Jean A. (Langlois)] Res & Dev Serv, US Dept Vet Affairs, Washington, DC USA. RP Corrigan, JD (reprint author), Ohio State Univ, Dept Phys Med & Rehabil, 480 Med Ctr Dr, Columbus, OH 43210 USA. EM corrigan.1@osu.edu RI Corrigan, John/E-2921-2011 FU Department of Education, National Institute on Disability and Rehabilitation Research [H133A070029] FX The contents of this article were developed under the grant from the Department of Education, National Institute on Disability and Rehabilitation Research (grant H133A070029 [Corrigan]). NR 51 TC 265 Z9 276 U1 6 U2 50 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0885-9701 J9 J HEAD TRAUMA REHAB JI J. Head Trauma Rehabil. PD MAR-APR PY 2010 VL 25 IS 2 BP 72 EP 80 DI 10.1097/HTR.0b013e3181ccc8b4 PG 9 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA 578EJ UT WOS:000276276000002 PM 20234226 ER PT J AU Paredes, R Lalama, CM Ribaudo, HJ Schackman, BR Shikuma, C Giguel, F Meyer, WA Johnson, VA Fiscus, SA D'Aquila, RT Gulick, RM Kuritzkes, DR AF Paredes, Roger Lalama, Christina M. Ribaudo, Heather J. Schackman, Bruce R. Shikuma, Cecilia Giguel, Francoise Meyer, William A., III Johnson, Victoria A. Fiscus, Susan A. D'Aquila, Richard T. Gulick, Roy M. Kuritzkes, Daniel R. CA ACTG TI Pre-existing Minority Drug-Resistant HIV-1 Variants, Adherence, and Risk of Antiretroviral Treatment Failure SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID IMMUNODEFICIENCY-VIRUS TYPE-1; REVERSE-TRANSCRIPTASE INHIBITORS; EFAVIRENZ-CONTAINING REGIMENS; SOCIETY-USA PANEL; VIROLOGICAL FAILURE; 2008 RECOMMENDATIONS; PROTEASE INHIBITORS; INFECTED PATIENTS; RANDOMIZED-TRIAL; CLINICAL-TRIALS AB Background. The clinical relevance of detecting minority drug-resistant human immunodeficiency virus type 1 (HIV-1) variants is uncertain. Methods. To determine the effect of pre-existing minority nonnucleoside reverse-transcriptase inhibitor (NNRTI)-resistant variants on the risk of virologic failure, we reanalyzed a case-cohort substudy of efavirenz recipients in AIDS Clinical Trials Group protocol A5095. Minority K103N or Y181C populations were determined by allele-specific polymerase chain reaction in subjects without NNRTI resistance by population sequencing. Weighted Cox proportional hazards models adjusted for recent treatment adherence estimated the relative risk of virologic failure in the presence of NNRTI-resistant minority variants. Results. The evaluable case-cohort sample included 195 subjects from the randomly selected subcohort (51 with virologic failure, 144 without virologic failure), plus 127 of the remaining subjects who experienced virologic failure. Presence of minority K103N or Y181C mutations, or both, was detected in 8 (4.4%), 54 (29.5%), and 11 (6%), respectively, of 183 evaluable subjects in the random subcohort. Detection of minority Y181C mutants was associated with an increased risk of virologic failure in the setting of recent treatment adherence (hazard ratio, 3.45 [95% confidence interval, 1.90-6.26]) but not in nonadherent subjects (hazard ratio, 1.39 [95% confidence interval, 0.58-3.29]). Of note, 70% of subjects with minority Y181C variants achieved long-term viral suppression. Conclusions. In adherent patients, pre-existing minority Y181C mutants more than tripled the risk of virologic failure of first-line efavirenz-based antiretroviral therapy. C1 [Paredes, Roger; Giguel, Francoise; Kuritzkes, Daniel R.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. [Lalama, Christina M.; Ribaudo, Heather J.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Paredes, Roger] Univ Autonoma Barcelona, Hosp Univ Germans Trias & Pujol, Fdn IrsiCaixa & Lluita SIDA, Badalona, Catalonia, Spain. [Schackman, Bruce R.; Gulick, Roy M.] Cornell Univ, Weill Med Coll, New York, NY 10021 USA. [Shikuma, Cecilia] Univ Hawaii, Honolulu, HI 96822 USA. [Meyer, William A., III] Quest Diagnost, Baltimore, MD USA. [Johnson, Victoria A.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Johnson, Victoria A.] Univ Alabama, Sch Med, Birmingham, AL USA. [Fiscus, Susan A.] Univ N Carolina, Chapel Hill, NC USA. [D'Aquila, Richard T.] Vanderbilt Univ, Nashville, TN USA. RP Kuritzkes, DR (reprint author), Brigham & Womens Hosp, Sect Retroviral Therapeut, 65 Landsdowne St,Rm 449, Cambridge, MA 02139 USA. EM dkuritzkes@partners.org FU NCRR NIH HHS [RR024996, UL1 RR024996, UL1 RR024996-01]; NIAID NIH HHS [P30 AI050410, AI027767, AI051966, AI060354, AI06836, AI068636, AI069419, AI069452, AI069472, AI38858, AI50410, K24 AI051966, K24 AI051966-07, P30 AI027767, P30 AI027767-099003, P30 AI050410-099003, P30 AI060354, P30 AI060354-019003, U01 AI038858, U01 AI038858-05, U01 AI068636, U01 AI068636-04S1, U01 AI069419, U01 AI069419-03, U01 AI069452, U01 AI069452-01, U01 AI069472, U01 AI069472-01, UM1 AI068636, UM1 AI069419, UM1 AI069452, UM1 AI069472] NR 35 TC 114 Z9 115 U1 0 U2 5 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD MAR 1 PY 2010 VL 201 IS 5 BP 662 EP 671 DI 10.1086/650543 PG 10 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 552MW UT WOS:000274296600007 PM 20102271 ER PT J AU Divers, J Sale, MM Lu, LY Chen, WM Lok, KH Spruill, IJ Fernandes, JK Langefeld, CD Garvey, WT AF Divers, Jasmin Sale, Michele M. Lu, Lingyi Chen, Wei-Min Lok, Kerry H. Spruill, Ida J. Fernandes, Jyotika K. Langefeld, Carl D. Garvey, W. Timothy TI The genetic architecture of lipoprotein subclasses in Gullah-speaking African American families enriched for type 2 diabetes: The Sea Islands Genetic African American Registry (Project SuGAR) SO JOURNAL OF LIPID RESEARCH LA English DT Article DE linkage analysis; lipids; lipoproteins; heritability; genetic correlation ID CORONARY-ARTERY-DISEASE; GENOME-WIDE ASSOCIATION; NUCLEAR-MAGNETIC-RESONANCE; TRAIT LINKAGE ANALYSIS; ISCHEMIC-HEART-DISEASE; CARDIOVASCULAR-DISEASE; PARTICLE-SIZE; INSULIN-RESISTANCE; HDL CHOLESTEROL; MYOCARDIAL-INFARCTION AB We sought to partition the genetic and environmental influences on lipoprotein subclasses and identify genomic regions that may harbor genetic variants that influence serum lipoprotein levels in a sample of Gullah-speaking African-Americans. We genotyped 5,974 SNPs in 979 subjects from 418 pedigrees and used the variance component approach to compute heritability estimates, genetic and environmental correlations, and linkage analyses for selected lipoprotein subclasses. The highest heritability estimate was observed for large VLDL particle concentration (0.56 +/- 0.14). Mean LDL particle size and small LDL particle concentration (-0.94) had the strongest genetic correlation estimate. The highest logarithm of odds (LOD) score detected (3.0) was on chromosome 6p24 for small LDL particle concentration. The strongest signal, obtained with the reduced sample of diabetic individuals only, was observed on chromosome 20p13 for small LDL particle concentration. The highest bivariate linkage signal (LOD 2.4) was observed on chromosome 6p24 for mean LDL particle size and small LDL particle concentration.jlr Our results suggest a significant genetic contribution to multiple lipoprotein subclasses studied in this sample and that novel loci on chromosomes 6, 10, 16, and 20 may harbor genes contributing to small, atherogenic LDL particle concentration and large, triglyceride-rich VLDL particle concentration.-Divers, J., M. M. Sale, L. Lu, W-M. Chen, K. H. Lok, I. J. Spruill, J. K. Fernandes, C. D. Langefeld, and W. T. Garvey. The genetic architecture of lipoprotein subclasses in Gullah-speaking African American families enriched for type 2 diabetes: The Sea Islands Genetic African American Registry (Project SuGAR). J. Lipid Res. 2010. 51: 586-597. C1 [Divers, Jasmin; Lu, Lingyi; Langefeld, Carl D.] Wake Forest Univ, Bowman Gray Sch Med, Dept Biostat Sci, Winston Salem, NC 27106 USA. [Divers, Jasmin; Langefeld, Carl D.] Wake Forest Univ, Bowman Gray Sch Med, Ctr Publ Hlth Genom, Winston Salem, NC USA. [Sale, Michele M.; Chen, Wei-Min] Univ Virginia, Ctr Publ Hlth Genom, Charlottesville, VA USA. [Sale, Michele M.] Univ Virginia, Dept Med, Charlottesville, VA USA. [Sale, Michele M.] Univ Virginia, Dept Biochem & Mol Genet, Charlottesville, VA USA. [Chen, Wei-Min] Univ Virginia, Dept Publ Hlth Sci, Charlottesville, VA USA. [Lok, Kerry H.; Garvey, W. Timothy] Univ Alabama, Dept Nutr Sci, Birmingham, AL 35294 USA. [Spruill, Ida J.; Fernandes, Jyotika K.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Garvey, W. Timothy] Birmingham VA Med Ctr, Birmingham, AL USA. RP Divers, J (reprint author), Wake Forest Univ, Bowman Gray Sch Med, Dept Biostat Sci, Winston Salem, NC 27106 USA. EM jdivers@wfubmc.edu FU W.M. Keck Foundation, Los Angeles; General Clinical Research Center at the Medical University of South Carolina [M01 RR-1070]; UAB [P30 DK-56336, P60 DK079626]; Wake Forest Health Sciences Center for Public Health Genomics; National Institutes of Health [DK47461, DK038765, DK66358, N01-HG-65403]; South Carolina Center of Biomedical Excellence (CO-BRE) for Oral Health [P20 RR17696]; American Diabetes Association FX Project SuGAR could not have been accomplished without a grant from the W.M. Keck Foundation, Los Angeles CA. We acknowledge the support of the General Clinical Research Center at the Medical University of South Carolina (M01 RR-1070), the Genetics Core Facility of the UAB Clinical Nutrition Research Unit (P30 DK-56336), and the UAB Diabetes Research and Training Center (P60 DK079626). The work was supported by the Wake Forest Health Sciences Center for Public Health Genomics (J.D. and C.D.L), research grants from the National Institutes of Health including DK47461 and DK038765 (W.T.G.), DK66358 (M.M.S.), the South Carolina Center of Biomedical Excellence (CO-BRE) for Oral Health P20 RR17696, and from the American Diabetes Association in the form of a GENNID Study Center grant (W.T.G.) and Career Development Award (M.M.S.). Center for Inherited Disease Research is funded through a federal contract from the National Institutes of Health to Johns Hopkins University, contract number N01-HG-65403. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health or other granting agencies. NR 79 TC 3 Z9 3 U1 1 U2 3 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0022-2275 J9 J LIPID RES JI J. Lipid Res. PD MAR PY 2010 VL 51 IS 3 BP 586 EP 597 DI 10.1194/jlr.M001842 PG 12 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 555LW UT WOS:000274513300015 PM 19783527 ER PT J AU McCurdy, S Baicu, CF Heymans, S Bradshaw, AD AF McCurdy, Sarah Baicu, Catalin F. Heymans, Stephane Bradshaw, Amy D. TI Cardiac extracellular matrix remodeling: Fibrillar collagens and Secreted Protein Acidic and Rich in Cysteine (SPARC) SO JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY LA English DT Review DE BM-40; Osteonectin; SPARC; Extracellular matrix; Remodeling; Review ID DIASTOLIC HEART-FAILURE; MYOCARDIAL-INFARCTION; PRESSURE-OVERLOAD; GENE-EXPRESSION; MATRICELLULAR PROTEINS; PULMONARY-FIBROSIS; LEFT-VENTRICLE; NULL MOUSE; RAT-HEART; HYPERTROPHY AB The cardiac interstitium is a unique and adaptable extracellular matrix (ECM) that provides a milieu in which myocytes, fibroblasts, and endothelial cells communicate and function. The composition of the ECM in the heart includes structural proteins such as fibrillar collagens and matricellular proteins that modulate cell: ECM interaction. Secreted Protein Acidic and Rich in Cysteine (SPARC), a collagen-binding matricellular protein, serves a key role in collagen assembly into the ECM. Recent results demonstrated increased cardiac rupture, dysfunction and mortality in SPARC-null mice in response to myocardial infarction that was associated with a decreased capacity to generate organized, mature collagen fibers. In response to pressure overload induced-hypertrophy, the decrease in insoluble collagen incorporation in the left ventricle of SPARC-null hearts was coincident with diminished ventricular stiffness in comparison to WT mice with pressure overload. This review will focus on the role of SPARC in the regulation of interstitial collagen during cardiac remodeling following myocardial infarction and pressure overload with a discussion of potential cellular mechanisms that control SPARC-dependent collagen assembly in the heart. (C) 2009 Elsevier Ltd. All rights reserved. C1 [McCurdy, Sarah] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Cardiol, San Antonio, TX 78229 USA. [Heymans, Stephane] Univ Maastricht, Heart Failure Res Ctr, Cardiovasc Res Inst Maastricht, Maastricht, Netherlands. [Baicu, Catalin F.; Bradshaw, Amy D.] Ralph H Johnson Vet Adm, Charleston, SC USA. [Bradshaw, Amy D.] Med Univ S Carolina, Gazes Cardiac Res Inst, Div Cardiol, Dept Med, Charleston, SC 29425 USA. RP Bradshaw, AD (reprint author), Med Univ S Carolina, Gazes Cardiac Res Inst, Div Cardiol, Dept Med, 114 Doughty St, Charleston, SC 29425 USA. EM bradshad@musc.edu FU American Physiological Society (SM); Netherlands Heart Foundation [200513082, 200713036, 200813011]; European Union [EST 2005-020706-2]; Dutch Scientific Organisation (NWO); Veteran's Administration; NIDCR, NIH [P20RR017696] FX This work was supported by an Undergraduate Student Summer Research Fellowship from the American Physiological Society (SM), Netherlands Heart Foundation (200513082, 200713036, 200813011), Ingenious Hypercare NoE from the European Union (EST 2005-020706-2), a VIDI grant of the Dutch Scientific Organisation (NWO) to (SH), and a Merit Award from the Veteran's Administration (ADB), and P20RR017696 from the NIDCR, NIH (CFB, ADB). NR 51 TC 44 Z9 48 U1 0 U2 7 PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 0022-2828 EI 1095-8584 J9 J MOL CELL CARDIOL JI J. Mol. Cell. Cardiol. PD MAR PY 2010 VL 48 IS 3 SI SI BP 544 EP 549 DI 10.1016/j.yjmcc.2009.06.018 PG 6 WC Cardiac & Cardiovascular Systems; Cell Biology SC Cardiovascular System & Cardiology; Cell Biology GA 560SI UT WOS:000274922300018 PM 19577572 ER PT J AU Alici, Y Smith, D Lu, HL Bailey, A Shreve, S Rosenfeld, K Ritchie, C Casarett, DJ AF Alici, Yesne Smith, Dawn Lu, Hien L. Bailey, Amos Shreve, Scott Rosenfeld, Kenneth Ritchie, Christine Casarett, David J. TI Families' Perceptions of Veterans' Distress Due to Post-Traumatic Stress Disorder-Related Symptoms at the End of Life SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Article DE End of life; post-traumatic stress disorder; families' perceptions of the quality of care ID PRIMARY-CARE; VIETNAM VETERANS; NATIONAL SAMPLE; QUALITY MEASURE; PREVALENCE; CANCER; PTSD; SETTINGS; DELIRIUM AB Objectives. To define the frequency of post-traumatic stress disorder (PTSD)related symptoms among veterans who are near the end of life and to describe the impact that these symptoms have on patients and their families. Methods. Patients had received inpatient or outpatient care from a participating VA facility in the last month of life, and one family member per patient was selected using predefined eligibility criteria. Family members then completed a telephone survey, The Family Assessment of Treatment at End-of-Life, which assessed their perceptions of the quality of the care that the patients and they themselves received during the patients' last month of life. Results. Seventeen percent of padents (89 of 524) were reported to have had PTSD-related symptoms in the last month of life. PTSD-related symptoms caused discomfort less often than pain did (mean frequency score 1.79 vs. 1.93; Wilcoxon sign rank test, P < 0.001) but more often than dyspnea did (mean severity score 1.79 vs. 1.73; Wilcoxon sign rank test, P < 0.001). Family members of patients with PTSD-related symptoms reported less satisfaction overall with the care the patient received (mean score 48 vs. 62; rank sum test, P < 0.001). Patients who received a palliative care consult (n = 49) had lower ratings of discomfort attributed to PTSD-related symptoms (mean 1.55 vs. 2.07; rank sum test, P = 0.007). Conclusion. PTSD-related symptoms may be common and severe among veterans near the end of life and may have a negative effect on families' perceptions of the quality of care that the veteran received. J Pain Symptom Manage 2010;39:507-514. (C) 2010 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved. C1 [Alici, Yesne] Cent Reg Hosp, Geriatr Serv Unit, Butner, NC 27509 USA. [Smith, Dawn; Casarett, David J.] Philadelphia VA Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Lu, Hien L.; Casarett, David J.] Univ Penn, Div Geriatr Med, Philadelphia, PA 19104 USA. [Bailey, Amos; Ritchie, Christine] Birmingham VA Med Ctr, Birmingham, AL USA. [Shreve, Scott] Lebanon VA Med Ctr, Lebanon, PA USA. [Rosenfeld, Kenneth] VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. RP Alici, Y (reprint author), Cent Reg Hosp, Geriatr Serv Unit, Butner, NC 27509 USA. EM yesne.alici@dhhs.nc.gov FU Department of Veterans Affairs; Presidential Early Career Award for Scientists and Engineers FX This work was supported by a Health Services Research and Development Merit Award from the Department of Veterans Affairs (Dr Casarett) and by a Presidential Early Career Award for Scientists and Engineers (Dr. Casarett). The views expressed here are those of the authors and do not necessarily reflect those of the Department of Veterans Affairs or the Department of Health and Human Services. NR 38 TC 6 Z9 6 U1 3 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD MAR PY 2010 VL 39 IS 3 BP 507 EP 514 DI 10.1016/j.jpainsymman.2009.07.011 PG 8 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 582EI UT WOS:000276578500004 PM 20083372 ER PT J AU Bekelman, DB Parry, C Curlin, FA Yamashita, TE Fairclough, DL Wamboldt, FS AF Bekelman, David B. Parry, Carla Curlin, Farr A. Yamashita, Traci E. Fairclough, Diane L. Wamboldt, Frederick S. TI A Comparison of Two Spirituality Instruments and Their Relationship With Depression and Quality of Life in Chronic Heart Failure SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Article DE Spirituality; quality of life; depression; questionnaires; measurement; heart failure ID COMPLICATED GRIEF; HEALTH-STATUS; RELIGIOUS SERVICES; TERMINALLY-ILL; MORTALITY; DISTINCT; ATTENDANCE; SYMPTOMS; SCALE; QUESTIONNAIRE AB Spirituality is a multifaceted construct related to health outcomes that remains ill defined and difficult to measure. Spirituality in patients with advanced chronic illnesses, such Os chronic heart failure, has received limited attention. We compared two widely used spirituality instruments, the Functional Assessment of Chronic Illness Therapy Spiritual Well-Being (FACIT-Sp) and the Ironson-Woods Spirituality/Religiousness Index (IW), to better understand what duo) measure in 60 outpatients with chronic heart failure. We examined lion) these instruments related to each other and to measures of depression and quality of life using correlations and principal component analyses. The FACIT-Sp measured aspects of spirituality related to feelings of peace and coping, whereas the IW measured beliefs, coping, and relational aspects of spirituality. Only the FACIT-Sp Meaning/Peace subscale consistently correlated with depression (r = -0.50, P < 0.0001) and quality of life (r 0.41, P = 0.001). Three items from the depression measure loaded onto the same factor as the FACIT-Sp Meaning/Peace subscale (r = 0.43, -0.43, and 0.71), whereas the remaining 12 items formed a separate factor (Cronbach's alpha = 0.82) when combined with the spirituality instruments in a principal component analysis. The results demonstrate several clinically useful constructs of spirituality in patients with heart failure and suggest that psychological and spiritual well-being, despite some overlap, remain distinct phenomena. J Pain Symptom Manage 2010;39:515-526. (C) 2010 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved. C1 [Bekelman, David B.] Denver VA Med Ctr, Denver, CO 80220 USA. [Curlin, Farr A.] Univ Chicago, MacLean Ctr Clin Med Eth, Gen Internal Med Sect, Chicago, IL 60637 USA. [Fairclough, Diane L.] Colorado Sch Publ Hlth, Dept Biostat & Informat, Aurora, CO USA. [Bekelman, David B.; Wamboldt, Frederick S.] Natl Jewish Hlth, Div Psychosocial Med, Denver, CO USA. [Bekelman, David B.; Yamashita, Traci E.] Univ Colorado Denver, Sch Med, Div Gen Internal Med, Aurora, CO USA. [Parry, Carla] Univ Colorado Denver, Sch Med, Div Hlth Care Policy & Res, Aurora, CO USA. [Fairclough, Diane L.] Univ Colorado Denver, Sch Med, Colorado Hlth Outcomes Program, Aurora, CO USA. [Wamboldt, Frederick S.] Univ Colorado Denver, Sch Med, Dept Psychiat, Aurora, CO USA. RP Bekelman, DB (reprint author), Denver VA Med Ctr, Res 151,1055 Clermont St, Denver, CO 80220 USA. EM david.bekelman@ucdenver.edu FU Johns Hopkins Center for Complementary and Alternative Medicine; National Center for Complementary and Alternative Medicine, National Institutes of Health; University of Colorado Denver Hartford/Jahnigen Center of Excellence in Geriatric Medicine FX This study was funded by the Johns Hopkins Center for Complementary and Alternative Medicine; the National Center for Complementary and Alternative Medicine, National Institutes of Health; and the University of Colorado Denver Hartford/Jahnigen Center of Excellence in Geriatric Medicine. The views in this article are those of the authors and do not necessarily reflect the views of the Department of Veterans Affairs. NR 36 TC 16 Z9 18 U1 1 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD MAR PY 2010 VL 39 IS 3 BP 515 EP 526 DI 10.1016/j.jpainsymman.2009.08.005 PG 12 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 582EI UT WOS:000276578500005 PM 20303028 ER PT J AU Wagner, GJ Riopelle, D Steckart, J Lorenz, KA Rosenfeld, KE AF Wagner, Glenn J. Riopelle, Deborah Steckart, Jillisa Lorenz, Karl A. Rosenfeld, Kenneth E. TI Provider Communication and Patient Understanding of Life-Limiting Illness and Their Relationship to Patient Communication of Treatment Preferences SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Article DE Physician-patient communication; prognosis; advance care planning; patient autonomy; medical decision making ID SERIOUSLY ILL PATIENTS; DECISION-MAKING; ADVANCE DIRECTIVES; CANCER-PATIENTS; HOSPITALIZED-PATIENTS; STATUS QUESTIONNAIRE; CONTROLLED TRIAL; MEDICAL-CARE; LUNG-CANCER; END AB Medical decision making in the context of serious illness ideally involves a patient who understands his or her condition and prognosis and can effectively formulate and communicate his or her care preferences. To understand the relationships among these care processes, we analyzed baseline into-view data from veterans enrolled in a randomized controlled trial of a palliative care intervention. Participants were 400 inpatient veterans admitted with a physician-estimated risk of one-year mortality more than, 25 %; 260 (65 %) had cancer as the primary diagnosis. Patients who believed that they had a illness (89% sample) reported that their provider had communicated this to them more frequently than those who did not share that belief (78% vs. 22%, P < 0.001). Over half (53%) of the participants reported discussing their cam preferences with their providers and 66% reported such discussions with their family; 35% had a living will. In multivariate analysis, greater functional impairment was associated with patients having discussed their care preferences with providers (P < 0.05), whereas patient understanding of prognosis (P < 0.05), better quality of life (P < 0.01), and not being African American (P < 0.05) were associated with patients having discussed their care preferences with family higher education (P < 0.001), and not being African American (P < 0.01) were associated with having a living will. Patients with poor understanding of prognosis are less likely to discuss care preferences with family members, suggesting the importance of provider communication with patients regarding prognosis. Because functional decline may prompt physicians to discuss prognosis with patients, patients with relatively preserved function may particularly need such communication. J Pain Symptom Manage 2010;39:527-534. (C) 2010 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved. C1 [Wagner, Glenn J.] RAND Corp, Santa Monica, CA 90407 USA. [Riopelle, Deborah; Steckart, Jillisa; Lorenz, Karl A.; Rosenfeld, Kenneth E.] Vet Adm Greater Los Angeles Healthcare Ctr, Los Angeles, CA USA. RP Wagner, GJ (reprint author), RAND Corp, 1776 Main St, Santa Monica, CA 90407 USA. EM gwagner@rand.org FU VA Center for the Study of Healthcare Provider Behavior; VA HSRD [IIR 02-294] FX Support for this study was provided by the VA Center for the Study of Healthcare Provider Behavior, and funding was provided by VA HSR&D grant IIR 02-294 (Principal Investigator, Dr. Rosenfeld). NR 38 TC 18 Z9 20 U1 4 U2 15 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD MAR PY 2010 VL 39 IS 3 BP 527 EP 534 DI 10.1016/j.jpainsymman.2009.07.012 PG 8 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 582EI UT WOS:000276578500006 PM 20171827 ER PT J AU Casarett, D Pickard, A Fishman, JM Alexander, SC Arnold, RM Pollak, KI Tulsky, JA AF Casarett, David Pickard, Amy Fishman, Jessica M. Alexander, Stewart C. Arnold, Robert M. Pollak, Kathryn I. Tulsky, James A. TI Can Metaphors and Analogies Improve Communication with Seriously Ill Patients? SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID OF-LIFE CARE; CONTROLLED-TRIAL; PULMONARY-DISEASE; ADVANCED CANCER; FAMILY-MEMBERS; END; CONSULTATION; DISCUSSIONS; EFFICACY; MEDICINE AB Objective: It is not known how often physicians use metaphors and analogies, or whether they improve patients' perceptions of their physicians' ability to communicate effectively. Therefore, the objective of this study was to determine whether the use of metaphors and analogies in difficult conversations is associated with better patient ratings of their physicians' communication skills. Design: Cross-sectional observational study of audio-recorded conversations between patients and physicians. Setting: Three outpatient oncology practices. Patients: Ninety-four patients with advanced cancer and 52 physicians. Intervention: None. Main outcome measures: Conversations were reviewed and coded for the presence of metaphors and analogies. Patients also completed a 6-item rating of their physician's ability to communicate. Results: In a sample of 101 conversations, coders identified 193 metaphors and 75 analogies. Metaphors appeared in approximately twice as many conversations as analogies did (65/101, 64% versus 31/101, 31%; sign test p<0.001). Conversations also contained more metaphors than analogies (mean 1.6, range 0-11 versus mean 0.6, range 0-5; sign rank test p<0.001). Physicians who used more metaphors elicited better patient ratings of communication (rho = 0.27; p = 0.006), as did physicians who used more analogies (Spearman rho = 0.34; p<0.001). Conclusions: The use of metaphors and analogies may enhance physicians' ability to communicate. C1 [Casarett, David] Univ Penn, Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA 19104 USA. [Pickard, Amy] Univ Penn, Div Geriatr Med, Philadelphia, PA 19104 USA. [Fishman, Jessica M.] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Tulsky, James A.] Duke Univ, Med Ctr, Ctr Palliat Care, Durham, NC USA. [Arnold, Robert M.] Univ Pittsburgh, Sch Med, Sect Palliat Care & Med Eth, Pittsburgh, PA USA. [Pollak, Kathryn I.] Duke Univ, Med Ctr, Duke Comprehens Canc Ctr, Duke Dept Family & Community Med, Durham, NC 27710 USA. [Tulsky, James A.] Durham Vet Affairs Med Ctr, Ctr Hlth Serv Res Primary Care, Durham, NC USA. RP Casarett, D (reprint author), 3615 Chestnut St, Philadelphia, PA 19104 USA. EM Casarett@mail.med.upenn.edu FU Greenwall Foundation; National Cancer Institute [R01-CA100387-01] FX This work was funded by grants from the Greenwall Foundation (Casarett) and from the National Cancer Institute (R01-CA100387-01) (Tulsky). NR 30 TC 25 Z9 25 U1 2 U2 13 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 J9 J PALLIAT MED JI J. Palliat. Med. PD MAR PY 2010 VL 13 IS 3 BP 255 EP 260 DI 10.1089/jpm.2009.0221 PG 6 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 559SH UT WOS:000274846700008 PM 19922170 ER PT J AU Durazzo, TC Pathak, V Gazdzinski, S Mon, A Meyerhoff, DJ AF Durazzo, Timothy C. Pathak, Varsha Gazdzinski, Stefan Mon, Anderson Meyerhoff, Dieter J. TI Metabolite Levels in the Brain Reward Pathway Discriminate Those Who Remain Abstinent From Those Who Resume Hazardous Alcohol Consumption After Treatment for Alcohol Dependence SO JOURNAL OF STUDIES ON ALCOHOL AND DRUGS LA English DT Article ID MAGNETIC-RESONANCE SPECTROSCOPY; FRONTAL-SUBCORTICAL CIRCUITS; DSM-IV ALCOHOL; NATIONAL EPIDEMIOLOGIC SURVEY; PROTON MR SPECTROSCOPY; USE DISORDERS; UNITED-STATES; POSTTREATMENT ALCOHOLICS; CIGARETTE-SMOKING; FAMILY-HISTORY AB Objective: This study compared baseline metabolite levels in components of the brain reward system among individuals who remained abstinent and those who resumed hazardous alcohol consumption after treatment for alcohol dependence. Method: Fifty-one treatment-seeking alcohol-dependent individuals (abstinent for approximately 7 days [SD = 3]) and 26 light-drinking nonsmoking controls completed 1.5-T proton magnetic resonance spectroscopic imaging, yielding regional concentrations of N-acetylaspartate, choline-containing compounds, creatinc-containing compounds, and myoinositol. Metabolite levels were obtained in the following component of the brain reward system: dorsolateral prefrontal cortex, anterior cingulate cortex, insula, superior corona radiata, and cerebellar vermis. Alcohol-dependent participants were followed over a 12-month period after baseline study (i.e., at 7 days of abstinence [SD = 3]) and were classified as abstainers (no alcohol consumption; n = 18) and resumers (any alcohol consumption; n = 33) at follow-up. Baseline metabolite levels in abstainers and resumers and light-drinking nonsmoking controls were compared in the above regions of interest. Results: Resumers demonstrated significantly lower baseline N-acetylaspartate concentrations than light-drinking nonsmoking controls and abstainers in all regions of interest. Resumers also exhibited lower creatine-containing-compound concentrations than abstainers in the dorsolateral prefrontal cortex, superior corona radiata, and cerebellar vermis. Abstainers did not differ from light-drinking nonsmoking controls on baseline metabolite concentrations in any region of interest. Conclusions: The significantly decreased N-acetylaspartate and creatine-containing-compound concentrations in resumers suggest compromised neuronal integrity and abnormalities in cellular bioenergetics in major neocortical components and white-matter interconnectivity of the brain reward pathway. The lack of metabolite differences between abstainers and light-drinking nonsmoking controls suggests premorbid factors potentially contributed to the baseline brain metabolite abnormalities observed in resumers. (J Stud. Alcohol Drugs, 71, 278-289, 2010) C1 [Durazzo, Timothy C.; Pathak, Varsha; Mon, Anderson; Meyerhoff, Dieter J.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA. [Durazzo, Timothy C.; Pathak, Varsha; Gazdzinski, Stefan; Mon, Anderson; Meyerhoff, Dieter J.] San Francisco Vet Adm Med Ctr, Ctr Imaging Neurodegenerat Dis 114M, San Francisco, CA 94121 USA. RP Durazzo, TC (reprint author), San Francisco Vet Adm Med Ctr, Ctr Imaging Neurodegenerat Dis 114M, 4150 Clement St, San Francisco, CA 94121 USA. EM timothy.durazzo@ucsf.edu FU National Institute on Alcohol Abuse and Alcoholism [AA10788]; National Institute on Drug Abuse [DA24136] FX This research was supported by National Institute on Alcohol Abuse and Alcoholism grant AA10788 awarded to Dieter J. Meyerhoff and National Institute on Drug Abuse grant DA24136 awarded to Timothy C. Durazzo, and with resources and the use of facilities at the San Francisco Veterans Administration Medical Center, San Francisco, CA. NR 87 TC 19 Z9 21 U1 2 U2 4 PU ALCOHOL RES DOCUMENTATION INC CENT ALCOHOL STUD RUTGERS UNIV PI PISCATAWAY PA C/O DEIRDRE ENGLISH, 607 ALLISON RD, PISCATAWAY, NJ 08854-8001 USA SN 1937-1888 J9 J STUD ALCOHOL DRUGS JI J. Stud. Alcohol Drugs PD MAR PY 2010 VL 71 IS 2 BP 278 EP 289 PG 12 WC Substance Abuse; Psychology SC Substance Abuse; Psychology GA 578FJ UT WOS:000276278700015 PM 20230726 ER PT J AU Yueh, B Collins, MP Souza, PE Boyko, EJ Loovis, CF Heagerty, PJ Liu, CF Hedrick, SC AF Yueh, Bevan Collins, Margaret P. Souza, Pamela E. Boyko, Edward J. Loovis, Carl F. Heagerty, Patrick J. Liu, Chuan-Fen Hedrick, Susan C. TI Long-Term Effectiveness of Screening for Hearing Loss: The Screening for Auditory Impairment-Which Hearing Assessment Test (SAI-WHAT) Randomized Trial SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE screening; hearing loss; hearing aids; randomized clinical trial ID QUALITY-OF-LIFE; ELDERLY PEOPLE; OLDER-ADULTS; PRIMARY-CARE; TASK-FORCE; HEALTH; AMPLIFICATION; VALIDATION; HANDICAP; AIDS AB OBJECTIVES To evaluate the effect of hearing screening on long-term hearing outcomes in a general population of older veterans. DESIGN Hearing loss in the elderly is underdetected and undertreated. Routine hearing screening has been proposed, but it is not clear whether screening identifies patients who are sufficiently motivated to adhere to treatment. A four-arm randomized clinical trial was conducted to compare three screening strategies with no screening in 2,305 older veterans seeking general medical care. SETTING Veterans Affairs Puget Sound Health Care System. INTERVENTIONS The screening strategies were a tone-emitting otoscope, a widely used questionnaire about hearing handicap, and a combination of both tools. MEASUREMENTS Hearing aid use 1 year after screening. RESULTS Of participants who underwent screening with the tone-emitting otoscope, questionnaire, and combined testing, 18.6%, 59.2%, and 63.6%, respectively, screened positive for hearing loss (P <.01 for test of equality across three arms). Patients proceeded to formal audiology evaluation 14.7%, 23.0%, and 26.6% of the time in the same screening arms, compared with 10.8% in the control arm (P <.01 for test of equality across four arms). Hearing aid use 1 year after screening was 6.3%, 4.1%, and 7.4% in the same arms, compared with 3.3% in the control arm (P <.01). Hearing aid users experienced significant improvements in hearing-related function and communication ability. CONCLUSION In older veterans, screening for hearing loss led to significantly more hearing aid use. Screening with the tone-emitting otoscope was more efficient. The results are most applicable to older populations with few cost barriers to hearing aids. C1 [Yueh, Bevan] Univ Minnesota, Dept Otolaryngol Head & Neck Surg, Minneapolis, MN 55455 USA. [Collins, Margaret P.; Boyko, Edward J.] Hlth Serv Res, Seattle, WA USA. [Collins, Margaret P.; Boyko, Edward J.] Dev Serv, Seattle, WA USA. [Collins, Margaret P.; Loovis, Carl F.] Rehabil Care Serv, Seattle, WA USA. [Boyko, Edward J.; Heagerty, Patrick J.] Vet Affairs Puget Sound Hlth Care Syst, Epidemiol Res & Informat Ctr, Seattle, WA USA. [Souza, Pamela E.] Univ Washington, Dept Speech & Hearing Sci, Seattle, WA 98195 USA. [Boyko, Edward J.] Univ Washington, Dept Internal Med, Seattle, WA 98195 USA. [Heagerty, Patrick J.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. RP Yueh, B (reprint author), Univ Minnesota, Dept Otolaryngol Head & Neck Surg, MMC396,420 Delaware St SE, Minneapolis, MN 55455 USA. EM byueh@umn.edu OI Yueh, Bevan/0000-0003-1380-1053; Boyko, Edward/0000-0002-3695-192X FU Health Services Research and Development Service of the Veterans Health Administration [99-377]; Department of Veterans Affairs; Veterans Health Administration; Health Services Research and Development Service [CD-98318] FX This work was supported by a grant from the Health Services Research and Development Service of the Veterans Health Administration (IIR 99-377). Dr. Yueh was also supported by a career development award from the Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service (CD-98318). The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. NR 46 TC 36 Z9 37 U1 1 U2 8 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAR PY 2010 VL 58 IS 3 BP 427 EP 434 DI 10.1111/j.1532-5415.2010.02738.x PG 8 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 568JS UT WOS:000275519200002 PM 20398111 ER PT J AU Pugh, MJV VanCott, AC Steinman, MA Mortensen, EM Amuan, ME Wang, CP Knoefe, JE Berlowitz, DR AF Pugh, Mary Jo V. VanCott, Anne C. Steinman, Michael A. Mortensen, Eric M. Amuan, Megan E. Wang, Chen-Pin Knoefe, Janice E. Berlowitz, Dan R. TI Choice of Initial Antiepileptic Drug for Older Veterans: Possible Pharmacokinetic Drug Interactions with Existing Medications SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE drug-drug interaction; epilepsy; geriatrics; antiepileptic drugs ID ONSET GERIATRIC EPILEPSY; ELDERLY VETERANS; ALZHEIMERS-DISEASE; SEIZURE DISORDERS; INAPPROPRIATE; CARBAMAZEPINE; POPULATION; PHENYTOIN; STROKE; HYPERTENSION AB OBJECTIVES To identify clinically meaningful potential drug-drug interactions (PDIs) with antiepileptic drugs (AEDs), the AEDs and co-administered drugs commonly associated with AED-PDIs, and characteristics of patients with high likelihood of AED-PDI exposure. DESIGN Five-year retrospective cohort study of veterans with new-onset epilepsy. SETTING National Veterans Affairs and Medicare databases. PARTICIPANTS Veterans aged 66 and older with a new diagnosis of epilepsy between October 1, 1999, and September 30, 2004 (N=9,682). MEASUREMENTS AED-PDI was restricted to clinically meaningful PDIs identified using prior literature review. AED-PDIs were identified using participants' date of initial AED prescription and overlapping concomitant medications. Logistic regression analysis identified factors associated with AED-PDI, including demographic characteristics, chronic disease states, and diagnostic setting. RESULTS AED-PDI exposure was found in 45.5% (4,406/9,682); phenytoin, a drug with many PDIs, was the most commonly prescribed AED. Cardiovascular drugs, lipid-lowering medications, and psychotropic agents were the most commonly co-administered AED-PDI medications. Individuals with AED-PDI exposure were more likely to have hypertension (odds ratio (OR)=1.46, 99% confidence interval (CI)=1.24-1.82) and hypercholesterolemia (OR=1.40, 99% CI=1.24-1.57) than those without and to be diagnosed in an emergency or primary care setting than a neurology setting (emergency: OR=1.30, 99% CI=1.08-1.58; primary care: OR=1.29 99% CI=1.12-1.49). CONCLUSION Exposure to AED-PDI was substantial but less common in patients with epilepsy diagnosed in a neurology setting. Because potential outcomes associated with AED-PDI include stroke and myocardial infarction in a population already at high risk, clinicians should closely monitor blood pressure, coagulation, and lipid measures to minimize adverse effects of AED-PDIs. Interventions to reduce AED-PDIs may improve patient outcomes. C1 [Pugh, Mary Jo V.; Mortensen, Eric M.; Wang, Chen-Pin] S Texas Hlth Care Syst, VERDICT REAP, San Antonio, TX 78229 USA. [Pugh, Mary Jo V.; Wang, Chen-Pin] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA. [Mortensen, Eric M.] Univ Texas Hlth Sci Ctr San Antonio, Div Gen Internal Med, Dept Med, San Antonio, TX 78229 USA. [VanCott, Anne C.] Vet Affairs Pittsburgh Healthcare Syst, Div Neurol, Pittsburgh, PA USA. [VanCott, Anne C.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA. [Steinman, Michael A.] San Francisco VA Med Ctr, San Francisco, CA USA. [Steinman, Michael A.; Knoefe, Janice E.] Univ Calif San Francisco, Dept Geriatr, San Francisco, CA 94143 USA. [Amuan, Megan E.; Berlowitz, Dan R.] Bedford Vet Affairs Hosp, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA. [Knoefe, Janice E.] New Mexico Vet Healthcare Syst, Geriatr Extended Care Sect, Albuquerque, NM USA. [Knoefe, Janice E.] Univ New Mexico, Dept Med, Div Gerontol, Albuquerque, NM 87131 USA. Univ New Mexico, Dept Neurol, Albuquerque, NM 87131 USA. [Berlowitz, Dan R.] Boston Univ, Sch Publ Hlth, Boston, MA USA. RP Pugh, MJV (reprint author), S Texas Hlth Care Syst, Audie L Murphy Div VERDICT 11C6, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM pughm@uthscsa.edu OI Pugh, Mary Jo/0000-0003-4196-7763; Mortensen, Eric/0000-0002-3880-5563 FU Department of Veterans Affairs, Health Services Research and Development Service [IIR-02-274]; Epilepsy Foundation; VA Health Services Research and Development Service (HSRD) [MRP-05-145]; VA HSR& D Career Development Transition Award [01-013]; National Institute on Aging Paul Beeson Career Development Award [1K23AG030999]; South Texas Veterans Healthcare System/Audie L. Murphy Division; VERDICT research program FX This study was funded by the Department of Veterans Affairs, Health Services Research and Development Service (IIR-02-274, Dr. Pugh PI) and the Epilepsy Foundation (Dr. Pugh PI). Dr. Copeland received funding from VA Health Services Research and Development Service (HSR&D) Merit Review Entry Program Award (MRP-05-145). Dr. Steinman was supported by a VA HSR& D Career Development Transition Award (01-013) and a National Institute on Aging Paul Beeson Career Development Award (1K23AG030999). The authors also acknowledge and appreciate support from the South Texas Veterans Healthcare System/Audie L. Murphy Division and the VERDICT research program. The views expressed in this article are those of the authors and do not necessarily represent the views of the VA. We also acknowledge contributions of other members of the TIGER research team: Joyce Cramer BA, Jeffrey Tabares BA, Francesca Cunningham PharmD, Omotola Hope MD, Nancy Kressin PhD, Barbara Bokhour PhD, Mark Glickman, PhD, Richard Lewis, MSA. NR 39 TC 16 Z9 16 U1 1 U2 1 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAR PY 2010 VL 58 IS 3 BP 465 EP 471 DI 10.1111/j.1532-5415.2010.02732.x PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 568JS UT WOS:000275519200007 PM 20398114 ER PT J AU Covinsky, KE Yaffe, K Lindquist, K Cherkasova, E Yelin, E Blazer, DG AF Covinsky, Kenneth E. Yaffe, Kristine Lindquist, Karla Cherkasova, Elena Yelin, Edward Blazer, Dan G. TI Depressive Symptoms in Middle Age and the Development of Later-Life Functional Limitations: The Long-Term Effect of Depressive Symptoms SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE depression; functional status; outcomes; aging; disability ID LIVING OLDER PERSONS; PHYSICAL-DISABILITY; MENTAL-DISORDERS; PROGNOSTIC INDEX; FUTURE-RESEARCH; ADULTS; DECLINE; HEALTH; VALIDATION; MORTALITY AB OBJECTIVES To determine whether middle-aged persons with depressive symptoms are at higher risk for developing activity of daily living (ADL) and mobility limitations as they advance into older age than those without. DESIGN Prospective cohort study. SETTING The Health and Retirement Study (HRS), a nationally representative sample of people aged 50 to 61. PARTICIPANTS Seven thousand two hundred seven community living participants in the 1992 wave of the HRS. MEASUREMENTS Depressive symptoms were measured using the 11-item Center for Epidemiologic Studies Depression Scale (CES-D 11), with scores of 9 or more (out of 33) classified as significant depressive symptoms. Difficulty with five ADLs and basic mobility tasks (walking several blocks or up one flight of stairs) was measured every 2 years through 2006. The primary outcome was persistent difficulty with ADLs or mobility, defined as difficulty in two consecutive waves. RESULTS Eight hundred eighty-seven (12%) subjects scored 9 or higher on the CES-D 11 and were classified as having significant depressive symptoms. Over 12 years of follow-up, subjects with depressive symptoms were more likely to reach the primary outcome measure of persistent difficulty with mobility or difficulty with ADL function (45% vs 23%, Cox hazard ratio (HR)=2.33, 95% confidence interval (CI)=2.06-2.63). After adjusting for age, sex, measures of socioeconomic status, comorbid conditions, high body mass index, smoking, exercise, difficulty jogging 1 mile, and difficulty climbing several flights of stairs, the risk was attenuated but still statistically significant (Cox HR=1.44, 95% CI=1.25-1.66). CONCLUSION Depressive symptoms independently predict the development of persistent limitations in ADLs and mobility as middle-aged persons advance into later life. Middle-aged persons with depressive symptoms may be at greater risk for losing their functional independence as they age. C1 [Covinsky, Kenneth E.; Lindquist, Karla; Cherkasova, Elena; Yelin, Edward] Univ Calif San Francisco, Dept Med, San Francisco, CA 94121 USA. [Covinsky, Kenneth E.; Lindquist, Karla; Cherkasova, Elena] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94121 USA. [Yelin, Edward] Univ Calif San Francisco, Div Rheumatol, San Francisco, CA 94121 USA. [Yelin, Edward] Univ Calif San Francisco, Inst Hlth Policy Studies, San Francisco, CA 94121 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94121 USA. [Covinsky, Kenneth E.; Yaffe, Kristine; Lindquist, Karla; Cherkasova, Elena] San Francisco VA Med Ctr, San Francisco, CA USA. [Blazer, Dan G.] Duke Univ, Dept Psychiat & Behav Sci, Durham, NC USA. RP Covinsky, KE (reprint author), Univ Calif San Francisco, San Francisco VA Med Ctr 181G, 4150 Clement, San Francisco, CA 94121 USA. EM ken.covinsky@ucsf.edu FU National Institute on Aging (NIA) [R01AG028481, K24AG029812] FX Interest: The editor in chief has reviewed the conflict of interest checklist provided by the authors and has determined that the authors have no financial or any other kind of personal conflicts with this paper. Kristine Yaffe served on the Women's Health Initiative Observational Study Monitoring Board. Supported by Grants R01AG028481 and K24AG029812 from the National Institute on Aging (NIA). The HRS is funded by the NIA. NR 30 TC 31 Z9 32 U1 3 U2 3 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAR PY 2010 VL 58 IS 3 BP 551 EP 556 DI 10.1111/j.1532-5415.2010.02723.x PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 568JS UT WOS:000275519200020 PM 20163486 ER PT J AU Gerber, JB Bloom, PA Ross, JS AF Gerber, Jaime B. Bloom, Patricia A. Ross, Joseph S. TI THE PHYSICAL ACTIVITY CONTRACT-TAILORED TO PROMOTE PHYSICAL ACTIVITY IN A GERIATRIC OUTPATIENT SETTING: A PILOT STUDY SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Letter ID CONTROLLED-TRIAL; PRIMARY-CARE C1 [Gerber, Jaime B.] Univ Washington, Dept Med, Seattle, WA 98195 USA. [Bloom, Patricia A.; Ross, Joseph S.] Mt Sinai Sch Med, Dept Geriatr & Palliat Med, New York, NY USA. [Ross, Joseph S.] James J Peters Vet Adm Med Ctr, Hlth Serv Res & Dev Res Enhancement Award Program, Bronx, NY USA. [Ross, Joseph S.] James J Peters Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA. RP Gerber, JB (reprint author), Univ Washington, Dept Med, Seattle, WA 98195 USA. FU NIA NIH HHS [K08 AG032886, K08 AG032886-02] NR 10 TC 1 Z9 1 U1 0 U2 1 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAR PY 2010 VL 58 IS 3 BP 604 EP 606 PG 3 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 568JS UT WOS:000275519200030 PM 20398129 ER PT J AU Gradman, AH Basile, JN Carter, BL Bakris, GL AF Gradman, Alan H. Basile, Jan N. Carter, Barry L. Bakris, George L. CA Hypertension Writing Grp TI Combination therapy in hypertension SO JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION LA English DT Article DE Hypertension; combination therapy; drug therapy; angiotensin converting enzyme inhibitor; angiotensin receptor blocker; beta blockers diuretic; calcium channel blocker ID BLOOD-PRESSURE CONTROL; LOW-DOSE HYDROCHLOROTHIAZIDE; FELODIPINE EXTENDED-RELEASE; CONVERTING-ENZYME-INHIBITOR; HIGH CARDIOVASCULAR RISK; CALCIUM-CHANNEL BLOCKER; DOUBLE-BLIND; RANDOMIZED-TRIAL; ANTIHYPERTENSIVE TREATMENT; SYSTEMIC HYPERTENSION AB The goal of antihypertensive therapy is to abolish the risks associated with blood pressure (BP) elevation without adversely affecting quality of life. Drug selection is based on efficacy in lowering BP and in reducing cardiovascular (CV) end points including stroke, myocardial infarction, and heart failure. Although the choice of initial drug therapy exerts some effect on long-term outcomes, it is evident that BP reduction per se is the primary determinant of CV risk reduction. Available data suggest that at least 75% of patients will require combination therapy to achieve contemporary BP targets, and increasing emphasis is being placed on the practical tasks involved in consistently achieving and maintaining goal BP in clinical practice. It is within this context that the American Society of Hypertension presents this Position Paper on Combination Therapy for Hypertension. It will address the scientific basis of combination therapy, present the pharmacologic rationale for choosing specific drug combinations, and review patient selection criteria for initial and secondary use. The advantages and disadvantages of single pill (fixed) drug combinations, and the implications of recent clinical trials involving specific combination strategies will also be discussed. J Am Soc Hypertens 2010;4(2):90-98. (C) 2010 American Society of Hypertension. All rights reserved. C1 [Gradman, Alan H.] Western Penn Hosp, Dept Med, Pittsburgh, PA 15224 USA. [Gradman, Alan H.] Temple Univ, Sch Med, Philadelphia, PA 19122 USA. [Basile, Jan N.] Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA. [Carter, Barry L.] Univ Iowa, Roy J & Lucille A Carver Coll Med, Iowa City, IA USA. [Bakris, George L.] Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA. RP Gradman, AH (reprint author), Western Penn Hosp, Dept Med, 4800 Friendship Ave, Pittsburgh, PA 15224 USA. EM gradmanmd@aol.com FU Novartis; NHLBI; NIH; Juvenile Diabetes Research Foundation (JDRF); GlaxoSmithKline; Forest Laboratories; CVRx; VA HSRD FX Dr. Gradman has served as a consultant for Novartis, Forest Laboratories, Daiich-Sankyo, NicOx, Merck; and speakers' bureau for Novartis, Merck, Forest Laboratories. and Daiichi-Sankyo. He has received grant/search support from Novartis. Dr. Basile has served as a consultant for Daiichi-Sankyo, Forest Laboratories, Novartis, Takeda; and speakers's bureau for Daiichi-Sankyo, Forest Laboratories, and Novartis. He has received grant/research support from the NHLBI. Dr. Carter has received grant/research support from the NIH, VA HSR&D. Dr. Bakris has served as a consultant for GlaxoSmithKline, Merck, Novartis, Boehringer-Ingelheim, Takeda, Abbott, Walgreen's, Bristol-Myers Squibb/Sanofi, Gilead, Forest Laboratories; and speakers' bureau for Forest Laboratories and Novartis. He has received grant/research support from the Juvenile Diabetes Research Foundation (JDRF), GlaxoSmithKline, Forest Laboratories and CVRx. NR 65 TC 62 Z9 69 U1 1 U2 12 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1933-1711 J9 J AM SOC HYPERTENS JI J. Am. Soc. Hypertens. PD MAR-APR PY 2010 VL 4 IS 2 SI SI BP 90 EP 98 DI 10.1016/j.jash.2010.03.001 PG 9 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 592RN UT WOS:000277397300007 PM 20400053 ER PT J AU Toole, JM Ikonomidis, JS Szeto, WY Zellner, JL Mulcahy, J Deardorff, RL Spinale, FG AF Toole, John M. Ikonomidis, John S. Szeto, Wilson Y. Zellner, James L. Mulcahy, John Deardorff, Rachael L. Spinale, Francis G. TI Selective endothelin-1 receptor type A inhibition in subjects undergoing cardiac surgery with preexisting left ventricular dysfunction: Influence on early postoperative hemodynamics SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY LA English DT Article ID PULMONARY ARTERIAL-HYPERTENSION; BYPASS GRAFT-SURGERY; CARDIOPULMONARY BYPASS; HEART-FAILURE; CARDIOVASCULAR-DISEASE; IN-VIVO; PATHOPHYSIOLOGY; ANTAGONISM; SYSTEM; SITAXSENTAN AB Objective: A robust release of endothelin-1 with subsequent endothelin-A subtype receptor activation occurs in patients after cardiac surgery requiring cardiopulmonary bypass. Increased endothelin-A subtype receptor activation has been identified in patients with poor left ventricular function (reduced ejection fraction). Accordingly, this study tested the hypothesis that a selective endothelin-A subtype receptor antagonist administered perioperatively would favorably affect post-cardiopulmonary bypass hemodynamic profiles in patients with a preexisting poor left ventricular ejection fraction. Methods: Patients (n = 29; 66 +/- 2 years) with a reduced left ventricular ejection fraction (37% +/- 2%) were prospectively randomized in a blinded fashion, at the time of elective coronary revascularization or valve replacement requiring cardiopulmonary bypass, to infusion of the highly selective and potent endothelin-A subtype receptor antagonist sitaxsentan at 1 or 2 mg/kg (intravenous bolus; n 9, 10 respectively) or vehicle (saline; n 10). Infusion of the endothelin-A subtype receptor antagonist/vehicle was performed immediately before separation from cardiopulmonary bypass and again at 12 hours after cardiopulmonary bypass. Endothelin and hemodynamic measurements were performed at baseline, at separation from cardiopulmonary bypass (time 0), and at 0.5, 6, 12, and 24 hours after cardiopulmonary bypass. Results: Baseline plasma endothelin (4.0 +/- 0.3 fmol/mL) was identical across all 3 groups, but when compared with preoperative values, baseline values obtained from age-matched subjects with a normal left ventricular ejection fraction (n 37; left ventricular ejection fraction>50%) were significantly increased (2.9 +/- 0.2 fmol/mL, P<.05). Baseline systemic (1358 +/- 83 dynes/sec/cm(-5)) and pulmonary (180 +/- 23 dynes/sec/cm(-5)) vascular resistance were equivalent in all 3 groups. As a function of time 0, systemic vascular resistance changed in an equivalent fashion in the post-cardiopulmonary bypass period, but a significant endothelin-A subtype receptor antagonist effect was observed for pulmonary vascular resistance (analysis of variance; P<.05). For example, at 24 hours post-cardiopulmonary bypass, pulmonary vascular resistance increased by 40 dynes/sec/cm(-5) in the vehicle group but directionally decreased by more than 40 dynes/sec/cm(-5) in the 2 mg/kg endothelin-A subtype receptor antagonist group (P<.05). Total adverse events were equivalently distributed across the endothelin-A subtype receptor antagonist/placebo groups. Conclusion: These unique findings demonstrated that infusion of an endothelin-A subtype receptor antagonist in high-risk patients undergoing cardiac surgery was not associated with significant hemodynamic compromise. Moreover, the endothelin-A subtype receptor antagonist favorably affected pulmonary vascular resistance in the early postoperative period. Thus, the endothelin-A subtype receptor serves as a potential pharmacologic target for improving outcomes after cardiac surgery in patients with compromised left ventricular function. (J Thorac Cardiovasc Surg 2010;139:646-54) C1 [Toole, John M.; Ikonomidis, John S.; Mulcahy, John; Deardorff, Rachael L.; Spinale, Francis G.] Med Univ S Carolina, Charleston, SC 29425 USA. [Toole, John M.; Ikonomidis, John S.; Mulcahy, John; Deardorff, Rachael L.; Spinale, Francis G.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Szeto, Wilson Y.] Univ Penn, Philadelphia, PA 19104 USA. [Zellner, James L.] Univ Tennessee, Chattanooga, TN USA. RP Spinale, FG (reprint author), Strom Thurmond Res Ctr, 114 Doughty St,Suite 625, Charleston, SC 29425 USA. EM wilburnm@musc.edu FU Encysive Pharmaceuticals; National Institutes of Health [HL87134]; Veterans' Affairs Health Administration FX This study was supported by an unrestricted research grant from Encysive Pharmaceuticals, which was acquired by Pfizer Inc in June 2008, National Institutes of Health grant HL87134, and a Merit Award from the Veterans' Affairs Health Administration. NR 37 TC 4 Z9 4 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5223 J9 J THORAC CARDIOV SUR JI J. Thorac. Cardiovasc. Surg. PD MAR PY 2010 VL 139 IS 3 BP 646 EP 654 DI 10.1016/j.jtcvs.2009.11.046 PG 9 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 558IS UT WOS:000274735400018 PM 20074751 ER PT J AU Isaac, C Griffin, L Carnes, M AF Isaac, Carol Griffin, Lindsay Carnes, Molly TI A Qualitative Study of Faculty Members' Views of Women Chairs SO JOURNAL OF WOMENS HEALTH LA English DT Article ID REQUISITE MANAGEMENT CHARACTERISTICS; SEX-ROLE STEREOTYPES; ACADEMIC MEDICINE; FEMALE LEADERS; GENDER STEREOTYPES; DOUBLE STANDARDS; METAANALYSIS; PHYSICIANS; PROMOTION; SUCCESS AB Background: Concurrent with the evolving role of the department chair in academic medicine is the entry of women physicians into chair positions. Because implicit biases that stereotypically masculine behaviors are required for effective leadership remain strong, examining faculty members' perceptions of their chair's leadership in medical school departments with women chairs can provide insight into the views of women leaders in academic medicine and the complex ways in which gender may impact these chairs' leadership style and actions. Methods: We conducted semistructured interviews with 13 male and 15 female faculty members representing all faculty tracks in three clinical departments chaired by women. Inductive, qualitative analysis of the subsequent text allowed themes to emerge across interviews. Results: Four themes emerged regarding departmental leadership. One dealt with the leadership of the previous chair. The other three described the current chair's characteristics (tough, direct, and transparent), her use of communal actions to help support and mentor her faculty, and her ability to build power through consensus. Because all three chairs were early in their tenure, a wait and see attitude was frequently expressed. Faculty generally viewed having a woman chair as an indication of positive change, with potential individual and institutional advantages. Conclusions: This exploratory study suggests that the culture of academic medicine has moved beyond questioning women physicians' competence to lead once they are in top organizational leadership positions. The findings are also consonant with experimental research indicating that women leaders are most successful when they pair stereotypic male (agentic) behaviors with stereotypic female (communal) behaviors. All three chairs exhibited features of a transformational leadership style and characteristics deemed essential for effective leadership in academic medicine. C1 [Isaac, Carol; Carnes, Molly] Univ Wisconsin, Ctr Womens Hlth Res, Madison, WI 53715 USA. [Isaac, Carol; Griffin, Lindsay; Carnes, Molly] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI 53715 USA. [Carnes, Molly] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Carnes, M (reprint author), Univ Wisconsin, Ctr Womens Hlth Res, 700 Regent St,Suite 301, Madison, WI 53715 USA. EM mlcarnes@wisc.edu FU School of Medicine and Public Health's; National Institute on Aging [T-32 AG 00265] FX L.G. was supported by the School of Medicine and Public Health's 2008 Shapiro Summer Research Program. Dr. Isaac was supported by grant No. T-32 AG 00265 from the National Institute on Aging. Dr. Carnes is employed part time by the William S. Middleton Memorial Veterans Hospital. NR 71 TC 11 Z9 11 U1 2 U2 12 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 J9 J WOMENS HEALTH JI J. Womens Health PD MAR PY 2010 VL 19 IS 3 BP 533 EP 546 DI 10.1089/jwh.2009.1506 PG 14 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 574IS UT WOS:000275983200020 PM 20156081 ER PT J AU Weston, AL Weinstein, AM Barton, C Yaffe, K AF Weston, Andrea L. Weinstein, Andrea M. Barton, Cynthia Yaffe, Kristine TI Potentially Inappropriate Medication Use in Older Adults With Mild Cognitive Impairment SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Article DE Mild cognitive impairment; Potentially inappropriate medication; Epidemiology ID CHOLINESTERASE-INHIBITORS; ANTICHOLINERGIC DRUGS; ALZHEIMERS-DISEASE; PRESCRIBED DRUGS; DEMENTIA AB Background. Patients with mild cognitive impairment (MCI) may be especially vulnerable to the side effects of potentially inappropriate medications (PIMs), especially those that impair cognition. Methods. We conducted a cross-sectional study to determine the prevalence of PIM use among 689 patients with MCI. We used the 2003 Beers Criteria for cognitive impairment to identify PIMs. We then determined if certain patients were more likely to use PIMs. Results. There were 143 (20.8%) patients with MCI taking a PIM: 108 (15.7%) patients were taking one PIM and 35 (5.1%) patients were taking two or more PIMs. The most common PIMs were anticholinergics (35.7%) and benzodiazepines (31.5%). Patients were more likely to be taking PIMs if they were women and were taking a greater number of medications and less likely if they had a history of myocardial infarction. Conclusions. Patients with MCI are frequently taking PIMs that may negatively affect cognition. Future research is needed to assess whether cognitive impairment symptoms are improved if PIM use is reduced. C1 [Weston, Andrea L.; Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA. [Weston, Andrea L.; Weinstein, Andrea M.; Barton, Cynthia; Yaffe, Kristine] San Francisco VA Med Ctr, Dept Geriatr Psychiat, San Francisco, CA USA. [Weinstein, Andrea M.] No Calif Inst Res & Educ, San Francisco, CA USA. [Barton, Cynthia; Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94121 USA. RP Weston, AL (reprint author), Univ Calif San Francisco, Dept Psychiat, Box 116H,4150 Clement St, San Francisco, CA 94121 USA. EM andrea.weston@ucsf.edu FU Mental Illness Research, Education, and Clinical Center at the Department of Veterans Affairs; California Department of Public Health ARCCs [99-86138]; National Institute of Aging [1K24AG031155-01] FX This work was supported by the Mental Illness Research, Education, and Clinical Center at the Department of Veterans Affairs: The California Department of Public Health ARCCs Grant (99-86138); and National Institute of Aging Grant (1K24AG031155-01 to K.Y.). NR 25 TC 20 Z9 20 U1 0 U2 2 PU GERONTOLOGICAL SOC AMER PI WASHINGTON PA 1030 15TH ST NW, STE 250, WASHINGTON, DC 20005202-842 USA SN 1079-5006 J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD MAR PY 2010 VL 65 IS 3 BP 318 EP 321 DI 10.1093/gerona/glp158 PG 4 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 567CV UT WOS:000275420800017 PM 19843646 ER PT J AU Jung, YY Gruenewald, TL Seeman, TE Sarkisian, CA AF Jung, Yunkyung Gruenewald, Tara L. Seeman, Teresa E. Sarkisian, Catherine A. TI Productive Activities and Development of Frailty in Older Adults SO JOURNALS OF GERONTOLOGY SERIES B-PSYCHOLOGICAL SCIENCES AND SOCIAL SCIENCES LA English DT Article DE Productive activities; Volunteering; Frailty ID MACARTHUR; HEALTH; WOMEN AB Objective. Our aim was to examine whether engagement in productive activities, including volunteering, paid work, and childcare, protects older adults against the development of geriatric frailty. Methods. Data from the first (1988) and second (1991) waves of the MacArthur Study of Successful Aging, a prospective cohort study of high-functioning older adults aged 70-79 years (n = 1,072), was used to examine the hypothesis that engagement in productive activities is associated with lower levels of frailty 3 years later. Results. Engagement in productive activities at baseline was associated with a lower cumulative odds of frailty 3 years later in unadjusted models (odds ratio [OR] = 0.74, 95% confidence interval [CI] = 0.58-0.96) but not after adjusting for age, disability, and cognitive function (adjusted OR = 0.78, 95% CI = 0.60-1.01). Examination of productive activity domains showed that volunteering (but neither paid work nor childcare) was associated with a lower cumulative odds of frailty after adjusting for age, disability, and cognitive function. This relationship diminished and was no longer statistically significant after adjusting for personal mastery and religious service attendance. Discussion. Though high-functioning older adults who participate in productive activities are less likely to become frail, after adjusting for age, disability, and cognitive function, only volunteering is associated with a lower cumulative odds of frailty. C1 [Sarkisian, Catherine A.] VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ Clin Ctr, Los Angeles, CA 90073 USA. [Gruenewald, Tara L.; Seeman, Teresa E.; Sarkisian, Catherine A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Geriatr, Los Angeles, CA 90095 USA. [Jung, Yunkyung] Univ Calif Los Angeles, Sch Publ Affairs, Dept Social Welf, Los Angeles, CA 90095 USA. RP Sarkisian, CA (reprint author), VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ Clin Ctr, Bldg 220,Room 315 11G,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM csarkisian@mednet.ucla.edu FU National Institute on Aging [1 R21 AG025764-02, K01-AG028582]; Catherine T. MacArthur Foundation FX National Institute on Aging ("Testing the Validity of a Construct of Geriatric Frailty" and 1 R21 AG025764-02 to C. A. S. and K01-AG028582 to T. L. G.); John D. and Catherine T. MacArthur Foundation (the MacArthur Research network on Successful Aging and the macArthur Research network on SES and Health grants). NR 26 TC 26 Z9 27 U1 6 U2 8 PU GERONTOLOGICAL SOC AMER PI WASHINGTON PA 1030 15TH ST NW, STE 250, WASHINGTON, DC 20005202-842 USA SN 1079-5014 J9 J GERONTOL B-PSYCHOL JI J. Gerontol. Ser. B-Psychol. Sci. Soc. Sci. PD MAR PY 2010 VL 65 IS 2 BP 256 EP 261 DI 10.1093/geronb/gbq005 PG 6 WC Geriatrics & Gerontology; Gerontology; Psychology; Psychology, Multidisciplinary SC Geriatrics & Gerontology; Psychology GA 558WT UT WOS:000274780100013 PM 20018794 ER PT J AU Wirth, W Benichou, O Kwoh, CK Guermazi, A Hunter, D Putz, R Eckstein, F AF Wirth, Wolfgang Benichou, Olivier Kwoh, C. Kent Guermazi, Ali Hunter, David Putz, Reinhard Eckstein, Felix CA OAI Investigators TI Spatial Patterns of Cartilage Loss in the Medial Femoral Condyle in Osteoarthritic Knees: Data From the Osteoarthritis Initiative SO MAGNETIC RESONANCE IN MEDICINE LA English DT Article DE cartilage; osteoarthritis; image analysis; 3 tesla; subregions ID JOINT SPACE WIDTH; ARTICULAR-CARTILAGE; STANDING ANTEROPOSTERIOR; TIBIOFEMORAL COMPARTMENT; PROGRESSION SUBCOHORT; REGIONAL-ANALYSIS; 3 TESLA; ASSOCIATION; MORPHOMETRY; PROTOCOL AB The objective of this study was to develop a technique for analyzing spatial patterns of cartilage loss in the medial femoral condyle (MF), and to study MF cartilage loss in participants of the Osteoarthritis Initiative. Using a 0.7mm sagittal double echo at steady state (DESS) sequence, 160 osteoarthritic knees from 80 participants with varying degrees of medial joint space narrowing were imaged at baseline and 1-year follow-up. MF cartilage was segmented and cartilage loss determined. Rate of change varied significantly (P = 0.0067) along the anterior-posterior extension of the MF, with the greatest changes (-45 mu m, -2.7%) observed 30-60 degrees posterior to the trochlear notch. The rate was greater in the central MF after excluding peripheral aspects of the MF from analysis. Sensitivity to change was greatest at 45-75 degrees (standardized response mean = -0.32) but was minimally affected by medial-lateral trimming. In conclusion, the greatest sensitivity to change was achieved when analyzing the posterior aspect of the central, weight-bearing MF Magn Reson Med 63:574-581, 2010. (C) 2010 Wiley-Liss, Inc. C1 [Wirth, Wolfgang; Eckstein, Felix] Chondrometr GmbH, D-83404 Ainring, Germany. [Wirth, Wolfgang; Putz, Reinhard] LMU Munchen, Inst Anat, Munich, Germany. [Benichou, Olivier] Eli Lilly & Co, Indianapolis, IN 46285 USA. [Kwoh, C. Kent] Univ Pittsburgh, Div Clin Immunol & Rheumatol, Pittsburgh, PA USA. [Kwoh, C. Kent] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Guermazi, Ali] Boston Univ, Med Ctr, Dept Radiol, Boston, MA 02118 USA. [Hunter, David] New England Baptist Hosp, Div Res, Boston, MA USA. [Eckstein, Felix] Paracelsus Med Univ, Inst Anat & Musculoskeletal Res, Salzburg, Austria. RP Wirth, W (reprint author), Chondrometr GmbH, Ulrichshoglerstr 23, D-83404 Ainring, Germany. EM wirth@chondrometrics.de RI Eckstein, Felix/E-1585-2011; Hunter, David/A-4622-2010; Wirth, Wolfgang/C-8724-2011 OI Hunter, David/0000-0003-3197-752X; Wirth, Wolfgang/0000-0002-2297-8283 FU National Institutes of Health [N01-AR-2-2258, N01-AR-2-2259, N01-AR-2-2260, N01-AR-2-2261, N01-AR-2-2262]; Department of Health and Human Services; OAI Study; OAI include Merck Research Laboratories; Novartis Pharmaceuticals Corporation; GlaxoSmithKline; Pfizer, Inc FX We thank the following readers for dedicated data segmentation: Gudrun Goldmann, Linda Jakobi, Manuela Kunz, Dr. Susanne Maschek, Sabine Muhlsimer, Annette Thebis, and Dr. Barbara Wehr. We thank Martin Hudelmaier for performing the quality control readings at data entry and Susanne Maschek for the quality control readings of the segmentations. The image analysis of this study was funded by Eli Lilly & Co, IN. The images were acquired by the OAI, a public-private partnership composed of five contracts (N01-AR-2-2258, N01-AR-2-2259, N01-AR-2-2260, N01-AR-2-2261, N01-AR-2-2262) funded by the National Institutes of Health, a branch of the Department of Health and Human Services, and conducted by the OAI Study Investigators. Private funding partners of the OAI include Merck Research Laboratories; Novartis Pharmaceuticals Corporation, GlaxoSmithKline; and Pfizer, Inc. Private sector funding for the OAI is managed by the Foundation for the National Institutes of Health. This manuscript has received the approval of the OAI Publications Committee based on a review of its scientific content and data interpretation. NR 30 TC 24 Z9 25 U1 0 U2 1 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0740-3194 J9 MAGN RESON MED JI Magn. Reson. Med. PD MAR PY 2010 VL 63 IS 3 BP 574 EP 581 DI 10.1002/mrm.22194 PG 8 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 560XJ UT WOS:000274938000005 PM 20146227 ER PT J AU Jayadevappa, R Schwartz, JS Chhatre, S Wein, AJ Malkowicz, SB AF Jayadevappa, Ravishankar Schwartz, J. Sanford Chhatre, Sumedha Wein, Alan J. Malkowicz, S. Bruce TI Satisfaction with Care: A Measure of Quality of Care in Prostate Cancer Patients SO MEDICAL DECISION MAKING LA English DT Article DE prostate cancer; satisfaction with care; health-related quality of life; external beam radiation therapy; radical prostatectomy ID HEALTH-CARE; OUTCOMES; LIFE; VALIDATION; QUESTIONNAIRE; ASSOCIATION; INFORMATION AB Background. Patients' assessment of satisfaction with care, quality of care, and outcomes has become a central issue in patient-centered prostate cancer (PCa) care. We sought to analyze the association between patient-reported satisfaction with care and health-related quality of life (HRQoL) in newly diagnosed PCa patients. Methods. Prospective cohort design was used to recruit 590 newly diagnosed PCa patients from an urban academic hospital and a VA hospital. Participants completed satisfaction with care (CSQ-8) and HRQoL (SF-36 and UCLA-PCI) surveys prior to treatment and at 3, 6, 12, and 24 months' follow-up. Cross-lagged analysis was used to ascertain the causal direction between satisfaction with care and HRQoL. Propensity scores were used to adjust for potential selection bias between treatment groups. Linear mixed models were used to analyze the association between satisfaction with care, process of care (treatment), and outcomes (generic and prostate-specific HRQoL) results are consistent with a cause-effect association between HRQoL and satisfaction with care. After controlling for clinical and demographic covariates, radical prostatectomy (RP) treatment was associated with higher satisfaction with care (odds ratio [OR], 7.9; P = 0.043). Improved generic and prostate-specific HRQoL were associated with higher satisfaction with care, after adjusting for demographic and clinical covariates. Conclusion. Satisfaction with care appears to be associated with process of care and outcomes of care. Assessment of satisfaction with care is useful for evaluating the quality of PCa care. Satisfaction with care is an important arena in cancer outcomesresearch, whose full potential remains unexploited. C1 [Jayadevappa, Ravishankar] Univ Penn, Dept Med, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Schwartz, J. Sanford] Univ Penn, Dept Hlth Care Syst, Wharton Sch, Philadelphia, PA 19104 USA. [Chhatre, Sumedha] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Wein, Alan J.; Malkowicz, S. Bruce] Univ Penn, Div Urol, Dept Surg, Philadelphia, PA 19104 USA. [Malkowicz, S. Bruce] Philadelphia VA Med Ctr, Philadelphia, PA USA. RP Jayadevappa, R (reprint author), Univ Penn, Dept Med, Leonard Davis Inst Hlth Econ, 224 Ralston Penn Ctr,3615 Chestnut St, Philadelphia, PA 19104 USA. EM jravi@mail.med.upenn.edu FU DOD Prostate Cancer Research Program [W81XWH-04-1-0257, DAMD17-02-10126]; Laddie and Linda Montague Research Fund FX Supported by the DOD Prostate Cancer Research Program W81XWH-04-1-0257 and DAMD17-02-10126 and Laddie and Linda Montague Research Fund. NR 31 TC 13 Z9 14 U1 0 U2 3 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0272-989X J9 MED DECIS MAKING JI Med. Decis. Mak. PD MAR-APR PY 2010 VL 30 IS 2 BP 234 EP 245 DI 10.1177/0272989X09342753 PG 12 WC Health Care Sciences & Services; Medical Informatics SC Health Care Sciences & Services; Medical Informatics GA 576RQ UT WOS:000276166000010 PM 19675320 ER PT J AU Duong, TQ AF Duong, Timothy Q. TI Diffusion tensor and perfusion MRI of non-human primates SO METHODS LA English DT Article DE Magnetic resonance imaging; Cerebral blood flow; Neuroimaging; Stroke; NHP; DTI; BOLD fMRI; Arterial spin-labeling; DWI ID CEREBRAL-BLOOD-FLOW; RESONANCE-IMAGING TECHNIQUES; TRANSORBITAL BABOON MODEL; IN-VIVO; FUNCTIONAL MRI; RHESUS-MONKEYS; WATER DIFFUSION; WHITE-MATTER; 3.0 T; AXONAL PROJECTIONS AB This paper reviews recent non-human primate (NHP) neuroimaging literature using MRI in macaque, baboon and chimpanzee. It describes general challenges and limitations for NHP MRI studies, and reviews recent applications of anatomical, diffusion tensor, cerebral blood flow MRI. Applications to NHP stroke is discussed in some detail. (C) 2009 Elsevier Inc. All rights reserved. C1 [Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Ctr, San Antonio, TX 78229 USA. [Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Ophthalmol, San Antonio, TX 78229 USA. [Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Radiol & Physiol, San Antonio, TX 78229 USA. [Duong, Timothy Q.] SW Fdn Biomed Res, SW Natl Primate Res Ctr, S Texas Vet Hlth Care Syst, Dept Vet Affairs, San Antonio, TX USA. RP Duong, TQ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Ctr, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA. EM duognt@uthscsa.edu RI Duong, Timothy/B-8525-2008 FU American Heart Association's [EIA 0940104N]; NHP FX This Work is funded in part by the American Heart Association's Established Investigator Award EIA 0940104N. The author would like to thank Drs. Frank Tong, Yoji Tanaka, Tsukasa Nagaoka for their contributions to the stroke project from which Fig. 11 was derived. I would also like to thank Drs. Helen D'Arceuil and Alex de Crespigny for numerous discussions on the NHP stroke project. NR 78 TC 10 Z9 10 U1 0 U2 4 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1046-2023 J9 METHODS JI Methods PD MAR PY 2010 VL 50 IS 3 BP 125 EP 135 DI 10.1016/j.ymeth.2009.08.001 PG 11 WC Biochemical Research Methods; Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 566WG UT WOS:000275403400002 PM 19665567 ER PT J AU McLaren, DG Kosmatka, KJ Kastman, EK Bendlin, BB Johnson, SC AF McLaren, Donald G. Kosmatka, Kristopher J. Kastman, Erik K. Bendlin, Barbara B. Johnson, Sterling C. TI Rhesus macaque brain morphometry: A methodological comparison of voxel-wise approaches SO METHODS LA English DT Article DE Rhesus macaque; MRI; Morphometry; Macaca mulatta; Brain mapping; Aging; Non-human primates ID HUMAN CEREBRAL-CORTEX; PRIMARY VISUAL-CORTEX; FALSE DISCOVERY RATE; AGE-RELATED DECLINE; GRAY-MATTER VOLUME; STRIATAL VOLUME; TEMPLATE IMAGES; CANINE MODEL; IN-VIVO; SURFACE AB Voxel-based morphometry studies have become increasingly common in human neuroimaging over the past several years; however, few studies have utilized this method to Study morphometry changes in non-human primates. Here we describe the application of voxel-wise morphometry methods to the rhesus macaque (Macaca mulatta) using the 112RM-SL template and priors (McLaren et al. (2009) [42]) and as an illustrative example we describe age-associated changes in grey matter morphometry. Specifically, we evaluated the unified segmentation routine implemented using Statistical Parametric Mapping (SPM) software and the FMRIB's Automated Segmentation Tool (FAST) in the FMRIB Software Library (FSL); the effect of varying the smoothing kernel: and the effect of the normalization routine. We found that when studying non-human primates, brain images need less smoothing than in human studies, 2-4 mm FWHM. Using flow field deformations (DARTEL) improved inter-subject alignment leading to results that were more likely due to morphometry differences as opposed to registration differences. (C) 2009 Elsevier Inc, All rights reserved. C1 [McLaren, Donald G.; Kosmatka, Kristopher J.; Kastman, Erik K.; Bendlin, Barbara B.; Johnson, Sterling C.] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI 53705 USA. [McLaren, Donald G.] Univ Wisconsin, Neurosci Training Program, Madison, WI 53706 USA. [McLaren, Donald G.; Kosmatka, Kristopher J.; Kastman, Erik K.; Bendlin, Barbara B.; Johnson, Sterling C.] Univ Wisconsin, Dept Med, Madison, WI 53705 USA. RP Johnson, SC (reprint author), William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, 2500 Overlook Terrace 11G, Madison, WI 53705 USA. EM scj@medicine.wisc.edu RI McLaren, Donald/G-9906-2011; Kastman, Erik/N-6645-2016 OI Kastman, Erik/0000-0001-7221-9042; Bendlin, Barbara/0000-0002-0580-9875 FU National Institutes of Health [RR000167, AG11915, AG000213, GM007507] FX This study was supported in part by the National Institutes of Health RR000167, AG11915, AG000213, and GM007507. The study was also supported with resources and use of facilities at the William S. Middleton Memorial Veterans Hospital, Madison, WI, USA. The assistance of Brent W. Thiel, Michele E. Fitzgerald, Ron Fisher, Scott T. Baum, Josh Smith, Ricki J. Colman, Ph.D., Andy. A. Alexander, Ph.D., and the Waisman Center for Brain Imaging are greatly appreciated. GRECC Manuscript Number: 2009-5. NR 72 TC 33 Z9 33 U1 2 U2 9 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1046-2023 J9 METHODS JI Methods PD MAR PY 2010 VL 50 IS 3 BP 157 EP 165 DI 10.1016/j.ymeth.2009.10.003 PG 9 WC Biochemical Research Methods; Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 566WG UT WOS:000275403400005 PM 19883763 ER PT J AU Sharma, SD Meeran, SM Katiyar, SK AF Sharma, Som D. Meeran, Syed M. Katiyar, Santosh K. TI Proanthocyanidins Inhibit In vitro and In vivo Growth of Human Non-Small Cell Lung Cancer Cells by Inhibiting the Prostaglandin E-2 and Prostaglandin E-2 Receptors SO MOLECULAR CANCER THERAPEUTICS LA English DT Article ID SKH-1 HAIRLESS MICE; ANTICANCER AGENTS; CARCINOMA-CELLS; KAPPA-B; CYCLOOXYGENASE-2; APOPTOSIS; EXPRESSION; PATHWAY; ADENOCARCINOMA; PROLIFERATION AB Overexpression of cyclooxygenase-2 (COX-2) and prostaglandins (PG) is linked to a wide variety of human cancers. Here, we assessed whether the chemotherapeutic effect of grape seed proanthocyanidins (GSP) on non-small cell lung cancer (NSCLC) cells is mediated through the inhibition of COX-2 and PGE(2)/PGE(2) receptor expression. The effects of GSPs on human NSCLC cell lines in terms of proliferation, apoptosis, and expression of COX-2, PGE(2), and PGE(2) receptors were determined using Western blotting, fluorescence-activated cell sorting analysis, and reverse transcription-PCR. In vitro treatment of NSCLC cells (A549, H1299, H460, H226, and H157) with GSPs resulted in significant growth inhibition and induction of apoptosis, which were associated with the inhibitory effects of GSPs on the overexpression of COX-2, PGE(2), and PGE(2) receptors (EP1 and EP4) in these cells. Treatment of cells with indomethacin, a pan-COX inhibitor, or transient transfection of cells with COX-2 small interfering RNA, also inhibited cell growth and induced cell death. The effects of a GSP-supplemented AIN76A control diet fed to nude mice bearing tumor xenografts on the expression of COX-2, PGE(2), and PGE(2) receptors in the xenografts were also evaluated. The growth-inhibitory effect of dietary GSPs (0.5%, w/w) on the NSCLC xenograft tumors was associated with the inhibition of COX-2, PGE(2), and PGE(2) receptors (EP1, EP3, and EP4) in tumors. This preclinical study provides evidence that the chemotherapeutic effect of GSPs on lung cancer cells in vitro and in vivo is mediated, at least in part, through the inhibition of COX-2 expression and subsequently the inhibition of PGE(2) and PGE(2) receptors. Mol Cancer Ther; 9(3); 569-80. (C) 2010 AACR. C1 [Sharma, Som D.; Meeran, Syed M.; Katiyar, Santosh K.] Univ Alabama, Dept Dermatol, Birmingham, AL 35294 USA. [Katiyar, Santosh K.] Birmingham VA Med Ctr, Birmingham, AL USA. RP Katiyar, SK (reprint author), Univ Alabama, Dept Dermatol, 1670 Univ Blvd,Volker Hall 557,POB 202, Birmingham, AL 35294 USA. EM skatiyar@uab.edu FU Veterans Administration FX Grant Support; Veterans Administration Merit Review Award (S. K. Katiyar). NR 37 TC 29 Z9 31 U1 1 U2 4 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1535-7163 J9 MOL CANCER THER JI Mol. Cancer Ther. PD MAR PY 2010 VL 9 IS 3 BP 569 EP 580 DI 10.1158/1535-7163.MCT-09-0638 PG 12 WC Oncology SC Oncology GA 607GO UT WOS:000278487300005 PM 20145019 ER PT J AU Ix, JH Shlipak, MG Wassel, CL Whooley, MA AF Ix, Joachim H. Shlipak, Michael G. Wassel, Christina L. Whooley, Mary A. TI Fibroblast growth factor-23 and early decrements in kidney function: the Heart and Soul Study SO NEPHROLOGY DIALYSIS TRANSPLANTATION LA English DT Article DE albuminuria; chronic; fibroblast growth factor-23; kidney disease; osteodystrophy ID CYSTATIN-C; CARDIOVASCULAR MORTALITY; ELDERLY PERSONS; DISEASE; FIBROBLAST-GROWTH-FACTOR-23; COMMUNITY; CALCIUM; RISK; ASSOCIATION; PHOSPHORUS AB Methods. In 792 outpatients with stable cardiovascular disease (CVD) and normal kidney function to moderate CKD, we evaluate the associations of estimated glomerular filtration rate (eGFR) and albumin-to-creatinine ratio (ACR) with plasma FGF-23 concentrations. Results. Compared to participants with eGFR >= 90 ml/min/1.73m(2), mean FGF-23 concentrations were 7.8 RU/ml higher (4.3-11.5, P = 0.01) in those with eGFR 60-89 ml/min/1.73m(2) in models adjusted for age, sex, race, ACR, blood pressure, diabetes and body mass index. More advanced decrements in eGFR were associated with much higher FGF-23 concentrations. In spline analysis, the slope of change in FGF-23 concentration was evident at eGFR < 90 ml/min/1.73m(2). Compared to participants with ACR < 30 mg/g, mean FGF-23 concentrations were 18.4 RU/ml higher (9.3-29.2, P < 0.001) in those with ACR 30-299 mg/g in models adjusted for identical covariates plus eGFR and much higher in individuals with ACR >= 300 mg/g. Spline analysis demonstrated a linear relationship of ACR with FGF-23, independent of eGFR, even among persons with ACR < 30 mg/g. Conclusion. Modest decrements in eGFR or elevations in albuminuria are each independently associated with higher FGF-23 concentrations in outpatients with stable CVD. C1 [Ix, Joachim H.] Univ Calif San Diego, Dept Med, Div Nephrol, San Diego, CA 92103 USA. [Ix, Joachim H.] Vet Affairs San Diego Healthcare Syst, Nephrol Sect, San Diego, CA USA. [Ix, Joachim H.; Wassel, Christina L.] Univ Calif San Diego, Dept Family & Prevent Med, Div Prevent Med, San Diego, CA 92103 USA. [Shlipak, Michael G.; Whooley, Mary A.] San Francisco VA Med Ctr, Gen Med Sect, San Francisco, CA USA. [Shlipak, Michael G.; Whooley, Mary A.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Shlipak, Michael G.; Whooley, Mary A.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. RP Ix, JH (reprint author), Univ Calif San Diego, Dept Med, Div Nephrol, San Diego, CA 92103 USA. EM joeix@ucsd.edu FU American Heart Association; Department of Veterans Epidemiology Merit Review Program; Department of Veterans Affairs Health Services Research and Development service; National Heart Lung and Blood Institute [R01 HL079235]; American Federation for Aging Research; Robert Wood Johnson Foundation; Ischemia Research and Education Foundation FX The authors thank Ms. Clydene Nee for review and assistance with the manuscript. This study was supported by an American Heart Association Fellow to Faculty Transition Award (JHI). The Heart and Soul Study was supported by the Department of Veterans Epidemiology Merit Review Program; the Department of Veterans Affairs Health Services Research and Development service; the National Heart Lung and Blood Institute (R01 HL079235); the American Federation for Aging Research ( Paul Beeson Scholars Program); the Robert Wood Johnson Foundation ( Generalist Physician Faculty Scholars Program); and the Ischemia Research and Education Foundation. NR 18 TC 68 Z9 72 U1 1 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0931-0509 J9 NEPHROL DIAL TRANSPL JI Nephrol. Dial. Transplant. PD MAR PY 2010 VL 25 IS 3 BP 993 EP 997 DI 10.1093/ndt/gfp699 PG 5 WC Transplantation; Urology & Nephrology SC Transplantation; Urology & Nephrology GA 561OQ UT WOS:000274987800054 PM 20037168 ER PT J AU Chao, LL Mueller, SG Buckley, ST Peek, K Raptentsetseng, S Elman, J Yaffe, K Miller, BL Kramer, JH Madison, C Mungas, D Schuff, N Weiner, MW AF Chao, L. L. Mueller, S. G. Buckley, S. T. Peek, K. Raptentsetseng, S. Elman, J. Yaffe, K. Miller, B. L. Kramer, J. H. Madison, C. Mungas, D. Schuff, N. Weiner, M. W. TI Evidence of neurodegeneration in brains of older adults who do not yet fulfill MCI criteria SO NEUROBIOLOGY OF AGING LA English DT Article DE Aging; MCI; AD; Structural MRI; MRS ID MILD COGNITIVE IMPAIRMENT; VOXEL-BASED MORPHOMETRY; MAGNETIC-RESONANCE SPECTROSCOPY; GRAY-MATTER LOSS; ALZHEIMERS-DISEASE; ENTORHINAL CORTEX; HIPPOCAMPAL ATROPHY; EXECUTIVE FUNCTION; CEREBRAL-CORTEX; ELDERLY-PEOPLE AB We sought to determine whether there are structural and metabolic changes in the brains of older adults with cognitive complaints yet who do not meet MCI criteria (i.e., preMCI). We compared the volumes of regional lobar gray matter (GM) and medial temporal lobe structures, including the hippocampus, entorhinal cortex (ERC), fusiform and parahippocampal gyri, and metabolite ratios from the posterior cingulate in individuals who had a Clinical Demetia Rating (CDR) of 0.5, but who did not meet MCI criteria (preMCI, N = 17), patients with mild cognitive impairment (MCI, N = 13), and cognitively normal controls (N = 18). Controls had more ERC, fusiform, and frontal gray matter volume than preMCI and MCI subjects and greater parahippocampal volume and more posterior cingulate N-acetylaspartate (NAA)/myoinosotil (mI) than MCI. There were no significant differences between MCI and preMCI subjects on any of these measures. These findings suggest there are neurodegenerative changes in the brains of older adults who have cognitive complaints severe enough to qualify for CDR = 0.5 yet show no deficits on formal neuropsychological testing. The results further support the hypothesis that detection of individuals with very mild forms of Alzheimer's disease (AD) may be facilitated by use of the CDR, which emphasizes changes in cognition over time within individuals rather than comparison with group norms. (C) 2008 Elsevier Inc. All rights reserved. C1 [Chao, L. L.; Mueller, S. G.; Buckley, S. T.; Peek, K.; Raptentsetseng, S.; Elman, J.; Schuff, N.; Weiner, M. W.] San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis, San Francisco, CA 94121 USA. [Chao, L. L.; Mueller, S. G.; Schuff, N.; Weiner, M. W.] Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94143 USA. [Chao, L. L.; Yaffe, K.; Weiner, M. W.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Yaffe, K.; Miller, B. L.; Kramer, J. H.; Weiner, M. W.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [Madison, C.] Calif Pacific Med Ctr, San Francisco, CA 94120 USA. [Mungas, D.] Univ Calif Davis, Dept Neurol, Davis, CA 95817 USA. RP Chao, LL (reprint author), San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis, 4150 Clement St,114M, San Francisco, CA 94121 USA. EM linda.chao@ucsf.edu RI Mungas, Dan/E-6810-2011 OI Elman, Jeffrey/0000-0002-8072-2294 FU National Institute on Aging [AG10897]; San Francisco Veterans Affairs Medical Center FX National Institute on Aging (Grant AG10897), Jennifer Hlavin, Kari Haws, Prediction of Cognitive Decline volunteers, and the San Francisco Veterans Affairs Medical Center. NR 82 TC 19 Z9 19 U1 0 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0197-4580 J9 NEUROBIOL AGING JI Neurobiol. Aging PD MAR PY 2010 VL 31 IS 3 BP 368 EP 377 DI 10.1016/j.neurobiolaging.2008.05.004 PG 10 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA 584NP UT WOS:000276759600002 PM 18550226 ER PT J AU Loftis, JM Huckans, M Morasco, BJ AF Loftis, Jennifer M. Huckans, Marilyn Morasco, Benjamin J. TI Neuroimmune mechanisms of cytokine-induced depression: Current theories and novel treatment strategies SO NEUROBIOLOGY OF DISEASE LA English DT Review DE Depression; Cytokines; Inflammation; Antidepressants; Animal models; Sickness behavior; Biomarkers ID TUMOR-NECROSIS-FACTOR; INTERFERON-INDUCED DEPRESSION; LONG-TERM POTENTIATION; CENTRAL-NERVOUS-SYSTEM; CHRONIC HEPATITIS-C; RAT DENTATE GYRUS; INTERLEUKIN-1-INDUCED SICKNESS BEHAVIOR; PRO-INFLAMMATORY CYTOKINES; IRRITABLE-BOWEL-SYNDROME; MAJOR DEPRESSION AB The relationships between immune and neural function are an increasingly important area of study for neuropsychiatric disorders, in particular depression. This is exemplified by the growing number of publications on cytokines and depression during the last 10 years, as compared to earlier decades. This review summarizes the current theories and novel treatment strategies for depression, with a focus on cytokine-induced depression. Neuroimmune mechanisms are now viewed as central to the development of depressive symptoms and emerging evidence is beginning to identify the neural circuits involved in cytokine-induced depression. The current diagnostic categories for depression, as defined by the Diagnostic and Statistical Manual of Mental Disorders, however, are not etiologically or biologically derived, and it has been proposed that "depression", likely reflects multiple pathogeneses leading to varying symptom constellations. As we move toward a better biological understanding of depression-related symptom constellations or syndromes, the term "depression" may prove inadequately broad, and an integration of interdisciplinary literatures will increase in importance. Future research should aim to characterize these depression-related symptom constellations or syndromes better with the goal of optimizing treatment strategies. (C) Published by Elsevier Inc. C1 [Loftis, Jennifer M.; Huckans, Marilyn; Morasco, Benjamin J.] Portland VA Med Ctr, Behav Hlth & Clin Neurosci Div, Res & Dev Serv, Portland, OR 97239 USA. [Loftis, Jennifer M.; Huckans, Marilyn; Morasco, Benjamin J.] Portland VA Med Ctr, NW Hepatitis Resource Ctr C, Portland, OR 97239 USA. [Loftis, Jennifer M.; Huckans, Marilyn; Morasco, Benjamin J.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97239 USA. [Loftis, Jennifer M.] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97239 USA. RP Loftis, JM (reprint author), Portland VA Med Ctr, Behav Hlth & Clin Neurosci Div, Res & Dev Serv, 3710 SW US Vet Hosp Rd,R&D 99, Portland, OR 97239 USA. EM loftisj@ohsu.edu FU NIDA NIH HHS [K23 DA023467-02, K23 DA023467] NR 180 TC 97 Z9 107 U1 3 U2 29 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0969-9961 J9 NEUROBIOL DIS JI Neurobiol. Dis. PD MAR PY 2010 VL 37 IS 3 SI SI BP 519 EP 533 DI 10.1016/j.nbd.2009.11.015 PG 15 WC Neurosciences SC Neurosciences & Neurology GA 560PH UT WOS:000274914100005 PM 19944762 ER PT J AU Shen, HX Hu, XM Liu, C Wang, SP Zhang, WT Gao, H Steder, RA Gao, YQ Chen, J AF Shen, Hongxia Hu, Xiaoming Liu, Can Wang, Suping Zhang, Wenting Gao, Hui Steder, R. Anne Gao, Yanqin Chen, Jun TI Ethyl pyruvate protects against hypoxic-ischemic brain injury via anti-cell death and anti-inflammatory mechanisms SO NEUROBIOLOGY OF DISEASE LA English DT Article DE Neonatal hypoxia-ischemia; Neuroprotection; Cell death; Inflammation; Microglia; Calpain; Calcium; NF-kappa B ID APOPTOSIS-INDUCING FACTOR; OXYGEN-GLUCOSE DEPRIVATION; WIDE THERAPEUTIC WINDOW; FOCAL CEREBRAL-ISCHEMIA; NEONATAL-RAT; OXIDATIVE STRESS; PERMEABILITY TRANSITION; INFLAMMATORY MEDIATORS; ACTIVATED MICROGLIA; REPERFUSION INJURY AB Ethyl pyruvate (EP) is protective in experimental models of many illnesses. This study investigates whether EP can protect against neonatal hypoxic-ischemic (H-I) brain injury. Pre-treatment with EP significantly reduced brain damage at 7 days post-H-I, with 50 mg/kg EP achieving over 50% recovery in tissue loss compared to vehicle-treated animals. Delayed treatment with EP until 30 min after H-I was still neuroprotective. EP-afforded brain protection, together with neurological function improvement, was observed up to 2 months after HA We further demonstrated an inhibitory effect of EP on cell death, both in an in vivo model of H-I and in in vitro neuronal cultures subjected to OGD, by reducing calpain activation and calcium dysregulation. Moreover, EP exerted an anti-inflammatory effect in microglia by inhibiting NF-kappa B activation and subsequent release of inflammatory mediators. Taken together, our results suggest that EP confers potent neuroprotection against neonatal H-I brain injury via its anti-cell death and antiinflammatory actions. EP is a potential novel therapeutic agent for neonatal H-I brain injury. (C) Published by Elsevier Inc. C1 [Hu, Xiaoming; Wang, Suping; Steder, R. Anne; Gao, Yanqin; Chen, Jun] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA. [Shen, Hongxia; Liu, Can; Zhang, Wenting; Gao, Hui; Gao, Yanqin; Chen, Jun] Fudan Univ, State Key Lab Med Neurobiol, Shanghai 200032, Peoples R China. [Shen, Hongxia; Liu, Can; Zhang, Wenting; Gao, Hui; Gao, Yanqin; Chen, Jun] Fudan Univ, Inst Brain Sci, Shanghai 200032, Peoples R China. [Hu, Xiaoming; Wang, Suping; Steder, R. Anne; Chen, Jun] Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15260 USA. RP Chen, J (reprint author), Univ Pittsburgh, Sch Med, Dept Neurol, S-507,Biomed Sci Tower, Pittsburgh, PA 15213 USA. EM yqgao@shmu.edu.cn; chenj2@upmc.edu RI Gao, Yanqin/I-6790-2016 OI Gao, Yanqin/0000-0002-4915-9819 FU NIH/NINDS [NS36736, NS43802, NS45048]; Chinese Natural Science Foundation [30470592, 30670642, J0730860] FX H.S. and X.H. contributed equally to this manuscript. This project was supported by NIH/NINDS grants NS36736, NS43802, and NS45048 (to J.C.). Y.G. was supported by the Chinese Natural Science Foundation (grants 30470592, 30670642 and J0730860). C.L. was supported by the Chinese Natural Science Foundation (grant J0730860). We thank Carol Culver for excellent editorial assistance. NR 76 TC 44 Z9 49 U1 1 U2 8 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0969-9961 EI 1095-953X J9 NEUROBIOL DIS JI Neurobiol. Dis. PD MAR PY 2010 VL 37 IS 3 SI SI BP 711 EP 722 DI 10.1016/j.nbd.2009.12.010 PG 12 WC Neurosciences SC Neurosciences & Neurology GA 560PH UT WOS:000274914100024 PM 20026271 ER PT J AU Eutamene, H Bradesi, S Larauche, M Theodorou, V Beaufrand, C Ohning, G Fioramonti, J Cohen, M Bryant, AP Kurtz, C Currie, MG Mayer, EA Bueno, L AF Eutamene, H. Bradesi, S. Larauche, M. Theodorou, V. Beaufrand, C. Ohning, G. Fioramonti, J. Cohen, M. Bryant, A. P. Kurtz, C. Currie, M. G. Mayer, E. A. Bueno, L. TI Guanylate cyclase C-mediated antinociceptive effects of linaclotide in rodent models of visceral pain SO NEUROGASTROENTEROLOGY AND MOTILITY LA English DT Article DE guanylate cyclase C; irritable bowel syndrome; linaclotide; visceral pain ID IRRITABLE-BOWEL-SYNDROME; CORTICOTROPIN-RELEASING-FACTOR; HEAT-STABLE ENTEROTOXIN; DEPENDENT PROTEIN-KINASE; ESCHERICHIA-COLI; CHRONIC CONSTIPATION; COLORECTAL DISTENSION; RECTAL DISTENSION; SMALL-INTESTINE; MAST-CELLS AB Background Linaclotide is a novel, orally administered investigational drug currently in clinical development for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) and chronic idiopathic constipation. Visceral hyperalgesia is a major pathophysiological mechanism in IBS-C. Therefore, we investigated the anti-nociceptive properties of linaclotide in rodent models of inflammatory and non-inflammatory visceral pain and determined whether these pharmacological effects are linked to the activation of guanylate cyclase C (GC-C). Methods Orally administered linaclotide was evaluated in non-inflammatory acute partial restraint stress (PRS) and acute water avoidance stress (WAS) models in Wistar rats, and in a trinitrobenzene sulfonic acid (TNBS)-induced inflammatory model in Wistar rats and GC-C null mice. Key Results In TNBS-induced colonic allodynia, linaclotide significantly decreased the number of abdominal contractions in response to colorectal distension without affecting the colonic wall elasticity change in response to distending pressures after TNBS. However, linaclotide had no effect on visceral sensitivity under basal conditions. In addition, linaclotide significantly decreased colonic hypersensitivity in the PRS and WAS models. In wild type (wt) and GC-C null mice, the instillation of TNBS induced similar hyperalgesia and allodynia. However, in post-inflammatory conditions linaclotide significantly reduced hypersensitivity only in wt mice, but not in GC-C null mice. Conclusions & Inferences These findings indicate that linaclotide has potent anti-nociceptive effects in several mechanistically different rodent models of visceral hypersensitivity and that these pharmacological properties of linaclotide are exerted through the activation of the GC-C receptor. Therefore, linaclotide may be capable of decreasing abdominal pain in patients suffering from IBS-C. C1 [Eutamene, H.; Theodorou, V.; Beaufrand, C.; Fioramonti, J.; Bueno, L.] INRA, UMR, Purpan Neurogastroenterol & Nutr Unit, F-31931 Toulouse 9, France. [Bradesi, S.; Larauche, M.; Mayer, E. A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Ctr Neurobiol Stress, Los Angeles, CA 90095 USA. [Ohning, G.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Cohen, M.] Cincinnati Childrens Hosp, Med Ctr, Cincinnati, OH USA. [Bryant, A. P.; Kurtz, C.; Currie, M. G.] Ironwood Pharmaceut, Cambridge, MA USA. RP Bueno, L (reprint author), INRA, UMR 1054, Neurogastroenterol & Nutr Unit, EI Purpan, 180 Chemin Tournefeuille,BP3, F-31931 Toulouse 9, France. EM lbueno@toulouse.inra.fr OI Larauche, Muriel/0000-0003-3320-3675; Cohen, Mitchell/0000-0002-4412-350X FU Ironwood Pharmaceuticals FX The authors acknowledge V. Tondereau for her expert technical assistance, the INRA institute for all experimental facilities and Ironwood Pharmaceuticals for their financial support to the laboratories of Dr Bueno and Dr Mayer for performing these studies. NR 47 TC 0 Z9 0 U1 1 U2 3 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1350-1925 J9 NEUROGASTROENT MOTIL JI Neurogastroenterol. Motil. PD MAR PY 2010 VL 22 IS 3 DI 10.1111/j.1365-2982.2009.01385.x PG 11 WC Gastroenterology & Hepatology; Clinical Neurology; Neurosciences SC Gastroenterology & Hepatology; Neurosciences & Neurology GA 553AG UT WOS:000274336200011 ER PT J AU Asch, DA Nicholson, S Srinivas, S Herrin, J Epstein, AJ AF Asch, David A. Nicholson, Sean Srinivas, Sindhu Herrin, Jeph Epstein, Andrew J. TI Evaluating Obstetrical Residency Programs Using Patient Outcomes EDITORIAL COMMENT SO OBSTETRICAL & GYNECOLOGICAL SURVEY LA English DT Editorial Material C1 [Asch, David A.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equity Res & Promot, Philadelphia, PA USA. Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. Univ Penn, Dept Obstet & Gynecol, Philadelphia, PA 19104 USA. Cornell Univ, Ithaca, NY USA. Yale Univ, New Haven, CT USA. RP Asch, DA (reprint author), Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equity Res & Promot, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0029-7828 J9 OBSTET GYNECOL SURV JI Obstet. Gynecol. Surv. PD MAR PY 2010 VL 65 IS 3 BP 152 EP 153 PG 2 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 575UQ UT WOS:000276095000005 ER PT J AU Richter, HE Burgio, KL Brubaker, L Nygaard, IE Ye, W Weidner, A Bradley, CS Handa, VL Borello-France, D Goode, PS Zyczynski, H Lukacz, ES Schaffer, J Barber, M Meikle, S Spino, C AF Richter, Holly E. Burgio, Kathryn L. Brubaker, Linda Nygaard, Ingrid E. Ye, Wen Weidner, Alison Bradley, Catherine S. Handa, Victoria L. Borello-France, Diane Goode, Patricia S. Zyczynski, Halina Lukacz, Emily S. Schaffer, Joseph Barber, Matthew Meikle, Susan Spino, Cathie CA Pelvic Floor Disorders Network TI Continence Pessary Compared With Behavioral Therapy or Combined Therapy for Stress Incontinence A Randomized Controlled Trial SO OBSTETRICS AND GYNECOLOGY LA English DT Article; Proceedings Paper CT 39th Annual Meeting of the International-Continence-Society CY SEP 29-OCT 03, 2009 CL San Francisco, CA SP Int Continence Soc ID URINARY-INCONTINENCE; ELECTRICAL-STIMULATION; MUSCLE EXERCISE; WOMEN; MANAGEMENT; VALIDATION AB OBJECTIVE: To compare the effectiveness of a continence pessary to evidence-based behavioral therapy for stress incontinence and to assess whether combined pessary and behavioral therapy is superior to single-modality therapy. METHODS: This was a multisite, randomized clinical trial (Ambulatory Treatments for Leakage Associated with Stress Incontinence [ATLAS]) that randomly assigned 446 women with stress incontinence to pessary, behavioral therapy, or combined treatment. Primary outcome measures, at 3 months, were Patient Global Impression of Improvement and the stress incontinence subscale of the Pelvic Floor Distress Inventory. A priori, to be considered clinically superior, combination therapy had to be better than both single-modality therapies. Outcome measures were repeated at 6 and 12 months. Primary analyses used an intention-to-treat approach. RESULTS: At 3 months, scores from 40% of the pessary group and 49% of the behavioral group were "much better" or "very much better" on the Patient Global Impression of Improvement (P=.10). Compared with the pessary group, more women in the behavioral group reported having no bothersome incontinence symptoms (49% compared with 33%, P=.006) and treatment satisfaction (75% compared with 63%, P=.02). Combination therapy was significantly better than pessary as shown on the Patient Global Impression of Improvement (53%, P=.02) and Pelvic Floor Distress Inventory (44%, P=.05) but not better than behavioral therapy; it was therefore not superior to single-modality therapy. Group differences were not sustained to 12 months on any measure, and patient satisfaction remained above 50% for all treatment groups. CONCLUSION: Behavioral therapy resulted in greater patient satisfaction and fewer bothersome incontinence symptoms than pessary at 3 months, but differences did not persist to 12 months. Combination therapy was not superior to single-modality therapy. C1 [Richter, Holly E.] Univ Alabama, Dept Obstet & Gynecol, Birmingham, AL 35233 USA. Birmingham VA Med Ctr, Birmingham, AL USA. Loyola Univ, Maywood, IL 60153 USA. Univ Utah, Salt Lake City, UT USA. Univ Michigan, Ann Arbor, MI 48109 USA. Duke Univ, Durham, NC USA. Univ Iowa, Iowa City, IA USA. Johns Hopkins Sch Med, Baltimore, MD USA. Duquesne Univ, Pittsburgh, PA 15219 USA. Magee Womens Hosp, Pittsburgh, PA USA. Univ Calif San Diego, San Diego, CA 92103 USA. Univ Texas SW, Dallas, TX USA. Cleveland Clin, Cleveland, OH 44106 USA. NIH, Bethesda, MD 20892 USA. RP Richter, HE (reprint author), Univ Alabama, Dept Obstet & Gynecol, 618 20th St,NHB 219, Birmingham, AL 35233 USA. EM hrichter@uabmc.edu FU NCATS NIH HHS [UL1 TR000005]; NICHD NIH HHS [U10 HD054241, U01 HD041249, U01 HD041249-09, U10 HD 41250, U10 HD041248, U10 HD041250, U10 HD041261, U10 HD041263, U10 HD041267, U10 HD041268, U10 HD054136, U10 HD054214, U10 HD054215, U10 HD41248, U10 HD41249, U10 HD41261, U10 HD41263, U10 HD41267, U10 HD41268, U10 HD54136, U10 HD54214, U10 HD54215, U10 HD54241, UG1 HD054214] NR 23 TC 41 Z9 43 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0029-7844 J9 OBSTET GYNECOL JI Obstet. Gynecol. PD MAR PY 2010 VL 115 IS 3 BP 609 EP 617 DI 10.1097/AOG.0b013e3181d055d4 PG 9 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 563LA UT WOS:000275132300019 PM 20177294 ER PT J AU Kacmaz, RO Kempen, JH Newcomb, C Daniel, E Gangaputra, S Nussenblatt, RB Rosenbaum, JT Suhler, EB Thorne, JE Jabs, DA Levy-Clarke, GA Foster, CS AF Kacmaz, R. Oktay Kempen, John H. Newcomb, Craig Daniel, Ebenezer Gangaputra, Sapna Nussenblatt, Robert B. Rosenbaum, James T. Suhler, Eric B. Thorne, Jennifer E. Jabs, Douglas A. Levy-Clarke, Grace A. Foster, C. Stephen TI Cyclosporine for Ocular Inflammatory Diseases SO OPHTHALMOLOGY LA English DT Article ID LOW-DOSE CYCLOSPORINE; TERM-FOLLOW-UP; BIRDSHOT RETINOCHOROIDOPATHY; IMMUNOMODULATORY THERAPY; ENDOGENOUS UVEITIS; BEHCETS-SYNDROME; MASKED TRIAL; CYCLOPHOSPHAMIDE; CHOROIDITIS; ARTHRITIS AB Purpose: To evaluate the clinical outcomes of cyclosporine treatment for noninfectious ocular inflammation. Design: Retrospective cohort study. Participants: A total of 373 patients with noninfectious ocular inflammation managed at 4 tertiary ocular inflammation clinics in the United States observed to use cyclosporine as a single noncorticosteroid immunosuppressive agent to their treatment regimen, between 1979 and 2007 inclusive. Methods: Participants were identified from the Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study. Demographic and clinical characteristics, including dosage of cyclosporine and main outcome measures, were obtained for every eye of every patient at every visit via medical record review by trained expert reviewers. Main Outcome Measures: Control of inflammation, sustained control after reducing corticosteroid dosages, and discontinuation of therapy because of toxicity. Results: Of the 373 patients (681 eyes) initiating cyclosporine monotherapy, 33.4% by 6 months and 51.9% by 1 year gained sustained, complete control of inflammation over at least 2 visits spanning at least 28 days. Approximately 25% more improved to a level of slight inflammatory activity by each of these time points. Corticosteroid-sparing success (completely controlled inflammation for at least 28 days with prednisone <= 10 mg/day) was achieved by 22.1% by 6 months and 36.1% within 1 year. Toxicity led to discontinuation of therapy within 1 year by 10.7% of the population. Patients aged more than 55 years were more than 3-fold more likely to discontinue therapy because of toxicity than patients aged 18 to 39 years. Doses of 151 to 250 mg/day tended to be more successful than lower doses and were not associated with a higher discontinuation for toxicity rate; higher doses did not seem to offer a therapeutic advantage. Conclusions: Cyclosporine, with corticosteroid therapy as indicated, was modestly effective for controlling ocular inflammation. Our data support a preference for cyclosporine adult dosing between 151 and 250 mg/day. Although cyclosporine was tolerated by the majority of patients, toxicity was more frequent with increasing age; alternative agents may be preferred for patients aged more than 55 years. Financial Disclosure(s): The authors have no proprietary or commercial interest in any materials discussed in this article. Ophthalmology 2010; 117: 576-584 (C) 2010 by the American Academy of Ophthalmology. C1 [Kacmaz, R. Oktay; Jabs, Douglas A.] Mt Sinai Sch Med, Dept Ophthalmol, New York, NY USA. [Jabs, Douglas A.] Mt Sinai Sch Med, Dept Med, New York, NY USA. [Kacmaz, R. Oktay; Foster, C. Stephen] Massachusetts Eye Res & Surg Inst, Cambridge, MA USA. [Kempen, John H.; Newcomb, Craig] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Kempen, John H.; Newcomb, Craig] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Kempen, John H.] Univ Penn, Ctr Prevent Ophthalmol & Biostat, Dept Ophthalmol, Philadelphia, PA 19104 USA. [Daniel, Ebenezer; Gangaputra, Sapna; Thorne, Jennifer E.] Johns Hopkins Univ, Dept Ophthalmol, Baltimore, MD USA. [Thorne, Jennifer E.; Jabs, Douglas A.] Johns Hopkins Univ, Dept Epidemiol, Baltimore, MD USA. [Gangaputra, Sapna] Univ Wisconsin, Dept Ophthalmol, Fundus Photog Reading Ctr, Madison, WI USA. [Nussenblatt, Robert B.; Levy-Clarke, Grace A.] NEI, Immunol Lab, Bethesda, MD USA. [Rosenbaum, James T.; Suhler, Eric B.] Oregon Hlth & Sci Univ, Dept Internal Med, Dept Ophthalmol, Portland, OR USA. [Rosenbaum, James T.] Oregon Hlth & Sci Univ, Dept Internal Med, Div Rheumatol, Portland, OR USA. [Suhler, Eric B.] Portland VA Med Ctr, Portland, OR USA. [Levy-Clarke, Grace A.] St Lukes Cataract & Laser Inst, Tarpon Springs, FL USA. [Foster, C. Stephen] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA. RP Kempen, JH (reprint author), Univ Penn, Ctr Prevent Ophthalmol & Biostat, Dept Ophthalmol, 3535 Market St,Suite 700, Philadelphia, PA 19104 USA. EM john.kempen@uphs.upenn.edu OI Daniel, Ebenezer/0000-0002-2027-2316 FU National Eye Institute [EY014943]; Research to Prevent Blindness; Paul and Evanina Mackall Foundation; RPB James S. Adams Special Scholar Award; National Eye Institute; Department of Veterans' Affairs FX Supported primarily by National Eye Institute Grant EY014943 (Dr. Kempen). Additional support was provided by Research to Prevent Blindness and the Paul and Evanina Mackall Foundation. Dr. Kempen is an RPB James S. Adams Special Scholar Award recipient. Drs. Jabs and Rosenbaum are Research to Prevent Blindness Senior Scientific Investigator Award recipients. Dr. Thorne is an RPB Harrington Special Scholar Award recipient. Dr. Levy-Clarke was previously supported by and Dr. Nussenblatt continues to be supported by intramural funds of the National Eye Institute. Dr. Suhler was supported in part by the Department of Veterans' Affairs. NR 41 TC 82 Z9 84 U1 1 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0161-6420 J9 OPHTHALMOLOGY JI Ophthalmology PD MAR PY 2010 VL 117 IS 3 BP 576 EP 584 DI 10.1016/j.ophtha.2009.08.010 PG 9 WC Ophthalmology SC Ophthalmology GA 563BQ UT WOS:000275101000025 PM 20031223 ER PT J AU Johnson, ES Weinstein, JR Thorp, ML Platt, RW Petrik, AF Yang, XH Anderson, S Smith, DH AF Johnson, Eric S. Weinstein, Jessica R. Thorp, Micah L. Platt, Robert W. Petrik, Amanda F. Yang, Xiuhai Anderson, Sharon Smith, David H. TI Predicting the risk of hyperkalemia in patients with chronic kidney disease starting lisinopril SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY LA English DT Article DE hyperkalemia; chronic kidney disease; ACE-inhibitors; risk score; cohort study; adverse effects ID CONVERTING ENZYME-INHIBITORS; RENIN-ANGIOTENSIN SYSTEM; PROGNOSTIC RESEARCH; THERAPY; MODEL; GUIDELINES AB Purpose Angiotensin-converting enzyme (ACE) inhibitors are recommended for patients with chronic kidney disease (CKD) because they slow disease progression. But physicians' concerns about the risk of hyperkalemia (elevated serum potassium level), a potentially fatal adverse effect, may limit optimal management with ACE-inhibitors. We synthesized known predictors of hyperkalemia into a prognostic risk score to predict the risk of hyperkalemia. Methods We assembled a retrospective cohort of adult patients with possible CKD (at least one estimated glomerular filtration rate (eGFR) value less than 60 ml/min/1.73 m(2)) who started an ACE-inhibitor (i.e., incident users) between 1998 and 2006 at a health maintenance organization. We followed patients for hyperkalemia: (1) potassium value >5.5 mmol/L; or (2) diagnosis code for hyperkalemia. Cox regression synthesized a priori predictors recorded in the electronic medical record into a risk score. Results We followed 5171 patients and 145 experienced hyperkalemia, a 90-day risk of 2.8%. Predictors included: age, eGFR, diabetes, heart failure, potassium supplements, potassium-sparing diuretics, and a high dose for the ACE-inhibitor (lisinopril). The risk score separated high-risk patients (top quintile, observed risk of 6.9%) from low-risk patients (bottom quintile, observed risk of 0.7%). Predicted and observed risks agreed within 1% for each quintile. The risk increased gradually in relation to declining eGFR with no apparent threshold for contraindicating ACE-inhibitors. Conclusions The risk score separated high-risk patients (who may need more intensive laboratory monitoring) from low-risk patients. The risk score should be validated in other populations before it is ready for use in clinical practice. Copyright (C) 2010 John Wiley & Sons, Ltd. C1 [Johnson, Eric S.; Petrik, Amanda F.; Yang, Xiuhai; Smith, David H.] Kaiser Permanente NW, Ctr Hlth Res, Portland, OR 97227 USA. [Weinstein, Jessica R.; Anderson, Sharon] Oregon Hlth & Sci Univ, Dept Med, Div Nephrol & Hypertens, Portland, OR 97201 USA. [Thorp, Micah L.] Kaiser Permanente NW, Dept Nephrol, Portland, OR 97227 USA. [Platt, Robert W.] McGill Univ, Dept Epidemiol & Biostat, Montreal, PQ, Canada. [Anderson, Sharon] Portland VA Med Ctr, Portland, OR USA. RP Johnson, ES (reprint author), Kaiser Permanente NW, Ctr Hlth Res, 3800 N Interstate Ave, Portland, OR 97227 USA. EM Eric.S.Johnson@kpchr.org RI Platt, Robert/G-5847-2012 OI Platt, Robert/0000-0002-5981-8443 FU Oregon Clinical and Translational Research Institute (OCTRI) [UL1 RR024140]; National Center for Research Resources (NCRR); National Institutes of Health (NIH) FX This study and manuscript were sponsored by the Oregon Clinical and Translational Research Institute (OCTRI), grant number UL1 RR024140 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NI,H), and NIH Roadmap for Medical Research. NR 21 TC 16 Z9 16 U1 0 U2 2 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 1053-8569 J9 PHARMACOEPIDEM DR S JI Pharmacoepidemiol. Drug Saf. PD MAR PY 2010 VL 19 IS 3 BP 266 EP 272 DI 10.1002/pds.1923 PG 7 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy GA 570QT UT WOS:000275693700007 PM 20112435 ER PT J AU Liu, TJ Jackevicius, CA AF Liu, Tina J. Jackevicius, Cynthia A. TI Drug Interaction Between Clopidogrel and Proton Pump Inhibitors SO PHARMACOTHERAPY LA English DT Review DE proton pump inhibitor; PPI; omeprazole; clopidogrel; drug-drug interaction; thienopyridine ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PERCUTANEOUS CORONARY INTERVENTION; PEPTIC-ULCER DISEASE; EXPERT CONSENSUS DOCUMENT; ANTIPLATELET THERAPY; ELDERLY PERSONS; CARDIOVASCULAR EVENTS; PLATELET INHIBITION; CIGARETTE-SMOKING; CONTROLLED TRIAL AB Proton pump inhibitors (PPIs) have been recommended for reducing the risk of gastrointestinal bleeding associated with dual antiplatelet therapy (aspirin plus clopidogrel) However, Studies have found decreased efficacy of clopidogrel when concurrently administered with a PPI To determine the mechanism of and evidence for the potential interaction between clopidogrel and PPIs, along with the clinical implications of this drug Interaction, we reviewed recently published reports of trials that examined the interaction A MEDLINE database search (1966-September 2009) for English-language reports of clinical trials in human Subjects was performed, Supplemented by a manual search of reference lists Four trials that examined surrogate Outcomes and eight trials that examined clinical Outcomes were included in this review. Two surrogate outcome studies showed that PPIs negatively affected clopidogrel response and increased platelet aggregation, whereas the other two did not filed a significant difference between groups receiving PPIs and not receiving PPIs Three of four published clinical outcomes Studies and three of four unpublished clinical outcomes Studies available as abstracts found a significant association between PPI use and rates of acute myocardial Infarction, rehospitalization, death, or Stroke. Most of the currently available data, primarily from Observational Studies, show that some PPIs may decrease clopidogrel's antiplatelet effectiveness, with increased cardiac adverse outcomes wheel clopidogrel is combined with PPIs. Although current data do not show causation of adverse outcomes with PPI use because the available data are conflicting, this topic is still controversial Careful risk-benefit assessment IS required before prescribing PPIs for individual patients taking dual antiplatelet therapy. More evidence from randomized controlled trials is needed to clarify this drug interaction dilemma. C1 [Liu, Tina J.; Jackevicius, Cynthia A.] Western Univ Hlth Sci, Coll Pharm, Dept Pharm Practice, Pomona, CA 91766 USA. [Liu, Tina J.; Jackevicius, Cynthia A.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Pharm, Los Angeles, CA USA. [Jackevicius, Cynthia A.] Univ Toronto, Toronto Gen Hosp, Dept Pharm,Dept Hlth Policy Management & Evaluat, Univ Hlth Network,Fac Med, Toronto, ON M5G 1L7, Canada. [Jackevicius, Cynthia A.] Inst Clin Evaluat Sci, Toronto, ON, Canada. RP Liu, TJ (reprint author), Western Univ Hlth Sci, Coll Pharm, Dept Pharm Practice, 309 E 2nd St, Pomona, CA 91766 USA. NR 64 TC 12 Z9 12 U1 0 U2 4 PU PHARMACOTHERAPY PUBLICATIONS INC PI BOSTON PA NEW ENGLAND MEDICAL CENTER, 806, 750 WASHINGTON ST, BOSTON, MA 02111 USA SN 0277-0008 J9 PHARMACOTHERAPY JI Pharmacotherapy PD MAR PY 2010 VL 30 IS 3 BP 275 EP 289 PG 15 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 566FT UT WOS:000275356200008 PM 20180611 ER PT J AU La Fountaine, MF Wecht, JM Spungen, AM Bauman, WA AF La Fountaine, M. F. Wecht, J. M. Spungen, A. M. Bauman, W. A. TI Intra-inter visit reproducibility of short-term linear and nonlinear measurement of heart rate variability in tetraplegia and neurologically intact controls SO PHYSIOLOGICAL MEASUREMENT LA English DT Article DE tetraplegia; heart rate variability; entropy; reproducibility; reliability; short-term recordings ID SPINAL-CORD-INJURY; CARDIOVASCULAR CONTROL; ATRIAL-FIBRILLATION; SPECTRAL-ANALYSIS; RELIABILITY; COMPLEXITY; DYNAMICS; AGE; RECORDINGS; STANDARDS AB Heart rate variability (HRV) from the frequency domain and three calculations of entropy (En), approximate (ApEn), sample (SampEn) and Lempel-Ziv (LZEn), were assessed for intra- and inter-visit reproducibility from short-term recordings in persons with tetraplegia and neurologically intact controls. The intraclass correlation coefficient (ICC) was calculated for multiple comparisons to determine the reproducibility in both groups during a 4h visit and across three visits. By ICC in both groups, ApEn, SampEn and LZEn possessed excellent intra- (>= 0.87) and inter-visit reproducibility (>= 0.90). In contrast, frequency domain measures were collectively less concise. In general on intra- and inter-visit comparisons for both groups, high frequency (HF) measures were more reliable than low frequency (LF). In control subjects relative to other units of expression, normalized units (nu) of LF had the best intra- visit reliability across all comparisons. This was not the case on inter-visit comparisons where absolute (>= 0.74) and natural log (ln) (>= 0.66) representations of LF were more reliable. In the group with tetraplegia, LFln was the most reliable for comparisons up to or including 180 min (>= 0.60) and two visits (>= 0.63). Thus, calculations of En and HF HRV appear to be more reliable than LF HRV and less confounded by small sample sizes. C1 [La Fountaine, M. F.; Wecht, J. M.; Spungen, A. M.; Bauman, W. A.] James J Peters VA Med Ctr, Ctr Excellence Med Consequences SCI, Bronx, NY USA. [Spungen, A. M.; Bauman, W. A.] Mt Sinai Sch Med, Dept Med, New York, NY USA. [Wecht, J. M.; Spungen, A. M.; Bauman, W. A.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA. RP La Fountaine, MF (reprint author), James J Peters VA Med Ctr, Ctr Excellence Med Consequences SCI, Bronx, NY USA. EM michael.lafountaine@va.gov FU Veteran Affairs Rehabilitation Research and Development Service [B4162C, B3600R]; James J Peters VA Medical Center FX This research was supported by the Veteran Affairs Rehabilitation Research and Development Service (#B4162C, #B3600R), and the James J Peters VA Medical Center. The authors would like to extend their gratitude to Dr Joseph P Weir of Des Moines University, Osteopathic Medical Center, for his statistical assistance and programming prowess which contributed significantly to the development of this paper. NR 39 TC 7 Z9 7 U1 0 U2 3 PU IOP PUBLISHING LTD PI BRISTOL PA DIRAC HOUSE, TEMPLE BACK, BRISTOL BS1 6BE, ENGLAND SN 0967-3334 J9 PHYSIOL MEAS JI Physiol. Meas. PD MAR PY 2010 VL 31 IS 3 BP 363 EP 374 DI 10.1088/0967-3334/31/3/006 PG 12 WC Biophysics; Engineering, Biomedical; Physiology SC Biophysics; Engineering; Physiology GA 559SQ UT WOS:000274848400006 PM 20130343 ER PT J AU Mochon, AB Ye, J Kayala, MA Wingard, JR Clancy, CJ Nguyen, MH Felgner, P Baldi, P Liu, HP AF Mochon, A. Brian Ye, Jin Kayala, Matthew A. Wingard, John R. Clancy, Cornelius J. Nguyen, M. Hong Felgner, Philip Baldi, Pierre Liu, Haoping TI Serological Profiling of a Candida albicans Protein Microarray Reveals Permanent Host-Pathogen Interplay and Stage-Specific Responses during Candidemia SO PLOS PATHOGENS LA English DT Article ID GENE-EXPRESSION; TRANSCRIPTIONAL RESPONSE; INVASIVE CANDIDIASIS; SYSTEMIC CANDIDIASIS; SACCHAROMYCES-CEREVISIAE; NORMALIZATION METHODS; ANTIBODY-RESPONSES; OXIDATIVE STRESS; DRUG-RESISTANCE; IMMUNE-RESPONSE AB Candida albicans in the immunocompetent host is a benign member of the human microbiota. Though, when host physiology is disrupted, this commensal-host interaction can degenerate and lead to an opportunistic infection. Relatively little is known regarding the dynamics of C. albicans colonization and pathogenesis. We developed a C. albicans cell surface protein microarray to profile the immunoglobulin G response during commensal colonization and candidemia. The antibody response from the sera of patients with candidemia and our negative control groups indicate that the immunocompetent host exists in permanent host-pathogen interplay with commensal C. albicans. This report also identifies cell surface antigens that are specific to different phases (i.e. acute, early and mid convalescence) of candidemia. We identified a set of thirteen cell surface antigens capable of distinguishing acute candidemia from healthy individuals and uninfected hospital patients with commensal colonization. Interestingly, a large proportion of these cell surface antigens are involved in either oxidative stress or drug resistance. In addition, we identified 33 antigenic proteins that are enriched in convalescent sera of the candidemia patients. Intriguingly, we found within this subset an increase in antigens associated with heme-associated iron acquisition. These findings have important implications for the mechanisms of C. albicans colonization as well as the development of systemic infection. C1 [Mochon, A. Brian; Ye, Jin; Baldi, Pierre; Liu, Haoping] Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92717 USA. [Kayala, Matthew A.; Baldi, Pierre] Univ Calif Irvine, Inst Genom & Bioinformat, Irvine, CA 92717 USA. [Wingard, John R.] Univ Florida, Coll Med, Dept Med, Gainesville, FL USA. [Clancy, Cornelius J.; Nguyen, M. Hong] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA. [Clancy, Cornelius J.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Kayala, Matthew A.; Baldi, Pierre] Univ Calif Irvine, Dept Comp Sci, Irvine, CA 92717 USA. [Felgner, Philip] Univ Calif Irvine, Dept Med, Irvine, CA 92717 USA. [Felgner, Philip] Univ Calif Irvine, Pacific SW Ctr Res Emerging Infect, Irvine, CA 92717 USA. RP Mochon, AB (reprint author), Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92717 USA. EM h4liu@uci.edu FU National Institute of Allergy and Infectious Diseases [P01AI061537]; National Institute of General Medical Sciences [R01GM/AI55155] FX National Institute of Allergy and Infectious Diseases (P01AI061537) and National Institute of General Medical Sciences (R01GM/AI55155). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 78 TC 46 Z9 65 U1 0 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1553-7366 J9 PLOS PATHOG JI PLoS Pathog. PD MAR PY 2010 VL 6 IS 3 AR e1000827 DI 10.1371/journal.ppat.1000827 PG 14 WC Microbiology; Parasitology; Virology SC Microbiology; Parasitology; Virology GA 596XY UT WOS:000277720400035 PM 20361054 ER PT J AU Basile, JN Bloch, MJ AF Basile, Jan N. Bloch, Michael J. TI Identifying and Managing Factors That Interfere with or Worsen Blood Pressure Control SO POSTGRADUATE MEDICINE LA English DT Article DE blood pressure; hypertension; cardiovascular disease ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; AMERICAN-HEART-ASSOCIATION; OXIDE DONATOR NAPROXCINOD; RESISTANT HYPERTENSION; SCIENTIFIC STATEMENT; CYCLOOXYGENASE-2 INHIBITORS; TREATING OSTEOARTHRITIS; ANTIDEPRESSANT DRUGS; CLINICAL-PRACTICE; OLDER PATIENTS AB Hypertension is a major risk factor for ischemic heart disease, stroke, and heart failure. Even moderate blood pressure ( BP) elevation can have a significant impact on outcomes. Maintaining BP within recommended levels significantly reduces the risk of cardiovascular morbidity and mortality. Yet, more than one-third of people receiving treatment for hypertension in the United States have uncontrolled BP. When faced with a patient whose BP is no longer controlled, clinicians need to develop a differential diagnosis of potential contributing factors. These factors may include BP measurement issues, poor adherence to antihypertensive medications, therapeutic inertia on the part of clinicians, lifestyle changes, secondary causes of hypertension, or ingestion of substances that interfere with BP control. Patients who demonstrate a deterioration in BP control should be questioned about adherence, recent changes to diet and lifestyle, signs and symptoms of secondary causes of hypertension, and use of any concomitant medications or other substances that may be known to increase BP or interfere with antihypertensive therapy. Common substances that can interfere with BP control include nonsteroidal anti-inflammatory drugs ( NSAIDs), oral contraceptives, glucocorticoids, antidepressants, decongestants, alcohol, or other stimulants like cocaine and methamphetamines. Because of the high prevalence of both osteoarthritis and hypertension among elderly people, NSAIDs are a common potential factor in this age group. In the face of worsening BP control, clinicians must actively investigate potential contributing factors and appropriately increase or adjust antihypertensive therapy. C1 [Basile, Jan N.] Med Univ S Carolina, Div Gen Internal Med Geriatr, Charleston, SC 29414 USA. [Basile, Jan N.] Ralph H Johnson VA Med Ctr, Charleston, SC 29414 USA. [Bloch, Michael J.] Univ Nevada, Sch Med, Reno, NV 89557 USA. [Bloch, Michael J.] Univ Nevada, St Marys Risk Reduct Ctr, Reno, NV 89557 USA. RP Basile, JN (reprint author), Med Univ S Carolina, Div Gen Internal Med Geriatr, Charleston, SC 29414 USA. EM basilejn@musc.edu FU NicOx FX Editorial support was provided by Catherine Rees on behalf of the Lippincott CME Institute, through an educational grant provided by NicOx. NR 80 TC 3 Z9 3 U1 1 U2 4 PU JTE MULTIMEDIA PI BERWYN PA 1235 WESTLAKES DR, STE 220, BERWYN, PA 19312 USA SN 0032-5481 J9 POSTGRAD MED JI Postgrad. Med. PD MAR PY 2010 VL 122 IS 2 BP 35 EP 48 PG 14 WC Medicine, General & Internal SC General & Internal Medicine GA 642VK UT WOS:000281248900004 PM 20203454 ER PT J AU Qian, DZ Rademacher, BLS Pittsenbarger, J Huang, CY Myrthue, A Higano, CS Garzotto, M Nelson, PS Beer, TM AF Qian, David Z. Rademacher, Brooks L. S. Pittsenbarger, Janet Huang, Chung-Ying Myrthue, Anne Higano, Celestia S. Garzotto, Mark Nelson, Peter S. Beer, Tomasz M. TI CCL2 Is Induced by Chemotherapy and Protects Prostate Cancer Cells From Docetaxel-Induced Cytotoxicity SO PROSTATE LA English DT Article DE prostate cancer; chemotherapy resistance; CCL2; inflammation ID N-TERMINAL KINASE; IN-VIVO; KAPPA-B; NEOADJUVANT DOCETAXEL; IMPORTANT MEDIATOR; GROWTH; ANGIOGENESIS; ACTIVATION; APOPTOSIS; PATHWAYS AB BACKGROUND. Metastatic prostate cancer is either inherently resistant to chemotherapy or rapidly acquires this phenotype after chemotherapy exposure. In this study, we identified a docetaxel-induced resistance mechanism centered on CCL2. METHODS. We compared the gene expression profiles in individual human prostate cancer specimens before and after exposure to chemotherapy collected from previously untreated patients who participated in a clinical trial of preoperative chemotherapy. Subsequently, we used the gain- and loss-of-function approach in vitro to identify a potential mechanism underlying chemotherapy resistance. RESULTS. Among the molecular signatures associated with treatment, several genes that regulate the inflammatory response and chemokine activity were upregulated including a significant increase in transcripts encoding the CC chemokine CCL2. Docetaxel increased CCL2 expression in prostate cancer cell lines in vitro. CCL2-specific siRNA inhibited LNCaP and LAPC4 cell proliferation and enhanced the growth inhibitory effect of low-dose docetaxel. In contrast, overexpression of CCL2 or recombinant CCL2 protein stimulated prostate cancer cell proliferation and rescued cells from docetaxel-induced cytotoxicity. This protective effect of CCL2 was associated with activation of the ERK/MAP kinase and PI3K/AKT, inhibition of docetaxel-induced Bcl2 phosphorylation at serine 70, phosphorylation of Bad, and activation of caspase-3. The addition of a PI3K/AKT inhibitor Ly294002 reversed the CCL2 protection and was additive to docetaxel-induced toxicity. CONCLUSION. These results support a mechanism of chemotherapy resistance mediated by cellular stress responses involving the induction of CCL2 expression and suggest that inhibiting CCL2 activity could enhance therapeutic responses to taxane-based therapy. Prostate 70: 433442, 2010. (C) 2009 Wiley-Liss, Inc. C1 [Beer, Tomasz M.] Oregon Hlth & Sci Univ, Dept Med, Div Hematol & Med Oncol, Portland, OR 97239 USA. [Huang, Chung-Ying; Nelson, Peter S.] Fred Hutchinson Canc Res Ctr, Div Human Biol & Clin Res, Seattle, WA 98104 USA. [Higano, Celestia S.; Nelson, Peter S.] Univ Washington, Div Med Oncol, Seattle, WA 98195 USA. [Garzotto, Mark] Oregon Hlth & Sci Univ, Div Urol, Portland VA Med Ctr, Portland, OR 97239 USA. RP Beer, TM (reprint author), Oregon Hlth & Sci Univ, Dept Med, Div Hematol & Med Oncol, 3303 SW Bond,CH14R, Portland, OR 97239 USA. EM beert@ohsu.edu FU Aventis Pharmaceuticals [16080]; OSI, Inc. [031.G0008]; NIH [3M01RR00334-33S2, 1 R01 CA119125-01, U54CA126540]; PNW Prostate SPORE [CA97186] FX Grant sponsor: Aventis Pharmaceuticals; Grant number: 16080; Grant sponsor: OSI, Inc.; Grant number: 031.G0008; Grant sponsor: NIH; Grant numbers: 3M01RR00334-33S2, 1 R01 CA119125-01, U54CA126540; Grant sponsor: PNW Prostate SPORE; Grant number: CA97186. NR 40 TC 37 Z9 42 U1 0 U2 4 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0270-4137 J9 PROSTATE JI Prostate PD MAR 1 PY 2010 VL 70 IS 4 BP 433 EP 442 DI 10.1002/pros.21077 PG 10 WC Endocrinology & Metabolism; Urology & Nephrology SC Endocrinology & Metabolism; Urology & Nephrology GA 566OS UT WOS:000275382600009 PM 19866475 ER PT J AU Tobias, MC O'Neill, J Hudkins, M Bartzokis, G Dean, AC London, ED AF Tobias, Marc C. O'Neill, Joseph Hudkins, Matthew Bartzokis, George Dean, Andrew C. London, Edythe D. TI White-matter abnormalities in brain during early abstinence from methamphetamine abuse SO PSYCHOPHARMACOLOGY LA English DT Article DE Diffusion tensor imaging (DTI); Methamphetamine; Frontal white matter; Corpus callosum; Perforant path; Psychiatric symptoms ID MAGNETIC-RESONANCE SPECTROSCOPY; DIFFUSION TENSOR MRI; PSYCHIATRIC-SYMPTOMS; STRUCTURAL ABNORMALITIES; ALZHEIMERS-DISEASE; CORPUS-CALLOSUM; USERS; MYELINATION; INVENTORY; ADDICTION AB Previous studies revealed microstructural abnormalities in prefrontal white matter and corpus callosum of long-term abstinent chronic methamphetamine abusers. In view of the importance of the early abstinence period in treatment retention, we compared 23 methamphetamine-dependent subjects abstinent from methamphetamine for 7-13 days with 18 healthy comparison subjects. As certain metabolic changes in the brain first manifest after early abstinence from methamphetamine, it is also possible that microstructural white-matter abnormalities are not yet present during early abstinence. Using diffusion tensor imaging at 1.5 T, fractional anisotropy (FA) was measured in prefrontal white matter at four inferior-superior levels parallel to the anterior commissure-posterior commissure (AC-PC) plane. We also sampled FA in the corpus callosum at the midline and at eight bilateral, fiber-tract sites in other regions implicated in effects of methamphetamine. The methamphetamine group exhibited lower FA in right prefrontal white matter above the AC-PC plane (11.9% lower; p = 0.007), in midline genu corpus callosum (3.9%; p = 0.019), in left and right midcaudal superior corona radiata (11.0% in both hemispheres, p's = 0.020 and 0.016, respectively), and in right perforant fibers (7.3%; p = 0.025). FA in left midcaudal superior corona radiata was correlated with depressive and generalized psychiatric symptoms within the methamphetamine group. The findings support the idea that methamphetamine abuse produces microstructural abnormalities in white matter underlying and interconnecting prefrontal cortices and hippocampal formation. These effects are already present during the first weeks of abstinence from methamphetamine and are linked to psychiatric symptoms assessed during this period. C1 [Tobias, Marc C.; O'Neill, Joseph; Hudkins, Matthew; Bartzokis, George; Dean, Andrew C.; London, Edythe D.] Univ Calif Los Angeles, Semel Inst Neurosci & Biobehav Studies, Los Angeles, CA 90024 USA. [O'Neill, Joseph] Univ Calif Los Angeles, Semel Inst Neurosci, Div Child & Adolescent Psychiat, Los Angeles, CA 90024 USA. [Bartzokis, George; London, Edythe D.] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90024 USA. [London, Edythe D.] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA 90024 USA. [Bartzokis, George] Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA. RP O'Neill, J (reprint author), Univ Calif Los Angeles, Semel Inst Neurosci, Div Child & Adolescent Psychiat, 760 Westwood Plaza 58-227A, Los Angeles, CA 90024 USA. EM joneill@mednet.ucla.edu RI Bartzokis, George/K-2409-2013 FU National Institute on Drug Abuse [P20DA022539, R01DA020726, R03DA20512, R21DA023192]; National Center for Research Resources [MOIRR00865]; Katherine K. and Thomas P. Pike Chair; Marjorie Green Family Trust (EDL) FX This work was supported by grants from the National Institute on Drug Abuse (P20DA022539, R01DA020726, R03DA20512, and R21DA023192; EDL and JON) and by the National Center for Research Resources grant MOIRR00865 (UCLA General Clinical Research Center). Additional funding was provided by endowments from the Katherine K. and Thomas P. Pike Chair in Addiction Studies and the Marjorie Green Family Trust (EDL). NR 67 TC 34 Z9 40 U1 3 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0033-3158 J9 PSYCHOPHARMACOLOGY JI Psychopharmacology PD MAR PY 2010 VL 209 IS 1 BP 13 EP 24 DI 10.1007/s00213-009-1761-7 PG 12 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 553YZ UT WOS:000274404000002 PM 20101394 ER PT J AU Shiotani, A Haruma, K Nishi, R Fujita, M Kamada, T Honda, K Kusunoki, H Hata, J Graham, DY AF Shiotani, Akiko Haruma, Ken Nishi, Ryuji Fujita, Minoru Kamada, Tomoari Honda, Keisuke Kusunoki, Hiroaki Hata, Jiro Graham, David Y. TI Randomized, double-blind, pilot study of geranylgeranylacetone versus placebo in patients taking low-dose enteric-coated aspirin. Low-dose aspirin-induced small bowel damage SO SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY LA English DT Article ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; GASTRIC-MUCOSAL CELLS; VIDEO CAPSULE ENDOSCOPY; INTESTINAL PERMEABILITY; EXPERIMENTAL PATHOLOGY; FIBROSING COLONOPATHY; HEALTHY-SUBJECTS; PLUS OMEPRAZOLE; INJURY; INFLAMMATION AB Objective. Low-dose enteric-coated aspirin is increasingly being used for prevention of cardiovascular disease. The aim of this study was to evaluate whether geranylgeranylacetone (GGA) could prevent aspirin-induced small bowel injury. Material and methods. This was a prospective, randomized, double-blind, pilot study of GGA versus placebo in subjects taking low-dose enteric-coated aspirin. Young healthy volunteers were enrolled and each received 100 mg of enteric-coated aspirin per day plus either GGA (150 mg/day) or matching placebo for 7 days. Video capsule endoscopy of the small bowel and the Gastrointestinal Symptom Rating Scale (GSRS) questionnaire were performed before and after the administration of aspirin. Results. Twenty volunteers were evaluated. There was no significant difference in the number of lesions in any category between those receiving or not receiving GGA. Large erosions or ulcers were observed in 12 (60%; 95% confidence interval 36%- 80%) aspirin users. Mucosal breaks were most frequently found in the latter half of the proximal small bowel. Conclusions. Short-term administration of low-dose enteric-coated aspirin was associated with visible small bowel damage in the majority of users. We could not prove that aspirin-induced small bowel mucosal injury was prevented by GGA. C1 [Shiotani, Akiko; Haruma, Ken; Nishi, Ryuji; Fujita, Minoru; Kamada, Tomoari] Kawasaki Med Univ, Dept Internal Med, Okayama, Japan. [Honda, Keisuke; Kusunoki, Hiroaki] Kawasaki Med Univ, Dept Comprehens Med, Okayama, Japan. [Hata, Jiro] Kawasaki Med Univ, Dept Clin Pathol & Lab Med, Okayama, Japan. [Graham, David Y.] VA Med Ctr, Dept Med, Houston, TX USA. [Graham, David Y.] Baylor Coll Med, Houston, TX 77030 USA. RP Shiotani, A (reprint author), 577 Matsushima, Kurashiki, Okayama 7010192, Japan. EM shiotani@med.kawasaki-m.ac.jp NR 36 TC 42 Z9 42 U1 0 U2 0 PU TAYLOR & FRANCIS AS PI OSLO PA KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY SN 0036-5521 J9 SCAND J GASTROENTERO JI Scand. J. Gastroenterol. PD MAR PY 2010 VL 45 IS 3 BP 292 EP 298 DI 10.3109/00365520903453182 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 559VR UT WOS:000274856600005 PM 19968611 ER PT J AU Zhang, ZL Rosenbaum, J Zhong, WW Lim, C Hinrichs, D AF Zhang, Zili Rosenbaum, James T. Zhong, Wenwei Lim, Carmen Hinrichs, David J. TI Costimulation of Th17 cells: adding fuel or putting out the fire in the inflamed gut? SO SEMINARS IN IMMUNOPATHOLOGY LA English DT Review DE CD4+T cells; Costimulatory molecules; Crohn's disease; Inflammatory bowel disease; Th17 cells; Ulcerative colitis ID INFLAMMATORY-BOWEL-DISEASE; CD4(+) T-CELLS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; ACTIVE CROHNS-DISEASE; NF-KAPPA-B; HUMAN COLONIC MYOFIBROBLASTS; GENOME-WIDE ASSOCIATION; HEPATITIS-A VIRUS; ULCERATIVE-COLITIS; RHEUMATOID-ARTHRITIS AB Inflammatory bowel disease, typified by Crohn's disease and ulcerative colitis, is a common disorder characterized by recurrent and serious inflammation of the gastrointestinal tract. It is well documented that T cells play a pivotal role in the development of inflammatory bowel disease. Th17 cells are a unique T cell subpopulation implicated in inflammatory bowel disease and many other autoimmune/inflammatory diseases. However, the regulatory mechanism of Th17 activation and proliferation has not been defined completely. Recent studies have shown that the ligation of several costimulatory receptor-ligand pairs contributes to the activation, differentiation, and proliferation of T lymphocytes including the Th17 subset. In this review, we will discuss the emerging evidence on the role of Th17 cells in inflammatory bowel disease pathogenesis as well as the effect of costimulatory molecules on Th17 development and consider if the need for such costimulation of T lymphocytes provides a target for the development of novel therapeutic strategy. C1 [Zhang, Zili; Zhong, Wenwei] Oregon Hlth & Sci Univ, Dept Pediat, CDRC, Portland, OR 97239 USA. [Rosenbaum, James T.; Lim, Carmen] Oregon Hlth & Sci Univ, Dept Internal Med, Portland, OR 97239 USA. [Rosenbaum, James T.] Oregon Hlth & Sci Univ, Dept Ophthalmol, Portland, OR 97239 USA. [Hinrichs, David J.] Portland VA Med Ctr, Portland, OR 97239 USA. RP Zhang, ZL (reprint author), Oregon Hlth & Sci Univ, Dept Pediat, CDRC, 707 Gaines St, Portland, OR 97239 USA. EM zhangzi@ohsu.edu FU National Institutes of Health [HD033703-10, EY016788, EY013093, EY006484]; Digestive Health and Nutrition Foundation/CCFA Young Investigator Award; Research to Prevent Blindness; Stan and Madelle Rosenfeld Family Trust; Kuzell Family Arthritis Research Foundation FX We thank Judie McDonald for help in preparing the manuscript. This study was supported by National Institutes of Health Grants HD033703-10 (ZZ), EY016788 (ZZ), EY013093 (JTR), and EY006484 (JTR) as well as Child Digestive Health and Nutrition Foundation/CCFA Young Investigator Award (ZZ). JTR is a scholar supported by Research to Prevent Blindness. Funds from the Stan and Madelle Rosenfeld Family Trust and the Kuzell Family Arthritis Research Foundation also contributed to this work. NR 167 TC 4 Z9 4 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1863-2297 J9 SEMIN IMMUNOPATHOL JI Semin. Immunopathol. PD MAR PY 2010 VL 32 IS 1 BP 55 EP 70 DI 10.1007/s00281-009-0190-3 PG 16 WC Immunology; Pathology SC Immunology; Pathology GA 567RR UT WOS:000275464800006 PM 20119686 ER PT J AU Vallabhaneni, R Kaczorowski, DJ Yaakovian, MD Rao, J Zuckerbraun, BS AF Vallabhaneni, Raghuveer Kaczorowski, David J. Yaakovian, Michael D. Rao, Jayashree Zuckerbraun, Brian S. TI HEME OXYGENASE 1 PROTECTS AGAINST HEPATIC HYPOXIA AND INJURY FROM HEMORRHAGE VIA REGULATION OF CELLULAR RESPIRATION SO SHOCK LA English DT Article DE Heme oxygenase; carbon monoxide; hemorrhage; hypoxia; hepatocytes; liver; respiration ID CARBON-MONOXIDE; NITRIC-OXIDE; RAT-LIVER; EXPRESSION PATTERN; GENE-TRANSFER; SHOCK; ACTIVATION; STRESS; RESUSCITATION; INHIBITION AB Heme oxygenase 1 (HO-1) is an important regulator of the cellular response to stress and inflammation. These investigations test the hypothesis that HO-1 overexpression protects against hemorrhage-induced hypoxia by regulating cellular respiration and oxygen availability. Male C57BL/6 mice or primary mouse hepatocytes were treated with adenoviral gene transfer of HO-1 (AdHO-1) or beta-galactosidase (AdLacZ). Mice were subjected to hemorrhagic shock and resuscitation or cannulation without hemorrhage. AdHO-1 prevented hemorrhagic shock/resuscitation-induced liver injury. In addition, AdHO-1 prevented hemorrhage-induced liver hypoxia and depletion of adenosine triphosphate. In vitro, HO-1 overexpression resulted in decreased cellular respiration under hypoxic conditions as determined by oxygen consumption and cytochrome c oxidase activity. This resulted in increased intracellular oxygen levels in the setting of low oxygen tensions. In conclusion, HO-1 overexpression protects the liver against hemorrhage-induced injury. This may be secondary to the ability of HO-1 to protect against bioenergetic failure via regulation of cellular respiration. C1 [Vallabhaneni, Raghuveer; Kaczorowski, David J.; Yaakovian, Michael D.; Rao, Jayashree; Zuckerbraun, Brian S.] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA USA. [Zuckerbraun, Brian S.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Zuckerbraun, BS (reprint author), NW653 MUH,3459 5th Ave, Pittsburgh, PA 15213 USA. EM zuckerbraunbs@upmc.edu NR 40 TC 19 Z9 19 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1073-2322 J9 SHOCK JI Shock PD MAR PY 2010 VL 33 IS 3 BP 274 EP 281 DI 10.1097/SHK.0b013e3181b0f566 PG 8 WC Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease SC General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology GA 564FE UT WOS:000275197900009 PM 19536046 ER PT J AU Canfield, KM Smyth, E Batki, SL AF Canfield, Kelly M. Smyth, Emily Batki, Steven L. TI Methadone Maintenance Patients' Knowledge, Attitudes, Beliefs, and Experiences Concerning Treatment for Hepatitis C Virus Infection SO SUBSTANCE USE & MISUSE LA English DT Article DE hepatitis C; treatment; knowledge; attitudes; beliefs; experiences; methadone; opioid; substance use; psychiatry ID INJECTION-DRUG USERS; FOLLOW-UP; RISK REDUCTION; UNITED-STATES; US CITIES; HIV; PREVALENCE; THERAPY; SEROCONVERSION; EPIDEMIOLOGY AB Hepatitis C virus (HCV) knowledge, attitudes, beliefs, and experiences (KABE) of 64 HCV antibody positive methadone maintenance treatment (MMT) patients were assessed in conjunction with acceptability of an on-site semi-structured HCV education session, HCV RNA diagnostic testing, HCV treatment motivational assessment, and initiation of HCV treatment. The KABE interviews were conducted in 2006 and 2007 in an urban New York State MMT clinic in affiliation with a NIDA-funded HCV research project. The majority had basic knowledge of HCV disease, but poor understanding of HCV testing and treatment. While the majority of participants expressed fear of HCV treatment side effects, 88% accepted HCV RNA testing and 78% expressed willingness to start HCV treatment with the majority of chronically infected choosing to start HCV treatment medications. Study limitations and implications are discussed. C1 [Canfield, Kelly M.] SUNY Upstate Med Univ, Addict Psychiat Res Program, Dept Psychiat, Syracuse, NY 13210 USA. [Batki, Steven L.] Univ Calif San Francisco, Dept Psychiat, Sch Med, San Francisco, CA 94143 USA. [Batki, Steven L.] San Francisco VA Med Ctr, Addict Psychiat Res Program, San Francisco, CA USA. RP Canfield, KM (reprint author), SUNY Upstate Med Univ, Addict Psychiat Res Program, Dept Psychiat, 450 E Adams St, Syracuse, NY 13210 USA. EM canfielk@upstate.edu FU National Institutes of Health (NIH)/National Institute on Drug Abuse (NIDA) [RO1 DA 016764] FX This work was supported by National Institutes of Health (NIH)/National Institute on Drug Abuse (NIDA) grant RO1 DA 016764. NIDA had no further role in study design; in the collection, analysis, and interpretation of the data; in the writing of this report; and in the decision to submit the paper for publication. NR 59 TC 8 Z9 8 U1 0 U2 7 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1082-6084 J9 SUBST USE MISUSE JI Subst. Use Misuse PD MAR PY 2010 VL 45 IS 4 BP 496 EP 514 DI 10.3109/10826080903452538 PG 19 WC Substance Abuse; Psychiatry; Psychology SC Substance Abuse; Psychiatry; Psychology GA 560DJ UT WOS:000274881900003 PM 20141461 ER PT J AU Li, Y Huang, XF Deng, C Meyer, B Wu, AM Yu, YH Ying, WH Yang, GY Yenari, MA Wang, Q AF Li, Yun Huang, Xu-Feng Deng, Chao Meyer, Barbara Wu, Aimin Yu, Yinghua Ying, Weihai Yang, Guo-Yuan Yenari, Midori A. Wang, Qing TI Alterations in 5-HT(2A) Receptor Binding in Various Brain Regions Among 6-Hydroxydopamine-Induced Parkinsonian Rats SO SYNAPSE LA English DT Article DE Parkinson's disease; serotonin; 5-HT(2A) receptors; tyrosine hydroxylase; striatum; downregulation ID IN-VIVO MICRODIALYSIS; DOPAMINE RELEASE; SEROTONIN RECEPTORS; PREFRONTAL CORTEX; ANIMAL-MODEL; DISEASE; MECHANISMS; BEHAVIORS; TRANSDUCTION; HALOPERIDOL AB The serotonergic system has close interactions with the dopaminergic system and is strongly implicated in the pathophysiological mechanisms and therapeutic paradigms of Parkinson's disease (PD). This study aims to investigate regional changes in 5-hydroxytryptamine (5-HT) 2A receptors in the rat brain 3 weeks after unilateral medial forebrain bundle lesion by 6-hydroxydopamine (6-OHDA). 5-HT 2A receptor distributions and alterations in the postmortem rat brain were detected by [(3)H]ketanserin-binding autoradiography. In the 6-OHDA-induced Parkinson's rat model, nigrostriatal dopaminergic neuron loss significantly mediated the decreased [(3)H]ketanserin binding, predominantly in the agranular insular cortex (17.3%, P = 0.03), cingulate cortex (18.2%, P < 0.001), prefrontal cortex (8%, P = 0.043), primary somatosensory cortex (17.7%, P = 0.002), and caudate putamen (14.5%, P = 0.02) compared to controls while a profound reduction of tyrosine hydroxylase (TH) immunostaining in the striatum was also observed. Alterations in [(3)H]ketanserin binding in the examined brain areas may represent the specific regions that mediate cognitive dysfunctions via the serotonin system. The downregulation of 5-HT(2A) receptor binding in this study also provides indirect evidence for plasticity in the serotonergic system in the rat brains. This study contributes to a better understanding of the critical roles of 5-HT(2A) receptors in treating neurodegenerative disorders and implicates 5-HT(2A) receptors as a novel therapeutic target in the treatment of PD. Synapse 64:224-230, 2010. (C)2009 Wiley-Liss, Inc. C1 [Wang, Qing] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Neurol, Guangzhou 510630, Guangdong, Peoples R China. [Li, Yun; Huang, Xu-Feng; Deng, Chao; Meyer, Barbara; Yu, Yinghua; Wang, Qing] Univ Wollongong, Sch Hlth Sci, Ctr Translat Neurosci, Wollongong, NSW 2522, Australia. [Li, Yun] Cent S Univ, Xiangya Hosp 2, Dept Ophthalmol & Visual Sci, Changsha, Hunan, Peoples R China. [Li, Yun] Hunan Engn Ctr Combinatorial Biosynth & Nat Prod, Changsha, Hunan, Peoples R China. [Ying, Weihai; Yang, Guo-Yuan] Shanghai Jiao Tong Univ, Med X Res Inst, Shanghai 200032, Peoples R China. [Yenari, Midori A.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA. [Yenari, Midori A.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. RP Wang, Q (reprint author), Sun Yat Sen Univ, Affiliated Hosp 3, Dept Neurol, 600 Tianhe Rd, Guangzhou 510630, Guangdong, Peoples R China. EM denniswq@yahoo.com RI Huang, Xu-Feng/D-6053-2013; Huang, Xu-Feng/H-7408-2015; Deng, Chao/F-4417-2016 OI Huang, Xu-Feng/0000-0002-5895-2253; Deng, Chao/0000-0003-1147-5741; Yu, Yinghua/0000-0003-2508-7512 FU Sun Yat-Sen University [A77]; FRC; University of Wollongong 2007/2008 Australia; Australia National Health Medical Research Council [514640] FX Third Affiliated Hospital of Sun Yat-Sen University; Contract grant number: A77; FRC small grant, University of Wollongong 2007/2008 Australia; Australia National Health Medical Research Council; Contract grant number: 514640. NR 33 TC 24 Z9 24 U1 0 U2 2 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0887-4476 J9 SYNAPSE JI Synapse PD MAR PY 2010 VL 64 IS 3 BP 224 EP 230 DI 10.1002/syn.20722 PG 7 WC Neurosciences SC Neurosciences & Neurology GA 544RU UT WOS:000273677600006 PM 19862688 ER PT J AU Hershman, JM Liwanpo, L AF Hershman, Jerome M. Liwanpo, Llanyee TI How Does Sunitinib Cause Hypothyroidism? SO THYROID LA English DT Editorial Material ID RENAL-CELL CARCINOMA; THYROTOXICOSIS; THYROIDITIS; CANCER C1 Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. Vet Adm Greater Los Angeles Healthcare Syst, Dept Med, Endocrinol & Diabet Div, Los Angeles, CA USA. RP Hershman, JM (reprint author), VA Med Ctr W Los Angeles, Endocrinol 111D,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM jhershmn@ucla.edu NR 16 TC 10 Z9 10 U1 0 U2 0 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1050-7256 J9 THYROID JI Thyroid PD MAR PY 2010 VL 20 IS 3 BP 243 EP 244 DI 10.1089/thy.2010.1620 PG 2 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 562IX UT WOS:000275044600002 PM 20187779 ER PT J AU Johnson, EE Ricketts, TA AF Johnson, Earl E. Ricketts, Todd A. TI Dispensing Rates of Four Common Hearing Aid Product Features: Associations With Variations in Practice Among Audiologists SO TRENDS IN AMPLIFICATION LA English DT Article DE hearing aid; product features; dispensing rates; variability; audiologists AB The purpose of the study was to develop and examine a list of potential variables that may account for variability in the dispensing rates of four common hearing aid features. A total of 29 potential variables were identified and placed into the following categories: (1) characteristics of the audiologist, (2) characteristics of the hearing aids dispensed by the audiologist, (3) characteristics of the audiologist's patient population, and (4) evidence-based practice grades of recommendation for each feature. The potentially associative variables then were examined using regression analyses from the responses of 257 audiologists to a dispensing practice survey. There was a direct relation between price and level of hearing aid technology with the frequency of dispensing product features. There was also a direct relation between the belief by the audiologist that a feature might benefit patients and the frequency of dispensing that feature. In general, the results suggested that personal differences among audiologists and the hearing aids audiologists choose to dispense are related more strongly to dispensing rates of product features than to differences in characteristics of the patient population served by audiologists. An additional finding indicated that evidence-based practice recommendations were inversely related to dispensing rates of product features. This finding, however, may not be the result of dispensing trends as much as hearing aid manufacturing trends. C1 [Johnson, Earl E.] US Dept Vet Affairs, Mountain Home, TN 37684 USA. [Johnson, Earl E.] E Tennessee State Univ, Johnson City, TN 37614 USA. [Ricketts, Todd A.] Vanderbilt Univ, Bill Wilkerson Ctr, Nashville, TN USA. RP Johnson, EE (reprint author), US Dept Vet Affairs, Mountain Home, TN 37684 USA. EM earl.johnson@va.gov FU Dan Maddox Hearing Aid Research Laboratory at Vanderbilt University; Mountain Home; TN VAMC Auditory; Vestibular Research Enhancement Award Program; U.S. Department of Veterans Affairs Rehabilitation Research and Development Office FX The authors disclosed receipt of the following financial support for the research and/or authorship of this article:; Dan Maddox Hearing Aid Research Laboratory at Vanderbilt University.; Mountain Home, TN VAMC Auditory and Vestibular Research Enhancement Award Program (sponsored by the U.S. Department of Veterans Affairs Rehabilitation Research and Development Office). NR 90 TC 1 Z9 1 U1 1 U2 5 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1084-7138 J9 TRENDS AMPLIF JI Trends Amplif. PD MAR PY 2010 VL 14 IS 1 BP 12 EP 45 DI 10.1177/1084713810362988 PG 34 GA V25ZP UT WOS:000208516200002 PM 20457726 ER PT J AU Anderson, RM Weindruch, R AF Anderson, Rozalyn M. Weindruch, Richard TI Metabolic reprogramming, caloric restriction and aging SO TRENDS IN ENDOCRINOLOGY AND METABOLISM LA English DT Review ID ACTIVATED PROTEIN-KINASE; LIFE-SPAN EXTENSION; MITOCHONDRIAL OXYGEN-CONSUMPTION; SKELETAL-MUSCLE CELLS; GENE-EXPRESSION; DIETARY RESTRICTION; ADIPOSE-TISSUE; POSTTRANSLATIONAL MODIFICATIONS; ENERGY-EXPENDITURE; MAMMALIAN TARGET AB Caloric restriction (CR) without malnutrition slows the aging process and extends lifespan in diverse species by unknown mechanisms. The inverse linear relationship between calorie intake and lifespan suggests that regulators of energy metabolism are important in the actions of CR. Studies in several species reveal tissue-specific changes in energy metabolism with CR and suggest that metabolic reprogramming plays a critical role in its mechanism of aging retardation. We herein describe common signatures of CR and suggest how they can slow aging. We discuss recent advances in understanding the function of key metabolic regulators that probably coordinate the response to altered nutrient availability with CR and how the pathways they regulate can retard the aging process. C1 [Anderson, Rozalyn M.; Weindruch, Richard] Univ Wisconsin, Geriatr Res Educ & Clin Ctr, William S Middleton Mem Vet Hosp, Madison, WI 53705 USA. [Anderson, Rozalyn M.; Weindruch, Richard] Univ Wisconsin, Wisconsin Natl Primate Res Ctr, Madison, WI 53715 USA. [Anderson, Rozalyn M.; Weindruch, Richard] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI 53706 USA. RP Anderson, RM (reprint author), Univ Wisconsin, Geriatr Res Educ & Clin Ctr, William S Middleton Mem Vet Hosp, Madison, WI 53705 USA. EM rmanderson5@wisc.edu FU National Institutes of Health/ National Institute on Aging (NIH/NIA) [AG11915]; NIH/National Cancer Institute (NIH/NCI) [CA103697]; NIH/National Center for Research Resources/Clinical and Translational Science Awards (NIH/NCRR/CTSA) [UL1RR025011] FX This work was supported by grants from National Institutes of Health/ National Institute on Aging (NIH/NIA) (AG11915), NIH/National Cancer Institute (NIH/NCI) (CA103697) and NIH/National Center for Research Resources/Clinical and Translational Science Awards (NIH/NCRR/CTSA) (UL1RR025011). We thank Mike Polewski and Josef Clarke for critical reading of the manuscript. NR 71 TC 102 Z9 105 U1 3 U2 23 PU ELSEVIER SCIENCE LONDON PI LONDON PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND SN 1043-2760 J9 TRENDS ENDOCRIN MET JI Trends Endocrinol. Metab. PD MAR PY 2010 VL 21 IS 3 BP 134 EP 141 DI 10.1016/j.tem.2009.11.005 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 576HW UT WOS:000276136100002 PM 20004110 ER PT J AU Liu, YY Brent, GA AF Liu, Yan-Yun Brent, Gregory A. TI Thyroid hormone crosstalk with nuclear receptor signaling in metabolic regulation SO TRENDS IN ENDOCRINOLOGY AND METABOLISM LA English DT Review ID CHOLESTEROL 7-ALPHA-HYDROXYLASE GENE; CARBOXYLASE-ALPHA TRANSCRIPTION; THYROTROPIN-RELEASING-HORMONE; NONALCOHOLIC FATTY LIVER; ELEMENT-BINDING PROTEIN; RETINOID-X-RECEPTOR; PEROXISOME-PROLIFERATOR; RESPONSE ELEMENT; DENSITY-LIPOPROTEIN; PPAR-ALPHA AB Thyroid hormone influences diverse metabolic pathways important in lipid and glucose metabolism, lipolysis and regulation of body weight. Recently, it has been recognized that thyroid hormone receptor interacts with transcription factors that predominantly respond to nutrient signals including the peroxisome proliferator-activated receptors, liver X receptor and others. Crosstalk between thyroid hormone signaling and these nutrient responsive factors occurs through a variety of mechanisms: competition for retinoid X receptor heterodimer partners, DNA binding sites and transcriptional cofactors. This review focuses on the mechanisms of interaction of thyroid hormone signaling with other metabolic pathways and the importance of understanding these interactions to develop therapeutic agents for treatment of metabolic disorders, such as dyslipidemias, obesity and diabetes. C1 [Brent, Gregory A.] Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Angeles Healthcare Syst, Mol Endocrinol Lab,Dept Med, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Angeles Healthcare Syst, Mol Endocrinol Lab,Dept Physiol, Los Angeles, CA 90073 USA. RP Brent, GA (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Angeles Healthcare Syst, Mol Endocrinol Lab,Dept Med, Los Angeles, CA 90073 USA. EM gbrent@ucla.edu FU National Institutes of Health [RO1 DK67233] FX Supported by National Institutes of Health grant RO1 DK67233 to G.B. NR 73 TC 52 Z9 57 U1 1 U2 12 PU ELSEVIER SCIENCE LONDON PI LONDON PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND SN 1043-2760 J9 TRENDS ENDOCRIN MET JI Trends Endocrinol. Metab. PD MAR PY 2010 VL 21 IS 3 BP 166 EP 173 DI 10.1016/j.tem.2009.11.004 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 576HW UT WOS:000276136100006 PM 20015660 ER PT J AU Lewis, MS Gallun, FJ Gordon, J Lilly, DJ Crandell, C AF Lewis, M. Samantha Gallun, Frederick J. Gordon, Jane Lilly, David J. Crandell, Carl TI A Pilot Investigation Regarding Speech-Recognition Performance in Noise for Adults with Hearing Loss in the FM plus HA Listening Condition SO VOLTA REVIEW LA English DT Article ID MULTIPLE-SCLEROSIS; INTELLIGIBILITY; MICROPHONE; RECEPTION; SYSTEMS; AMPLIFICATION; PERCEPTION; AIDS AB While the concurrent use of the hearing aid (HA) microphone with frequency modulation (FM) technology can decrease speech-recognition performance, the FM+HA condition is still an important setting for users of both HA and FM technology. The primary goal of this investigation was to evaluate the effect of attenuating HA gain in the FM+HA listening condition on the signal-to-noise ratio for 50% sentence recognition in two situations: (1) when speech was presented to the FM transmitter microphone and (2) when speech was presented to the HA microphone. A second goal was to determine whether measures based on the Articulation Index (AI) could be used to predict speech-recognition performance. The best speech-recognition performance for the first situation occurred when the HA gain was attenuated by 20 decibels (dB), while the best performance for the second situation occurred when there was 0 dB of attenuation. The AI measures were directly related to speech-recognition performance. C1 [Lewis, M. Samantha; Gallun, Frederick J.; Gordon, Jane; Lilly, David J.] Portland VA Med Ctr, NCRAR, Portland, OR USA. [Lewis, M. Samantha; Gallun, Frederick J.] Oregon Hlth & Sci Univ, Dept Otolaryngol Head & Neck Surg, Portland, OR 97201 USA. [Lilly, David J.] Univ Iowa, Dept Speech Pathol & Audiol, Iowa City, IA 52242 USA. [Crandell, Carl] Univ Florida, Dept Commun Sci & Disorders, Gainesville, FL USA. RP Lewis, MS (reprint author), Portland VA Med Ctr, NCRAR, Portland, OR USA. RI Gallun, Frederick/G-3792-2012 OI Gallun, Frederick/0000-0002-4145-2199 NR 45 TC 1 Z9 1 U1 1 U2 1 PU ALEXANDER GRAHAM BELL ASSOC FOR THE DEAF PI WASHINGTON PA 3417 VOLTA PLACE NW, WASHINGTON, DC 20007 USA SN 0042-8639 J9 VOLTA REV JI Volta Rev. PD SPR PY 2010 VL 110 IS 1 BP 31 EP 54 PG 24 WC Education, Special; Rehabilitation SC Education & Educational Research; Rehabilitation GA 589FJ UT WOS:000277131900003 ER PT J AU Wang, Z Inslicht, SS Metzler, TJ Henn-Haase, C McCaslin, SE Tong, HQ Neylan, TC Marmar, CR AF Wang, Zhen Inslicht, Sabra S. Metzler, Thomas J. Henn-Haase, Clare McCaslin, Shannon E. Tong, Huiqi Neylan, Thomas C. Marmar, Charles R. TI A prospective study of predictors of depression symptoms in police SO PSYCHIATRY RESEARCH LA English DT Article DE Depression; Childhood trauma; Self-worth; Work stress ID CHILDHOOD SEXUAL-ABUSE; POSTTRAUMATIC-STRESS; MAJOR DEPRESSION; WORK STRESS; SELF-ESTEEM; TRAUMA; VULNERABILITY; DISORDER; OFFICERS; RISK AB Police work is one of the most stressful occupations. Previous research has indicated that work stress and trauma exposure may place individuals at heightened risk for the development of depression symptomatology. This prospective longitudinal study was designed to examine predictors of depression symptoms in police service. Participants comprised 119 healthy police recruits from an ongoing prospective study. They completed baseline measures of depression symptoms, childhood trauma exposure, neuroticism, and self-worth during academy training. Follow-up measures of depression symptoms, PTSD symptoms, critical incident exposure, negative life events, and routine work environment stress were assessed after 12 months of police service. Hierarchical linear regression analysis was conducted to examine predictors of current levels of depression symptoms, controlling for baseline depression symptoms and current PTSD symptoms. Greater childhood trauma exposure, lower self-worth during training, and greater perceived work stress in the first year of police service predicted greater depression symptoms at 12 months. Depression symptoms at 1 year of police service were partly independent from PTSD symptoms at 12 months. Greater childhood trauma exposure and lower self-worth during training may be important variables to screen as risk factors for duty-related depression. Strategies to reduce routine work environment stress have the potential to decrease duty-related depression in law enforcement. (C) 2008 Elsevier Ireland Ltd. All rights reserved. C1 [Wang, Zhen] Shanghai Jiao Tong Univ, Shanghai Mental Hlth Ctr, Shanghai 200030, Peoples R China. [Wang, Zhen; Inslicht, Sabra S.; Metzler, Thomas J.; Henn-Haase, Clare; McCaslin, Shannon E.; Tong, Huiqi; Neylan, Thomas C.; Marmar, Charles R.] San Francisco VA Med Ctr, San Francisco, CA USA. [Wang, Zhen; Inslicht, Sabra S.; Metzler, Thomas J.; Henn-Haase, Clare; McCaslin, Shannon E.; Neylan, Thomas C.; Marmar, Charles R.] Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Wang, Z (reprint author), Vet Adm Med Ctr, PTSD Res Program, 4150 Clement St 116P, San Francisco, CA 94121 USA. EM wangzhen@smhc.org.cn FU National Institute of Mental Health [R01-MH056350-06] FX This research was supported by National Institute of Mental Health grant (R01-MH056350-06) to Dr. Marmar. We thank the police cadets who volunteered their time to participate in this research. NR 42 TC 35 Z9 38 U1 8 U2 28 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0165-1781 J9 PSYCHIAT RES JI Psychiatry Res. PD FEB 28 PY 2010 VL 175 IS 3 BP 211 EP 216 DI 10.1016/j.psychres.2008.11.010 PG 6 WC Psychiatry SC Psychiatry GA 560BY UT WOS:000274878000005 PM 20044144 ER PT J AU Butler, PL Mallampalli, RK AF Butler, Phillip L. Mallampalli, Rama K. TI Cross-talk between Remodeling and de Novo Pathways Maintains Phospholipid Balance through Ubiquitination SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; CHOLINE-PHOSPHATE CYTIDYLYLTRANSFERASE; PLATELET-ACTIVATING-FACTOR; ADULT-RAT LUNG; PHOSPHATIDYLCHOLINE BIOSYNTHESIS; II CELLS; LYSOPHOSPHATIDYLCHOLINE ACYLTRANSFERASE; ACYL-COA; CHOLINEPHOSPHATE CYTIDYLYLTRANSFERASE; MOLECULAR DETERMINANTS AB Phosphatidylcholine (PtdCho), the major phospholipid of animal membranes, is generated by its remodeling and de novo synthesis. Overexpression of the remodeling enzyme, LPCAT1 (acyl-CoA: lysophosphatidylcholine acyltransferase) in epithelia decreased de novo PtdCho synthesis without significantly altering cellular PtdCho mass. Overexpression of LPCAT1 increased degradation of CPT1 (cholinephosphotransferase), a resident Golgi enzyme that catalyzes the terminal step for de novo PtdCho synthesis. CPT1 degradation involved its multiubiquitination and processing via the lysosomal pathway. CPT1 mutants harboring arginine substitutions at multiple carboxyl-terminal lysines exhibited proteolytic resistance to effects of LPCAT1 overexpression in cells and restored de novo PtdCho synthesis. Thus, cross-talk between phospholipid remodeling and de novo pathways involves ubiquitin-lysosomal processing of a key molecular target that mechanistically provides homeostatic control of cellular PtdCho content. C1 Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Biochem, Iowa City, IA 52242 USA. [Mallampalli, Rama K.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. [Mallampalli, Rama K.] Univ Pittsburgh, Dept Internal Med, Pittsburgh, PA 15213 USA. RP Mallampalli, RK (reprint author), UPMC Montefiore, NW628,3459 5th Ave, Pittsburgh, PA 15213 USA. EM mallampallirk@upmc.edu FU National Institutes of Health R01 [HL097376, HL096376, HL098174, HL081784, HL068135]; Department of Veterans Affairs FX This work was supported, in whole or in part, by National Institutes of Health R01 Grants HL097376, HL096376, HL098174, HL081784, and HL068135 (to R. K. M.). This work was also supported by a Merit Review Award from the Department of Veterans Affairs. NR 55 TC 24 Z9 24 U1 0 U2 0 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD FEB 26 PY 2010 VL 285 IS 9 BP 6246 EP 6258 DI 10.1074/jbc.M109.017350 PG 13 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 566JW UT WOS:000275367500029 PM 20018880 ER PT J AU Latif, R Michalek, K Morshed, SA Davies, TF AF Latif, Rauf Michalek, Krzysztof Morshed, Syed Ahmed Davies, Terry F. TI A Tyrosine Residue on the TSH Receptor Stabilizes Multimer Formation SO PLOS ONE LA English DT Article ID HUMAN THYROTROPIN RECEPTOR; PROTEIN-COUPLED RECEPTORS; NEGATIVE COOPERATIVITY; STIMULATING-HORMONE; LIPID RAFTS; OLIGOMERIZATION; COMPLEX; ECTODOMAIN; AUTOANTIBODIES; DIMERIZATION AB Background: The thyrotropin stimulating hormone receptor (TSHR) is a G protein coupled receptor (GPCR) with a large ectodomain. The ligand, TSH, acting via this receptor regulates thyroid growth and thyroid hormone production and secretion. The TSH receptor (TSHR) undergoes complex post -translational modifications including intramolecular cleavage and receptor multimerization. Since monomeric and multimeric receptors coexist in cells, understanding the functional role of just the TSHR multimers is difficult. Therefore, to help understand the physiological significance of receptor multimerization, it will be necessary to abrogate multimer formation, which requires identifying the ectodomain and endodomain interaction sites on the TSHR. Here, we have examined the contribution of the ectodomain to constitutive multimerization of the TSHR and determined the possible residue(s) that may be involved in this interaction. Methodology/Principal Findings: We studied ectodomain multimer formation by expressing the extracellular domain of the TSHR linked to a glycophosphotidyl (GPI) anchor in both stable and transient expression systems. Using co-immunoprecipitation and FRET of tagged receptors, we established that the TSH receptor ectodomain was capable of multimerization even when totally devoid of the transmembrane domain. Further, we studied the effect of two residues that likely made critical contact points in this interaction. We showed that a conserved tyrosine residue (Y116) on the convex surface of the LRR3 was a critical residue in ectodomain multimer formation since mutation of this residue to serine totally abrogated ectodomain multimers. This abrogation was not seen with the mutation of cysteine 176 on the inner side of the LRR5, demonstrating that inter-receptor disulfide bonding was not involved in ectodomain multimer formation. Additionally, the Y116 mutation in the intact wild type receptor enhanced receptor degradation. Conclusions/Significance: These data establish the TSH receptor ectodomain as one site of multimerization, independent of the transmembrane region, and that this interaction was primarily via a conserved tyrosine residue in LRR3. C1 [Latif, Rauf; Michalek, Krzysztof; Morshed, Syed Ahmed; Davies, Terry F.] Mt Sinai Sch Med, James J Peters VA Med Ctr, Thyroid Res Unit, New York, NY 10029 USA. [Michalek, Krzysztof] Karol Marcinkowski Univ Med Sci, Dept Endocrinol Metab & Internal Dis, Poznan, Poland. RP Latif, R (reprint author), Mt Sinai Sch Med, James J Peters VA Med Ctr, Thyroid Res Unit, New York, NY 10029 USA. EM rauf.latif@mssm.edu FU National Institutes of Health (NIH) [DK069713, DK052464]; VA Merit Award program; David Owen Segal Endowment FX National Institutes of Health (NIH) grants DK069713, DK052464, the VA Merit Award program (TFD) and the David Owen Segal Endowment (to KM). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 43 TC 10 Z9 10 U1 0 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD FEB 26 PY 2010 VL 5 IS 2 AR e9449 DI 10.1371/journal.pone.0009449 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 561RS UT WOS:000274997000015 PM 20195479 ER PT J AU Saha, S Coffman, DD Smits, AK AF Saha, Somnath Coffman, Darren D. Smits, Ariel K. TI Giving Teeth to Comparative-Effectiveness Research - The Oregon Experience SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Editorial Material C1 [Saha, Somnath] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Gen Internal Med Sect, Portland, OR 97201 USA. [Saha, Somnath] Oregon Hlth & Sci Univ, Div Gen Internal Med & Geriatr, Portland, OR 97201 USA. [Smits, Ariel K.] Oregon Hlth & Sci Univ, Dept Family Med, Portland, OR 97201 USA. [Saha, Somnath; Coffman, Darren D.; Smits, Ariel K.] Oregon Hlth Serv Commiss, Salem, OR USA. RP Saha, S (reprint author), Oregon Hlth & Sci Univ, Portland VA Med Ctr, Gen Internal Med Sect, Portland, OR 97201 USA. NR 5 TC 12 Z9 12 U1 0 U2 4 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD FEB 18 PY 2010 VL 362 IS 7 DI 10.1056/NEJMp0912938 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 556ED UT WOS:000274571200004 PM 20130249 ER PT J AU Chapko, MK Yee, HS Monto, A Dominitz, JA AF Chapko, Michael K. Yee, Helen S. Monto, Alexander Dominitz, Jason A. TI Cost-effectiveness of hepatitis A vaccination for individuals with chronic hepatitis C SO VACCINE LA English DT Article DE Hepatitis A; Vaccine; Cost-effectiveness ID CHRONIC LIVER-DISEASE; UNITED-STATES; VIRUS-INFECTION; 2 STRATEGIES; US VETERANS; PREVALENCE; PREVENTION; IMMUNITY; ADULTS AB The incidence of hepatitis A infection in the United States has decreased dramatically in recent years because of childhood immunization programs. A decision analysis of the cost-effectiveness of hepatitis A vaccination for adults with hepatitis C was conducted. No vaccination strategy is cost-effective for adults with hepatitis C using the recent lower anticipated hepatitis A incidence, private sector costs, and a cost-effectiveness criterion of $100,000/QALY. Vaccination is cost-effective only for individuals who have cleared the hepatitis C virus when Department of Veterans Affairs costs are used. The recommendation to vaccinate adults with hepatitis C against hepatitis A should be reconsidered. Published by Elsevier Ltd. C1 [Chapko, Michael K.; Dominitz, Jason A.] VA Puget Sound Hlth Care Syst, Hepatitis C Resource Ctr, Seattle, WA 98101 USA. [Chapko, Michael K.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Yee, Helen S.; Monto, Alexander] San Francisco VA, Hepatitis C Resource Ctr, San Francisco, CA USA. [Yee, Helen S.] Univ Calif San Francisco, Dept Clin Pharmacy, San Francisco, CA 94143 USA. [Monto, Alexander] Univ Calif San Francisco, Div Gastroenterol, San Francisco, CA 94143 USA. [Dominitz, Jason A.] Univ Washington, Dept Med, Div Gastroenterol, Seattle, WA USA. RP Chapko, MK (reprint author), VA Puget Sound Hlth Care Syst, Hepatitis C Resource Ctr, Metropolitan Pk W,Suite 1400,1100 Olive Way, Seattle, WA 98101 USA. EM chapko@u.washington.edu OI Dominitz, Jason/0000-0002-8070-7086 NR 35 TC 2 Z9 2 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD FEB 17 PY 2010 VL 28 IS 7 BP 1726 EP 1731 DI 10.1016/j.vaccine.2009.12.019 PG 6 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 563TX UT WOS:000275158500010 PM 20044051 ER PT J AU Foy, R Hempel, S Rubenstein, L Suttorp, M Seelig, M Shanman, R Shekelle, PG AF Foy, Robbie Hempel, Susanne Rubenstein, Lisa Suttorp, Marika Seelig, Michelle Shanman, Roberta Shekelle, Paul G. TI Meta-analysis: Effect of Interactive Communication Between Collaborating Primary Care Physicians and Specialists SO ANNALS OF INTERNAL MEDICINE LA English DT Review ID RANDOMIZED CONTROLLED-TRIAL; DISEASE MANAGEMENT PROGRAM; MENTAL-HEALTH-SERVICES; GENERAL-PRACTICE; UNITED-STATES; DIABETES CARE; PSYCHIATRIC-CONSULTATION; QUALITY IMPROVEMENT; LIAISON PSYCHIATRY; CLINICAL-TRIALS AB Background: Whether collaborative care models that enable interactive communication (timely, 2-way exchange of pertinent clinical information directly between primary care and specialist physicians) improve patient outcomes is uncertain. Purpose: To assess the effects of interactive communication between collaborating primary care physicians and key specialists on outcomes for patients receiving ambulatory care. Data Sources: PubMed, PsycInfo, EMBASE, CINAHL, Cochrane Database of Systematic Reviews, Database of Abstracts of Reviews of Effects, and Web of Science through June 2008 and secondary references, with no language restriction. Study Selection: Studies that evaluated the effects of interactive communication between collaborating primary care physicians and specialists on outcomes for patients with diabetes, psychiatric conditions, or cancer. Data Extraction: Contextual, intervention, and outcome data from 23 studies were extracted by one reviewer and checked by another. Study quality was assessed with a 13-item checklist. Disagreement was resolved by consensus. Main outcomes for analysis were selected by reviewers who were blinded to study results. Data Synthesis: Meta-analysis indicated consistent effects across 11 randomized mental health studies (pooled effect size, -0.41 [95% CI, -0.73 to -0.10]), 7 nonrandomized mental health studies (pooled effect size, -0.47 [CI, -0.84 to -0.09]), and 5 nonrandomized diabetes studies (pooled effect size, -0.64 [CI, -0.93 to -0.34]). These findings remained robust to sensitivity analyses. Meta-regression indicated studies that included interventions to enhance the quality of information exchange had larger effects on patient outcomes than those that did not (-0.84 vs. -0.27; P = 0.002). Limitations: Because collaborative interventions were inherently multifaceted, the efficacy of interactive communication by itself cannot be established. Inclusion of study designs with lower internal validity increased risk for bias. No studies involved oncologists. Conclusion: Consistent and clinically important effects suggest a potential role of interactive communication for improving the effectiveness of primary care-specialist collaboration. C1 [Foy, Robbie] Univ Leeds, Leeds Inst Hlth Sci, Leeds LS2 9LJ, W Yorkshire, England. RAND Hlth Div, So Calif Evidence Based Practice Ctr, Santa Monica, CA USA. Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Grp Hlth Cooperat Puget Sound, Seattle, WA USA. RP Foy, R (reprint author), Univ Leeds, Leeds Inst Hlth Sci, Charles Thackrah Bldg,101 Clarendon Rd, Leeds LS2 9LJ, W Yorkshire, England. EM r.foy@leeds.ac.uk FU RAND Health's Comprehensive Assessment of Reform Options Initiative; Veterans Affairs Center for the Study of Provider Behavior; Commonwealth Fund; Health Foundation FX RAND Health's Comprehensive Assessment of Reform Options Initiative, the Veterans Affairs Center for the Study of Provider Behavior, The Commonwealth Fund, and the Health Foundation. NR 99 TC 52 Z9 52 U1 6 U2 17 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD FEB 16 PY 2010 VL 152 IS 4 BP 247 EP U95 DI 10.7326/0003-4819-152-4-201002160-00010 PG 20 WC Medicine, General & Internal SC General & Internal Medicine GA 560AF UT WOS:000274873300007 PM 20157139 ER PT J AU Swanlund, JM Kregel, KC Oberley, TD AF Swanlund, Jamie M. Kregel, Kevin C. Oberley, Terry D. TI Investigating autophagy Quantitative morphometric analysis using electron microscopy SO AUTOPHAGY LA English DT Editorial Material DE autophagy; electron microscopy; immunogold; morphometry; ultrastructure ID MONITORING AUTOPHAGY; LOCALIZATION; MITOCHONDRIA; HEPATOCYTES; DEGRADATION; MEMBRANES; PROTEINS; TISSUES; PATHWAY; DISEASE AB Autophagy is a compensatory pathway involving isolation and subsequent degradation of cytosolic material and organelles in eukaryotic cells.(1) The autophagic process can provide a "house-keeping" function by removing damaged proteins and organelles in a selective or nonselective fashion in order to exert a protective effect following stress.(2) Remarkably, after being discovered to be much more of a targeted process than a random one, the role of autophagy became implicated in many normal cellular and disease processes.(3) Several methodologies are routinely employed to monitor the entire autophagic process.(4) Microtubule-associated protein light chain 3, a mammalian homolog of yeast Atg8, has been widely used as a specific marker to monitor autophagy in numerous cell types.(5) While monitoring autophagic flux is extremely important, it is also beneficial to perform a detailed analysis by electron microscopy (EM) to evaluate changes in various autophagic structures, quantify the areas involved, and determine if any particular organelle(s) or area of the cell cytoplasm is being targeted for degradation.(6) The following article describes methods to localize and quantify subcellular areas of autophagy using transmission EM. Also discussed are methods for subcellular localization of specific proteins by employing immunogold EM; this method becomes particularly useful in detecting early changes in cellular homeostasis that may occur before later signs of cellular insult can be observed morphologically. C1 [Swanlund, Jamie M.; Oberley, Terry D.] William S Middleton Mem Vet Adm Med Ctr, Dept Pathol & Lab Med, Madison, WI USA. [Kregel, Kevin C.] Univ Iowa, Dept Radiat Oncol, Free Radical & Radiat Biol Program, Iowa City, IA USA. [Kregel, Kevin C.] Univ Iowa, Dept Integrat Physiol, Iowa City, IA USA. [Oberley, Terry D.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pathol & Lab Med, Madison, WI USA. RP Oberley, TD (reprint author), William S Middleton Mem Vet Adm Med Ctr, Dept Pathol & Lab Med, Madison, WI USA. EM toberley@wisc.edu FU NIA NIH HHS [R01 AG012350-08] NR 30 TC 32 Z9 38 U1 0 U2 15 PU LANDES BIOSCIENCE PI AUSTIN PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA SN 1554-8627 J9 AUTOPHAGY JI Autophagy PD FEB 16 PY 2010 VL 6 IS 2 BP 270 EP 277 PG 8 WC Cell Biology SC Cell Biology GA 577CI UT WOS:000276198100008 PM 19923921 ER PT J AU You, Z Cao, XH Taylor, AB Hart, PJ Levine, RL AF You, Zheng Cao, Xiaohang Taylor, Alexander B. Hart, P. John Levine, Rodney L. TI Characterization of a Covalent Polysulfane Bridge in Copper-Zinc Superoxide Dismutase SO BIOCHEMISTRY LA English DT Article ID AMYOTROPHIC-LATERAL-SCLEROSIS; CU,ZN-SUPEROXIDE DISMUTASE; DISULFIDE REDUCTION; HYDROGEN-PEROXIDE; WILD-TYPE; BIOPHYSICAL PROPERTIES; DIMER STABILITY; LABILE SULFUR; DNA CLEAVAGE; FAMILIAL ALS AB In the course of studies on human copper-zinc Superoxide dismutase (SOD1), We observed a modified form of the protein whose mass wits increased by 158 mass units. The covalent modification Was characterized, and we established that it is a novel heptasulfane bridge connecting the two Cys111 residues in the SOD1 homodimer. The heptasulfane bridge was visualized directly in the crystal structure of it recombinant human mutant SODI, H46R/H48Q, produced in yeast. The modification is reversible, with the bridge being cleaved by thiols, by cyanide, and by unfolding of the protein to expose the polysulfane. The polysulfane bridge can be introduced in vitro by incubation of purified SOD1 with elemental sulfur, even under anaerobic conditions and in the presence of a metal chelator. Because polysulfanes and polysulfides can catalyze the generation of reactive oxygen and sulfur species, the modification may endow SOD1 with a toxic gain of function. C1 [You, Zheng; Levine, Rodney L.] NHLBI, Biochem Lab, Bethesda, MD 20892 USA. [Cao, Xiaohang; Taylor, Alexander B.; Hart, P. John] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA. [Cao, Xiaohang; Taylor, Alexander B.; Hart, P. John] Univ Texas Hlth Sci Ctr San Antonio, Xray Crystallog Core Lab, San Antonio, TX 78229 USA. [Hart, P. John] S Texas Vet Hlth Care Syst, Dept Vet Affairs, Ctr Geriatr Res Educ & Clin, San Antonio, TX 78229 USA. RP Levine, RL (reprint author), NHLBI, Biochem Lab, Bldg 3, Bethesda, MD 20892 USA. EM rlevine@nih.gov RI Levine, Rodney/D-9885-2011 FU Intramural NIH HHS [ZIA HL000225-32]; NINDS NIH HHS [NS39112, R01 NS039112, R01 NS039112-08] NR 67 TC 21 Z9 21 U1 0 U2 2 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0006-2960 J9 BIOCHEMISTRY-US JI Biochemistry PD FEB 16 PY 2010 VL 49 IS 6 BP 1191 EP 1198 DI 10.1021/bi901844d PG 8 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 553CI UT WOS:000274342000016 PM 20052996 ER PT J AU Mathew, M Tay, E Cusi, K AF Mathew, Manoj Tay, Eric Cusi, Kenneth TI Elevated plasma free fatty acids increase cardiovascular risk by inducing plasma biomarkers of endothelial activation, myeloperoxidase and PAI-1 in healthy subjects SO CARDIOVASCULAR DIABETOLOGY LA English DT Article ID CORONARY-ARTERY-DISEASE; HUMAN ATHEROSCLEROTIC LESIONS; CELLULAR ADHESION MOLECULES; INSULIN-RESISTANCE SYNDROME; TYPE-2 DIABETES-MELLITUS; SKELETAL-MUSCLE CELLS; E-SELECTIN; METABOLIC SYNDROME; MYOCARDIAL-INFARCTION; INFLAMMATORY MARKERS AB Background: CVD in obesity and T2DM are associated with endothelial activation, elevated plasma vascular inflammation markers and a prothrombotic state. We examined the contribution of FFA to these abnormalities following a 48-hour physiological increase in plasma FFA to levels of obesity and diabetes in a group of healthy subjects. Methods: 40 non-diabetic subjects (age = 38 +/- 3 yr, BMI = 28 +/- 1 kg/m(2), FPG = 95 +/- 1 mg/dl, HbA(1c) = 5.3 +/- 0.1%) were admitted twice and received a 48-hour infusion of normal saline or low-dose lipid. Plasma was drawn for intracellular (ICAM-1) and vascular (VCAM-1) adhesion molecules-1, E-selectin (sE-S), myeloperoxidase (MPO) and total plasminogen inhibitor-1 (tPAI-1). Insulin sensitivity was measured by a hyperglycemic clamp (M/I). Results: Lipid infusion increased plasma FFA to levels observed in obesity and T2DM and reduced insulin sensitivity by 27% (p = 0.01). Elevated plasma FFA increased plasma markers of endothelial activation ICAM-1 (138 +/- 10 vs. 186 +/- 25 ng/ml), VCAM-1 (1066 +/- 67 vs. 1204 +/- 65 ng/ml) and sE-S (20 +/- 1 vs. 24 +/- 1 ng/ml) between 13-35% and by >= 2-fold plasma levels of myeloperoxidase (7.5 +/- 0.9 to 15 +/- 25 ng/ml), an inflammatory marker of future CVD, and tPAI-1 (9.7 +/- 0.6 to 22.5 +/- 1.5 ng/ml), an indicator of a prothrombotic state (all p = 0.01). The FFA-induced increase was independent from the degree of adiposity, being of similar magnitude in lean, overweight and obese subjects. Conclusions: An increase in plasma FFA within the physiological range observed in obesity and T2DM induces markers of endothelial activation, vascular inflammation and thrombosis in healthy subjects. This suggests that even transient (48-hour) and modest increases in plasma FFA may initiate early vascular abnormalities that promote atherosclerosis and CVD. C1 [Mathew, Manoj; Tay, Eric; Cusi, Kenneth] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Diabet Div, San Antonio, TX 78229 USA. [Cusi, Kenneth] Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX 78229 USA. RP Cusi, K (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Diabet Div, San Antonio, TX 78229 USA. EM cusi@uthscsa.edu FU VA Merit Award; Veterans Affairs Medical Research Fund; National Center for Research Resources [UL 1RR025767] FX The project described was supported by a VA Merit Award, the Veterans Affairs Medical Research Fund and by Award Number UL 1RR025767 from the National Center for Research Resources. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources of the National Institutes of Health. NR 66 TC 56 Z9 59 U1 1 U2 5 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1475-2840 J9 CARDIOVASC DIABETOL JI Cardiovasc. Diabetol. PD FEB 16 PY 2010 VL 9 AR 9 DI 10.1186/1475-2840-9-9 PG 9 WC Cardiac & Cardiovascular Systems; Endocrinology & Metabolism SC Cardiovascular System & Cardiology; Endocrinology & Metabolism GA 570NJ UT WOS:000275684700001 PM 20158910 ER PT J AU Ahmed, MI Gladden, JD Litovsky, SH Lloyd, SG Gupta, H Inusah, S Denney, T Powell, P McGiffin, DC Dell'Italia, LJ AF Ahmed, Mustafa I. Gladden, James D. Litovsky, Silvio H. Lloyd, Steven G. Gupta, Himanshu Inusah, Seidu Denney, Thomas, Jr. Powell, Pamela McGiffin, David C. Dell'Italia, Louis J. TI Increased Oxidative Stress and Cardiomyocyte Myofibrillar Degeneration in Patients With Chronic Isolated Mitral Regurgitation and Ejection Fraction > 60% SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Article DE mitral regurgitation; oxidative stress; magnetic resonance imaging; tissue tagging ID LEFT-VENTRICULAR FUNCTION; VALVE REPAIR; XANTHINE OXIDOREDUCTASE; HUMAN FIBROBLASTS; WALL STRESS; EXERCISE; RECONSTRUCTION; REPLACEMENT; DYSFUNCTION; INHIBITION AB Objectives This study assessed myocardial damage in patients with chronic isolated mitral regurgitation (MR) and left ventricular ejection fraction (LVEF) > 60%. Background Typically, MR patients have decreased LVEF after mitral valve (MV) repair despite normal pre-operative LVEF. Methods Twenty-seven patients with isolated MR had left ventricular (LV) biopsies taken at time of MV repair. Magnetic resonance imaging with tissue tagging was performed in 40 normal subjects and in MR patients before and 6 months after MV repair. Results LVEF (66 +/- 5% to 54 +/- 9%, p < 0.0001) and LV end-diastolic volume index (108 +/- 28 ml/m(2) to 78 +/- 24 ml/m(2), p < 0.0001) decreased, whereas left ventricular end-systolic (LVES) volume index was 60% above normal pre- and post-MV repair (p < 0.05). The LV circumferential and longitudinal strain rates decreased below normal following MV repair (6.38 +/- 1.38 vs. 5.11 +/- 1.28, p = 0.0009, and 7.51 +/- 2.58 vs. 5.31 +/- 1.61, percentage of R to R interval, p < 0.0001), as LVES stress/LVES volume index ratio was depressed at baseline and following MV repair versus normal subjects (0.25 +/- 0.10 and 0.28 +/- 0.05 vs. 0.33 +/- 0.12, p < 0.01). LV biopsies demonstrated cardiomyocyte myofibrillar degeneration versus normal subjects (p = 0.035). Immunostaining and immunoblotting demonstrated increased xanthine oxidase in MR versus normal subjects (p < 0.05). Lipofuscin deposition was increased in cardiomyocytes of MR versus normal subjects (0.62 +/- 0.20 vs. 0.33 +/- 0.11, percentage of area: p < 0.01). Conclusions Decreased LV strain rates and LVES wall stress/LVES volume index following MV repair indicate contractile dysfunction, despite pre-surgical LVEF > 60%. Increased oxidative stress could cause myofibrillar degeneration and lipofuscin accumulation resulting in LV contractile dysfunction in MR. (J Am Coll Cardiol 2010;55:671-9) (C) 2010 by the American College of Cardiology Foundation C1 [Dell'Italia, Louis J.] UAB, Ctr Heart Failure Res, Div Cardiol, Dept Med, Birmingham, AL 35294 USA. [Ahmed, Mustafa I.; Gladden, James D.; Litovsky, Silvio H.; Lloyd, Steven G.; Gupta, Himanshu; Inusah, Seidu; Powell, Pamela; McGiffin, David C.; Dell'Italia, Louis J.] UAB, Ctr Heart Failure Res, Dept Cardiovasc Surg, Birmingham, AL 35294 USA. [Ahmed, Mustafa I.; Gladden, James D.; Litovsky, Silvio H.; Lloyd, Steven G.; Gupta, Himanshu; Inusah, Seidu; Powell, Pamela; McGiffin, David C.; Dell'Italia, Louis J.] UAB, Ctr Heart Failure Res, Dept Pathol, Birmingham, AL 35294 USA. [Ahmed, Mustafa I.; Gladden, James D.; Litovsky, Silvio H.; Lloyd, Steven G.; Gupta, Himanshu; Inusah, Seidu; Powell, Pamela; McGiffin, David C.; Dell'Italia, Louis J.] UAB, Ctr Heart Failure Res, Dept Biostat, Birmingham, AL 35294 USA. [Dell'Italia, Louis J.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Denney, Thomas, Jr.] Auburn Univ, Samuel Ginn Coll Engn, Auburn, AL 36849 USA. RP Dell'Italia, LJ (reprint author), UAB, Ctr Heart Failure Res, Div Cardiol, Dept Med, 434 BMR2,901 19th St S, Birmingham, AL 35294 USA. EM loudell@uab.edu FU NHLBI NIH HHS [P50 HL077100, P50 HL077100-05] NR 32 TC 46 Z9 47 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD FEB 16 PY 2010 VL 55 IS 7 BP 671 EP 679 DI 10.1016/j.jacc.2009.08.074 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 556JT UT WOS:000274587600011 PM 20170794 ER PT J AU Ben-Zvi, I Aranow, C Mackay, M Stanevsky, A Kamen, DL Marinescu, LM Collins, CE Gilkeson, GS Diamond, B Hardin, JA AF Ben-Zvi, Ilan Aranow, Cynthia Mackay, Meggan Stanevsky, Anfisa Kamen, Diane L. Marinescu, L. Manuela Collins, Christopher E. Gilkeson, Gary S. Diamond, Betty Hardin, John A. TI The Impact of Vitamin D on Dendritic Cell Function in Patients with Systemic Lupus Erythematosus SO PLOS ONE LA English DT Article ID INDUCIBLE GENE-EXPRESSION; INTERFERON-ALPHA ACTIVITY; 1-ALPHA,25-DIHYDROXYVITAMIN D-3; 1,25-DIHYDROXYVITAMIN D-3; MULTIPLE-SCLEROSIS; AUTOIMMUNE-DISEASE; D DEFICIENCY; IFN-ALPHA; RHEUMATOID-ARTHRITIS; MICROARRAY ANALYSIS AB Background: Excessive activity of dendritic cells (DCs) is postulated as a central disease mechanism in Systemic Lupus Erythematosus (SLE). Vitamin D is known to reduce responsiveness of healthy donor DCs to the stimulatory effects of Type I IFN. As vitamin D deficiency is reportedly common in SLE, we hypothesized that vitamin D might play a regulatory role in the IFN alpha amplification loop in SLE. Our goals were to investigate the relationship between vitamin D levels and disease activity in SLE patients and to investigate the effects of vitamin D on DC activation and expression of IFN alpha-regulated genes in vitro. Methodology/Principal Findings: In this study, 25-OH vitamin D (25-D) levels were measured in 198 consecutively recruited SLE patients. Respectively, 29.3% and 11.8% of African American and Hispanic SLE patient had 25-D levels <10 ng/ml. The degree of vitamin D deficiency correlated inversely with disease activity; R = -.234, p = .002. In 19 SLE patients stratified by 25-D levels, there were no differences between circulating DC number and phenotype. Monocyte-derived DCs (MDDCs) of SLE patients were normally responsive to the regulatory effects of vitamin D in vitro as evidenced by decreased activation in response to LPS stimulation in the presence of 1,25-D. Additionally, vitamin D conditioning reduced expression of IFN alpha-regulated genes by healthy donor and SLE MDDCs in response to factors in activating SLE plasma. Conclusions/Significance: We report on severe 25-D deficiency in a substantial percentage of SLE patients tested and demonstrate an inverse correlation with disease activity. Our results suggest that vitamin D supplementation will contribute to restoring immune homeostasis in SLE patients through its inhibitory effects on DC maturation and activation. We are encouraged to support the importance of adequate vitamin D supplementation and the need for a clinical trial to assess whether vitamin D supplementation affects IFN alpha activity in vivo and, most importantly, improves clinical outcome. C1 [Ben-Zvi, Ilan; Aranow, Cynthia; Mackay, Meggan; Stanevsky, Anfisa; Diamond, Betty] Feinstein Inst Med Res, Div Autoimmune & Musculoskeletal Dis, Manhasset, NY 11030 USA. [Marinescu, L. Manuela; Hardin, John A.] Albert Einstein Coll Med, Dept Med, Bronx, NY 10467 USA. [Kamen, Diane L.; Gilkeson, Gary S.] Med Univ S Carolina, Div Rheumatol, Charleston, SC 29425 USA. [Collins, Christopher E.; Gilkeson, Gary S.] Ralph H Johnson Vet Adm Med Ctr, Dept Med, Charleston, SC USA. [Hardin, John A.] NIAID, NIH, Washington, DC USA. RP Ben-Zvi, I (reprint author), Feinstein Inst Med Res, Div Autoimmune & Musculoskeletal Dis, Manhasset, NY 11030 USA. EM johnhardin@arthritis.org OI Ben-Zvi, Ilan/0000-0002-9160-3098 FU National Institutes of Health [P60 AR049459, RR01070, AR052364]; National Institutes of Health (National Institute of Allergy and Infectious Disease) and the Autoimmunity Centers of Excellence; Autoimmunity Centers of Excellence; American College of Rheumatology Research and Education Foundation; Alliance for Lupus Research; NIAMS FX This work is supported by grants from the National Institutes of Health to GSG (P60 AR049459) and DLK (General Clinical Research Center grant #RR01070); by grants from the National Institutes of Health (National Institute of Allergy and Infectious Disease) and the Autoimmunity Centers of Excellence to BD, MM, CA, and JAH; by an American College of Rheumatology Research and Education Foundation award to DLK; and by a grant from the Alliance for Lupus Research to JAH. Additional support for DLK: K23 Award from NIAMS: NIH K23 AR052364. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 66 TC 69 Z9 76 U1 1 U2 5 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD FEB 16 PY 2010 VL 5 IS 2 AR e9193 DI 10.1371/journal.pone.0009193 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 556KT UT WOS:000274590500003 PM 20169063 ER PT J AU Ahmadi, N Tsimikas, S Hajsadeghi, F Saeed, A Nabavi, V Bevinal, MA Kadakia, J Flores, F Ebrahimi, R Budoff, MJ AF Ahmadi, Naser Tsimikas, Sotirios Hajsadeghi, Fereshteh Saeed, Anila Nabavi, Vahid Bevinal, Manzoor A. Kadakia, Jigar Flores, Ferdinand Ebrahimi, Ramin Budoff, Matthew J. TI Relation of Oxidative Biomarkers, Vascular Dysfunction, and Progression of Coronary Artery Calcium SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Article ID LOW-DENSITY-LIPOPROTEIN; OXIDIZED PHOSPHOLIPIDS; RISK-FACTORS; ENDOTHELIAL DYSFUNCTION; CARDIOVASCULAR EVENTS; PROGNOSTIC VALUE; STATIN THERAPY; CLINICAL-TRIAL; ATHEROSCLEROSIS; DISEASE AB The relation between oxidative stress and coronary artery calcium (CAC) progression is currently not well described. The present study evaluated the relation among the biomarkers of oxidative stress, vascular dysfunction, and CAC. Sixty asymptomatic subjects participated in a randomized trial evaluating the effect of aged garlic extract plus supplement versus placebo and underwent measurement of CAC. The postcuff deflation temperature-rebound index of vascular function was assessed using a reactive hyperemia procedure. The content of oxidized phospholipids (OxPL) on apolipoprotein B-100 (apoB) particles detected by antibody E06 (OxPL/apoB), lipoprotein(a), IgG and IgM autoantibodies to malondialdehyde low-density lipoprotein and apoB-immune complexes were measured at baseline and after 12 months of treatment. CAC progression was defined as an annual increase in CAC >15%. Vascular dysfunction was defined according to the tertiles of temperature-rebound at 1 year of follow-up. From baseline to 12 months, a strong inverse correlation was noted between an increase in CAC scores and increases in temperature-rebound (r(2) = -0.90), OxPL/apoB (r(2) = -0.85), and lipoprotein(a) (r(2) = -0.81) levels (p <0.0001 for all). The improvement in temperature-rebound correlated positively with the increases in OxPL/apoB (r(2) = 0.81, p = 0.0008) and lipoprotein(a) (r(2) = 0.79, p = 0.0001) but inversely with autoantibodies to malondialdehyde low-density lipoprotein and apoB-immune complexes. The greatest CAC progression was noted with the lowest tertiles of increases in temperature-rebound, OxPL/apoB and lipoprotein(a) and the highest tertiles of increases in IgG and IgM malondialdehyde low-density lipoprotein. In conclusion, the present results have documented a strong relation among markers of oxidative stress, vascular dysfunction, and progression of coronary atherosclerosis. Increases in OxPL/apoB and lipoprotein(a) correlated strongly with increases in vascular function and predicted a lack of progression of CAC. (C) 2010 Elsevier Inc. All rights reserved. (Am J Cardiol 2010;105:459-466) C1 [Ahmadi, Naser; Hajsadeghi, Fereshteh; Saeed, Anila; Nabavi, Vahid; Bevinal, Manzoor A.; Kadakia, Jigar; Flores, Ferdinand; Budoff, Matthew J.] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Torrance, CA 90509 USA. [Tsimikas, Sotirios] Univ Calif San Diego, Vasc Med Program, San Diego, CA 92103 USA. [Ebrahimi, Ramin] Univ Calif Los Angeles, Vet Affairs Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. RP Budoff, MJ (reprint author), Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Torrance, CA 90509 USA. EM mbudoff@labiomed.org NR 30 TC 30 Z9 30 U1 2 U2 4 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9149 J9 AM J CARDIOL JI Am. J. Cardiol. PD FEB 15 PY 2010 VL 105 IS 4 BP 459 EP 466 DI 10.1016/j.amjcard.2009.09.052 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 602JZ UT WOS:000278136700006 PM 20152239 ER PT J AU LaMarr, B Valdez, C Driscoll, K Ryan, M AF LaMarr, Brandon Valdez, Connie Driscoll, Katie Ryan, Mary TI Influence of pharmacist intervention on prescribing of angiotensin-converting-enzyme inhibitors, angiotensin II-receptor blockers, and aspirin for diabetic patients SO AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY LA English DT Article DE American Diabetes Association; Angiotensin antagonists; Angiotensin-converting-enzyme inhibitors; Aspirin; Diabetes mellitus; Education; Interventions; Pharmaceutical services; Pharmacists; Physicians; Platelet aggregation inhibitors; Prescribing; Protocols; Rational therapy ID MICROVASCULAR COMPLICATIONS; BLOOD-PRESSURE; MANAGEMENT AB Purpose. The influence of pharmacist intervention on the prescribing of angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II-receptor blockers (ARBs), and aspirin for patients with diabetes was evaluated. Methods. A retrospective chart review was performed for diabetic patients seen in a family medicine clinic. Patients were included in the analyses if they were 18-88 years old, had a diagnosis of type 1 or type 2 diabetes, had been seen in the family medicine clinic between July 2006 and October 2008, and had received a consultation by pharmacy services. All selected charts were reviewed to assess appropriate use of ACE inhibitor, ARB, and aspirin therapy, as recommended by American Diabetes Association (ADA) guidelines, before and after pharmacist intervention. Typical pharmacist interventions consisted of direct consultation with the prescriber and therapeutic education sessions conducted by pharmacy personnel. All patients were seen and evaluated by pharmacy personnel before meeting with the prescriber. Results. Before pharmacist intervention, 41 (59%) of 70 patients were receiving appropriate ACE inhibitor or ARB therapy and 24 (34%) of 71 patients were receiving appropriate aspirin therapy as recommended by ADA. After pharmacist intervention, 63 (90%) of 70 patients were receiving appropriate ACE inhibitor or ARB therapy and 48 (68%) of 71 patients were receiving appropriate aspirin therapy as recommended by ADA (p < 0.0001 for both differences). Conclusion. A pharmacy intervention program in a primary care setting was associated with a significant increase in prescriber adherence to ADA guidelines for ACE inhibitor or ARB therapy and for aspirin therapy in diabetic patients. C1 [LaMarr, Brandon] So Arizona Vet Affairs Healthcare Syst, Tucson, AZ 85723 USA. [Valdez, Connie] Univ Colorado Denver, Sch Pharm, Dept Clin Pharm, Aurora, CO USA. [Driscoll, Katie] Denver Vet Affairs Med Ctr, Denver, CO USA. [Driscoll, Katie] Eastern Colorado Vet Affairs Hlth Care Syst, Serv Pharm, Denver, CO USA. [Ryan, Mary] Childrens Hosp, Aurora, CO USA. RP LaMarr, B (reprint author), So Arizona Vet Affairs Healthcare Syst, 3601 S 6th Ave 13-119, Tucson, AZ 85723 USA. EM brandon.lamarr2@va.gov NR 17 TC 10 Z9 10 U1 0 U2 1 PU AMER SOC HEALTH-SYSTEM PHARMACISTS PI BETHESDA PA 7272 WISCONSIN AVE, BETHESDA, MD 20814 USA SN 1079-2082 J9 AM J HEALTH-SYST PH JI Am. J. Health-Syst. Pharm. PD FEB 15 PY 2010 VL 67 IS 4 BP 290 EP 294 DI 10.2146/ajhp090009 PG 5 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 556DV UT WOS:000274569900009 PM 20133534 ER PT J AU Attardi, BJ Page, ST Hild, SA Coss, CC Matsumoto, AM AF Attardi, Barbara J. Page, Stephanie T. Hild, Sheri A. Coss, Christopher C. Matsumoto, Alvin M. TI Mechanism of action of bolandiol (19-nortestosterone-3 beta, 17 beta-diol), a unique anabolic steroid with androgenic, estrogenic, and progestational activities SO JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY LA English DT Article DE Androgens; Transactivation; Aromatization; 5 alpha-Reductase; Ventral prostate; Seminal vesicles; Levator ani; Androgen receptors; Progestin receptors; Estrogen receptors ID RESISTANCE-TRAINED MEN; BONE-MINERAL DENSITY; SELECTIVE MODULATION; RECEPTOR MODULATORS; BODY-COMPOSITION; MUSCLE MASS; HUMAN URINE; PROSTATE; TRANSCRIPTION; CELLS AB Bolandiol is a synthetic anabolic steroid that increases lean body mass and bone mineral density without significant stimulation of sex accessory glands in castrate adult male rats. Since bolandiol suppresses gonadotropins and endogenous testosterone (T) production, we investigated its mechanism of action. We compared the potency of bolandiol in vitro and in vivo with T, 5 alpha-dihydrotestosterone (DHT), 19-nortestosterome (19-NT) and estradiol (E(2)). Bolandiol bound with lower affinity to the recombinant rat androgen receptor (AR) than the other androgens and had low, but measurable, affinity for recombinant human progestin receptors (PR-A, PR-B), and estrogen receptors (ER alpha and beta-1). Functional agonist activity was assessed in transcription assays mediated by AR. PR, or ER. Bolandiol was stimulatory in all these assays, but only 4-9% as potent as T, DHT, and 19-NT via AR, 1% as potent as progesterone via PR, and 3% and 1% as potent as E(2) acting through ER alpha or ER beta, respectively. In immature castrate rats, bolandiol was equipotent to T in stimulating growth of the levator ani muscle but less potent than T in stimulating growth of the sex accessory glands. Bolandiol also stimulated uterine weight increases in immature female rats, which were partly blocked by ICI 182,780, but it was not aromatized in vitro by recombinant human aromatase. In contrast to T, stimulation of sex accessory gland weights by bolandiol was not inhibited by concomitant treatment with the dual 5 alpha-reductase inhibitor dutastericle. As bolandiol exhibits tissue selectivity in vivo, it may act via AR, PR, and/or ER, utilize alternative signaling pathway(s) or transcriptional coregulators, and/or be metabolized to a more potent selective steroid. (C) 2009 Elsevier Ltd. All rights reserved. C1 [Attardi, Barbara J.] BIOQUAL Inc, Mol Endocrinol Lab, Rockville, MD 20850 USA. [Page, Stephanie T.; Matsumoto, Alvin M.] Univ Washington, Sch Med, Seattle, WA USA. [Coss, Christopher C.] GTx Inc, Memphis, TN 38163 USA. [Matsumoto, Alvin M.] VA Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA USA. RP Attardi, BJ (reprint author), BIOQUAL Inc, Mol Endocrinol Lab, 9600 Med Ctr Dr, Rockville, MD 20850 USA. EM bjattardi@verizon.net FU NIH [NO1-HD-2-3338]; BIOQUAL, Inc.; NIA [K23 AG027238-01] FX This work was supported by contract NIH NO1-HD-2-3338 awarded to BIOQUAL, Inc. and NIA Grant K23 AG027238-01 A1 awarded to STP. We would like to thank Dr. June Lee of the Contraception and Reproductive Health Branch of NICHD, Project Officer on the contract and Dr. Richard Blye, former Project Officer, for their support, and Trung Pham, Laurent Pessaint, Jessica Pray, jean Engbring, Bruce Till, David Gropp and Anne Semon for technical help. NR 37 TC 6 Z9 6 U1 0 U2 5 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0960-0760 J9 J STEROID BIOCHEM JI J. Steroid Biochem. Mol. Biol. PD FEB 15 PY 2010 VL 118 IS 3 BP 151 EP 161 DI 10.1016/j.jsbmb.2009.11.008 PG 11 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA 559ZT UT WOS:000274872100003 PM 19941958 ER PT J AU Duda, JE AF Duda, John E. TI Olfactory system pathology as a model of Lewy neurodegenerative disease SO JOURNAL OF THE NEUROLOGICAL SCIENCES LA English DT Article; Proceedings Paper CT 9th International Congress on Mental Dysfunction and Other Non-Motor Features in Parkinsons Disease and Related Disorderes CY OCT 16-19, 2008 CL Dresden, GERMANY DE Olfaction; Parkinson's disease; Lewy bodies; Neurodegeneration; Pathophysiology ID IDIOPATHIC PARKINSONS-DISEASE; ALPHA-SYNUCLEIN; ESSENTIAL TREMOR; BRAIN PATHOLOGY; BODY PATHOLOGY; BULB; DYSFUNCTION; BODIES; TAU; DEMENTIA AB Olfactory dysfunction has gained recognition as an early and nearly universal feature of Lewy body Parkinson's disease (PD) Recently. research efforts have focused on the use of early non-motor symptoms of PD as early biomarkers and have Suggested that investigating neurodegeneration in the aspects of the nervous system subserving these symptoms may offer important insights into the pathophysiology of Lewy body PD Therefore, there has been interest in characterizing the pathology observed in the olfactory bulb and system of patients with PD, dementia with Lewy bodies and perhaps more importantly, in subjects with incidental Lewy pathology, defined as people with Lewy pathology without evidence of Parkinsonism or dementia during life. The olfactory bulb may be ideally suited to investigations into the pathophysiology of the Lewy body disorders as it is one of the few areas of the brain wherein the entirety of neurons susceptible to Lewy neurodegeneration. including the dendritic arborization, cell soma, axon and synaptic terminals, can be examined in the same preparation Interestingly, there is a lack of Lewy neurodegeneration in the dopaminergic neurons of the olfactory bulb and paradoxically, an apparent increase in dopaminergic neurons in some PD patients compared to controls In this report, the known neuropathology of the olfactory system in PD will be reviewed and the advantages of investigating degeneration of the olfactory bulb as a model of Lewy neurodegeneration will be discussed Published by Elsevier B V C1 [Duda, John E.] Philadelphia VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr MS 127, Philadelphia, PA 19104 USA. [Duda, John E.] Univ Penn, Dept Neurol, Sch Med, Philadelphia, PA 19104 USA. RP Duda, JE (reprint author), Philadelphia VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr MS 127, 3900 Woodland Ave, Philadelphia, PA 19104 USA. NR 41 TC 27 Z9 28 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0022-510X J9 J NEUROL SCI JI J. Neurol. Sci. PD FEB 15 PY 2010 VL 289 IS 1-2 SI SI BP 49 EP 54 DI 10.1016/j.jns.2009.08.042 PG 6 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 560TL UT WOS:000274925700012 PM 19783257 ER PT J AU Blumenthal, K Volpp, KG AF Blumenthal, Karen Volpp, Kevin G. TI Enhancing the Effectiveness of Food Labeling in Restaurants SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Editorial Material ID CONSUMER VIEWS; CHOICES; INFORMATION C1 [Blumenthal, Karen; Volpp, Kevin G.] Univ Penn, Ctr Hlth Incent, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Volpp, Kevin G.] Univ Penn, Dept Hlth Care Management, Wharton Sch, Philadelphia, PA 19104 USA. [Blumenthal, Karen; Volpp, Kevin G.] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA. [Volpp, Kevin G.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. RP Volpp, KG (reprint author), Univ Penn, Ctr Hlth Incent, Leonard Davis Inst Hlth Econ, 1232 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM volpp70@wharton.upenn.edu NR 10 TC 22 Z9 22 U1 0 U2 10 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD FEB 10 PY 2010 VL 303 IS 6 BP 553 EP 554 DI 10.1001/jama.2010.85 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 553PG UT WOS:000274378700028 PM 20145233 ER PT J AU Choi, AI Li, YM Deeks, SG Grunfeld, C Volberding, PA Shlipak, MG AF Choi, Andy I. Li, Yongmei Deeks, Steven G. Grunfeld, Carl Volberding, Paul A. Shlipak, Michael G. TI Association Between Kidney Function and Albuminuria With Cardiovascular Events in HIV-Infected Persons SO CIRCULATION LA English DT Article DE cardiovascular diseases; glomerular filtration rate; heart failure; HIV; proteinuria ID OF-VETERANS-AFFAIRS; IMMUNODEFICIENCY-VIRUS-INFECTION; ACTIVE ANTIRETROVIRAL THERAPY; INTIMA-MEDIA THICKNESS; MYOCARDIAL-INFARCTION; DISEASE; DEATH; MORTALITY; RISK; ASCERTAINMENT AB Background-Cardiovascular disease (CVD) is now a leading cause of death in HIV-infected persons; however, risk markers for CVD are ill defined in this population. We examined the association between longitudinal measures of kidney function and albuminuria with risk of atherosclerotic CVD and heart failure in a contemporary cohort of HIV-infected individuals. Methods and Results-We followed a national sample of 17 264 HIV-infected persons receiving care in the Veterans Health Administration for (1) incident CVD, defined as coronary, cerebrovascular, or peripheral arterial disease, and (2) incident heart failure. Rates of CVD and heart failure were at least 6-fold greater in the highest-risk patients with an estimated glomerular filtration rate (eGFR) <30 mL/min per 1.73 m(2) and albuminuria >300 mg/dL versus those with no evidence of kidney disease (eGFR >= 60 mL/min per 1.73 m2 and no albuminuria). After multivariable adjustment, eGFR levels 45 to 59, 30 to 44, and <30 mL/min per 1.73 m2 were associated with hazard ratios for incident CVD of 1.46 (95% confidence interval, 1.15 to 1.86), 2.03 (1.47 to 2.82), and 1.99 (1.46 to 2.70) compared with eGFR >= 60 mL/min per 1.73 m2. Similarly, albuminuria levels 30, 100, and >= 300 mg/dL had hazard ratios for CVD of 1.28 (1.09 to 1.51), 1.48 (1.15 to 1.90), and 1.71 (1.30 to 2.27) compared with absent albuminuria. The associations between eGFR and albuminuria with heart failure were larger in magnitude and followed the same trends. Conclusions-In this national sample of HIV-infected persons, eGFR and albuminuria levels were strongly associated with risk of CVD and heart failure. Kidney function and albuminuria provide complementary prognostic information that may aid CVD risk stratification in HIV-infected persons. (Circulation. 2010; 121: 651-658.) C1 [Choi, Andy I.; Li, Yongmei; Grunfeld, Carl; Volberding, Paul A.; Shlipak, Michael G.] San Francisco VA Med Ctr, Dept Med, San Francisco, CA 94121 USA. [Choi, Andy I.; Shlipak, Michael G.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Deeks, Steven G.] San Francisco Gen Hosp, Posit Hlth Program, San Francisco, CA 94110 USA. RP Choi, AI (reprint author), San Francisco VA Med Ctr, Dept Med, Box 111J,4150 Clement St, San Francisco, CA 94121 USA. EM andy.choi@ucsf.edu RI Max, Mad/E-5238-2010 OI Max, Mad/0000-0001-6966-6829 FU NCRR NIH HHS [KL2 RR024130, KL2RR024130]; NIA NIH HHS [R03 AG034871-01, 1R03AG034871-01, R03 AG034871]; NIAID NIH HHS [K24 AI069994, K24AI069994]; NIDDK NIH HHS [K23 DK080645, K23 DK080645-02, K23DK080645-01A1, R01 DK066488, R01DK066488-01] NR 44 TC 89 Z9 94 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD FEB 9 PY 2010 VL 121 IS 5 BP 651 EP 658 DI 10.1161/CIRCULATIONAHA.109.898585 PG 8 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 553JO UT WOS:000274362800007 PM 20100969 ER PT J AU Peterfy, M Harris, TE Fujita, N Reue, K AF Peterfy, Miklos Harris, Thurl E. Fujita, Naoya Reue, Karen TI Insulin-stimulated Interaction with 14-3-3 Promotes Cytoplasmic Localization of Lipin-1 in Adipocytes SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID MG2+-DEPENDENT PHOSPHATIDATE PHOSPHATASE; SUBCELLULAR-LOCALIZATION; RAT HEPATOCYTES; DEPENDENT ACTIVATION; MAMMALIAN TARGET; KINASE-ACTIVITY; RAF-1 KINASE; FATTY-ACIDS; PHOSPHORYLATION; PROTEINS AB Lipin-1 is a bifunctional protein involved in lipid metabolism and adipogenesis. Lipin-1 plays a role in the biosynthesis of triacylglycerol through its phosphatidate phosphatase activity and also acts as a transcriptional co-activator of genes involved in oxidative metabolism. Lipin-1 resides in the cytoplasm and translocates to the endoplasmic reticulum membrane to catalyze the phosphatidate phosphatase reaction. It also possesses a nuclear localization signal, which is required for its translocation to the nucleus and may therefore be important for lipin-1 co- activator function. Thus, subcellular localization may be an important factor in the regulation of this protein. Here, we show that the nuclear localization signal alone is not sufficient for lipin-1 nuclear localization, and identify lipin-1 interaction with 14-3-3 as a determinant of its subcellular localization. We demonstrate that lipin-1 interacts with 14-3-3 proteins and that overexpression of 14-3-3 promotes the cytoplasmic localization of lipin-1 in 3T3-L1 adipocytes. The effect of 14-3-3 is mediated through a serine-rich domain in lipin-1. Functional mapping of the 14-3-3-interacting region within the serine-rich domain indicates redundancy and cooperativity among several sites, including five phosphorylated serine and threonine residues. Insulin stimulation of 3T3-L1 adipocytes results in increased lipin-1 phosphorylation, enhanced interaction with 14-3-3, and predominantly cytoplasmic localization. In summary, our studies suggest that insulin may modulate the cellular function of lipin-1 by regulating its subcellular localization through interactions with 14-3-3 proteins. C1 [Reue, Karen] Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Peterfy, Miklos] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Peterfy, Miklos] Cedars Sinai Med Ctr, Inst Med Genet, Los Angeles, CA 90048 USA. [Harris, Thurl E.] Univ Virginia, Dept Pharmacol, Charlottesville, VA 22908 USA. [Fujita, Naoya] Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Tokyo 1358550, Japan. RP Reue, K (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Gonda 6506A,695 Charles E Young Dr S, Los Angeles, CA 90095 USA. EM reuek@ucla.edu FU National Institutes of Health [HL28481, DK28312]; American Diabetes Association [23018]; Cedars-Sinai Medical Center FX This work was supported, in whole or in part, by National Institutes of Health Grants HL28481 (to M. P. and K. R.) and DK28312 (to T. E. H.). This work was also supported by American Diabetes Association Grant 23018 (to M. P.) and the Cedars-Sinai Medical Center (to M. P.). NR 47 TC 39 Z9 40 U1 1 U2 6 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD FEB 5 PY 2010 VL 285 IS 6 BP 3857 EP 3864 DI 10.1074/jbc.M109.072488 PG 8 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 564YF UT WOS:000275254000039 PM 19955570 ER PT J AU Samuvel, DJ Sundararaj, KP Li, YC Lopes-Virella, MF Huang, Y AF Samuvel, Devadoss J. Sundararaj, Kamala P. Li, Yanchun Lopes-Virella, Maria F. Huang, Yan TI Adipocyte-Mononuclear Cell Interaction, Toll-like Receptor 4 Activation, and High Glucose Synergistically Up-regulate Osteopontin Expression via an Interleukin 6-mediated Mechanism SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID LOW-GRADE INFLAMMATION; DIET-INDUCED OBESITY; ADIPOSE-TISSUE; INSULIN-RESISTANCE; MACROPHAGE INFILTRATION; HUMAN MONOCYTES; DISEASE; FIBROBLASTS; CYTOKINE; ADHESION AB Although it has been reported that osteopontin, a matrix glycoprotein and proinflammatory cytokine, mediates obesity-induced adipose tissue macrophage infiltration and insulin resistance, it remains unclear how osteopontin is up-regulated in adipose tissue in obese humans and animals. In this study, we incubated U937 mononuclear cells with adipocytes in a transwell system and studied how cell interaction regulated osteopontin expression. Results showed that coculture of U937 cells with adipocytes led to a marked increase in osteopontin production when compared with that released by independent cultures of U937 cells. Moreover, lipopolysaccharide or palmitic acid-induced TLR4 activation and high glucose further augmented the coculture-stimulated osteopontin secretion. Similar observations were made in the coculture of human primary monocytes and adipocytes. Real time PCR studies showed that coculture of U937 cells and adipocytes increased osteopontin mRNA in U937 cells, but not adipocytes, suggesting that adipocyte-derived soluble factor may stimulate osteopontin expression by U937 cells. In our studies to explore the underlying mechanism, we found that the neutralizing antibodies against interleukin (IL)-6 or IL-6 small interfering RNA transfection in adipocytes effectively inhibited coculture-stimulated osteopontin expression, suggesting that IL-6 released by adipocytes plays an essential role in the coculture-stimulated osteopontin expression by U937 cells. In conclusion, this study has demonstrated that cell interaction, TLR4 activation, and high glucose up-regulate osteopontin expression, and adipocyte-derived IL-6 played a major role in the up-regulation. C1 [Lopes-Virella, Maria F.; Huang, Yan] Med Univ S Carolina, Dept Med, Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29425 USA. [Samuvel, Devadoss J.; Sundararaj, Kamala P.; Li, Yanchun; Lopes-Virella, Maria F.; Huang, Yan] Med Univ S Carolina, Dept Med, Div Endocrinol Diabet & Med Genet, Charleston, SC 29425 USA. RP Huang, Y (reprint author), 114 Doughty St, Charleston, SC 29403 USA. EM huangyan@musc.edu FU National Institutes of Health [DE16353]; Department of Veterans Affairs FX This work was supported by National Institutes of Health Grant DE16353 (to Y.H.). This work was also supported by a Merit Review grant from the Department of Veterans Affairs (to Y.H.). NR 33 TC 20 Z9 20 U1 0 U2 0 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD FEB 5 PY 2010 VL 285 IS 6 BP 3916 EP 3927 DI 10.1074/jbc.M109.033951 PG 12 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 564YF UT WOS:000275254000045 PM 20007708 ER PT J AU Saxena, G Chen, JQ Shalev, A AF Saxena, Geetu Chen, Junqin Shalev, Anath TI Intracellular Shuttling and Mitochondrial Function of Thioredoxin-interacting Protein SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID SIGNAL-REGULATING KINASE-1; BETA-CELL APOPTOSIS; OXIDATIVE STRESS; GENE-EXPRESSION; MAMMALIAN THIOREDOXIN; CARDIAC-HYPERTROPHY; GLUCOSE TOXICITY; BINDING-PROTEINS; REDOX REGULATION; IMPORTIN-ALPHA AB The thioredoxin-interacting protein TXNIP is a ubiquitously expressed redox protein that promotes apoptosis. Recently, we found that TXNIP deficiency protects against type 1 and 2 diabetes by inhibiting beta cell apoptosis and maintaining pancreatic beta cell mass, indicating that TXNIP plays a key role in beta cell biology. However, very little is known about the intracellular localization and function of TXNIP, and although TXNIP has been thought to be a cytoplasmic protein, our immunohistochemistry studies in beta cells surprisingly revealed a nuclear TXNIP localization, suggesting that TXNIP may shuttle within the cell. Using immunohistochemistry/confocal imaging and cell fractionation/co-immunoprecipitation, we found that, under physiological conditions, TXNIP is localized primarily in the nucleus of pancreatic beta cells, whereas oxidative stress leads to TXNIP shuttling into the mitochondria. In mitochondria, TXNIP binds to and oxidizes Trx2, thereby reducing Trx2 binding to ASK1 and allowing for ASK1 phosphorylation/activation, resulting in induction of the mitochondrial pathway of apoptosis with cytochrome c release and caspase-3 cleavage. TXNIP overexpression and Trx2 (but not cytosolic Trx1) silencing mimic these effects. Thus, we discovered that TXNIP shuttles between subcellular compartments in response to oxidative stress and identified a novel redox-sensitive mitochondrial TXNIP-Trx2-ASK1 signaling cascade. C1 [Shalev, Anath] Univ Wisconsin, Dept Med, Clin Sci Ctr H4 526, Madison, WI 53792 USA. William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53792 USA. RP Shalev, A (reprint author), Univ Wisconsin, Dept Med, Clin Sci Ctr H4 526, 600 Highland Ave, Madison, WI 53792 USA. EM as7@medicine.wisc.edu FU National Institutes of Health [R01DK-078752]; NIDDK [R21HL-089205]; NHLBI; American Diabetes Association [7-07-CD-22]; Juvenile Diabetes Research Foundation [1-2007-790]; William S. Middleton Memorial Veterans Hospital FX This work was supported, in whole or in part, by National Institutes of Health Grants R01DK-078752 from NIDDK and R21HL-089205 from NHLBI (to A. S.). This work was also supported by American Diabetes Association Grant 7-07-CD-22 and Juvenile Diabetes Research Foundation Grant 1-2007-790) (to A. S.) and is the result of work supported by resources and use of facilities at the William S. Middleton Memorial Veterans Hospital (Madison, WI). NR 43 TC 87 Z9 89 U1 5 U2 9 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD FEB 5 PY 2010 VL 285 IS 6 BP 3997 EP 4005 DI 10.1074/jbc.M109.034421 PG 9 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 564YF UT WOS:000275254000053 PM 19959470 ER PT J AU Shen, KZ Johnson, SW AF Shen, Ke-Zhong Johnson, Steven W. TI Ca2+ Influx through NMDA-Gated Channels Activates ATP-Sensitive K+ Currents through a Nitric Oxide-cGMP Pathway in Subthalamic Neurons SO JOURNAL OF NEUROSCIENCE LA English DT Article ID METHYL-D-ASPARTATE; CEREBELLAR GRANULE CELLS; PARS COMPACTA NEURONS; SUBSTANTIA-NIGRA; DOPAMINE NEURONS; GUINEA-PIG; IN-VITRO; PARKINSONS-DISEASE; HIPPOCAMPAL-NEURONS; POTASSIUM CHANNELS AB Excessive burst firing of action potentials in subthalamic nucleus (STN) neurons has been correlated with the bradykinesia and rigidity seen in Parkinson's disease. Consequently, there is much interest in characterizing mechanisms that promote burst firing, such as the regulation of NMDA receptor function. Using whole-cell recording techniques in rat brain slices, we report that inward currents evoked by NMDA are greatly potentiated by ATP-sensitive K+ (K-ATP) channel blocking agents in STN neurons but not in dopamine neurons in the substantia nigra. Moreover, we found that the ability of NMDA to evoke K-ATP current was blocked by inhibitors of nitric oxide synthase, guanylyl cyclase, and calcium/calmodulin. By altering firing patterns of STN neurons, this NMDA/K-ATP interaction may exert an important influence on basal ganglia output and thereby affect the clinical expression of Parkinson's disease. C1 [Shen, Ke-Zhong; Johnson, Steven W.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA. [Johnson, Steven W.] Portland VA Med Ctr, Portland, OR 97207 USA. RP Shen, KZ (reprint author), Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA. EM shenk@ohsu.edu FU National Institutes of Health [NS38715]; Portland Veterans Affairs Parkinson's Disease Research, Education, and Clinical Center FX This work was supported by National Institutes of Health Grant NS38715 and the Portland Veterans Affairs Parkinson's Disease Research, Education, and Clinical Center. We also thank Dr. Anne I. Taupignon for helpful comments on the data. NR 60 TC 20 Z9 20 U1 0 U2 3 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD FEB 3 PY 2010 VL 30 IS 5 BP 1882 EP 1893 DI 10.1523/JNEUROSCI.3200-09.2010 PG 12 WC Neurosciences SC Neurosciences & Neurology GA 551XM UT WOS:000274246700031 PM 20130197 ER PT J AU Garg, S Ahnen, DJ AF Garg, Samita Ahnen, Dennis J. TI Is Computed Tomographic Colonography Being Held to a Higher Standard? SO ANNALS OF INTERNAL MEDICINE LA English DT Editorial Material ID COLONOSCOPIC MISS RATES; SERVICES TASK-FORCE; CT COLONOGRAPHY; COLORECTAL-CANCER; EXTRACOLONIC FINDINGS; ASYMPTOMATIC ADULTS; POPULATION; ADENOMAS; NEOPLASIA AB Recent guidelines for colorectal cancer screening have reached different conclusions on whether computed tomographic colonography (CTC) is an acceptable screening option, and the Centers for Medicare & Medicaid Services recently decided not to cover CTC screening. The rationale against recommending or covering CTC screening includes concerns about radiation exposure, false-negative rates for small polyps, the discovery of extracolonic findings, variability in performance, a lack of targeted studies, a higher adenoma rate in the Medicare-eligible age group, and an absence of evidence that covering CTC would increase overall screening rates. Similar concerns can be raised for other recommended and covered colon cancer screening tests, but it seems that CTC is being held to a new and higher standard. C1 Univ Colorado, Ctr Canc, Denver Vet Affairs Med Ctr, Denver, CO 80262 USA. Univ Colorado Denver, Sch Med, Denver, CO USA. RP Ahnen, DJ (reprint author), Denver Vet Affairs Med Ctr 111E, 1055 Clermont St, Denver, CO 80220 USA. EM dennis.ahnen@ucdenver.edu NR 24 TC 7 Z9 7 U1 0 U2 0 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD FEB 2 PY 2010 VL 152 IS 3 BP 178 EP 181 DI 10.7326/0003-4819-152-3-201002020-00009 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA 552WN UT WOS:000274324600006 PM 20124234 ER PT J AU Plebani, JG Tirado, CF Pettinati, HM Kampman, KM Volpicelli, JR Oslin, DW AF Plebani, Jennifer G. Tirado, Carlos F. Pettinati, Helen M. Kampman, Kyle M. Volpicelli, Joseph R. Oslin, David W. TI Combined effects of alcohol and hepatitis C: A secondary analysis of alcohol use biomarkers and high-risk behaviors from two medication trials for alcohol dependence SO ADDICTIVE BEHAVIORS LA English DT Article DE Hepatitis C; Alcohol dependence; CDT (carbohydrate-deficient transferrin); GGT (gamma glutamyl transpeptidase); Risk-assessment ID CARBOHYDRATE-DEFICIENT TRANSFERRIN; ADDICTION SEVERITY INDEX; GAMMA-GLUTAMYL-TRANSFERASE; LIVER-DISEASE; VIRUS-INFECTION; HIV-INFECTION; UNITED-STATES; DRUG-USERS; ABUSE; NALTREXONE AB Objectives: The goal of this secondary analysis was to examine the combined effects of HCV infection and recent alcohol use on baseline biologic markers of alcohol consumption in two outpatient medication trials for alcohol dependence. In addition. the relationship between Hepatitis C virus (HCV) infection and behavioral risk factors for HCV infection in these clinical populations were examined. Methods: Data (n=345) from two randomized, placebo-controlled trials of naltrexone and psychosocial treatment for alcohol dependence (Study 1, n=212) and comorbid alcohol and cocaine dependence (Study 11, n=133) were used to examine baseline measures of HCV risk behaviors (injection drug use, needle sharing), and biomarkers of alcohol use (AST, ALT, GGT and CDT) were compared by HCV serostatus first within each study and then across studies, Results: Although groups had differing sociodemographic profiles (as indicated by race, marital status, level of education) Subjects in Study I exhibited no statistically significant differences from the Study 11 cohort in HCV prevalence (12.7 vs. 20.0%. p=0.07), lifetime history of injection drug use (13.8 vs. 22.0%, p=0.74), lifetime history of needle sharing (9.1 vs. 18.0%, p=0.62). As such, the data from both studies were analyzed together. Regardless of drinking status. HCV infection was significantly associated with an upward shift in the baseline level of ALT, AST, and GGT (p<0.006 for all measures) and a downward shift in baseline CDT (p=0.002). When using standard laboratory cutoff values to determine clinically significant elevations, HCV seropositivity was significantly associated with elevations in ALT, AST, GGT (p <0.001), and with decreases in CDT (p=.002). Conclusions: These data emphasize the importance of evaluating HCV infection and HCV risk behaviors at intake in medication trials for alcohol dependence and also raise questions regarding the use of cutoff scores for ALT. AST, GGT and CDT levels as biologic markers of alcohol use in subjects when HCV status is unknown. (C) 2009 Elsevier Ltd. All rights reserved. C1 [Plebani, Jennifer G.; Pettinati, Helen M.; Kampman, Kyle M.; Volpicelli, Joseph R.; Oslin, David W.] Univ Penn, Ctr Study Addict, Dept Psychiat, Philadelphia, PA 19104 USA. [Oslin, David W.] Univ Penn, Sect Geriatr Psychiat, Dept Psychiat, Philadelphia, PA 19104 USA. [Oslin, David W.] Philadelphia VA Med Ctr, MIRECC, Philadelphia, PA USA. [Tirado, Carlos F.] Univ Texas SW Med Ctr Dallas, Dept Psychiat, Div Addict, Dallas, TX 75390 USA. RP Plebani, JG (reprint author), Univ Penn, Treatment Res Ctr, 3900 Chestnut St, Philadelphia, PA 19104 USA. EM plebani_j@mail.trc.upenn.edu FU National institute of Alcoholism and Alcohol Abuse (NIAAA) [ROIAA007517]; National Institute of Drug Abuse (NIDA) [P60DA05187, ST32DA007241] FX Supported, in part, by grants from the National institute of Alcoholism and Alcohol Abuse (NIAAA) ROIAA007517. and National Institute of Drug Abuse (NIDA) P60DA05187 and ST32DA007241. NR 39 TC 4 Z9 4 U1 0 U2 1 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4603 J9 ADDICT BEHAV JI Addict. Behav. PD FEB PY 2010 VL 35 IS 2 BP 123 EP 128 DI 10.1016/j.addbeh.2009.09.012 PG 6 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA 532QD UT WOS:000272763600008 PM 19783106 ER PT J AU Barnes, DE Haight, TJ Mehta, KM Carlson, MC Kuller, LH Tager, IB AF Barnes, Deborah E. Haight, Thaddeus J. Mehta, Kala M. Carlson, Michelle C. Kuller, Lewis H. Tager, Ira B. TI Secondhand Smoke, Vascular Disease, and Dementia Incidence: Findings From the Cardiovascular Health Cognition Study SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Article DE aged; dementia; longitudinal studies; models; statistical; tobacco smoke pollution ID MARGINAL STRUCTURAL MODELS; ALZHEIMERS-DISEASE; CAUSAL INFERENCE; TOBACCO-SMOKE; RISK-FACTORS; BRAIN; PERFORMANCE; EXPOSURE; NICOTINE; ASSOCIATION AB Recent studies have found that smoking is associated with an increased risk of dementia, but the effects of secondhand smoke (SHS) on dementia risk are not known to have previously been studied. The authors used Cox proportional hazards marginal structural models to examine the association between self-reported lifetime household SHS exposure and risk of incident dementia over 6 years among 970 US participants in the Cardiovascular Health Cognition Study (performed from 1991 to 1999) who were never smokers and were free of clinical cardiovascular disease (CVD), dementia, and mild cognitive impairment at baseline. In addition, because prior studies have found that SHS is associated with increased risk of CVD and that CVD is associated with increased risk of dementia, the authors tested for interactions between SHS and measures of clinical and subclinical CVD on dementia risk. Moderate (16-25 years) and high (> 25 years) SHS exposure levels were not independently associated with dementia risk; however, subjects with > 25 years of SHS exposure and > 25% carotid artery stenosis had a 3-fold increase (hazard ratio = 3.00, 95% confidence interval: 1.03, 9.72) in dementia risk compared with subjects with no/low (0-15 years) SHS exposure and < 25% carotid artery stenosis. High lifetime SHS exposure may increase the risk of dementia in elderly with undiagnosed CVD. C1 [Barnes, Deborah E.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA. [Mehta, Kala M.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94121 USA. [Barnes, Deborah E.] San Francisco VA Med Ctr, Dept Mental Hlth, San Francisco, CA USA. [Mehta, Kala M.] San Francisco VA Med Ctr, Dept Geriatr, San Francisco, CA USA. [Haight, Thaddeus J.; Tager, Ira B.] Univ Calif Berkeley, Dept Epidemiol & Biostat, Berkeley, CA 94720 USA. [Carlson, Michelle C.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mental Hlth, Baltimore, MD USA. [Carlson, Michelle C.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Kuller, Lewis H.] Univ Pittsburgh, Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA. RP Barnes, DE (reprint author), Univ Calif San Francisco, Dept Psychiat, 4150 Clement St,151R, San Francisco, CA 94121 USA. EM deborah.barnes@ucsf.edu FU National Institutes of Health, National Heart, Lung, and Blood Institute [N01-HC-85079, N01-HC-85086, N01-HC-35129, N01-HC-15103, N01-HC-55222, N01-HC-75150, N01-HC-45133, U01 HL080295]; National Institute of Neurological Disorders and Stroke; National Institute on Aging [R01 AG15928-02]; Flight Attendants Medical Research Institute; K01 Career Development Award [K01 AG024069] FX This work was supported by the National Institutes of Health (contracts N01-HC-85079 through N01-HC-85086, N01-HC-35129, N01-HC-15103, N01-HC-55222, N01-HC-75150, N01-HC-45133 and grant U01 HL080295 from the National Heart, Lung, and Blood Institute, with an additional contribution from the National Institute of Neurological Disorders and Stroke. The Cardiovascular Health Cognition Study was supported by a grant from the National Institute on Aging (R01 AG15928-02). Additional support for this study was provided by the Flight Attendants Medical Research Institute. Dr. Barnes was supported in part by a K01 Career Development Award (K01 AG024069). NR 49 TC 22 Z9 24 U1 2 U2 5 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD FEB 1 PY 2010 VL 171 IS 3 BP 292 EP 302 DI 10.1093/aje/kwp376 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 547DN UT WOS:000273866000005 PM 20051462 ER PT J AU Papachristou, GI Muddana, V Yadav, D O'Connell, M Sanders, MK Slivka, A Whitcomb, DC AF Papachristou, Georgios I. Muddana, Venkata Yadav, Dhiraj O'Connell, Michael Sanders, Michael K. Slivka, Adam Whitcomb, David C. TI Comparison of BISAP, Ranson's, APACHE-II, and CTSI Scores in Predicting Organ Failure, Complications, and Mortality in Acute Pancreatitis SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article ID INFLAMMATORY RESPONSE; SEVERITY; DYSFUNCTION; MARKERS AB OBJECTIVES: Identification of patients at risk for severe disease early in the course of acute pancreatitis (AP) is an important step to guiding management and improving outcomes. A new prognostic scoring system, the bedside index for severity in AP (BISAP), has been proposed as an accurate method for early identification of patients at risk for in-hospital mortality. The aim of this study was to compare BISAP (blood urea nitrogen > 25 mg/dl, impaired mental status, systemic inflammatory response syndrome (SIRS), age > 60 years, and pleural effusions) with the "traditional" multifactorial scoring systems: Ranson's, Acute Physiology and Chronic Health Examination (APACHE)-II, and computed tomography severity index (CTSI) in predicting severity, pancreatic necrosis (PNec), and mortality in a prospective cohort of patients with AP. METHODS: Extensive demographic, radiographic, and laboratory data from consecutive patients with AP admitted or transferred to our institution was collected between June 2003 and September 2007. The BISAP and APACHE-II scores were calculated using data from the first 24 h from admission. Predictive accuracy of the scoring systems was measured by the area under the receiver-operating curve (AUC). RESULTS: There were 185 patients with AP (mean age 51.7, 51% males), of which 73% underwent contrast-enhanced CT scan. Forty patients developed organ failure and were classified as severe AP (SAP; 22%). Thirty-six developed PNec (19%), and 7 died (mortality 3.8%). The number of patients with a BISAP score of >= 3 was 26; Ranson's = 3 was 47, APACHE-II = 8 was 66, and CTSI = 3 was 59. Of the seven patients that died, one had a BISAP score of 1, two had a score of 2, and four had a score of 3. AUCs for BISAP, Ranson's, APACHE-II, and CTSI in predicting SAP are 0.81 (confidence interval (CI) 0.74-0.87), 0.94 (CI 0.89-0.97), 0.78 (CI 0.71-0.84), and 0.84 (CI 0.76-0.89), respectively. CONCLUSIONS: We confirmed that the BISAP score is an accurate means for risk stratification in patients with AP. Its components are clinically relevant and easy to obtain. The prognostic accuracy of BISAP is similar to those of the other scoring systems. We conclude that simple scoring systems may have reached their maximal utility and novel models are needed to further improve predictive accuracy. C1 [Papachristou, Georgios I.; Muddana, Venkata; Yadav, Dhiraj; O'Connell, Michael; Sanders, Michael K.; Slivka, Adam; Whitcomb, David C.] Univ Pittsburgh, Med Ctr, Div Gastroenterol Hepatol & Nutr, Dept Med, Pittsburgh, PA USA. [Papachristou, Georgios I.] Vet Affairs Pittsburgh Hlth Syst, Div Gastroenterol, Dept Med, Pittsburgh, PA USA. [Whitcomb, David C.] Univ Pittsburgh, Dept Cell Biol & Physiol, Sch Med, Pittsburgh, PA USA. [Whitcomb, David C.] Univ Pittsburgh, Sch Med, Dept Human Genet, Pittsburgh, PA USA. RP Papachristou, GI (reprint author), UPMC Presbyterian, Dept Med, M2 C Wing,200 Lothrop St, Pittsburgh, PA 15213 USA. EM papachri@pitt.edu FU A Stars and Stripes Healthcare Network FX This work was supported by the VA Stars and Stripes Healthcare Network 2007 Competitive Pilot Project Fund (GIP). NR 23 TC 126 Z9 154 U1 0 U2 22 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD FEB PY 2010 VL 105 IS 2 BP 435 EP 441 DI 10.1038/ajg.2009.622 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 554RP UT WOS:000274452400025 PM 19861954 ER PT J AU Singh, H Petersen, LA El-Serag, HB AF Singh, Hardeep Petersen, Laura A. El-Serag, Hashem B. TI A Paradigm Shift Is Required to Facilitate Recognition of Iron Deficiency Response SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Letter ID COMMUNICATION C1 [Singh, Hardeep; Petersen, Laura A.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Dept Med, Houston VA HSR&D Ctr Excellence, Houston, TX 77030 USA. [Singh, Hardeep; Petersen, Laura A.] Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA. [El-Serag, Hashem B.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Dept Med, Sect Gastroenterol & Hepatol, Houston, TX 77030 USA. RP Singh, H (reprint author), Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Dept Med, Houston VA HSR&D Ctr Excellence, 2002 Holcombe Blvd 152, Houston, TX 77030 USA. EM hardeeps@bcm.edu NR 3 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD FEB PY 2010 VL 105 IS 2 BP 470 EP 470 DI 10.1038/ajg.2009.595 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 554RP UT WOS:000274452400034 ER PT J AU Hanlon, JT AF Hanlon, Joseph T. TI Perspective: Is Pharmacy Ready for the Baby Boomers? SO AMERICAN JOURNAL OF GERIATRIC PHARMACOTHERAPY LA English DT Editorial Material ID EDUCATION; CARE C1 [Hanlon, Joseph T.] Univ Pittsburgh, Dept Med, Sch Med, Pittsburgh, PA 15213 USA. [Hanlon, Joseph T.] Univ Pittsburgh, Clin & Translat Sci Inst, Pittsburgh, PA 15213 USA. [Hanlon, Joseph T.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15213 USA. [Hanlon, Joseph T.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15213 USA. [Hanlon, Joseph T.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA USA. [Hanlon, Joseph T.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA. RP Hanlon, JT (reprint author), Univ Pittsburgh, Dept Med, Sch Med, Kaufmann Med Bldg,Suite 500,3471 5th Ave, Pittsburgh, PA 15213 USA. EM jth14@pitt.edu FU AHRQ HHS [R01 HS017695]; NIA NIH HHS [R01AG027017, P30AG024827, K07AG033174, T32 AG021885, P30 AG024827, 3U01AG012553-15A1S1, R01AG034056]; NIMH NIH HHS [R34 MH082682]; NINR NIH HHS [R01 NR010135] NR 14 TC 3 Z9 3 U1 0 U2 0 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 1543-5946 J9 AM J GERIATR PHARMAC JI Am. J. Geriatr. Pharmacother. PD FEB PY 2010 VL 8 IS 1 BP 1 EP 3 DI 10.1016/j.amjopharm.2010.02.001 PG 3 WC Geriatrics & Gerontology; Pharmacology & Pharmacy SC Geriatrics & Gerontology; Pharmacology & Pharmacy GA 563HL UT WOS:000275118700001 PM 20226389 ER PT J AU Fung, HB Monteagudo-Chu, MO AF Fung, Horatio B. Monteagudo-Chu, Maricelle O. TI Community-Acquired Pneumonia in the Elderly SO AMERICAN JOURNAL OF GERIATRIC PHARMACOTHERAPY LA English DT Review DE community-acquired pneumonia; pneumonia; pneumonia prevention; elderly ID RESPIRATORY-TRACT INFECTIONS; RISK-FACTORS; ASPIRATION PNEUMONIA; OLDER-ADULTS; HOSPITALIZED-PATIENTS; CAUSATIVE ORGANISMS; IMPROVING OUTCOMES; ACE-INHIBITORS; SWITCH THERAPY; POPULATION AB Background: Community-acquired pneumonia (CAP) is a frequent cause of hospitalization and death among the elderly. Objective: This article reviews information on CAP among the elderly, including age-related changes, predisposing risk factors, causes, treatment strategies, and prevention. Methods: Searches of MEDLINE (January 1990-November 2009), International Pharmaceutical Abstracts (January 1990-November 2009), and Google Scholar were conducted using the terms community-acquired pneumonia, pneumonia, treatment guidelines, and elderly. Additional publications were found by searching the reference lists of the identified articles. Studies that reported diagnostic criteria as well as the treatment outcomes achieved in adult patients with CAP were selected for this review. Results: Three practice guidelines, 5 reviews, and 43 Studies on CAP in the elderly were identified in the literature search. Based on those publications, risk factors that predispose the elderly to pneumonia include comorbid conditions, poor functional and nutritional status, consumption of alcohol, and smoking. The clinical presentation of pneumonia in the elderly (>= 65 years of age) may be Subtle, lacking the typical acute symptoms (fever, cough, dyspnea and purulent Sputum) observed in younger adults. Pneumonia should be suspected in all elderly patients who have fever, altered mental status, or a sudden decline in functional status, with or without lower respiratory tract symptoms such as cough, purulent sputum, and dyspnea. Treatment of CAP in the elderly should be guided by the latest recommendations of the Infectious Diseases Society of America and the American Thoracic Society (IDSA/ATS), along with consideration of local rates and patterns of antimicrobial resistance, as well as individual patient risk factors for acquiring less common or more resistant pathogens. Recommended empiric antimicrobial regimens generally consist of either a beta-lactam Plus a macrolide or a respiratory fluoroquinolone alone. Adherence to the IDSA/ATS guidelines has been found to improve in-hospital mortality (adherence vs nonadherence, 8%; 95% CI, 7%-10% vs 17%; 95% CI, 14%-20%; P < 0.01), length of hospital stay (8 days; interquartile range [IQR], 5-15 vs 10 days; IQR, 6-24 days, respectively; P < 0.01), and time to clinical stability in elderly patients with CAP (percentage of stable patients by day 7, 71%; 95% CI, 68%-74% vs 57%; 95% CI, 53%-61%, respectively; P < 0.01). All elderly patients should be vaccinated against pneumococcal disease and influenza based on recommendations from the Centers for Disease Control and Prevention. Lifestyle modifications and nutritional support are also important elements in the prevention of pneumonia in the elderly. Conclusion: Adherence to established guidelines, along with customization of antimicrobial therapy based on local rates and patterns of resistance and patient-specific risk factors, likely will improve the treatment outcome of elderly patients with CAR (Am J Geriatr Pharmacother. 2010;8:47-62) (C) 2010 Excerpta Medica Inc. C1 [Fung, Horatio B.] James J Peters Vet Affairs Med Ctr, Serv Pharm, Bronx, NY 10468 USA. [Monteagudo-Chu, Maricelle O.] Kingsbrook Jewish Med Ctr, Dept Pharm, Brooklyn, NY USA. RP Fung, HB (reprint author), James J Peters Vet Affairs Med Ctr, Serv Pharm, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM horatio.fung@va.gov NR 76 TC 29 Z9 36 U1 1 U2 11 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 1543-5946 J9 AM J GERIATR PHARMAC JI Am. J. Geriatr. Pharmacother. PD FEB PY 2010 VL 8 IS 1 BP 47 EP 62 DI 10.1016/j.amjopharm.2010.01.003 PG 16 WC Geriatrics & Gerontology; Pharmacology & Pharmacy SC Geriatrics & Gerontology; Pharmacology & Pharmacy GA 563HL UT WOS:000275118700004 PM 20226392 ER PT J AU Marcum, ZA Handler, SM Boyce, R Gellad, W Hanlon, JT AF Marcum, Zachary A. Handler, Steven M. Boyce, Richard Gellad, Walid Hanlon, Joseph T. TI Medication Misadventures in the Elderly: A Year in Review SO AMERICAN JOURNAL OF GERIATRIC PHARMACOTHERAPY LA English DT Review DE medication errors; medication adherence; monitoring; adverse drug events; aged; computerized physician order entry ID INAPPROPRIATE DRUG-USE; OLDER-ADULTS; PREDICTIVE-VALIDITY; SAFETY ALERTS; HOSPITALIZATION; DISCREPANCIES; ADHERENCE; RISK; CARE; ASSOCIATION AB Objective: This paper reviews recent articles examining medication misadventures that can be defined as medication errors and adverse drug events in the elderly. Methods: MEDLINE and International Pharmaceutical Abstracts were searched for articles published in English in 2009 using a combination of the terms medication errors, medication adherence, suboptimal prescribing, monitoring, adverse drug events, adverse drug withdrawal events, therapeutic failure, and aged. A manual search of the reference lists of the identified articles and the authors' article files, book chapters, and recent reviews was conducted to identify, additional publications. Those studies that described unique approaches to evaluating medication misadventures in the elderly were included in the review. Results: The search identified 5 unique Studies relating to medication misadventures in the elderly. A cross-sectional Study found that a new 8-item paper-and-pencil adherence survey-the Morisky Medication Adherence Scale-was significantly associated with antihypertensive drug pharmacy refill adherence (P < 0.05). A cross-sectional study of medication discrepancies that occurred during transition from the hospital to a nursing home found discrepancies in almost 75% of patients. A randomized controlled trial of a computer-generated decision Support intervention to reduce potentially inappropriate prescribing in an emergency department found that the intervention was associated with a significant reduction in prescriptions for such medications (P = 0.02). One study found that patients who were taking digoxin and had been hospitalized during the previous 2 months were at significantly increased risk for additional hospitalizations due to digoxin toxicity. A survey study of Medicare beneficiaries found that use of multiple types of inappropriate medications was a risk factor for self-reported adverse drug events, independent of the number of medications taken. Conclusion: Data from these recently published studies could be used to guide the development and evaluation of quality improvement, research, or clinical practice initiatives. (Am J Geriatr Pharmacother. 2010;8:77-85) (C) 2010 Excerpta Medica Inc. C1 [Marcum, Zachary A.; Handler, Steven M.; Gellad, Walid; Hanlon, Joseph T.] Univ Pittsburgh, Dept Med, Sch Med, Pittsburgh, PA 15213 USA. [Handler, Steven M.; Hanlon, Joseph T.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA. [Handler, Steven M.; Boyce, Richard] Univ Pittsburgh, Dept Biomed Informat, Sch Med, Pittsburgh, PA 15213 USA. [Gellad, Walid; Hanlon, Joseph T.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA USA. [Hanlon, Joseph T.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15213 USA. [Hanlon, Joseph T.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15213 USA. [Hanlon, Joseph T.] Univ Pittsburgh, Clin & Translat Sci Inst, Pittsburgh, PA 15213 USA. RP Hanlon, JT (reprint author), Univ Pittsburgh, Dept Med, Sch Med, Kaufmann Med Bldg,Suite 500,3471 5th Ave, Pittsburgh, PA 15213 USA. EM jth14@pitt.edu OI Handler, Steven/0000-0002-3940-3224; Boyce, Richard/0000-0002-2993-2085 FU National Institute of Aging [R01AG027017, P30AG024827, T32 AG021885, K07AG033174, R01AG034056]; National Institute of Mental Health [R34 MH082682]; National Institute of Nursing Research [R01 NR010135]; Agency for Healthcare Research and Quality [R01 HS017695]; Veterans Affairs Health Services Research [HR-06-062]; National Institutes of Health Roadmap Multidisciplinary Clinical Research Career Development Award [K12 RR023267] FX This study was supported by National Institute of Aging grants (R01AG027017, P30AG024827, T32 AG021885, K07AG033174, R01AG034056), a National Institute of Mental Health grant (R34 MH082682), a National Institute of Nursing Research grant (R01 NR010135), an Agency for Healthcare Research and Quality grant (R01 HS017695), a Veterans Affairs Health Services Research grant (HR-06-062), and a National Institutes of Health Roadmap Multidisciplinary Clinical Research Career Development Award grant (K12 RR023267). Dr. Hanlon is Co-Editor-in-Clilef of The American Journal of Geriatric Pharmacotherapy. The authors have indicated that they have no other conflicts of interest regarding the content of this article. NR 30 TC 10 Z9 12 U1 1 U2 13 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 1543-5946 J9 AM J GERIATR PHARMAC JI Am. J. Geriatr. Pharmacother. PD FEB PY 2010 VL 8 IS 1 BP 77 EP 85 DI 10.1016/j.amjopharm.2010.02.002 PG 9 WC Geriatrics & Gerontology; Pharmacology & Pharmacy SC Geriatrics & Gerontology; Pharmacology & Pharmacy GA 563HL UT WOS:000275118700007 PM 20226395 ER PT J AU Deming, D Silverman, E AF Deming, Dustin Silverman, Elizabeth TI Pasteurella multocida tracheobronchitis in a patient with CLL on rituximab SO AMERICAN JOURNAL OF HEMATOLOGY LA English DT Letter ID CHRONIC LYMPHOCYTIC-LEUKEMIA; HAIRY-CELL LEUKEMIA; LYMPHOMA; SEPSIS C1 [Deming, Dustin; Silverman, Elizabeth] Univ Wisconsin, Dept Med, Madison, WI 53706 USA. [Silverman, Elizabeth] William S Middleton Mem Vet Adm Med Ctr, Dept Med, Hematol Oncol Sect, Madison, WI USA. RP Deming, D (reprint author), Univ Wisconsin, Dept Med, Madison, WI 53706 USA. NR 11 TC 2 Z9 2 U1 0 U2 2 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0361-8609 J9 AM J HEMATOL JI Am. J. Hematol. PD FEB PY 2010 VL 85 IS 2 BP 144 EP 145 DI 10.1002/ajh.21592 PG 2 WC Hematology SC Hematology GA 550WD UT WOS:000274162500019 PM 20033893 ER PT J AU Valente, S Saunders, J AF Valente, Sharon Saunders, Judith TI Psychiatric Nurses' Expertise, Interest in End-of-Life Care, and Requests for Continuing Education on End of Life SO AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE LA English DT Article DE end-of-life; psychiatric nursing skills; continuing education ID PALLIATIVE CARE; NEEDS AB Background: The time before dying can be extremely challenging and stressful. Gaps in end-of-life care include inadequate communication, education about end-of-life options, symptom control, and management of common mental illnesses (eg, mood disorders, dementia), and death anxiety. Psychiatric nurses are in a pivotal position to help address these gaps and improve end-of-life care. Psychiatric nurses can facilitate communication about end of life, educate patients about options, and provide consultation, assessment, and management of common psychosocial needs (eg, mood disorders, grief, and loss). Objective: This survey examined psychiatric nurses' perspectives of their skills, knowledge, expertise, continuing education needs, and recommendations for the role of the psychiatric nurse. Study design: Using a descriptive design, we surveyed a convenience sample of psychiatric nurses from the American Psychiatric Nurses Association. Results: Psychiatric nurses reported they were skilled in discussions of difficult topics, evaluation of mental status, and assessment and management of mood disorders, grief, and suicide risk. However, nurses asked for continuing education in focusing these skills for end of life, knowing the needs of the dying patient, and differentiating depression and dementia at end of life. Requests for continuing education on end-of-life care included issues about how to apply these psychiatric skills and knowledge to the dying patient and their families. Conclusions: Psychiatric nurses have skills and knowledge to reduce the gaps in end-of-life care. Many request continuing education to assist them to expand and focus their knowledge to use their psychosocial skills and to develop a specialty area in end-of-life care.. C1 [Valente, Sharon] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Saunders, Judith] Vet Affairs Greater Los Angeles Healthcare Syst, Pasadena, CA USA. RP Valente, S (reprint author), 346 N Bowling Green Way, Los Angeles, CA 90049 USA. EM sharonvalente725@hotmail.com NR 20 TC 3 Z9 3 U1 1 U2 8 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1049-9091 J9 AM J HOSP PALLIAT ME JI Am. J. Hosp. Palliat. Med. PD FEB-MAR PY 2010 VL 27 IS 1 BP 24 EP 30 DI 10.1177/1049909109341873 PG 7 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 551GA UT WOS:000274193800004 PM 19789391 ER PT J AU Weiner, DE Watnick, SG AF Weiner, Daniel E. Watnick, Suzanne G. TI The 2009 Proposed Rule for Prospective ESRD Payment: Historical Perspectives and Public Policies-Bundle Up! SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Editorial Material ID RECOMBINANT-HUMAN-ERYTHROPOIETIN; RENAL-DISEASE PATIENTS; UNITED-STATES; DIALYSIS; HEMODIALYSIS; MEDICARE; QUALITY; HEALTH; LIFE C1 [Weiner, Daniel E.] Tufts Med Ctr, Boston, MA 02111 USA. [Watnick, Suzanne G.] Portland VA Med Ctr, Portland, OR USA. RP Weiner, DE (reprint author), Tufts Med Ctr, 800 Washington St,Box 391, Boston, MA 02111 USA. EM dweiner@tuftsmedicalcenter.org NR 22 TC 5 Z9 6 U1 0 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 EI 1523-6838 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD FEB PY 2010 VL 55 IS 2 BP 217 EP 222 DI 10.1053/j.ajkd.2009.12.005 PG 6 WC Urology & Nephrology SC Urology & Nephrology GA 555TA UT WOS:000274537000006 PM 20116682 ER PT J AU Fischer, MJ Stroupe, KT Kaufman, JS O'Hare, AM Browning, MM Huo, ZP Hynes, DM AF Fischer, Michael J. Stroupe, Kevin T. Kaufman, James S. O'Hare, Ann M. Browning, Margaret M. Huo, Zhiping Hynes, Denise M. TI Predialysis Nephrology Care Among Older Veterans Using Department of Veterans Affairs or Medicare-Covered Services SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Article ID CHRONIC KIDNEY-DISEASE; RENAL REPLACEMENT THERAPY; PRE-ESRD CARE; HEALTH-CARE; PATIENT OUTCOMES; REFERRED LATE; ESTIMATED GFR; MORTALITY; PREDICTORS; CONTINUITY AB Objective: To examine the effect of exclusive and dual use of Department of Veterans Affairs (VA) and Medicare healthcare systems on outpatient predialysis nephrology care. Study Design: Retrospective cohort study. Methods: Receipt, timeliness, and intensity of predialysis nephrology care were evaluated among 8033 veterans who initiated dialysis in 2000 and 2001 and were eligible for both VA and Medicare coverage in the 12 months preceding dialysis initiation. Propensity scores were incorporated into analyses to minimize potential selection bias from nonrandom veteran allocation to healthcare systems. Results: Among the cohort, 17.4% were users of VA services only (VA-only users), 38.5% were users of Medicare-covered services only (Medicare-only users), and 44.1% were users of both VA and Medicare-covered services (dual users). Sixty-six percent of VA-only and dual users and 58.1% of Medicare-only users received predialysis nephrology care. Compared with Medicare-only users, dual users were more likely (risk ratio [RR], 1.12; 95% confidence interval [CI], 1.07-1.17) and VA-only users were as likely (RR, 0.98; 95% CI, 0.88-1.08) to have received predialysis nephrology care. Compared with Medicare-only use, VA-only use (RR, 0.63; 95% CI, 0.50-0.81) and dual use (RR, 0.78; 95% CI, 0.70-0.88) were associated with a lower likelihood of late nephrology care (< 3 months before dialysis initiation). Conclusions: More than one-third of older veterans initiating dialysis do not receive nephrology care beforehand. Dual use of VA and Medicare-covered services was associated with greater receipt and favorable timeliness of predialysis nephrology care, while use of only Medicare-covered services was associated with late predialysis nephrology care. Further studies to identify reasons for system-level variations in access to predialysis nephrology care may assist in identifying opportunities for improvement. (Am J Manag Care. 2010; 16(2): e57-e66) C1 [Fischer, Michael J.; Stroupe, Kevin T.; Browning, Margaret M.; Huo, Zhiping; Hynes, Denise M.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Ctr Management Complex Chron Care, Hines, IL 60141 USA. [Fischer, Michael J.] Jesse Brown VA Med Ctr, Div Nephrol, Chicago, IL USA. [Fischer, Michael J.] Univ Illinois, Div Nephrol, Chicago, IL USA. [Hynes, Denise M.] Univ Illinois, Div Hlth Promot Res, Chicago, IL USA. [Stroupe, Kevin T.] Northwestern Univ, Div Gen Internal Med, Chicago, IL 60611 USA. [Kaufman, James S.] Boston VA Med Ctr, Div Nephrol, Boston, MA USA. [Kaufman, James S.] Boston Univ, Boston, MA 02215 USA. [O'Hare, Ann M.] VA Puget Sound Healthcare Syst, Div Nephrol, Seattle, WA USA. RP Fischer, MJ (reprint author), Edward Hines Jr VA Med Ctr, Ctr Management Complex Chron Care, 5000 S 5th Ave,151H, Hines, IL 60141 USA. EM fischerm@uic.edu FU Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service [IIR 02-244, IIR 20-016]; National Kidney Foundation of Illinois; National Institutes of Health (NIH) [K23AG28980] FX The authors received funding support for this research project from the Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service (VA HSR&D IIR 02-244 and IIR 20-016 to KTS, MMB, and DMH; VA HSR&D Research Career Scientist Award to DMH; and VA HSR&D Career Development Award to MJF); from the National Kidney Foundation of Illinois (to MJF); and from the National Institutes of Health (NIH K23AG28980 to AMO). The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs or Health Services Research and Development Service. NR 52 TC 10 Z9 10 U1 0 U2 2 PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC PI PLAINSBORO PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD FEB PY 2010 VL 16 IS 2 BP E57 EP E66 PG 10 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 556KW UT WOS:000274590800012 PM 20148611 ER PT J AU Bradshaw, AD Baicu, CF Rentz, TJ Van Laer, AO Bonnema, DD Zile, MR AF Bradshaw, Amy D. Baicu, Catalin F. Rentz, Tyler J. Van Laer, An O. Bonnema, D. Dirk Zile, Michael R. TI Age-dependent alterations in fibrillar collagen content and myocardial diastolic function: role of SPARC in post-synthetic procollagen processing SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY LA English DT Article DE secreted protein acidic and rich in cysteine; aging ID CHRONIC HEART-FAILURE; NULL MICE; MATRIX METALLOPROTEINASES; GENE-EXPRESSION; MESSENGER-RNA; DYSFUNCTION; PROTEIN; FIBROBLASTS; HYPERTENSION; ANGIOGENESIS AB Bradshaw AD, Baicu CF, Rentz TJ, Van Laer AO, Bonnema DD, Zile MR. Age-dependent alterations in fibrillar collagen content and myocardial diastolic function: role of SPARC in post-synthetic procollagen processing. Am J Physiol Heart Circ Physiol 298: H614-H622, 2010. First published December 11, 2009; doi:10.1152/ajpheart.00474.2009.-Advanced age, independent of concurrent cardiovascular disease, can be associated with increased extracellular matrix (ECM) fibrillar collagen content and abnormal diastolic function. However, the mechanisms causing this left ventricular (LV) remodeling remain incompletely defined. We hypothesized that one determinant of age-dependent remodeling is a change in the extent to which newly synthesized procollagen is processed into mature collagen fibrils. We further hypothesized that secreted protein acidic and rich in cysteine (SPARC) plays a key role in the changes in post-synthetic procollagen processing that occur in the aged myocardium. Young (3 mo old) and old (18-24 mo old) wild-type (WT) and SPARC-null mice were studied. LV collagen content was measured histologically by collagen volume fraction, collagen composition was measured by hydroxyproline assay as soluble collagen (1 M NaCl extractable) versus insoluble collagen (mature cross-linked), and collagen morphological structure was examined by scanning electron microscopy. SPARC expression was measured by immunoblot analysis. LV and myocardial structure and function were assessed using echocardiographic and papillary muscle experiments. In WT mice, advanced age increased SPARC expression, myocardial diastolic stiffness, fibrillar collagen content, and insoluble collagen. In SPARC-null mice, advanced age also increased myocardial diastolic stiffness, fibrillar collagen content, and insoluble collagen but significantly less than those seen in WT old mice. As a result, insoluble collagen and myocardial diastolic stiffness were lower in old SPARC-null mice (1.36 +/- 0.08 mg hydroxyproline/g dry wt and 0.04 +/- 0.005) than in old WT mice (1.70 +/- 0.10 mg hydroxyproline/g dry wt and 0.07 +/- 0.005, P < 0.05). In conclusion, the absence of SPARC reduced age-dependent alterations in ECM fibrillar collagen and diastolic function. These data support the hypothesis that SPARC plays a key role in post-synthetic procollagen processing and contributes to the increase in collagen content found in the aged myocardium. C1 [Bradshaw, Amy D.] Med Univ S Carolina, Dept Med, Div Cardiol, Gazes Cardiac Res Inst, Charleston, SC 29425 USA. Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC USA. RP Bradshaw, AD (reprint author), Med Univ S Carolina, Dept Med, Div Cardiol, Gazes Cardiac Res Inst, Gazes Strom Thurmond Res Bldg,114 Doughty St,Rm 2, Charleston, SC 29425 USA. EM bradshad@musc.edu FU Department of Veterans Affairs; National Heart, Lung, and Blood Institute [PO1-HL-48788] FX This work was supported by the Research Service of the Department of Veterans Affairs (to M. R. Zile and A. D. Bradshaw) and by National Heart, Lung, and Blood Institute Grant PO1-HL-48788 (to M. R. Zile). NR 49 TC 58 Z9 58 U1 0 U2 1 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6135 J9 AM J PHYSIOL-HEART C JI Am. J. Physiol.-Heart Circul. Physiol. PD FEB PY 2010 VL 298 IS 2 BP H614 EP H622 DI 10.1152/ajpheart.00474.2009 PG 9 WC Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular Disease SC Cardiovascular System & Cardiology; Physiology GA 546AW UT WOS:000273780400040 PM 20008277 ER PT J AU Chirinos, JA Segers, P Raina, A Saif, H Swillens, A Gupta, AK Townsend, R Emmi, AG Kirkpatrick, JN Keane, MG Ferrari, VA Wiegers, SE Sutton, MGSJ AF Chirinos, Julio A. Segers, Patrick Raina, Amresh Saif, Hassam Swillens, Abigail Gupta, Amit K. Townsend, Raymond Emmi, Anthony G., Jr. Kirkpatrick, James N. Keane, Martin G. Ferrari, Victor A. Wiegers, Susan E. Sutton, Martin G. St. John TI Arterial pulsatile hemodynamic load induced by isometric exercise strongly predicts left ventricular mass in hypertension SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY LA English DT Article DE arterial load; arterial compliance; wave reflections; aortic stiffness ID BLOOD-PRESSURE RESPONSES; WAVE REFLECTION; ANTIHYPERTENSIVE THERAPY; CARDIOVASCULAR HEALTH; INPUT IMPEDANCE; HEART-DISEASE; HYPERTROPHY; STIFFNESS; STRESS; RISK AB Chirinos JA, Segers P, Raina A, Saif H, Swillens A, Gupta AK, Townsend R, Emmi AG, Jr., Kirkpatrick JN, Keane MG, Ferrari VA, Wiegers SE, Sutton MG. Arterial pulsatile hemodynamic load induced by isometric exercise strongly predicts left ventricular mass in hypertension. Am J Physiol Heart Circ Physiol 298: H320-H330, 2010. First published December 4, 2009; doi:10.1152/ajpheart.00334.2009.-Although resting hemodynamic load has been extensively investigated as a determinant of left ventricular (LV) hypertrophy, little is known about the relationship between provoked hemodynamic load and the risk of LV hypertrophy. We studied central pressure-flow relations among 40 hypertensive and 19 normotensive adults using carotid applanation tonometry and Doppler echocardiography at rest and during a 40% maximal voluntary forearm contraction (handgrip) maneuver. Carotid-femoral pulse wave velocity (CF-PWV) was measured at rest. Hypertensive subjects demonstrated various abnormalities in resting and induced pulsatile load. Isometric exercise significantly increased systemic vascular resistance, aortic characteristic impedance (Zc), induced earlier wave reflections, increased augmentation index, and decreased total arterial compliance (TAC; all P <= 0.01). In hypertensive subjects, CF-PWV was the strongest resting predictor of LV mass index (LVMI) and remained an independent predictor after adjustment for age, gender, systemic vascular resistance, reflection magnitude, aortic Zc, and TAC (beta = 2.52 m/s; P < 0.0001). Age, sex, CF-PWV, and resting hemodynamic indexes explained 48% of the interindividual variability in LVMI. In stepwise regression, TAC (beta = -17.85; P < 0.0001) during handgrip, Zc during handgrip (beta = -150; P < 0.0001), and the change in the timing of wave reflections during handgrip (beta = -0.63; P = 0.03) were independent predictors of LVMI. A model that included indexes of provoked hemodynamic load explained 68% of the interindividual variability in LVMI. Hemodynamic load provoked by isometric exercise strongly predicts LVMI in hypertension. The magnitude of this association is far greater than for resting hemodynamic load, suggesting that provoked testing captures important arterial properties that are not apparent at rest and is advantageous to assess dynamic arterial load in hypertension. C1 [Chirinos, Julio A.] Philadelphia VA Med Ctr, Div Cardiol, Philadelphia, PA 19104 USA. [Chirinos, Julio A.; Raina, Amresh; Saif, Hassam; Gupta, Amit K.; Townsend, Raymond; Emmi, Anthony G., Jr.; Kirkpatrick, James N.; Keane, Martin G.; Ferrari, Victor A.; Wiegers, Susan E.; Sutton, Martin G. St. John] Univ Penn, Philadelphia, PA 19104 USA. [Segers, Patrick; Swillens, Abigail] Univ Ghent, IBiTech, B-9000 Ghent, Belgium. RP Chirinos, JA (reprint author), Philadelphia VA Med Ctr, Div Cardiol, 8B111,3900 Woodland Ave, Philadelphia, PA 19104 USA. EM Julio.chirinos@uphs.upenn.edu RI Gupta, amit/B-3831-2012; Santana, Fabio/C-8745-2012 NR 34 TC 23 Z9 25 U1 0 U2 0 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6135 J9 AM J PHYSIOL-HEART C JI Am. J. Physiol.-Heart Circul. Physiol. PD FEB PY 2010 VL 298 IS 2 BP H320 EP H330 DI 10.1152/ajpheart.00334.2009 PG 11 WC Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular Disease SC Cardiovascular System & Cardiology; Physiology GA 546AW UT WOS:000273780400005 PM 19966060 ER PT J AU Brooks, VL Mulvaney, JM Azar, AS Zhao, D Goldman, RK AF Brooks, Virginia L. Mulvaney, Julia M. Azar, Afaf S. Zhao, Ding Goldman, Robert K. TI Pregnancy impairs baroreflex control of heart rate in rats: role of insulin sensitivity SO AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY LA English DT Article DE hyperinsulinemic-euglycemic clamp; mean arterial pressure; telemetry; spontaneous baroreflex sensitivity; insulin resistance ID SYMPATHETIC-NERVE ACTIVITY; GLUCOSE CLAMP TECHNIQUE; CONSCIOUS RATS; ARTERIAL BAROREFLEX; BARORECEPTOR REFLEX; BLOOD-PRESSURE; AUTONOMIC FUNCTION; NITRIC-OXIDE; BRAIN; OXYTOCIN AB Brooks VL, Mulvaney JM, Azar AS, Zhao D, Goldman RK. Pregnancy impairs baroreflex control of heart rate in rats: role of insulin sensitivity. Am J Physiol Regul Integr Comp Physiol 298: R419-R426, 2010. First published November 25, 2009; doi:10.1152/ajpregu.00441.2009.-Recent studies in rabbits suggest that insulin resistance and reduced brain insulin contribute to impaired baroreflex control of heart rate (HR) during pregnancy; however, the mechanisms are unknown. The rat model is ideal to investigate these mechanisms because much is known about rat brain baroreflex neuro-circuitry and insulin receptor locations. However, it is unclear in rats whether pregnancy impairs the HR baroreflex or whether insulin resistance is involved. Therefore, this study tested the hypothesis that in rats pregnancy decreases HR baroreflex sensitivity (BRS) and that this decrease is related to concurrent decreases in insulin sensitivity (IS). BRS was quantified before, during, and after pregnancy using complementary methods: 1) spontaneous BRS (sBRS) derived from sequence method analysis of telemetric, continuous arterial pressure recordings; and 2) maximal BRS of complete sigmoidal baroreflex relationships. IS was measured (hyperinsulinemic euglycemic clamp) to determine whether BRS and IS change in parallel. sBRS was reduced at midgestation [pregnancy day 10 (P10)], returned to nonpregnant (NP) levels on P18, and fell again at late gestation (P20) (sBRS in ms/mmHg: NP, 1.66 +/- 0.04; P10, 1.17 +/- 0.11; P18, 1.55 +/- 0.12; P20, 1.31 +/- 0.05; n = 5; P < 0.05). Similar triphasic patterns were observed for both maximal BRS [in beats.min(-1).mmHg(-1): NP, 4.45 +/- 0.52 (n = 10); P11-12, 2.76 +/- 0.11 (n = 7); P17-18, 3.79 +/- 0.14 (n = 5); P19-20, 2.32 +/- 0.40 (n = 8); P < 0.0001] and previous and current measurements of IS (in mg glucose.kg(-1).min(-1): NP, 32 +/- 2; P19-20, 15 +/- 1; P < 0.0005). Furthermore, during pregnancy, the standard deviation (SD) of MAP increased, and the SD of HR decreased, indirectly suggesting baroreflex impairment. sBRS increased transiently during parturition, and sBRS, maximal BRS, and IS normalized 3-4 days postpartum. In conclusion, pregnancy decreases HR BRS in rats. The parallel temporal changes in BRS and IS suggest a mechanistic link. C1 [Goldman, Robert K.] Portland VA Med Ctr, Dept Surg, Portland, OR 97239 USA. [Brooks, Virginia L.; Mulvaney, Julia M.; Azar, Afaf S.; Zhao, Ding] Oregon Hlth & Sci Univ, Dept Physiol & Pharmacol, Portland, OR 97201 USA. RP Goldman, RK (reprint author), Portland VA Med Ctr, Dept Surg, P3SURG,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM robert.goldman@va.gov FU National Heart, Lung, and Blood Institute [HL-088552]; American Heart Association [0750172Z]; Medical Research Foundation of Oregon FX This work was supported in part by National Heart, Lung, and Blood Institute Grant HL-088552 and American Heart Association Grant 0750172Z, as well as a grant from the Medical Research Foundation of Oregon. NR 54 TC 10 Z9 10 U1 0 U2 1 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6119 J9 AM J PHYSIOL-REG I JI Am. J. Physiol.-Regul. Integr. Comp. Physiol. PD FEB PY 2010 VL 298 IS 2 BP R419 EP R426 DI 10.1152/ajpregu.00441.2009 PG 8 WC Physiology SC Physiology GA 547CI UT WOS:000273862700023 PM 19939977 ER PT J AU Acierno, R Hernandez, MA Amstadter, AB Resnick, HS Steve, K Muzzy, W Kilpatrick, DG AF Acierno, Ron Hernandez, Melba A. Amstadter, Ananda B. Resnick, Heidi S. Steve, Kenneth Muzzy, Wendy Kilpatrick, Dean G. TI Prevalence and Correlates of Emotional, Physical, Sexual, and Financial Abuse and Potential Neglect in the United States: The National Elder Mistreatment Study SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; VIOLENCE; ADULTS; RISK AB Objectives. We estimated prevalence and assessed correlates of emotional, physical, sexual, and financial mistreatment and potential neglect (defined as an identified need for assistance that no one was actively addressing) of adults aged 60 years or older in a randomly selected national sample. Methods. We compiled a representative sample by random digit dialing across geographic strata. We used computer-assisted telephone interviewing to standardize collection of demographic, risk factor, and mistreatment data. We subjected prevalence estimates and mistreatment correlates to logistic regression. Results. We analyzed data from 5777 respondents. One-year prevalence was 4.6% for emotional abuse, 1.6% for physical abuse, 0.6% for sexual abuse, 5.1% for potential neglect, and 5.2% for current financial abuse by a family member. One in 10 respondents reported emotional, physical, or sexual mistreatment or potential neglect in the past year. The most consistent correlates of mistreatment across abuse types were low social support and previous traumatic event exposure. Conclusions. Our data showed that abuse of the elderly is prevalent. Addressing low social support with preventive interventions could have significant public health implications. (Am J Public Health. 2010;100:292-297. doi:10.2105/AJPH.2009.163089) C1 [Acierno, Ron; Amstadter, Ananda B.; Resnick, Heidi S.; Muzzy, Wendy; Kilpatrick, Dean G.] Med Univ S Carolina, Charleston, SC USA. [Acierno, Ron] Ralph H Johnson Vet Adm Med Ctr, Charleston, SC USA. [Hernandez, Melba A.] Univ Simon Bolivar, Caracas, Venezuela. [Steve, Kenneth] Abt SRBI, New York, NY USA. RP Acierno, R (reprint author), Natl Crime Victims Res & Treatment Ctr, 67 President St,MUSC 861,2nd Floor,1OP S, Charleston, SC 29425 USA. EM acierno@musc.edu FU National Institute of Justice [2007-WG-BX-0009]; National Institute on Aging [R21AG030667] FX This study was supported primarily by the National Institute of Justice (grant 2007-WG-BX-0009) and by the National Institute on Aging (grant R21AG030667). NR 20 TC 220 Z9 234 U1 5 U2 57 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD FEB PY 2010 VL 100 IS 2 BP 292 EP 297 DI 10.2105/AJPH.2009.163089 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 554DF UT WOS:000274415000025 PM 20019303 ER PT J AU Anaya, DA Lahat, G Wang, X Xiao, L Pisters, PW Cormier, JN Hunt, KK Feig, W Lev, DC Pollock, RE AF Anaya, D. A. Lahat, G. Wang, X. Xiao, L. Pisters, P. W. Cormier, J. N. Hunt, K. K. Feig, W. Lev, D. C. Pollock, R. E. TI Postoperative nomogram for survival of patients with retroperitoneal sarcoma treated with curative intent SO ANNALS OF ONCOLOGY LA English DT Article DE postoperative nomogram; prognosis; retroperitoneal sarcoma; staging ID SOFT-TISSUE SARCOMA; RESECTION PREDICT PATTERN; PROGNOSTIC NOMOGRAM; HISTOLOGIC SUBTYPE; SINGLE INSTITUTION; LIPOSARCOMA; RECURRENCE; CLASSIFICATION; CARCINOMA; EXTREMITY AB Background: Current American Joint Committee on Cancer retroperitoneal sarcoma (RPS) staging is not representative of patients with RPS specifically and has limited discriminative power. Our objective was to develop a RPS disease-specific nomogram capable of stratifying patients based on probability of overall survival (OS) after resection. Patients and methods: In all, 1118 RPS patients were evaluated at our institution (1996-2006). Patients with resectable, nonmetastatic disease were selected (n = 343) and baseline, treatment and outcome variables were retrieved. A nomogram was created and its performance was evaluated by calculating its discrimination (concordance index) and calibration and by subsequent internal validation. Results: Median follow-up and OS were 50 and 59 months, respectively. Independent predictors of OS were included in the nomogram: age (>= 65), tumor size (>= 15 cm), type of presentation (primary versus recurrent), multifocality, completeness of resection and histology. The concordance index was 0.73 [95% confidence interval (CI) 0.71-0.75] and the calibration was excellent, with all observed outcomes within the 95% CI of each predicted survival probability. Conclusions: A RPS-specific postoperative nomogram was developed. It improves RPS staging by allowing a more dynamic and robust disease-specific risk stratification. This prognostic tool can help in patient counseling and for selection of high-risk patients that may benefit from adjuvant therapies or inclusion into clinical trials. C1 [Pollock, R. E.] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, U444, Houston, TX 77030 USA. [Wang, X.; Xiao, L.] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA. [Lev, D. C.] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA. [Anaya, D. A.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Dept Surg, Houston, TX 77030 USA. RP Pollock, RE (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, U444, 1400 Holcombe Blvd,POB 301402, Houston, TX 77030 USA. EM rpollock@mdanderson.org NR 32 TC 34 Z9 34 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 J9 ANN ONCOL JI Ann. Oncol. PD FEB PY 2010 VL 21 IS 2 BP 397 EP 402 DI 10.1093/annonc/mdp298 PG 6 WC Oncology SC Oncology GA 549XK UT WOS:000274087600032 PM 19622598 ER PT J AU Kakkar, AK Cohen, AT Tapson, VF Bergmann, JF Goldhaber, S Deslandes, B Huang, W Anderson, FA Cherfi, L Ammour, D Bentakouk, C Bourenane, R Grainat, N Maarouf, A Sissaoui, A Gallus, A Ayyar, V Crimmins, D Gan, E McRae, S Seldon, M Singh, B Siddiqui, FM Moula, K Nawaz, T Nazimuddin, K Rahman, S Sarker, S Rocha, A Brandao, C Costa, J Macedo, A Marino, R Menezes, P Oigman, W Paiva, M Pantoja, J Schramm, E Tandeitnik, L Timi, J Benov, H Borisov, SD Lalov, A Mirazchijski, B Postadziyan, A Sokolov, K Statelov, E Stefanov, C Stoykova, A Tadzher, S Todorov, R Dennis, R Duran, FRM Posada, A Restrepo, H Roa, J Villadiego, J Maly, J Brabec, T Gumulec, J Jochymek, R Kellnerova, I Kvasnicka, J Penka, M Skarkova, J Slezak, P Vit, P Vojtisek, P Gobran, H El Rahman, AMA El Haddad, A Gorgy, GS Rizk-Allah, M Sholkamy, S Bergmann, JF Abinader, M Abou Khoudir, F Boyer, JF Brun, N Canet, B Collard, C Cordier, C Durroux, C Emmerich, J Friocourt, P Genay, P Ibouanga, F Moumen, A Philippe, P Planchon, P Protin, Y Quere, I Rizcallah, MJ Zotz, R Bensch, K Bensmann, K Dropmann, A Gerold, D Gussmann, A Kortmann, B Kube, L Kuster, S Leupolz, W Neuhaus, T Nobel, W Pfiel, S Pleger, E Trautmann, H Voigt, I Wolf, S Antoniadis, P Arvanitis, D Bakatsglos, S Christakis, C Gerassimidis, T Kostakis, A Liovpis, A Manolis, A Matsagas, M Pappas, S Alsayegh, F Losonczy, H Bernath, B Domjan, G Gyani, E Kecskes, G Lakatos, J Ledniczki, I Mayer, K Nyuzo, B Zeher, M Pinjala, R Agnihotri, V Balraj, A Chakraborty, A Desai, S Elangovan, A Goswami, P Rupert, E Toraskar, K Venkatesh, K Gaine, S Connaughton, J Costello, R Liston, R Zubieta, RM Fematt, FMA Esponda, JAB Maldonado, DRB Serrano, ME Perez, FEG Montalvo, CL Marquez, SL Sanchez, AQ Diaz, SR Serrano, AT de la Vega, MIV Faridi, S Javaid, M Khan, F Malik, AZ Sadiq, M Yusaf-Shah, M Musial, J Biedziuk, B Gellert, R Klonowski, W Kosiniau-Kamysz, A Kuta, M Prajs, Z Sell, M Tadeusz, K Witkiewicz, W Wysota, J Franca, A Abreu, R Campello, MDC Cartucho, D Lohmann, C Moreira, P Paulino, A Reis, A de Morais, MLR de Abreu, TT Tulbure, D Andrei, M Christian, P Ciurea, M Constantin, P Enachescu, M Gostian, O Grintescu, IM Mimor, O Natalia, H Puiac, C Valerica, S Sulimov, VA Belentsov, S Dubrovnaya, N Eliseeva, E Fridman, I Kazantchian, P Mashtacov, B Redkin, A Rodoman, G Shershnev, V Zhidkov, K Gaspa, L Barta, P Benova, K Duris, T Fecik, J Hajas, J Herman, O Lehotsky, J Macek, V Pradova, V Arcelus, J Carrascosa, M Luque, RC Gil, JD de Souza, PD Enfedaque, MA Gonzalo, FE Sanchez, FG Garcia, MG Lobo-Beristain, JL Lopez, L Rodriguez, JAN Paredes, RM Rodriguez, JLR Cantero, AR Lorenzo, PR Legarre, ALS Sanchez, AC Cardenas, MJS Bernad, RV Moreno, JRV Doerffler, J Beer, J Brunner, B Chopard, P Doerffler, J Fischer, J Ludwig, C Peter, J Rime, F Salomon, F Ulrich, M Angchaisuksiri, P Chetanachan, M Chuamuangphan, N Insiripong, S Nawarawong, W Ben Salah, A Ghedira, H Houman, MH Mohamed, M Samir, K Zouheir, J Ongen, G Altintas, F Cirak, AK Demirtas, N Dokucu, A Erden, F Guven, H Halezeroglu, S Karaoglan, H Kaynar, L Tereci, H Yildirim, C Cohen, A Calvey, T Gallegos, N Gaminara, E James, A Jeffreys, M Jowett, N Keaney, N Kesteven, P Khan, Z Mackie, P Mallick, A Marval, P Parapia, L Picozzi, N Praveen, B Satchi, G Valerio, D Tapson, V Anderson, F Antonacci, A Baker, G Beaver, R Becker, W Beckett, C Borchardt, C Briggs, M Bruckman, J Buck, L Caushaj, P Chausow, A Chowdary, M Christopulos, D Cica, P Cody, J Condit, B Cronin, S Cysyk, B Diefendorf, A Driggers, S Ellis, P Elvenia, J Feinbloom, D Feldman, M Fischer, M Froehlich, J Frost, C Gaffey, J Galster, R Geldmeier, R George, J Glielmi, V Goodwin, J Gottlieb, A Gray, B Harrington, D Henry, E Hernandez, C Hill, D Hutchinson, M Johnson, J Johnson, R Kapre, S Kowaloff, H Krodel, J Lehman, J Marney, T Marshall, I McDaniels, M Middleton, R Mitchell, P Nelson, C Netherland, S Ogden, M Packard, K Pieske, M Poole, L Radford, M Rathbun, S Roberts, C Robinson, M Rollins, D Rubinate, D Schmidt, C Scott, J Shutt, S Slone, B Spyropoulos, A Subramanian, S Sullivan, J Timmerman, C Wheeler, C White, D White, N Whitehead, A Wright, J Young, D AF Kakkar, Ajay K. Cohen, Alexander T. Tapson, Victor F. Bergmann, Jean-Francois Goldhaber, Samuel Deslandes, Bruno Huang, Wei Anderson, Frederick A., Jr. Cherfi, Lyes Ammour, Dehbia Bentakouk, Cherif Bourenane, Razika Grainat, Nadia Maarouf, Abderahmane Sissaoui, Abdelhak Gallus, Alexander Ayyar, Venkatraman Crimmins, Denis Gan, Eng McRae, Simon Seldon, Michael Singh, Bhuwan Siddiqui, F. M. Moula, Kaniz Nawaz, Taimor Nazimuddin, Khwaja Rahman, Saiyeedur Sarker, Shyamal Rocha, Ana Brandao, Carlos Costa, Jose Macedo, Alex Marino, Roberto Menezes, Paulo Oigman, Wille Paiva, Marcelo Pantoja, Joao Schramm, Edgar Tandeitnik, Liane Timi, Jorge Benov, Haralambi Borisov, Stefan Dimitrov Lalov, Anton Mirazchijski, Boyko Postadziyan, Arman Sokolov, Krassimir Statelov, Evgenii Stefanov, Chavdar Stoykova, Antoaneta Tadzher, Sheri Todorov, Radostin Dennis, Rodolfo Duran, Freddy Rafael Mendez Posada, Alfredo Restrepo, Hector Roa, Jairo Villadiego, Juan Maly, Jaroslav Brabec, Tomas Gumulec, Jaromir Jochymek, Roman Kellnerova, Ivana Kvasnicka, Jan Penka, Miroslav Skarkova, Jindra Slezak, Premysl Vit, Patrik Vojtisek, Petr Gobran, Hadi El Rahman, Alaa Mahmaud Aba El Haddad, Alaa Gorgy, George Sobhy Rizk-Allah, Mounir Sholkamy, Sherif Bergmann, Jean Francois Abinader, Marid Abou Khoudir, Falah Boyer, Jean-Francois Brun, Natacha Canet, Bernard Collard, Catherine Cordier, Christophe Durroux, Claire Emmerich, Joseph Friocourt, Patrick Genay, Patrick Ibouanga, Florent Moumen, Abdelrhani Philippe, Pierre Planchon, Pierre Protin, Yves Quere, Isabelle Rizcallah, Marie-Jeanne Zotz, Rainer Bensch, Kristina Bensmann, Klaus Dropmann, Axl Gerold, Dieter Gussmann, Andreas Kortmann, Bernd Kube, Lutz Kuster, Stefan Leupolz, Werner Neuhaus, Thomas Nobel, Wolfgang Pfiel, Sascha Pleger, Eberhard Trautmann, Harald Voigt, Ingo Wolf, Stefan Antoniadis, Pavlos Arvanitis, Dimitrios Bakatsglos, Spyridon Christakis, Christos Gerassimidis, Thomas Kostakis, Alkiviadis Liovpis, Anthanasios Manolis, Anastasakis Matsagas, Miltiadis Pappas, Stavros Alsayegh, Faisal Losonczy, Hajna Bernath, Bela Domjan, Gyula Gyani, Eva Kecskes, Gabor Lakatos, Jozsef Ledniczki, Istvan Mayer, Klara Nyuzo, Balint Zeher, Margit Pinjala, Ramakrishna Agnihotri, Vinod Balraj, A. Chakraborty, Amiya Desai, Sanjay Elangovan, Antony Goswami, Partha Rupert, Emmanuel Toraskar, Kedar Venkatesh, Kakollu Gaine, Sean Connaughton, John Costello, Richard Liston, Richard Zubieta, Ricardo Martinez Avila Fematt, Flor Mario Baeza Esponda, Juan Alejandro Benitez Maldonado, Daniel R. Escarela Serrano, Maricela Garcia Perez, Fernando Elias Lavalle Montalvo, Carlos Lopez Marquez, Santa Quesada Sanchez, Alejandro Ramirez Diaz, Santiago Tovar Serrano, Alejandro Villa de la Vega, Maria Isabel Faridi, Salman Javaid, Mansur Khan, Farrukh Malik, Asif Zafar Sadiq, Muzafaruddin Yusaf-Shah, Muhammad Musial, Jacek Biedziuk, Bartlomiej Gellert, Ryszard Klonowski, Wlodzimierz Kosiniau-Kamysz, Andrzey Kuta, Marcin Prajs, Zozislav Sell, Marek Tadeusz, Kalbarczyk Witkiewicz, Wojciech Wysota, Janusz Franca, Ana Abreu, Rui Cabral Campello, Maria da Gloria Cartucho, Daniel Lohmann, Corinna Moreira, Pedro Paulino, Aida Reis, Abilio Rojao de Morais, Maria Luisa de Abreu, Tiago Tribolet Tulbure, Dan Andrei, Muresan Christian, Pricop Ciurea, Mircea Constantin, Palivan Enachescu, Mihaela Gostian, Ovidiu Grintescu, Ioana Marina Mimor, Ovidiu Natalia, Hagau Puiac, Claudiu Valerica, Stan Sulimov, Vitalyi Andreevich Belentsov, Sergey Dubrovnaya, Nina Eliseeva, Ekaterina Fridman, Irina Kazantchian, Perch Mashtacov, Boris Redkin, Alexander Rodoman, Grigory Shershnev, Vladislav Zhidkov, Konstantin Gaspa, L'udovit Barta, Peter Benova, Katarina Duris, Tibor Fecik, Juraj Hajas, Jan Herman, Oto Lehotsky, Jan Macek, Vladimir Pradova, Viera Arcelus, Juan Carrascosa, Miguel Cuenca Luque, Rafael del Val Gil, Jose Diaz de Souza, Pedro Alvaro Enfedaque, Muriel Epelde Gonzalo, Francesc Garcia Sanchez, Florentino Guil Garcia, M. Luis Lobo-Beristain, Jose Lopez, Luciano Nieto Rodriguez, Jose Antonio Mateo Paredes, Ramon Ramos Rodriguez, Jose Luis Ruiz Cantero, Alberto Ruiz Lorenzo, Pedro Samperiz Legarre, Angel Luis Clavo Sanchez, Antonio Soto Cardenas, Maria Jose Valle Bernad, Reina Vela Moreno, Jeronimo Ramon Doerffler, Janine Beer, Jurg Brunner, Brigitte Chopard, Pierre Doerffler, Janine Fischer, Joseph Ludwig, Christian Peter, Jurg Rime, Francis Salomon, Franco Ulrich, Munch Angchaisuksiri, Pantep Chetanachan, Mariam Chuamuangphan, Nonlawan Insiripong, Somchai Nawarawong, Weerasak Ben Salah, Afif Ghedira, Habib Houman, Mohamed Habib Mohamed, Mnif Samir, Kammoun Zouheir, Jerbi Ongen, Gul Altintas, Faik Cirak, Ali Kadri Demirtas, Nazmi Dokucu, Ali Erden, Faruk Guven, Hulya Halezeroglu, Semih Karaoglan, Halim Kaynar, Leylagul Tereci, Hikmet Yildirim, Cuma Cohen, Alexander Calvey, Thomas Gallegos, Nick Gaminara, Elizabeth James, Anthony Jeffreys, Mike Jowett, Nigel Keaney, Niall Kesteven, Patrick Khan, Zafar Mackie, Peter Mallick, Abhiram Marval, Paul Parapia, L. Picozzi, Natalie Praveen, Bandipalyam Satchi, Gnanam Valerio, David Tapson, Victor Anderson, Fred Antonacci, Anthony Baker, Gennfer Beaver, Richard Becker, William Beckett, Cynthia Borchardt, Carla Briggs, Michael Bruckman, Joseph Buck, Lisa Caushaj, Philip Chausow, Alan Chowdary, Madhu Christopulos, Danielle Cica, Paula Cody, Jean Condit, Bruce Cronin, Sherill Cysyk, Barbara Diefendorf, Anne Driggers, Steven Ellis, Paula Elvenia, Jaeda Feinbloom, David Feldman, Mark Fischer, Marian Froehlich, James Frost, Christopher Gaffey, Joseph Galster, Ruth Geldmeier, Richard George, Joyce Glielmi, Vincent Goodwin, James Gottlieb, Anita Gray, Bruce Harrington, Darrell Henry, Edwina Hernandez, Cecilia Hill, David Hutchinson, Melissa Johnson, Juanita Johnson, Roberta Kapre, Sheela Kowaloff, Harvey Krodel, John Lehman, James Marney, Terri Marshall, Ingeborg McDaniels, Mary Middleton, Robert, III Mitchell, Phillip Nelson, Carrie Netherland, Susan Ogden, Maureen Packard, Keith Pieske, Marlys Poole, Lorie Radford, Martha Rathbun, Suman Roberts, Cathy Robinson, Margaret Rollins, David Rubinate, Donna Schmidt, Cheryl Scott, Julia Shutt, Sandra Slone, Betty Spyropoulos, Alex Subramanian, Seshan Sullivan, Jacqueline Timmerman, Carman Wheeler, Connie White, Diane White, Nancy Whitehead, Alva Wright, Joyce Young, Dereck CA ENDORSE Investigators TI Venous Thromboembolism Risk and Prophylaxis in the Acute Care Hospital Setting (ENDORSE Survey) Findings in Surgical Patients SO ANNALS OF SURGERY LA English DT Article ID FATAL PULMONARY-EMBOLISM; PREVENTION; SURGERY; HEPARIN; THROMBOSIS AB Objective: To evaluate venous thromboembolism (VTE) risk in patients who underwent a major operation, including the use of, and factors influencing, American College of Chest Physicians-recommended types of VTE prophylaxis. Summary Background Data: The Epidemiologic International Day for the Evaluation of Patients at Risk for Venous Thromboembolism in the Acute Hospital Care Setting (ENDORSE) survey, conducted in 358 hospitals in 3 2 countries, reported that globally, more than 40% of at-risk patients do not receive VTE prophylaxis. Limited data are available regarding VTE prophylaxis practices according to surgery type and patient characteristics. Methods: Patients aged >= 18 years undergoing major surgery were included in this prespecified subanalysis. VTE risk and use of prophylaxis were determined from hospital medical records according to the 2004 American College of Chest Physicians guidelines. Multivariable analyses were performed to identify factors associated with VTE prophylaxis use. Results: Of the 18,461 patients in ENDORSE who had undergone major surgery, 17,084 (92.5%) were at-risk for VTE and 10,638 (62,3%) received prophylaxis. Use of prophylaxis varied according to major surgery type from 86.0% for orthopedic surgery to 53.8% in urologic/gynecologic and 53.6% in other procedures. Major orthopedic surgery was most strongly associated with prophylaxis use (hip replacement: odds ratio 6.2, 95% confidence interval [CI] 5.0-7.6; knee replacement: odds ratio 5.9, 95% CI 4.6-7.8). Conclusions: The majority of surgical patients are at high-risk for VTE Despite long-standing recognition of the high-risk for VTE in surgical patients, thromboprophylaxis remains underutilized. C1 [Kakkar, Ajay K.] Barts & London Queen Marys Sch Med & Dent, London SW3 6LR, England. [Kakkar, Ajay K.] Thrombosis Res Inst, London SW3 6LR, England. [Cohen, Alexander T.] Kings Coll Hosp London, London, England. [Tapson, Victor F.] Duke Univ, Med Ctr, Durham, NC USA. [Bergmann, Jean-Francois] Univ Paris 07, Hop Lariboisiere, Paris, France. [Goldhaber, Samuel] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. [Deslandes, Bruno] Sanofi Aventis, Paris, France. [Huang, Wei; Anderson, Frederick A., Jr.] Univ Massachusetts, Sch Med, Dept Surg, Ctr Outcomes Res, Worcester, MA USA. [Cherfi, Lyes] CHU Nedir Mohamed, Tizi Ouzou, Algeria. [Bentakouk, Cherif] CHU Annaba, Annaba, Algeria. [Bourenane, Razika] Sect Sanit Guelma, Guelma, Algeria. [Grainat, Nadia] Benflis Touhami Hosp, Batna, Algeria. [Maarouf, Abderahmane] Chu Bab El Oued, Algiers, Algeria. [Sissaoui, Abdelhak] Salim Zmirli Hosp, Algiers, Algeria. [Ayyar, Venkatraman] Sir Charles Gairdner Hosp, Perth, WA, Australia. [Crimmins, Denis] Gosford Hosp, E Gosford, NSW, Australia. [Gallus, Alexander] Flinders Private Hosp, Bedford Pk, SA, Australia. [Gallus, Alexander] Repatriat Gen Hosp, Bedford Pk, SA, Australia. [Gan, Eng] Monash Med Ctr, Clayton, Vic 3168, Australia. [McRae, Simon] Queen Elizabeth Hosp, Woodville, SA 5011, Australia. [Seldon, Michael] John Hunter Hosp, Waratah, NSW, Australia. [Singh, Bhuwan] Launceston Gen Hosp, Launceston, Tas, Australia. [Moula, Kaniz] Holy Family Red Crescent Med Coll Hosp, Dhaka, Bangladesh. [Nawaz, Taimor] Bangladesh Med Coll Hosp, Dhaka, Bangladesh. [Nazimuddin, Khwaja] BIRDEM, Dhaka, Bangladesh. [Rahman, Saiyeedur] Mymensingh Med Coll Hosp, Mymensingh, Bangladesh. [Sarker, Shyamal] Dhaka Med Coll Hosp, Dhaka, Bangladesh. [Brandao, Carlos] Hosp Univ Gaffree & Guinle, Rio De Janeiro, RJ, Brazil. [Costa, Jose] Conjunto Hosp Sorocaba, Sao Paulo, Brazil. [Macedo, Alex] Santa Casa De Santos, Sao Paulo, Brazil. [Marino, Roberto] Madre Teresa, Belo Horizonte, MG, Brazil. [Menezes, Paulo] Hosp Santa Izabel, Salvador, BA, Brazil. [Oigman, Wille] Hosp Univ Pedro Ernesto, Rio De Janeiro, Brazil. [Paiva, Marcelo] Hosp 9 Julho, Sao Paulo, Brazil. [Pantoja, Joao] Hosp Copador, Rio De Janeiro, RJ, Brazil. [Rocha, Ana] Hosp Univ Prof Edgard Santos, Salvador, BA, Brazil. [Schramm, Edgar] Sao Francisco de Paula, Pelotas, RS, Brazil. [Tandeitnik, Liane] Hosp Agamenon Magalhaes, Recife, PE, Brazil. [Timi, Jorge] UFPR, Hosp Clin, Curitiba, Parana, Brazil. [Benov, Haralambi] MHAT Dr StTcherkezov, Veliko Tarnovo, Bulgaria. [Borisov, Stefan Dimitrov] MHATEM Dr Atanas Dafovski, Kardrzhali, Bulgaria. [Lalov, Anton] MBAL Dr Braton Shukerov AD Smoljan, Smoljan, Bulgaria. [Mirazchijski, Boyko] MHATEM Bourgas, Burgas, Bulgaria. [Postadziyan, Arman] Univ Hosp St Anne, Sofia, Bulgaria. [Sokolov, Krassimir] Gen Hosp Pazardzhik, Pazardzhik, Bulgaria. [Statelov, Evgenii] MBAL Plovdiv AD, Plovdiv, Bulgaria. [Stefanov, Chavdar] Univ Hosp St George, Plovdiv, Bulgaria. [Stoykova, Antoaneta] MHATEM Tota Venkova, Gabrovo, Bulgaria. [Tadzher, Sheri] MHATEM Pirogov, Sofia, Bulgaria. [Todorov, Radostin] MHATEM Dr Ivan Seliminski, Sliven, Bulgaria. [Duran, Freddy Rafael Mendez] Clin Soma, Medellin, Antioquia, Colombia. [Posada, Alfredo] Clin Villapilar, Manizales, Colombia. [Restrepo, Hector] Fdn Cardioinfantil, Bogota, Cundinamarca, Colombia. [Roa, Jairo] Hosp Univ Fdn Santa Fe Bogota, Bogota, DC, Colombia. [Villadiego, Juan] Clin Rafael Uribe Uribe, Cali, Colombia. [Brabec, Tomas] Mil Hosp BRNO, Brno, Czech Republic. [Gumulec, Jaromir] Nemocnice Valasske Mezirici, Novy Jiojn, Czech Republic. [Jochymek, Roman] Nemocnice Trinec Po, Hradek, Czech Republic. [Kellnerova, Ivana] Nemocnice Svitavach, Svitavy, Czech Republic. [Kvasnicka, Jan] Gen Univ Hosp VFN, Prague 2, Czech Republic. [Penka, Miroslav] Fac Hosp BRNO, Brno, Czech Republic. [Skarkova, Jindra] HTO, Mestska Masarykova Nemocnice, Jilemnice, Czech Republic. [Slezak, Premysl] Sumperska Hosp, Sumperk, Czech Republic. [Vit, Patrik] Mestska Nemocnico Dvur Kralove ML RS, Dvur Kralove Labem, Czech Republic. [Vojtisek, Petr] Krajska Nemocnice Pardubice, Kardiol Oddeleni, Pardubice, Czech Republic. [Gobran, Hadi] Kasr E Eine Cairo Univ Hosp, Cairo, Egypt. [El Haddad, Alaa] Natl Canc Inst, Cairo, Egypt. [Gorgy, George Sobhy] Dr Mohammed Al Shabrawishi Hosp, Giza, Egypt. [Rizk-Allah, Mounir] Alsalam Hosp, Cairo, Egypt. [Sholkamy, Sherif] Cairo Specialized Hosp, Cairo, Egypt. [Sholkamy, Sherif] Cleopatra Hosp, Cairo, Egypt. [Abinader, Marid] Clin Arc Ciel Olcomendy, Oloron Sainte Marie, France. [Abou Khoudir, Falah] Hop Henri Duffaut, Avignon, France. [Boyer, Jean-Francois] Clin St Privat, Beziers, France. [Brun, Natacha] Ctr Hosp Combarel, Rodex, France. [Canet, Bernard] Hop Langres, Langres, France. [Collard, Catherine] Ctr Hosp Luneville, Luneville, France. [Cordier, Christophe] Ctr Hosp Seclin, Seclin, France. [Durroux, Claire] Ctr Hosp Cassabel, Castelnaudary, France. [Emmerich, Joseph] Hop European George Pompidou, Paris, France. [Friocourt, Patrick] Ctr Hosp Blois, Blois, France. [Genay, Patrick] Ctr Hosp Dept, La Roche Sur Yon 9, France. [Ibouanga, Florent] Ctr Hosp Reg St Omer, St Omer, France. [Moumen, Abdelrhani] Ctr Hosp Nord Mayenne, Mayenne, France. [Philippe, Pierre] Chu Clermont Ferrand, Hotel Dieu, Clermont Ferrand, France. [Planchon, Pierre] Hop Hotel Dieu, Nantes, France. [Protin, Yves] Ctr Hosp Sedan, Sedan, France. [Quere, Isabelle] St Eloi Hop, Montpellier, France. [Rizcallah, Marie-Jeanne] Ctr Hosp Cornouaille, Quimper, France. [Bensch, Kristina] Stadt Klinikum Magdeburg, Magdeburg, Germany. [Bensmann, Klaus] St Imgardis Krankenhaus, Viersen, Germany. [Dropmann, Axl] Chirurg Klin Seefeld, Seefeld, Germany. [Gerold, Dieter] DRK KH Diez, Diez, Germany. [Gussmann, Andreas] Humaine Klinikum Bad Saarow, Bad Saarow Pieskow, Germany. [Kortmann, Bernd] Ammerland Klin, Westerstede, Germany. [Kube, Lutz] Orthopad Klin Braunfels, Braunfels, Germany. [Kuster, Stefan] DRK Krankenhaus Ratzeburg, Ratzeburg, Germany. [Leupolz, Werner] Klin Oberstdorf, Oberstdorf, Bavaria, Germany. [Neuhaus, Thomas] Johanniter Krankenhaus, Bonn, Germany. [Nobel, Wolfgang] Klinikum Bremen Nord, Bremen, Germany. [Pfiel, Sascha] Evangel Krankenhaus Bad Gandersheim, Bad Gandersheim, Germany. [Pleger, Eberhard] Vivantes Klinikum Prenzlauer Berg, Berlin, Germany. [Trautmann, Harald] Klin AM Buergerpk, Bremerhaven, Germany. [Voigt, Ingo] Evangel Krankenhaus Herne, Herne, Germany. [Wolf, Stefan] Kreiskrankenhaus Crailsheim, Crailsheim, Germany. [Antoniadis, Pavlos] Konstantopoulio Agia Olga Gen Hosp, Athens, Greece. [Arvanitis, Dimitrios] Sismanoglio Gen Hosp, Holargos, Greece. [Bakatsglos, Spyridon] Gen Hosp Drama, Drama, Greece. [Christakis, Christos] 2nd IKA Hosp Panagia, Thessaloniki, Greece. [Gerassimidis, Thomas] Hippocrateio Hosp, Thessaloniki, Greece. [Kostakis, Alkiviadis] Laikon Gen Hosp, Athens, Greece. [Liovpis, Anthanasios] Achillopoulio Gen Hosp Volos, Volos, Greece. [Manolis, Anastasakis] Hosp KOS, Kos, Greece. [Matsagas, Miltiadis] Ioannina Univ Hosp, Ioannina, Greece. [Pappas, Stavros] Gen Hosp Nikea Piraeus, Nikea, Greece. [Bernath, Bela] Baranya Megyei Korhaz, Pecs, Hungary. [Domjan, Gyula] St Rokus Hosp, Budapest, Hungary. [Gyani, Eva] Toldy Ferenc Korhaz Rendeloint, Cegled, Hungary. [Kecskes, Gabor] Zala Cty Hosp, Zalaegerszeg, Hungary. [Lakatos, Jozsef] Siklosi Korhaz Kht, Siklos, Hungary. [Ledniczki, Istvan] Marcali Vavosi Korhaz Randeloint, Marcali, Hungary. [Mayer, Klara] Hodmezovasarhely Megyei Jogu Varos Onkormanyzat E, Hodmezovasarhely, Hungary. [Nyuzo, Balint] Municipal Hosp Kiskunfelegyhaza, Kiskunfelegyhaza, Hungary. [Zeher, Margit] Univ Debrecen, Med & Hlth Sci Ctr, Debrecen, Hungary. [Agnihotri, Vinod] Holy Family Hosp, Delhi, India. [Balraj, A.] Chennai Port Trust Hosp, Madras, Tamil Nadu, India. [Chakraborty, Amiya] St Johns Med Coll Hosp, Bangalore, Karnataka, India. [Desai, Sanjay] MS Ramaiah Hosp, Bangalore, Karnataka, India. [Elangovan, Antony] Southern Railway Hosp, Madras, Tamil Nadu, India. [Goswami, Partha] Woodlands Med Ctr Ltd, Kolkata, W Bengal, India. [Rupert, Emmanuel] Rabindranath Tagore Int Inst Cardiac Sci, Kolkata, W Bengal, India. [Toraskar, Kedar] Prince Aly Khan Hosp, Bombay, Maharashtra, India. [Venkatesh, Kakollu] Gandhi Hosp, Hyderabad, Andhra Pradesh, India. [Connaughton, John] Midland Reg Hosp Portlaoise, Laois, Ireland. [Costello, Richard] Beaumont Hosp 1, Dublin, Ireland. [Liston, Richard] Kerry Gen Hosp, Kerry, Ireland. [Avila Fematt, Flor Mario] Hosp Ilc Adolfo Lopez Mateos Isssteson, Mexico City, DF, Mexico. [Baeza Esponda, Juan Alejandro] Hosp Gen Dr Ruben Lenero, Mexico City, DF, Mexico. [Benitez Maldonado, Daniel R.] Hosp Gen La Villa, Mexico City, DF, Mexico. [Escarela Serrano, Maricela] Ctr Med Nacl 20 Noviembre, Mexico City, DF, Mexico. [Garcia Perez, Fernando Elias] Corporat Hosp Satelite SA EU, Naucalpan, Mexico. [Lavalle Montalvo, Carlos] Hosp Gen XOCO, Mexico City, DF, Mexico. [Lopez Marquez, Santa] Hosp Espanol Mexico, Mexico City, DF, Mexico. [Quesada Sanchez, Alejandro] Hosp Cent Dr Ignacio Morones Prieto, San Luis Potosi, San Luis Potosi, Mexico. [Ramirez Diaz, Santiago] Centenario Hosp Miguel Hidalgo, Aguascalientes, Mexico. [Tovar Serrano, Alejandro] Ctr Hosp, Mexico City, DF, Mexico. [Villa de la Vega, Maria Isabel] Ctr Med Dalinde, Benito Juarez, DF, Mexico. [Javaid, Mansur] Shaukat Khanum Mem Canc Hosp, La Hore, Punjab, Pakistan. [Khan, Farrukh] Liaquat Natl Hosp, Karachi, Sindh, Pakistan. [Malik, Asif Zafar] Holy Family Hosp, Rawalpindi, Punjab, Pakistan. [Sadiq, Muzafaruddin] Lady Reading Hosp, Peshawar, Pakistan. [Yusaf-Shah, Muhammad] Allied Hosp, Faisalabad, Punjab, Pakistan. [Biedziuk, Bartlomiej] Zaklad Opieki Zdrowotnej Minist Spraw, Olsztyn, Mazowiecki, Poland. [Gellert, Ryszard] Szpital Bielanski, Warsaw, Poland. [Klonowski, Wlodzimierz] Wojewodski Szpital Zespolony, Plock, Poland. [Kosiniau-Kamysz, Andrzey] J Dietl Hosp, Krakow, Poland. [Kuta, Marcin] Specjalisty Szpital Im E Szczeklika, Tarnow, Malopolska, Poland. [Prajs, Zozislav] Spozoz Prymasa Kardynala Stefana Wyszynskiego, Sieradz, Lodzkie, Poland. [Sell, Marek] Reg Hosp Lung Dis, Szczecin, Poland. [Tadeusz, Kalbarczyk] Radomski Szpital Specjalisty, Radom, Poland. [Witkiewicz, Wojciech] Wojewodzki Szpital Specjalisty Wroclawiu, Wroclaw, Poland. [Wysota, Janusz] Szpital Wojewodzki, Opole, Poland. [Abreu, Rui] Hosp Dist Chaves, Chaves, Vila Real, Portugal. [Cabral Campello, Maria da Gloria] ULS Matosinhos EPE, Hosp Pedro Hispano, Matosinhos, Portugal. [Cartucho, Daniel] Hosp Barlavento Algarvio, Portimao, Portugal. [Lohmann, Corinna] Hosp Garcia de Orta, Almada, Portugal. [Moreira, Pedro] Hosp Litoral Alentejano, Santiago Do Cacem, Portugal. [Paulino, Aida] Hosp Amato Lusitano, Castelo Branco, Portugal. [Reis, Abilio] Hosp Geral Santo Antonio, Oporto, Portugal. [Rojao de Morais, Maria Luisa] Hosp Reynaldo dos Santos, Vila Franca De Xira, Portugal. [de Abreu, Tiago Tribolet] Hosp Espirito Santo Evora, Evora, Portugal. [Andrei, Muresan] Spitalul Judatean Urgenta Baia Mare, Baia Mare, Romania. [Christian, Pricop] Emergency Hosp Braila, Braila, Romania. [Ciurea, Mircea] Spitalul Univ Urgenta Bucuresti, Bucharest, Romania. [Constantin, Palivan] Spitalul Judetean Tg Jiu, Tg Jiu, Romania. [Enachescu, Mihaela] Spitalul Judetean Urgenta Ploiesti, Ploiesti, Romania. [Gostian, Ovidiu] Inst Fundeni, Bucharest, Romania. [Grintescu, Ioana Marina] Spitalul Clin Urgenta Bucuresti, Bucharest, Romania. [Mimor, Ovidiu] Spitalul Jud Urgenta Mavromati Botosani, Botosani, Romania. [Natalia, Hagau] Spitalul Clin Judetean Cluj Napoca, Cluj Napoca, Romania. [Puiac, Claudiu] Spitalul Clin Judetean Urgenta Mures, Targu Mures, Tg Mures, Romania. [Valerica, Stan] Spitalul Judatean Urgenta Bacau, Bacau, Romania. [Belentsov, Sergey] City Clin Hosp 40, Ekaterinburg, Russia. [Dubrovnaya, Nina] City Clin Hosp 28, Nizhnii Novgorod, Russia. [Eliseeva, Ekaterina] City Hosp 2 Vladivostok, Vladivostok, Russia. [Fridman, Irina] City Clin Hosp 1, Samara, Russia. [Kazantchian, Perch] Moscow Reg Clin Sci Res Inst, Moscow, Russia. [Mashtacov, Boris] Krasnoyarsk Reg Hosp, Krasnoyarsk, Russia. [Redkin, Alexander] Municipal Acute Care Hosp, Rostov Na Donu, Russia. [Rodoman, Grigory] City Clin Hosp 13, Moscow, Russia. [Shershnev, Vladislav] Novosibirsk Municipal Clin Hosp 1, Novosibirsk, Russia. [Zhidkov, Konstantin] City Hosp 26, St Petersburg, Russia. [Barta, Peter] Nemocnica Poprad As, Poprad, Slovakia. [Benova, Katarina] FNsP JA Reimana, Presov, Slovakia. [Duris, Tibor] Fac Hosp Nove Zamky, Nove Zamky, Slovakia. [Fecik, Juraj] NsP Spiesska Nova Ves As, Sp Nova Ves, Slovakia. [Hajas, Jan] NsP Liptovsky Mikulas, Liptovsky Mikulas, Slovakia. [Herman, Oto] Hosp Trencin, Trencin, Slovakia. [Lehotsky, Jan] Nemocnica S Poliklin Zilina, Zilina, Slovakia. [Macek, Vladimir] Fac Hosp Trnava, Trnava, Slovakia. [Pradova, Viera] Nemocnica A Wintera No, Piestany, Slovakia. [Carrascosa, Miguel] Hosp Laredo, Laredo, Spain. [Cuenca Luque, Rafael] Hosp Comarcal Sant Jaume de Calella, Barcelona, Spain. [del Val Gil, Jose] Hosp Obispo Polanco, Teruel, Spain. [Diaz de Souza, Pedro] Hosp La Linea, Cadiz, Spain. [Alvaro Enfedaque, Muriel] Hosp Comarcal Alt Penedes, Barcelona, Spain. [Epelde Gonzalo, Francesc] Hosp Santa Creu & Sant Pau, Barcelona, Spain. [Garcia Sanchez, Florentino] Hosp Univ Principe Asturias, Madrid, Spain. [Guil Garcia, M.] Hosp Comarcal Axarquia, Malaga, Spain. [Luis Lobo-Beristain, Jose] Hosp Txagorritxu, Vitoria, Spain. [Lopez, Luciano] Hosp Univ Reina Sofia, Cordoba, Spain. [Nieto Rodriguez, Jose Antonio] Hosp Virgen de la Luz, Castilla La Mancha, Spain. [Mateo Paredes, Ramon] Hosp Rafael Mendez, Murcia, Spain. [Ramos Rodriguez, Jose Luis] Hosp Univ Getafe, Madrid, Spain. [Ruiz Cantero, Alberto] Hosp Serrania, Malaga, Spain. [Ruiz Lorenzo, Pedro] Hosp Gen Basico de Baza, Granada, Spain. [Samperiz Legarre, Angel Luis] Hosp Reina Sofia de Tudela, Navarra, Spain. [Clavo Sanchez, Antonio] Hosp Juan Grande, Cadiz, Spain. [Soto Cardenas, Maria Jose] Hosp Univ Puerta Mar, Cadiz, Spain. [Valle Bernad, Reina] Hosp Sierrallana, Torrelavega, Spain. [Vela Moreno, Jeronimo Ramon] Hosp Alcaniz, Alcaniz, Spain. [Beer, Jurg] Kantonsspital Baden, Baden, Switzerland. [Brunner, Brigitte] Kantonsspital Uri, Altdorf, Switzerland. [Chopard, Pierre] Univ Hosp Geneva, Geneva, Switzerland. [Doerffler, Janine] Univ Zurich Hosp, CH-8091 Zurich, Switzerland. [Fischer, Joseph] Spitalzentrum Oberwallis Brig Visp, Brig, Switzerland. [Ludwig, Christian] St Claraspital Basel, Basel, Switzerland. [Peter, Jurg] Kantonsspital Schaffhausen, Schaffhausen, Switzerland. [Rime, Francis] Hop Sud Fribourgeois, Riaz, Switzerland. [Salomon, Franco] Spital Lachen, Lachen, Switzerland. [Ulrich, Munch] Spital Buelach, Bulach, Switzerland. [Chetanachan, Mariam] Prapokkloa Hosp, Ampur Muang, Thailand. [Chuamuangphan, Nonlawan] Chiangrai Prachanukroh Hosp, Chiangrai, Thailand. [Insiripong, Somchai] Maharat Nakornratchasima Hosp, Korat, Thailand. [Nawarawong, Weerasak] Chiang Mai Med Sch, Chiang Mai, Thailand. [Ghedira, Habib] Hop Abderrahmane MAMI Ariana, Ariana, Tunisia. [Houman, Mohamed Habib] Hosp La Rabta, Tunis, Tunisia. [Mohamed, Mnif] Reg Hosp Mahares, Mahares, Tunisia. [Samir, Kammoun] Hedi Chaker Hosp, Sfax, Tunisia. [Zouheir, Jerbi] Hosp Habib Thameur, Tunis, Tunisia. [Altintas, Faik] Goztepe Training Hosp, Istanbul, Turkey. [Cirak, Ali Kadri] Dr Suat Seren Gogus Hastaliklari & Cerrahisi EAH, Izmir, Turkey. [Demirtas, Nazmi] Ozel Anadolu Cinar Hosp, Istanbul, Turkey. [Dokucu, Ali] Sisli Etfal Educ & Res Hosp, Istanbul, Turkey. [Erden, Faruk] Kacaeli Univ, Fac Med Hosp, Kacaeli, Turkey. [Guven, Hulya] Esrefpaza Hosp Izmir Metropolitan Municipal, Izmir, Turkey. [Halezeroglu, Semih] Sureyyapasa Thorac & Cardio Vasc Dis Teaching Hos, Istanbul, Turkey. [Karaoglan, Halim] Ozel Hatay Hosp, Antakya, Turkey. [Kaynar, Leylagul] MKD Oncol Hosp, Kayseri, Turkey. [Tereci, Hikmet] Vezirkopru Devlet Hastanesi, Samsun, Turkey. [Yildirim, Cuma] Gaziantep Univ, Sahinbey Hosp, Gaziantep, Turkey. [Calvey, Thomas] Royal Lancaster Infirm, Lancaster, Lancs, England. [Gallegos, Nick] Weston Gen Hosp, Weston Super Mare, N Somerset, England. [Gaminara, Elizabeth] West Herts Hosp NHS Trust, Hemel Hempstead, Herts, England. [James, Anthony] Neath Port Talbot Hosp, Bridgend, Mid Glam, Wales. [James, Anthony] Princess Wales Hosp, Bridgend, Mid Glam, Wales. [Jeffreys, Mike] Royal Devon & Exeter NHS Fdn Trust, Exeter, Devon, England. [Jowett, Nigel] Withybush Gen Hosp, Haverfordwest, Pembroke, Wales. [Keaney, Niall] Sunderland Royal Hosp, Sunderland, Tyne & Wear, England. [Kesteven, Patrick] Newcastle Upon Tyne NHS Hosp Trust, Newcastle Upon Tyne, Tyne & Wear, England. [Khan, Zafar] Pilgrim Hosp, Boston, Lincs, England. [Mackie, Peter] Heatherwood & Wexham Pk Hosp NHS Trust, Slough, Berks, England. [Mallick, Abhiram] Leeds Gen Infirm, Leeds, W Yorkshire, England. [Mallick, Abhiram] St James Univ Hosp, Leeds LS9 7TF, W Yorkshire, England. [Marval, Paul] Derby Hosp NHS Fdn Trust, Derby, Derby, England. [Parapia, L.] Bradford Royal Infirm Univ Hosp, Bradford, Mid Glam, Wales. [Picozzi, Natalie] W Suffolk Hosp, Bury St Edmunds, Suffolk, England. [Praveen, Bandipalyam] Southend Hosp NHS Trust, Westcliff On Sea, Essex, England. [Satchi, Gnanam] Whiston Hosp, Prescot, England. [Valerio, David] Grantham Dist Hosp, Grantham, England. [Anderson, Fred] Univ Massachusetts, Med Ctr, Worcester, MA USA. [Anderson, Fred] Univ Massachusetts Mem Hlth Care, Worcester, MA USA. [Antonacci, Anthony] Christ Hosp, Jersey City, NJ USA. [Baker, Gennfer] Cullman Reg Med Ctr, Cullman, AL USA. [Beaver, Richard] Sewickley Valley Hosp, Sewickley, PA USA. [Beaver, Richard] Med Ctr, Sewickley, PA USA. [Becker, William] VAMC Fargo, Fargo, ND USA. [Beckett, Cynthia] Flagstaff Med Ctr, Flagstaff, AZ USA. [Borchardt, Carla] Avera McKennan, Sioux Falls, SD USA. [Briggs, Michael] Innovis Hlth, Fargo, ND USA. [Bruckman, Joseph] Floyd Mem Hosp & Hlth Serv, New Albany, IN USA. [Buck, Lisa] Wadley Reg Med Ctr, Texarkana, TX USA. [Caushaj, Philip] Western Penn Hosp, Pittsburgh, PA 15224 USA. [Chausow, Alan] El Camino Hosp, Sunnyvale, CA USA. [Chowdary, Madhu] Jeanes Hosp, Philadelphia, PA USA. [Christopulos, Danielle] Ogden Reg Med Ctr, Ogden, UT USA. [Cica, Paula] UPMC Horizon, Greenville, PA USA. [Cody, Jean] Southwestern Vermont Med Ctr, Bennington, VT USA. [Condit, Bruce] Cent Maine Med Ctr, Lewiston, ME USA. [Cronin, Sherill] Jewish Hosp, Louisville, KY USA. [Cysyk, Barbara] Upper Chesapeake Hlth Syst, Bel Air, MD USA. [Diefendorf, Anne] Concord Hosp, Concord, NH USA. [Driggers, Steven] Holy Family Mem, Manitowoc, WI USA. [Ellis, Paula] St Francis Hlth Ctr, Topeka, KS USA. [Elvenia, Jaeda] Wilcox Mem Hosp, Lihue, HI USA. [Feinbloom, David] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Feldman, Mark] Presbyterian Med Ctr, Dallas, TX USA. [Fischer, Marian] FF Thompson Hosp, Canandaigua, NY USA. [Froehlich, James] Univ Michigan Hlth Syst, Ann Arbor, MI USA. [Frost, Christopher] Methodist Med Ctr Oak Ridge, Oak Ridge, TN USA. [Gaffey, Joseph] McAllen Med Ctr, Mcallen, TX USA. [Galster, Ruth] Mercy Med Ctr, Roseburg, OR USA. [Geldmeier, Richard] Watauga Med Ctr, Boone, NC USA. [George, Joyce] St Johns Hosp, Tulsa, OK USA. [Glielmi, Vincent] Ephrata Community Hosp, Ephrata, PA USA. [Goodwin, James] Harrington Mem Hosp, Southbridge, MA USA. [Gottlieb, Anita] St Josephs Mercy Hlth Ctr, Hot Springs, AR USA. [Gray, Bruce] Greenville Hosp Syst Greenville Mem, Greenville, SC USA. [Harrington, Darrell] Harbor UCLA Med Ctr, Torrance, CA 90509 USA. [Henry, Edwina] Med Ctr Terrell, Terrell, TX USA. [Hernandez, Cecilia] Sutter Med Ctr Sacramento SMG SMH, Sacramento, CA USA. [Hill, David] Waterbury Hosp & Hlth Ctr, Ctr Hlth, Waterbury, CT USA. [Hutchinson, Melissa] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Johnson, Juanita] Albemarle Hosp, Elizabeth City, NC USA. [Johnson, Roberta] John C Lincoln Hosp NM, Phoenix, AZ USA. [Kapre, Sheela] San Joaquin Gen Hosp, Stockton, CA USA. [Kowaloff, Harvey] Jordan Hosp Inc, Plymouth, MA USA. [Krodel, John] Norman Reg Hosp, Norman, OK USA. [Lehman, James] Genesis Med Ctr Davenport, Davenport, IA USA. [Marney, Terri] Plains Reg Med Ctr, Clovis, NM USA. [Marshall, Ingeborg] Gulf Hlth Hosp Inc DBA Thomas Hosp, Fairhope, AL USA. [McDaniels, Mary] Catawba Valley Med Ctr, Hickory, NC USA. [Middleton, Robert, III] Southwest Mississippi Reg Med Ctr, Mccomb, MS USA. [Mitchell, Phillip] Ft Sanders Reg Med Ctr, Knoxville, TN USA. [Nelson, Carrie] Rush Copley Med Ctr, Aurora, IL USA. [Netherland, Susan] Morehead Mem Hosp, Eden, NC USA. [Ogden, Maureen] Tampa Gen Hosp, Tampa, FL 33606 USA. [Packard, Keith] Alta Vista Reg Hosp, Las Vegas, NM USA. [Pieske, Marlys] Jamestown Hosp, Jamestown, ND USA. [Poole, Lorie] Thomasville Med Ctr, Thomasville, NC USA. [Radford, Martha] New York Univ Hosp Syst, New York, NY USA. [Rathbun, Suman] VAMC Oklahoma City, Oklahoma City, OK USA. [Roberts, Cathy] St Marys Hosp, Grand Junction, CO USA. [Robinson, Margaret] Midland Mem Hosp, Midland, TX USA. [Rollins, David] Lake Hosp Syst Inc, Willoughby, OH USA. [Rubinate, Donna] St Annes Hosp, Fall River, MA USA. [Schmidt, Cheryl] St Elizabeth Hosp, Appleton, WI USA. [Scott, Julia] Northern Nevada Med Ctr, Sparks, NV USA. [Shutt, Sandra] Blanchard Valley Reg Hlth Ctr, Findlay, OH USA. [Slone, Betty] Three Rivers Med Ctr, Louisa, KY USA. [Spyropoulos, Alex] Lovelace Med Ctr, Albuquerque, NM USA. [Subramanian, Seshan] Mercy Hosp & Med Ctr, Chicago, IL USA. [Sullivan, Jacqueline] Thomas Jefferson Univ Hosp, Philadelphia, PA 19107 USA. [Timmerman, Carman] Rapid City Reg Hosp, Rapid City, SD USA. [Wheeler, Connie] Jordan Valley Hosp, W Jordan, UT USA. [White, Diane] Exeter Hosp, Exeter, NH USA. [White, Nancy] Mary Black Mem Hosp, Spartanburg, SC USA. [Whitehead, Alva] McLeod Reg Med Ctr, Florence, SC USA. [Wright, Joyce] Armstrong Cty Mem Hosp, Kittanning, PA USA. [Young, Dereck] North Mississippi Med Ctr, Tupelo, MS USA. RP Kakkar, AK (reprint author), Barts & London Queen Marys Sch Med & Dent, London SW3 6LR, England. EM akkakkar@tri-london.ac.uk RI Kaynar, Leylagul/F-6991-2013; Hagau, Natalia/B-7787-2012 OI Kaynar, Leylagul/0000-0002-2035-9462; FU sanofi-aventis (Paris, France) FX Sponsored by sanofi-aventis (Paris, France). Statistical analyses were performed by the Center for Outcomes Research (University of Massachusetts Medical School, Worcester, USA), which receives research funding from sanofi-aventis. NR 13 TC 52 Z9 56 U1 4 U2 23 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0003-4932 EI 1528-1140 J9 ANN SURG JI Ann. Surg. PD FEB PY 2010 VL 251 IS 2 BP 330 EP 338 DI 10.1097/SLA.0b013e3181c0c58f PG 9 WC Surgery SC Surgery GA 549KC UT WOS:000274046300024 PM 20054273 ER PT J AU Wasif, N Ko, CY Farrell, J Wainberg, Z Hines, OJ Reber, H Tomlinson, JS AF Wasif, N. Ko, C. Y. Farrell, J. Wainberg, Z. Hines, O. J. Reber, H. Tomlinson, J. S. TI Impact of Tumor Grade on Prognosis in Pancreatic Cancer: Should We Include Grade in AJCC Staging? SO ANNALS OF SURGICAL ONCOLOGY LA English DT Meeting Abstract CT 63rd Annual Cancer Symposium of the Society-of-Surgical-Oncology CY MAR 03-07, 2010 CL St Louis, MO SP Soc Surg Oncol C1 [Wasif, N.] John Wayne Canc Inst, Santa Monica, CA USA. [Ko, C. Y.; Farrell, J.; Wainberg, Z.; Hines, O. J.; Reber, H.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Tomlinson, J. S.] Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1068-9265 J9 ANN SURG ONCOL JI Ann. Surg. Oncol. PD FEB PY 2010 VL 17 SU 1 BP S91 EP S91 PG 1 WC Oncology; Surgery SC Oncology; Surgery GA 560KY UT WOS:000274902700269 ER PT J AU Bakaeen, FG Chu, D Ratcliffe, M Gopaldas, RR Blaustein, AS Venkat, R Huh, J LeMaire, SA Coselli, JS Carabello, BA AF Bakaeen, Faisal G. Chu, Danny Ratcliffe, Mark Gopaldas, Raja R. Blaustein, Alvin S. Venkat, Raghunandan Huh, Joseph LeMaire, Scott A. Coselli, Joseph S. Carabello, Blase A. TI Severe Aortic Stenosis in a Veteran Population: Treatment Considerations and Survival SO ANNALS OF THORACIC SURGERY LA English DT Article ID VALVE-REPLACEMENT; ELDERLY-PATIENTS; DECISION-MAKING; IMPLANTATION; SURGERY; OCTOGENARIANS; ASSOCIATION; OUTCOMES AB Background. We examined factors affecting the choice of surgical versus medical treatment of severe aortic stenosis and evaluated associated patient survival. Methods. We retrospectively reviewed data from all patients diagnosed with severe aortic stenosis at a Veterans Affairs medical facility between January 1997 and April 2008. Results. Of 345 patients with severe aortic stenosis, 260 (75%) underwent surgical evaluation, and 205 (59%) underwent aortic valve replacement (AVR). The patient's decision to decline surgical referral or AVR (n = 47) and severe comorbidities (n = 34) were the top two reasons for medical treatment rather than AVR. The AVR group was younger (69.5 +/- 9.6 years versus 75.7 +/- 8.6 years; p < 0.001) and had a higher prevalence of symptoms (96% versus 71%; p < 0.001) than the medical group. The medical group had a lower cardiac ejection fraction (0.42 +/- 0.15 versus 0.50 +/- 0.12; p < 0.001) and was less likely to be independent in activities of daily living (64% versus 74%). The AVR group had higher survival rates than the medical patients at 1 year (92% versus 65%), 3 years (85% versus 29%), and 5 years (73% versus 16%; log-rank test p < 0.0001). Valve replacement was independently associated with decreased mortality (hazard ratio, 0.17; 95% confidence interval, 0.10 to 0.27; p < 0.0001). Conclusions. The management of severe aortic stenosis in veterans is sometimes limited to medical evaluation and treatment. Surgeons should be involved in the complex process of risk assessment, to select patients with severe aortic stenosis who would benefit from the survival advantage associated with AVR. (Ann Thorac Surg 2010;89:453-8) (C) 2010 by The Society of Thoracic Surgeons C1 [Bakaeen, Faisal G.] Michael E DeBakey VAMC, Dept Cardiothorac Surg, Houston, TX 77030 USA. Michael E DeBakey VAMC, Div Cardiol, Houston, TX 77030 USA. Baylor Coll Med, Houston, TX 77030 USA. St Lukes Episcopal Hosp, Texas Heart Inst, Sect Adult Cardiac Surg, Houston, TX USA. San Francisco VA Med Ctr, San Francisco, CA USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Bakaeen, FG (reprint author), Michael E DeBakey VAMC, Dept Cardiothorac Surg, OCL 112,2002 Holcombe Blvd, Houston, TX 77030 USA. EM fbakaeen@bcm.edu NR 22 TC 21 Z9 21 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-4975 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD FEB PY 2010 VL 89 IS 2 BP 453 EP 458 DI 10.1016/j.athoracsur.2009.10.033 PG 6 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 547BV UT WOS:000273861100020 PM 20103320 ER PT J AU Lat, A Thompson, GR Rinaldi, MG Dorsey, SA Pennick, G Lewis, JS AF Lat, Asma Thompson, George R., III Rinaldi, Michael G. Dorsey, Sheryl A. Pennick, Gennethel Lewis, James S., II TI Micafungin Concentrations from Brain Tissue and Pancreatic Pseudocyst Fluid SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID PRACTICE GUIDELINES; PHARMACOKINETICS; CANDIDIASIS; FK463; ECHINOCANDIN; CASPOFUNGIN; INFECTIONS; RABBITS AB We report the attainment of micafungin concentrations from brain tissue and pancreatic pseudocyst fluid from two patients with invasive candidiasis. Micafungin was present in low levels at both body sites, indicating limited penetration into central nervous system (CNS) tissue and pancreatic fluid. Further studies are needed to fully characterize its pharmacokinetics at these locations, as micafungin may potentially serve as an alternative antifungal therapy for CNS or pancreatic candidal infections for which the currently recommended first-line therapy fails. C1 [Lewis, James S., II] Univ Hlth Syst, Dept Pharm, San Antonio, TX 78229 USA. [Lat, Asma; Thompson, George R., III] S Texas Vet Affairs Hlth Care Syst, San Antonio, TX 78229 USA. [Lat, Asma; Thompson, George R., III; Lewis, James S., II] Univ Texas Hlth Sci Ctr San Antonio, Dept Internal Med, Div Infect Dis, San Antonio, TX 78229 USA. [Rinaldi, Michael G.; Dorsey, Sheryl A.; Pennick, Gennethel] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, Fungus Testing Lab, San Antonio, TX 78229 USA. RP Lewis, JS (reprint author), Univ Hlth Syst, Dept Pharm, 4502 Med Dr, San Antonio, TX 78229 USA. EM james.lewis@uhs-sa.com NR 13 TC 11 Z9 11 U1 0 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD FEB PY 2010 VL 54 IS 2 BP 943 EP 944 DI 10.1128/AAC.01294-09 PG 2 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA 547BR UT WOS:000273860600054 PM 19933794 ER PT J AU Kim, MS Boone, KB Victor, T Marion, SD Amano, S Cottingham, ME Ziegler, EA Zeller, MA AF Kim, Michelle S. Boone, Kyle B. Victor, Tara Marion, Sarah D. Amano, Stacy Cottingham, Maria E. Ziegler, Elizabeth A. Zeller, Michelle A. TI The Warrington Recognition Memory Test for Words as a Measure of Response Bias: Total Score and Response Time Cutoffs Developed on "Real World" Credible and Noncredible Subjects SO ARCHIVES OF CLINICAL NEUROPSYCHOLOGY LA English DT Article DE Malingering; symptom validity testing; Forensic neuropsychology; Head injury; Traumatic brain injury ID TRAUMATIC BRAIN-INJURY; MILD HEAD-INJURY; SUSPECT EFFORT; TEST-PERFORMANCE; SENSITIVITY; SPECIFICITY; IMPAIRMENT; DEFICITS; DYSFUNCTION; SYMPTOMS AB Several studies have examined the usefulness of the Warrington Recognition Memory Test-Words as a measure to detect suspect effort, although samples have generally been small and/or comprised of simulators rather than "real world" credible and noncredible patients. The current study examined the Warrington Recognition Memory Test-Words total score and response time of "real world" noncredible patients (as determined by motive to feign, failure on >= 2 independent measures of response bias, low cognitive scores inconsistent with normal ADLs; n = 190) versus credible patients (as determined by no motive to feign, failure of < 1 measure of response bias; n = 124) derived from an archival database of individuals from the Harbor-UCLA Medical Center, Department of Psychiatry, Outpatient Neuropsychology Service, and the private practice of the second author. Noncredible patients obtained significantly lower total scores and longer times to complete the task. A total correct cutoff of < 42 was found to have excellent specificity (91.9%) and sensitivity (88.9%), whereas a time cutoff of >= 207 ' was associated with 65.5% sensitivity at 90.7% specificity, and when the time cut-score was used in combination with the total score cutoff, an additional 5% of the noncredible participants were captured, raising overall sensitivity to 93.7% (at 87.1% specificity). Thus, the Warrington Recognition Memory Test-Words, although not originally created for the purposes of measuring suspect effort, appears to be an excellent measure for detecting response bias on neuropsychological testing. C1 [Kim, Michelle S.; Marion, Sarah D.; Amano, Stacy] Fuller Grad Sch Psychol, Pasadena, CA USA. [Boone, Kyle B.] Alliant Int Univ, Calif Sch Forens Studies, Ctr Forens Studies, Los Angeles, CA USA. [Victor, Tara] Calif State Univ Dominguez Hills, Dept Psychol, Carson, CA USA. [Cottingham, Maria E.] Harbor UCLA Med Ctr, Torrance, CA 90509 USA. [Ziegler, Elizabeth A.] Spokane VA Med Ctr, Spokane, WA USA. [Zeller, Michelle A.] W Los Angeles VA Med Ctr, Dept Psychol, Los Angeles, CA USA. RP Boone, KB (reprint author), 24564 Hawthorne Blvd,Suite 208, Torrance, CA 90505 USA. EM kboone@labiomed.org NR 35 TC 26 Z9 26 U1 4 U2 11 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0887-6177 J9 ARCH CLIN NEUROPSYCH JI Arch. Clin. Neuropsychol. PD FEB PY 2010 VL 25 IS 1 BP 60 EP 70 DI 10.1093/arclin/acp088 PG 11 WC Psychology, Clinical; Psychology SC Psychology GA 547DI UT WOS:000273865400007 PM 19906738 ER PT J AU Yu, CE Bird, TD Bekris, LM Montine, TJ Leverenz, JB Steinbart, E Galloway, NM Feldman, H Woltjer, R Miller, CA Wood, EM Grossman, M McCluskey, L Clark, CM Neumann, M Danek, A Galasko, DR Arnold, SE Chen-Plotkin, A Karydas, A Miller, BL Trojanowski, JQ Lee, VMY Schellenberg, GD Van Deerlin, VM AF Yu, Chang-En Bird, Thomas D. Bekris, Lynn M. Montine, Thomas J. Leverenz, James B. Steinbart, Ellen Galloway, Nichole M. Feldman, Howard Woltjer, Randall Miller, Carol A. Wood, Elisabeth McCarty Grossman, Murray McCluskey, Leo Clark, Christopher M. Neumann, Manuela Danek, Adrian Galasko, Douglas R. Arnold, Steven E. Chen-Plotkin, Alice Karydas, Anna Miller, Bruce L. Trojanowski, John Q. Lee, Virginia M. -Y. Schellenberg, Gerard D. Van Deerlin, Vivianna M. TI The Spectrum of Mutations in Progranulin A Collaborative Study Screening 545 Cases of Neurodegeneration SO ARCHIVES OF NEUROLOGY LA English DT Article ID FRONTOTEMPORAL LOBAR DEGENERATION; AMYOTROPHIC-LATERAL-SCLEROSIS; SINGLE-NUCLEOTIDE POLYMORPHISMS; MESSENGER-RNA; DEMENTIA; GENE; DISEASE; TDP-43; TAU; INCLUSIONS AB Background: Mutation in the progranulin gene (GRN) can cause frontotemporal dementia (FTD). However, it is unclear whether some rare FTD-related GRN variants are pathogenic and whether neurodegenerative disorders other than FTD can also be caused by GRN mutations. Objectives: To delineate the range of clinical presentations associated with GRN mutations and to define pathogenic candidacy of rare GRN variants. Design: Case-control study. Setting: Clinical and neuropathology dementia research studies at 8 academic centers. Participants: Four hundred thirty-four patients with FTD, including primary progressive aphasia, semantic dementia, FTD/amyotrophic lateral sclerosis (ALS), FTD/motor neuron disease, corticobasal syndrome/corticobasal degeneration, progressive supranuclear palsy, Pick disease, dementia lacking distinctive histopathology, and pathologically confirmed cases of frontotemporal lobar degeneration with ubiquitin-positive inclusions (FTLD-U); and 111 non-FTD cases (controls) in which TDP-43 deposits were a prominent neuropathological feature, including subjects with ALS, Guam ALS and/or parkinsonism dementia complex, Guam dementia, Alzheimer disease, multiple system atrophy, and argyrophilic grain disease. Main Outcome Measures: Variants detected on sequencing of all 13 GRN exons and at least 80 base pairs of flanking introns, and their pathogenic candidacy determined by in silico and ex vivo splicing assays. Results: We identified 58 genetic variants that included 26 previously unknown changes. Twenty-four variants appeared to be pathogenic, including 8 novel mutations. The frequency of GRN mutations was 6.9% (30 of 434) of all FTD-spectrum cases, 21.4% (9 of 42) of cases with a pathological diagnosis of FTLD-U, 16.0% ( 28 of 175) of FTD-spectrum cases with a family history of a similar neurodegenerative disease, and 56.2% (9 of 16) of cases of FTLD-U with a family history. Conclusions: Pathogenic mutations were found only in FTD-spectrum cases and not in other related neurodegenerative diseases. Haploinsufficiency of GRN is the predominant mechanism leading to FTD. C1 [Yu, Chang-En; Bird, Thomas D.; Bekris, Lynn M.; Steinbart, Ellen; Galloway, Nichole M.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr, Res Educ & Clin Ctr, Seattle, WA USA. [Leverenz, James B.] Vet Affairs Puget Sound Hlth Care Syst, Mental Illness, Res Educ & Clin Ctr, Seattle, WA USA. [Yu, Chang-En; Bekris, Lynn M.] Univ Washington, Sch Med, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA. [Bird, Thomas D.] Univ Washington, Sch Med, Dept Med, Div Med Genet, Seattle, WA 98195 USA. [Bird, Thomas D.; Leverenz, James B.; Steinbart, Ellen] Univ Washington, Sch Med, Dept Med, Div Neurol, Seattle, WA 98195 USA. [Montine, Thomas J.] Univ Washington, Sch Med, Dept Med, Div Pathol, Seattle, WA 98195 USA. [Feldman, Howard] Univ British Columbia, Dept Med, Vancouver, BC, Canada. [Woltjer, Randall] Oregon Hlth & Sci Univ, Dept Neuropathol, Portland, OR 97201 USA. [Miller, Carol A.] Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA. [Wood, Elisabeth McCarty; Chen-Plotkin, Alice; Trojanowski, John Q.; Lee, Virginia M. -Y.; Van Deerlin, Vivianna M.] Univ Penn, Sch Med, Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA. [Trojanowski, John Q.; Lee, Virginia M. -Y.; Schellenberg, Gerard D.; Van Deerlin, Vivianna M.] Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA. [Grossman, Murray; McCluskey, Leo; Clark, Christopher M.; Arnold, Steven E.; Chen-Plotkin, Alice] Univ Penn, Sch Med, Dept Neurol, Philadelphia, PA 19104 USA. [Arnold, Steven E.] Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. [Clark, Christopher M.; Arnold, Steven E.; Trojanowski, John Q.; Lee, Virginia M. -Y.; Schellenberg, Gerard D.; Van Deerlin, Vivianna M.] Univ Penn, Sch Med, Inst Aging, Philadelphia, PA 19104 USA. [Neumann, Manuela] Univ Munich, Ctr Neuropathol & Prion Res, Munich, Germany. [Danek, Adrian] Univ Munich, Neurol Klin, Munich, Germany. [Galasko, Douglas R.] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA. [Galasko, Douglas R.] Vet Affairs Med Ctr, San Diego, CA 92161 USA. [Karydas, Anna; Miller, Bruce L.] Univ Calif San Francisco, Dept Neurol, Memory & Aging Ctr, San Francisco, CA 94143 USA. RP Bird, TD (reprint author), 1660 S Columbian Way,GRECC, Seattle, WA 98108 USA. EM tomnroz@u.washington.edu RI Neumann, Manuela/F-6558-2011; Arnold, Steven/J-7546-2012; Danek, Adrian/G-7339-2011 OI Danek, Adrian/0000-0001-8857-5383; Feldman, Howard/0000-0002-9258-4538 FU Veterans Affairs Biomedical Laboratory Research Development Merit Review; National Institutes of Health [AG10124, AG17586, AG005136-22, AG14382, AG008017]; German Federal Ministry of Education and Research [01GI0704] FX This work was funded by Veterans Affairs Biomedical Laboratory Research Development Merit Review, the National Institutes of Health (grants AG10124, AG17586, AG005136-22, AG14382, and AG008017), and the German Federal Ministry of Education and Research (grant 01GI0704). NR 54 TC 85 Z9 85 U1 0 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9942 J9 ARCH NEUROL-CHICAGO JI Arch. Neurol. PD FEB PY 2010 VL 67 IS 2 BP 161 EP 170 PG 10 WC Clinical Neurology SC Neurosciences & Neurology GA 553NR UT WOS:000274374600005 PM 20142524 ER PT J AU Kind, AJH Smith, MA Liou, JI Pandhi, N Frytak, JR Finch, MD AF Kind, Amy J. H. Smith, Maureen A. Liou, Jinn-Ing Pandhi, Nancy Frytak, Jennifer R. Finch, Michael D. TI Discharge Destination's Effect on Bounce-Back Risk in Black, White, and Hispanic Acute Ischemic Stroke Patients SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE Ethnic groups; Hospitalization; Rehabilitation; Skilled nursing facilities; Stroke ID LONG-TERM-CARE; NURSING-HOME RESIDENTS; RACIAL DISPARITIES; INTERNATIONAL-CLASSIFICATION; ADMINISTRATIVE DATA; POSTHOSPITAL CARE; MEDICARE; HOSPITALIZATION; COMMUNITY; REHOSPITALIZATION AB Kind AJH, Smith MA, Liou J-I, Pandhi N, Frytak JR, Finch MD. Discharge destination's effect on bounce-back risk in black, white, and Hispanic acute ischemic stroke patients. Arch Phys Med Rehabil 2010;91:189-95. Objective: To determine whether racial and ethnic effects on bounce-back risk (ie, movement to settings of higher care intensity within 30d of hospital discharge) in acute stroke patients vary depending on initial posthospital discharge destination. Design: Retrospective analysis of administrative data. Setting: Four hundred twenty-two hospitals, southern/eastern United States. Participants: All Medicare beneficiaries 65 years or more with hospitalization for acute ischemic stroke within one of the 422 target hospitals during the years 1999 or 2000 (N=63,679). Interventions: Not applicable. Main Outcome Measures: Adjusted predicted probabilities for discharge to and for bouncing back from each initial discharge site (ie, home, home with home health care, skilled nursing facility [SNF], or rehabilitation center) by race (ie, black, white, and Hispanic). Models included sociodemographics, comorbidities, stroke severity, and length of stay. Results: Blacks and Hispanics were significantly more likely to be discharged to home health care (blacks=21% [95% confidence interval (CI), 19.9-22.81, Hispanic=19% [17.1-21.7] vs whites=16% [15.5-16.8]) and less likely to be discharged to SNFs (blacks=26% [95% CI, 23.6-29.3], Hispanics=28% [25.4-31.6] vs whites=33% [31.8-35.1]) than whites. However, blacks and Hispanics were significantly more likely to bounce back when discharged to SNFs than whites (blacks=26% [95% CI, 24.2-28.6], Hispanics=28% [24-32.6] vs whites=21% [20.3-21.9]). Hispanics had a lower risk of bouncing back when discharged home than either blacks or whites (Hispanics=14% [95% CI, 11.3-17] vs blacks=20% [18.4-22.2], whites=18% [16.8-18.3]). Patients discharged to home health care or rehabilitation centers demonstrated no significant differences ill bounce-back risk. Conclusions: Racial/ethnic bounce-back risk differs depending on initial discharge destination. Additional research is needed to fully understand this variation in effect. C1 [Kind, Amy J. H.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Geriatr Sect, Madison, WI USA. [Kind, Amy J. H.; Smith, Maureen A.; Liou, Jinn-Ing; Pandhi, Nancy] Univ Wisconsin, Sch Med & Publ Hlth, Dept Populat Hlth Sci, Madison, WI USA. [Pandhi, Nancy] Univ Wisconsin, Sch Med & Publ Hlth, Dept Family Med, Madison, WI USA. [Kind, Amy J. H.] William S Middleton Hosp, GRECC, US Dept Vet Affairs, Madison, WI USA. [Frytak, Jennifer R.] I3 Innovus, Eden Prairie, MN USA. [Finch, Michael D.] Ctr Hlth Care Policy & Evaluat, Eden Prairie, MN USA. RP Kind, AJH (reprint author), William S Middleton VA Hosp, GRECC, 2500 Overlook Terrace, Madison, WI 53705 USA. EM ajk@medicine.wisc.edu FU National Institute of Aging [R01-AG19747]; University of Wisconsin's John A. Hartford Center of Excellence in Geriatrics Medicine and Education; National Institutes of Health [1KL2RR025012-01, KL2]; National Center for Research Resources, National Institutes of Health [1UL1RR025011] FX Supported by the National Institute of Aging (grant no. R01-AG19747); the University of Wisconsin's John A. Hartford Center of Excellence in Geriatrics Medicine and Education; National Institutes of Health (grant no. 1KL2RR025012-01) (Institutional Clinical and Translational Science Award [UW-Madison] [KL2]); the Health Innovation Program and the Community-Academic Partnerships core of the University of Wisconsin Institute for Clinical and Translational Research (grant no. 1UL1RR025011) from the Clinical and Translational Science Award program of the National Center for Research Resources, National Institutes of Health. NR 40 TC 6 Z9 6 U1 2 U2 5 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD FEB PY 2010 VL 91 IS 2 BP 189 EP 195 DI 10.1016/j.apmr.2009.10.015 PG 7 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 592YJ UT WOS:000277417600005 PM 20159120 ER PT J AU Oates, JC AF Oates, Jim C. TI The biology of reactive intermediates in systemic lupus erythematosus SO AUTOIMMUNITY LA English DT Article DE Nitric oxide; systemic lupus erythematosus; reactive oxygen species; free radicals; oxidative stress ID NITRIC-OXIDE SYNTHASE; MRL-LPR/LPR MICE; SMOOTH-MUSCLE-CELLS; MRL/LPR MICE; MITOCHONDRIAL HYPERPOLARIZATION; ENDOTHELIAL-CELLS; 3-NITROTYROSINE LEVELS; MYCOPHENOLATE-MOFETIL; AUTOIMMUNE-DISEASE; SIGNALING PATHWAYS AB Systemic lupus erythematosus (SLE) is an autoimmune syndrome marked by autoantibody production. Innate immunity is essential to transform humoral autoimmunity into the clinical lupus phenotype. Nitric oxide (NO) is a membrane-permeable signaling molecule involved in a broad array of biologic processes through its ability to modify proteins, lipids, and DNA and alter their function and immunogenicity. The literature regarding mechanisms through which NO regulates inflammation and cell survival is filled with contradictory findings. However, the effects of NO on cellular processes depend on its concentration and its interaction with reactive oxygen. Understanding this interaction will be essential to determine mechanisms through which reactive intermediates induce cellular autoimmunity and contribute to a sustained innate immune response and organ damage in SLE. C1 [Oates, Jim C.] Ralph H Johnson VA Med Ctr, Med Serv, Charleston, SC USA. [Oates, Jim C.] Med Univ S Carolina, Dept Med, Div Rheumatol, Charleston, SC 29425 USA. RP Oates, JC (reprint author), 96 Jonathan Lucas St,Suite 912,MSC 637, Charleston, SC 29425 USA. EM oatesjc@musc.edu FU National Institute of Arthritis and Musculoskeletal and Skin Diseases [AR045476]; GCRC [M01RR001070]; VA Research Enhancement; Arthritis Foundation; Alliance for Lupus Research FX This publication was made possible by Grant AR045476 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases, GCRC Grant M01RR001070, an award from the VA Research Enhancement Award Program, a VA Merit Award funding from the Arthritis Foundation, and the Alliance for Lupus Research. Special thanks go to Gary Gilkeson, MD, for reviewing the manuscript before submission. The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper. NR 60 TC 18 Z9 18 U1 0 U2 0 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0891-6934 J9 AUTOIMMUNITY JI Autoimmunity PD FEB PY 2010 VL 43 IS 1 BP 56 EP 63 DI 10.3109/08916930903374683 PG 8 WC Immunology SC Immunology GA 545GU UT WOS:000273721300007 PM 20001422 ER PT J AU Ellis, BC Gattoni-Celli, S Kindy, MS AF Ellis, Blake C. Gattoni-Celli, Sebastiano Kindy, Mark S. TI The impact of methylmercury on 1,25-dihydroxyvitamin D3-induced transcriptomic responses in dolphin skin cells SO BIOLOGICAL CHEMISTRY LA English DT Article DE cell signaling; dolphin; gene expression; keratinocyte; toxicity; transcription factors; vitamin D ID BOTTLE-NOSED-DOLPHIN; VITAMIN-D-RECEPTOR; ANTIMICROBIAL PROTEIN HCAP18; TURSIOPS-TRUNCATUS; METHYL-MERCURY; GLUCOCORTICOID-RECEPTOR; MOLECULAR CHAPERONES; STEROID-RECEPTORS; STRESS-PROTEINS; CALCITROIC ACID AB The Atlantic bottlenose dolphin has been the focus of much attention owing to the considerable impact of environmental stress on its health and the associated implications for human health. Here, we used skin cells from the dolphin to investigate the protective role of the vitamin D pathway against environmental stressors. We previously reported that dolphin skin cells respond to 1,25-dihydroxyvitamin D3 (1,25D3), the bioactive metabolite of vitamin D3, by upregulation of the vitamin D receptor (VDR) and expression of several genes. Methylmercury is a highly bioaccumulative environmental stressor of relevance to the dolphin. We currently report that in dolphin cells sublethal concentrations of methylmercury compromise the ability of 1,25D3 to upregulate VDR, to transactivate a vitamin D-sensitive promoter, and to express specific target genes. These results help elucidate the effects of vitamin D and methylmercury on innate immunity in dolphin skin and potentially in human skin as well, considering similarities in the vitamin D pathway between the two species. C1 [Ellis, Blake C.; Gattoni-Celli, Sebastiano; Kindy, Mark S.] Med Univ S Carolina, Marine Biomed & Environm Sci Ctr, Charleston, SC 29412 USA. [Gattoni-Celli, Sebastiano] Med Univ S Carolina, Dept Radiat Oncol, Charleston, SC 29425 USA. [Gattoni-Celli, Sebastiano; Kindy, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA. [Kindy, Mark S.] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA. [Kindy, Mark S.] Med Univ S Carolina, Inst Neurosci, Charleston, SC 29425 USA. RP Kindy, MS (reprint author), Med Univ S Carolina, Marine Biomed & Environm Sci Ctr, 331 Ft Johnson Rd, Charleston, SC 29412 USA. EM kindyms@musc.edu NR 99 TC 1 Z9 1 U1 1 U2 9 PU WALTER DE GRUYTER & CO PI BERLIN PA GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY SN 1431-6730 J9 BIOL CHEM JI Biol. Chem. PD FEB-MAR PY 2010 VL 391 IS 2-3 BP 245 EP 258 DI 10.1515/BC.2010.014 PG 14 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 564DU UT WOS:000275194300014 PM 20030593 ER PT J AU Lloyd, JC Banez, LL Aronson, WJ Terris, MK Presti, JC Amling, CL Kane, CJ Freedland, SJ AF Lloyd, Jessica C. Banez, Lionel L. Aronson, William J. Terris, Martha K. Presti, Joseph C., Jr. Amling, Christopher L. Kane, Christopher J. Freedland, Stephen J. TI Estimated blood loss as a predictor of PSA recurrence after radical prostatectomy: results from the SEARCH database SO BJU INTERNATIONAL LA English DT Article DE prostate cancer; radical prostatectomy; blood loss ID RETROPUBIC PROSTATECTOMY; CANCER RECURRENCE; LEARNING-CURVE; TRANSFUSION; SURVIVAL; SURGERY; RISK; METAANALYSIS; EXPERIENCE; CARCINOMA AB OBJECTIVE To clarify the relationship between estimated blood loss (EBL) and biochemical recurrence, assessed by prostate-specific antigen (PSA) level, as blood loss is a long-standing concern associated with radical prostatectomy (RP), and no studies to date have examined the association between blood loss and cancer control. PATIENTS AND METHODS In all, 1077 patients were identified in the Shared Equal-Access Regional Cancer Hospital database who underwent retropubic RP (between 1998 and 2008) and had EBL and follow-up data available. We examined the relationship between EBL and recurrence using multivariate Cox regression analyses. RESULTS Increased EBL was correlated with PSA recurrence in a multivariate-adjusted model (P = 0.01). When analysed by 500-mL EBL categories, those with an EBL of < 1500 mL had a similar risk of recurrence. However, the risk of PSA recurrence tended to increase for an EBL of 1500-3499 mL, before decreasing again for patients with an EBL of >= 3500 mL. Men with an EBL of 2500-3499 mL had more than twice the risk of recurrence than men with an EBL of < 1500 mL (P = 0.02). EBL was not associated with adverse tumour stage, grade or margin status. CONCLUSIONS There was a significant correlation between EBL at the time of RP and biochemical recurrence. We hypothesized that this association might be due to transfusion-related immunosuppression, excessive blood obscuring the operative field, EBL being a marker of aggressive disease, or EBL being a marker of poor surgical technique. However, our data did not completely fit any one of these hypotheses, and thus the ultimate cause for the increased risk of recurrence remains unclear and requires further study. C1 [Lloyd, Jessica C.; Banez, Lionel L.; Freedland, Stephen J.] Duke Univ, Sch Med, Div Urol Surg, Dept Surg, Durham, NC 27710 USA. [Lloyd, Jessica C.; Banez, Lionel L.; Freedland, Stephen J.] Duke Univ, Sch Med, Duke Prostate Ctr, Durham, NC 27710 USA. [Lloyd, Jessica C.; Banez, Lionel L.; Freedland, Stephen J.] Duke Univ, Sch Med, Vet Affairs Med Ctr, Urol Sect, Durham, NC 27710 USA. [Freedland, Stephen J.] Duke Univ, Sch Med, Dept Pathol, Durham, NC 27710 USA. [Aronson, William J.] Univ Calif Los Angeles, Sch Med, Urol Sect, Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Aronson, William J.] Univ Calif Los Angeles, Sch Med, Dept Urol, Los Angeles, CA USA. [Terris, Martha K.] Med Coll Georgia, Urol Sect, Vet Affairs Med Ctr, Augusta, GA 30912 USA. [Presti, Joseph C., Jr.] Stanford Univ, Sch Med, Dept Urol, Stanford, CA 94305 USA. [Presti, Joseph C., Jr.] Vet Affairs Med Ctr, Urol Sect, Palo Alto, CA 94304 USA. [Amling, Christopher L.] Univ Alabama, Div Urol, Birmingham, AL USA. [Kane, Christopher J.] Univ Calif San Diego, Sch Med, Urol Sect, Vet Affairs Med Ctr, San Diego, CA 92103 USA. [Kane, Christopher J.] Univ Calif San Diego, Sch Med, Div Urol, San Diego, CA 92103 USA. RP Freedland, SJ (reprint author), Duke Univ, Sch Med, Div Urol, Box 2626 DUMC, Durham, NC 27710 USA. EM steve.freedland@duke.edu OI Terris, Martha/0000-0002-3843-7270 FU Department of Veterans Affairs; National Institute of Health [RR024126]; NIH [R01CA100938]; NIH Specialized Programs of Research Excellence [P50 CA92131-01A1]; Georgia Cancer Coalition; Department of Defense, Prostate Cancer Research Program; American Urological Association Foundation/Astellas Rising Star in Urology Award (SJF) FX Supported by the Department of Veterans Affairs, National Institute of Health Training Grant TLq RR024126 (JCL), NIH R01CA100938 (WJA), NIH Specialized Programs of Research Excellence Grant P50 CA92131-01A1 (WJA), the Georgia Cancer Coalition (MKT), the Department of Defense, Prostate Cancer Research Program (LLB/SJF), and the American Urological Association Foundation/Astellas Rising Star in Urology Award (SJF). Views and opinions of, and endorsements by the author(s) do not reflect those of the US Army or the Department of Defense. NR 21 TC 5 Z9 5 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1464-4096 J9 BJU INT JI BJU Int. PD FEB PY 2010 VL 105 IS 3 BP 347 EP 351 DI 10.1111/j.1464-410X.2009.08792.x PG 5 WC Urology & Nephrology SC Urology & Nephrology GA 544KW UT WOS:000273656600011 PM 19709073 ER PT J AU Mulligan, JK Young, MRI AF Mulligan, Jennifer Konopa Young, M. Rita I. TI Tumors induce the formation of suppressor endothelial cells in vivo SO CANCER IMMUNOLOGY IMMUNOTHERAPY LA English DT Article DE Endothelial cell; Tumor; Immune suppression; Lewis lung carcinoma ID REGULATORY T-CELLS; NECK-CANCER; DIFFERENTIATION; HEAD; MACROPHAGES; PROGRESSION; INFLAMMATION; ACTIVATION; MECHANISMS; SECRETION AB Patients with solid tumors have defects in immune effector cells, which have been associated with a poorer prognosis. Previous studies by our laboratory have shown that exposure to Lewis lung carcinoma (LLC)-secreted products induces the formation of suppressor endothelial cells in vitro. The current studies examined if tumors could induce the formation of suppressor endothelial cells in vivo. Endothelial cells were immunomagnetically isolated from the lungs of tumor-bearing mice or normal controls and examined for their ability to modulate NK cell, T-cell and macrophage functions. Compared to normal controls, supernatants from endothelial cells isolated from tumor-bearing lungs had elevated secretion of PGE(2), IL-6, IL-10 and VEGF. Conditioned media from endothelial cells isolated from normal lungs increased CD8(+) T-cell IFN-gamma and CD4(+) T-cell IL-2 production in response to anti-CD3 stimulation, while media conditioned by endothelial cells from tumor-bearing lungs had a diminished stimulatory capacity. Examination of NK cell functions showed that supernatants from endothelial cells isolated from normal lungs were potent activators of NK cells, as indicated by their secretion of TNF-alpha and IFN-gamma. Endothelial cells isolated from tumor-bearing lungs had a significantly diminished capacity to activate NK cells. Finally, supernatants from endothelial cells of tumor-bearing lungs diminished macrophage phagocytosis compared to either treatment with supernatants of normal endothelial cells or treatment with media alone. The results of these studies demonstrate that tumors induce the formation of suppressor endothelial cells in vivo and provide support for the role of endothelial cells in tumor-induced immune suppression. C1 [Mulligan, Jennifer Konopa; Young, M. Rita I.] Ralph H Johnson VA Med Ctr, Res Serv, Charleston, SC 29401 USA. [Mulligan, Jennifer Konopa; Young, M. Rita I.] Med Univ S Carolina, Dept Otolaryngol, Charleston, SC 29425 USA. [Young, M. Rita I.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. RP Young, MRI (reprint author), Ralph H Johnson VA Med Ctr, Res Serv, 109 Bee St, Charleston, SC 29401 USA. EM konopa@musc.edu; rita.young@va.gov FU Research Services of the Department of Veterans Affairs; National Institutes of Health [R01CA85266, R01CA97813, R01DE018168, 1R01CA128837] FX This work was supported by Research Services of the Department of Veterans Affairs and by grants R01CA85266, R01CA97813, R01DE018168 and 1R01CA128837 from the National Institutes of Health to MRIY. NR 28 TC 12 Z9 12 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0340-7004 J9 CANCER IMMUNOL IMMUN JI Cancer Immunol. Immunother. PD FEB PY 2010 VL 59 IS 2 BP 267 EP 277 DI 10.1007/s00262-009-0747-y PG 11 WC Oncology; Immunology SC Oncology; Immunology GA 519EU UT WOS:000271748600009 PM 19669642 ER PT J AU Katiyar, SK Vaid, M van Steeg, H Meeran, SM AF Katiyar, Santosh K. Vaid, Mudit van Steeg, Harry Meeran, Syed M. TI Green Tea Polyphenols Prevent UV-Induced Immunosuppression by Rapid Repair of DNA Damage and Enhancement of Nucleotide Excision Repair Genes SO CANCER PREVENTION RESEARCH LA English DT Article ID CYCLOBUTANE PYRIMIDINE DIMERS; INDUCED IMMUNE SUPPRESSION; SKIN-CANCER; ULTRAVIOLET-RADIATION; CONTACT HYPERSENSITIVITY; XERODERMA-PIGMENTOSUM; IRRADIATED MICE; INHIBITION; INDUCTION; CELLS AB UV radiation-induced immunosuppression has been implicated in the development of skin cancers. Green tea polyphenols (GTP) in drinking water prevent photocarcinogenesis in the skin of mice. We studied whether GTPs in drinking water (0.1-0.5%, w/v) prevent UV-induced immunosuppression and (if so) potential mechanisms of this effect in mice. GTPs (0.2% and 0.5%, w/v) reduced UV-induced suppression of contact hypersensitivity (CHS) in response to a contact sensitizer in local (58-62% reductions; P < 0.001) and systemic (51-55% reductions; P < 0.005) models of CHS. Compared with untreated mice, GTP-treated mice (0.2%, w/v) had a reduced number of cyclobutane pyrimidine dimer-positive (CPD(+)) cells (59%; P < 0.001) in the skin, showing faster repair of UV-induced DNA damage, and had a reduced (2-fold) migration of CPD(+) cells from the skin to draining lymph nodes, which was associated with elevated levels of nucleotide excision repair (NER) genes. GTPs did not prevent UV-induced immunosuppression in NER-deficient mice but significantly prevented it in NER-proficient mice (P < 0.001); immunohistochemical analysis of CPD(+) cells indicated that GTPs reduced the numbers of UV-induced CPD(+) cells in NER-proficient mice (P < 0.001) but not in NER-deficient mice. Southwestern dot-blot analysis revealed that GTPs repaired UV-induced CPDs in xeroderma pigmentosum complementation group A (XPA)-proficient cells of a healthy person but did not in XPA-deficient cells obtained from XPA patients, indicating that a NER mechanism is involved in DNA repair. This study is the first to show a novel NER mechanism by which drinking GTPs prevents UV-induced immunosuppression and that inhibiting UV-induced immunosuppression may underlie the chemopreventive activity of GTPs against photocarcinogenesis. Cancer Prev Res; 3(2); 179-89. (C) 2010 AACR. C1 [Katiyar, Santosh K.; Vaid, Mudit; Meeran, Syed M.] Univ Alabama, Dept Dermatol, Birmingham, AL 35294 USA. [Katiyar, Santosh K.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [van Steeg, Harry] Natl Inst Publ Hlth & Environm, Hlth Effects Res Lab, NL-3720 BA Bilthoven, Netherlands. RP Katiyar, SK (reprint author), Univ Alabama, Dept Dermatol, 1670 Univ Blvd,Volker Hall 557,POB 202, Birmingham, AL 35294 USA. EM skatiyar@uab.edu FU National Center for Complementary and Alternative Medicine/NIH [R01 AT002536]; Veterans Administration Merit Review Award FX National Center for Complementary and Alternative Medicine/NIH grant R01 AT002536 (S. K. Katiyar) and Veterans Administration Merit Review Award (S. K. Katiyar). NR 27 TC 31 Z9 33 U1 3 U2 8 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1940-6207 J9 CANCER PREV RES JI Cancer Prev. Res. PD FEB PY 2010 VL 3 IS 2 BP 179 EP 189 DI 10.1158/1940-6207.CAPR-09-0044 PG 11 WC Oncology SC Oncology GA 551XP UT WOS:000274247000009 PM 20103727 ER PT J AU Scheuner, MT Setodji, CM Pankow, JS Blumenthal, RS Keeler, E AF Scheuner, Maren T. Setodji, Claude Messan Pankow, James S. Blumenthal, Roger S. Keeler, Emmett TI General Cardiovascular Risk Profile Identifies Advanced Coronary Artery Calcium and Is Improved by Family History The Multiethnic Study of Atherosclerosis SO CIRCULATION-CARDIOVASCULAR GENETICS LA English DT Article DE cardiovascular diseases; imaging; coronary artery calcium; family history; risk factors; subclinical atherosclerosis ID BEAM COMPUTED-TOMOGRAPHY; C-REACTIVE PROTEIN; HEART-DISEASE; MYOCARDIAL-INFARCTION; TASK-FORCE; PREDICTION; SCORE; CALCIFICATION; ACCURACY; EVENTS AB Background -The General Cardiovascular Risk Profile is a multivariable model that predicts global cardiovascular disease risk. Our goal was to assess the ability of the General Cardiovascular Risk Profile to identify individuals with advanced coronary artery calcification (CAC) and determine whether identification is improved with family history. Methods and Results - Using data from the Multiethnic Study of Atherosclerosis, 3 sex-specific models were developed with ordinal logistic regressions to relate risk factors to CAC scores. Model 1 included covariates in the General Cardiovascular Risk Profile. Then family history was added, defined as having at least 1 first-degree relative with premature coronary heart disease (model 2) or as a weak, moderate, or strong family history based on number of relatives with coronary heart disease, age at onset, and the presence of stroke or diabetes in the family (model 3). For each model, we estimated mathematical CAC risk functions, derived CAC score sheets, evaluated the ability to discriminate persons having positive CAC scores, and assessed reclassification of individuals with low, intermediate, or high probability of CAC > 300. Model 1 worked well to identify women and men with positive CAC scores; c-statistics were 0.752 and 0.718 and chi(2) values were 821.2 (P < 0.0001) and 730.6 (P < 0.0001), respectively. Addition of family history improved discrimination and fit of model 1. However, reclassification of participants with advanced CAC was significantly improved with model 3 only. Conclusions -The General Cardiovascular Risk Profile identifies advanced CAC, an emerging indication for aggressive risk factor modification. Incorporation of family history, especially comprehensive familial risk stratification, provides incremental prognostic value. (Circ Cardiovasc Genet. 2010;3:97-105.) C1 [Scheuner, Maren T.; Keeler, Emmett] RAND Corp, Santa Monica, CA 90407 USA. [Scheuner, Maren T.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Scheuner, Maren T.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Serv, Los Angeles, CA 90024 USA. [Setodji, Claude Messan] RAND Corp, Pittsburgh, PA USA. [Pankow, James S.] Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN USA. [Blumenthal, Roger S.] Johns Hopkins Ciccarone Ctr Prevent Heart Dis, Baltimore, MD USA. RP Scheuner, MT (reprint author), RAND Corp, 1776 Main St,POB 2138, Santa Monica, CA 90407 USA. EM Scheuner@rand.org FU National Heart, Lung, and Blood Institute [1 R21 HL081175-01A1, NO1-HC-95159, N01-HC-95165, N01-HC95169] FX This work was supported by National Heart, Lung, and Blood Institute grant 1 R21 HL081175-01A1. MESA was supported by contracts NO1-HC-95159 through N01-HC-95165 and N01-HC95169 from the National Heart, Lung, and Blood Institute. NR 37 TC 18 Z9 18 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1942-325X J9 CIRC-CARDIOVASC GENE JI Circ.-Cardiovasc. Genet. PD FEB PY 2010 VL 3 IS 1 BP 97 EP U302 DI 10.1161/CIRCGENETICS.109.894527 PG 17 WC Cardiac & Cardiovascular Systems; Genetics & Heredity SC Cardiovascular System & Cardiology; Genetics & Heredity GA 574HJ UT WOS:000275979700014 PM 20160201 ER PT J AU Sanborn, TA Ebrahimi, R Manoukian, SV McLaurin, BT Cox, DA Feit, F Hamon, M Mehran, R Stone, GW AF Sanborn, Timothy A. Ebrahimi, Ramin Manoukian, Steven V. McLaurin, Brent T. Cox, David A. Feit, Frederick Hamon, Martial Mehran, Roxana Stone, Gregg W. TI Impact of Femoral Vascular Closure Devices and Antithrombotic Therapy on Access Site Bleeding in Acute Coronary Syndromes The Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) Trial SO CIRCULATION-CARDIOVASCULAR INTERVENTIONS LA English DT Article DE angioplasty; anticoagulants; myocardial infarction; stents; vascular closure devices ID CARDIAC-CATHETERIZATION; MANUAL COMPRESSION; RANDOMIZED-TRIAL; COMPLICATIONS; METAANALYSIS; BIVALIRUDIN; ANGIOPLASTY; HEMOSTASIS AB Background-The Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial demonstrated that bivalirudin monotherapy significantly reduces major bleeding compared with heparin (unfractionated or enoxaparin) or bivalirudin plus a glycoprotein IIb/IIIa inhibitor in acute coronary syndromes. Whether vascular closure devices (VCD) impact these results is unknown. Therefore, this study sought to determine whether VCD impact major access site bleeding (ASB) in patients with acute coronary syndromes undergoing early invasive management by the femoral approach. Methods and Results-Major ASB in ACUITY was defined as ASB requiring interventional or surgical correction, hematoma >= 5 cm at the access site, retroperitoneal bleeding, or hemoglobin drop >= 3 g/dL with ecchymosis or hematoma <5 cm, oozing blood, or prolonged bleeding (>30 minutes) at the access site. Stepwise logistical regression was performed to identify the independent determinants of ASB. Of 11 621 patients undergoing angiography with or without percutaneous coronary intervention by the femoral approach, 4307 (37.1%) received a VCD and 7314 (62.9%) did not. Rates of major ASB were lower with VCD compared with no VCD (2.5% versus 3.3%, relative risk, 0.76; 95% CI, 0.61 to 0.94; P = 0.01) and were lowest in patients treated with bivalirudin monotherapy and a VCD (0.7%). Stepwise logistic regression revealed that a VCD (odds ratio, 0.78; 95% CI, 0.61 to 0.99; P = 0.04) and bivalirudin monotherapy (odds ratio, 0.35; 95% CI, 0.25 to 0.49; P < 0.0001) were both independent determinates of freedom from major ASB. Conclusion-In patients with acute coronary syndromes undergoing an early invasive management strategy by the femoral approach, the use of a VCD, bivalirudin monotherapy, or both minimizes rates of major ASB. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique Identifier: NCT00093158. (Circ Cardiovasc Interv. 2010;3:57-62.) C1 [Sanborn, Timothy A.] Evanston NW Healthcare, Evanston, IL USA. [Ebrahimi, Ramin] Univ Calif Los Angeles, Los Angeles, CA USA. [Ebrahimi, Ramin] Greater Los Angeles VA Med Ctr, Los Angeles, CA USA. [Manoukian, Steven V.] Sarah Cannon Res Inst, Nashville, TN USA. [Manoukian, Steven V.] Hosp Corp Amer, Nashville, TN USA. [McLaurin, Brent T.] AnMed Hlth, Anderson, SC USA. [Cox, David A.] Lehigh Valley Hosp, Allentown, PA USA. [Feit, Frederick] NYU, Sch Med, New York, NY USA. [Hamon, Martial] Univ Hosp Caen, Normandy, France. [Ebrahimi, Ramin; Stone, Gregg W.] Columbia Univ, Med Ctr, New York, NY USA. [Ebrahimi, Ramin; Stone, Gregg W.] Cardiovasc Res Fdn, New York, NY USA. RP Sanborn, TA (reprint author), NorthShore Univ HealthSyst, Dept Med, Div Cardiol, 2650 Ridge Ave,Walgreen Bldg,3rd Floor, Evanston, IL 60201 USA. EM tsanborn@northshore.org FU Medicines Company (Parsippany, NJ); Boston Scientific; Abbott FX The ACUITY trial was sponsored by The Medicines Company (Parsippany, NJ).; Dr Sanborn received honoraria from and is a member of speaker's bureau of The Medicines Company and Merck. Dr Ebrahimi received honoraria from and is a member of speaker's bureau of The Medicines Company and Abbott. Dr Manoukian received honoraria from and is a member of speaker's bureau of The Medicines Company. Dr McLaurin has no financial support to disclose. Dr Cox received honoraria from and is a member of speaker's bureau of Abbott, The Medicines Company, and Boston Scientific and is a consultant and a member of the advisory board of Abbott and Boston Scientific. Dr Feit holds an ownership interest in Johnson & Johnson, Lilly, and The Medicines Company and received honoraria and is a member of the speaker's bureau of The Medicines Company. Dr Hamon received honoraria from and is a member of the speaker's bureau of The Medicines Company and is a consultant and a member of the advisory board of The Medicines Company. Dr Mehran received honoraria from and is a member of speaker's bureau of The Medicines Company, Boston Scientific, Regardo, Therox, Sanofi/Aventis/ BMS, Lilly, Gubert, Abiomed, Cordis, Medtronic, and Abbott; is a consultant and a member of the advisory board of The Medicines Company, Boston Scientific, Sanofi/Aventis/BMS, Cordis, Medtronic, BRACCO, and Abbott; and received other research support (receipt of drugs, supplies, equipment, or other in-kind support) and research grant (principal investigator, collaborator or consultant, and pending or already received grants) from Boston Scientific. Dr Stone received other research support (receipt of drugs, supplies, equipment, or other in-kind support) and research grant (principal investigator, collaborator or consultant, and pending or already received grants) from The Medicines Company, Boston Scientific, and Abbott and received honoraria from and is a member of speaker's bureau of St Jude and Lilly. NR 16 TC 68 Z9 71 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1941-7640 J9 CIRC-CARDIOVASC INTE JI Circ.-Cardiovasc. Interv. PD FEB PY 2010 VL 3 IS 1 BP 57 EP 62 DI 10.1161/CIRCINTERVENTIONS.109.896704 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 575LV UT WOS:000276069500009 PM 20118151 ER PT J AU Jegede, AB Rosado-Rivera, D Bauman, WA Cardozo, CP Sano, M Moyer, JM Brooks, M Wecht, JM AF Jegede, Adejoke B. Rosado-Rivera, Dwindally Bauman, William A. Cardozo, Christopher P. Sano, Mary Moyer, Jeremy M. Brooks, Monifa Wecht, Jill Maria TI Cognitive performance in hypotensive persons with spinal cord injury SO CLINICAL AUTONOMIC RESEARCH LA English DT Article DE Blood pressure; Tetraplegia; Paraplegia; Cognitive testing; Hypotension; Spinal cord injury ID CEREBRAL-BLOOD-FLOW; CONTINGENT NEGATIVE-VARIATION; 110 MM HG; ORTHOSTATIC HYPOTENSION; REDEFINING HYPOTENSION; MEMORY CONSOLIDATION; TETRAPLEGIC MAN; HEALTHY HUMANS; LOWER LIMIT; PRESSURE AB Due to sympathetic de-centralization, individuals with spinal cord injury (SCI), especially those with tetraplegia, often present with hypotension, worsened with upright posture. Several investigations in the non-SCI population have noted a relationship between chronic hypotension and deficits in memory, attention and processing speed and delayed reaction times. To determine cognitive function in persons with SCI who were normotensive or hypotensive over a 24-h observation period while maintaining their routine activities. Subjects included 20 individuals with chronic SCI (2-39 years), 13 with tetraplegia (C4-8) and 7 with paraplegia (T2-11). Individuals with hypotension were defined as having a mean 24-h systolic blood pressure (SBP) below 110 mmHg for males and 100 mmHg for females, and having spent a parts per thousand yen50% of the total time below these gender-specific thresholds. The cognitive battery used included assessment of memory (CVLT), attention and processing speed (Digit Span, Stroop word and color and Oral Trails A), language (COWAT) and executive function (Oral Trails B and Stroop color-word). Demographic parameters did not differ among the hypotensive and normotensive groups; the proportion of individuals with tetraplegia (82%) was higher in the hypotensive group. Memory was significantly impaired (P < 0.05) and there was a trend toward slowed attention and processing speed (P < 0.06) in the hypotensive compared to the normotensive group. These preliminary data suggest that chronic hypotension in persons with SCI is associated with deficits in memory and possibly attention and processing speed, as previously reported in the non-SCI population. C1 [Jegede, Adejoke B.; Rosado-Rivera, Dwindally; Bauman, William A.; Cardozo, Christopher P.; Moyer, Jeremy M.; Wecht, Jill Maria] James J Peters VA Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, VA Rehabil Res & Dev Serv, Bronx, NY 10468 USA. [Bauman, William A.; Cardozo, Christopher P.; Sano, Mary; Moyer, Jeremy M.] James J Peters VAMC, Med Serv, Bronx, NY 10468 USA. [Bauman, William A.; Cardozo, Christopher P.; Sano, Mary; Wecht, Jill Maria] Mt Sinai Sch Med, Dept Med, New York, NY USA. [Bauman, William A.; Cardozo, Christopher P.; Wecht, Jill Maria] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA. [Sano, Mary] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Moyer, Jeremy M.; Brooks, Monifa] Kessler Inst Rehabil, W Orange, NJ USA. [Sano, Mary] James J Peters VA Med Ctr, Dept Res & Dev, Bronx, NY 10468 USA. RP Wecht, JM (reprint author), James J Peters VA Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, VA Rehabil Res & Dev Serv, Rm 1E-02 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM jm.wecht@va.gov FU Veterans Affairs Rehabilitation Research and Development Service [B3346V, B4723H, B4162C]; National Institute of Health [P50AG005138] FX This research was supported by the Veterans Affairs Rehabilitation Research and Development Service (# B3346V, # B4723H and # B4162C), the National Institute of Health (# P50AG005138). NR 61 TC 18 Z9 18 U1 1 U2 5 PU DR DIETRICH STEINKOPFF VERLAG PI HEIDELBERG PA TIERGARTENSTRASSE 17, 69121 HEIDELBERG, GERMANY SN 0959-9851 J9 CLIN AUTON RES JI Clin. Auton. Res. PD FEB PY 2010 VL 20 IS 1 BP 3 EP 9 DI 10.1007/s10286-009-0036-z PG 7 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 555HY UT WOS:000274501000002 PM 19842013 ER PT J AU Perfect, JR Dismukes, WE Dromer, F Goldman, DL Graybill, JR Hamill, RJ Harrison, TS Larsen, RA Lortholary, O Nguyen, MH Pappas, PG Powderly, WG Singh, N Sobel, JD Sorrell, TC AF Perfect, John R. Dismukes, William E. Dromer, Francoise Goldman, David L. Graybill, John R. Hamill, Richard J. Harrison, Thomas S. Larsen, Robert A. Lortholary, Olivier Nguyen, Minh-Hong Pappas, Peter G. Powderly, William G. Singh, Nina Sobel, Jack D. Sorrell, Tania C. TI Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America SO CLINICAL INFECTIOUS DISEASES LA English DT Review ID HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY; ORGAN TRANSPLANT RECIPIENTS; RECONSTITUTION INFLAMMATORY SYNDROME; LIPOSOMAL AMPHOTERICIN-B; HIGH-DOSE FLUCONAZOLE; PLACEBO-CONTROLLED TRIAL; NEOFORMANS VAR GATTII; HIGH HIV SEROPREVALENCE; SOUTH-AFRICAN PROVINCE AB Cryptococcosis is a global invasive mycosis associated with significant morbidity and mortality. These guidelines for its management have been built on the previous Infectious Diseases Society of America guidelines from 2000 and include new sections. There is a discussion of the management of cryptococcal meningoencephalitis in 3 risk groups: (1) human immunodeficiency virus (HIV)-infected individuals, (2) organ transplant recipients, and (3) non-HIV-infected and nontransplant hosts. There are specific recommendations for other unique risk populations, such as children, pregnant women, persons in resource-limited environments, and those with Cryptococcus gattii infection. Recommendations for management also include other sites of infection, including strategies for pulmonary cryptococcosis. Emphasis has been placed on potential complications in management of cryptococcal infection, including increased intracranial pressure, immune reconstitution inflammatory syndrome (IRIS), drug resistance, and cryptococcomas. Three key management principles have been articulated: (1) induction therapy for meningoencephalitis using fungicidal regimens, such as a polyene and flucytosine, followed by suppressive regimens using fluconazole; (2) importance of early recognition and treatment of increased intracranial pressure and/or IRIS; and (3) the use of lipid formulations of amphotericin B regimens in patients with renal impairment. Cryptococcosis remains a challenging management issue, with little new drug development or recent definitive studies. However, if the diagnosis is made early, if clinicians adhere to the basic principles of these guidelines, and if the underlying disease is controlled, then cryptococcosis can be managed successfully in the vast majority of patients. C1 [Perfect, John R.] Duke Univ, Med Ctr, Div Infect Dis, Durham, NC 27710 USA. [Dismukes, William E.; Pappas, Peter G.] Univ Alabama Birmingham, Div Infect Dis, Birmingham, AL USA. [Goldman, David L.] Albert Einstein Coll Med, Dept Pediat Infect Dis, Bronx, NY 10467 USA. [Graybill, John R.] Univ Texas San Antonio, Div Infect Dis, Audie L Murphy Vet Affairs Hosp, San Antonio, TX USA. [Hamill, Richard J.] VA Med Ctr, Div Infect Dis, Houston, TX USA. [Larsen, Robert A.] Univ So Calif, Sch Med, Dept Med, Los Angeles, CA 90033 USA. [Larsen, Robert A.] Univ So Calif, Sch Med, Dept Infect Dis, Los Angeles, CA USA. [Nguyen, Minh-Hong] Univ Pittsburgh, Div Infect Dis, Coll Med, Pittsburgh, PA USA. VA Med Ctr, Infect Dis Sect, Pittsburgh, PA USA. [Singh, Nina; Sobel, Jack D.] Wayne State Univ, Harper Hosp, Detroit, MI USA. [Dromer, Francoise; Lortholary, Olivier] Inst Pasteur, Ctr Natl Reference Mycol & Antifong, Unite Mycol Mol, Paris, France. [Lortholary, Olivier] Univ Paris 05, Serv Malad Infect & Trop, Hop Necker Enfants Malad, Ctr Infectiol Necker Pasteur, Paris, France. [Powderly, William G.] Univ Coll Dublin, Dublin 2, Ireland. [Harrison, Thomas S.] St George Hosp, Sch Med, Dept Infect Dis, London, England. [Sorrell, Tania C.] Univ Sydney Westmead, Ctr Infect Dis & Microbiol, Sydney, NSW, Australia. RP Perfect, JR (reprint author), Duke Univ, Med Ctr, Div Infect Dis, Hanes House,Rm 163,Box 102359, Durham, NC 27710 USA. EM perfe001@mc.duke.edu FU Infectious Diseases Society of America [AI73896] FX The Infectious Diseases Society of America (Public Health Service Grant AI73896 to J.R.P.). NR 194 TC 645 Z9 720 U1 7 U2 74 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD FEB 1 PY 2010 VL 50 IS 3 BP 291 EP 322 DI 10.1086/649858 PG 32 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 542NG UT WOS:000273500300001 PM 20047480 ER PT J AU Granda-Cameron, C DeMille, D Lynch, MP Huntzinger, C Alcorn, T Levicoff, J Roop, C Mintzer, D AF Granda-Cameron, Clara DeMille, Debra Lynch, Mary Pat Huntzinger, Christine Alcorn, Theresa Levicoff, Joan Roop, Carly Mintzer, David TI An Interdisciplinary Approach to Manage Cancer Cachexia SO CLINICAL JOURNAL OF ONCOLOGY NURSING LA English DT Article ID WEIGHT-LOSS; NUTRITIONAL ASSESSMENT; PALLIATIVE CARE; CHEMOTHERAPY; FATIGUE; MALABSORPTION; EXERCISE; ANOREXIA AB Cancer cachexia occurs in about 33% of newly diagnosed patients with cancer and may lead to delayed, missed, or decreased treatments. An interdisciplinary team approach to manage cancer cachexia may result in fewer missed treatments and improved outcomes. The palliative care program of an urban community cancer center developed an interdisciplinary clinic to treat cancer cachexia with the goal of using an interdisciplinary approach to improve symptom management, nutrition, function, and quality of life (QOL) for patients with cancer at high risk for malnutrition. The Cancer Appetite and Rehabilitation Clinic team completes medical, nutritional, speech, swallowing, and physical therapy evaluations and then develops an individualized program directed to meet patients' needs and improve overall QOL. Patient outcomes are measured by symptom management and nutritional and functional parameters. Early intervention and aggressive symptom management may improve performance status and overall QOL. Results from this project will be used to expand this innovative program. The process of developing and implementing this clinic may help oncology nurses and other healthcare professionals to improve management of cancer cachexia and overall cancer care. C1 [Granda-Cameron, Clara] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [DeMille, Debra; Lynch, Mary Pat; Alcorn, Theresa; Roop, Carly] Penn Hosp, Joan Karnell Canc Ctr, Philadelphia, PA 19107 USA. [Huntzinger, Christine] Good Shepherd Penn Partners, Inpatient Rehabil Serv, Philadelphia, PA USA. [Mintzer, David] Penn Hosp, Pain & Support Care Program, Philadelphia, PA 19107 USA. RP Granda-Cameron, C (reprint author), Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. EM claritacameron@gmail.com NR 45 TC 17 Z9 19 U1 3 U2 10 PU ONCOLOGY NURSING SOC PI PITTSBURGH PA 125 ENTERPRISE DR, PITTSBURGH, PA 15275 USA SN 1092-1095 J9 CLIN J ONCOL NURS JI Clin. J. Oncol. Nurs. PD FEB PY 2010 VL 14 IS 1 BP 72 EP 80 DI 10.1188/10.CJON.72-80 PG 9 WC Oncology; Nursing SC Oncology; Nursing GA 556UI UT WOS:000274618000015 PM 20118029 ER PT J AU Doolittle, MH Peterfy, M AF Doolittle, Mark H. Peterfy, Miklos TI Mechanisms of lipase maturation SO CLINICAL LIPIDOLOGY LA English DT Review DE chaperone; endoplasmic reticulum; endothelial lipase; glycosylation; hepatic lipase; lipase maturation factor 1; lipoprotein lipase protein folding ID HIGH-DENSITY-LIPOPROTEIN; N-LINKED GLYCOSYLATION; HUMAN HEPATIC LIPASE; ER QUALITY-CONTROL; ENDOPLASMIC-RETICULUM; ENDOTHELIAL LIPASE; INSULIN-RESISTANCE; PANCREATIC LIPASE; SEVERE HYPERTRIGLYCERIDEMIA; TRIGLYCERIDE LIPASE AB Lipases are acyl hydrolases that represent a diverse-group of enzymes present in organisms ranging from prokaryotes to humans. This article focuses on an evolutionarily related family of extracellular lipases that include lipoprotein lipase, hepatic lipase and endothelial lipase. As newly synthesized proteins, these lipases undergo a series of co- and post-translational maturation steps, occurring in the endoplasmic reticulum, including glycosylation and glycan processing, and protein folding and subunit assembly. This article identifies key factors that facilitate this process and discusses mechanisms that direct early and late events in lipase folding and assembly. Lipase maturation employs the two general chaperone systems operating in the endoplasmic reticulum, as well as a recently identified lipase-specific chaperone termed lipase maturation factor 1. We propose that the two general chaperone systems act in a coordinated manner early in lipase maturation in order to help create partially folded monomers; lipase maturation factor 1 then facilitates final monomer folding and subunit assembly into fully functional homodimers. Once maturation is complete, the lipases exit the endoplasmic reticulum and are secreted to extracellular sites, where they carry out a number of functions related and lipid metabolism. C1 [Doolittle, Mark H.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Doolittle, Mark H.; Peterfy, Miklos] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Peterfy, Miklos] Cedars Sinai Med Ctr, Inst Med Genet, Los Angeles, CA 90048 USA. RP Doolittle, MH (reprint author), VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd,Bldg 113,Rm 312, Los Angeles, CA 90073 USA. EM markdool@ucla.edu FU David Geffen School of Medicine; University of California; Los Angeles; Cedars-Sinai Medical Center; National Institutes of Health [HL24841] FX We acknowledge the support of the David Geffen School of Medicine, University of California, Los Angeles, the Cedars-Sinai Medical Center, the Department of Veterans Affairs and grant HL24841 from the National Institutes of Health. We would also like to acknowledge Drs Howard Wong and Keith Munson for their generous contribution of the structural model of hepatic lipase presented in Figure 1. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. NR 114 TC 1 Z9 1 U1 2 U2 3 PU FUTURE MEDICINE LTD PI LONDON PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND SN 1758-4299 J9 CLIN LIPIDOL JI Clin. Lipidol. PD FEB PY 2010 VL 5 IS 1 BP 117 EP 130 DI 10.2217/CLP.09.84 PG 14 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 555NW UT WOS:000274520200016 ER PT J AU Tsourounis, C Bent, S AF Tsourounis, C. Bent, S. TI Why Change Is Needed in Research Examining Dietary Supplements SO CLINICAL PHARMACOLOGY & THERAPEUTICS LA English DT Editorial Material C1 [Tsourounis, C.] Univ Calif San Francisco, Sch Pharm, Dept Clin Pharm, San Francisco, CA 94143 USA. [Bent, S.] Univ Calif San Francisco, Dept Med, Osher Ctr Integrat Med, San Francisco, CA 94143 USA. [Bent, S.] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA. RP Tsourounis, C (reprint author), Univ Calif San Francisco, Sch Pharm, Dept Clin Pharm, San Francisco, CA 94143 USA. EM tsourounisc@pharmacy.ucsf.edu NR 7 TC 4 Z9 4 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0009-9236 J9 CLIN PHARMACOL THER JI Clin. Pharmacol. Ther. PD FEB PY 2010 VL 87 IS 2 BP 147 EP 149 DI 10.1038/clpt.2009.241 PG 3 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 550PK UT WOS:000274140200006 PM 20107446 ER PT J AU Frei, CR Attridge, RT Mortensen, EM Restrepo, MI Yu, YF Oramasionwu, CU Ruiz, JL Burgess, DS AF Frei, Christopher R. Attridge, Russell T. Mortensen, Eric M. Restrepo, Marcos I. Yu, Yifan Oramasionwu, Christine U. Ruiz, Jessica L. Burgess, David S. TI Guideline-Concordant Antibiotic Use and Survival Among Patients With Community-Acquired Pneumonia Admitted to the Intensive Care Unit SO CLINICAL THERAPEUTICS LA English DT Article DE bacterial pneumonia; community-acquired pneumonia; guidelines; antibiotics; health outcomes; mortality ID LENGTH-OF-STAY; ANTIMICROBIAL THERAPY; CONTROLLED-TRIAL; MORTALITY; IMPLEMENTATION; MANAGEMENT; OUTCOMES; STABILITY; CRITERIA; PATHWAY AB Objective: This study evaluated the survival benefit of US community-acquired pneumonia (CAP) practice guidelines in the intensive care unit (ICU) setting. Methods: We conducted a retrospective cohort study of adult patients with CAP who were admitted to 5 community hospital ICUs between November 1, 1999, and April 30, 2000. The guidelines for antibiotic prescriptions were the 2007 Infectious Diseases Society of America/American Thoracic Society guidelines. Guideline-concordant antimicrobial therapy was defined as a beta-lactam plus fluoroquinolone or macrolide, antipseudomonal beta-lactam plus fluoroquinolone, or antipseudomonal beta-lactam plus ammoglycoside plus fluoroquinolone or macrolide. Patients with a documented beta-lactam allergy were considered to have received guideline-concordant therapy if they received a fluoroquinolone with or without clindamycin, or aztreonam plus fluoroquinolone with or without aminoglycoside. All other antibiotic regimens were considered to be guideline discordant. Time to clinical stability, time to oral antibiotics, length of hospital stay, and in-hospital mortality were evaluated with regression models that included the outcome as the dependent variable, guideline-concordant antibiotic therapy as the independent variable, and the Pneumonia Severity Index (PSI) score and facility as covariates. Results: The median age of the 129 patients included in the study was 71 years (interquartile range, 60-79 years). Sixty-two of 129 patients (48%) were male. Comorbidities included liver dysfunction (7 pa-tients [5%]), heart failure (62 [48%]), renal dysfunction (39 [30%]), cerebrovascular disease (21 [16%]), and cancer (14 [11%]). The median (25th-75th percentile) PSI score was 119 (98-142), and overall mortality was 19% (25 patients). Patient demographics were similar between groups. Fifty-three patients (41%) received guideline-endorsed therapies. Guideline-discordant therapy was associated with an increase in inpatient mortality (25% vs 11%; odds ratio = 2.99 [95% CI, 1.08-9.54]). Receipt of guideline-concordant antibiotics was not associated with reductions in time to clinical stability, time to oral antibiotics, or length of hospital stay when patients who died were excluded from the analysis. Conclusion: Guideline-concordant empiric antibiotic therapy was associated with improved survival among these patients with CAP who were admitted to 5 ICUs. (Clin Ther. 2010;32:293-299) (C) 2010 Excerpta Medica Inc. C1 [Burgess, David S.] Univ Texas Hlth Sci Ctr San Antonio, Pharmacotherapy Educ & Res Ctr, Sch Med, San Antonio, TX 78229 USA. [Frei, Christopher R.; Attridge, Russell T.; Yu, Yifan; Oramasionwu, Christine U.; Ruiz, Jessica L.; Burgess, David S.] Univ Texas Austin, Coll Pharm, Austin, TX 78712 USA. [Mortensen, Eric M.; Restrepo, Marcos I.] Vet Evidence Based Res Disseminat Implementat Ctr, San Antonio, TX USA. [Mortensen, Eric M.; Restrepo, Marcos I.] S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. RP Burgess, DS (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Pharmacotherapy Educ & Res Ctr, Sch Med, 7703 Floyd Curl Dr,MSC 6220, San Antonio, TX 78229 USA. EM burgessD@uthscsa.edu RI Restrepo, Marcos/H-4442-2014 OI Mortensen, Eric/0000-0002-3880-5563 FU Department of Veterans Affairs Vertically Integrated Service Network; Howard Hughes Medical Institute FX Dr. Frei has received research grants from Ortho-McNeil Janssen, Elan, AstraZeneca, Abbott, Merck, Roche, and Wyeth, and has served as a consultant and advisory-board member for Ortho-McNeil Janssen. Dr. Restrepo has served on speakers' bureaus for Ortho-McNeil Janssen, Johnson & Johnson, and Pfizer, and on advisory boards for Ortho-McNeil Janssen and Johnson & Johnson. Dr. Mortensen's work was supported by grants from the Department of Veterans Affairs Vertically Integrated Service Network and Howard Hughes Medical Institute. Dr. Burgess has received honoraria, received research grants, served as a consultant, or served on speakers' bureaus for the following pharmaceutical companies: Abbott, AstraZeneca, Merck, Ortho-McNeil Janssen, Roche, sanofiaventis, and Wyeth. The authors have indicated that they have no other conflicts of interest regarding the content of this article.; The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs.; The authors acknowledge the assistance of the following clinical pharmacists from the Baptist Health System, who assisted with data collection: Brian Barthol, PharmD; Renee Bellanger, PharmD; Donna Burgess, RPh; Paige Cuellar, PharmD; Julie Gilbert, PharmD; Jennifer Hammond, PharmD; Scott Hollis, RPh; Loretta Lemoine, RPh; Andi Lewis, PharmD; Jane Mondino, RPh; Jon Olson, PharmD; Nish Patel, PharmD; Liz Sanchez, RPh; Morris Sauter, PharmD; Thomas Shank, PharmD; Jacque Snow, PharmD; Paige Staudt, PharmD; and Mary Allyn Watson, PharmD. NR 22 TC 40 Z9 42 U1 1 U2 7 PU ELSEVIER PI BRIDGEWATER PA 685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA SN 0149-2918 J9 CLIN THER JI Clin. Ther. PD FEB PY 2010 VL 32 IS 2 BP 293 EP 299 DI 10.1016/j.clinthera.2010.02.006 PG 7 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 568AZ UT WOS:000275495200008 PM 20206787 ER PT J AU Swick, JM Grattan, EG Burges, GE AF Swick, Julie M. Grattan, Elizabeth G. Burges, Gene E. TI What Is Your Diagnosis? - The Diagnosis: Metastatic Adenocarcinoma SO CUTIS LA English DT Editorial Material ID CUTANEOUS METASTASES; CARCINOMA; SKIN C1 [Swick, Julie M.; Grattan, Elizabeth G.; Burges, Gene E.] Med Univ S Carolina, Charleston, SC 29425 USA. [Burges, Gene E.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Swick, JM (reprint author), Med Univ S Carolina, Charleston, SC 29425 USA. NR 5 TC 0 Z9 0 U1 0 U2 0 PU QUADRANT HEALTHCOM INC PI PARSIPPANY PA 7 CENTURY DRIVE, STE 302, PARSIPPANY, NJ 07054-4603 USA SN 0011-4162 EI 2326-6929 J9 CUTIS JI Cutis PD FEB PY 2010 VL 85 IS 2 BP 64 EP + PG 2 WC Dermatology SC Dermatology GA 560NZ UT WOS:000274910700002 PM 20349678 ER PT J AU Fioramonti, X Marsollier, N Song, ZT Fakira, KA Patel, RM Brown, S Duparc, T Pica-Mendez, A Sanders, NM Knauf, C Valet, P McCrimmon, RJ Beuve, A Magnan, C Routh, VH AF Fioramonti, Xavier Marsollier, Nicolas Song, Zhentao Fakira, Kurt A. Patel, Reema M. Brown, Stacey Duparc, Thibaut Pica-Mendez, Arnaldo Sanders, Nicole M. Knauf, Claude Valet, Philippe McCrimmon, Rory J. Beuve, Annie Magnan, Christophe Routh, Vanessa H. TI Ventromedial Hypothalamic Nitric Oxide Production Is Necessary for Hypoglycemia Detection and Counterregulation SO DIABETES LA English DT Article ID CEREBRAL-BLOOD-FLOW; GLUCOSE-INHIBITED NEURONS; INSULIN-INDUCED HYPOGLYCEMIA; DEPENDENT DIABETES-MELLITUS; ACTIVATED PROTEIN-KINASE; ARCUATE NUCLEUS; HORMONE-RELEASE; EXCITED NEURONS; NEUROPEPTIDE-Y; HEART-RATE AB OBJECTIVE-The response of ventromedial hypothalamic (VMH) glucose-inhibited neurons to decreased glucose is impaired under conditions where the counterregulatory response (CRR) to hypoglycemia is impaired (e.g., recurrent hypoglycemia). This suggests a role for glucose-inhibited neurons in the CRR. We recently showed that decreased glucose increases nitric oxide (NO) production in cultured VMH glucose-inhibited neurons. These in vitro data led us to hypothesize that NO release from VMH glucose-inhibited neurons is critical for the CRR. RESEARCH DESIGN AND METHODS-The CRR was evaluated in rats and mice in response to acute insulin-induced hypoglycemia and hypoglycemic clamps after modulation of brain NO signaling. The glucose sensitivity of ventromedial nucleus glucose-inhibited neurons was also assessed. RESULTS-Hypoglycemia increased hypothalamic constitutive NO synthase (NOS) activity and neuronal NOS (nNOS) but not endothelial NOS (eNOS) phosphorylation in rats. Intracerebro-ventricular and VMH injection of the nonselective NOS inhibitor N(G)-monomethyl-L-arginine (L-NMMA) slowed the recovery to euglycemia after hypoglycemia. VMH L-NMMA injection also increased the glucose infusion rate (GIR) and decreased epinephrine secretion during hyperinsulinemic/hypoglycemic clamp in rats. The GIR required to maintain the hypoglycemic plateau was higher in nNOS knockout than wild-type or eNOS knockout mice. Finally, VMH glucose-inhibited neurons were virtually absent in nNOS knockout mice. CONCLUSIONS-We conclude that VMH NO production is necessary for glucose sensing in glucose-inhibited neurons and full generation of the CRR to hypoglycemia. These data suggest that potentiating NO signaling may improve the defective CRR resulting from recurrent hypoglycemia in patients using intensive insulin therapy. Diabetes 59:519-528, 2010 C1 [Fioramonti, Xavier; Song, Zhentao; Fakira, Kurt A.; Patel, Reema M.; Pica-Mendez, Arnaldo; Beuve, Annie; Routh, Vanessa H.] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Physiol & Pharmacol, Newark, NJ 07103 USA. [Marsollier, Nicolas; Magnan, Christophe] Univ Paris Diderot, Natl Ctr Sci Res, Paris, France. [Brown, Stacey] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA. [Duparc, Thibaut; Knauf, Claude; Valet, Philippe; McCrimmon, Rory J.] Univ Toulouse 3, INSERM, Inst Med Mol Rangueil, U858,IFR150, F-31062 Toulouse, France. [Sanders, Nicole M.] Vet Affairs Puget Sound Hlth Care Syst, Div Endocrinol Metab, Seattle, WA USA. RP Routh, VH (reprint author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Physiol & Pharmacol, 185 S Orange Ave, Newark, NJ 07103 USA. EM routhvh@umdnj.edu OI McCrimmon, Rory/0000-0002-3957-1981 FU Juvenile Diabetes Research Foundation; National Institutes of Health [28O1-DK-55619, 1RO1-DK-64566]; Philippe Foundation FX This work was supported in part by the Juvenile Diabetes Research Foundation (X.F. and V.H.R.) and the National Institutes of Health (28O1-DK-55619 and 1RO1-DK-64566) (V.H.R.). X.F. was also supported in part by the Philippe Foundation. NR 44 TC 32 Z9 32 U1 1 U2 6 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0012-1797 J9 DIABETES JI Diabetes PD FEB PY 2010 VL 59 IS 2 BP 519 EP 528 DI 10.2337/db09-0421 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 554LG UT WOS:000274435900024 PM 19934009 ER PT J AU Lin, EHB Rutter, CM Katon, W Heckbert, SR Ciechanowski, P Oliver, MM Ludman, EJ Young, BA Williams, LH McCulloch, DK Von Korff, M AF Lin, Elizabeth H. B. Rutter, Carolyn M. Katon, Wayne Heckbert, Susan R. Ciechanowski, Paul Oliver, Malia M. Ludman, Evette J. Young, Bessie A. Williams, Lisa H. McCulloch, David K. Von Korff, Michael TI Depression and Advanced Complications of Diabetes - A prospective cohort study SO DIABETES CARE LA English DT Article ID CARDIOVASCULAR EVENTS; SELF-REPORT; SYMPTOMS; CARE; INDIVIDUALS; ASSOCIATION; ADHERENCE; APPRAISAL; RISK AB OBJECTIVE - To prospectively examine the association of depression with risks for advanced macrovascular and microvascular complications among patients with type 2 diabetes. RESEARCH DESIGN AND METHODS - A longitudinal cohort of 4,623 primary care patients with type 2 diabetes was enrolled in 2000-2002 and followed through 2005-2007. Advanced microvascular complications included blindness, end-Stage renal disease, amputations, and renal failure deaths. Advanced macrovascular complications included myocardial infarction, stroke, cardiovascular procedures, and deaths. Medical record review, ICD-9 diagnostic and procedural codes, and death certificate data were used to ascertain outcomes in the 5-year follow-up. Proportional hazard models analyzed the association between baseline depression and risks of adverse outcomes. RESULTS - After adjustment for prior complications and demographic, clinical and diabetes self-care variables, major depression was associated with significantly higher rises of adverse microvascular outcomes (hazard ratio 1.36 [95% CI 1.05-1.75]) and adverse macrovascular outcomes (1.24 [1.0-1.54]). CONCLUSIONS - Among people with type 2 diabetes, major depression is associated with an increased risk of clinically significant microvascular and macrovascular complications over the ensuing 5 years, even after adjusting for diabetes severity and self-care activities. Clinical and public health significance of these Findings rises as the incidence of type 2 diabetes soars. Further research is needed to clarify the underlying mechanisms for this association and to Lest Interventions to reduce the risk of diabetes complications among patients with comorbid depression. C1 [Lin, Elizabeth H. B.; Rutter, Carolyn M.; Oliver, Malia M.; Ludman, Evette J.; McCulloch, David K.; Von Korff, Michael] Grp Hlth, Grp Hlth Res Inst, Seattle, WA USA. [Katon, Wayne; Ciechanowski, Paul] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Heckbert, Susan R.] Univ Washington, Sch Publ Hlth & Community Med, Cardiovasc Hlth Res Unit, Dept Epidemiol, Seattle, WA 98195 USA. [Young, Bessie A.] Univ Washington, Sch Med, Epidemiol Res & Informat Ctr, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Williams, Lisa H.] Univ Washington, Sch Med, Dept Med Dermatol, Seattle, WA 98195 USA. RP Lin, EHB (reprint author), Grp Hlth, Grp Hlth Res Inst, Seattle, WA USA. EM lin.e@ghc.org FU National Institutes of Health [MH 073686] FX This research was supported by grants from the National Institutes of Health (MH 073686). NR 24 TC 180 Z9 185 U1 4 U2 20 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD FEB PY 2010 VL 33 IS 2 BP 264 EP 269 DI 10.2337/dc09-1068 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 563PA UT WOS:000275143700009 PM 19933989 ER PT J AU Friedlander, AH AF Friedlander, Arthur H. TI Exodontia may improve glycemic control of diabetic patients with periodontitis SO DIABETES & METABOLISM LA English DT Letter C1 [Friedlander, Arthur H.] Univ Calif Los Angeles, Sch Dent, Hosp Dent Serv, Med Ctr, Los Angeles, CA 90095 USA. RP Friedlander, AH (reprint author), VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM arthur.friedlander@va.gov NR 2 TC 0 Z9 0 U1 0 U2 1 PU MASSON EDITEUR PI MOULINEAUX CEDEX 9 PA 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE SN 1262-3636 J9 DIABETES METAB JI Diabetes Metab. PD FEB PY 2010 VL 36 IS 1 BP 88 EP 88 DI 10.1016/j.diabet.2009.10.002 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 565IX UT WOS:000275285000013 PM 20080427 ER PT J AU Grasing, K Mathur, D Newton, TF DeSouza, C AF Grasing, Kenneth Mathur, Deepan Newton, Thomas F. DeSouza, Cherilyn TI Donepezil treatment and the subjective effects of intravenous cocaine in dependent individuals SO DRUG AND ALCOHOL DEPENDENCE LA English DT Article DE Acetylcholine; Cholinesterase inhibitors; Cocaine; Cocaine-related disorders; Donepezil ID NUCLEUS-ACCUMBENS; ALZHEIMERS-DISEASE; RATS; ACETYLCHOLINE; METHAMPHETAMINE; STIMULATION; AMPHETAMINE; VOLUNTEERS; WITHDRAWAL; RESPONSES AB Acetylcholinesterase (ACNE) inhibitors increase synaptic levels of acetylcholine (ACh) by inhibiting its breakdown. Donepezil is a reversible ACNE inhibitor that is clinically available and relatively selective for inhibiting ACNE but not other cholinesterases. Because ACNE inhibitors have been shown to decrease the reinforcing effects of cocaine in animals, our hypothesis was that pretreatment with donepezil would attenuate the perceived value and other positive subjective effects of cocaine. We conducted a within-subject, double-blind, placebo-controlled, laboratory-based evaluation of the subjective effects produced by intravenous cocaine in human subjects receiving oral donepezil. Following three days of daily treatment with 5 mg of donepezil or oral placebo, participants received intravenous placebo or cocaine (0.18 and 0.36 mg/kg). After a three-clay washout period, participants were crossed over to the opposite oral treatment, which was followed by identical intravenous infusions. Donepezil was well-tolerated with only two drug-related adverse events reported that were mild and self-limiting. Treatment with donepezil increased ratings of 'any' and 'good' drug effect produced by low-dose cocaine, without modifying the response to high-close cocaine. When collapsed across intravenous close, treatment with donepezil decreased dysphoric effects and somatic symptoms, but did not modify the value of cocaine injections as determined by the Multiple Choice Questionnaire (MCQ). In summary, pretreatment with donepezil potentiated some measures for nonspecific and positive effects of low-dose cocaine. Across all intravenous treatments, participants receiving donepezil reported fewer somatic-dysphoric effects. Neither of these actions support the value of donepezil as a treatment for cocaine dependence. Published by Elsevier Ireland Ltd. C1 [Grasing, Kenneth; Mathur, Deepan; DeSouza, Cherilyn] Kansas City VA Med Ctr, Subst Abuse Res Lab, Kansas City, MO 64128 USA. [Grasing, Kenneth] Univ Kansas, Sch Med, Dept Med, Div Clin Pharmacol, Kansas City, KS 66160 USA. [DeSouza, Cherilyn] Univ Kansas, Sch Med, Dept Psychiat, Kansas City, KS 66160 USA. [Newton, Thomas F.] Baylor Coll Med, Dept Psychiat & Behav Sci, Houston, TX 77030 USA. [Newton, Thomas F.] Michael E DeBakey Dept Vet Affairs Med Ctr, Houston, TX USA. RP Grasing, K (reprint author), Kansas City VA Med Ctr, Subst Abuse Res Lab, 151,4801 Linwood Blvd, Kansas City, MO 64128 USA. EM kenneth.grasing@med.va.gov; deepan.mathur@va.gov; tnewton@bcm.tmc.edu; cherilyn.desouza@med.va.gov OI newton, thomas/0000-0002-3198-5901 NR 44 TC 15 Z9 15 U1 4 U2 5 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0376-8716 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD FEB 1 PY 2010 VL 107 IS 1 BP 69 EP 75 DI 10.1016/j.drugalcdep.2009.09.010 PG 7 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA 566FI UT WOS:000275355100010 PM 19836169 ER PT J AU Leon, C de Nijs, L Chanas, G Delgado-Escueta, AV Grisar, T Lakaye, B AF Leon, Christine de Nijs, Laurence Chanas, Grazyna Delgado-Escueta, Antonio V. Grisar, Thierry Lakaye, Bernard TI Distribution of EFHC1 or Myoclonin 1 in mouse neural structures SO EPILEPSY RESEARCH LA English DT Article DE Juvenile myoclonic epilepsy; Brain development; Ependymal cells; Radial glia; Motile cilia; Neural stem cells ID EPILEPSY; EXPRESSION; MIGRATION; BRAIN; CELLS; MICROTUBULES; MUTATIONS; SPINDLE; CILIA AB EFHC1, a gene mutated in juvenile myoclonic epilepsy, encodes EFHC1, a protein with three DM10 domains and one EF-hand motif. We recently demonstrated that this molecule is a microtubule-associated protein (MAP) implicated in neuronal. migration. Because some controversies persist about the precise localization in the CNS, we studied the neuroanatomical distribution of EFHC1 in mature and developing mouse brain. In the adult, low mRNA expression was detected in several brain structures such as cortex, striatum, hippocampus and cerebellum. At E16, EFHC1 mRNA was shown to be expressed in cortex and not only in cells lining ventricles. Using a purified polyclonal antibody, EFHC1 staining was observed in all cortical layers, in piriform cortex, in hippocampus and in Purkinje cells of cerebellum. In the cortex, the majority of EFHC1 positive cells correspond to neurons, however some glial. cells were also stained. In agreement with a previous study, we demonstrated strong EFHC1 expression in cilia of ependymal cells lining cerebral ventricles. Moreover, at Ell 6, the protein was observed at the borders of brain ventricles, in choroid plexus, but also, although to a lesser extent, in piriform and neocortex. In these latter structures, the pattern of expression seems to correspond to the extensions of the radial glia fibers as demonstrated by BLBP immunostaining. Finally, we confirmed that EFHC1 was also expressed and co-localized with the mitotic spindle of neural stem cells. These results confirm that EFHC1 is a protein with a likely low expression level, in mouse brain but detectable both in adult and embryonic brain supporting our previous data and hypothesis that EFHC1 could play an important role during brain development. As discussed, this opens the door to a new conceptual approach viewing some idiopathic generalized epilepsies as developmental diseases instead of classical channelopathies. (C) 2009 Elsevier B.V. All rights reserved. C1 [Leon, Christine; de Nijs, Laurence; Chanas, Grazyna; Grisar, Thierry; Lakaye, Bernard] Univ Liege, GIGA Neurosci, Liege, Belgium. [Delgado-Escueta, Antonio V.] Univ Calif Los Angeles, David Geffen Sch Med, Epilepsy Genet Genom Labs, Comprehens Epilepsy Program, Los Angeles, CA 90073 USA. [Delgado-Escueta, Antonio V.] VA GLAHS W Los Angeles Med Ctr, Los Angeles, CA 90073 USA. RP Grisar, T (reprint author), Univ Liege, GIGA Neurosci, Ave Hop 1, Liege, Belgium. EM tgrisar@ulg.ac.be OI Delgado-Escueta, Antonio V./0000-0002-1581-6999 FU Fonds National de la Recherche Scientifique [FRSM 3.4565.03.F]; Leon Fredericq Foundation; Fonds pour la Recherche dans l'Industrie et l'Agriculture (FRIA) FX We thank the Dr. Ritsu Kamiya (University of Tokyo) for kindly providing the polyclonal anti-EFHC1 antibody used in this study. This work was supported by the Fonds National de la Recherche Scientifique (F.R.S.-FNRS; FRSM 3.4565.03.F to TG and BL) and the Leon Fredericq Foundation (to CL). CL is fellow of the Fonds pour la Recherche dans l'Industrie et l'Agriculture (FRIA). BL is a research associate at the F.R.S.-FNRS. NR 24 TC 8 Z9 8 U1 0 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-1211 J9 EPILEPSY RES JI Epilepsy Res. PD FEB PY 2010 VL 88 IS 2-3 BP 196 EP 207 DI 10.1016/j.eplepsyres.2009.11.009 PG 12 WC Clinical Neurology SC Neurosciences & Neurology GA 568RF UT WOS:000275539500015 PM 20015616 ER PT J AU Ogunyemi, O Rojas, A Hematpour, K Rogers, D Head, C Bennett, C AF Ogunyemi, Ore Rojas, A. Hematpour, K. Rogers, D. Head, C. Bennett, C. TI Metastasis of genitourinary tumors to the head and neck region SO EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY LA English DT Article DE Carcinoma of the prostate; Renal cell carcinoma; Transitional cell carcinoma; Genitourinary tumors ID RENAL-CELL CARCINOMA; UROGENITAL TRACT CARCINOMA; PROGNOSTIC FACTORS; PROSTATE-CANCER AB The objective of the present study is to characterize genitourinary tumors (GU) metastatic to the head and neck and to determine long-term prognoses. Using a retrospective chart review of 734 patients treated between January 1995 and May 2005 with an ICD-9 code pertaining to a metastatic head and neck cancer, we found 37 patients with primary GU tumors. There were 24 cases of prostate cancer, 10 cases of renal cell carcinoma, and 4 cases of transitional cell carcinoma. Sixteen of 24 patients (67%) with prostate cancer had a cranial metastasis while 6 of 9 (67%) patients with renal cell carcinoma had cerebral metastasis. We concluded that prolonged survival is possible in prostate cancer patients treated aggressively with radiation and chemotherapy, indicating that early detection and aggressive screening are important in these patients. C1 [Bennett, C.] Greater Los Angeles Healthcare Syst, Dept Urol, Los Angeles, CA 90073 USA. [Ogunyemi, Ore; Rojas, A.; Bennett, C.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Hematpour, K.] Columbia Univ Coll Phys & Surg, Dept Internal Med, St Lukes Roosevelt Hosp, New York, NY 10032 USA. [Rogers, D.] Greater Los Angeles VA Med Ctr, Dept Pathol, Los Angeles, CA USA. [Head, C.] Greater Los Angeles VA Med Ctr, Dept Otolaryngol, Los Angeles, CA USA. [Bennett, C.] Greater Los Angeles VA Med Ctr, Dept Urol, Los Angeles, CA USA. RP Bennett, C (reprint author), Greater Los Angeles Healthcare Syst, Dept Urol, 11301 Wilshire Blvd 10H2, Los Angeles, CA 90073 USA. EM carol.bennett@med.va.gov FU Pfizer FX The authors declare that they have no stated conflicts of interest. Dr. Carol Bennett has a grant from Pfizer. NR 26 TC 5 Z9 6 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0937-4477 J9 EUR ARCH OTO-RHINO-L JI Eur. Arch. Oto-Rhino-Laryn. PD FEB PY 2010 VL 267 IS 2 BP 273 EP 279 DI 10.1007/s00405-009-1006-8 PG 7 WC Otorhinolaryngology SC Otorhinolaryngology GA 537HC UT WOS:000273102900018 PM 19536555 ER PT J AU Vidan, MT Bueno, H Wang, YF Schreiner, G Ross, JS Chen, J Krumholz, HM AF Vidan, Maria T. Bueno, Hector Wang, Yongfei Schreiner, Geoffrey Ross, Joseph S. Chen, Jersey Krumholz, Harlan M. TI The relationship between systolic blood pressure on admission and mortality in older patients with heart failure SO EUROPEAN JOURNAL OF HEART FAILURE LA English DT Article DE Systolic blood pressure; Heart failure; Mortality; Prediction ID PRESERVED EJECTION FRACTION; IN-HOSPITAL MORTALITY; CLINICAL CHARACTERISTICS; RANDOMIZED-TRIAL; UNITED-STATES; RISK; HYPERTENSION; SURVIVAL; ASSOCIATION; PROGRESSION AB To determine the relationship between admission systolic blood pressure (SBP) and mortality in older patients hospitalized for heart failure (HF) and among various subgroups. We evaluated the independent association between initial SBP and 30-day and 1-year mortality, and potential interactions by age, gender, race, previous hypertension, and left ventricular dysfunction using multivariable logistic regression in the National Heart Failure Project, a database of Medicare patients > 65 years old recruited from 1998 through 2001. Among 56 942 patients, mean admission SBP was 147.0 +/- 92.3 mmHg, 15% presenting with SBP > 180 mmHg. Systolic blood pressure showed an inverse relationship with 30-day and 1-year mortality rates in all subgroups analysed. Using admission SBP of 120-149 mmHg as the reference, the adjusted odds ratios (95% confidence intervals) for 1-year mortality were 2.18 (1.77-2.69) for SBP < 90 mmHg, 1.57 (1.47-1.69) for SBP 90-119 mmHg, 0.71 (0.67-0.76) for SBP 150-179 mmHg, 0.63 (0.57-0.68) for SBP 180-209 mmHg, and 0.51 (0.44-0.59) for SBP >= 210 mmHg. Higher SBP on admission is associated with significant lower 30-day and 1-year mortality in patients hospitalized for HF. The relationship is strong, graded, independent of other clinical factors and consistent among subgroups. C1 [Vidan, Maria T.] Hosp Gen Univ Gregorio Maranon, Dept Geriatr Med, Madrid 28007, Spain. [Bueno, Hector] Hosp Gen Univ Gregorio Maranon, Dept Cardiol, Madrid 28007, Spain. [Ross, Joseph S.] Mt Sinai Sch Med, Dept Geriatr & Adult Dev & Med, New York, NY USA. [Ross, Joseph S.] James J Peters Vet Adm Med Ctr, HSR&D Targeted Res Enhancement Program, Bronx, NY USA. [Ross, Joseph S.] James J Peters Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Bronx, NY USA. [Wang, Yongfei; Chen, Jersey; Krumholz, Harlan M.] Yale Univ, Sch Med, Sect Cardiovasc Med, New Haven, CT USA. [Krumholz, Harlan M.] Yale Univ, Sch Med, Dept Robert Wood Johnson Clin Scholars Program, New Haven, CT USA. [Krumholz, Harlan M.] Yale Univ, Sch Med, Dept Med, Sch Publ Hlth, New Haven, CT 06510 USA. [Krumholz, Harlan M.] Yale Univ, Sch Med, Sch Publ Hlth, Sect Hlth Policy & Adm, New Haven, CT 06510 USA. [Schreiner, Geoffrey; Krumholz, Harlan M.] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, New Haven, CT 06504 USA. RP Vidan, MT (reprint author), Hosp Gen Univ Gregorio Maranon, Dept Geriatr Med, Dr Esquerdo 46, Madrid 28007, Spain. EM mvidan.hgugm@salud.madrid.org RI BUENO, HECTOR/I-3910-2015 OI BUENO, HECTOR/0000-0003-0277-7596 FU Fondo de Investigacion Sanitaria del Instituto de Salud Carlos III, Spain [BA08/90012, BA08/90010]; National Institute on Aging [K08 AG032886]; American Federation of Aging Research FX M. T. V. and H. B. were supported in part by grants of the Fondo de Investigacion Sanitaria del Instituto de Salud Carlos III, Spain (BA08/90012 and BA08/90010, respectively) during their stay at the Centre for Outcomes Research and Evaluation, Yale-New Haven Hospital, where they participated in the development of this study. J.S.R. is supported by the National Institute on Aging (K08 AG032886) and by the American Federation of Aging Research through the Paul B. Beeson Career Development Award Program. NR 29 TC 19 Z9 20 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1388-9842 J9 EUR J HEART FAIL JI Eur. J. Heart Fail. PD FEB PY 2010 VL 12 IS 2 BP 148 EP 155 DI 10.1093/eurjhf/hfp195 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 547EN UT WOS:000273868800008 PM 20083624 ER PT J AU Quinn, LS Anderson, BG Strait-Bodey, L Wolden-Hanson, T AF Quinn, LeBris S. Anderson, Barbara G. Strait-Bodey, Lena Wolden-Hanson, Tami TI Serum and muscle interleukin-15 levels decrease in aging mice: Correlation with declines in soluble interleukin-15 receptor alpha expression SO EXPERIMENTAL GERONTOLOGY LA English DT Article DE Aging; Cytokines; IL-15; Skeletal muscle; Sarcopenia; IL-15 receptors; Soluble IL-15 alpha receptor; Body composition ID TUMOR-BEARING RATS; SKELETAL-MUSCLE; BODY-COMPOSITION; FAT MASS; IL-15; AGE; ASSOCIATION; ADIPOCYTES; RESISTANCE; COMPLEXES AB Interleukin-15 (IL-15) is a skeletal muscle-derived cytokine with favorable effects on muscle mass and body composition. Modulation of IL-15 levels has been suggested as a treatment for sarcopenia and age-associated increases in adiposity. However, it is unclear whether IL-15 levels change during aging, as measurement of IL-15 at physiological concentrations in mice has been technically difficult, and translational regulation of IL-15 is complex. Moreover, the IL-15 receptor alpha (IL-15R alpha) can comprise part of a membrane-associated receptor complex, or appear as a soluble form which stabilizes IL-15 and facilitates IL-15 secretion. Here, we report measurement of physiological levels of murine IL-15, and determine that muscle and serum IL-15 levels decline progressively with age. However, expression of IL-15 mRNA and membrane-associated subunits of the IL-15 receptor did not change with age in muscle. Expression of soluble IL-15R alpha (sIL-15R alpha) mRNA declined 5-fold with age, and serum IL-15 levels correlated highly with muscle sIL-15 mRNA expression, suggesting declines in sIL-15R alpha expression lead to decreased circulating IL-15 levels during aging. These findings complement studies which described several single-nucleotide polymorphisms in the human IL-15R alpha gene which impact muscularity and adiposity, and provide a technical basis for further investigation of IL-15 and the sIL-15R alpha in determining body composition in aging mice, as a model for humans. (C) 2009 Elsevier Inc. All rights reserved. C1 [Quinn, LeBris S.] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Amer Lake Div 151, Tacoma, WA 98493 USA. [Quinn, LeBris S.; Anderson, Barbara G.; Wolden-Hanson, Tami] Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA USA. [Strait-Bodey, Lena; Wolden-Hanson, Tami] VA Puget Sound Hlth Care Syst, Res Serv, Seattle, WA USA. RP Quinn, LS (reprint author), VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Amer Lake Div 151, Tacoma, WA 98493 USA. EM quinnL@u.washington.edu FU National Institute on Aging (LSQ) [1101AG024136] FX Supported by NIH Grant #1101AG024136 from the National Institute on Aging (LSQ), and use of resources and facilities at VA Puget Sound Health Care System. NR 36 TC 13 Z9 15 U1 0 U2 3 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0531-5565 J9 EXP GERONTOL JI Exp. Gerontol. PD FEB PY 2010 VL 45 IS 2 BP 106 EP 112 DI 10.1016/j.exger.2009.10.012 PG 7 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 561TW UT WOS:000275003100004 PM 19854259 ER PT J AU Yamuy, J Fung, SJ Xi, MC Chase, MH AF Yamuy, Jack Fung, Simon J. Xi, Mingchu Chase, Michael H. TI State-dependent control of lumbar motoneurons by the hypocretinergic system SO EXPERIMENTAL NEUROLOGY LA English DT Review DE Brainstem; Reticular formation; Spinal cord; Neuropeptides; Narcolepsy; Presynaptic ID PONTINE RETICULAR-FORMATION; EYE-MOVEMENT SLEEP; MELANIN-CONCENTRATING HORMONE; INDUCED MOTOR INHIBITION; CAT MASSETER MOTONEURONS; AMINO-ACID ANTAGONISTS; INDUCED REM-SLEEP; ACTIVE SLEEP; BRAIN-STEM; PARADOXICAL SLEEP AB Neurons in the lateral hypothalamus (LH) that synthesize hypocretins (Hcrt-1 and Hcrt-2) are active during wakefulness and excite lumbar motoneurons. Because hypocretinergic cells also discharge during phasic periods of rapid eye movement (REM) sleep, we sought to examine their action on the activity of motoneurons during this state. Accordingly, cat lumbar motoneurons were intracellularly recorded, under alpha-chloralose anesthesia, prior to (control) and during the carbachol-induced REM sleep-like atonia (REMc). During control conditions, LH Stimulation induced excitatory postsynaptic potentials (composite EPSP) in motoneurons. In contrast, during REMc, identical LH stimulation induced inhibitory PSPs in motoneurons. We then tested the effects of LH stimulation on motoneuron responses following the stimulation of the nucleus reticularis gigantocellularis (NRGc) which is part of a brainstem-spinal cord system that controls motoneuron excitability in a state-dependent manner. LH stimulation facilitated NRGc stimulation-induced composite EPSP during control conditions whereas it enhanced NRGc stimulation-induced IPSPs during REMc. These intriguing data indicate that the LH exerts a state-dependent control of motor activity. As a first step to understand these results, we examined whether hypocretinergic synaptic mechanisms in the spinal cord were state dependent. We found that the juxtacellular application of Hcrt-1 induced motoneuron excitation during control conditions whereas motoneuron inhibition was enhanced during REMc. These data indicate that the hypocretinergic system acts on motoneurons in a state-dependent manner via spinal synaptic mechanisms. Thus, deficits in Hcrt-1 may cause the coexistence of incongruous motor signs in cataplectic patients, such as motor suppression during wakefulness and movement disorders during REM sleep. (C) 2009 Elsevier Inc. All rights reserved. C1 [Yamuy, Jack; Fung, Simon J.; Xi, Mingchu; Chase, Michael H.] WebSci Int, Los Angeles, CA 90024 USA. RP Yamuy, J (reprint author), VA Greater Angeles Healthcare Syst, Los Angeles, CA 90073 USA. EM jyamuy@ucla.edu FU USPHS [MH 43362, NS 09999, NS 23426, AGO 4307, HL 60296] FX The authors thank Oscar Ramos, Andrui Nazarian, and Matthew Fruzza for their valuable technical support and Trent Wenzel for his useful additions to the Axograph analysis package. Supported by USPHS grant nos. MH 43362, NS 09999, NS 23426, AGO 4307, and HL 60296. NR 117 TC 12 Z9 12 U1 1 U2 3 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0014-4886 EI 1090-2430 J9 EXP NEUROL JI Exp. Neurol. PD FEB PY 2010 VL 221 IS 2 BP 335 EP 345 DI 10.1016/j.expneurol.2009.11.020 PG 11 WC Neurosciences SC Neurosciences & Neurology GA 556BD UT WOS:000274560800008 PM 19962375 ER PT J AU Davis, GL Alter, MJ El-Serag, H Poynard, T Jennings, LW AF Davis, Gary L. Alter, Miriam J. El-Serag, Hashem Poynard, Thierry Jennings, Linda W. TI Aging of Hepatitis C Virus (HCV)-Infected Persons in the United States: A Multiple Cohort Model of HCV Prevalence and Disease Progression SO GASTROENTEROLOGY LA English DT Article ID CHRONIC LIVER-DISEASE; NON-B-HEPATITIS; SUSTAINED VIROLOGICAL RESPONSE; HEPATOCELLULAR-CARCINOMA; NATURAL-HISTORY; FIBROSIS PROGRESSION; FOLLOW-UP; NON-A; COMPENSATED CIRRHOSIS; CLINICAL-OUTCOMES AB BACKGROUND & AIMS: The prevalence of chronic hepatitis C (CH-C) remains high and the complications of infection are common. Our goal was to project the future prevalence of CH-C and its complications. METHODS: We developed a multicohort natural history model to overcome limitations of previous models for predicting disease outcomes and benefits of therapy. RESULTS: Prevalence of CH-C peaked in 2001 at 3.6 million. Fibrosis progression was inversely related to age at infection, so cirrhosis and its complications were most common after the age of 60 years, regardless of when infection occurred. The proportion of CH-C with cirrhosis is projected to reach 25% in 2010 and 45% in 2030, although the total number with cirrhosis will peak at 1.0 million (30.5% higher than the current level) in 2020 and then decline. Hepatic decompensation and liver cancer will continue to increase for another 10 to 13 years. Treatment of all infected patients in 2010 could reduce risk of cirrhosis, decompensation, cancer, and liver-related deaths by 16%, 42%, 31%, and 36% by 2020, given current response rates to antiviral therapy. CONCLUSIONS: Prevalence of hepatitis C cirrhosis and its complications will continue to increase through the next decade and will mostly affect those older than 60 years of age. Current treatment patterns will have little effect on these complications, but wider application of antiviral treatment and better responses with new agents could significantly reduce the impact of this disease in coming years. C1 [Davis, Gary L.; Jennings, Linda W.] Baylor Univ, Med Ctr, Div Hepatol, Dallas, TX 75246 USA. [Davis, Gary L.; Jennings, Linda W.] Baylor Reg Transplant Inst, Dallas, TX USA. Univ Texas Med Branch, Infect Dis Epidemiol Program, Galveston, TX USA. [El-Serag, Hashem] Baylor Coll Med, Houston, TX 77030 USA. [El-Serag, Hashem] Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. [Poynard, Thierry] Univ Paris 06, Ctr Liver, AP HP, Paris, France. RP Davis, GL (reprint author), Baylor Univ, Med Ctr, Div Hepatol, 4 Roberts,3500 Gaston Ave, Dallas, TX 75246 USA. EM GaryDav@BaylorHealth.edu OI Poynard, Thierry/0000-0002-2050-640X FU Vertex Pharmaceutical Inc. FX Sponsored by an unrestricted grant from Vertex Pharmaceutical Inc. NR 67 TC 471 Z9 478 U1 6 U2 28 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD FEB PY 2010 VL 138 IS 2 BP 513 EP U141 DI 10.1053/j.gastro.2009.09.067 PG 15 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 552OB UT WOS:000274300900019 PM 19861128 ER PT J AU Weinberg, BM Spiegel, BMR Tomlinson, JS Farrell, JJ AF Weinberg, Benjamin M. Spiegel, Brennan M. R. Tomlinson, James S. Farrell, James J. TI Asymptomatic Pancreatic Cystic Neoplasms: Maximizing Survival and Quality of Life Using Markov-Based Clinical Nomograms SO GASTROENTEROLOGY LA English DT Article ID PAPILLARY MUCINOUS NEOPLASMS; BRANCH DUCT TYPE; PYLORUS-PRESERVING PANCREATICODUODENECTOMY; RANDOMIZED CONTROLLED-TRIAL; FINE-NEEDLE-ASPIRATION; LONG-TERM SURVIVAL; INTRADUCTAL PAPILLARY; FOLLOW-UP; SURGICAL RESECTION; WHIPPLE RESECTION AB BACKGROUND & AIMS: The natural history and management of pancreatic cysts, especially for branch duct intraductal papillary mucinous neoplasms (BD-IPMNs), remain uncertain. We developed evidence-based nomograms to assist with clinical decision making. METHODS: We used decision analysis with Markov modeling to compare competing management strategies in a patient with a pancreatic head cyst radiographically suggestive of BD-IPMN, including the following: (1) initial pancreaticoduodenectomy (PD), (2) yearly noninvasive radiographic surveillance, (3) yearly invasive surveillance with endoscopic ultrasound, and (4) "do nothing." We derived probability estimates from a systematic literature review. The primary outcomes were overall and quality-adjusted survival. We depicted the results in a series of nomograms accounting for age, comorbidities, and cyst size. RESULTS: Initial PD was the dominant strategy to maximize overall survival for any cyst greater than 2 cm, regardless of age or comorbidities. In contrast, surveillance was the dominant strategy for any lesion less than 1 cm. However, when measuring quality-adjusted survival, the do-nothing approach maximized quality of life for all cysts less than 3 cm in patients younger than age 75. Once age exceeded 85 years, noninvasive surveillance dominated. Initial PD did not maximize quality of life in any age group or cyst size. CONCLUSIONS: Management of pancreatic cysts can be guided using novel Markov-based clinical nomograms, and depends on age, cyst size, comorbidities, and whether patients value overall survival vs quality-adjusted survival. For patients focused on overall survival, regardless of quality of life, surgery is optimal for lesions greater than 2 cm. For patients focused on quality-adjusted survival, a 3-cm threshold is more appropriate for surgery except for the extreme elderly. C1 [Spiegel, Brennan M. R.; Farrell, James J.] Univ Calif Los Angeles, VA Ctr Outcomes Res & Educ, Los Angeles, CA 90073 USA. [Weinberg, Benjamin M.; Spiegel, Brennan M. R.; Farrell, James J.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Gastroenterol, Los Angeles, CA 90073 USA. [Tomlinson, James S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Weinberg, Benjamin M.; Spiegel, Brennan M. R.; Farrell, James J.] Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Los Angeles, CA 90073 USA. [Tomlinson, James S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90073 USA. [Spiegel, Brennan M. R.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Serv, Los Angeles, CA 90073 USA. RP Farrell, JJ (reprint author), Univ Calif Los Angeles, VA Ctr Outcomes Res & Educ, 11301 Wilshire Blvd,Bldg 115,Room 215, Los Angeles, CA 90073 USA. EM bspiegel@mednet.ucla.edu; JFarrell@mednet.ucla.edu FU Veteran's Affairs Health Services Research [RCD 03-179-2]; National Institutes of Health [2P30 DK 041301-17] FX Dr Spiegel is supported by a Veteran's Affairs Health Services Research and Development Career Development Transition Award (RCD 03-179-2), and by the CURE Digestive Disease Research Center (National Institutes of Health 2P30 DK 041301-17); Dr Farrell is supported by a National Institutes of Health K12 Career Development Award. NR 79 TC 46 Z9 47 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD FEB PY 2010 VL 138 IS 2 BP 531 EP 540 DI 10.1053/j.gastro.2009.10.001 PG 10 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 552OB UT WOS:000274300900021 PM 19818780 ER PT J AU Chan, ED Iseman, MD AF Chan, Edward D. Iseman, Michael D. TI Slender, Older Women Appear to Be More Susceptible to Nontuberculous Mycobacterial Lung Disease SO GENDER MEDICINE LA English DT Editorial Material DE nontuberculous mycobacteria; leptin; estrogen; fat ID GROWTH-FACTOR-BETA; RAPIDLY GROWING MYCOBACTERIA; INTERFERON-GAMMA PRODUCTION; NECROSIS-FACTOR-ALPHA; AVIUM COMPLEX; PULMONARY TUBERCULOSIS; CYTOKINE PRODUCTION; TNF-ALPHA; TGF-BETA; MACROPHAGE APOPTOSIS AB Background: Nontuberculous mycobacteria (NTM) are environmental microbes that are associated with a variety of human diseases, particularly chronic lung infections. Over the past several decades, NTM lung disease has been increasingly seen in postmenopausal women with slender body habitus. Objective: This article reviewed the clinical and experimental evidence that supports the observation that thin older women (aged 50-80 years) are predisposed to NTM lung disease. We posited 3 potential pathways for this predisposition: relative estrogen deficiency, abnormal levels of adipokines that alter immune responses, and abnormal expression of transforming growth factor-beta (TGF-beta) related to fibrillin anomalies similar to Marfan syndrome (MFS). Methods: Using the PubMed database, a literature search was performed (all publications up to July 2009) by pairing the key phrase nontuberculous mycobacteria with weight, malnutrition, female gender, body habitus, leptin, adipokines, estrogen, menopause, postmenopausal, or body mass index. Non-English-language articles were included if their abstracts were in English. Relevant articles were also identified from the abstracts. Results: Published case reports and series indicate that in the past 20 years, NTM lung disease has been recognized in disproportionately increased numbers in postmenopausal women. Among these patients, slender body habitus and thoracic cage abnormalities, such as pectus excavatum and scoliosis, are commonly described. Notably, no long-term prospective clinical studies exist to corroborate that low weight is an independent risk factor for NTM lung disease. However, based on the findings of a limited number of experimental studies, we hypothesize that decreased leptin, increased adiponectin, and/or decreased estrogen in older women with slender body habitus may account for their increased susceptibility to NTM infections. We further speculate that in some patients with features mindful of MFS (slender, scoliosis, pectus excavatum, or mitral valve prolapse), there may be anomalies of fibrillin, similar to MFS, that lead to the expression of the immunosuppressive cytokine TGF-beta, further increasing their susceptibility to NTM. Conclusions: It is likely that both sufficient environmental exposure and host susceptibility are required for the establishment of NTM lung disease. The observation that NTM lung infections are more common in slender, older women without any overt immune defects suggests that abnormal expression of adipokines, sex hormones, and/or TGF-beta may play an important role in their susceptibility. (Gend Med. 2010;7:5-18) (C) 2010 Excerpta Medica Inc. C1 [Chan, Edward D.; Iseman, Michael D.] Natl Jewish Hlth, Dept Med, Denver, CO 80206 USA. [Chan, Edward D.] Natl Jewish Hlth, Cell Biol Program, Denver, CO 80206 USA. [Chan, Edward D.] Denver Vet Affairs Med Ctr, Denver, CO USA. [Chan, Edward D.; Iseman, Michael D.] Univ Colorado, Div Pulm Sci & Crit Care Med, Denver, CO 80202 USA. [Chan, Edward D.; Iseman, Michael D.] Univ Colorado, Hlth Sci Ctr, Denver, CO USA. RP Chan, ED (reprint author), Natl Jewish Hlth, Dept Med, K720 Goodman Bldg,1400 Jackson St, Denver, CO 80206 USA. EM chane@njhealth.org NR 74 TC 25 Z9 25 U1 1 U2 2 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 1550-8579 J9 GENDER MED JI Gend. Med. PD FEB PY 2010 VL 7 IS 1 BP 5 EP 18 DI 10.1016/j.genm.2010.01.005 PG 14 WC Medicine, General & Internal SC General & Internal Medicine GA 567VS UT WOS:000275475600003 PM 20189150 ER PT J AU Rose, DE Tisnado, DM Malin, JL Tao, ML Maggard, MA Adams, J Ganz, PA Kahn, KL AF Rose, Danielle E. Tisnado, Diana M. Malin, Jennifer L. Tao, May L. Maggard, Melinda A. Adams, John Ganz, Patricia A. Kahn, Katherine L. TI Use of Interpreters by Physicians Treating Limited English Proficient Women with Breast Cancer: Results from the Provider Survey of the Los Angeles Women's Health Study SO HEALTH SERVICES RESEARCH LA English DT Article DE Physician survey; limited English proficient patients; interpreters; breast cancer care ID QUALITY-OF-CARE; LANGUAGE BARRIERS; UNITED-STATES; PATIENT CHARACTERISTICS; MEDICAL INTERPRETATION; SERVICES; IMPACT; COMMUNICATION; SATISFACTION; ACCESS AB Objective Little is known about how cancer physicians communicate with limited English proficient (LEP) patients. We studied physician-reported use and availability of interpreters. Data Sources A 2004 survey was fielded among physicians identified by a population-based sample of breast cancer patients. Three hundred and forty-eight physicians completed mailed surveys (response rate: 77 percent) regarding the structure and organization of care. Study Design and Settings We used logistic regression to analyze use and availability of interpreters. Principal Findings Most physicians reported treating LEP patients. Among physicians using interpreters within the last 12 months, 42 percent reported using trained medical interpreters, 21 percent telephone interpreter services, and 75 percent reported using untrained interpreters to communicate with LEP patients. Only one-third of physicians reported good availability of trained medical interpreters or telephone interpreter services when needed. Compared with HMO physicians, physicians in solo practice and single-specialty medical groups were less likely to report using trained medical interpreters or telephone interpreter services, and they were less likely to report good availability of these services. Conclusions There were important practice setting differences predicting use and availability of trained medical interpreters and telephone interpretation services. These findings may have troubling implications for effective physician-patient communication critically needed during cancer treatment. C1 [Rose, Danielle E.] VA Greater Los Angeles Healthcare Syst, VAHSR&D Ctr Study Healthcare Provider Behav, Sepulveda, CA 91343 USA. [Tisnado, Diana M.; Kahn, Katherine L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA. [Tao, May L.] E Bay Partners Canc Care, Antioch, CA USA. [Maggard, Melinda A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Div Canc Prevent & Control Res,Sch Publ Hlth, Los Angeles, CA 90095 USA. [Ganz, Patricia A.] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Sch Publ Hlth, Los Angeles, CA 90024 USA. [Adams, John; Kahn, Katherine L.] RAND Corp, Santa Monica, CA USA. RP Rose, DE (reprint author), VA Greater Los Angeles Healthcare Syst, VAHSR&D Ctr Study Healthcare Provider Behav, 16111 Plummer St 152, Sepulveda, CA 91343 USA. EM droseash@gmail.com FU UCLA Cancer Education and Career Development Program; National Cancer Institute [R25 CA087949]; U.S. Department of Defense Breast Cancer Research Program Postdoctoral [DAMD17-03-1-0328]; University of California Los Angeles Resource Center for Minority Aging Research/Center for Health Improvement of Minority Elderly (RCMAR/CHIME) NIH/NIA [P30-AG021684]; California Breast Cancer Research [7PB-0126S]; National Cancer Institute and the Agency for Health Care Research and Quality [1-R01-CA81338-01A1] FX Joint Acknowledgment/Disclosure Statement: Dr. Rose received support from the UCLA Cancer Education and Career Development Program, National Cancer Institute grant R25 CA087949. Dr. Tisnado received support from a U.S. Department of Defense Breast Cancer Research Program Postdoctoral Award DAMD17-03-1-0328 and The University of California Los Angeles Resource Center for Minority Aging Research/Center for Health Improvement of Minority Elderly (RCMAR/CHIME) NIH/NIA grant P30-AG021684. This research was funded by the California Breast Cancer Research program grant 7PB-0126S and the National Cancer Institute and the Agency for Health Care Research and Quality grant 1-R01-CA81338-01A1. We thank the two anonymous referees for suggestions that significantly strengthened the analysis. Disclosure: None. Disclaimer: The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States Government. NR 53 TC 7 Z9 7 U1 3 U2 8 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0017-9124 J9 HEALTH SERV RES JI Health Serv. Res. PD FEB PY 2010 VL 45 IS 1 BP 172 EP 194 DI 10.1111/j.1475-6773.2009.01057.x PG 23 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 541YC UT WOS:000273456400011 PM 19878346 ER PT J AU Justice, AC McGinnis, KA Skanderson, M Chang, CC Gibert, CL Goetz, MB Rimland, D Rodriguez-Barradas, MC Oursler, KK Brown, ST Braithwaite, RS May, M Covinsky, KE Roberts, MS Fultz, SL Bryant, KJ AF Justice, A. C. McGinnis, K. A. Skanderson, M. Chang, C. C. Gibert, C. L. Goetz, M. B. Rimland, D. Rodriguez-Barradas, M. C. Oursler, K. K. Brown, S. T. Braithwaite, R. S. May, M. Covinsky, K. E. Roberts, M. S. Fultz, S. L. Bryant, K. J. CA VACS Project Team TI Towards a combined prognostic index for survival in HIV infection: the role of 'non-HIV' biomarkers SO HIV MEDICINE LA English DT Article DE anaemia; CD4 cell count; hepatitis C coinfection; hepatology; injecting drug use; outcomes; renal; kidney; risk groups; viral load ID ACTIVE ANTIRETROVIRAL THERAPY; SURROGATE END-POINTS; INTENSIVE-CARE-UNIT; COLLABORATIVE ANALYSIS; HIV-1-INFECTED PATIENTS; PROSPECTIVE COHORT; CLINICAL-TRIALS; LIVER-DISEASE; MORTALITY; VETERANS AB Background As those with HIV infection live longer, 'non-AIDS' condition associated with immunodeficiency and chronic inflammation are more common. We ask whether 'non-HIV' biomarkers improve differentiation of mortality risk among individuals initiating combination antiretroviral therapy (cART). Methods Using Poisson models, we analysed data from the Veterans Aging Cohort Study (VACS) on HIV-infected veterans initiating cART between 1 January 1997 and 1 August 2002. Measurements included: HIV biomarkers (CD4 cell count, HIV RNA and AIDS-defining conditions); 'non-HIV' biomarkers (haemoglobin, transaminases, platelets, creatinine, and hepatitis B and C serology); substance abuse or dependence (alcohol or drug); and age. Outcome was all cause mortality. We tested the discrimination (C statistics) of each biomarker group alone and in combination in development and validation data sets, over a range of survival intervals, and adjusting for missing data. Results Of veterans initiating cART, 9784 (72%) had complete data. Of these, 2566 died. Subjects were middle-aged (median age 45 years), mainly male (98%) and predominantly black (51%). HIV and 'non-HIV' markers were associated with each other (P < 0.0001) and discriminated mortality (C statistics 0.68-0.73); when combined, discrimination improved (P < 0.0001). Discrimination for the VACS Index was greater for shorter survival intervals [30-day C statistic 0.86, 95% confidence interval (CI) 0.80-0.91], but good for intervals of up to 8 years (C statistic 0.73, 95% CI 0.72-0.74). Results were robust to adjustment for missing data. Conclusions When added to HIV biomarkers, 'non-HIV' biomarkers improve differentiation of mortality. When evaluated over similar intervals, the VACS Index discriminates as well as other established indices. After further validation, the VACS Index may provide a useful, integrated risk assessment for management and research. C1 [Justice, A. C.] Yale Univ, Sch Med, Dept Internal Med, West Haven, CT 06516 USA. [Justice, A. C.; Braithwaite, R. S.] VA Connecticut Healthcare Syst, Gen Internal Med Sect, West Haven, CT USA. [McGinnis, K. A.] Univ Pittsburgh, Ctr Social & Urban Res, Pittsburgh, PA USA. [Skanderson, M.] Pittsburgh VA Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Chang, C. C.; Roberts, M. S.] Univ Pittsburgh, Sch Med, Sect Decis Sci & Clin Syst Modeling, Pittsburgh, PA USA. [Gibert, C. L.] George Washington Univ, Med Ctr, VA Med Ctr, Washington, DC 20037 USA. [Goetz, M. B.] Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90095 USA. [Rimland, D.] Emory Univ, Sch Med, Atlanta, GA USA. [Rimland, D.] VA Med Ctr, Atlanta, GA USA. [Rodriguez-Barradas, M. C.] Baylor Coll Med, Michael E DeBakey VA Med Ctr, Houston, TX 77030 USA. [Oursler, K. K.] Univ Maryland, Sch Med, Baltimore VA Med Ctr, Baltimore, MD 21201 USA. [Brown, S. T.] James J Peters VA Med Ctr, Bronx, NY USA. [Brown, S. T.] Mt Sinai Sch Med, New York, NY USA. [May, M.] Univ Bristol, Dept Social Med, Bristol, Avon, England. [Covinsky, K. E.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Covinsky, K. E.] San Francisco VA Med Ctr, San Francisco, CA USA. [Fultz, S. L.] US Dept Vet Affairs, Vet Hlth Adm, Off Publ Hlth & Environm Hazards, Washington, DC USA. [Bryant, K. J.] NIAAA, Bethesda, MD USA. RP Justice, AC (reprint author), Yale Univ, Sch Med, Dept Internal Med, 950 Campbell Ave,11 ACSL,Bldg 35A,2nd Fl,Rm 212, West Haven, CT 06516 USA. EM amy.justice2@va.gov RI May, Margaret/E-8099-2013; Andrade, Hugo/M-6631-2013 OI May, Margaret/0000-0002-9733-1003; Andrade, Hugo/0000-0001-6781-6125; Goetz, Matthew/0000-0003-4542-992X FU National Institute on Alcohol Abuse and Alcoholism [2U10 AA 13566] FX This study was funded by the National Institute on Alcohol Abuse and Alcoholism (2U10 AA 13566). NR 52 TC 77 Z9 77 U1 1 U2 3 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1464-2662 J9 HIV MED JI HIV Med. PD FEB PY 2010 VL 11 IS 2 BP 143 EP 151 DI 10.1111/j.1468-1293.2009.00757.x PG 9 WC Infectious Diseases SC Infectious Diseases GA 540CS UT WOS:000273309000007 PM 19751364 ER PT J AU Gurubhagavatula, I AF Gurubhagavatula, Indira TI Consequences of obstructive sleep apnoea SO INDIAN JOURNAL OF MEDICAL RESEARCH LA English DT Review DE Day time sleepiness; health care cost; obstructive sleep apnoea; quality of life; traffic accidents; vigilence ID HEALTH-CARE UTILIZATION; QUALITY-OF-LIFE; POSITIVE AIRWAYS PRESSURE; MOTOR-VEHICLE CRASHES; LATENCY TEST MSLT; AUTOMOBILE ACCIDENTS; COMMERCIAL DRIVERS; DAYTIME SLEEPINESS; COGNITIVE FUNCTION; WAKEFULNESS TEST AB A plethora of medical consequences have been associated with the syndrome of obstructive sleep apnoea (OSA). These are global, affecting nearly every body function, and have been related to two key pathophysiological findings in sleep apnoea: repetitive falls in oxyhaemoglobin saturation during sleep, and recurrent arousals from sleep which terminate apnoea episodes. Sufferers of OSA may experience daytime sleepiness, which has been measured both subjectively using the Epworth Sleepiness Scale and the Stanford Sleepiness Scale, but also objectively, using Multiple Sleep Latency Testing, Maintenance of Wakefulness testing, and the Oxford Sleep Resistance test. In addition to the loss of alertness, sleep apnoea contributes to memory deficits, reduced vigilance, impaired executive function, increased risk for automobile and occupational accidents, and decreased quality of life. Importantly, afflicted individuals experience improvements in these outcomes with treatment. Taken together, this evidence forms a compelling basis to identify and treat latent cases of sleep apnoea. Not only do patients have the opportunity to achieve improvements in these outcomes and health-related quality of life, but the enormous economic burden that untreated apnoea imposes on the health care system may be eased. C1 [Gurubhagavatula, Indira] Univ Penn, Med Ctr, Ctr Sleep & Resp Neurobiol, Philadelphia, PA 19104 USA. [Gurubhagavatula, Indira] Univ Penn, Med Ctr, Div Sleep Med, Philadelphia, PA 19104 USA. [Gurubhagavatula, Indira] Philadelphia VA Med Ctr, Pulm & Crit Care & Sleep Sect, Philadelphia, PA USA. RP Gurubhagavatula, I (reprint author), Univ Penn, Med Ctr, Ctr Sleep & Resp Neurobiol, 3624 Market St,Suite 205, Philadelphia, PA 19104 USA. EM gurubhag@mail.med.upenn.edu NR 49 TC 11 Z9 12 U1 1 U2 3 PU INDIAN COUNCIL MEDICAL RES PI NEW DELHI PA PO BOX 4911 ANSARI NAGAR, NEW DELHI 110029, INDIA SN 0971-5916 J9 INDIAN J MED RES JI Indian J. Med. Res. PD FEB PY 2010 VL 131 IS 2 SI SI BP 188 EP 195 PG 8 WC Immunology; Medicine, General & Internal; Medicine, Research & Experimental SC Immunology; General & Internal Medicine; Research & Experimental Medicine GA 569XD UT WOS:000275635200010 PM 20308744 ER PT J AU Steinhauer, SR Condray, R AF Steinhauer, Stuart R. Condray, Ruth TI Psychophysiology of language processes in psychopathology: An overview of the special issue SO INTERNATIONAL JOURNAL OF PSYCHOPHYSIOLOGY LA English DT Editorial Material ID BRAIN POTENTIALS; RESPONSES; STIMULI C1 [Steinhauer, Stuart R.; Condray, Ruth] Univ Pittsburgh, Sch Med, Dept Psychiat, VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15260 USA. RP Steinhauer, SR (reprint author), Univ Pittsburgh, Sch Med, Dept Psychiat, VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15260 USA. EM sthauer@pitt.edu FU NIMH NIH HHS [R01 MH055762-11, R01 MH050631, MH50631, R01 MH055762]; PHS HHS [55762] NR 13 TC 0 Z9 0 U1 1 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0167-8760 J9 INT J PSYCHOPHYSIOL JI Int. J. Psychophysiol. PD FEB PY 2010 VL 75 IS 2 SI SI BP 63 EP 65 DI 10.1016/j.ijpsycho.2009.12.009 PG 3 WC Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental SC Psychology; Neurosciences & Neurology; Physiology GA 570TK UT WOS:000275700800001 PM 20034522 ER PT J AU Siegle, GJ Condray, R Thase, ME Keshavan, M Steinhauer, SR AF Siegle, Greg J. Condray, Ruth Thase, Michael E. Keshavan, Matcheri Steinhauer, Stuart R. TI Sustained gamma-band EEG following negative words in depression and schizophrenia SO INTERNATIONAL JOURNAL OF PSYCHOPHYSIOLOGY LA English DT Review DE Depression; Schizophrenia; Emotion; Gamma; EEG; Rumination ID FREQUENCY CORTICAL RESPONSES; AFFECTIVE REACTIVITY; EMOTIONAL INFORMATION; UNIPOLAR DEPRESSION; MOOD; STIMULI; FMRI; OSCILLATIONS; MEMORY; BRAIN AB Introduction: Sustained and elaborative emotional information processing in depression and decreased affective elaboration in schizophrenia are considered hallmarks of these disorders but have not been directly measured. Gamma-band (35-45 Hz) EEG has been associated with semantic functions such as feature binding and may index these elaborative processing. This study examined whether there were group differences in baseline and sustained gamma-band EEG following emotional stimuli in healthy adults as well as adults with depression and schizophrenia. Methods: 24 never-depressed healthy controls, 14 patients with DSM-IV unipolar major depressive disorder, and 15 patients with DSM-IV schizophrenia completed a lexical emotion identification task during EEG assessment. Gamma-band (35-45 Hz) EEG in response to negative words was the primary dependent measure. Results: As predicted, depressed individuals displayed sustained and increased gamma-band EEG throughout the task, and particularly in the seconds following negative words. Individuals with schizophrenia displayed decreased gamma-band activity throughout the task. Conclusions: These data suggest that gamma-band EEG, measured over several seconds, may serve as a useful index of sustained semantic information processing. Depressed individuals appear to engage in sustained elaboration following emotional stimuli, whereas individuals with schizophrenia are not as prone to this type of elaborative processing. (C) 2009 Published by Elsevier B.V. C1 [Siegle, Greg J.; Condray, Ruth; Thase, Michael E.; Keshavan, Matcheri; Steinhauer, Stuart R.] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA. [Steinhauer, Stuart R.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Siegle, GJ (reprint author), Western Psychiat Inst & Clin, 3811 OHara St, Pittsburgh, PA 15213 USA. EM gsiegle@pitt.edu FU NARSAD; Veteran's Research Foundation [MH30915, MH58356, MH60473]; [MH50631]; [MH64159] FX Supported by MH50631, NARSAD, MH64159, the Veteran's Research Foundation MH30915, MH58356, and MH60473. NR 57 TC 13 Z9 13 U1 3 U2 9 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0167-8760 J9 INT J PSYCHOPHYSIOL JI Int. J. Psychophysiol. PD FEB PY 2010 VL 75 IS 2 SI SI BP 107 EP 118 DI 10.1016/j.ijpsycho.2008.04.008 PG 12 WC Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental SC Psychology; Neurosciences & Neurology; Physiology GA 570TK UT WOS:000275700800006 PM 20005267 ER PT J AU Condray, R Siegle, GJ Keshavan, MS Steinhauer, SR AF Condray, Ruth Siegle, Greg J. Keshavan, Matcheri S. Steinhauer, Stuart R. TI Effects of word frequency on semantic memory in schizophrenia: Electrophysiological evidence for a deficit in linguistic access SO INTERNATIONAL JOURNAL OF PSYCHOPHYSIOLOGY LA English DT Review DE N400; Semantic relatedness; Word frequency; Schizophrenia; Atypical antipsychotics ID ACETYLCHOLINE-RECEPTOR AVAILABILITY; ALZHEIMERS-DISEASE; ATYPICAL ANTIPSYCHOTICS; PREFRONTAL CORTEX; BRAIN POTENTIALS; IMPAIRMENT; KNOWLEDGE; DISORDER; LANGUAGE; STORAGE AB Background: Abnormal storage and/or access are among the hypothesized causes of semantic memory deficit in schizophrenia. Neuropsychological and connectionist models have emphasized functional systems that serve the processing of word meaning and frequency: semantic storage disturbance is presumed to result from weak representations of word meaning; defective access is assumed to result from compromises to pathways that activate word frequency knowledge. Candidate biological systems include neuromodulatory pathways that normally function to enhance neural signals (e.g., cholinergic system). Electrophysiological responding may be informative regarding the storage-access distinction for schizophrenia. Methods: Visual event-related potentials were recorded for 14 schizophrenia outpatients receiving atypical antipsychotics, and 14 healthy controls group-matched to patients on age, gender, and demographics. N400 was elicited using an incidental semantic priming paradigm, in which semantic relatedness and word frequency were varied, and a letter probe task. Results: Compared to controls, patients showed reduced N400 (mu V) discrimination of semantic relatedness. Groups also showed different patterns of N400 to word frequency. Controls' N400 increased in negativity as words decreased in frequency of occurrence, while patients did not show a linear relationship between N400 and word frequency. Groups also differed for N400 to frequently occurring words. Patients exhibited increased negativity to high and very high frequency words, compared to controls. A subgroup of patients receiving antipsychotics with known affinity binding for muscarinic receptors (clozapine and olanzapine) showed significant albeit limited N400 priming, but their N400 to word frequency remained nonsignificant. Conclusions: Results suggest a deficit in semantic access for schizophrenia, as well as an influence of neuromodulators on the activation of connections among semantic representations. Cumulative findings indicating only limited N400 priming for patients receiving either typical or atypical antipsychotics support the hypothesis that semantic memory deficit represents a trait marker for schizophrenia. (C) 2009 Elsevier B.V. All rights reserved. C1 [Condray, Ruth; Siegle, Greg J.; Keshavan, Matcheri S.; Steinhauer, Stuart R.] Univ Pittsburgh, Sch Med, Dept Psychiat, Western Psychiat Inst & Clin, Pittsburgh, PA 15213 USA. [Steinhauer, Stuart R.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15206 USA. [Keshavan, Matcheri S.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Psychiat, Boston, MA 02215 USA. RP Condray, R (reprint author), 3811 OHara St, Pittsburgh, PA 15213 USA. EM condrayr@upmc.edu FU National Institute of Mental Health [MH50631, MH55762, MH64023] FX This research was supported by the National Institute of Mental Health (MH50631 (RC), MH55762 (SRS), and MH64023 (MSK)), and with resources and use of facilities at Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine. We are grateful to the patients who served as study participants. We are also grateful to a number of individuals who made valuable contributions to the study, including Debra Montrose, Ph.D., and the clinical and nursing staff of Western Psychiatric Institute and Clinic. Sincere thanks to Gregory A. Miller, Ph.D., for providing software for correction of eye movement artifacts, and to Patricia Carpenter, Ph.D., Daniel P. van Kammen, M.D., Ph.D., and William P. Wallace, Ph.D., for their generosity during discussions with the first author (R.C.) regarding study design and analytic approaches. Technical support was provided by Elisa LaDonne, M.Ed., Vince Penkrot, M.S., Carole Turocy, M.S.W., and jean Turocy, B.S. NR 76 TC 15 Z9 15 U1 1 U2 6 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0167-8760 J9 INT J PSYCHOPHYSIOL JI Int. J. Psychophysiol. PD FEB PY 2010 VL 75 IS 2 SI SI BP 141 EP 156 DI 10.1016/j.ijpsycho.2009.10.010 PG 16 WC Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental SC Psychology; Neurosciences & Neurology; Physiology GA 570TK UT WOS:000275700800010 PM 19896508 ER PT J AU Dale, CL Findlay, AM Adcock, RA Vertinski, M Fisher, M Genevsky, A Aldebot, S Subramaniam, K Luks, TL Simpson, GV Nagarajan, SS Vinogradov, S AF Dale, Corby L. Findlay, Anne M. Adcock, R. Alison Vertinski, Mary Fisher, Melissa Genevsky, Alexander Aldebot, Stephanie Subramaniam, Karuna Luks, Tracy L. Simpson, Gregory V. Nagarajan, Srikantan S. Vinogradov, Sophia TI Timing is everything: Neural response dynamics during syllable processing and its relation to higher-order cognition in schizophrenia and healthy comparison subjects SO INTERNATIONAL JOURNAL OF PSYCHOPHYSIOLOGY LA English DT Review DE Schizophrenia; MEG; Auditory processing; Linguistic perception; M100; Voice onset time; Place of articulation; Second syllable attenuation ID MISMATCH NEGATIVITY; LEARNING-PROBLEMS; SPEECH-PERCEPTION; LANGUAGE LATERALIZATION; AUDITORY DYSFUNCTION; EVOKED-POTENTIALS; MAGNETIC-FIELDS; VERBAL MEMORY; HUMAN-BRAIN; DEFICITS AB Successful linguistic processing requires efficient encoding of successively-occurring auditory input in a time-constrained manner, especially under noisy conditions. In this study we examined the early neural response dynamics to rapidly-presented successive syllables in schizophrenia participants and healthy comparison subjects, and investigated the effects of noise on these responses. We used magnetoencephalography (MEG) to reveal the time-course of stimulus-locked activity over bilateral auditory cortices during discrimination of syllable pairs that differed either in voice onset time (VOT) or place of articulation (POA), in the presence or absence of noise. We also examined the association of these early neural response patterns to higher-order cognitive functions. The M100 response, arising from auditory cortex and its immediate environs, showed less attenuation to the second syllable in patients with schizophrenia than healthy comparison subjects during VOT-based discrimination in noise. M100 response amplitudes were similar between groups for the first syllable during all three discrimination conditions, and for the second syllable during VOT-based discrimination in quiet and POA-based discrimination in noise. Across subjects, the lack of M100 attenuation to the second syllable during VOT-based discrimination in noise was associated with poorer task accuracy, lower education and IQ and lower scores on measures of Verbal Learning and Memory and Global Cognition. Because the neural response to the first syllable was not significantly different between groups, nor was a schizophrenia-related difference obtained in all discrimination tasks, early linguistic processing dysfunction in schizophrenia does not appear to be due to general sensory input problems. Rather, data suggest that faulty temporal integration occurs during successive syllable processing when the signal-to-noise ratio is low. Further, the neural mechanism by which the second syllable is suppressed during noise-challenged VOT discrimination appears to be important for higher-order cognition and provides a promising target for neuroscience-guided cognitive training approaches to schizophrenia. Published by Elsevier B.V. C1 [Vinogradov, Sophia] San Francisco VA Med Ctr, Mental Hlth Serv, San Francisco, CA USA. [Dale, Corby L.; Findlay, Anne M.; Luks, Tracy L.; Simpson, Gregory V.; Nagarajan, Srikantan S.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA. [Adcock, R. Alison] Duke Univ, Dept Psychiat, Durham, NC 27706 USA. [Adcock, R. Alison] Duke Univ, Ctr Cognit Neurosci, Durham, NC 27706 USA. [Dale, Corby L.; Fisher, Melissa; Vinogradov, Sophia] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. RP Vinogradov, S (reprint author), San Francisco VA Med Ctr, Mental Hlth Serv, San Francisco, CA USA. EM Sophia.vinogradov@ucsf.edu FU NIH [MH068725, R01 DC4855, R01 DC6435] FX We would like to thank Leighton Hinkley, Alexander B. Herman, Kasra Khatibi, and Darren Weber for their help with the analysis and presentation of this research. This project was supported with resources and the use of facilities at the San Francisco VA Medical Center, San Francisco, CA, and by NIH RO1 grant MH068725 to SM. and NIH R01 DC4855 and DC6435 to S.S.N. NR 74 TC 23 Z9 23 U1 1 U2 10 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0167-8760 J9 INT J PSYCHOPHYSIOL JI Int. J. Psychophysiol. PD FEB PY 2010 VL 75 IS 2 SI SI BP 183 EP 193 DI 10.1016/j.ijpsycho.2009.10.009 PG 11 WC Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental SC Psychology; Neurosciences & Neurology; Physiology GA 570TK UT WOS:000275700800014 PM 19879305 ER PT J AU Yin, MT Lu, DL Cremers, S Tien, PC Cohen, MH Shi, QH Shane, E Golub, ET Anastos, K AF Yin, Miehael T. Lu, Dalian Cremers, Serge Tien, Phyllis C. Cohen, Mardge H. Shi, Qiuhu Shane, Elizabeth Golub, Elizabeth T. Anastos, Kathryn TI Short-Term Bone Loss in HIV-Infected Premenopausal Women SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE bone density; bone loss; bone turnover markers; HIV; osteoporosis; premenopausal women ID ACTIVE ANTIRETROVIRAL THERAPY; IMMUNODEFICIENCY-VIRUS-INFECTION; KAPPA-B LIGAND; MINERAL DENSITY; RECEPTOR ACTIVATOR; OSTEOPROTEGERIN; ASSOCIATION; MARKERS; WEIGHT; SYSTEM AB Background: Low bone mineral density (BMD) has been reported in HIV+ women, but less is known about the longitudinal evolution of BMD and fracture incidence. Methods: In 100 HIV+ and 68 HIV- premenopausal women in the Women's Interagency HIV Study, BMD was measured by dual energy x-ray absorptiometry at the femoral neck (FN) and lumbar spine (LS) at index visit and after a median of 2.5 years. Results: In HIV+ women, BMD at index visit was normal but 5% lower at the LS and FN than in HIV- women. Annual percent decrease in BMD did not differ between HIV+ and HIV- women at the LS (-0.8% +/- 0.2% vs -0.4% +/- - 0.2%, P = 0.20) or FN (-0.8% +/- 0.3% vs -0.6% +/- 0.3%, P = 0.56) and remained similar after adjustment for age, weight, and BMD at index visit. Among HIV+ women, bone loss was associated with vitamin D deficiency and opiate use but not with use or class of antiretrovirals. Incidence of self-reported fracture was 0.74 per 100 person-years in HIV+ women and similar in HIV- women. Conclusions: in premenopausal HIV+ women, index BMD was lower than comparable HIV- women; however, rates of bone loss at the LS and FN were similar over 2.5 years of observation, irrespective of antiretroviral therapy. C1 [Yin, Miehael T.] Columbia Univ, Div Infect Dis, Med Ctr, Dept Med, New York, NY 10032 USA. [Lu, Dalian] Data Solut LLC, Bronx, NY USA. [Tien, Phyllis C.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Tien, Phyllis C.] San Francisco VA Med Ctr, San Francisco, CA USA. [Cohen, Mardge H.] Stroger Hosp, Dept Med, Chicago, IL USA. [Cohen, Mardge H.] Rush Univ, Chicago, IL 60612 USA. [Shi, Qiuhu] New York Med Coll, Dept Med, Valhalla, NY 10595 USA. [Golub, Elizabeth T.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Anastos, Kathryn] Montefiore Med Ctr, Dept Med, Bronx, NY 10467 USA. RP Yin, MT (reprint author), Columbia Univ, Div Infect Dis, Med Ctr, Dept Med, 630 W168th St,PH8 876, New York, NY 10032 USA. EM mty4@columbia.edu FU National Institute of Allergy and Infectious Diseases [UO1-AI-35004, UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UO1-AI-34993, UO1-AI-42590]; National Institute of Child Health and Human Development [UO1-HD-32632]; National Cancer Institute; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Center for Research Resources [UL1 RR024131]; [A1059884]; [A11065200] FX The Women's Interagency HIV Study is funded by the National Institute of Allergy and Infectious Diseases (UO1-AI-35004, UO1-AI-31834: UO1-AI-34994, UO1-AI-34989, UO1-AI-34993, and UO1-AI-42590) and by the National Institute of Child Health and Human Development (UO1-HD-32632). The study is cofunded by the National Cancer Institute, the National Institute on Drug Abuse, and the National Institute on Deafness and Other Communication Disorders. Funding is provided by the National Center for Research Resources (UCSF-CTSI Grant Number UL1 RR024131). Also supported by A1059884 (MY) and A11065200 (ES). NR 36 TC 43 Z9 46 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD FEB 1 PY 2010 VL 53 IS 2 BP 202 EP 208 PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 549EQ UT WOS:000274029000007 PM 19890216 ER PT J AU Fischer, MJ Wyatt, CM Gordon, K Gibert, CL Brown, ST Rimland, D Rodriguez-Barradas, MC Justice, AC Parikh, CR AF Fischer, Michael J. Wyatt, Christina M. Gordon, Kirsha Gibert, Cynthia L. Brown, Sheldon T. Rimland, David Rodriguez-Barradas, Maria C. Justice, Amy C. Parikh, Chirag R. CA VACS Project Team TI Hepatitis C and the Risk of Kidney Disease and Mortality in Veterans With HIV SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE death; HIV; hepatitis C; kidney failure; veterans ID ACTIVE ANTIRETROVIRAL THERAPY; HUMAN-IMMUNODEFICIENCY-VIRUS; STAGE RENAL-DISEASE; INFECTED PATIENTS; COINFECTION; PROGRESSION; COHORT; IMPACT; ASSOCIATION; OUTCOMES AB Objectives: To examine the effect of hepatitis C virus (HCV) oil the prevalence of chronic kidney disease (CKD) among veterans with HIV and to evaluate independent associations of HCV and CKD with mortality. Methods: We studied a national cohort of HIV-infected patients receiving care through the Veterans Healthcare Administration from 1998 to 2004. CKD was defined as an estimated glomerular filtration rate [eGFR (mL/min/1.73 m(2))] < 60. Poisson regression was used to assess relationships between CKD, HCV, and mortality. Results: Among 23,155 HIV-infected veterans, 12% had CKD. Forty percent of the cohort was coinfected with HCV, and a higher proportion of coinfected subjects had CKD compared with monoinfected subjects (14% vs 11%, P < 0.001). During the median follow-up of 7.6 years, 37% of subjects died and a graduated increase in adjusted mortality rates occurred with lower levels of eGFR (P < 0.001). Adjusted mortality rates were consistently higher in HCV-coinfected subjects across all levels of eGFR (P < 0.001). HCV was independently associated with increased mortality (incidence rate ratio 1.23, 95% confidence interval 1.17-1.29). Conclusions: CKD is prevalent in HIV-infected veterans and associated with substantially higher mortality. Compared with their monoinfected counterparts, veterans coinfected with HCV have significantly higher rates of CKD and mortality. C1 [Fischer, Michael J.] Univ Illinois, Dept Med, Nephrol Sect, Jesse Brown VA Med Ctr, Chicago, IL 60612 USA. [Fischer, Michael J.] Hines VA Hosp, Ctr Management Complex Chron Care, Hines, IL USA. [Wyatt, Christina M.] Mt Sinai Sch Med, Dept Med, Div Nephrol, New York, NY USA. [Gordon, Kirsha; Justice, Amy C.; Parikh, Chirag R.; VACS Project Team] W Haven VA Med Ctr, New Haven, CT USA. [Gibert, Cynthia L.] George Washington Univ, Div Infect Dis, Dept Med, VA Med Ctr,Med Ctr, Washington, DC 20037 USA. [Brown, Sheldon T.] Mt Sinai Sch Med, Dept Med, Infect Dis Sect, James J Peters VA Med Ctr, New York, NY USA. [Rimland, David] Atlanta VA Emory Univ, Dept Med, Div Infect Dis, Sch Med, Atlanta, GA USA. [Rodriguez-Barradas, Maria C.] Baylor Coll Med, Dept Med, Infect Dis Sect, Michael E DeBakey VA Med Ctr, Houston, TX 77030 USA. [Justice, Amy C.] Yale Univ, Dept Med, Sch Med, New Haven, CT 06520 USA. [Justice, Amy C.] Yale Univ, Sch Publ Hlth, New Haven, CT 06520 USA. [Parikh, Chirag R.] Yale Univ, Dept Med, Nephrol Sect, New Haven, CT 06520 USA. RP Fischer, MJ (reprint author), Univ Illinois, Sect Nephrol MC 793, 820 S Wood St, Chicago, IL 60612 USA. EM fischerm@uic.edu FU National Institute on Alcohol Abuse and Alcoholism [U10 AA 13566]; VHA Public Health Strategic Healthcare Group; Department of Veterans Affairs; Veterans Health Administration; Health Services Research and Development Service; National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases [IK23DK077568] FX The Veterans Aging Cohort Study is supported by National Institute on Alcohol Abuse and Alcoholism (U10 AA 13566) and VHA Public Health Strategic Healthcare Group; Department of Veterans Affairs, Veterans Health Administration, Health Services Research, and Development Service (VA HSR&D Career Development Award to M.F); and the National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases (IK23DK077568 to CW). NR 37 TC 20 Z9 21 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD FEB 1 PY 2010 VL 53 IS 2 BP 222 EP 226 PG 5 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 549EQ UT WOS:000274029000010 PM 20104121 ER PT J AU Freiberg, M McGinnis, KA Kraemer, K Samet, JH Conigliaro, J Ellison, RC Bryant, K Kuller, LH Justice, AC AF Freiberg, Matthew McGinnis, Kathleen A. Kraemer, Kevin Samet, Jeffrey H. Conigliaro, Joseph Ellison, R. Curtis Bryant, Kendall Kuller, Lewis H. Justice, Amy C. CA VACS Project Team TI The Association Between Alcohol Consumption and Prevalent Cardiovascular Diseases Among HIV-Infected and HIV-Uninfected Men SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article; Proceedings Paper CT 14th Conference on Retroviruses and Opportunistic Infections CY FEB 25-28, 2007 CL Los Angeles, CA DE alcohol consumption; alcohol abuse; alcohol dependence; cardiovascular disease; HIV infection; veterans ID IMMUNODEFICIENCY-VIRUS-INFECTION; CORONARY-HEART-DISEASE; MYOCARDIAL-INFARCTION; RISK-FACTORS; METABOLIC ABNORMALITIES; ANTIRETROVIRAL THERAPY; ISCHEMIC-STROKE; VETERANS; DRINKING; COHORT AB Objective: To determine whether alcohol consumption is associated with cardiovascular disease (CVD) among HIV-infected veterans. Methods: Using established thresholds for alcohol consumption, we analyzed cross-sectional data from 4743 men (51% HIV infected) from the Veterans Aging Cohort Study, a prospective cohort of HIV-infected veterans and demographically similar HIV-uninfected veterans. Using logistic regression, we estimated the odds ratio (OR) for the association between alcohol consumption and prevalent CVD. Results: Among HIV-infected and HIV-uninfected men, respectively, hazardous drinking (33.2% vs. 30.9%,), alcohol abuse and a dependence (20.9% vs. 26.2%), and CVD (14.6% vs. 19.8%) were common. Among HIV-infected men, hazardous drinking [OR = 1.43, 95% confidence interval (CI) = 1.05 to 1.94] and alcohol abuse and dependence (OR = 1.55, 95% CI = 1.07 to 2.23) were associated with a higher prevalence of CVD compared with infrequent and moderate drinking. Among HIV-uninfected men, past drinkers had a higher prevalence of CVD (OR = 1.30, 95% CI = 1.01 to 1.67). For HIV-infected and HIV-uninfected men, traditional risk factors and kidney disease were associated with CVD. Conclusions: Among HIV-infected men, hazardous drinking and alcohol abuse and dependence were associated with a higher prevalence of CVD compared with infrequent and moderate drinking even after adjusting for traditional CVD risk factors, antiretroviral therapy, and CD4 count. C1 [Freiberg, Matthew; Kraemer, Kevin] Univ Pittsburgh, Dept Med, Div Gen Internal Med, Sch Med, Pittsburgh, PA 15213 USA. [Freiberg, Matthew; Kuller, Lewis H.] Univ Pittsburgh, Dept Epidemiol, Grad Sch Publ Hlth, Pittsburgh, PA 15213 USA. [McGinnis, Kathleen A.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Samet, Jeffrey H.] Boston Univ, Sch Med, Dept Med, Gen Internal Med Sect, Boston, MA 02118 USA. [Conigliaro, Joseph] Lexington Veteran Affairs Med Ctr, Div Gen Internal Med, Lexington, KY USA. [Conigliaro, Joseph] Univ Kentucky, Albert B Chandler Med Ctr, Lexington, KY 40536 USA. [Ellison, R. Curtis] Boston Univ, Sch Med, Prevent Med & Epidemiol Sect, Evans Dept Med, Boston, MA 02118 USA. [Bryant, Kendall] NIAAA, NIH, Rockville, MD 20852 USA. [Justice, Amy C.] Veteran Affairs Connecticut Healthcare Syst, West Haven, CT USA. [Justice, Amy C.] Yale Univ, Sch Med, Dept Med, New Haven, CT 06510 USA. RP Freiberg, M (reprint author), Univ Pittsburgh, Dept Med, Div Gen Internal Med, Sch Med, 230 McKee Pl,Suite 600, Pittsburgh, PA 15213 USA. EM freibergms@upmc.edu FU NHLBI NIH HHS [R01 HL095136, R01 HL095136-01, R01HL095136]; NIAAA NIH HHS [R01 AA013304-05, 2U10AA13566, K23 AA015914, K23 AA015914-05, K24 AA0155674, K24 AA015674, K24 AA015674-04, R01 AA013304, U10 AA013566, U10 AA013566-09] NR 34 TC 28 Z9 28 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD FEB 1 PY 2010 VL 53 IS 2 BP 247 EP 253 PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 549EQ UT WOS:000274029000014 PM 20009766 ER PT J AU Horan, WP Wynn, JK Kring, AM Simons, RF Green, MF AF Horan, William P. Wynn, Jonathan K. Kring, Ann M. Simons, Robert F. Green, Michael F. TI Electrophysiological. Correlates of Emotional Responding in Schizophrenia SO JOURNAL OF ABNORMAL PSYCHOLOGY LA English DT Article DE schizophrenia; anhedonia; emotion; pleasure; event-related potentials (ERPs) ID LOVING-KINDNESS MEDITATION; PSYCHIATRIC RATING-SCALE; NEGATIVE SYMPTOMS; UNPLEASANT PICTURES; AFFECTIVE-DISORDERS; QUALITY-ASSURANCE; BRAIN POTENTIALS; NEURAL RESPONSE; AFFECTIVE STYLE; EXPERIENCE AB People with schizophrenia consistently report normal levels of pleasant emotion when exposed to evocative stimuli, suggesting intact consummatory pleasure. However, little is known about the neural correlates and time course of emotion in schizophrenia. This study used a well-validated affective picture viewing task that elicits a characteristic pattern of event-related potentials (ERPs) from early to later processing stages (i.e., P1, P2, P3, and late positive potentials [LPPs]). Thirty-eight stabilized outpatients with schizophrenia and 36 healthy controls viewed standardized pleasant, unpleasant, and neutral pictures while ERPs were recorded and subsequently rated their emotional responses to the stimuli. Patients and controls responded to the pictures similarly in terms of their valence ratings, as well as the initial ERP components (P I, P2, and P3). However, at the later LPP component (500-1,000 ms), patients displayed diminished electrophysiological discrimination between pleasant versus neutral stimuli. This pattern suggests that patients demonstrated normal self-reported emotional experience and intact initial sensory processing of and resource allocation to emotional stimuli. However, they showed a disruption in a later component associated with sustained attentional processing of emotional stimuli. C1 [Horan, William P.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Horan, William P.; Wynn, Jonathan K.; Green, Michael F.] VA Greater Los Angeles Healthcare Syst, Dept Psychiat, Los Angeles, CA USA. [Kring, Ann M.] Univ Calif Berkeley, Dept Psychol, Berkeley, CA 94720 USA. [Simons, Robert F.] Univ Delaware, Dept Psychol, Newark, DE 19716 USA. RP Horan, WP (reprint author), Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd,Bldg 210A, Los Angeles, CA 90073 USA. EM horan@ucla.edu RI Wynn, Jonathan/H-3749-2014 OI Wynn, Jonathan/0000-0002-1763-8540 FU NIMH NIH HHS [MH43292, MH077141, MH65707, R01 MH043292, R01 MH065707, R03 MH077141, R03 MH077141-01, R29 MH043292] NR 72 TC 58 Z9 60 U1 4 U2 11 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0021-843X J9 J ABNORM PSYCHOL JI J. Abnorm. Psychol. PD FEB PY 2010 VL 119 IS 1 BP 18 EP 30 DI 10.1037/a0017510 PG 13 WC Psychology, Clinical; Psychology, Multidisciplinary SC Psychology GA 554OT UT WOS:000274445000002 PM 20141239 ER PT J AU Yee, CM Williams, TJ White, PM Nuechterlein, KH Ames, D Subotnik, KL AF Yee, Cindy M. Williams, Terrance J. White, Patricia M. Nuechterlein, Keith H. Ames, Donna Subotnik, Kenneth L. TI Attentional Modulation of the P50 Suppression Deficit in Recent-Onset and Chronic Schizophrenia SO JOURNAL OF ABNORMAL PSYCHOLOGY LA English DT Article DE schizophrenia; P50; sensory gating; attention; stage of illness ID SELECTIVE ATTENTION; SMOOTH-PURSUIT; EYE TRACKING; MANIPULATIONS; DYSFUNCTION; INDEXES; CORTEX AB Schizophrenia is associated with deficits in P50 suppression to the second stimulus in a pair, a process often conceptualized as a preattentive index of sensory gating. This study assessed the malleability c of the deficit by determining whether early attentional control can influence P50 gating across different pleases of schizophrenia. Participants included 28 patients in the recent-onset (n = 16) or chronic (n = 12) phase of illness and 28 healthy comparison subjects. During the standard paradigm, chronic schizophrenia patients exhibited impaired P50 suppression relative to healthy subjects, whereas recent-onset schizophrenia patients were intermediate. Directing voluntary attention toward the initial stimulus yielded substantial improvements in the P50 ratio; recent-onset schizophrenia patients achieved ratio stores comparable to those of healthy participants, whereas chronic patients also improved and could no second be distinguished clearly from the healthy comparison sample. Directing attention toward the second stimulus enhanced P50 amplitude to the second stimulus across groups, possibly because activation c of the inhibitory mechanism was overridden or circumvented by task demands. Thus, P50 suppression may be primarily preattentive under standard conditions, but manipulation of early attention can expert a modulatory influence on P50, indicating that the suppression deficit is malleable in schizophrenia without pharmacological agents. C1 [Yee, Cindy M.; Williams, Terrance J.; White, Patricia M.; Nuechterlein, Keith H.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA. [Yee, Cindy M.; Williams, Terrance J.; Nuechterlein, Keith H.; Ames, Donna; Subotnik, Kenneth L.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Ames, Donna] Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Yee, CM (reprint author), Univ Calif Los Angeles, Dept Psychol, 1285 Franz Hall,Box 951563, Los Angeles, CA 90095 USA. EM yee@psych.ucla.edu FU NIMH NIH HHS [MH57322, MH37705, P50 MH066286, R01 MH037705, R01 MH057322, R01 MH057322-01A2] NR 39 TC 24 Z9 24 U1 3 U2 5 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0021-843X J9 J ABNORM PSYCHOL JI J. Abnorm. Psychol. PD FEB PY 2010 VL 119 IS 1 BP 31 EP 39 DI 10.1037/a0018265 PG 9 WC Psychology, Clinical; Psychology, Multidisciplinary SC Psychology GA 554OT UT WOS:000274445000003 PM 20141240 ER PT J AU Yee, CM Mathis, KI Sun, JC Sholty, GL Lang, PJ Bachman, P Williams, TJ Bearden, CE Cannon, TD Green, MF Subotnik, KL Ventura, J Nuechterlein, KH AF Yee, Cindy M. Mathis, Kristopher Ian Sun, Jane C. Sholty, Gretchen L. Lang, Peter J. Bachman, Peter Williams, Terrance J. Bearden, Carrie E. Cannon, Tyrone D. Green, Michael F. Subotnik, Kenneth L. Ventura, Joseph Nuechterlein, Keith H. TI Integrity of Emotional and Motivational States During the Prodromal, First-Episode, and Chronic Phases of Schizophrenia SO JOURNAL OF ABNORMAL PSYCHOLOGY LA English DT Article DE schizophrenia; emotion; motivation; attention; startle reflex ID STARTLE REFLEX; NEURAL RESPONSE; MODULATION; REWARD; ATTENTION; SALIENCE; PICTURES; BEHAVIOR; MEMORY; BRAIN AB Emotional and motivational dysfunction is fundamental to schizophrenia, and yet, the nature an, I scope of associated deficits are not well understood. This study assessed the integrity of emotional responding from the perspective of its underlying motivational systems during different phases of schizophrenia. Evaluative, somatic, and autonomic responses were measured during viewing of pictures categorized by emotional content, including threat, mutilation, contamination, illness, pollution, mild erotica, further food, and nature. Participants were 13 patients at ultra high risk or prodromal for psychosis, 40 first-episode schizophrenia patients, 37 chronic schizophrenia patients, and 74 healthy comparison subjects. Irrespective of phase of illness, schizophrenia patients showed a robust and normal pattern of response across multiple systems, with differential engagement of the defensive and appetitive E systems as a function of the motivational significance assigned to specific emotional contexts. Although the integrity of core motivational states also appeared to be intact in prodromal patients, a less consistent pattern of response was observed. As continuing efforts are made to identify emotional and motivational abnormalities in schizophrenia, identified deficits will likely be independent of a fundamental dysfunction in basic emotion and motivation response systems and involve integration with higher order processes. C1 [Yee, Cindy M.; Mathis, Kristopher Ian; Sun, Jane C.; Sholty, Gretchen L.; Bachman, Peter; Williams, Terrance J.; Cannon, Tyrone D.; Nuechterlein, Keith H.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA. [Yee, Cindy M.; Williams, Terrance J.; Bearden, Carrie E.; Cannon, Tyrone D.; Green, Michael F.; Subotnik, Kenneth L.; Ventura, Joseph; Nuechterlein, Keith H.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Lang, Peter J.] Univ Florida, Dept Clin & Hlth Psychol, Gainesville, FL 32611 USA. [Green, Michael F.] Vet Adm Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. RP Yee, CM (reprint author), Univ Calif Los Angeles, Dept Psychol, 1285 Franz Hall,Box 951563, Los Angeles, CA 90095 USA. EM yee@psych.ucla.edu FU NIMH NIH HHS [L30 MH081486-01, T32 MH014584, L30 MH081486, P50 MH066286, R01 MH037705, P50 MH066286-01A10006] NR 39 TC 14 Z9 14 U1 2 U2 4 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0021-843X J9 J ABNORM PSYCHOL JI J. Abnorm. Psychol. PD FEB PY 2010 VL 119 IS 1 BP 71 EP 82 DI 10.1037/a0018475 PG 12 WC Psychology, Clinical; Psychology, Multidisciplinary SC Psychology GA 554OT UT WOS:000274445000007 PM 20141244 ER PT J AU Amirzadeh, A Klaustermeyer, W AF Amirzadeh, A. Klaustermeyer, W. TI Epipen Demographics and Use in a VA Population SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT 66th Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology CY FEB 26-MAR 02, 2010 CL New Orleans, LA SP Amer Acad Allergy, Asthma & Immunol C1 [Amirzadeh, A.; Klaustermeyer, W.] VA Greater Los Angeles, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD FEB PY 2010 VL 125 IS 2 SU 1 BP AB33 EP AB33 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA 629MS UT WOS:000280204100131 ER PT J AU Beckner, V Howard, I Vella, L Mohr, DC AF Beckner, Victoria Howard, Isa Vella, Lea Mohr, David C. TI Telephone-administered psychotherapy for depression in MS patients: moderating role of social support SO JOURNAL OF BEHAVIORAL MEDICINE LA English DT Article DE Social support; Depression; Multiple sclerosis; Cognitive Behavioral Therapy; Emotion-Focused Therapy; Treatment outcome ID PRIMARY-CARE PATIENTS; COGNITIVE-BEHAVIORAL THERAPY; RANDOMIZED CONTROLLED-TRIAL; SPINAL-CORD-INJURY; MULTIPLE-SCLEROSIS; MAJOR DEPRESSION; RATING-SCALE; CLINICAL PREDICTORS; BREAST-CANCER; OLDER-ADULTS AB Depression is common in individuals with multiple sclerosis (MS). While psychotherapy is an effective treatment for depression, not all individuals benefit. We examined whether baseline social support might differentially affect treatment outcome in 127 participants with MS and depression randomized to either Telephone-administered Cognitive-Behavioral Therapy (T-CBT) or Telephone-administered Emotion-Focused Therapy (T-EFT). We predicted that those with low social support would improve more in T-EFT, since this approach emphasizes the therapeutic relationship, while participants with strong social networks and presumably more emotional resources might fare better in the more structured and demanding T-CBT. We found that both level of received support and satisfaction with that support at baseline did moderate treatment outcome. Individuals with high social support showed a greater reduction in depressive symptoms in the T-CBT as predicted, but participants with low social support showed a similar reduction in both treatments. This suggests that for participants with high social support, CBT may be a more beneficial treatment for depression compared with EFT. C1 [Beckner, Victoria] San Francisco Grp Evidence Based Psychotherapy, San Francisco, CA 94123 USA. [Beckner, Victoria] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Howard, Isa] San Francisco VA Med Ctr, San Francisco, CA USA. [Vella, Lea] Univ Calif San Diego, San Diego State Univ, Joint Doctoral Program Clin Psychol, San Diego, CA 92103 USA. [Mohr, David C.] Northwestern Univ, Dept Prevent Med, Evanston, IL USA. RP Beckner, V (reprint author), San Francisco Grp Evidence Based Psychotherapy, 1777 Union St, San Francisco, CA 94123 USA. EM victoria.beckner@ucsf.edu FU NCRR NIH HHS [UL1 RR025741]; NIMH NIH HHS [R01 MH059708, R01 MH059708-06] NR 54 TC 17 Z9 17 U1 4 U2 9 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0160-7715 J9 J BEHAV MED JI J. Behav. Med. PD FEB PY 2010 VL 33 IS 1 BP 47 EP 59 DI 10.1007/s10865-009-9235-2 PG 13 WC Psychology, Clinical SC Psychology GA 549XP UT WOS:000274088100005 PM 19941048 ER PT J AU Belogrudov, GI AF Belogrudov, Grigory I. TI Coupling factor B affects the morphology of mitochondria SO JOURNAL OF BIOENERGETICS AND BIOMEMBRANES LA English DT Article DE Coupling factor B; Inner mitochondrial membrane; Mitochondrial crista; Mitochondrial morphology ID ATP SYNTHASE COMPLEX; OXIDATIVE-PHOSPHORYLATION; SUPRAMOLECULAR ORGANIZATION; SUBMITOCHONDRIAL PARTICLES; CRISTAE MORPHOLOGY; P-I; MEMBRANE; YEAST; TRANSLOCATION; SUBUNITS AB Ectopic expression of coupling factor B in animal cells resulted in altered mitochondrial morphology. Cells expressing factor B fused to green fluorescent protein (GFP) contained fragmented, balloon-shaped or thinned, filamentous mitochondria, terminating at one end with balloon-like structures. Ultrastructural analysis using transmission electron microscopy revealed changes in the organization of mitochondrial cristae in cells expressing factor B-GFP fusion protein. C1 W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. RP Belogrudov, GI (reprint author), W Los Angeles Vet Affairs Med Ctr, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM gbelo@ucla.edu FU NIH [R01GM066085] FX I thank Dr. George Sachs for access to a laser scanning confocal microscope LSM 510, Dr. Olga Vagin for advice on confocal microscopy, Marianne Cilluffo for preparing specimens and for help with transmission electron microscopy, and Dr. William C. Claycomb for providing the HL-1 cells. This work was supported by NIH grant R01GM066085. I dedicate this article to Dr. Youssef Hatefi on the occasion of his 80th birthday. NR 42 TC 2 Z9 3 U1 0 U2 1 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0145-479X J9 J BIOENERG BIOMEMBR JI J. Bioenerg. Biomembr. PD FEB PY 2010 VL 42 IS 1 BP 29 EP 35 DI 10.1007/s10863-009-9263-1 PG 7 WC Biophysics; Cell Biology SC Biophysics; Cell Biology GA 571UU UT WOS:000275782100004 PM 20069349 ER PT J AU Roodman, GD AF Roodman, G. David TI Pathogenesis of Myeloma Bone Disease SO JOURNAL OF CELLULAR BIOCHEMISTRY LA English DT Article DE MYELOMA; BONE DISEASE; METASTASIS ID TUMOR-NECROSIS-FACTOR; KAPPA-B LIGAND; OSTEOCLAST DIFFERENTIATION FACTOR; INTERACTING PROTEIN P62; MULTIPLE-MYELOMA; IN-VIVO; RECEPTOR ACTIVATOR; OSTEOBLAST DIFFERENTIATION; MARROW MICROENVIRONMENT; CELL-GROWTH AB Multiple myeloma (mm) is the most common cancer to involve bone with Up to 90% of patients developing bone lesions. The bone lesions are purely osteolytic in nature and do not heal in the vast majority of patients. Up to 60% of patients develop pathologic fractures over the course of their disease. Bone disease is a hallmark of MM, and myeloma bone disease differs front hone metastasis caused by other tumors. Although myeloma and other osteolytic metastases induce increased osteoclastic bone destruction, in contrast to other tumors, once myeloma tumor exceeds 50% in it local area, osteoblast activity is either severely depressed of absent. The basis For this severe imbalance between increased osteoclastic bone resorption and decreased bone formation has been the topic of intensive investigation over the last several years. These studies have helped to identify novel targets for treating myeloma bone disease and Will he discussed in this chapter. J. Cell. Biochem. 109: 283-29 1, 2010. (C) 2009 Wiley-Liss, Inc. C1 [Roodman, G. David] Univ Pittsburgh, Sch Med, VA Pittsburgh Healthcare Syst, Dept Med Hematol Oncol, Pittsburgh, PA 15240 USA. RP Roodman, GD (reprint author), Univ Pittsburgh, Sch Med, VA Pittsburgh Healthcare Syst, Dept Med Hematol Oncol, Res & Dev 151-U,Univ Dr C,Rm 2E113, Pittsburgh, PA 15240 USA. EM roodmangd@upmc.edu NR 86 TC 48 Z9 54 U1 1 U2 3 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0730-2312 J9 J CELL BIOCHEM JI J. Cell. Biochem. PD FEB 1 PY 2010 VL 109 IS 2 BP 283 EP 291 DI 10.1002/jcb.22403 PG 9 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 554YB UT WOS:000274471400002 PM 20014067 ER PT J AU Gandhi, CR Murase, N Starzl, TE AF Gandhi, Chandrashekhar R. Murase, Noriko Starzl, Thomas E. TI Cholera Toxin-Sensitive GTP-Binding Protein-Coupled Activation of Augmenter of Liver Regeneration (ALR) Receptor and Its Function in Rat Kupffer Cells SO JOURNAL OF CELLULAR PHYSIOLOGY LA English DT Article ID HEPATIC STIMULATORY SUBSTANCE; NITRIC-OXIDE; PARTIAL-HEPATECTOMY; GROWTH-FACTORS; CULTURED-HEPATOCYTES; DNA-SYNTHESIS; GENE; MICE; EXPRESSION; APOPTOSIS AB Mitogenic effect of augmenter of liver regeneration (ALR), a protein produced and released by hepatocytes, on hepatocytes in vivo but not in vitro suggests that the effect is mediated by nonparenchymal cells. Since mediators produced by Kupffer cells are implicated in hepatic regeneration, we investigated receptor for ALR and its functions in rat Kupffer cells. Kupffer cells were isolated from rat liver by enzymatic digestion and centrifugal elutriation. Radioligand ([(125)I] ALR) receptor binding, ALR-induced GTP/G-protein association, and nitric oxide (NO), tumor necrosis factor (TNF)-alpha, and interleukin-6 (IL-6) synthesis were determined. High-affinity receptor for ALR, belonging to the G-protein family, with K(d) of 1.25 +/- 0.18 nM and B(max) of 0.26 +/- 0.02 fmol/mu g DNA was identified. ALR stimulated NO, TNF-alpha, and IL-6 synthesis via cholera toxin-sensitive G-protein, as well as p38-MAPK activity and nuclear translocation of NF kappa B. While inhibitor of NF kappa B (MG132) inhibited ALR-induced NO synthesis, MG132 and p38-MAPK inhibitor (SB203580) abrogated ALR-induced TNF-alpha and IL-6 synthesis. ALR also prevented the release of mediator(s) from Kupffer cells that cause inhibition of DNA synthesis in hepatocytes. Administration of ALR to 40% partially hepatectomized rats increased expression of TNF-alpha, IL-6, and inducible nitric oxide synthase (iNOS) and caused augmentation of hepatic regeneration. These results demonstrate specific G-protein coupled binding of ALR and its function in Kupffer cells and suggest that mediators produced by ALR-stimulated Kupffer cells may elicit physiologically important effects on hepatocytes. J. Cell. Physiol. 222: 365-373, 2010. (C) 2009 Wiley-Liss, Inc. C1 [Gandhi, Chandrashekhar R.; Murase, Noriko; Starzl, Thomas E.] Univ Pittsburgh, Thomas E Starzi Transplantat Inst, Dept Surg, Pittsburgh, PA 15213 USA. [Gandhi, Chandrashekhar R.] Univ Pittsburgh, Thomas E Starzi Transplantat Inst, Dept Pathol, Pittsburgh, PA 15213 USA. [Gandhi, Chandrashekhar R.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Gandhi, CR (reprint author), Univ Pittsburgh, Thomas E Starzi Transplantat Inst, Dept Surg, E-1542 BST,200 Lothrop St, Pittsburgh, PA 15213 USA. EM gandhics@msx.upmc.edu FU NIH [DK 54411] FX This work was supported by a VA Merit award and a grant from the NIH (DK 54411) to C.R.G. We thank Ms. Holly Grunebach, Ms. Kristin Anselmi, and Mr. Chao Huang for excellent technical assistance. NR 50 TC 15 Z9 18 U1 0 U2 1 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0021-9541 J9 J CELL PHYSIOL JI J. Cell. Physiol. PD FEB PY 2010 VL 222 IS 2 BP 365 EP 373 DI 10.1002/jcp.21957 PG 9 WC Cell Biology; Physiology SC Cell Biology; Physiology GA 544MV UT WOS:000273662300014 PM 19859909 ER PT J AU Belfort, R Berria, R Cornell, J Cusi, K AF Belfort, Renata Berria, Rachele Cornell, John Cusi, Kenneth TI Fenofibrate Reduces Systemic Inflammation Markers Independent of Its Effects on Lipid and Glucose Metabolism in Patients with the Metabolic Syndrome SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID C-REACTIVE PROTEIN; CARDIOVASCULAR-DISEASE RISK; ALPHA AGONIST FENOFIBRATE; CORONARY-HEART-DISEASE; PPAR-ALPHA; INSULIN SENSITIVITY; NONALCOHOLIC STEATOHEPATITIS; PRIMARY-PREVENTION; DIABETES-MELLITUS; CONTROLLED-TRIAL AB Context: Fenofibrate is a peroxisome proliferator-activated receptor alpha agonist widely used in clinical practice, but its mechanism of action is incompletely understood. Objective: The aim of the study was to assess whether improvement in subclinical inflammation or glucose metabolism contributes to its antiatherogenic effects in insulin-resistant subjects with the metabolic syndrome (MetS). Design and Setting: We conducted a randomized, double-blind, placebo-controlled study in the research unit at an academic center. Patients: We studied 25 nondiabetic insulin-resistant MetS subjects. Intervention(s): We administered fenofibrate (200 mg/d) and placebo for 12 wk. Main Outcome Measures: Before and after treatment, we measured plasma lipids/apolipoproteins, inflammatory markers (high-sensitivity C-reactive protein, IL-6, intercellular adhesion molecule/vascular cell adhesion molecule), adipocytokines (adiponectin, TNF alpha, leptin), and insulin secretion (oral glucose tolerance test). We also assessed adipose tissue, hepatic and peripheral (muscle) insulin resistance fasting and during a euglycemic insulin clamp with (3)H glucose and (14)C palmitate infusion combined with indirect calorimetry. Results: Subjects displayed severe insulin resistance and systemic inflammation. Fenofibrate significantly reduced plasma triglyceride, apolipoprotein (apo) CII, apo CIII, and apo E (all P < 0.01), with a modest increase in high-density lipoprotein-cholesterol (+ 12%; P = 0.06). Fenofibrate markedly decreased plasma high-sensitivity C-reactive protein by 49.5 +/- 8% (P = 0.005) and IL-6 by 29.8 +/- 7% (P = 0.03) vs. placebo. However, neither insulin secretion nor adipose tissue, hepatic or muscle insulin sensitivity or glucose/lipid oxidation improved with treatment. Adiponectin and TNF-alpha levels were also unchanged. Improvement in plasma markers of vascular/systemic inflammation was dissociated from changes in triglyceride/high-density lipoprotein-cholesterol, apo CII/CIII, or free fatty acid concentrations or insulin secretion/insulin sensitivity. Conclusions: In subjects with the MetS, fenofibrate reduces systemic inflammation independent of improvements in lipoprotein metabolism and without changing insulin sensitivity. This suggests a direct peroxisome proliferator-activated receptor alpha-mediated effect of fenofibrate on inflammatory pathways, which may be important for the prevention of CVD in high-risk patients. (J Clin Endocrinol Metab 95: 829-836, 2010) C1 [Belfort, Renata; Berria, Rachele; Cusi, Kenneth] Univ Texas Hlth Sci Ctr San Antonio, Diabet Div, Dept Med, San Antonio, TX 78229 USA. [Cornell, John] Univ Texas Hlth Sci Ctr San Antonio, Diabet Div, Dept Epidemiol, San Antonio, TX 78229 USA. [Cornell, John; Cusi, Kenneth] Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX 78284 USA. RP Cusi, K (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Diabet Div, Dept Med, Room 3-380S,7703 Floyd Curl Dr, San Antonio, TX 78284 USA. EM cusi@uthscsa.edu FU Veterans Administration; Howard Hughes Medical Institute; Veterans Affairs Medical Research Fund; National Center for Research Resources [1RR025767] FX This work was supported by a Veterans Administration Research Career Development Award (to K. C.), a Howard Hughes Medical Institute Grant (to K. C.), the Veterans Affairs Medical Research Fund, and Award no. UL 1RR025767 from the National Center for Research Resources. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources of the National Institutes of Health. NR 34 TC 73 Z9 74 U1 0 U2 5 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD FEB PY 2010 VL 95 IS 2 BP 829 EP 836 DI 10.1210/jc.2009-1487 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 552NH UT WOS:000274298200046 PM 20061429 ER PT J AU Smith, MW Ma, J Stafford, RS AF Smith, Mark W. Ma, Jun Stafford, Randall S. TI Bar charts enhance Bland-Altman plots when value ranges are limited SO JOURNAL OF CLINICAL EPIDEMIOLOGY LA English DT Article DE Statistics, nonparametric; Survey methods; Health services/utilization; Biometry; Reproducibility of results; Humans ID AGREEMENT AB Objective: A common form of validation study compares alternative methods for collecting data. The Bland-Altman plot pairs observations across methods and plots their mean values vs. their difference. This method provides only limited information, however, when the range of observed values is small relative to the number of observations. This brief report shows how adding a simple barchart to a Bland-Altman plot adds essential additional information. Study Design and Setting: The methodological approach is illustrated using data from a randomized controlled clinical trial of patients in a U.S. county health system. Results: When the number of unique values is small, a Bland-Altman plot alone may provide inadequate information. Adding a bar chart yields new and essential information about agreement, bias, and heteroscedasticity. Conclusion: Studies validating one data-collection method against another can be performed successfully even when the number of unique values is small. (C) 2010 Elsevier Inc. All rights reserved. C1 [Smith, Mark W.] VA Palo Alto HCS, Hlth Econ Resource Ctr, US Dept Vet Affairs, Menlo Pk, CA 94025 USA. [Ma, Jun] Stanford Univ, Sch Med, Ctr Primary Care & Outcomes Res, Stanford, CA 94305 USA. [Ma, Jun] Palo Alto Med Fdn, Res Inst, Dept Hlth Serv Res, Palo Alto, CA 94301 USA. [Stafford, Randall S.] Stanford Univ, Sch Med, Stanford Prevent Res Ctr, Program Prevent Outcomes & Practices, Stanford, CA 94305 USA. [Stafford, Randall S.] Stanford Univ, Sch Med, Dept Internal Med, Stanford, CA 94305 USA. RP Smith, MW (reprint author), VA Palo Alto HCS, Hlth Econ Resource Ctr, US Dept Vet Affairs, 795 Willow Rd,152 MPD, Menlo Pk, CA 94025 USA. EM mark.smith9@va.gov RI Smith, Mark/G-1522-2012 OI Smith, Mark/0000-0002-4582-9088 FU National Heart, Lung, and Blood Institute [R01 HL070781]; U.S. Department of Veterans Affairs, Office of Research and Development, Health Services Research and Development Service FX This research was supported by a grant from the National Heart, Lung, and Blood Institute (R01 HL070781). Additional support was provided by the U.S. Department of Veterans Affairs, Office of Research and Development, Health Services Research and Development Service. NR 11 TC 9 Z9 9 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0895-4356 J9 J CLIN EPIDEMIOL JI J. Clin. Epidemiol. PD FEB PY 2010 VL 63 IS 2 BP 180 EP 184 DI 10.1016/j.jclinepi.2009.06.001 PG 5 WC Health Care Sciences & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 549OG UT WOS:000274062400013 PM 19716265 ER PT J AU Robinson, JG Wallace, R Safford, MM Pettinger, M Cochrane, B Ko, MG O'Sullivan, MJ Masaki, K Petrovich, H AF Robinson, Jennifer G. Wallace, Robert Safford, Monika M. Pettinger, Mary Cochrane, Barbara Ko, Marcia G. O'Sullivan, Mary Jo Masaki, Kamal Petrovich, Helen TI Another treatment gap: Restarting secondary prevention medications: The Women's Health Initiative SO JOURNAL OF CLINICAL LIPIDOLOGY LA English DT Article DE Adherence; Coronary heart disease; Secondary prevention; Statins; Women ID ACUTE MYOCARDIAL-INFARCTION; DIETARY MODIFICATION TRIAL; BASE-LINE CHARACTERISTICS; CORONARY-ARTERY-DISEASE; LONG-TERM MORTALITY; MEDICARE BENEFICIARIES; CARDIOVASCULAR DRUGS; ADHERENCE; DISCHARGE; PARTICIPANTS AB BACKGROUND: Women's long-term patterns of evidence-based preventive medication use after a diagnosis of coronary heart disease have not been sufficiently studied. METHODS: Postmenopausal women ages 50 to 79 years were eligible for randomization in the Women's Health Initiative's hormone trials if they met inclusion and exclusion criteria and were >80% adherent during a placebo-lead-in period and in the dietary modification trial if they were willing to follow a 20% fat diet. Those with adjudicated myocardial infarction or coronary revascularization after the baseline visit were included in the analysis (n = 2627). Baseline visits occurred between 1993 and 1998, then annually until the trials ended in 2002 through 2005; medication inventories were obtained at baseline and years 1, 3, 6, and 9. RESULTS: Use at the first Women's Health Initiative visit after a coronary heart disease diagnosis increased over time for statins (49% to 72%; P < .0001), beta-blockers (49% to 62%; P =.003), and angiotensin-converting enzyme inhibitors/angiotensin-II receptor blockers (ACEI/ARBs; 26%-43%; P <.0001). Aspirin use remained stable at 76% (P = .09). Once women reported using a statin, aspirin, or beta-blocker, 84% to 89% reported use at 1 or more subsequent visits, with slightly lower rates for ACEI/ARBS (76%). Statin, aspirin, beta-blocker, or ACEI/ARB use was reported at 2 or more consecutive visits by 57%, 66%, 48%, and 28%, respectively. These drugs were initiated or resumed at a later visit by 24%, 17%, 15%, and 17%, respectively, and were never used during the period of follow-up by 19%, 10%, 33%, and 49% respectively. CONCLUSIONS: Efforts to improve secondary prevention medication use should target both drug initiation and restarting drugs in patients who have discontinued them. (C) 2010 National Lipid Association. All rights reserved. C1 [Robinson, Jennifer G.] Univ Iowa, Dept Med, Iowa City, IA 52242 USA. [Robinson, Jennifer G.; Wallace, Robert] Univ Iowa, Dept Epidemiol, Iowa City, IA 52242 USA. [Safford, Monika M.] Birmingham VA Med Ctr, Deep S Ctr Effectiveness, Birmingham, AL USA. [Safford, Monika M.] Univ Alabama, Birmingham, AL USA. [Pettinger, Mary] Fred Hutchinson Canc Ctr, Seattle, WA USA. [Cochrane, Barbara] Univ Washington, Seattle, WA 98195 USA. [Ko, Marcia G.] Mayo Clin, Div Womens Hlth, Scottsdale, AZ USA. [O'Sullivan, Mary Jo] Univ Miami, Miller Sch Med, Miami, FL 33136 USA. [Masaki, Kamal] Univ Hawaii, Dept Geriatr Med, Manoa, HI USA. [Masaki, Kamal; Petrovich, Helen] Univ Hawaii, John A Burns Sch Med, Manoa, HI USA. [Masaki, Kamal; Petrovich, Helen] Univ Hawaii, Sch Publ Hlth, Manoa, HI USA. RP Robinson, JG (reprint author), Univ Iowa, Dept Med, 200 Hawkins Dr SE 21C GH, Iowa City, IA 52242 USA. EM jennifer-g-robinson@uiowa.edu FU Abbott; Bristol-Myers Squibb; Hoffman La Roche; Merck; Merck Schering-Plough; NIH; Pfizer; Agency for Healthcare Research and Quality (AHRQ) Centers for Education and Research [5 U18 HS016094] FX Dr. Robinson in the past year has received grants from Abbott, Bristol-Myers Squibb, Hoffman La Roche, Merck, and Merck Schering-Plough and was a consul tan tladvisory board for Astra-Zeneca and Wellmark. Dr. Wallace has received grants/research from NIH and Pfizer; was a consultant for Merck and Co.; and on the clinical trial monitoring board of Novartis. Dr. Masaki was on the speaker's bureau for Pfizer. This project was also supported (or supported in part) by an Agency for Healthcare Research and Quality (AHRQ) Centers for Education and Research on Therapeutics cooperative agreement #5 U18 HS016094. NR 22 TC 2 Z9 2 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1933-2874 J9 J CLIN LIPIDOL JI J. Clin. Lipidol. PD FEB PY 2010 VL 4 IS 1 BP 36 EP 45 DI 10.1016/j.jacl.2009.12.006 PG 10 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 561NL UT WOS:000274984300005 PM 20354566 ER PT J AU Bergman, J Logan, S Fink, A Ganz, DA Peterson, MA Litwin, MS AF Bergman, Jonathan Logan, Susan Fink, Arlene Ganz, David A. Peterson, Mark A. Litwin, Mark S. TI Caring for the Uninsured with Prostate Cancer: A Comparison of Four Policy Alternatives in California SO JOURNAL OF COMMUNITY HEALTH LA English DT Article DE Prostate cancer; Medically uninsured; Vulnerable populations; Community health services ID QUALITY-OF-LIFE; MEDICAID MANAGED CARE; LOW-INCOME; UNITED-STATES; RADICAL PROSTATECTOMY; HEALTH-INSURANCE; SAFETY-NET; MEN; ACCESS; ISSUES AB The IMPACT Program seeks to improve access to prostate cancer care for low-income, uninsured men. The objective of the current study was to compare the cost-effectiveness of four policy alternatives in treating this population. We analyzed the cost-effectiveness of four policy alternatives for providing care to low-income, uninsured men with prostate cancer: (1) IMPACT as originally envisioned, (2) a version of IMPACT with reduced physician fees, (3) a hypothetical Medicaid prostate cancer treatment program, and (4) the existing county safety net. We calculated cost-effectiveness based on incremental cost-effectiveness ratios (ICERs) with the formula ICER = (Cost(alternative strategy) - Cost(baseline strategy)) / (QALY(alternative strategy) - QALY(baseline strategy)). We measured outcomes as quality-adjusted life years (QALYs). "Best-case" scenarios assumed timely access to care in 50% of cases in the county system and 70% of cases in any system that reimbursed providers at Medicaid fee-for-service rates. "Worst-case" scenarios assumed timely access in 35 and 50% of corresponding cases. In fiscal year 2004-2005, IMPACT allocated 11% of total expenditures to administrative functions and 23% to fixed clinical costs, with an overall budget of $5.9 million. The ICERs ($/QALY) assuming "best-case" scenarios for original IMPACT, modified IMPACT, and a hypothetical Medicaid program were $32,091; $64,663; and $10,376; respectively. ICERs assuming "worst-case" scenarios were $27,189; $84,236; and $10,714; respectively. County safety net was used as a baseline. In conclusion, IMPACT provides underserved Californians with prostate cancer care and value-added services with only 11% of funds allocated to administrative fixed costs. Both the original IMPACT program and the hypothetical Medicaid prostate cancer program were cost-effective compared to the county safety net, while the reduced-fees version of IMPACT was not. C1 [Bergman, Jonathan; Litwin, Mark S.] Univ Calif Los Angeles, Dept Urol, Los Angeles, CA 90095 USA. [Logan, Susan] Washington Univ, Dept Surg, St Louis, MO 63108 USA. [Fink, Arlene] Univ Calif Los Angeles, Dept Med, Pacific Palisades, CA 90272 USA. [Fink, Arlene; Litwin, Mark S.] Univ Calif Los Angeles, Dept Hlth Serv, Pacific Palisades, CA 90272 USA. [Ganz, David A.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA. [Ganz, David A.] VA Greater LA Healthcare Sys 11G, VA Greater Los Angeles Healthcare Syst, Dept Geriatr Res, Educ & Clin Ctr, Los Angeles, CA 90095 USA. [Peterson, Mark A.] Univ Calif Los Angeles, Sch Publ Affairs, Los Angeles, CA 90095 USA. [Litwin, Mark S.] Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA. RP Bergman, J (reprint author), Univ Calif Los Angeles, Dept Urol, Box 951738, Los Angeles, CA 90095 USA. EM jbergman@mednet.ucla.edu NR 42 TC 0 Z9 0 U1 2 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0094-5145 J9 J COMMUN HEALTH JI J. Community Health PD FEB PY 2010 VL 35 IS 1 BP 18 EP 26 DI 10.1007/s10900-009-9199-8 PG 9 WC Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 552LN UT WOS:000274292300004 PM 19911260 ER PT J AU Mckay, JR Lynch, KG Coviello, D Morrison, R Cary, MS Skalina, L Plebani, J AF McKay, James R. Lynch, Kevin G. Coviello, Donna Morrison, Rebecca Cary, Mark S. Skalina, Lauren Plebani, Jennifer TI Randomized Trial of Continuing Care Enhancements for Cocaine-Dependent Patients Following Initial Engagement SO JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY LA English DT Article DE cocaine dependence; treatment; contingency management; relapse prevention ID SUBSTANCE USE DISORDERS; ADDICTION SEVERITY INDEX; CONTINGENCY MANAGEMENT; RELAPSE PREVENTION; REINFORCEMENT THERAPY; ESTABLISHING SPECIFICITY; OUTPATIENT TREATMENT; DRINKING BEHAVIOR; SELF-REPORTS; ABSTINENCE AB Objective: The effects of cognitive-behavioral relapse prevention (RP), contingency management (CM), and their combination (CM + RP) were evaluated in a randomized trial with 100 cocaine-dependent patients (58% female, 89% African American) who were engaged in treatment for at least 2 weeks and had an average of 44 days of abstinence at baseline. Method: The participants were from intensive outpatient programs, which provide 10 hr per week of group counseling. The CM protocol provided gift certificates (maximum value $1,150; mean received = $740) for cocaine-free urines over 12 weeks on an escalating reinforcement schedule, and weekly individual RP sessions were offered for up to 20 weeks. Average number of RP sessions attended was 3 in RP and 13 in CM + RP. Results: Generalizing estimation equation analyses over 18 months postrandomization showed significant effects for CM (but not RP) on urine toxicology and self-reported cocaine use (p = .05), with no significant CM x RP interactions. Secondary analyses indicated CM + RP produced better cocaine urine toxicology outcomes at 6 months than treatment as usual, odds ratio [OR] = 3.96 (1.33, 11.80), p < .01, and RP, OR = 4.89 (1.51, 15.86), p < .01, and produced better cocaine urine toxicology outcomes at 9 months than treatment as usual, OR = 4.21 (1.37, 12.88), p < .01, and RP, OR = 4.24 (1.32, 13.65), p < .01. Trends also favored CM + RP over CM at 6 months, OR = 2.93 (0.94, 9.07), p = .06, and 9 months, OR = 2.93 (0.94, 9.10), p = .06. Differences between the conditions were not significant after 9 months. Conclusions: These results suggest CM can improve outcomes in cocaine-dependent patients in intensive outpatient programs who have achieved initial engagement, particularly when it is combined with RP. C1 [McKay, James R.] Univ Penn, Ctr Continuum Care Addict, Dept Psychol, Philadelphia, PA 19104 USA. [McKay, James R.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Lynch, Kevin G.; Coviello, Donna; Morrison, Rebecca; Skalina, Lauren; Plebani, Jennifer] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Cary, Mark S.] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. RP Mckay, JR (reprint author), Univ Penn, Ctr Continuum Care Addict, Dept Psychol, 3440 Market St,Suite 370, Philadelphia, PA 19104 USA. EM mckay_j@mail.trc.upenn.edu FU NIDA NIH HHS [K02 DA000361-02, R01 DA014059, R01 DA014059-01, R01 DA14059, K02 DA000361] NR 57 TC 19 Z9 19 U1 1 U2 5 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0022-006X J9 J CONSULT CLIN PSYCH JI J. Consult. Clin. Psychol. PD FEB PY 2010 VL 78 IS 1 BP 111 EP 120 DI 10.1037/a0018139 PG 10 WC Psychology, Clinical SC Psychology GA 548UO UT WOS:000273993600012 PM 20099956 ER PT J AU Borrero, S Moore, CG Qin, L Schwarz, EB Akers, A Creinin, MD Ibrahim, SA AF Borrero, Sonya Moore, Charity G. Qin, Li Schwarz, Eleanor B. Akers, Aletha Creinin, Mitchell D. Ibrahim, Said A. TI Unintended Pregnancy Influences Racial Disparity in Tubal Sterilization Rates SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE unintended pregnancy; minority women; tubal sterilization ID FAMILY-PLANNING-SERVICES; UNITED-STATES; CONTRACEPTIVE USE; PHYSICIANS PERCEPTIONS; PRIVATE PROVIDERS; PUBLIC-HEALTH; NEW-ORLEANS; WOMEN; RACE; CARE AB BACKGROUND: Minority women are more likely than white women to choose tubal sterilization as a contraceptive method. Disparities in rates of unintended pregnancy may help explain observed racial/ethnic differences in sterilization, but this association has not been investigated. OBJECTIVE: To examine the associations among race/ethnicity, unintended pregnancy, and tubal sterilization. DESIGN AND PARTICIPANTS: Cross-sectional analysis of data from a nationally representative sample of women aged 15-44 years [65.7% white, 14.8% Hispanic, and 13.9% African American (AA)] who participated in the 2002 National Survey of Family Growth. MAIN MEASURES: race/ethnicity, history of unintended pregnancy, and tubal sterilization. A logistic regression model was used to estimate the effect of race/ethnicity on unintended pregnancy while adjusting for socio-demographic variables. A series of logistic regression models was then used to examine the role of unintended pregnancy as a confounder for the relationship between race/ethnicity and sterilization. KEY RESULTS: Overall, 40% of white. 48% of Hispanic, and 59% of AA women reported a history of unintended pregnancy. After adjusting for socio-demographic variables, AA women were more likely (OR: 2.0; 95% CI: 1.6-2.4) and Hispanic women as likely (OR: 1.0: 95% CI: 0.80-1.2) as white women to report unintended pregnancy. Sterilization was reported by 29% of women who had ever had an unintended pregnancy compared to 7% of women who reported never having an unintended pregnancy. In unadjusted analysis, AA and Hispanic women had significantly higher odds of undergoing sterilization (OR: 1.5; 95% CI: 1.3-1.9 and OR: 1.4: 95% CI: 1.2-1.7, respectively). After adjusting for unintended pregnancy, this relationship was attenuated and no longer significant (OR: 1.2: 95% CI: 0.95-1.4 for AA women and OR: 1.3:95% CI: 1.0-1.6 for Hispanic women). CONCLUSION: Minority women, who more frequently experience unintended pregnancy, may choose tubal sterilization in response to prior experiences with an unintended pregnancy. C1 [Borrero, Sonya; Moore, Charity G.; Qin, Li; Schwarz, Eleanor B.; Ibrahim, Said A.] Univ Pittsburgh, Sch Med, Div Gen Internal Med, Pittsburgh, PA 15213 USA. [Borrero, Sonya; Ibrahim, Said A.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Schwarz, Eleanor B.; Akers, Aletha; Creinin, Mitchell D.] Univ Pittsburgh, Sch Med, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA 15213 USA. [Schwarz, Eleanor B.; Akers, Aletha; Creinin, Mitchell D.] Magee Womens Res Inst, Pittsburgh, PA USA. [Creinin, Mitchell D.] Univ Pittsburgh, Dept Epidemiol, Grad Sch Publ Hlth, Pittsburgh, PA 15213 USA. RP Borrero, S (reprint author), Univ Pittsburgh, Sch Med, Div Gen Internal Med, 230 McKee Pl,Suite 600, Pittsburgh, PA 15213 USA. EM borrerosp@upmc.edu RI Potter, Joseph/A-3122-2008 OI Schwarz, Eleanor Bimla/0000-0002-9912-8236; Moore, Charity/0000-0002-0060-0124 FU National Center for Research Resources (NCRR) [05 KL2 RR024154-04]; National Institutes of Health (NIH) FX This manuscript was made possible by Dr. Borrero's grant (05 KL2 RR024154-04) from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research. The content of this publication is solely the responsibility of tire authors and does not necessarily represent the official view of NCRR or NIH. NR 50 TC 17 Z9 17 U1 1 U2 9 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD FEB PY 2010 VL 25 IS 2 BP 122 EP 128 DI 10.1007/s11606-009-1197-0 PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 558LV UT WOS:000274744800007 PM 19967463 ER PT J AU Dhand, A Dhaliwal, G AF Dhand, Amar Dhaliwal, Gurpreet TI Examining Patient Conceptions: A Case of Metastatic Breast Cancer in an African American Male to Female Transgender Patient SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE transgender; breast cancer; estrogen; ethnography ID CARE; CULTURE; WOMEN AB An African American male to female transgender patient treated with estrogen detected a breast lump that was confirmed by her primary care provider. The patient refused mammography and 14 months later she was diagnosed with metastatic breast cancer with spinal cord compression. We used ethnographic interviews and observations to elicit the patient's conceptions of her illness and actions. The patient identified herself as biologically male and socially female; she thought that the former protected her against breast cancer: she had fears that excision would make a breast tumor spread; and she believed injectable estrogens were less likely than oral estrogens to cause cancer. Analysis suggests dissociation between the patient's social and biological identities, fear and fatalism around cancer screening, and legitimization of injectable hormones. This case emphasizes the importance of eliciting and interpreting a patient's conceptions of health and illness when discordant understandings develop between patient and physician. C1 [Dhaliwal, Gurpreet] San Francisco VA Med Ctr, Med Serv 1111, San Francisco, CA 94121 USA. [Dhaliwal, Gurpreet] San Francisco VA Med Ctr, Dept Med, San Francisco, CA 94121 USA. [Dhand, Amar] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. RP Dhaliwal, G (reprint author), San Francisco VA Med Ctr, Med Serv 1111, 4150 Clement St, San Francisco, CA 94121 USA. EM gurpreet.dhaliwal@va.gov NR 16 TC 10 Z9 10 U1 1 U2 7 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD FEB PY 2010 VL 25 IS 2 BP 158 EP 161 DI 10.1007/s11606-009-1159-6 PG 4 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 558LV UT WOS:000274744800014 PM 19898907 ER PT J AU Washington, DL Yano, EM McGuire, J Hines, V Lee, M Gelberg, L AF Washington, Donna L. Yano, Elizabeth M. McGuire, James Hines, Vivian Lee, Martin Gelberg, Lillian TI Risk Factors for Homelessness among Women Veterans SO JOURNAL OF HEALTH CARE FOR THE POOR AND UNDERSERVED LA English DT Article DE Homeless people; women; hospitals; veterans/utilization; ambulatory care/utilization; health services accessibility; health services needs and demands ID AMBULATORY-CARE USE; HEALTH-CARE; LOGISTIC-REGRESSION; PATIENT POPULATION; FEMALE VETERANS; MEDICAL-CARE; NEEDS; VICTIMIZATION; RELIABILITY; DISORDER AB Background. Women veterans are three to four times more likely than non-veteran women to become homeless. However, their risk factors for homelessness have not been defined. Methods. Case-control study of non-institutionalized homeless women veterans (n=33) and age-matched housed women veterans (n=165). Health, health care, and factors associated with homelessness were assessed using multiple logistic regression with a Monte Carlo algorithm to estimate exact standard errors of the model coefficients and p-values. Results. Characteristics associated with homelessness were sexual assault during military service, being unemployed, being disabled, having worse overall health, and screening positive for an anxiety disorder or post-traumatic stress disorder. Protective factors were being a college graduate or married. Conclusions. Efforts to assess housed women veterans' risk factors for homelessness should be integrated into clinical care programs within and outside the Veterans Administration. Programs that work to ameliorate risk factors may prevent these women's living situations from deteriorating over time. C1 [Washington, Donna L.; Yano, Elizabeth M.; Lee, Martin] VA Greater Los Angeles HSR&D Ctr Excellence, Los Angeles, CA USA. [Washington, Donna L.] Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90024 USA. [Yano, Elizabeth M.] Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA. [Hines, Vivian] VA Los Angeles Ambulatory Care Ctr VA Greater Los, Los Angeles, CA USA. RP Washington, DL (reprint author), VA Greater Los Angeles Hlth Care Syst, 11301 Wilshire Blvd,111G, Los Angeles, CA 90073 USA. EM donna.washington@va.gov NR 37 TC 17 Z9 17 U1 0 U2 14 PU JOHNS HOPKINS UNIV PRESS PI BALTIMORE PA JOURNALS PUBLISHING DIVISION, 2715 NORTH CHARLES ST, BALTIMORE, MD 21218-4363 USA SN 1049-2089 J9 J HEALTH CARE POOR U JI J. Health Care Poor Underserved PD FEB PY 2010 VL 21 IS 1 BP 81 EP 91 PG 11 WC Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 557WM UT WOS:000274700800007 ER PT J AU Parada, JP Yarnold, PR Uphold, CR Chmiel, JS DeHovitz, JA Goetz, MB Weinstein, RA McKoy, JM Chandler, KL Bennett, CL AF Parada, Jorge P. Yarnold, Paul R. Uphold, Constance R. Chmiel, Joan S. DeHovitz, Jack A. Goetz, Matthew B. Weinstein, Robert A. McKoy, June M. Chandler, Kevin L. Bennett, Charles L. TI Racial Variations in Care and Outcomes for Inpatient HIV-Related Pneumocystis Pneumonia SO JOURNAL OF HEALTH CARE FOR THE POOR AND UNDERSERVED LA English DT Article DE AIDS; HIV; Pneumocystis; PCP; race; ethnic; disparities; quality of care; outcomes ID ACQUIRED-IMMUNODEFICIENCY-SYNDROME; AFFAIRS MEDICAL SYSTEM; CARINII-PNEUMONIA; UNITED-STATES; MYOCARDIAL-INFARCTION; REPERFUSION THERAPY; INFECTED ADULTS; PHYSICIANS; RACE; EXPERIENCE AB Racial disparities in HIV-care include the disproportionate impact of HIV/AIDS on African Americans. We conducted a retrospective review of 1,855 cases at 78 hospitals in nine cities to evaluate racial variations in inpatient care for AIDS-related Pneumocystis pneumonia (PCP) shortly after the introduction of highly active anti-retroviral therapies. While inpatient HIV-related PCP mortality was comparable between Whites and Hispanics (p=0.94), African Americans were less likely than Whites to die in-hospital (AOR 0.69, 95% CI 0.48, 0.99) and more likely to receive timely anti-PCP medications (AOR 1.67, 95% CI 1.21, 2.30) and timely corticosteroids (AOR 1.46, 95% CI 1.17, 1.82). Findings were compared with those from our study involving 1,547 patients at 82 hospitals in five cities over the first decade of the AIDS epidemic. In contrast to the first study, in the second decade African Americans were more likely to receive timely and appropriate therapy for HIV-related PCP, and resultantly were more likely to survive the hospitalization. C1 [Parada, Jorge P.] Hines VA Hosp, Midwest Ctr Hlth Serv Res & Policy, Hines, IL USA. [Parada, Jorge P.] Loyola Univ, Stritch Sch Med, Maywood, IL 60153 USA. [Yarnold, Paul R.] Northwestern Univ, Feinberg Sch Med NW SOM, Dept Emergency Med, Chicago, IL 60611 USA. [Uphold, Constance R.] N Florida S Georgia Vet Hlth Syst, Gainesville, FL USA. [DeHovitz, Jack A.] SUNY Hlth Sci Ctr, Dept Preventat Med, Brooklyn, NY 11203 USA. [Goetz, Matthew B.] VA Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA USA. [Goetz, Matthew B.] Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90024 USA. [Weinstein, Robert A.] John H Stroger Jr Hosp Cook Cty, Rush Med Coll, Dept Med, Chicago, IL USA. [Bennett, Charles L.] Jesse Brown VA Med Ctr, Midwest Ctr Hlth Serv Res & Policy, Chicago, IL USA. [DeHovitz, Jack A.] SUNY Hlth Sci Ctr, Dept Med, Brooklyn, NY 11203 USA. RP McKoy, JM (reprint author), Northwestern Univ, 645 N Michigan Ave,Suite 630, Chicago, IL 60611 USA. EM jmmckoy@aol.com OI Goetz, Matthew/0000-0003-4542-992X NR 30 TC 0 Z9 0 U1 3 U2 6 PU JOHNS HOPKINS UNIV PRESS PI BALTIMORE PA JOURNALS PUBLISHING DIVISION, 2715 NORTH CHARLES ST, BALTIMORE, MD 21218-4363 USA SN 1049-2089 J9 J HEALTH CARE POOR U JI J. Health Care Poor Underserved PD FEB PY 2010 VL 21 IS 1 BP 318 EP 333 PG 16 WC Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 557WM UT WOS:000274700800022 PM 20173272 ER PT J AU Hiremath, J Thanikachalam, S Parikh, K Shanmugasundaram, S Bangera, S Shapiro, L Pott, GB Vnencak-Jones, CL Arneson, C Wade, M White, RJ AF Hiremath, Jagdish Thanikachalam, Sadagopa Parikh, Keyur Shanmugasundaram, Somasundaram Bangera, Sudhakar Shapiro, Leland Pott, Gregory B. Vnencak-Jones, Cindy L. Arneson, Carl Wade, Michael White, R. James CA TRUST Study Grp TI Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: A placebo-controlled trial SO JOURNAL OF HEART AND LUNG TRANSPLANTATION LA English DT Article DE pulmonary hypertension; prostacyclin; biomarkers; angiopoietin; six minute walk ID ENDOTHELIAL GROWTH-FACTOR; CONGESTIVE-HEART-FAILURE; EPOPROSTENOL PROSTACYCLIN; CELL GROWTH; ANGIOPOIETIN-2; SURVIVAL; GENE; INFUSION; MUTATION; DYSPNEA AB BACKGROUND: Pulmonary arterial hypertension (PAH) remains a poorly understood and frequently lethal disease with few treatment options. METHODS: We conducted a placebo-controlled trial of intravenous treprostinil, a prostacyclin analog, in treatment-naive PAH patients. During 12 weeks of treatment with treprostinil or placebo, we quantified 6-minute walk distance (6MW), clinical symptoms and 11 cytokines/growth factors. RESULTS: Forty-two of 44 study patients had idiopathic/familial PAH in New York Heart Association (NYHA) Class III. Treprostinil increased 6MW by a placebo-corrected median of 83 meters (p = 0.008; mean increase 93 +/- 42 meters), reduced Borg score by a median 2.0 units (p = 0.02), and improved NYHA class by a median of 1.0 (p = 0.02). There was a trend toward improved survival with treprostinil (p = 0.051). Baseline plasma angiopoietin-2 (Ang-2), vascular endothelial growth factor (VEGF), matrix metalloproteinase-9 (MMP-9) and platelet-derived growth factor (PDGF) were elevated compared with reported normal ranges. Treatment with treprostinil was associated with decreased Ang-2 levels. Improvement in 6MW distance after treatment was associated with reductions in Ang-2 and MMP-9 levels. Most of the cytokines and growth factors studied were not abnormal with disease nor did they change with treatment. CONCLUSIONS: We conclude that treprostinil treatment significantly improved exercise capacity, dyspnea and functional class. Several plasma proteins that might track disease were abnormal at baseline, and changes were associated with improved exercise capacity. J Heart Lung Transplant 2010;29:137-49 (C) 2010 International Society for Heart and Lung Transplantation. All rights reserved. C1 [White, R. James] Univ Rochester, Div Pulm & Crit Care Med, Rochester, NY 14623 USA. [Hiremath, Jagdish] Ruby Hall Clin, Pune, Maharashtra, India. [Thanikachalam, Sadagopa] Sri Ramachandra Med Coll, Chennai, Tamil Nadu, India. [Parikh, Keyur] SAL Hosp & Med Inst, Ahmadabad, Gujarat, India. [Shanmugasundaram, Somasundaram] KS Hosp, Chennai, Tamil Nadu, India. [Bangera, Sudhakar] Asian Clin Trials Ltd, Hyderabad, Andhra Pradesh, India. [Shapiro, Leland; Pott, Gregory B.] Denver Vet Affairs Med Ctr, Denver, CO USA. [Shapiro, Leland; Pott, Gregory B.] Univ Colorado, Denver, CO 80202 USA. [Vnencak-Jones, Cindy L.] Vanderbilt Univ, Med Ctr, Dept Pathol & Pediat, Nashville, TN USA. [Arneson, Carl; Wade, Michael] United Therapeut Corp, Res Triangle Pk, NC USA. RP White, RJ (reprint author), Univ Rochester, Div Pulm & Crit Care Med, 400 Red Creek Dr, Rochester, NY 14623 USA. EM jim_white@urmc.rochester.edu FU United Therapeutics Corporation; American Heart Association [073540N] FX Supported by United Therapeutics Corporation and by an American Heart Association National Scientist Development Grant (073540N) to R.J.W. NR 46 TC 80 Z9 84 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1053-2498 J9 J HEART LUNG TRANSPL JI J. Heart Lung Transplant. PD FEB PY 2010 VL 29 IS 2 SI SI BP 137 EP 149 DI 10.1016/j.healun.2009.09.005 PG 13 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery; Transplantation SC Cardiovascular System & Cardiology; Respiratory System; Surgery; Transplantation GA 558PC UT WOS:000274755700001 PM 20022264 ER PT J AU Murray, DR Osaki, S Jewel-Ripp, P Johnson, MR Lozonschi, L Edwards, NM Kohmoto, T AF Murray, D. R. Osaki, S. Jewel-Ripp, P. Johnson, M. R. Lozonschi, L. Edwards, N. M. Kohmoto, T. TI Heart Transplant Therapy in United States Veterans: 16-year Experience at A Single Center SO JOURNAL OF HEART AND LUNG TRANSPLANTATION LA English DT Meeting Abstract CT 30th Annual Meeting and Scientific Sessions of the International-Society-for-Heart-and-Lung-Transplantation CY APR 21-24, 2010 CL Chicago, IL SP Int Soc Heart & Lung Transplantat C1 [Murray, D. R.; Osaki, S.; Jewel-Ripp, P.; Johnson, M. R.; Lozonschi, L.; Edwards, N. M.; Kohmoto, T.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA. [Murray, D. R.; Osaki, S.; Jewel-Ripp, P.; Johnson, M. R.; Lozonschi, L.; Edwards, N. M.; Kohmoto, T.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1053-2498 J9 J HEART LUNG TRANSPL JI J. Heart Lung Transplant. PD FEB PY 2010 VL 29 IS 2 SU S MA 456 BP S150 EP S151 PG 2 WC Cardiac & Cardiovascular Systems; Respiratory System; Transplantation SC Cardiovascular System & Cardiology; Respiratory System; Transplantation GA 558PF UT WOS:000274756100454 ER PT J AU Mulligan, JK Rosenzweig, SA Young, MRI AF Mulligan, Jennifer K. Rosenzweig, Steven A. Young, M. Rita I. TI Tumor Secretion of VEGF Induces Endothelial Cells to Suppress T cell Functions Through the Production of PGE(2) SO JOURNAL OF IMMUNOTHERAPY LA English DT Article DE endothelial cell; T cells; tumor immunity; lung; cytokines ID GROWTH-FACTOR VEGF; HEPATOCELLULAR-CARCINOMA; SIGNALING PATHWAY; DENDRITIC CELLS; CANCER-PATIENTS; FACTOR-BETA; IN-VITRO; SU5416; ANGIOGENESIS; INHIBITION AB Endothelial cells are potent regulators of immune cell functions and have therefore been examined to determine their role in tumor-induced immune suppression. Previous studies by our laboratory showed that exposure to Lewis lung carcinoma (LLC)secreted products induced endothelial cells to suppress T-cell functions in vitro. The current studies examined in vitro and in vivo the mechanism by which tumors induce the formation of suppressor endothelial cells and the means by which suppressor endothelial cells disrupt T-cell functions. In vitro studies demonstrated that inhibition of tumor-derived VEGF with neutralizing antibodies or treatment of endothelial cells with the VEGF receptor tyrosine kinase inhibitor, SU5416, prevented endothelial cells from being induced to suppress T-cell functions. Treatment of tumor-bearing mice with SU5416 blocked the development of endothelial cells that are suppressive to CD4(+) and CD8(+) T-cell functions. We next examined the role of suppressor endothelial cell-derived PGE(2) in the inhibition of T-cell functions. Abrogation of endothelial cell PGE(2) production in vitro with indomethacin prevented tumor-conditioned media from stimulating endothelial cell production of immune inhibitory activity toward T-cell functions. Similar treatment of endothelial cells from lungs of tumor-bearing mice blocked their capacity to produce T-cell-inhibitory mediators. These studies demonstrate that tumor-derived VEGF induces endothelial cells to upregulate production of PGE(2) which, in turn, leads to suppression of T-cell functions. C1 [Mulligan, Jennifer K.; Young, M. Rita I.] Med Univ S Carolina, Dept Otolaryngol, Charleston, SC 29425 USA. [Rosenzweig, Steven A.] Med Univ S Carolina, Dept Cell & Mol Pharmacol & Expt Therapeut, Charleston, SC 29425 USA. [Young, M. Rita I.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Rosenzweig, Steven A.] Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA. [Young, M. Rita I.] Ralph H Johnson VA Med Ctr, Res Serv, Charleston, SC 29401 USA. RP Young, MRI (reprint author), Ralph H Johnson VA Med Ctr, Res Serv 151, 109 Bee St, Charleston, SC 29401 USA. EM rita.young@va.gov FU Research Services of the Department of Veterans Affairs; National Institutes of Health [R01CA85266, R01DE018168, 1R01CA128837] FX Supported by Research Services of the Department of Veterans Affairs and by grants R01CA85266, R01DE018168, and 1R01CA128837 from the National Institutes of Health to MRIY. NR 50 TC 16 Z9 16 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1524-9557 J9 J IMMUNOTHER JI J. Immunother. PD FEB-MAR PY 2010 VL 33 IS 2 BP 126 EP 135 DI 10.1097/CJI.0b013e3181b91c9c PG 10 WC Oncology; Immunology; Medicine, Research & Experimental SC Oncology; Immunology; Research & Experimental Medicine GA 562NZ UT WOS:000275060300002 PM 20145550 ER PT J AU Rueda, AM Ormond, M Gore, M Matloobi, M Giordano, TP Musher, DM AF Rueda, Adriana M. Ormond, Mandy Gore, Meghana Matloobi, Mahsa Giordano, Thomas P. Musher, Daniel M. TI Hyperglycemia in diabetics and non-diabetics: Effect on the risk for and severity of pneumococcal pneumonia SO JOURNAL OF INFECTION LA English DT Article DE Pneumococcus; Pneumonia; Diabetes mellitus; Hyperglycemia; Severity of disease ID COMMUNITY-ACQUIRED PNEUMONIA; BACTERICIDAL FUNCTION; GLYCEMIC CONTROL; INFECTIONS; OUTCOMES; GLUCOSE; HOSPITALIZATION; NEUTROPHILS; INHIBITION; MELLITUS AB Objectives: We sought to determine whether poor glucose control among diabetics is associated with increased risk for pneumococcal pneumonia and whether elevated admitting plasma glucose (APG) levels are associated with increased severity of this infection in diabetic and non-diabetic patients. Methods: We compared hemoglobin A(1c) (HbA(1c)) in diabetics who had pneumococcal pneumonia with diabetic case-controls who did not have pneumonia. In patients with pneumococcal pneumonia, we related APG to disease severity as determined by SMART-COP score, need for ICU admission, and mortality at 7 and 30 days. Results: Fifty-three of 233 patients with pneumococcal pneumonia (22.7%) were diabetic. Diabetics with pneumonia had poorer glycemic control than diabetic case-controls (HbA(1c) 8.2% vs. 7.2%, respectively, P < 0.01). In pneumococcal pneumonia patients, SMART-COP scores, need for ICU admission, and mortality increased in proportion to the APG. These findings were attributable to the significant association between hyperglycemia and severity in non-diabetics. Conclusions: Poor glycemic control predisposes diabetics to pneumococcal pneumonia but, among diabetics, the degree of hyperglycemia at admission is not associated with increased disease severity. In contrast, among non-diabetics with pneumococcal pneumonia, hyperglycemia is a marker for severe disease and increased mortality, perhaps reflecting massive release of cytokines and glucocorticosteroids in overwhelming infection. (C) 2009 The British Infection Society. Published by Elsevier Ltd. All rights reserved. C1 [Rueda, Adriana M.; Gore, Meghana; Matloobi, Mahsa; Musher, Daniel M.] Michael E DeBakey VA Med Ctr, Infect Dis Sect, Med Serv, Houston, TX 77030 USA. [Giordano, Thomas P.] Michael E DeBakey Vet Affairs Med Ctr, Hlth Serv Res & Dev Ctr Excellence, Houston, TX 77030 USA. [Rueda, Adriana M.; Ormond, Mandy; Giordano, Thomas P.; Musher, Daniel M.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. RP Rueda, AM (reprint author), Michael E DeBakey VA Med Ctr, Infect Dis Sect, Med Serv, Room 4B-370, Houston, TX 77030 USA. EM adrianam.rueda@med.va.gov FU Department of Veterans Affairs; Houston VA HSR&D Center of Excellence [HFP90-020] FX Dr. Musher's research is supported by the Department of Veterans Affairs through the Merit Review Program. Dr. Giordano is supported in part by the Houston VA HSR&D Center of Excellence (HFP90-020).; We gratefully acknowledge Christine Hartman and Louis Henderson for their assistance with the statistical analysis. NR 30 TC 20 Z9 20 U1 0 U2 7 PU W B SAUNDERS CO LTD PI LONDON PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND SN 0163-4453 J9 J INFECTION JI J. Infect. PD FEB PY 2010 VL 60 IS 2 BP 99 EP 105 DI 10.1016/j.jinf.2009.12.003 PG 7 WC Infectious Diseases SC Infectious Diseases GA 552IH UT WOS:000274282400002 PM 20005251 ER PT J AU McLarry, JD Aljaroudi, W Venkataraman, R Faulkner, M Heo, J Iskandrian, AE Hage, FG AF McLarry, J. D. Aljaroudi, W. Venkataraman, R. Faulkner, M. Heo, J. Iskandrian, A. E. Hage, F. G. TI VIABILITY ASSESSMENT USING AUTOMATED QUANTITATIVE ANALYSIS OF THALLIUM-201 MYOCARDIAL PERFUSION IMAGING SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Southern Regional Meeting 2010 CY FEB 25-27, 2010 CL New Orleans, LA SP SSCI, SAFMR, SSPR, SSGIM, APA C1 [McLarry, J. D.; Aljaroudi, W.; Venkataraman, R.; Faulkner, M.; Heo, J.; Iskandrian, A. E.; Hage, F. G.] Univ Alabama, Birmingham, AL USA. [Hage, F. G.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD FEB PY 2010 VL 58 IS 2 MA 94 BP 382 EP 383 PG 2 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 555HL UT WOS:000274499600100 ER PT J AU Hage, FG Oparil, S Xing, D Chen, Y McCrory, M Szalai, AJ AF Hage, F. G. Oparil, S. Xing, D. Chen, Y. McCrory, M. Szalai, A. J. TI C-REACTIVE PROTEIN MEDIATED VASCULAR INJURY REQUIRES COMPLEMENT SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Southern Regional Meeting 2010 CY FEB 25-27, 2010 CL New Orleans, LA SP SSCI, SAFMR, SSPR, SSGIM, APA C1 [Hage, F. G.; Oparil, S.; Xing, D.; Chen, Y.; McCrory, M.; Szalai, A. J.] Univ Alabama, Birmingham, AL USA. [Hage, F. G.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD FEB PY 2010 VL 58 IS 2 MA 287 BP 436 EP 437 PG 2 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 555HL UT WOS:000274499600293 ER PT J AU Ding, Y Wang, J Xie, S Li, H Mountz, JD AF Ding, Y. Wang, J. Xie, S. Li, H. Mountz, J. D. TI NUCLEAR EXPRESSION OF CXCR5 IN SPLEEN FOLLICULAR T HELPER CELLS IN AUTOIMMUNE BXD2 MICE SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Southern Regional Meeting 2010 CY FEB 25-27, 2010 CL New Orleans, LA SP SSCI, SAFMR, SSPR, SSGIM, APA C1 [Ding, Y.; Wang, J.; Xie, S.; Li, H.; Mountz, J. D.] Univ Alabama, Birmingham, AL USA. [Mountz, J. D.] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD FEB PY 2010 VL 58 IS 2 MA 304 BP 441 EP 442 PG 2 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 555HL UT WOS:000274499600310 ER PT J AU Martinez, DY Heudebert, G Henostroza, G Rodriguez, M Zamudio, C Centor, RM Gotuzzo, E Estrada, CA AF Martinez, D. Y. Heudebert, G. Henostroza, G. Rodriguez, M. Zamudio, C. Centor, R. M. Gotuzzo, E. Estrada, C. A. TI A NOVEL CLINICAL PREDICTION RULE FOR MULTIDRUG-RESISTANT TUBERCULOSIS SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Southern Regional Meeting 2010 CY FEB 25-27, 2010 CL New Orleans, LA SP SSCI, SAFMR, SSPR, SSGIM, APA C1 [Martinez, D. Y.; Henostroza, G.; Zamudio, C.; Gotuzzo, E.] Univ Peruana Cayetano Heredia, Lima, Peru. [Martinez, D. Y.; Heudebert, G.; Henostroza, G.; Rodriguez, M.; Centor, R. M.; Estrada, C. A.] Univ Alabama, Birmingham, AL USA. [Heudebert, G.; Centor, R. M.; Estrada, C. A.] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD FEB PY 2010 VL 58 IS 2 MA 461 BP 486 EP 486 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 555HL UT WOS:000274499600467 ER PT J AU Snyder, ED Salanitro, A Castiglioni, A Estrada, C AF Snyder, E. D. Salanitro, A. Castiglioni, A. Estrada, C. TI PRACTICE MATTERS: RELATIONSHIP BETWEEN PREPARATION STYLE AND CHANGES MADE TO SCIENTIFIC PRESENTATIONS SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Southern Regional Meeting 2010 CY FEB 25-27, 2010 CL New Orleans, LA SP SSCI, SAFMR, SSPR, SSGIM, APA C1 [Snyder, E. D.; Salanitro, A.; Castiglioni, A.; Estrada, C.] UAB, Birmingham, AL USA. [Snyder, E. D.; Salanitro, A.; Castiglioni, A.; Estrada, C.] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD FEB PY 2010 VL 58 IS 2 MA 498 BP 497 EP 497 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 555HL UT WOS:000274499600504 ER PT J AU Snyder, ED Salanitro, A Castiglioni, A Estrada, C AF Snyder, E. D. Salanitro, A. Castiglioni, A. Estrada, C. TI PREPARING FOR ORAL PRESENTATIONS: VARIATIONS IN PREPARATION BY LEVEL OF TRAINING SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Southern Regional Meeting 2010 CY FEB 25-27, 2010 CL New Orleans, LA SP SSCI, SAFMR, SSPR, SSGIM, APA C1 [Snyder, E. D.; Salanitro, A.; Castiglioni, A.; Estrada, C.] UAB, Birmingham, AL USA. [Snyder, E. D.; Salanitro, A.; Castiglioni, A.; Estrada, C.] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD FEB PY 2010 VL 58 IS 2 MA 508 BP 500 EP 500 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 555HL UT WOS:000274499600514 ER PT J AU Burton, M Charlton, K Estrada, C Ritchie, C AF Burton, M. Charlton, K. Estrada, C. Ritchie, C. TI RESIDENT INPATIENT HANDOFFS: A MULTI-METHOD QUALITY IMPROVEMENT INITIATIVE SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Southern Regional Meeting 2010 CY FEB 25-27, 2010 CL New Orleans, LA SP SSCI, SAFMR, SSPR, SSGIM, APA C1 [Burton, M.; Charlton, K.; Estrada, C.; Ritchie, C.] UAB, Birmingham, AL USA. [Burton, M.; Estrada, C.; Ritchie, C.] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD FEB PY 2010 VL 58 IS 2 MA 510 BP 501 EP 501 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 555HL UT WOS:000274499600516 ER PT J AU Estrada, C Salanitro, A Safford, M Curry, W Williams, J Ovalle, F Payne-Foster, P Kim, Y Houston, T Allison, J AF Estrada, C. Salanitro, A. Safford, M. Curry, W. Williams, J. Ovalle, F. Payne-Foster, P. Kim, Y. Houston, T. Allison, J. TI A CLUSTER-RANDOMIZED TRIAL OF A WEB-BASED PHYSICIAN INTERVENTION TO IMPROVE DIABETES CARE SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Southern Regional Meeting 2010 CY FEB 25-27, 2010 CL New Orleans, LA SP SSCI, SAFMR, SSPR, SSGIM, APA C1 [Estrada, C.; Salanitro, A.; Curry, W.] Birmingham VA Med Ctr, Birmingham, AL USA. [Estrada, C.; Salanitro, A.; Safford, M.; Curry, W.; Williams, J.; Ovalle, F.; Kim, Y.] Univ Alabama, Birmingham, AL USA. [Payne-Foster, P.] Univ Alabama, Tuscaloosa, AL USA. [Houston, T.; Allison, J.] Univ Massachusetts, Boston, MA 02125 USA. RI Houston, Thomas/F-2469-2013 NR 0 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD FEB PY 2010 VL 58 IS 2 MA 512 BP 501 EP 501 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 555HL UT WOS:000274499600518 ER PT J AU Conde, M Wathen, P Lawrence, V AF Conde, M. Wathen, P. Lawrence, V. TI USING STANDARDIZED PATIENTS TO TEACH ALCOHOL SCREENING SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Southern Regional Meeting 2010 CY FEB 25-27, 2010 CL New Orleans, LA SP SSCI, SAFMR, SSPR, SSGIM, APA C1 [Conde, M.; Lawrence, V.] Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX 78284 USA. [Conde, M.; Wathen, P.; Lawrence, V.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD FEB PY 2010 VL 58 IS 2 MA 515 BP 502 EP 502 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 555HL UT WOS:000274499600521 ER PT J AU Newson, J Willett, L Panisko, D Estrada, C AF Newson, J. Willett, L. Panisko, D. Estrada, C. TI SELECTING THE BEST CLINICAL VIGNETTES: SHOULD THE SCORING TOOL CRITERIA BE MODIFIED? SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Southern Regional Meeting 2010 CY FEB 25-27, 2010 CL New Orleans, LA SP SSCI, SAFMR, SSPR, SSGIM, APA C1 [Newson, J.; Willett, L.; Estrada, C.] Univ Alabama, Birmingham, AL USA. [Panisko, D.] Univ Toronto, Toronto, ON, Canada. [Estrada, C.] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD FEB PY 2010 VL 58 IS 2 MA 522 BP 504 EP 504 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 555HL UT WOS:000274499600528 ER PT J AU Georgopoulos, AP Tan, HRM Lewis, SM Leuthold, AC Winskowski, AM Lynch, JK Engdahl, B AF Georgopoulos, A. P. Tan, H-R M. Lewis, S. M. Leuthold, A. C. Winskowski, A. M. Lynch, J. K. Engdahl, B. TI The synchronous neural interactions test as a functional neuromarker for post-traumatic stress disorder (PTSD): a robust classification method based on the bootstrap SO JOURNAL OF NEURAL ENGINEERING LA English DT Article ID BIOMARKER AB Traumatic experiences can produce post-traumatic stress disorder (PTSD) which is a debilitating condition and for which no biomarker currently exists (Institute of Medicine ( US) 2006 Posttraumatic Stress Disorder: Diagnosis and Assessment (Washington, DC: National Academies)). Here we show that the synchronous neural interactions (SNI) test which assesses the functional interactions among neural populations derived from magnetoencephalographic (MEG) recordings (Georgopoulos A P et al 2007 J. Neural Eng. 4 349-55) can successfully differentiate PTSD patients from healthy control subjects. Externally cross-validated, bootstrap-based analyses yielded >90% overall accuracy of classification. In addition, all but one of 18 patients who were not receiving medications for their disease were correctly classified. Altogether, these findings document robust differences in brain function between the PTSD and control groups that can be used for differential diagnosis and which possess the potential for assessing and monitoring disease progression and effects of therapy. C1 [Georgopoulos, A. P.; Tan, H-R M.; Lewis, S. M.; Leuthold, A. C.; Winskowski, A. M.; Lynch, J. K.] US Dept Vet Affairs, Med Ctr 11B, Brain Sci Ctr, Minneapolis, MN 55417 USA. [Georgopoulos, A. P.; Tan, H-R M.; Leuthold, A. C.; Lynch, J. K.] Univ Minnesota, Sch Med, Dept Neurosci, Minneapolis, MN 55455 USA. [Lewis, S. M.] Univ Minnesota, Sch Med, Dept Neurol, Minneapolis, MN 55455 USA. [Georgopoulos, A. P.] Univ Minnesota, Sch Med, Dept Psychiat, Minneapolis, MN 55455 USA. [Georgopoulos, A. P.] Univ Minnesota, Ctr Cognit Sci, Minneapolis, MN 55455 USA. [Georgopoulos, A. P.; Winskowski, A. M.; Engdahl, B.] US Dept Vet Affairs, Med Ctr 11B, Psychol Sect, Minneapolis, MN 55417 USA. [Engdahl, B.] Univ Minnesota, Dept Psychol, Minneapolis, MN USA. [Tan, H-R M.] Univ Glasgow, Ctr Cognit Neuroimaging, Glasgow G12 8QB, Lanark, Scotland. RP Georgopoulos, AP (reprint author), US Dept Vet Affairs, Med Ctr 11B, Brain Sci Ctr, Minneapolis, MN 55417 USA. EM omega@umn.edu OI Tan, Heng-Ru May/0000-0003-2109-0781 FU United States Department of Veterans Affairs [VISN23]; American Legion Brain Sciences Chair FX We thank Nancy Tabaka and Cynthia Marceau for their help in patient consent and various aspects of database entry. This work was partially supported by a grant from the United States Department of Veterans Affairs VISN23 and the American Legion Brain Sciences Chair. A P Georgopoulos has a financial interest in the technology described in this publication. NR 13 TC 38 Z9 38 U1 1 U2 11 PU IOP PUBLISHING LTD PI BRISTOL PA DIRAC HOUSE, TEMPLE BACK, BRISTOL BS1 6BE, ENGLAND SN 1741-2560 J9 J NEURAL ENG JI J. Neural Eng. PD FEB PY 2010 VL 7 IS 1 AR 016011 DI 10.1088/1741-2560/7/1/016011 PG 7 WC Engineering, Biomedical; Neurosciences SC Engineering; Neurosciences & Neurology GA 567WQ UT WOS:000275479000011 PM 20086271 ER PT J AU Aqel, RA Hage, FG Iskandrian, AE AF Aqel, Raed A. Hage, Fadi G. Iskandrian, Ami E. TI Improvement of myocardial perfusion with a percutaneously inserted left ventricular assist device SO JOURNAL OF NUCLEAR CARDIOLOGY LA English DT Article ID CARDIOGENIC-SHOCK; INFARCTION; SAFETY; LP2.5 C1 [Aqel, Raed A.; Hage, Fadi G.; Iskandrian, Ami E.] Univ Alabama, Div Cardiovasc Dis, Birmingham, AL 35294 USA. [Aqel, Raed A.; Hage, Fadi G.] Birmingham Vet Affairs Med Ctr, Div Cardiol, Birmingham, AL USA. RP Aqel, RA (reprint author), Univ Alabama, Div Cardiovasc Dis, BDB 383,1530 3rd AVE S, Birmingham, AL 35294 USA. EM raed.aqel@med.va.gov OI Hage, Fadi/0000-0002-1397-4942 NR 10 TC 3 Z9 4 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1071-3581 J9 J NUCL CARDIOL JI J. Nucl. Cardiol. PD FEB PY 2010 VL 17 IS 1 BP 158 EP 160 DI 10.1007/s12350-009-9127-4 PG 3 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA 546ZF UT WOS:000273853600019 PM 19685267 ER PT J AU Nourhashemi, F Rikkert, MGO Burns, A Winblad, B Frisoni, GB Fitten, J Vellas, B AF Nourhashemi, F. Rikkert, M. G. Olde Burns, A. Winblad, B. Frisoni, G. B. Fitten, J. Vellas, B. TI FOLLOW-UP FOR ALZHEIMER PATIENTS: EUROPEAN ALZHEIMER DISEASE CONSORTIUM POSITION PAPER SO JOURNAL OF NUTRITION HEALTH & AGING LA English DT Article DE Alzheimer; follow-up; management; treatment; caregiver ID RANDOMIZED CONTROLLED-TRIAL; NURSING-HOME RESIDENTS; MINI NUTRITIONAL ASSESSMENT; MILD COGNITIVE IMPAIRMENT; MENTAL-STATE-EXAMINATION; HIP FRACTURE PATIENTS; LOW BODY-WEIGHT; OF-LIFE CARE; RISK-FACTORS; ELDERLY-PATIENTS AB Background and purpose: Alzheimer disease (AD) is one of the leading causes of dependence in the elderly. Providing care for patients with AD is complex and the type of care required depends on the stage of the disease and varies over time. The aim of this article is to discuss available care strategies once the AD diagnosis has been made and to propose a follow-up plan as standard of care at a European level. Methods: The proposals developed in this article stem from the collaborative work of a panel of multidisciplinary experts involved in the care of AD patients (European Alzheimer Disease Consortium) based on the results of published scientific studies and on their experience from clinical practice. Conclusion: Suggestions for follow-up frequency and easily administered and scored assessment tools are provided, thereby increasing efficiency and quality of care for patients with Alzheimer disease. C1 [Nourhashemi, F.; Vellas, B.] Hop Toulouse, Toulouse, France. [Nourhashemi, F.; Vellas, B.] Fac Med Toulouse, INSERM, U558, F-31073 Toulouse, France. [Rikkert, M. G. Olde] Radboud Univ Nijmegen, Alzheimer Ctr Nijmegen, Dept Geriatr, Med Ctr, Nijmegen, Netherlands. [Burns, A.] Univ Manchester, Psychiat Res Grp, Manchester M13 9PL, Lancs, England. [Winblad, B.] Karolinska Inst, Alzheimer Dis Res Ctr, Stockholm, Sweden. [Frisoni, G. B.] IRCCS, Ctr San Giovanni Dio Fatebenefratelli, Brescia, Italy. [Fitten, J.] Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA. RP Nourhashemi, F (reprint author), Univ Hosp, Dept Internal Med & Clin Gerontol, Alzheimers Dis Res & Clin Ctr, 170 Chemin Casselardit, F-31059 Toulouse, France. EM nourhashemi.f@chu-toulouse.fr RI Olde Rikkert, Marcel/D-9773-2012; Olde Rikkert, M.G.M./H-8078-2014; Frisoni, Giovanni B/K-1360-2016 OI Olde Rikkert, M.G.M./0000-0003-1397-1677; Frisoni, Giovanni B/0000-0002-6419-1753; Burns, Alistair/0000-0002-9837-0645 NR 217 TC 3 Z9 3 U1 6 U2 7 PU SPRINGER FRANCE PI PARIS PA 22 RUE DE PALESTRO, PARIS, 75002, FRANCE SN 1279-7707 J9 J NUTR HEALTH AGING JI J. Nutr. Health Aging PD FEB PY 2010 VL 14 IS 2 BP 121 EP 130 DI 10.1007/s12603-010-0023-z PG 10 WC Geriatrics & Gerontology; Nutrition & Dietetics SC Geriatrics & Gerontology; Nutrition & Dietetics GA 581MG UT WOS:000276526800008 PM 20126960 ER PT J AU Harber, P Santiago, S Wu, S Bansal, S Liu, YH Yun, D AF Harber, Philip Santiago, Silverio Wu, Samantha Bansal, Siddharth Liu, Yihang Yun, David TI Subjective Response to Respirator Type: Effect of Disease Status and Gender SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID NEW-ORLEANS; SIMULATED WORK; HEART-RATE; EXERCISE; PROTECTION; MASKS; ACCEPTABILITY; TEMPERATURE; PERFORMANCE; TOLERANCE AB Objective: To assess the effect of respirator type and user characteristics (eg, health status) on the subjective response to respirator use. Methods: The subjective responses for multiple domains were evaluated in 104 volunteers performing work tasks in a simulated work environment. Each used a dual cartridge half face mask and a filtering facepiece (N95) respirator. The study population was recruited to include four groups (normal respiratory status, mild asthma, chronic obstructive pulmonary disease, or chronic rhinitis). Mixed model regression analyses determined the effects of respirator type, disease, gender, and age. Results: Half face mask produced more adverse Subjective response than the N95 for most scales. There were significant interactions such that disease status modified the effect of respirator type. In general, women reported greater adverse ratings than did men. Conclusions: The effect of respirator type depends oil disease status. Respirator design evaluation panels should include persons with mild respiratory disease. C1 [Harber, Philip; Wu, Samantha; Bansal, Siddharth; Liu, Yihang; Yun, David] Univ Calif Los Angeles, David Geffen Sch Med, Occupat & Environm Med Div, Dept Family Med, Los Angeles, CA 90024 USA. [Santiago, Silverio] VA Greater Los Angeles Healthcare Syst, Dept Med, Div Pulm Med, Los Angeles, CA USA. RP Harber, P (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Occupat & Environm Med Div, Dept Family Med, 10880 Wilshire,1800, Los Angeles, CA 90024 USA. EM pharber@mednet.ucla.edu FU CDC/NIOSH [R01 OH-8119] FX This work was supported by grant R01 OH-8119 from CDC/NIOSH NR 32 TC 4 Z9 4 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1076-2752 J9 J OCCUP ENVIRON MED JI J. Occup. Environ. Med. PD FEB PY 2010 VL 52 IS 2 BP 150 EP 154 DI 10.1097/JOM.0b013e3181cfcf09 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 555ET UT WOS:000274491600006 PM 20134339 ER PT J AU Harber, P Santiago, S Bansal, S Liu, YH Yun, D Wu, S AF Harber, Philip Santiago, Silverio Bansal, Siddharth Liu, Yihang Yun, David Wu, Samantha TI Respirator Physiologic Impact in Persons With Mild Respiratory Disease SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID CONTAINED BREATHING APPARATUS; INDUCTIVE PLETHYSMOGRAPHY; INSPIRATORY RESISTANCE; EXHALATION RESISTANCES; PHYSICAL PERFORMANCE; DEMAND RESPIRATOR; WORK PERFORMANCE; SIMULATED WORK; LUNG-DISEASE; FACE MASKS AB Objective: To assess whether mild respiratory disease affects physiologic adaptation to respirator use. Methods: The study compared the respiratory effects of dual cartridge half face mask and filtering facepeice (N95) respirators while performing simulated-work tasks. Subjects with mild chronic obstructive pulmonary disease (n = 14), asthma (n = 42), chronic rhinitis (n = 17), and normal respiratory status (n = 24) were studied. Mixed model regression analyses determined the effects of respirator type, disease status. and the respirator-disease interactions. Results: Respirator type significantly affected several physiologic measures. Respirator type effects differed among disease categories as shown by statistically significant interaction terms. Respiratory timing parameters were more affected than ventilatory volumes. In general, persons with asthma showed greater respirator-disease interactions than chronic obstructive pulmonary disease, rhinitis, or healthy Subjects. Conclusions: The effects of respirator type differ according to the category of respiratory disease. C1 [Harber, Philip; Bansal, Siddharth; Liu, Yihang; Yun, David; Wu, Samantha] Univ Calif Los Angeles, David Geffen Sch Med, Occupat & Environm Med Div, Dept Family Med, Los Angeles, CA 90095 USA. [Santiago, Silverio] VA Greater Los Angeles Healthcare Syst, Div Pulm Med, Dept Med, Los Angeles, CA USA. RP Harber, P (reprint author), UCLA Occupat & Environm Med, 10880 Wilshire,1800, Los Angeles, CA 90024 USA. EM pharber@mednet.ucla.edu FU CDC/NIOSH [R01 OH-8119] FX Supported by Grant R01 OH-8119 from CDC/NIOSH. NR 45 TC 7 Z9 7 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1076-2752 J9 J OCCUP ENVIRON MED JI J. Occup. Environ. Med. PD FEB PY 2010 VL 52 IS 2 BP 155 EP 162 DI 10.1097/JOM.0b013e3181ca0ec9 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 555ET UT WOS:000274491600007 PM 20134350 ER PT J AU Morishita, Y Naito, M Miyazaki, M He, WB Wu, GZ Wei, F Sintuu, C Hymanson, H Brochmann, EJ Murray, SS Wang, JC AF Morishita, Yuichiro Naito, Masatoshi Miyazaki, Masashi He, Wubing Wu, Guizhong Wei, Feng Sintuu, Chananit Hymanson, Henry Brochmann, Elsa J. Murray, Samuel S. Wang, Jeffrey C. TI Enhanced Effects of BMP-Binding Peptide Combined with Recombinant Human BMP-2 on the Healing of a Rodent Segmental Femoral Defect SO JOURNAL OF ORTHOPAEDIC RESEARCH LA English DT Article DE recombinant human bone morphogenetic protein-2 (rhBMP-2); BMP binding peptide (BBP); segmental femoral bone defect; osteogenic activity ID BONE MORPHOGENETIC PROTEIN; HUMAN OSTEOGENIC PROTEIN-1; FUSION; MODEL; REPAIR; RATS AB BMP-binding peptide (BBP) enhances the osteogenic activity of recombinant human bone morphogenetic protein-2 (rhBMP-2), but the mechanism underlying the enhancement remains unclear. We aimed to elucidate the potential enhanced efficacy of BBP using critical-sized segmental femoral bone defects in rats. Seventy defects in seven groups of rats were filled with various amounts (0, 2, 5, and 10 mu g) of rhBMP-2 with or without 1000 mu g BBP. Radiographs were obtained after 4 and 8 weeks. The animals were euthanized at 8 weeks, and femoral specimens were assessed manually, evaluated for bone volume using microcomputed tomography, and subjected to histological or biomechanical analysis. Although 10 mu g rhBMP-2 yielded consistent results in terms of bone healing and quality of bone repair across the segmental defect, lower doses of rhBMP-2 failed to induce satisfactory bone healing. However, the combined administration of lower doses of rhBMP-2 and BBP induced the formation of significantly large amounts of bone. Our results suggest that the combined administration of rhBMP-2 and BBP facilitates bone healing and has potential clinical applications. (C) 2009 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 28:258-264, 2010 C1 [Miyazaki, Masashi; He, Wubing; Wu, Guizhong; Wei, Feng; Sintuu, Chananit; Hymanson, Henry; Wang, Jeffrey C.] Univ Calif Santa Monica, Dept Orthopaed Surg, UCLA Comprehens Spine Ctr, Santa Monica, CA 90404 USA. [Morishita, Yuichiro; Naito, Masatoshi] Fukuoka Univ, Dept Orthopaed Surg, Fukuoka 81401, Japan. [Brochmann, Elsa J.; Murray, Samuel S.] VA Greater Los Angeles Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Sepulveda, CA 91343 USA. RP Wang, JC (reprint author), Univ Calif Santa Monica, Dept Orthopaed Surg, UCLA Comprehens Spine Ctr, 1250 16th St,Suite 745, Santa Monica, CA 90404 USA. EM JWang@mednet.ucla.edu NR 20 TC 9 Z9 9 U1 1 U2 8 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0736-0266 J9 J ORTHOP RES JI J. Orthop. Res. PD FEB PY 2010 VL 28 IS 2 BP 258 EP 264 DI 10.1002/jor.20970 PG 7 WC Orthopedics SC Orthopedics GA 544RD UT WOS:000273675700018 PM 19639633 ER PT J AU Sheahan, P Ahn, CN Harvey, RJ Wise, SK Mulligan, RM Lathers, DMR Schlosser, RJ AF Sheahan, Patrick Ahn, Chadwick N. Harvey, Richard J. Wise, Sarah K. Mulligan, Ryan M. Lathers, Deanne M. R. Schlosser, Rodney J. TI Local IgE Production in Nonatopic Nasal Polyposis SO JOURNAL OF OTOLARYNGOLOGY-HEAD & NECK SURGERY LA English DT Article DE chronic rhinosinusitis; IgE; local production; nasal polyps; specific IgE ID ALLERGIC FUNGAL RHINOSINUSITIS; EOSINOPHILIC INFLAMMATION; DIAGNOSIS; PATHOPHYSIOLOGY; SINUSITIS; RHINITIS; TISSUE; ASTHMA AB Introduction: Chronic rhinosinusitis with nasal polyposis (CRSwNP) represents an eosinophilic T-helper 2 inflammatory response. Local production of IgE within nasal polyps (NPs) has been demonstrated, suggesting a role for local IgE in the pathogenesis of NP in atopic CRS patients. We hypothesized that local IgE specific to inhalant allergens may also play a role in the genesis of NP in nonatopic CRS patients. Methods: Sinus and inferior turbinate tissue was obtained from nonatopic CRSwNP patients (n = 7), chronic rhinosinusitis without nasal polyps (CRSsNP) patients (n = 15), and healthy controls (n = 9) at the time of surgery. ImmunoCAP analysis (Phadia AB, Portage, MI) for 14 common inhalant antigens was performed on tissue homogenates to determine the antigen-specific response. Results: Total IgE levels did not differ in sinus or turbinate tissue between CRSwNP, CRSsNP, or control patients. CRSwNP sinus tissue had higher levels of specific IgE for cockroach and plantain (p = .03) than other groups and elevated Alternaria IgE levels when compared with CRSsNP sinus tissue (p < .05). No significant differences were found for any of the other antigen-specific IgE levels. Fifty-seven percent of CRSwNP polyps demonstrated a polyclonal IgE response, whereas the other 43% had no demonstrable antigen-specific IgE. In contrast, only 17% of CRSsNP patients demonstrated a polyclonal response within sinus tissue, whereas 67% had no detectable antigen-specific IgE. There was no significant difference in levels of IgE in inferior turbinate tissue between the groups (p > .05). Conclusions: Localized mucosal IgE specific to common inhalant allergens appears to play a role in a subset of CRSwNP patients without evidence of systemic atopy. C1 [Ahn, Chadwick N.; Harvey, Richard J.; Wise, Sarah K.; Mulligan, Ryan M.; Schlosser, Rodney J.] Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, Charleston, SC 29425 USA. [Sheahan, Patrick] S Infirm Victoria Univ Hosp, Dept Otolaryngol Head & Neck Surg, Cork, Ireland. [Wise, Sarah K.] Emory Univ, Dept Otolaryngol Head & Neck Surg, Atlanta, GA 30322 USA. [Lathers, Deanne M. R.] Ralph H Johnson VAMC, Res Serv, Charleston, SC USA. RP Schlosser, RJ (reprint author), Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, 135 Rutledge Ave,Suite 1130,MSC 550, Charleston, SC 29425 USA. EM schlossr@musc.edu RI Sheahan, Patrick/H-6153-2013 FU American Academy of Otolaryngic Allergy (AAOA); Flight Attendant Medical Research Institute; XoranTech; NeilMed FX Financial disclosure of authors: This research was supported in part by a grant from the American Academy of Otolaryngic Allergy (AAOA) ROADS Scholarship program. Dr. Schlosser receives grant support from the Flight Attendant Medical Research Institute, XoranTech, and NeilMed. Dr. Schlosser is a consultant for BrainLAB, Medtronic Xomed, and Gyrus and serves on the speaker's bureau for GlaxoSmithKlein and Schering Plough. Dr. Wise has received grant support from XoranTech. Dr. Lathers is currently employed by Bristol Myers Squibb. NR 22 TC 14 Z9 15 U1 1 U2 3 PU B C DECKER INC PI HAMILTON PA 50 KING STREET EAST, 2ND FLOOR, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA SN 1916-0216 J9 J OTOLARYNGOL-HEAD N JI J. Otolaryngol-Head Neck Surg. PD FEB PY 2010 VL 39 IS 1 BP 45 EP 51 DI 10.2310/7070.2009.080280 PG 7 WC Otorhinolaryngology SC Otorhinolaryngology GA 678BP UT WOS:000284043400009 PM 20122344 ER PT J AU Claxton, RN Blackhall, L Weisbord, SD Holley, JL AF Claxton, Rene N. Blackhall, Leslie Weisbord, Steven D. Holley, Jean L. TI Undertreatment of Symptoms in Patients on Maintenance Hemodialysis SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Article DE Dialysis patients; quality of life; symptom burden; symptom management; symptom assessment ID QUALITY-OF-LIFE; CHRONIC DIALYSIS PATIENTS; STAGE RENAL-DISEASE; DEPRESSION; CARE; PAIN; PREVALENCE; MORTALITY; PATTERNS; DOPPS AB Context. Hemodialysis patients suffer a large symptom burden, and little is known about how effectively symptoms are treated. Objectives. To assess the management of treatable symptoms in hemodialysis patients, we administered a 30-item questionnaire on physical and emotional symptoms to patients receiving outpatient hemodialysis at the University of Virginia. Methods. We asked patients whether they were prescribed therapy for potentially treatable symptoms and assessed who prescribed the therapy. By means of chart review, we also documented whether medications were prescribed for these symptoms. Results. We approached 87 patients and enrolled 62 (71%). The most commonly reported, potentially treatable symptoms included bone/joint pain, insomnia, mood disturbance, sexual dysfunction, paresthesia, and nausea. Only 45% of patients with bone/joint pain reported receiving an analgesic medication. Twenty-three percent of patients with trouble falling asleep and 53% of patients with nausea reported receiving a medication to alleviate this symptom. Chart review revealed that 58% of patients who reported the presence of bone/joint pain were prescribed an analgesic, 23% of patients with trouble falling asleep were prescribed a sleep aid, and 42% of patients with nausea received an antiemetic. Primary care providers were more likely than nephrologists to provide for all symptoms except nausea and numbness or tingling in the feet, and this difference was significant for the treatment of worrying (3/3 vs. 0/3, P= 0.05) and nervousness (4/5 vs. 0/5, P= 0.02). Conclusion. Potentially treatable symptoms in hemodialysis are undertreated. Pharmacologic therapy, particularly for emotional symptoms, was more commonly prescribed by primary care providers than nephrologists. Additional study of the barriers to symptom treatment and interventions that increase nephrologist and primary care provider symptom management are needed. J Pain Symptom Manage 2010;39:211-218. 2010 (C) U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved. C1 [Claxton, Rene N.] Univ Pittsburgh, Sch Med, Dept Internal Med, Div Palliat Care & Eth, Pittsburgh, PA 15213 USA. [Weisbord, Steven D.] Univ Pittsburgh, Sch Med, Dept Internal Med, Div Nephrol, Pittsburgh, PA 15213 USA. [Weisbord, Steven D.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Blackhall, Leslie] Univ Virginia Hlth Syst, Dept Internal Med, Div Gen Med Geriatr & Palliat Care, Charlottesville, VA USA. [Holley, Jean L.] Univ Illinois, Dept Internal Med, Div Nephrol, Urbana, IL 61801 USA. RP Claxton, RN (reprint author), Univ Pittsburgh, Sch Med, Dept Internal Med, Div Palliat Care & Eth, 200 Lothrop St,MUH G-100, Pittsburgh, PA 15213 USA. EM claxtonrn@upmc.edu NR 28 TC 38 Z9 42 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2010 VL 39 IS 2 BP 211 EP 218 DI 10.1016/j.jpainsymman.2009.07.003 PG 8 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 617KU UT WOS:000279280400005 PM 19963337 ER PT J AU Walling, A Asch, S Lorenz, K Roth, C Monica, S Barry, T Wenger, N AF Walling, Anne Asch, Steven Lorenz, Karl Roth, Carol Monica, Santa Barry, Tod Wenger, Neil TI Quality of End-of-Life Care in the Hospital SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract C1 [Walling, Anne; Monica, Santa; Barry, Tod; Wenger, Neil] Univ Calif Los Angeles, Los Angeles, CA USA. [Asch, Steven; Lorenz, Karl] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA. [Roth, Carol] RAND Corp, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2010 VL 39 IS 2 BP 332 EP 333 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 617KU UT WOS:000279280400042 ER PT J AU Goebel, J Compton, P Lanto, A Asch, S Sherbourne, C Zubkoff, L Lorenz, K AF Goebel, Joy Compton, Peggy Lanto, Andy Asch, Steven Sherbourne, Cathy Zubkoff, Lisa Lorenz, Karl TI Is it Pseudoaddiction? Prescription Sharing, Alcohol, and Street Drug Use to Manage Pain among Veterans SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract C1 [Goebel, Joy] Calif State Univ Long Beach, Long Beach, CA 90840 USA. [Compton, Peggy] Univ Calif Los Angeles, Los Angeles, CA USA. [Lanto, Andy] Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Asch, Steven] W Angeles VA, Los Angeles, CA USA. [Sherbourne, Cathy] RAND, Santa Monica, CA USA. [Zubkoff, Lisa] Dept Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Lorenz, Karl] Vet Adm Greater Los Angeles, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2010 VL 39 IS 2 BP 340 EP 340 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 617KU UT WOS:000279280400053 ER PT J AU Bikson, K Lorenz, K Milch, M AF Bikson, Karra Lorenz, Karl Milch, Mario TI Organizational Challenges to Implementing Hospital-Based Palliative Care SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract C1 [Bikson, Karra] NYU, New York, NY USA. [Lorenz, Karl] VA Greater Angeles, Los Angeles, CA USA. [Milch, Mario] Vitas, Encino, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2010 VL 39 IS 2 BP 386 EP 387 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 617KU UT WOS:000279280400129 ER PT J AU Walling, A Lorenz, K Asch, S Malin, J Roth, C Wenger, N AF Walling, Anne Lorenz, Karl Asch, Steven Malin, Jennifer Roth, Carol Wenger, Neil TI Quality of Supportive Care among Inpatients Dying with Advanced Cancer SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract C1 [Walling, Anne; Wenger, Neil] Univ Calif Los Angeles, Los Angeles, CA USA. [Lorenz, Karl] VA Greater Los Angeles, Los Angeles, CA USA. [Asch, Steven] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA. [Roth, Carol] RAND Corp, Santa Monica, CA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2010 VL 39 IS 2 BP 393 EP 393 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 617KU UT WOS:000279280400139 ER PT J AU Hadid, T Sanchez-Reilly, S AF Hadid, Tank Sanchez-Reilly, Sandra TI Implications of Interdisciplinary Palliative Care when Caring for Older Adults with Advanced Cancer SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract C1 [Hadid, Tank; Sanchez-Reilly, Sandra] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Sanchez-Reilly, Sandra] S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2010 VL 39 IS 2 BP 394 EP 394 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 617KU UT WOS:000279280400141 ER PT J AU Davila, A Garza, M Lee, S Ross, J Sanchez-Reilly, S AF Davila, Angelica Garza, Mary Lee, Shuko Ross, Jeanette Sanchez-Reilly, Sandra TI Effectiveness of a Geriatric Palliative Care Consult on Pain Management and Advance Directives among Older Adults SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract C1 [Davila, Angelica; Ross, Jeanette; Sanchez-Reilly, Sandra] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Garza, Mary] Univ Texas San Antonio, San Antonio, TX USA. [Lee, Shuko] S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2010 VL 39 IS 2 BP 395 EP 395 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 617KU UT WOS:000279280400142 ER PT J AU Goldstein, NE Gabrielle, W AF Goldstein, Nathan E. Gabrielle, Wendy TI State of the Science: Update in Hospice and Palliative Care SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract C1 [Goldstein, Nathan E.] Mt Sinai Sch Med, New York, NY USA. [Goldstein, Nathan E.] James J Peters VA Med Ctr, New York, NY USA. [Gabrielle, Wendy] Univ Calif San Francisco, Sch Med, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2010 VL 39 IS 2 BP 405 EP 405 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 617KU UT WOS:000279280400160 ER PT J AU Fromme, E Lorenz, K Kutner, J AF Fromme, Erik Lorenz, Karl Kutner, Jean TI Palliative Care Research Issues and Methods: Pain Assessment, Prognostication, and CAM (518) SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract C1 [Fromme, Erik] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Lorenz, Karl] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA. [Kutner, Jean] Univ Colorado, Denver Sch Med, Aurora, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2010 VL 39 IS 2 BP 414 EP 414 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 617KU UT WOS:000279280400177 ER PT J AU Dy, S Lorenz, K Bull, J Abernethy, A AF Dy, Sydney Lorenz, Karl Bull, Janet Abernethy, Amy TI Update in Quality and How to Use New Resources for Quality Measurement in Palliative Care (521) SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract C1 [Dy, Sydney] Johns Hopkins Sch Publ Hlth, Linthicum, MD USA. [Lorenz, Karl] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA. [Bull, Janet] Four Seasons, Flat Rock, NC USA. [Abernethy, Amy] Duke Univ, Sch Med, Durham, NC USA. OI Abernethy, Amy/0000-0001-6930-8722 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2010 VL 39 IS 2 BP 415 EP 416 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 617KU UT WOS:000279280400180 ER PT J AU Andrews, C Patel, J Sanchez-Reilly, S Ross, J AF Andrews, Cody Patel, Jignesh Sanchez-Reilly, Sandra Ross, Jeanette TI Do Older Adults with Completed Advance Directives Really Understand Them? (704) SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract C1 [Andrews, Cody; Patel, Jignesh; Sanchez-Reilly, Sandra; Ross, Jeanette] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Sanchez-Reilly, Sandra] S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2010 VL 39 IS 2 BP 423 EP 423 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 617KU UT WOS:000279280400194 ER PT J AU Lowery, A Lee, S Sanchez-Reilly, S Ross, J AF Lowery, Ashlei Lee, Shuko Sanchez-Reilly, Sandra Ross, Jeanette TI Effect of Prior Experience with a Dying Person on Medical Students' Communication Skill with Terminally Ill Patients (732) SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract C1 [Sanchez-Reilly, Sandra] Univ Texas Hlth Sci Ctr San Antonio, S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2010 VL 39 IS 2 BP 439 EP 440 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 617KU UT WOS:000279280400220 ER PT J AU Patel, T Tabares, J Pugh, MJ AF Patel, Taral Tabares, Jeff Pugh, Mary Jo TI A Cause for Concern: Chronic Propoxyphene Use among Older Adults with Pain (740) SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract C1 [Patel, Taral; Tabares, Jeff] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Pugh, Mary Jo] S Texas Vet Hlth Care Syst, Helotes, TX USA. OI Pugh, Mary Jo/0000-0003-4196-7763 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2010 VL 39 IS 2 BP 444 EP 444 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 617KU UT WOS:000279280400228 ER PT J AU Anderson, WG Goldstein, NE AF Anderson, Wendy G. Goldstein, Nathan E. TI Update in Hospice and Palliative Care SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Review ID ADVANCED CANCER; METHADONE; THERAPY; ILLNESS; QTC C1 [Anderson, Wendy G.] Univ Calif San Francisco, Div Hosp Med, San Francisco, CA 94143 USA. [Anderson, Wendy G.] Univ Calif San Francisco, Palliat Care Program, San Francisco, CA 94143 USA. [Goldstein, Nathan E.] Mt Sinai Sch Med, Dept Geriatr & Adult Dev, New York, NY USA. [Goldstein, Nathan E.] James J Peters VA Med Ctr, Bronx, NY USA. RP Anderson, WG (reprint author), Univ Calif San Francisco, Div Hosp Med, 521 Parnassus Ave,Box 0903, San Francisco, CA 94143 USA. EM anderson.wg@gmail.com FU National Institute of Aging [K23 AG025933] FX Dr. Anderson was supported by a Junior Faculty Career Development Award from the National Palliative Care Research Center. Dr. Goldstein was supported by a Mentored Patient-Oriented Research Career Development Award from the National Institute of Aging (K23 AG025933). Drs. Anderson and Goldstein presented these articles for the State of the Science Plenary Session at the Annual Assembly of the American Academy of Hospice and Palliative Medicine and the Hospice and Palliative Nurses Association on March 28, 2009 in Austin, Texas. NR 15 TC 1 Z9 1 U1 0 U2 1 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 J9 J PALLIAT MED JI J. Palliat. Med. PD FEB PY 2010 VL 13 IS 2 BP 197 EP 202 DI 10.1089/jpm.2009.0252 PG 6 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 549VU UT WOS:000274083200021 PM 19929227 ER PT J AU Zhong, WW Xia, ZW Hinrichs, D Rosenbaum, JT Wegmann, KW Meyrowitz, J Zhang, ZL AF Zhong, Wenwei Xia, Zhenwei Hinrichs, David Rosenbaum, James T. Wegmann, Keith W. Meyrowitz, Jeffery Zhang, Zili TI Hemin Exerts Multiple Protective Mechanisms and Attenuates Dextran Sulfate Sodium-induced Colitis SO JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION LA English DT Article DE colitis; inflammatory bowel disease; interleukin-17; regulatory T cells ID INFLAMMATORY-BOWEL-DISEASE; REGULATORY T-CELLS; ROR-GAMMA-T; INTESTINAL INFLAMMATION; IL-17 PRODUCTION; MURINE COLITIS; OXYGENASE-1; DIFFERENTIATION; INTERLEUKIN-17; EXPRESSION AB Objective: Inflammatory bowel disease (IBD) is characterized by recurrent and severe gastrointestinal inflammation. Activation of inflammatory cells, such as T(H)17 lymphocytes, and/or deficiency of regulatory T cells (T(reg)) are responsible for the pathogenesis of 11313, As an acute phase reactant, heme oxygenase-1 (HO-1) has been shown to play an anti-inflammatory and immunomodulatory role in many disease processes. In this study, we used a dextran sulfate sodium (DSS)-induced murine colitis model to investigate the effect of upregulating HO-1 by hemin on the development of colonic inflammation. Materials and Methods: The mice were enterically challenged with 4% DSS. In addition, some mice were intraperitoneally administered with hemin or Sn-protoporphyrin (SnPP) on days 0, 1, and 6 after DSS treatment. The severity of colitis was evaluated by daily monitoring of weight change and diarrhea. At the end of the experiment, the colon, spleen, and mesenteric lymph nodes were harvested for histology and various immunological assays. Results: Compared to control groups, DSS challenge markedly induced HO-1 expression in the colon epithelium. Upregulation of HO-1 by hemin was further correlated with attenuation of DSS-induced colitis. In contrast, inhibition of endogenous HO-1 by SnPP aggravated the colitis. To further assess the anti-inflammatory mechanisms, we examined whether hemin enhanced the proliferation of T(reg) cells and suppressed the production of interleukin (IL)-17. Flow cytometry analysis revealed that hemin markedly expanded the CD4 + CD25 + Foxp3+ T(reg) population. Moreover, hemin attenuated IL-17 and T(H)17-related cytokines. This inhibition coincided with the attenuation of DSS-induced colitis. Finally, terminal deoxynucleotidyl transferase deoxyuridine triphosphate nick end-labeling assay showed that hemin treatment markedly reduced programmed cell death of colonic epithelium, indicating that hemin exerts a modulatory effect on the induction of T(re)g, IL-17, and apoptosis. Conclusions: These results demonstrate that upregulation of HO-1 by hemin ameliorated experimental colitis. Moreover, our study suggests a broader protective mechanism of hemin. C1 [Zhang, Zili] Oregon Hlth & Sci Univ, Dept Pediat, CDRCP, Portland, OR 97239 USA. [Zhong, Wenwei; Xia, Zhenwei] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Pediat, Shanghai 200030, Peoples R China. [Hinrichs, David; Wegmann, Keith W.] Portland VA Med Ctr, Dept Pediat, Portland, OR USA. [Rosenbaum, James T.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97239 USA. [Rosenbaum, James T.] Oregon Hlth & Sci Univ, Dept Ophthalmol, Portland, OR 97239 USA. RP Zhang, ZL (reprint author), Oregon Hlth & Sci Univ, Dept Pediat, CDRCP, 707 SW Gaines St, Portland, OR 97239 USA. EM zhangzi@ohsu.edu FU National Natural Science Foundation of China [30871022, 30570798]; National Institutes of Health [EY016788]; CDHNF/CCFA FX This study was supported by National Natural Science Foundation of China Grants 30871022 and 30570798 (Z.W.), National Institutes of Health Grants EY016788 (Z.Z.), and CDHNF/CCFA Young Investigator Award (Z.Z.). NR 61 TC 34 Z9 36 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0277-2116 J9 J PEDIATR GASTR NUTR JI J. Pediatr. Gastroenterol. Nutr. PD FEB PY 2010 VL 50 IS 2 BP 132 EP 139 DI 10.1097/MPG.0b013e3181c61591 PG 8 WC Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics SC Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics GA 548UQ UT WOS:000273994000006 PM 20081544 ER PT J AU Goodman, M New, AS Triebwasser, J Collins, KA Siever, L AF Goodman, Marianne New, Antonia S. Triebwasser, Joseph Collins, Katherine A. Siever, Larry TI PHENOTYPE, ENDOPHENOTYPE, AND GENOTYPE COMPARISONS BETWEEN BORDERLINE PERSONALITY DISORDER AND MAJOR DEPRESSIVE DISORDER SO JOURNAL OF PERSONALITY DISORDERS LA English DT Article ID SEROTONIN TRANSPORTER GENE; DEXAMETHASONE-SUPPRESSION TEST; POSTTRAUMATIC-STRESS-DISORDER; POSITRON-EMISSION-TOMOGRAPHY; HIPPOCAMPAL VOLUME REDUCTION; PITUITARY-ADRENAL AXIS; II COMPARISON SUBJECTS; OXIDASE-A GENE; FOLLOW-UP; MONOAMINE-OXIDASE AB Borderline personality disorders (BPD) and major depressive disorder (MDD) are distinct disorders with overlapping biological processes pertaining to emotional regulatory functions. However, while both disorders share affective symptomatology, the disturbance central to BPD is affective lability and its character is entirely different from the affective disturbance of MDD. This review highlights data from the last ten years and compares the two disorders' phenotypes, putative endophenotypes and genotypes, focusing heavily on neuroimaging findings. The familiality and phenotypic differences suggest that BPD differs in important ways with respect to symptomatology, prognosis, and heritability. The neurobiological findings in both MDD and BPD are still preliminary at present, and no coherent model for either disorder can be said to have emerged. Overlapping biological processes including amygdala hyperreactivity, volume changes in subgenual anterior cingulate cortex, and deficient serotonergic function appear to underlie emotional dysregulation in both disorders. However, the disorders seem to differ in their patterns of brain region involvement, neurohormonal indices, and sleep architecture. At present, the minimal data available for putative genotypes of BPD is still emerging. nonspecific to the disorder and demonstrates significant overlap with MDD. The ability to discern commonalities and differences in the neurobiology of these two disorders is limited by the differing methodologies applied in different studies. Definitive clarification of what MDD and BPD have in common and in what ways they are distinct will only be derived from studies that examine both illnesses using the same study design and methodology. C1 [Goodman, Marianne; New, Antonia S.; Triebwasser, Joseph; Siever, Larry] James J Peters VA Med Ctr, Bronx, NY 10468 USA. [Collins, Katherine A.] Mt Sinai Sch Med, New York, NY USA. RP Goodman, M (reprint author), James J Peters VA Med Ctr, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM Marianne.goodman@va.gov NR 137 TC 24 Z9 26 U1 5 U2 8 PU GUILFORD PUBLICATIONS INC PI NEW YORK PA 72 SPRING STREET, NEW YORK, NY 10012 USA SN 0885-579X J9 J PERS DISORD JI J. Pers. Disord. PD FEB PY 2010 VL 24 IS 1 BP 38 EP 59 PG 22 WC Psychiatry SC Psychiatry GA 563XW UT WOS:000275173700005 PM 20205498 ER PT J AU Koenigsberg, HW AF Koenigsberg, Harold W. TI AFFECTIVE INSTABILITY: TOWARD AN INTEGRATION OF NEUROSCIENCE AND PSYCHOLOGICAL PERSPECTIVES SO JOURNAL OF PERSONALITY DISORDERS LA English DT Article ID BORDERLINE-PERSONALITY-DISORDER; TEMPORAL-LOBE EPILEPSY; POSTTRAUMATIC-STRESS-DISORDER; POSITRON-EMISSION-TOMOGRAPHY; BIPOLAR SPECTRUM DISORDERS; MANIC-DEPRESSIVE PARENT; ATYPICAL DEPRESSION; INTERICTAL BEHAVIOR; AFFECTIVE LABILITY; EMOTION PERCEPTION AB Affective instability is a prominent feature of a wide variety of psychiatric and neurological disorders, yet it has not been systematically studied. It encompasses a number of distinct phenomena, including: (1) frequent affective category shifts, (2) disturbances in affect intensity, (3) excessively rapid emotion rise-times, (4) delayed return to emotional baseline, (5) excessive reactivity to psychosocial cues, (6) endogenously driven, random, chaotic or rapid-cycling changes, and (7) overdramatic expression. To further clarify the construct of affective instability, this article examines the manifestations of affective instability in a range of psychiatric and neurologic disorders, reviews relevant neurobiological and psychological emotion regulatory processes, and considers the psychology of affective instability. C1 [Koenigsberg, Harold W.] James J Peters VA Med Ctr, MHPCC, Bronx, NY 10468 USA. [Koenigsberg, Harold W.] Mt Sinai Sch Med, New York, NY USA. RP Koenigsberg, HW (reprint author), James J Peters VA Med Ctr, MHPCC, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM harold.w.koenigsberg@gmail.com NR 114 TC 45 Z9 46 U1 5 U2 13 PU GUILFORD PUBLICATIONS INC PI NEW YORK PA 72 SPRING STREET, NEW YORK, NY 10012 USA SN 0885-579X J9 J PERS DISORD JI J. Pers. Disord. PD FEB PY 2010 VL 24 IS 1 BP 60 EP 82 PG 23 WC Psychiatry SC Psychiatry GA 563XW UT WOS:000275173700006 PM 20205499 ER PT J AU Tarica, DY Alvarado, VM Truong, ST AF Tarica, Diane Yoshinobu Alvarado, Veronica M. Truong, Samantha T. TI SURVEY OF UNITED STATES DENTAL SCHOOLS ON CEMENTATION PROTOCOLS FOR IMPLANT CROWN RESTORATIONS SO JOURNAL OF PROSTHETIC DENTISTRY LA English DT Article; Proceedings Paper CT 73rd Annual Meeting of the Pacific-Coast-Society-of-Prosthodontics CY JUN 21, 2008 CL Kona, HI SP Pacific Coast Soc Prosthodont ID PROVISIONAL LUTING AGENTS; SUPPORTED CROWNS; RETENTION; ABUTMENT; SYSTEM; CASTINGS; FORCES AB Statement of problem. With conflicting results in the literature and various manufacturer recommendations, it is not known what cementation protocols are currently being used for implant restorations in US dental schools. Purpose. The purpose of this survey was to determine what dental cementation protocols are taught and recommended by 62 US dental schools and postgraduate programs. Material and methods. From February to September 2008, 96 questionnaires consisting of 8 questions were sent to the chairperson or director of restorative departments, advanced prosthodontics programs, and implant programs. The questionnaire asked recipients which implant manufacturers provided the products used at their dental schools. Additionally, recipients were queried as to the choice of material and techniques for abutment and restoration preparations prior to definitive cementation. Data were analyzed with descriptive statistics. Results. A total of 68 (71%) surveys were returned, and 52 (84%) of the 62 predoctoral and postgraduate programs were represented. After deleting duplicate responses, 31 surveys were returned from restorative department chairpersons, 29 from advanced prosthodontic program directors, and 2 from implant program directors. Frequency of responses to each question was tabulated, and results are presented in 3 sections. For all 3 types of programs, Nobel Biocare was reported to be the most widely used implant system, followed by Biomet 3i, Straumann, Astra Tech, and Zimmer Dental systems. The most commonly used technique prior to definitive cementation is to airborne-particle abrade the intaglio surface of the restoration. Resin-modified glass ionomer is the most frequently used luting agent for cementing implant restorations. The 5 most commonly used materials to fill screw access openings are cotton pellets, composite resin, rubber-based material, gutta-percha, and light-polymerized provisional composite resin. Most predoctoral and postgraduate programs teach students to fill the screw access opening completely to the occlusal surface. Conclusions. There area wide range of implant cementation protocols and materials used; however, some common trends were identified among predoctoral and postgraduate programs. (J Prosthet Dent 2010;103:68-79) C1 [Tarica, Diane Yoshinobu] Vet Adm Greater Los Angeles Healthcare Syst, Dent Dept 160, Los Angeles, CA 90073 USA. RP Tarica, DY (reprint author), Vet Adm Greater Los Angeles Healthcare Syst, Dent Dept 160, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM dctarica@earthlink.net NR 25 TC 25 Z9 26 U1 0 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-3913 J9 J PROSTHET DENT JI J. Prosthet. Dent. PD FEB PY 2010 VL 103 IS 2 BP 68 EP 79 PG 12 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 572KD UT WOS:000275829700001 PM 20141811 ER PT J AU Jin, W AF Jin, Wei TI Age-related increase of beta(1)-adrenergic receptor gene expression in rat liver: a potential mechanism contributing to increased beta-adrenergic receptor density and responsiveness during aging SO JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION LA English DT Article DE beta AR; receptor density; aging; gene expression; liver ID C-MYC TRANSCRIPT; ADENYLATE-CYCLASE; MOLECULAR-CLONING; CYCLIC-AMP; TISSUE; GLYCOGENOLYSIS; STATE; RNA AB In this study we examined whether the levels of gene expressions of the three beta-adrenergic receptor (PAR) subtypes, beta(1), beta(2), and beta(3), contribute to age-related increase in beta AR density. Liver membranes and total RNA were prepared from young (4- to 6-month-old) and old (24-month-old) male Fischer 344 rats. beta AR density (B-max) in liver membranes was measured by a radioligand receptor binding assay using the receptor subtype nonselective beta AR antagonist I-125-pindolol as the radioligand. Steady-state levels of beta(2)AR mRNA in rat liver were measured by Northern blot analysis; because of the low abundance of beta(1)AR and beta(3)AR mRNA in rat liver, the expressions of these genes were measured by a semiquantitative RT-PCR or an RT-PCR. Scatchard analysis of saturation binding curves of the binding assay confirmed an age-related increase in B-max (young: 7.1 +/- 0.8 fmol/mg protein vs. old: 18.1 +/- 4.3 fmol/mg protein). No age-related differences were found in the levels of beta(2)AR mRNA. However, semiquantitative RT-PCR revealed an approximately twofold increase in beta(1)AR mRNA level between young and old rats (P < 0.05). beta(1)AR mRNA levels were also correlated with B-max for I-125-pindolol binding sites in individual rats (r = 0.67; P = 0.012). beta(3)AR mRNA, which was demonstrable in rat white adipose tissue by RT-PCR, was generally not detected in livers from young or old rats, with the exception of two old rats with the highest B-max. These results suggest that an age-related increase of beta(1)AR gene expression contributes to increased beta AR density and beta adrenergic responsiveness in rat liver during aging. C1 [Jin, Wei] Univ Texas Hlth Sci Ctr San Antonio, GRECC, Audie L Murphy Mem Vet Hosp, San Antonio, TX 78229 USA. [Jin, Wei] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78229 USA. RP Jin, W (reprint author), 2451-200-13-301 Zhong Shan Bei Rd, Shanghai 200063, Peoples R China. EM mazwang@fudan.edu.cn NR 23 TC 5 Z9 5 U1 0 U2 1 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1079-9893 J9 J RECEPT SIG TRANSD JI J. Recept. Signal Transduct. PD FEB PY 2010 VL 30 IS 1 BP 24 EP 30 DI 10.3109/10799890903358206 PG 7 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 572WG UT WOS:000275864200003 PM 19883205 ER PT J AU Rice, I Gagnon, D Gallagher, J Boninger, M AF Rice, Ian Gagnon, Dany Gallagher, Jere Boninger, Michael TI Hand Rim Wheelchair Propulsion Training Using Biomechanical Real-Time Visual Feedback Based on Motor Learning Theory Principles SO JOURNAL OF SPINAL CORD MEDICINE LA English DT Article DE Spinal cord injuries; Wheelchair; Smart Wheel; Prevention; Motor skills; Rehabilitation; Paraplegia; Tetraplegia; Task performance and analysis; Upper extremity injuries; Carpal tunnel syndrome; Rotator cuff tendinopathy; Shoulder pain ID SPINAL-CORD-INJURY; BEARING UPPER EXTREMITY; CARPAL-TUNNEL SYNDROME; LONG-TERM PARAPLEGIA; MECHANICAL EFFICIENCY; CONTEXTUAL INTERFERENCE; PUSHRIM BIOMECHANICS; EXTERNAL-FOCUS; NERVE FUNCTION; SHOULDER PAIN AB Background/Objective: As considerable progress has been made in laboratory-based assessment of manual wheelchair propulsion biomechanics, the necessity to translate this knowledge into new clinical tools and treatment programs becomes imperative. The objective of this study was to describe the development of a manual wheelchair propulsion training program aimed to promote the development of an efficient propulsion technique among long-term manual wheelchair users. Methods: Motor learning theory principles were applied to the design of biomechanical feedback-based learning software, which allows for random discontinuous real-time visual presentation of key spatio-temporal and kinetic parameters. This software was used to train a long-term wheelchair user on a dynamometer during 3 low-intensity wheelchair propulsion training sessions over a 3-week period. Biomechanical measures were recorded with a Smart Wheel during over ground propulsion on a 50-m level tile surface at baseline and 3 months after baseline. Results: Training software was refined and administered to a participant who was able to improve his propulsion technique by increasing contact angle while simultaneously reducing stroke cadence, mean resultant force, peak and mean moment out of plane, and peak rate of rise of force applied to the pushrim after training. Conclusions: The proposed propulsion training protocol may lead to favorable changes in manual wheelchair propulsion technique. These changes could limit or prevent upper limb injuries among manual wheelchair users. In addition, many of the motor learning theory based techniques examined in this study could be applied to training individuals in various stages of rehabilitation to optimize propulsion early on. C1 [Rice, Ian; Gallagher, Jere; Boninger, Michael] Univ Pittsburgh, Pittsburgh, PA USA. [Gagnon, Dany] Univ Montreal, Ecole Readaptat, Montreal, PQ, Canada. RP Boninger, M (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs 151R 1, 7180 Highland Dr,Bldg 4,2nd Floor E,151R-1, Pittsburgh, PA 15206 USA. EM boninger@pitt.edu OI Boninger, Michael/0000-0001-6966-919X NR 52 TC 14 Z9 14 U1 0 U2 7 PU AMER PARAPLEGIA SOC PI JACKSON HWIGHTS PA 75-20 ASTORIA BLVD, JACKSON HWIGHTS, NY 11370-1177 USA SN 1079-0268 J9 J SPINAL CORD MED JI J. Spinal Cord. Med. PD FEB PY 2010 VL 33 IS 1 BP 33 EP 42 PG 10 WC Clinical Neurology SC Neurosciences & Neurology GA 586IP UT WOS:000276900700006 PM 20397442 ER PT J AU Hamilton, BH Ko, CY Richards, K Hall, BL AF Hamilton, Barton H. Ko, Clifford Y. Richards, Karen Hall, Bruce Lee TI Missing Data in the American College of Surgeons National Surgical Quality Improvement Program Are Not Missing at Random: Implications and Potential Impact on Quality Assessments SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Article ID VETERANS-AFFAIRS; PATIENT SAFETY; RISK-ADJUSTMENT; NONCARDIAC SURGERY; MORTALITY; CARE; HOSPITALS; PERFORMANCE; MORBIDITY; CANCER AB BACKGROUND: Studying risk-adjusted outcomes in health care relies on statistical approaches to handling missing data. The American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) provides risk-adjusted assessments of surgical programs, traditionally imputing certain missing data points using a single round of multivariable imputation. Such imputation assumes that data are missing at random-without systematic bias-and does not incorporate estimation uncertainty. Alternative approaches, including using multiple imputation to incorporate uncertainty or using an indicator of missingness, can enhance robustness of evaluations. STUDY DESIGN: One year of de-identified data from the ACS NSQIP, representing 117 institutions and 106,113 patients, was analyzed. Using albumin variables as the missing data modeled, several imputation/adjustment models were compared, including the traditional NSQIP imputation, a new single imputation, a multiple imputation, and use of a missing indicator. RESULTS: Coefficients for albumin values changed under new single imputation and multiple imputation approaches. Multiple imputation resulted in increased standard errors, as expected. An indicator of missingness was highly explanatory, disproving the missing-at-random assumption. The effects of changes in approach differed for different outcomes, such as mortality and morbidity, and effects were greatest in smaller datasets. However, ultimate changes in patient risk assessment and institutional assessment were minimal. CONCLUSIONS: Newer statistical approaches to modeling missing (albumin) values result in noticeable statistical distinctions, including improved incorporation of imputation uncertainty. In addition, the missing-at-random assumption is incorrect for albumin. Despite these findings, effects on institutional assessments are small. Although effects can be most important with smaller datasets, the current approach to imputing missing values in the ACS NSQIP appears reasonably robust. (J Am Coll Surg 2010;210:125-139. Published by Elsevier Inc. on behalf of the American College of Surgeons) C1 [Hall, Bruce Lee] Washington Univ, Dept Surg, Sch Med, St Louis, MO 63110 USA. [Hamilton, Barton H.; Hall, Bruce Lee] Washington Univ, John M Olin Sch Business, St Louis, MO 63110 USA. [Hall, Bruce Lee] Washington Univ, Ctr Hlth Policy, St Louis, MO 63110 USA. [Ko, Clifford Y.; Richards, Karen] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL USA. [Ko, Clifford Y.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA. [Ko, Clifford Y.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Hall, Bruce Lee] John Cochran Vet Affairs Med Ctr, Dept Surg, St Louis, MO USA. RP Hall, BL (reprint author), Washington Univ, Dept Surg, Sch Med, Campus Box 8109,660 S Euclid Ave, St Louis, MO 63110 USA. EM HallB@WUStL.edu RI Hamilton, Barton/P-5187-2015 FU Center for Health Policy; Center for Health Policy, under Washington University in St Louis, St Louis, MO FX Dr Hall was supported by the Center for Health Policy, under the direction of Dr William Peck, Washington University in St Louis, St Louis, MO. We thank Patrick Hosokawa, from the Colorado Health Outcomes program at the University of Colorado (Denver), for his assistance with supplemental information on missing variables within NSQIP. We also thank Dr Shukri Khuri and his staff, Dr William Henderson and his staff, all of the principals of the VA NSQIP and ACS NSQIP (Patient Safety in Surgery), and the staff of QCMetrix, Inc, for their critical roles in the conduct of the VA and ACS NSQIP and Patient Safety in Surgery programs. NR 38 TC 41 Z9 41 U1 1 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD FEB PY 2010 VL 210 IS 2 BP 125 EP 139 DI 10.1016/j.jamcollsurg.2009.10.021 PG 15 WC Surgery SC Surgery GA 617KP UT WOS:000279279900001 PM 20113932 ER PT J AU Ingraham, AM Cohen, ME Bilimoria, KY Feinglass, JM Richards, KE Hall, BL Ko, CY AF Ingraham, Angela M. Cohen, Mark E. Bilimoria, Karl Y. Feinglass, Joseph M. Richards, Karen E. Hall, Bruce Lee Ko, Clifford Y. TI Comparison of Hospital Performance in Nonemergency Versus Emergency Colorectal Operations at 142 Hospitals SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Article; Proceedings Paper CT 95th Annual Clinical Congress of the American-College-of-Surgeons/64th Annual Sessions of the Owen H Wangensteen Forum on Fundamental Surgical Problems CY OCT 11-15, 2009 CL Chicago, IL SP Amer Coll Surg ID QUALITY IMPROVEMENT PROGRAM; SEGMENTAL COLON RESECTION; ACUTE-CARE SURGERY; CARDIAC-SURGERY; THORACIC-SURGEONS; VETERANS-AFFAIRS; SURGICAL CARE; DECADES EXPERIENCE; PATIENT OUTCOMES; ADVERSE OUTCOMES AB BACKGROUND: Quality improvement efforts have demonstrated considerable hospital-to-hospital variation in surgical outcomes. However, information about the quality of emergency surgical care is lacking. The objective of this study was to assess whether hospitals have comparable outcomes for emergency and nonemergency operations. STUDY DESIGN: Patients undergoing colorectal resections were identified from the American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) 2005 to 2007 dataset. Logistic regression models for 30-day morbidity and mortality after emergency and nonemergency colorectal resections were constructed. Hospital risk-adjusted outcomes as measured by observed to expected (O/E) ratios, outlier status, and rank-order differences were compared. RESULTS: Of 25,710 nonemergency colorectal resections performed at 142 ACS NSQIP hospitals, 6,138 (23.9%) patients experienced at least 1 complication, and 492 (1.9%) patients died. There were 5,083 emergency colorectal resections; 2,442 (48%) patients experienced at least 1 complication, and 780 (15.3%) patients died. Outcomes for nonemergency versus emergency operations were weakly correlated for morbidity and mortality (Pearson correlation coefficient: 0.28 versus 0.13). Median differences in hospital rankings based on O/E ratios between nonemergency and emergency performance were 30.5 ranks (interquartile range [IQR] 13 to 59) for morbidity and 34 ranks (interquartile ratio 17 to 61) for mortality. CONCLUSIONS: Hospitals with favorable outcomes after nonemergency colorectal resections do not necessarily have similar outcomes for emergency operations. Hospitals should specifically examine their performance on emergency surgical procedures to identify quality improvement opportunities and focus quality improvement efforts appropriately. (J Am Coll Surg 2010;210:155-165. (C) 2010 by the American College Of Surgeons) C1 [Ingraham, Angela M.; Cohen, Mark E.; Richards, Karen E.; Ko, Clifford Y.] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL 60611 USA. [Bilimoria, Karl Y.] Northwestern Univ, Dept Surg, Feinberg Sch Med, Chicago, IL 60611 USA. [Feinglass, Joseph M.] Northwestern Univ, Div Gen Internal Med, Feinberg Sch Med, Chicago, IL 60611 USA. [Ingraham, Angela M.] Univ Cincinnati, Coll Med, Dept Surg, Cincinnati, OH 45267 USA. [Hall, Bruce Lee] John Cochran Vet Affairs Med Ctr, Dept Surg, St Louis, MO USA. [Hall, Bruce Lee] Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA. [Hall, Bruce Lee] Barnes Jewish Hosp, St Louis, MO 63110 USA. [Hall, Bruce Lee] Washington Univ, John M Olin Sch Business, St Louis, MO 63130 USA. [Hall, Bruce Lee] Washington Univ, Ctr Hlth Policy, St Louis, MO USA. [Ko, Clifford Y.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA. [Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Ingraham, AM (reprint author), Amer Coll Surg, Div Res & Optimal Patient Care, 633 N St Clair St,Floor 22NE, Chicago, IL 60611 USA. NR 29 TC 52 Z9 52 U1 1 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD FEB PY 2010 VL 210 IS 2 BP 155 EP 165 DI 10.1016/j.jamcollsurg.2009.10.016 PG 11 WC Surgery SC Surgery GA 617KP UT WOS:000279279900004 PM 20113935 ER PT J AU Lin, JC Karno, MP Barry, KL Blow, FC Davis, JW Tang, LQ Moore, AA AF Lin, James C. Karno, Mitchell P. Barry, Kristen L. Blow, Frederic C. Davis, James W. Tang, Lingqi Moore, Alison A. TI Determinants of Early Reductions in Drinking in Older At-Risk Drinkers Participating in the Intervention Arm of a Trial to Reduce At-Risk Drinking in Primary Care SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE alcohol; physician advice; at-risk drinking ID ALCOHOL TREATMENT TRIAL; FOLLOW-UP INTERVIEWS; AGED 75; READINESS; CONSUMPTION; COMMUNITY; PEOPLE; ADULTS; MOTIVATION; BEHAVIORS AB OBJECTIVES: To describe differences between older at-risk drinkers, as determined using the Comorbidity Alcohol Risk Evaluation Tool, who reduced drinking and those who did not after an initial intervention and to determine factors associated with early reductions in drinking. DESIGN: Secondary analyses of data from a randomized controlled trial. SETTING: Seven primary care sites. PARTICIPANTS: Subjects randomized to the intervention group who completed the first health educator call approximately 2 weeks after enrollment (n = 239). INTERVENTION: Personalized risk reports, booklets on alcohol-associated risks, and advice from physicians, followed by a health educator call. MEASURMENTS: Reductions in number of alcoholic drinks. RESULTS: Thirty-nine percent of the sample had reduced drinking within 2 weeks of receiving the initial intervention. According to the final multiple logistic regression model, those who were concerned about alcohol-related risks (odds ratio (OR) = 2.03, 95% confidence interval (CI) = 1.01-4.07), read through the educational booklet (OR = 2.97, 95% CI = 1.48-5.95), or perceived that their physicians discussed risks and advised changing drinking behaviors (OR = 4.1, 95% CI = 2.02-8.32) had greater odds of reducing drinking by the first health educator call. CONCLUSION: Concern about risks, reading educational material, and perception of physicians providing advice to reduce drinking were associated with early reductions in alcohol use in older at-risk drinkers. Understanding these factors will enable development of better intervention strategies to reduce unhealthy alcohol use. J Am Geriatr Soc 58:227-233, 2010. C1 [Lin, James C.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Lin, James C.] Cheng Ching Hosp, Dept Med, Taichung, Taiwan. [Karno, Mitchell P.; Moore, Alison A.] Univ Calif Los Angeles, Integrated Substance Abuse Programs, Los Angeles, CA USA. [Davis, James W.; Moore, Alison A.] Univ Calif Los Angeles, Dept Med, David Geffen Sch Med, Los Angeles, CA 90024 USA. [Tang, Lingqi] Univ Calif Los Angeles, Hlth Serv Res Ctr, Semel Inst Neurosci & Human Behav, Los Angeles, CA USA. [Barry, Kristen L.; Blow, Frederic C.] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA. RP Lin, JC (reprint author), 11301 Wilshire Ave,Bldg 220,Room 302, Los Angeles, CA 90073 USA. EM jlin1207@ucla.edu FU Veterans Affairs Greater Los Angeles Healthcare System; National Institutes of Health, National Institute on Alcoholism and Alcohol Abuse [AA013937, AA15957] FX The editor in chief has reviewed the conflict of interest checklist provided by the authors and has determined that the authors have no financial or any other kind of personal conflicts with this paper.Special Fellowship in Advanced Geriatrics, Veterans Affairs Greater Los Angeles Healthcare System and National Institutes of Health, National Institute on Alcoholism and Alcohol Abuse (AA013937 and AA15957). NR 31 TC 8 Z9 8 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD FEB PY 2010 VL 58 IS 2 BP 227 EP 233 DI 10.1111/j.1532-5415.2009.02676.x PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 551CQ UT WOS:000274183800002 PM 20070414 ER PT J AU Yaffe, K Ackerson, L Tamura, MK Le Blanc, P Kusek, JW Sehgal, AR Cohen, D Anderson, C Appel, L DeSalvo, K Ojo, A Seliger, S Robinson, N Makos, G Go, AS AF Yaffe, Kristine Ackerson, Lynn Tamura, Manjula Kurella Le Blanc, Patti Kusek, John W. Sehgal, Ashwini R. Cohen, Debbie Anderson, Cheryl Appel, Lawrence DeSalvo, Karen Ojo, Akinlolu Seliger, Stephen Robinson, Nancy Makos, Gail Go, Alan S. CA Chronic Renal Insufficiency Cohort TI Chronic Kidney Disease and Cognitive Function in Older Adults: Findings from the Chronic Renal Insufficiency Cohort Cognitive Study SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE chronic kidney disease; cognitive impairment; cognitive function ID CYSTATIN-C; ALZHEIMERS-DISEASE; CARDIOVASCULAR HEALTH; DEMENTIA; IMPAIRMENT; MEMORY; STROKE; WOMEN; RISK; PERFORMANCE AB OBJECTIVES: To investigate cognitive impairment in older, ethnically diverse individuals with a broad range of kidney function, to evaluate a spectrum of cognitive domains, and to determine whether the relationship between chronic kidney disease (CKD) and cognitive function is independent of demographic and clinical factors. DESIGN: Cross-sectional. SETTING: Chronic Renal Insufficiency Cohort Study. PARTICIPANTS: Eight hundred twenty-five adults aged 55 and older with CKD. MEASUREMENTS: Estimated glomerular filtration rate (eGFR, mL/min per 1.73 m(2)) was estimated using the four-variable Modification of Diet in Renal Disease equation. Cognitive scores on six cognitive tests were compared across eGFR strata using linear regression; multivariable logistic regression was used to examine level of CKD and clinically significant cognitive impairment (score <= 1 standard deviations from the mean). RESULTS: Mean age of the participants was 64.9, 50.4% were male, and 44.5% were black. After multivariable adjustment, participants with lower eGFR had lower cognitive scores on most cognitive domains (P < .05). In addition, participants with advanced CKD (eGFR < 30) were more likely to have clinically significant cognitive impairment on global cognition (adjusted odds ratio (AOR) 2.0, 95% CI = 1.1-3.9), naming (AOR = 1.9, 95% CI = 1.0-3.3), attention (AOR = 2.4, 95% CI = 1.3-4.5), executive function (AOR = 2.5, 95% CI = 1.9-4.4), and delayed memory (AOR = 1.5, 95% CI = 0.9-2.6) but not on category fluency (AOR = 1.1, 95% CI = 0.6-2.0) than those with mild to moderate CKD (eGFR 45-59). CONCLUSION: In older adults with CKD, lower level of kidney function was associated with lower cognitive function on most domains. These results suggest that older patients with advanced CKD should be screened for cognitive impairment. J Am Geriatr Soc 58:338-345,2010. C1 [Yaffe, Kristine; Le Blanc, Patti] Univ Calif San Francisco, Sch Med, Dept Psychiat, San Francisco, CA 94143 USA. [Yaffe, Kristine] Univ Calif San Francisco, Sch Med, Dept Neurol, San Francisco, CA 94143 USA. [Yaffe, Kristine] Univ Calif San Francisco, Sch Med, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA. [Ackerson, Lynn; Go, Alan S.] Kaiser Permanente, Div Res, Oakland, CA USA. [Tamura, Manjula Kurella] Stanford Univ, Sch Med, Div Nephrol, Palo Alto, CA 94304 USA. [Kusek, John W.] NIDDK, NIH, Bethesda, MD USA. [Sehgal, Ashwini R.] Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA. [Sehgal, Ashwini R.] Case Western Reserve Univ, Dept Biomed Eth, Cleveland, OH 44106 USA. [Sehgal, Ashwini R.] Case Western Reserve Univ, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA. [Cohen, Debbie; Robinson, Nancy] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA. [Anderson, Cheryl; Appel, Lawrence] Johns Hopkins Univ, Dept Epidemiol, Baltimore, MD USA. [Appel, Lawrence] Johns Hopkins Univ, Dept Med, Baltimore, MD USA. [Appel, Lawrence] Johns Hopkins Univ, Dept Int Hlth, Baltimore, MD USA. [DeSalvo, Karen] Tulane Univ, Sch Med, Dept Med, New Orleans, LA 70112 USA. [Ojo, Akinlolu] Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI USA. [Ojo, Akinlolu] Univ Michigan, Sch Med, Div Nephrol, Ann Arbor, MI USA. [Seliger, Stephen] Univ Maryland, Sch Med, Div Nephrol, Baltimore, MD 21201 USA. [Makos, Gail] St Clair Specialty Phys PC, Chron Kidney Dis Clin, Detroit, MI USA. RP Yaffe, K (reprint author), 4150 Clement St,VAMC 181, San Francisco, CA 94121 USA. EM kristine.yaffe@ucsf.edu RI Kurella Tamura, Manjula/C-8284-2014 OI Kurella Tamura, Manjula/0000-0001-5227-2479 FU National Institute of Health [U01-DK060990, U01 DK60980, U01 DK 60902, U01 DK61021, U01 DK60984, R01 DK069406]; [K24 AG 031155] FX This study was funded by National Institute of Health Grants U01-DK060990, U01 DK60980, U01 DK 60902, U01 DK61021, U01 DK60984, and R01 DK069406 (CRIC COG). Dr. Yaffe is also supported in part by K24 AG 031155 and an anonymous foundation. NR 35 TC 101 Z9 111 U1 2 U2 13 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD FEB PY 2010 VL 58 IS 2 BP 338 EP 345 DI 10.1111/j.1532-5415.2009.02670.x PG 8 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 551CQ UT WOS:000274183800017 PM 20374407 ER PT J AU Kottgen, A Hwang, SJ Larson, MG Van Eyk, JE Fu, Q Benjamin, EJ Dehghan, A Glazer, NL Kao, WHL Harris, TB Gudnason, V Shlipak, MG Yang, Q Coresh, J Levy, D Fox, CS AF Koettgen, Anna Hwang, Shih-Jen Larson, Martin G. Van Eyk, Jennifer E. Fu, Qin Benjamin, Emelia J. Dehghan, Abbas Glazer, Nicole L. Kao, W. H. Linda Harris, Tamara B. Gudnason, Vilmundur Shlipak, Michael G. Yang, Qiong Coresh, Josef Levy, Daniel Fox, Caroline S. TI Uromodulin Levels Associate with a Common UMOD Variant and Risk for Incident CKD SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID CHRONIC KIDNEY-DISEASE; TAMM-HORSFALL GLYCOPROTEIN; JUVENILE HYPERURICAEMIC NEPHROPATHY; GLOMERULAR-FILTRATION-RATE; CARDIOVASCULAR-DISEASE; SERUM CREATININE; MUTATIONS; URINARY; PROTEIN; GENE AB Common variants in the region of the UMOD gene, which encodes uromodulin (Tamm-Horsfall protein), associate with chronic kidney disease (CKD) and estimated GFR (eGFR). Whether uromodulin levels associate with UMOD variants or with the risk for developing CKD is unknown. We conducted an age- and gender-matched case-control study (n = 200) of incident CKD (eGFR <60 ml/min per 1.73 m(2)) within the Framingham Heart Study (FHS). Baseline urinary uromodulin concentrations were related to case-control status 9.9 yr later and to genotype at rs4293393. As a replication set, we tested the genotype association with uromodulin concentration in the Atherosclerosis Risk in Communities (ARIC) Study (n = 42). Geometric means of uromodulin concentrations were 51% higher in case than in control subjects (P = 0.016). The adjusted odds ratio of CKD per 1-SD higher concentration of uromodulin was 1.72 (95% confidence interval 1.07 to 2.77; P = 0.03) after accounting for CKD risk factors and baseline eGFR. We observed lower urinary uromodulin concentrations per each copy of the C allele at rs4293393 in both cohorts. In summary, elevated uromodulin concentrations precede the onset of CKD and associate with a common polymorphism in the UMOD region. C1 [Koettgen, Anna; Kao, W. H. Linda; Coresh, Josef] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Hwang, Shih-Jen; Benjamin, Emelia J.; Levy, Daniel; Fox, Caroline S.] Framingham Heart Dis Epidemiol Study, Framingham, MA USA. [Hwang, Shih-Jen; Levy, Daniel; Fox, Caroline S.] NHLBI, Ctr Populat Studies, Bethesda, MD 20892 USA. [Harris, Tamara B.] NIA, Lab Epidemiol Demog & Biometry, Intramural Res Program, NIH, Bethesda, MD 20892 USA. [Larson, Martin G.; Yang, Qiong] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA. [Benjamin, Emelia J.] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA. [Van Eyk, Jennifer E.; Fu, Qin] Johns Hopkins Univ, Dept Med, Baltimore, MD USA. [Dehghan, Abbas] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands. [Glazer, Nicole L.] Univ Washington, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA. [Glazer, Nicole L.] Univ Washington, Dept Med, Seattle, WA 98195 USA. [Gudnason, Vilmundur] Iceland Heart Assoc Res Inst, Kopavogur, Iceland. [Gudnason, Vilmundur] Univ Iceland, Reykjavik, Iceland. [Shlipak, Michael G.] Univ Calif San Francisco, Div Gen Internal Med, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. [Fox, Caroline S.] Brigham & Womens Hosp, Dept Med, Div Endocrinol Diabet & Metab, Boston, MA 02115 USA. [Fox, Caroline S.] Harvard Univ, Sch Med, Boston, MA USA. RP Fox, CS (reprint author), 73 Mt Wayte Ave,Suite 2, Framingham, MA 01702 USA. EM foxca@nhlbi.nih.gov RI Kottgen, Anna/D-2920-2012; Yang, Qiong/G-5438-2014; Gudnason, Vilmundur/K-6885-2015 OI Gudnason, Vilmundur/0000-0001-5696-0084; Larson, Martin/0000-0002-9631-1254; Benjamin, Emelia/0000-0003-4076-2336; Dehghan, Abbas/0000-0001-6403-016X FU National Heart, Lung, and Blood Institute's Framingham Heart Study [N01-HC-25195]; Center for Population Studies; National Heart, Lung, and Blood Institute [N01-HC-55020, R01-DK076770-01, R01-HL087652, 5UL1 RR025005-3, 1U54RR023561-01A1]; NIH [N01-HV-28180, AG028321] FX This work was supported by the National Heart, Lung, and Blood Institute's Framingham Heart Study (N01-HC-25195), the Center for Population Studies, National Heart, Lung, and Blood Institute intramural program, N01-HC-55020, R01-DK076770-01, R01-HL087652, 5UL1 RR025005-3, 1U54RR023561-01A1 , NIH N01-HV-28180, AG028321, and HL092577-01A1 NR 30 TC 65 Z9 69 U1 0 U2 4 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD FEB PY 2010 VL 21 IS 2 BP 337 EP 344 DI 10.1681/ASN.2009070725 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA 557PG UT WOS:000274680900019 PM 19959715 ER PT J AU Ayus, JC Achinger, SG Lee, S Sayegh, MH Go, AS AF Ayus, Juan Carlos Achinger, Steven G. Lee, Shuko Sayegh, Mohamed H. Go, Alan S. TI Transplant Nephrectomy Improves Survival following a Failed Renal Allograft SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID C-REACTIVE PROTEIN; HEMODIALYSIS-PATIENTS; DIALYSIS PATIENTS; FAILURE; MORTALITY; ERYTHROPOIETIN; MANAGEMENT; GRAFTS; IMPACT AB There is a growing number of patients returning to dialysis after a failed kidney transplant, and there is increasing evidence of higher mortality among this population. Whether removal of the failed renal allograft affects survival while receiving long-term dialysis is not well understood. We identified all adults who received a kidney transplant and returned to long-term dialysis after renal allograft failure between January 1994 and December 2004 from the US Renal Data System. Among 10,951 transplant recipients who returned to long-term dialysis, 3451 (31.5%) received an allograft nephrectomy during follow-up. Overall, 34.6% of these patients died during follow-up. Receiving an allograft nephrectomy associated with a 32% lower adjusted relative risk for all-cause death (adjusted hazard ratio 0.68; 95% confidence interval 0.63 to 0.74) after adjustment for sociodemographic characteristics, comorbidity burden, donor characteristics, interim clinical conditions associated with receiving allograft nephrectomy, and propensity to receive an allograft nephrectomy. In conclusion, within a large, nationally representative sample of high-risk patients returning to long-term dialysis after failed kidney transplant, receipt of allograft nephrectomy independently associated with improved survival. C1 [Ayus, Juan Carlos] Renal Consultants Houston, Dept Clin Res, Houston, TX USA. [Achinger, Steven G.] Phys Clin Res, San Antonio, TX USA. [Lee, Shuko] Vet Adm Hosp, San Antonio, TX USA. [Sayegh, Mohamed H.] Brigham & Womens Hosp, Div Renal, Transplantat Res Ctr, Boston, MA 02115 USA. [Sayegh, Mohamed H.] Harvard Univ, Sch Med, Childrens Hosp Boston, Boston, MA USA. [Go, Alan S.] Kaiser Permanente No Calif, Div Res, Oakland, CA USA. [Go, Alan S.] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA. [Go, Alan S.] Univ Calif San Francisco, Dept Biostat, San Francisco, CA 94143 USA. [Go, Alan S.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. RP Ayus, JC (reprint author), Renal Consultants Houston, Dept Clin Res, 2412 Westgate St, Houston, TX USA. EM carlosayus@yahoo.com FU National Institutes of Health (NIH) [U01 DK066481, U01 DK60902, R01 DK067126, R01 DK58411] FX J.C.A. was Supported by National Institutes of Health (NIH) grant U01 DK066481, and S.G.A. was Supported by an NIH T32 Training Grant. A.S.G. has received research support from NIH grants U01 DK60902, R01 DK067126, and R01 DK58411. NR 26 TC 61 Z9 64 U1 0 U2 2 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD FEB PY 2010 VL 21 IS 2 BP 374 EP 380 DI 10.1681/ASN.2009050480 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA 557PG UT WOS:000274680900023 PM 19875809 ER PT J AU Foster, PP Williams, JH Estrada, CA Higginbotham, JC Voltz, ML Safford, MM Allison, J AF Foster, Pamela Payne Williams, Jessica H. Estrada, Carlos A. Higginbotham, John C. Voltz, Mukesha L. Safford, Monika M. Allison, Jeroan TI Recruitment of Rural Physicians in a Diabetes Internet Intervention Study: Overcoming Challenges and Barriers SO JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION LA English DT Article DE recruitment; physicians; diabetes; Internet intervention ID HEALTH-CARE; PARTICIPANTS; COMMUNITY; PROGRAM; TRIAL; LONG AB Purpose: This paper highlights a descriptive study of the challenges and lessons learned in the recruitment of rural primary care physicians into a randomized clinical trial using an Internet-based approach. Methods: A multidisciplinary/multi-institutional research team used a multilayered recruitment approach, including generalized mailings and personalized strategies such as personal office visits, letters, and faxes to specific contacts. Continuous assessment of recruitment strategies was used throughout study in order to readjust strategies that were not successful. Results: We recruited 205 primary care physicians from 11 states. The 205 lead physicians who enrolled in the study were randomized, and the overall recruitment yield was 1.8% (205/11231). in addition, 8 physicians from the some practices participated and 12 nonphysicians participated. The earlier participants logged on to the study Web site, the greater yield of participation. Most of the study participants had logged on within 10 weeks of the study. Conclusion: Despite successful recruitment, the 2 major challenges in recruitment in this study included defining a standardized definition of rurality and the high cost of chart abstractions. Because many of the patients of study recruits were African American, the potential implications of this study on the field of health disparities in diabetes are important. C1 [Foster, Pamela Payne; Higginbotham, John C.] Univ Alabama, Sch Med, Tuscaloosa, AL 35401 USA. [Foster, Pamela Payne; Higginbotham, John C.] Univ Alabama, Rural Hlth Inst Clin & Translat Sci, Tuscaloosa, AL 35401 USA. [Williams, Jessica H.; Estrada, Carlos A.; Safford, Monika M.] Univ Alabama, Birmingham, AL USA. [Estrada, Carlos A.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Estrada, Carlos A.] VA Natl Qual Scholars Program, Birmingham, AL USA. [Allison, Jeroan] Univ Massachusetts, Sch Med, Amherst, MA 01003 USA. RP Foster, PP (reprint author), Univ Alabama, Sch Med, Tuscaloosa Campus, Tuscaloosa, AL 35401 USA. EM ppayne-foster@cchs.ua.edu OI Allison, Jeroan/0000-0003-4472-2112 FU National Institutes of Diabetes and Digestive and Kidney Diseases [X050111012, R18DK065001-01] FX Funding/Support: This work was supported by National Institutes of Diabetes and Digestive and Kidney Diseases X050111012 and R18DK065001-01 AZ (Drs Allison and Safford), and Clinical Trials registration NCT00403091, Internet Intervention to Improve Rural Diabetes Care (http://www.clinicaltdals.gov/). NR 26 TC 5 Z9 5 U1 1 U2 3 PU NATL MED ASSOC PI WASHINGON PA 1012 10TH ST, N W, WASHINGON, DC 20001 USA SN 0027-9684 J9 J NATL MED ASSOC JI J. Natl. Med. Assoc. PD FEB PY 2010 VL 102 IS 2 BP 101 EP 107 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 557VV UT WOS:000274699100003 PM 20191922 ER PT J AU Lai, EH Dincher, KL Lee, T Andersen, M Abdelfattah, F AF Lai, Eunha Dincher, Kathryn L. Lee, Todd Andersen, Mara Abdelfattah, Faten TI A Retrospective Analysis of the Effects of a Pharmacist Managed Inpatient Anticoagulation Service at a VA Hospital SO JOURNAL OF THROMBOSIS AND THROMBOLYSIS LA English DT Meeting Abstract C1 [Lai, Eunha; Dincher, Kathryn L.; Lee, Todd; Andersen, Mara; Abdelfattah, Faten] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0929-5305 J9 J THROMB THROMBOLYS JI J. Thromb. Thrombolysis PD FEB PY 2010 VL 29 IS 2 BP 244 EP 244 PG 1 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA 550AJ UT WOS:000274097500019 ER PT J AU Seal, KH Maguen, S Cohen, B Gima, KS Metzler, TJ Ren, L Bertenthal, D Marmar, CR AF Seal, Karen H. Maguen, Shira Cohen, Beth Gima, Kristian S. Metzler, Thomas J. Ren, Li Bertenthal, Daniel Marmar, Charles R. TI VA Mental Health Services Utilization in Iraq and Afghanistan Veterans in the First Year of Receiving New Mental Health Diagnoses SO JOURNAL OF TRAUMATIC STRESS LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; COMORBIDITY SURVEY REPLICATION; PRIMARY-CARE PATIENTS; RANDOMIZED CONTROLLED-TRIAL; WAR; DEPRESSION; INTERVENTION; MANAGEMENT; SYMPTOMS AB Little is known about mental health services utilization among Iraq and Afghanistan veterans receiving care tit Department of Veterans Affairs (VA)facilities. Of 49,425 veterans with newly diagnosed Posttraumatic stress disorder (PTSD), only 9.5% attended 9 or more VA mental health sessions in 15 weeks or less in the first year of diagnosis. In addition, engagement in 9 or more VA treatment sessions for PTSD within 15 weeks varied by predisposing variables (age and gender), enabling variables (clinic of first mental health diagnosis and distance from VA facility), and need (type and complexity of mental health diagnoses). Thus, only a minority of Iraq and Afghanistan veterans with new PTSD diagnoses received a recommended number and intensity of VA menial health treatment sessions within the first year of diagnosis. C1 [Seal, Karen H.; Maguen, Shira; Bertenthal, Daniel] San Francisco VA Med Ctr, Hlth Serv Res & Dev Res Enhancement Award Program, San Francisco, CA 94121 USA. [Seal, Karen H.; Cohen, Beth] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Seal, Karen H.; Maguen, Shira; Marmar, Charles R.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. RP Seal, KH (reprint author), San Francisco VA Med Ctr, Hlth Serv Res & Dev Res Enhancement Award Program, 4150 Clement St,Box 111A-1, San Francisco, CA 94121 USA. EM Karen.Seal@va.gov FU NCRR NIH HHS [KL2 RR024130] NR 53 TC 188 Z9 189 U1 3 U2 12 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0894-9867 J9 J TRAUMA STRESS JI J. Trauma Stress PD FEB PY 2010 VL 23 IS 1 BP 5 EP 16 DI 10.1002/jts.20493 PG 12 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 571FW UT WOS:000275738100003 PM 20146392 ER PT J AU Tuerk, PW Yoder, M Ruggiero, KJ Gros, DF Acierno, R AF Tuerk, Peter W. Yoder, Matthew Ruggiero, Kenneth J. Gros, Daniel F. Acierno, Ron TI A Pilot Study of Prolonged Exposure Therapy for Posttraumatic Stress Disorder Delivered via Telehealth Technology SO JOURNAL OF TRAUMATIC STRESS LA English DT Article ID COGNITIVE-BEHAVIORAL THERAPY; RURAL TELEPSYCHIATRY; RANDOMIZED-TRIAL; TELEMEDICINE; PTSD; CARE; SYMPTOMS; VETERANS; PROGRAM; IRAQ AB The authors present a study study of 12 veterans diagnosed with combat-related PTSD and treated with prolonged exposure therapy (PE) via telehealth technology. A reference sample of 35 combat veterans treated with in-person IT in the same clinic is also included for a comparison. Feasibility and clinical outcomes of interest include technical performance and practicality of the telehealth equipment, patient safety, treatment completion rates, number of sessions required for termination, and clinical outcomes. Results indicated large statistically significant decreases in self-reported pathology fir veterans treated with PE via telehealth technology. Preliminary results support the feasibility and safety of the modality Suggestions for the implementation of PE via telehealth technology are discussed. C1 Med Univ S Carolina, Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. RP Tuerk, PW (reprint author), 109 Bee St,Mental Hlth 116, Charleston, SC 29401 USA. EM Tuerk@musc.edu FU NCATS NIH HHS [UL1 TR000062]; NCRR NIH HHS [KL2 RR029880] NR 43 TC 96 Z9 97 U1 1 U2 11 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0894-9867 J9 J TRAUMA STRESS JI J. Trauma Stress PD FEB PY 2010 VL 23 IS 1 BP 116 EP 123 DI 10.1002/jts.20494 PG 8 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 571FW UT WOS:000275738100017 PM 20135675 ER PT J AU McCauley, JL Ruggiero, KJ Resnick, HS Kilpatrick, DG AF McCauley, Jenna L. Ruggiero, Kenneth J. Resnick, Heidi S. Kilpatrick, Dean G. TI Incapacitated, Forcible, and Drug/Alcohol-Facilitated Rape in Relation to Binge Drinking, Marijuana Use, and Illicit Drug Use: A National Survey SO JOURNAL OF TRAUMATIC STRESS LA English DT Article ID SEXUAL ASSAULT; SUBSTANCE USE; ALCOHOL-CONSUMPTION; SAMPLE; WOMEN; VICTIMIZATION; PREVALENCE; OUTCOMES; VICTIMS; VIOLENT AB This study examined the relation between rape and substance use problems as a function of three legally recognized firms of rape: forcible, incapacitated, and drug/alcohol facilitated rape. Data were collected via structured telephone interview within a national household sample of U.S. women aged 18-34 years (n = 1, 998). Lifetime experience of incapacitated rape was associated with increased odds of past-year binge drinking, marijuana use, and illicit drug use. Lifetime history of forcible rape and drug/alcohol facilitated rape were associated with increased odds of marijuana and illicit drug use. Findings highlight the importance of including incapacitated and drug/alcohol facilitated rape in trauma history assessments, particularly among substance abusing populations, and have implications for secondary prevention and treatment of women with victimization histories. C1 [McCauley, Jenna L.] Med Univ S Carolina, Natl Crime Victims Res & Treatment Ctr, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Ruggiero, Kenneth J.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP McCauley, JL (reprint author), Med Univ S Carolina, Natl Crime Victims Res & Treatment Ctr, Dept Psychiat & Behav Sci, 67 President St,MSC 861, Charleston, SC 29425 USA. EM mccaule@musc.edu NR 29 TC 18 Z9 18 U1 0 U2 7 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0894-9867 J9 J TRAUMA STRESS JI J. Trauma Stress PD FEB PY 2010 VL 23 IS 1 BP 132 EP 140 DI 10.1002/jts.20489 PG 9 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 571FW UT WOS:000275738100019 PM 20135676 ER PT J AU Makarov, DV AF Makarov, Danil V. TI Cost Analysis of Robotic Versus Open Radical Cystectomy for Bladder Cancer EDITORIAL COMMENT SO JOURNAL OF UROLOGY LA English DT Editorial Material C1 Yale Univ, Sch Med, Dept Surg, US Dept Vet Affairs,Sect Urol, New Haven, CT 06510 USA. RP Makarov, DV (reprint author), Yale Univ, Sch Med, Dept Surg, US Dept Vet Affairs,Sect Urol, New Haven, CT 06510 USA. OI Makarov, Danil/0000-0002-0565-9272 NR 2 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5347 J9 J UROLOGY JI J. Urol. PD FEB PY 2010 VL 183 IS 2 BP 509 EP 509 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA 543AD UT WOS:000273540600028 PM 20006853 ER PT J AU Moatamed, NA Apple, SK Moatamed, F AF Moatamed, N. A. Apple, S. K. Moatamed, F. TI Inclusion of the Uniform Tetraploid Cells Reduces the Specificity of the Urine FISH Assay SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 99th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 20-26, 2010 CL Washington, DC SP US & Canadian Acac Pathol C1 Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. VA Greater LA Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2010 VL 90 SU 1 MA 447 BP 102A EP 102A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 553AR UT WOS:000274337300447 ER PT J AU Corrales-Medina, VF Madjid, M Musher, DM AF Corrales-Medina, Vicente F. Madjid, Mohammad Musher, Daniel M. TI Role of acute infection in triggering acute coronary syndromes SO LANCET INFECTIOUS DISEASES LA English DT Review ID ACUTE MYOCARDIAL-INFARCTION; C-REACTIVE PROTEIN; RESPIRATORY-TRACT INFECTIONS; COMMUNITY-ACQUIRED PNEUMONIA; AMERICAN-HEART-ASSOCIATION; HEAVY PHYSICAL EXERTION; CARDIOVASCULAR-DISEASE; INFLUENZA VACCINATION; UNSTABLE ANGINA; ARTERY-DISEASE AB Acute coronary syndromes are a leading cause of morbidity and mortality worldwide. The mechanisms underlying the triggering of these events are diverse and include increased coronary and systemic inflammatory activity dominant prothrombotic conditions, increased biomechanical stress on coronary arteries, variations in the coronary arterial tone, disturbed haemodynamic homoeostasis, and altered myocardial metabolic balance. There is experimental evidence that acute infections can promote the development of acute coronary syndromes, and clinical data strongly support a role for acute infections in triggering these events. In our Review, we summarise the pathogenesis of coronary artery disease and present the evidence linking acute infections with the development of acute coronary syndromes. Greater awareness of this association is likely to encourage research into ways of protecting patients who are at high risk. C1 [Corrales-Medina, Vicente F.] Univ Ottawa, Dept Med, Div Infect Dis, Ottawa, ON K1N 6N5, Canada. [Madjid, Mohammad; Musher, Daniel M.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Musher, Daniel M.] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA. [Musher, Daniel M.] Baylor Coll Med, Infect Dis Sect, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Madjid, Mohammad] Univ Texas Hlth Sci Ctr Houston, Dept Med, Houston, TX USA. [Madjid, Mohammad] St Lukes Episcopal Hosp, Texas Heart Inst, Atherosclerosis Res Lab, Houston, TX USA. RP Musher, DM (reprint author), Baylor Coll Med, Infect Dis Sect, Michael E DeBakey Vet Affairs Med Ctr, Room 4B-370,2002 Holcombe Blvd, Houston, TX 77030 USA. EM Daniel.Musher@va.gov FU Department of Veterans Affairs; VFC-M FX We thank Karla Absi-Delgado for her invaluable contribution to the creation of the figures and the Medical Media Department of the Michael E DeBakey VA Medical Center for assisting with their preparation. This work was partly funded by the Department of Veterans Affairs through the Merit Review Program for DMM. Funds from this source were used for financial support of VFC-M in his role as Research Fellow at Baylor College of Medicine under the direction of DMM. NR 120 TC 90 Z9 97 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1473-3099 J9 LANCET INFECT DIS JI Lancet Infect. Dis. PD FEB PY 2010 VL 10 IS 2 BP 83 EP 92 PG 10 WC Infectious Diseases SC Infectious Diseases GA 558DS UT WOS:000274721600014 PM 20113977 ER PT J AU Butt, AA McGinnis, KA Skanderson, M Justice, AC AF Butt, Adeel A. McGinnis, Kathleen A. Skanderson, Melissa Justice, Amy C. TI Hepatitis C treatment completion rates in routine clinical care SO LIVER INTERNATIONAL LA English DT Article DE anaemia; depression; hepatitis C; HIV infection; pegylated interferon; practice variation; treatment completion ID CHRONIC KIDNEY-DISEASE; INTERFERON-ALPHA-2B PLUS RIBAVIRIN; IMMUNODEFICIENCY-VIRUS-INFECTION; UNITED-STATES VETERANS; COMBINATION THERAPY; PEGINTERFERON ALPHA-2A; EPOETIN-ALPHA; HEPATOCELLULAR-CARCINOMA; ANTIVIRAL THERAPY; HIV AB Background Treatment completion rates for hepatitis C virus (HCV) infection in clinical practice settings are unknown. Methods We assembled a national cohort of HCV-infected veterans-in-care from 1998 to 2003, using the VA National Patient Care Database for demographical/clinical information, Pharmacy Benefits Management database for pharmacy records and the Decision Support Systems database for laboratory data. We used logistic regression to determine the factors predicting treatment non-completion for HCV. Results We identified 134 934 HCV-infected veterans of whom 16 043 [11.9%; 95% confidence interval (CI) 11.7-12.1] were prescribed treatment for HCV. Among the 10 641 veterans with > 1 year of follow-up, 2396 (22.5%; 95% CI 21.7-23.3) completed a 48-week course. Non-completers were more likely to have pre-treatment anaemia, coronary artery disease, depression, substance abuse, used standard interferon, higher comorbidity count, and been treated at a low-volume treatment site (defined as sites initiating HCV treatment for < 200 individuals). In multivariable analyses, treatment completion was positively associated with pegylated interferon use [odds ratio (OR) 1.59, 95% CI 1.40-1.80] and site treatment volume (OR 1.87, 95% CI 1.56-2.24 for sites initiating treatment for > 200 individuals) and negatively associated with pre-treatment anaemia (OR 0.68, 95% CI 0.58-0.80 for haemoglobin 10-14 g/dl) and depression (OR 0.78, 95% CI 0.69-0.89). Human immunodeficiency virus coinfection and minority race were not associated with failing to complete treatment. Conclusions Among veterans-in-care with known HCV, 11.9% initiate therapy of whom 22.5% (one in 56 with known HCV infection) complete a 48-week course of treatment. Higher completion rates among higher volume treatment sites suggest that some factors associated with non-completion (pre-treatment depression and anaemia), may be modifiable with experience. C1 [Butt, Adeel A.] Univ Pittsburgh, Med Ctr, Ctr Hlth Equ Res & Promot, Sch Med,VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15213 USA. [Justice, Amy C.] VA Connecticut Healthcare Syst, West Haven, CT USA. [Justice, Amy C.] Yale Univ, Sch Med, VA Connecticut Healthcare Syst, New Haven, CT USA. RP Butt, AA (reprint author), Univ Pittsburgh, Med Ctr, Ctr Hlth Equ Res & Promot, Sch Med,VA Pittsburgh Healthcare Syst, 3601 5th Ave,Suite 3A, Pittsburgh, PA 15213 USA. EM butta@dom.pitt.edu FU National Institutes of Health/National Institute on Drug Abuse [DA016175-01A1]; National Institutes of Health/National Institute on Alcohol Abuse and Alcoholism [U10AA13566]; Valeant Pharmaceuticals FX This study was funded by the National Institutes of Health/National Institute on Drug Abuse (DA016175-01A1, Dr Butt). Dr Justice's time was supported by National Institutes of Health/National Institute on Alcohol Abuse and Alcoholism (U10AA13566). This material is the result of work supported with resources and the use of facilities at the VA Pittsburgh Healthcare System and the central data repositories maintained by the VA Information Resource center, including the National Patient Care Database, Decisions Support System database and the Pharmacy Benefits Management database. Disclaimer/Conflict: The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs. Dr Butt has received grant funding from Valeant Pharmaceuticals. NR 43 TC 32 Z9 32 U1 1 U2 3 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1478-3223 J9 LIVER INT JI Liver Int. PD FEB PY 2010 VL 30 IS 2 BP 240 EP 250 DI 10.1111/j.1478-3231.2009.02156.x PG 11 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 536DB UT WOS:000273021300012 PM 19889081 ER PT J AU Sun, HY Cacciarelli, TV Singh, N AF Sun, Hsin-Yun Cacciarelli, Thomas V. Singh, Nina TI Impact of Pretransplant Infections on Clinical Outcomes of Liver Transplant Recipients SO LIVER TRANSPLANTATION LA English DT Article ID SPONTANEOUS BACTERIAL PERITONITIS; HEPATITIS-C; PREEMPTIVE THERAPY; CIRRHOSIS; CYTOMEGALOVIRUS; VALGANCICLOVIR; SUSCEPTIBILITY; RECURRENCE; SEPSIS AB Whether pretransplant nonviral infections influence outcomes after transplantation in liver transplant recipients in the current era is not well defined. One hundred consecutive patients undergoing liver transplantation in 2005-2008 were studied. Demographics, posttransplant clinical events, and mortality were compared between recipients with and without infections within 12 months before transplantation. In all, 32% of the patients (32/100) developed 45 episodes of pretransplant infections, which included spontaneous bacterial peritonitis (35.6%), bloodstream infections (28.9%), cellulitis (13.3%), pneumonia (8.9%), urinary tract infections (6.7%), and other infections (6.7%). Compared with 68 recipients without pretransplant infections, those with infections had a higher Model for End-Stage Liver Disease score and a lower likelihood of transplantation from home and required longer and more frequent hospital care before and after transplantation (P < 0.05). Mortality at 90 (9.4% versus 2.9%) and 180 days (15.6% versus 10.3%) post-transplant did not differ significantly between recipients with and without pretransplant infections (P = not significant). A higher Model for End-Stage Liver Disease score (P < 0.05) and posttransplant infections (P < 0.05 and P < 0.001), but not pretransplant infections, were associated with posttransplant mortality at 90 and 180 days. In conclusion, pretransplant infections that have been adequately treated do not pose a significant risk for poor outcomes, including posttransplant mortality. Liver Transpl 16:222-228, 2010. (C) 2010 AASLD. C1 [Sun, Hsin-Yun; Cacciarelli, Thomas V.; Singh, Nina] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Sun, Hsin-Yun] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan. [Sun, Hsin-Yun] Natl Taiwan Univ, Coll Med, Taipei 10764, Taiwan. [Cacciarelli, Thomas V.; Singh, Nina] Univ Pittsburgh, Pittsburgh, PA USA. RP Singh, N (reprint author), Vet Adm Med Ctr, Infect Dis Sect, Univ Dr C, Pittsburgh, PA 15240 USA. EM nis5@pitt.edu OI SUN, HSIN-YUN/0000-0003-0074-7721 NR 22 TC 15 Z9 16 U1 0 U2 3 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1527-6465 J9 LIVER TRANSPLANT JI Liver Transplant. PD FEB PY 2010 VL 16 IS 2 BP 222 EP 228 DI 10.1002/lt.21982 PG 7 WC Gastroenterology & Hepatology; Surgery; Transplantation SC Gastroenterology & Hepatology; Surgery; Transplantation GA 554LZ UT WOS:000274437800014 PM 20104499 ER PT J AU Bendlin, BB Carlsson, CM Gleason, CE Johnson, SC Sodhi, A Gallagher, CL Puglielli, L Engelman, CD Ries, ML Xu, G Wharton, W Asthana, S AF Bendlin, B. B. Carlsson, C. M. Gleason, C. E. Johnson, S. C. Sodhi, A. Gallagher, C. L. Puglielli, L. Engelman, C. D. Ries, M. L. Xu, G. Wharton, W. Asthana, S. TI Midlife predictors of Alzheimer's disease SO MATURITAS LA English DT Review DE Alzheimer's disease; Dementia; Midlife; Genes; Family history; Estrogen; Vascular risk; Education; MRI ID APOLIPOPROTEIN-E EPSILON-4; ESTROGEN REPLACEMENT THERAPY; RANDOMIZED CONTROLLED-TRIAL; MILD COGNITIVE IMPAIRMENT; HEALTH INITIATIVE MEMORY; GENOME-WIDE ASSOCIATION; SYSTOLIC BLOOD-PRESSURE; WHITE-MATTER INTEGRITY; FEMALE 3XTG-AD MICE; WOMENS HEALTH AB Factors contributing to increased risk for Alzheimer's disease (AD) include age, sex, genes, and family history of AD. Several risk factors for AD are endogenous; however, accumulating evidence implicates modifiable risk factors in the pathogenesis of AD. Although the continued task of identifying new genes will be critical to learning more about the disease, several research findings suggest that potentially alterable environmental factors influence genetic contributions, providing targets for disease prevention and treatment. Here, we review midlife risk factors for AD, and address the potential for therapeutic intervention in midlife. (C) 2009 Elsevier Ireland Ltd. All rights reserved. C1 [Bendlin, B. B.; Carlsson, C. M.; Gleason, C. E.; Johnson, S. C.; Sodhi, A.; Gallagher, C. L.; Puglielli, L.; Ries, M. L.; Xu, G.; Wharton, W.; Asthana, S.] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI USA. [Bendlin, B. B.; Carlsson, C. M.; Gleason, C. E.; Johnson, S. C.; Sodhi, A.; Gallagher, C. L.; Puglielli, L.; Ries, M. L.; Xu, G.; Wharton, W.; Asthana, S.] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI USA. [Engelman, C. D.] Univ Wisconsin, Dept Populat Hlth Sci, Sch Med & Publ Hlth, Madison, WI USA. RP Bendlin, BB (reprint author), Vet Adm Hosp, Geriatr Res Educ & Clin Ctr, Madison, WI 53705 USA. EM bbb@medicine.wisc.edu OI Bendlin, Barbara/0000-0002-0580-9875 FU University of Wisconsin, Madison FX Completion of this work was supported by the help of the Section of Geriatrics and Gerontology, Department of Medicine at the University of Wisconsin, Madison, and the Geriatric Research, Education and Clinical Center (GRECC manuscript number 2009-16), William S. Middleton Memorial Veterans Hospital. NR 132 TC 16 Z9 18 U1 5 U2 11 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0378-5122 J9 MATURITAS JI Maturitas PD FEB PY 2010 VL 65 IS 2 SI SI BP 131 EP 137 DI 10.1016/j.maturitas.2009.12.014 PG 7 WC Geriatrics & Gerontology; Obstetrics & Gynecology SC Geriatrics & Gerontology; Obstetrics & Gynecology GA 560ZO UT WOS:000274944600009 PM 20044221 ER PT J AU Hooker, RS AF Hooker, Roderick S. TI The future of the physician assistant movement SO MEDICAL JOURNAL OF AUSTRALIA LA English DT Editorial Material ID BRAIN-DRAIN C1 [Hooker, Roderick S.] Univ N Texas, Hlth Sci Ctr, Sch Publ Hlth, Ft Worth, TX USA. [Hooker, Roderick S.] US Dept Vet Affairs, Vet Hlth Adm, Dallas, TX USA. RP Hooker, RS (reprint author), Univ N Texas, Hlth Sci Ctr, Sch Publ Hlth, Ft Worth, TX USA. EM roderick.hooker@va.gov NR 6 TC 3 Z9 3 U1 0 U2 0 PU AUSTRALASIAN MED PUBL CO LTD PI PYRMONT PA LEVEL 2, 26-32 PYRMONT BRIDGE RD, PYRMONT, NSW 2009, AUSTRALIA SN 0025-729X J9 MED J AUSTRALIA JI Med. J. Aust. PD FEB 1 PY 2010 VL 192 IS 3 BP 116 EP 116 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 563RF UT WOS:000275150400001 PM 20121674 ER PT J AU Moatamed, NA Apple, SK Moatamed, F AF Moatamed, N. A. Apple, S. K. Moatamed, F. TI Inclusion of the Uniform Tetraploid Cells Reduces the Specificity of the Urine FISH Assay SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 99th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 20-26, 2010 CL Washington, DC SP US & Canadian Acac Pathol C1 Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. VA Greater Healthcare Syst, Los Angeles, CA USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2010 VL 23 SU 1 MA 447 BP 102A EP 102A PG 1 WC Pathology SC Pathology GA 556HX UT WOS:000274582500447 ER PT J AU Cowart, LA Shotwell, M Worley, ML Richards, AJ Montefusco, DJ Hannun, YA Lu, XH AF Cowart, L. Ashley Shotwell, Matthew Worley, Mitchell L. Richards, Adam J. Montefusco, David J. Hannun, Yusuf A. Lu, Xinghua TI Revealing a signaling role of phytosphingosine-1-phosphate in yeast SO MOLECULAR SYSTEMS BIOLOGY LA English DT Article DE information integration; lipidomics; signal transduction; sphingolipids; transcriptomics ID HEAT-STRESS RESPONSE; TRANSCRIPTIONAL REGULATORY NETWORKS; SACCHAROMYCES-CEREVISIAE; COMPONENT ANALYSIS; GENE-EXPRESSION; SPHINGOID BASE; SPHINGOLIPIDS; SPHINGOSINE-1-PHOSPHATE; BIOSYNTHESIS; METABOLOMICS AB Sphingolipids including sphingosine-1-phosphate and ceramide participate innumerous cell programs through signaling mechanisms. This class of lipids has important functions in stress responses; however, determining which sphingolipid mediates specific events has remained encumbered by the numerous metabolic interconnections of sphingolipids,such that modulating a specific lipid of interest through manipulating metabolic enzymes causes 'ripple effects', which change levels of many other lipids. Here, we develop a method of integrative analysis for genomic, transcriptomic, and lipidomic data to address this previously intractable problem. This method revealed a specific signaling role for phytosphingosine-1-phosphate, a lipid with no previously defined specific function in yeast, in regulating genes required for mitochondrial respiration through the HAP complex transcription factor. This approach could be applied to extract meaningful biological information from a similar experimental design that produces multiple sets of high-throughput data. Molecular Systems Biology 6: 349; published online 16 February 2010; doi:10.1038/msb.2010.3 C1 [Cowart, L. Ashley; Worley, Mitchell L.; Richards, Adam J.; Montefusco, David J.; Hannun, Yusuf A.; Lu, Xinghua] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. [Shotwell, Matthew] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Cowart, L. Ashley] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Lu, XH (reprint author), Med Univ S Carolina, Dept Biochem & Mol Biol, 174 Ashley Ave, Charleston, SC 29425 USA. EM hannun@musc.edu; lux@musc.edu FU Department of Veterans' Affairs Merit award [5R01LM009153, 3T15LM07438, 5T32GM074934]; [P20 RR017677-]; [1R01LM10144]; [5R01GM63265] FX We acknowledge the following grant supports: P20 RR017677-07 (to LAC and XL). 1R01LM10144 to XL, 5R01GM63265 to YAH, the Department of Veterans' Affairs Merit award to LAC, 5R01LM009153, 3T15LM07438 to XL and AJR, and 5T32GM074934 to MS. We thank Alan Wilder and Jason Gandy for technical assistance. We also acknowledge the MUSC Lipidomics Core Facility of the COBRE in Lipidomics and Pathobiology for sample analysis, the MUSC Proteogenomics Core Facility for microarray assays, the MUSC department of Art Services for assistance with figure preparation, and Dr Hiroko Hama for critical reading of the paper. NR 39 TC 27 Z9 27 U1 0 U2 5 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1744-4292 J9 MOL SYST BIOL JI Mol. Syst. Biol. PD FEB PY 2010 VL 6 AR 349 DI 10.1038/msb.2010.3 PG 9 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 564AU UT WOS:000275183700002 PM 20160710 ER PT J AU Liu, XH Lee, DJ Skittone, LK Natsuhara, K Kim, HT AF Liu, Xuhui Lee, David J. Skittone, Laura K. Natsuhara, Kyle Kim, Hubert T. TI ROLE OF GELATINASES IN DISUSE-INDUCED SKELETAL MUSCLE ATROPHY SO MUSCLE & NERVE LA English DT Article DE gelatinases; muscular atrophy; extracellular matrix; disuse; basement membrane ID MATRIX METALLOPROTEINASES; IV COLLAGENASE; HINDLIMB IMMOBILIZATION; HUMAN-FIBROBLASTS; EXPRESSION; RATS; INHIBITOR; SECRETION; RECOVERY AB Gelatinases are a subgroup of the family of matrix metalloproteinases, which contains two members-gelatinase A and B. These enzymes play an important role in basement membrane homeostasis. Previous studies have associated basement membrane degradation with skeletal muscle atrophy. However, the specific contribution of gelatinases to the pathobiology of muscle atrophy remains unknown. In this study we examined the specific roles of gelatinase A and B in disuse-induced skeletal muscle atrophy using knockout mice. Although both gelatinase A and B are highly upregulated in disused muscle, only gelatinase A null mice had significantly reduced muscle atrophy as compared to wildtype littermates. Type IV collagen and laminin, two major components of basement membrane, were relatively well-preserved in disused muscle in gelatinase A null mice, but not in gelatinase B null mice. These findings suggest that gelatinase A, and not gelatinase B, plays a critical role in disuse-induced skeletal muscle atrophy. Muscle Nerve 41: 174-178, 2010 C1 [Liu, Xuhui; Skittone, Laura K.; Natsuhara, Kyle; Kim, Hubert T.] San Francisco VA Med Ctr, Dept Vet Affairs, San Francisco, CA 94121 USA. [Liu, Xuhui; Lee, David J.; Kim, Hubert T.] Univ Calif San Francisco, Dept Orthoped Surg, San Francisco, CA 94143 USA. RP Kim, HT (reprint author), San Francisco VA Med Ctr, Dept Vet Affairs, 4150 Clement St 112, San Francisco, CA 94121 USA. EM Kimh@orthosurg.ucsf.edu FU Orthopedic Research & Education Foundation; Illinois Bone and Joint Institute FX Supported by the Orthopedic Research & Education Foundation and the Illinois Bone and Joint Institute. We thank Dr. Rajabrata Sarkar for gifts of MMP-2 and MMP-9 knockout, mice. We think Dr. Mostafa Gabr for technique help in histology. NR 26 TC 5 Z9 5 U1 0 U2 1 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0148-639X J9 MUSCLE NERVE JI Muscle Nerve PD FEB PY 2010 VL 41 IS 2 BP 174 EP 178 DI 10.1002/mus.21463 PG 5 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 550LZ UT WOS:000274130700003 PM 19790245 ER PT J AU Odden, MC Tager, IB Gansevoort, RT Bakker, SJL Katz, R Fried, LF Newman, AB Canada, RB Harris, T Sarnak, MJ Siscovick, D Shlipak, MG AF Odden, Michelle C. Tager, Ira B. Gansevoort, Ron T. Bakker, Stephan J. L. Katz, Ronit Fried, Linda F. Newman, Anne B. Canada, Robert B. Harris, Tamara Sarnak, Mark J. Siscovick, David Shlipak, Michael G. TI Age and cystatin C in healthy adults: a collaborative study SO NEPHROLOGY DIALYSIS TRANSPLANTATION LA English DT Article DE ageing; chronic kidney disease; cystatin C; epidemiology ID URINARY ALBUMIN EXCRETION; SERUM CREATININE; RENAL-FUNCTION; PULMONARY-FUNCTION; KIDNEY-FUNCTION; UNITED-STATES; DISEASE; DYSFUNCTION; POPULATION; DECLINE AB Methods. The authors pooled individual-level cross-sectional data from 18 253 persons aged 28-100 years in four studies: the Cardiovascular Health Study; the Health, Aging and Body Composition Study; the Multi-Ethnic Study of Atherosclerosis and the Prevention of Renal and Vascular End-Stage Disease cohort. Kidney function was measured by cystatin C. Clinical risk factors for kidney disease included diabetes, hypertension, obesity, smoking, coronary heart disease, cerebrovascular disease, peripheral arterial disease and heart failure. Results. Across the age range, there was a strong, non-linear association of age with cystatin C concentration. This association was substantial, even among participants free of clinical risk factors for kidney disease; mean cystatin C levels were 46% higher in participants 80 and older compared with those < 40 years (1.06 versus 0.72 mg/L, P < 0.001). Participants with one or more risk factors had higher cystatin C concentrations for a given age, and the age association was slightly stronger (P < 0.001 for age and risk factor interaction). Conclusions. There is a strong, non-linear association of age with kidney function, even in healthy individuals. An important area for research will be to investigate the mechanisms that lead to deterioration of kidney function in apparently healthy persons. C1 [Odden, Michelle C.; Tager, Ira B.] Univ Calif Berkeley, Sch Publ Hlth, Dept Epidemiol, Berkeley, CA 94720 USA. [Odden, Michelle C.] Univ Calif San Francisco, Dept Gen Internal Med, San Francisco, CA 94143 USA. [Gansevoort, Ron T.; Bakker, Stephan J. L.] Univ Groningen, Univ Med Ctr Groningen, Dept Internal Med, Div Nephrol, Groningen, Netherlands. [Katz, Ronit] Univ Washington, Collaborat Hlth Studies Coordinating Ctr, Seattle, WA 98195 USA. [Fried, Linda F.] Vet Affairs Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA USA. [Newman, Anne B.] Univ Pittsburgh, Sch Med, Dept Epidemiol, Pittsburgh, PA USA. [Canada, Robert B.] Univ Tennessee, Ctr Hlth Sci, Dept Med, Memphis, TN 38163 USA. [Canada, Robert B.] Univ Tennessee, Ctr Hlth Sci, Dept Nephrol, Memphis, TN 38163 USA. [Harris, Tamara] NIA, Lab Epidemiol, Demog Biometry Program, NIH, Bethesda, MD 20892 USA. [Sarnak, Mark J.] Tufts Med Ctr, Dept Med, Div Nephrol, Boston, MA USA. [Siscovick, David] Univ Washington, Dept Med, Seattle, WA USA. [Siscovick, David] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Shlipak, Michael G.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Shlipak, Michael G.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Shlipak, Michael G.] San Francisco VA Med Ctr, Dept Gen Internal Med, San Francisco, CA USA. RP Odden, MC (reprint author), Univ Calif Berkeley, Sch Publ Hlth, Dept Epidemiol, Berkeley, CA 94720 USA. EM michelle.odden@ucsf.edu RI Newman, Anne/C-6408-2013; Bakker, Stephan/J-4023-2015 OI Newman, Anne/0000-0002-0106-1150; Bakker, Stephan/0000-0003-3356-6791 FU National Heart, Lung and Blood Institute [N01HC-85079, N01-HC-85086, N01-HC-35129, N01 HC-15103, N01 HC-55222, N01-HC-75150, N01-HC-45133, U01 HL080295, R01-HL-63963-01A1, N01-HC-95159, N01-HC-95165, N01-HC-95169]; National Institute on Aging [N01-AG-6-2101, N01AG-6-2103, N01-AG-6-2106, R01AG027002]; NIH, National Institute on Aging; Dutch Kidney Foundation, Bussum, The Netherlands [E013]; National Institute of Diabetes and Digestive, and Kidney Diseases [T32DK07791, DK52866]; institutional Health Resources & Services Administration National Research Service Award [T32HP19025]; American Federation for Aging Research; Robert Wood Johnson Foundation; American Heart Association FX CHS was supported by contract numbers N01HC-85079 through N01-HC-85086, N01-HC-35129, N01 HC-15103, N01 HC-55222, N01-HC-75150, N01-HC-45133, grant number U01 HL080295 from the National Heart, Lung and Blood Institute, with additional contribution from the National Institute of Neurological Disorders and Stroke. A full list of principal CHS investigators and institutions can be found at http://www.chs-nhlbi.org/pi.htm. Health ABC was supported through the National Institute on Aging contracts N01-AG-6-2101, N01AG-6-2103 and N01-AG-6-2106 and in part by the Intramural Research Program of the NIH, National Institute on Aging. MESA was supported by grant R01-HL-63963-01A1 and by contracts N01-HC-95159 through N01-HC-95165 and N01-HC-95169 from the National Heart, Lung and Blood Institute. PREVEND is supported by grant E013 of the Dutch Kidney Foundation, Bussum, The Netherlands, and grants T32DK07791 and DK52866 from the National Institute of Diabetes and Digestive, and Kidney Diseases. This project was also supported by grant R01AG027002 from the National Institutes on Aging. Dr Odden is supported by an institutional Health Resources & Services Administration National Research Service Award (T32HP19025). Dr Shlipak was supported by the American Federation for Aging Research and National Institute on Aging (Paul Beeson Scholars Program), by the Robert Wood Johnson Foundation (Generalist Faculty Scholars Program), and the American Heart Association. NR 34 TC 28 Z9 29 U1 0 U2 2 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0931-0509 J9 NEPHROL DIAL TRANSPL JI Nephrol. Dial. Transplant. PD FEB PY 2010 VL 25 IS 2 BP 463 EP 469 DI 10.1093/ndt/gfp474 PG 7 WC Transplantation; Urology & Nephrology SC Transplantation; Urology & Nephrology GA 547LY UT WOS:000273891600024 PM 19749145 ER PT J AU Lopez-Meraz, ML Wasterlain, CG Rocha, LL Allen, S Niquet, J AF Lopez-Meraz, Maria-Leonor Wasterlain, Claude G. Rocha, Luisa L. Allen, Suni Niquet, Jerome TI Vulnerability of postnatal hippocampal neurons to seizures varies regionally with their maturational stage SO NEUROBIOLOGY OF DISEASE LA English DT Article DE Necrosis; Apoptosis; Caspase; Doublecortin; Hippocampus; Status epilepticus; Pilocarpine; Development ID PILOCARPINE STATUS EPILEPTICUS; LONG-TERM POTENTIATION; Q-VD-OPH; CELL-DEATH; RAT HIPPOCAMPUS; DENTATE GYRUS; CASPASE INHIBITOR; IMMATURE RATS; NEONATAL-RAT; CA1 REGION AB The mechanism of status epilepticus-induced neuronal death in the immature brain is not fully understood. In the present study, we examined the contribution of caspases in our lithium-pilocarpine model of status epilepticus in 14 days old rat pups. In CA1, upregulation of caspase-8, but not caspase-9, preceded caspase-3 activation in morphologically necrotic cells. Pretreatment with a pan-caspase inhibitor provided neuroprotection, showing that caspase activation was not an epiphenomenon but contributed to neuronal necrosis. By contrast, upregulation of active caspase-9 and caspase-3, but not caspase-8, was detected in apoptotic dentate gyrus neurons. which were immunoreactive for doublecortin and calbindin-negative, two features of immature neurons. These results suggest that, in cells which are aligned in series as parts of the same excitatory hippocampal circuit, the same seizures induce neuronal death through different mechanisms. The regional level of neuronal maturity may be a determining factor in the execution of a specific death program. (c) 2009 Elsevier Inc. All rights reserved. C1 [Lopez-Meraz, Maria-Leonor; Wasterlain, Claude G.; Allen, Suni; Niquet, Jerome] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Lopez-Meraz, Maria-Leonor; Wasterlain, Claude G.; Allen, Suni; Niquet, Jerome] VA Greater Los Angeles Healthcare Syst, Epilepsy Res Lab, Los Angeles, CA 90073 USA. [Wasterlain, Claude G.] Univ Calif Los Angeles, David Geffen Sch Med, Brain Res Inst, Los Angeles, CA 90095 USA. [Rocha, Luisa L.] Ctr Res & Adv Studies, Pharmacobiol Dept, Mexico City, DF, Mexico. [Lopez-Meraz, Maria-Leonor] Univ Veracruzana, Programa Neurobiol, Xalapa 91000, Veracruz, Mexico. RP Niquet, J (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. EM jniquet@ucla.edu FU Epilepsy Foundation; VHA Research Service; NINDS [R01 NS13515]; UC MEXUS-CONACyT FX This work is supported by Epilepsy Foundation (JN), VHA Research Service (CW), NINDS (grant R01 NS13515; CW), and UC MEXUS-CONACyT (CW and LR). MLLM received a UC MEXUS-CONACYT postdoctoral fellowship. NR 44 TC 24 Z9 25 U1 1 U2 4 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0969-9961 J9 NEUROBIOL DIS JI Neurobiol. Dis. PD FEB PY 2010 VL 37 IS 2 SI SI BP 394 EP 402 DI 10.1016/j.nbd.2009.10.019 PG 9 WC Neurosciences SC Neurosciences & Neurology GA 551QP UT WOS:000274224400019 PM 19879360 ER PT J AU Anderson, A Dinov, ID Sherin, JE Quintana, J Yuille, AL Cohen, MS AF Anderson, Ariana Dinov, Ivo D. Sherin, Jonathan E. Quintana, Javier Yuille, A. L. Cohen, Mark S. TI Classification of spatially unaligned fMRI scans SO NEUROIMAGE LA English DT Article DE Classification; FMRI; Discrimination; Schizophrenia; Dementia; Machine learning; Independent components analysis ID SCHIZOPHRENIA; MRI AB The analysis of fMRI data is challenging because they consist generally of a relatively modest signal contained in a high-dimensional space: a single scan can contain millions of voxel recordings over space and time We present a method for classification and discrimination among fMRI that is based on modeling the scans as distance matrices, where each matrix measures the divergence of spatial network signals that fluctuate over time. We used single-subject independent components analysis (ICA). decomposing an fMRI scan into a set of statistically independent spatial networks, to extract spatial networks and time courses front each Subject unique relationship with the other components within that Subject Mathematical properties of that have these relationships reveal information about the infrastructure of the brain by measuring the interaction between and strength of the components Our technique IS unique, in that it does not require spatial alignment of the scans across subjects Instead, the classifications are made solely on the temporal activity taken by the subject's unique ICs. Multiple scans are not required and multivariate classification is implementable, and the algorithm is effectively blind to the subject-uniform underlying task paradigm Classification accuracy of Lip to 90% was realized on a resting-scanned schizophrenia/normal dataset and a tasked multivariate Alzheimer's/old/young dataset We propose that the ICs represent a plausible set of imaging basis functions consistent with network-driven theories Of Mural activity in which the observed signal is an aggregate of independent spatial networks having possibly dependent temporal activity (C) 2009 Elsevier Inc. All rights reserved C1 [Anderson, Ariana; Dinov, Ivo D.; Yuille, A. L.] Univ Calif Los Angeles, Dept Stat, Los Angeles, CA 90095 USA. [Anderson, Ariana; Cohen, Mark S.] Univ Calif Los Angeles, Ctr Cognit Neurosci, Los Angeles, CA 90095 USA. [Sherin, Jonathan E.; Quintana, Javier; Cohen, Mark S.] Univ Calif Los Angeles, Dept Psychiat & Behav Sci, Los Angeles, CA 90095 USA. [Anderson, Ariana; Dinov, Ivo D.; Sherin, Jonathan E.; Quintana, Javier; Cohen, Mark S.] UCLA Sch Med, Los Angeles, CA 90095 USA. [Dinov, Ivo D.] Univ Calif Los Angeles, Ctr Computat Biol, Los Angeles, CA 90095 USA. [Sherin, Jonathan E.; Quintana, Javier] Greater Los Angeles VA Healthcare Syst, Los Angeles, CA 90073 USA. [Yuille, A. L.] Univ Calif Los Angeles, Dept Comp Sci, Los Angeles, CA 90095 USA. [Yuille, A. L.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA. RP Cohen, MS (reprint author), UCLA Ctr Cognit Neurosci, Suite C8-881,740 Westwood Plaza, Los Angeles, CA 90095 USA. RI Cohen, Mark/C-6610-2011 OI Cohen, Mark/0000-0001-6731-4053; Dinov, Ivo/0000-0003-3825-4375 FU NCRR NIH HHS [U54 RR021813]; NIDA NIH HHS [R21 DA026109, R21 DA026109-01, R21 DA026109-02, R21DA026109, R33 DA026109, R90 DA023422, R90 DA023422-01, T90 DA022768, T90DA022768] NR 22 TC 12 Z9 12 U1 1 U2 4 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1053-8119 J9 NEUROIMAGE JI Neuroimage PD FEB 1 PY 2010 VL 49 IS 3 BP 2509 EP 2519 DI 10.1016/j.neuroimage.2009.08.036 PG 11 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA 544BN UT WOS:000273626400053 PM 19712744 ER PT J AU Zivkovic, SA Abdel-Hamid, H AF Zivkovic, Sasa A. Abdel-Hamid, Hoda TI Neurologic Manifestations of Transplant Complications SO NEUROLOGIC CLINICS LA English DT Article DE Posttransplant recovery; Neurotoxicity; Opportunistic infections; Transplant complications ID BONE-MARROW-TRANSPLANTATION; SOLID-ORGAN TRANSPLANTATION; STEM-CELL TRANSPLANTATION; INDUCED PAIN SYNDROME; LIVER-TRANSPLANTATION; LUNG TRANSPLANTATION; CARDIAC TRANSPLANTATION; RENAL-TRANSPLANTATION; PEDIATRIC-PATIENTS; TACROLIMUS FK506 AB Neurologic complications affect posttransplant recovery of more than 20% of transplant recipients. Etiology is usually related to surgical procedure of transplantation, primary disorders causing failure of transplanted organ, opportunistic infections, and neurotoxicity of immunosuppressive medications. Risk of opportunistic infections and immunosuppressant neurotoxicity is greatest within the first six months, but it persists along with long-term maintenance immunosuppression required to prevent graft rejection. Neurotoxicity may require alteration of immunosuppressive regimen, and prompt therapy of opportunistic infections improves outcomes. C1 [Zivkovic, Sasa A.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA. [Zivkovic, Sasa A.] VA Pittsburgh Healthcare Syst, Neurol Serv, Pittsburgh, PA 15240 USA. [Abdel-Hamid, Hoda] Univ Pittsburgh, Div Pediat Neurol, Childrens Hosp Pittsburgh, Sch Med, Pittsburgh, PA 15201 USA. RP Zivkovic, SA (reprint author), Univ Pittsburgh, Sch Med, Dept Neurol, PUH F878,200 Lothrop St, Pittsburgh, PA 15213 USA. EM zivkovics@upmc.edu FU Health Resources and Services Administration [231-00-0115] FX This work was supported in part by Health Resources and Services Administration contract 231-00-0115. The content is the responsibility of the authors alone and does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government. NR 97 TC 7 Z9 7 U1 0 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0733-8619 J9 NEUROL CLIN JI Neurol. Clin. PD FEB PY 2010 VL 28 IS 1 BP 235 EP + DI 10.1016/j.ncl.2009.09.011 PG 18 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 617CL UT WOS:000279258300014 PM 19932384 ER PT J AU Costello, MR Mandelkern, MA Shoptaw, S Shulenberger, S Baker, SK Abrams, AL Xia, C London, ED Brody, AL AF Costello, Matthew R. Mandelkern, Mark A. Shoptaw, Stephen Shulenberger, Stephanie Baker, Stephanie K. Abrams, Anna L. Xia, Catherine London, Edythe D. Brody, Arthur L. TI Effects of Treatment for Tobacco Dependence on Resting Cerebral Glucose Metabolism SO NEUROPSYCHOPHARMACOLOGY LA English DT Article DE tobacco dependence; nicotine; cigarette; 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET); statistical parametric mapping; bupropion HCl ID SUSTAINED-RELEASE BUPROPION; SMOKING-CESSATION; CIGARETTE-SMOKING; CONTROLLED-TRIAL; DOPAMINE TRANSPORTER; RELAPSE PREVENTION; PLASMA NICOTINE; DEFAULT MODE; HUMAN BRAIN; BLOOD-FLOW AB While bupropion HCl and practical group counseling (PGC) are commonly used treatments for tobacco dependence, the effects of these treatments on brain function are not well established. For this study, 54 tobacco-dependent cigarette smokers underwent resting (18)F-fluorodeoxyglucose-positron emission tomography (FDG-PET) scanning before and after 8 weeks of treatment with bupropion HCl, PGC, or pill placebo. Using Statistical Parametric Mapping (SPM 2), changes in cerebral glucose metabolism from before to after treatment were compared between treatment groups and correlations were determined between amount of daily cigarette usage and cerebral glucose metabolism. Compared with placebo, the two active treatments (bupropion HCl and PGC) had reductions in glucose metabolism in the posterior cingulate gyrus. Further analysis suggested that PGC had a greater effect than bupropion HCl on glucose metabolism in this region. We also found positive correlations between daily cigarette use and glucose metabolism in the left occipital gyrus and parietal-temporal junction. There were no significant negative correlations between daily cigarette use and glucose metabolism. Our findings suggest that bupropion HCl and PGC reduce neural activity much as the performance of a goal-oriented task does in the default mode network of the brain, including the posterior cingulate gyrus. Thus, this study supports the theory that active treatments for tobacco dependence move the brain into a more goal-oriented state. Neuropsychopharmacology (2010) 35, 605-612; doi:10.1038/npp.2009.165; published online 28 October 2009 C1 [Shoptaw, Stephen; London, Edythe D.; Brody, Arthur L.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Costello, Matthew R.; Mandelkern, Mark A.; Shulenberger, Stephanie; Baker, Stephanie K.; Abrams, Anna L.; Xia, Catherine; Brody, Arthur L.] Greater Los Angeles Vet Adm Healthcare Syst, Los Angeles, CA USA. [Mandelkern, Mark A.] UCI, Dept Phys, Irvine, CA USA. [London, Edythe D.; Brody, Arthur L.] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90095 USA. [London, Edythe D.] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA. RP Brody, AL (reprint author), Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, 300 UCLA Med Plaza,Suite 2200, Los Angeles, CA 90095 USA. EM abrody@ucla.edu FU National Institute on Drug Abuse [R01 DA20872]; Veterans Administration; Tobacco-Related Disease Research Program [16RT-0098]; Office of National Drug Control Policy [DABT 63-00C-1003]; National Alliance for Research on Schizophrenia and Depression FX Supported by the National Institute on Drug Abuse ( ALB ( R01 DA20872)), the Veterans Administration ( ALB ( Merit Review Type I Award)), the Tobacco-Related Disease Research Program ( ALB ( 16RT-0098)), the Office of National Drug Control Policy ( EDL ( DABT 63-00C-1003)), and the National Alliance for Research on Schizophrenia and Depression ( ALB). Initial study results were presented at the 2008 Society for Research on Nicotine and Tobacco meeting. We thank Josephine Ribe and Michael Clark for technical support in performing positron emission tomography and magnetic resonance imaging scans, respectively. NR 54 TC 4 Z9 4 U1 1 U2 6 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0893-133X J9 NEUROPSYCHOPHARMACOL JI Neuropsychopharmacology PD FEB PY 2010 VL 35 IS 3 BP 605 EP 612 DI 10.1038/npp.2009.165 PG 8 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 544EK UT WOS:000273635100002 PM 19865076 ER PT J AU Gray, KM DeSantis, SM Carpenter, MJ Saladin, ME LaRowe, SD Upadhyaya, HP AF Gray, Kevin M. DeSantis, Stacia M. Carpenter, Matthew J. Saladin, Michael E. LaRowe, Steven D. Upadhyaya, Himanshu P. TI Menstrual cycle and cue reactivity in women smokers SO NICOTINE & TOBACCO RESEARCH LA English DT Article ID SMOKING-BEHAVIOR; CIGARETTE-SMOKING; PHASE; NICOTINE; ABSTINENCE; CESSATION; SESSIONS; RELAPSE AB Introduction: Emerging research suggests potential effects of the menstrual cycle on various aspects of smoking behavior in women, but results to date have been mixed. The present study sought to explore the influence of menstrual cycle phase on reactivity to smoking in vivo and stressful imagery cues in a sample of non-treatment-seeking women smokers. Methods: Via a within-subjects design, nicotine-dependent women (N = 37) participated in a series of four cue reactivity sessions, each during a distinct biologically verified phase of the menstrual cycle (early follicular [EF], mid-follicular [MF], midluteal [ML], and late luteal [LL]). Subjective (Questionnaire of Smoking Urges-Brief; QSU-B) and physiological (skin conductance and heart rate) measures of craving and reactivity were collected and compared across phases. Results: Subjective reactive craving (QSU-B) to smoking in vivo cues varied significantly across the menstrual cycle (p = .02) and was higher in both EF and MF phases versus ML and LL phases, but this finding was not sustained when controlling for reactivity to neutral cues. Heart rate reactivity to stressful imagery cues (p = .01) and skin conductance reactivity to smoking in vivo cues (p = .05) varied significantly across the menstrual cycle upon controlling for reactivity to neutral cues, with highest reactivity during the MF phase. Discussion: Menstrual cycle phase may have an effect on reactivity to smoking-related and stressful cues among women smokers. These findings contribute to an expanding literature, suggesting menstrual cycle effects on smoking behaviors in women. C1 [Gray, Kevin M.] Med Univ S Carolina, Youth Div, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [DeSantis, Stacia M.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Carpenter, Matthew J.] Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA. [Saladin, Michael E.] Med Univ S Carolina, Dept Hlth Sci & Res, Charleston, SC 29425 USA. [LaRowe, Steven D.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Gray, KM (reprint author), Med Univ S Carolina, Youth Div, Dept Psychiat & Behav Sci, 67 President St,POB 250861, Charleston, SC 29425 USA. EM graykm@musc.edu OI LaRowe, Steven/0000-0002-7664-2451 FU National Institute on Drug Abuse [P50 DA016511, K12 DA000357, K23 DA020482]; United States Public Health Service [M01 RR01070] FX This research was supported by National Institute on Drug Abuse grants P50 DA016511 (HPU, component PI; Drs. Kathleen T. Brady and Ronald See, Center PIs), K12 DA000357 (KMG), and K23 DA020482 (MJC) as well as United States Public Health Service grant M01 RR01070 (Medical University of South Carolina Clinical and Translational Research Center). NR 27 TC 11 Z9 11 U1 4 U2 4 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1462-2203 J9 NICOTINE TOB RES JI Nicotine Tob. Res. PD FEB PY 2010 VL 12 IS 2 BP 174 EP 178 DI 10.1093/ntr/ntp179 PG 5 WC Substance Abuse; Public, Environmental & Occupational Health SC Substance Abuse; Public, Environmental & Occupational Health GA 553CQ UT WOS:000274342900013 PM 19996146 ER PT J AU Brubaker, L Rickey, L Xu, Y Markland, A Lemack, G Ghetti, C Kahn, MA Nagaraju, P Norton, P Chang, TD Stoddard, A AF Brubaker, Linda Rickey, Leslie Xu, Yan Markland, Alayne Lemack, Gary Ghetti, Chiara Kahn, Margie A. Nagaraju, Pradeep Norton, Peggy Chang, T. Debuene Stoddard, Anne CA Urinary Incontinence Treatment Net TI Symptoms of Combined Prolapse and Urinary Incontinence in Large Surgical Cohorts SO OBSTETRICS AND GYNECOLOGY LA English DT Article ID PELVIC ORGAN PROLAPSE; QUALITY-OF-LIFE; UROGENITAL DISTRESS INVENTORY; STRESS-INCONTINENCE; IMPACT QUESTIONNAIRE; FLOOR DISORDERS; WOMEN; PREVALENCE; SEVERITY; STANDARDIZATION AB OBJECTIVE: To estimate whether prolapse severity is a major contributor to urinary incontinence severity, as measured by validated incontinence questionnaires. METHODS: We analyzed data from two large female stress urinary incontinence (SUI) surgical cohorts: the Stress Incontinence Surgical Treatment Efficacy Trial (SISTEr) study (N=655) and the subsequent Trial of Mid-Urethral Slings (TOMUS) study (N=597). All participants completed a standardized baseline assessment including validated measures of symptom severity, quality of life, objective measures of urine loss (Urogenital Distress Inventory [UDI], Medical, Epidemiologic, and Social Aspects of Aging questionnaire, Incontinence Impact Questionnaire, and pad test), as well as the Pelvic Organ Prolapse Quantification assessment. Groups were compared using the) chi(2); test (categorical measures) or the one-way analysis of variance (continuous measures). Statistical significance was defined as P<.05. RESULTS: The SISTEr and TOMUS samples were similar for many variables including age (52 and 53 years, respectively), nulliparity (9% and 12%), prior urinary incontinence (UI) surgery (14% and 13%), and prior hysterectomy (31% and 28%), but other differences necessitated separate analysis of the two cohorts. There was not a statistically significant difference in UDI scores according to prolapse stage in either study population. Patients with prior surgery for pelvic organ prolapse and SUI had more incontinence symptoms and were more bothered by their UI regardless of prolapse stage. CONCLUSION: Prolapse stage is not strongly or consistently associated with incontinence severity in women who select surgical treatment of SUI. Prior pelvic organ prolapse and UI surgery is associated with worse UI severity and bother. C1 Loyola Univ, Stritch Sch Med, Dept Obstet & Gynecol, Chicago, IL 60611 USA. Loyola Univ, Stritch Sch Med, Dept Urol, Chicago, IL 60611 USA. Univ Maryland, Dept Urol, Baltimore, MD 21201 USA. New England Res Inst, Watertown, MA 02172 USA. Univ Alabama, Dept Med, Birmingham, AL 35294 USA. Univ Alabama, Birmingham VA Med Ctr, Birmingham, AL USA. Univ Texas SW Med Ctr Dallas, Dept Urol, Dallas, TX 75390 USA. Univ Pittsburgh, Dept Obstet & Gynecol, Pittsburgh, PA USA. Kaiser Permanente, San Diego, CA USA. William Beaumont Hosp, Dept Urol, Royal Oak, MI 48072 USA. Univ Utah, Dept Obstet & Gynecol, Salt Lake City, UT USA. NIDDK, NIH, Bethesda, MD USA. RP Brubaker, L (reprint author), Loyola Univ Chicago, Stritch Sch Med, 2160 S 1st Ave,Bldg 103, Maywood, IL 60153 USA. EM LBrubaker@lumc.edu FU Pfizer (New York, AT); Allergan (Irvine, CA) FX Dr. Brubaker has received research funding from Pfizer (New York, AT) and Allergan (Irvine, CA) and. has been a research consultant for Pfizer. Dr. Lemak has been a clinical trial participant for Allergan, a consultant and lecturer for Astellas (Deerfield, IL) and Pfizer, and a lecturer for Novartis (Basel, Switzerland). Dr. Ghetti served as a co-investigator for the Bridges study with the University of California, San Francisco, which was partially funded by Pfizer. The other authors did not report any potential conflicts of interest. NR 24 TC 4 Z9 6 U1 2 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0029-7844 J9 OBSTET GYNECOL JI Obstet. Gynecol. PD FEB PY 2010 VL 115 IS 2 BP 310 EP 316 PN 1 PG 7 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 547FS UT WOS:000273872500015 PM 20093904 ER PT J AU Pujari, SS Kempen, JH Newcomb, CW Gangaputra, S Daniel, E Suhler, EB Thorne, JE Jabs, DA Levy-Clarke, GA Nussenblatt, RB Rosenbaum, JT Foster, CS AF Pujari, Siddharth S. Kempen, John H. Newcomb, Craig W. Gangaputra, Sapna Daniel, Ebenezer Suhler, Eric B. Thorne, Jennifer E. Jabs, Douglas A. Levy-Clarke, Grace A. Nussenblatt, Robert B. Rosenbaum, James T. Foster, C. Stephen TI Cyclophosphamide for Ocular Inflammatory Diseases SO OPHTHALMOLOGY LA English DT Article ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; KOYANAGI-HARADA-SYNDROME; WEGENERS-GRANULOMATOSIS; INTRAVENOUS CYCLOPHOSPHAMIDE; RHEUMATOID-ARTHRITIS; IMMUNOSUPPRESSIVE THERAPY; PULSE CYCLOPHOSPHAMIDE; FOLLOW-UP; DRUGS; MANAGEMENT AB Purpose: To evaluate the outcomes of cyclophosphamide therapy for noninfectious ocular inflammation. Design: Retrospective cohort study. Participants: Two hundred fifteen patients with noninfectious ocular inflammation observed from initiation of cyclophosphamide. Methods: Patients initiating cyclophosphamide, without other immunosuppressive drugs (other than corticosteroids), were identified at 4 centers. Dose of cyclophosphamide, response to therapy, corticosteroid-sparing effects, frequency of discontinuation, and reasons for discontinuation were obtained by medical record review of every visit. Main Outcome Measures: Control of inflammation, corticosteroid-sparing effects, and discontinuation of therapy. Results: The 215 patients (381 involved eyes) meeting eligibility criteria carried diagnoses of uveitis (20.4%), scleritis (22.3%), ocular mucous membrane pemphigoid (45.6%), or other forms of ocular inflammation (11.6%). Overall, approximately 49.2% (95% confidence interval [CI], 41.7%-57.2%) gained sustained control of inflammation (for at least 28 days) within 6 months, and 76% (95% CI, 68.3%-83.7%) gained sustained control of inflammation within 12 months. Corticosteroid-sparing success (sustained control of inflammation while tapering prednisone to 10 mg or less among those not meeting success criteria initially) was gained by 30.0% and 61.2% by 6 and 12 months, respectively. Disease remission leading to discontinuation of cyclophosphamide occurred at the rate of 0.32/person-year (95% CI, 0.24-0.41), and the estimated proportion with remission at or before 2 years was 63.1% (95% CI, 51.5%-74.8%). Cyclophosphamide was discontinued by 33.5% of patients within 1 year because of side effects, usually of a reversible nature. Conclusions: The data suggest that cyclophosphamide is effective for most patients for controlling inflammation and allowing tapering of systemic corticosteroids to 10 mg prednisone or less, although 1 year of therapy may be needed to achieve these goals. Unlike with most other immunosuppressive drugs, disease remission was induced by treatment in most patients who were able to tolerate therapy. To titrate therapy properly and to minimize the risk of serious potential side effects, a systematic program of laboratory monitoring is required. Judicious use of cyclophosphamide seems to be beneficial for severe ocular inflammation cases where the potentially vision-saving benefits outweigh the substantial potential side effects of therapy, or when indicated for associated systemic inflammatory diseases. Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. Ophthalmology 2010; 117: 356-365 (C) 2010 by the American Academy of Ophthalmology. C1 [Kempen, John H.] Univ Penn, Dept Ophthalmol, Ctr Prevent Ophthalmol & Biostat, Philadelphia, PA 19104 USA. [Pujari, Siddharth S.; Foster, C. Stephen] Massachusetts Eye Res & Surg Inst, Cambridge, MA USA. [Kempen, John H.; Newcomb, Craig W.] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Kempen, John H.; Newcomb, Craig W.] Univ Penn, Dept Biostat, Philadelphia, PA 19104 USA. [Kempen, John H.; Newcomb, Craig W.] Univ Penn, Dept Epidemiol, Philadelphia, PA 19104 USA. [Gangaputra, Sapna] Univ Wisconsin, Dept Ophthalmol, Fundus Photograph Reading Ctr, Madison, WI USA. [Gangaputra, Sapna; Daniel, Ebenezer; Thorne, Jennifer E.; Jabs, Douglas A.] Johns Hopkins Univ, Dept Ophthalmol, Baltimore, MD USA. [Suhler, Eric B.; Rosenbaum, James T.] Oregon Hlth & Sci Univ, Dept Ophthalmol, Portland, OR 97201 USA. [Suhler, Eric B.] Portland VA Med Ctr, Portland, OR USA. [Thorne, Jennifer E.; Jabs, Douglas A.] Johns Hopkins Univ, Dept Epidemiol, Baltimore, MD USA. [Jabs, Douglas A.] Mt Sinai Sch Med, Dept Ophthalmol, New York, NY USA. [Jabs, Douglas A.] Mt Sinai Sch Med, Dept Med, New York, NY USA. [Levy-Clarke, Grace A.] St Lukes Cataract & Laser Inst, Tarpon Springs, FL USA. [Levy-Clarke, Grace A.; Nussenblatt, Robert B.] NEI, Immunol Lab, Bethesda, MD 20892 USA. [Rosenbaum, James T.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA. [Foster, C. Stephen] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA. RP Kempen, JH (reprint author), Univ Penn, Dept Ophthalmol, Ctr Prevent Ophthalmol & Biostat, 3535 Market St,Suite 700, Philadelphia, PA 19104 USA. EM john.kempen@uphs.upenn.edu OI Daniel, Ebenezer/0000-0002-2027-2316 FU National Eye Institute, Bethesda, Maryland [EY014943]; Research to Prevent Blindness, Inc., New York; Paul and Evanina Mackall Foundation, New York; National Eye Institute; Veterans' Administration, Washington, DC FX Supported primarily by the National Eye Institute, Bethesda, Maryland (grant no.: EY014943 [JHK]). Additional support was provided by Research to Prevent Blindness, Inc., New York, New York, and the Paul and Evanina Mackall Foundation, New York, NY. Dr Kempen is a Research to Prevent Blindness James S. Adams Special Scholar Award recipient. Drs. Jabs and Rosenbaum are Research to Prevent Blindness Senior Scientific Investigator Award recipients. Dr. Thorne is a Research to Prevent Blindness Harrington Special Scholar Award recipient. Dr Levy- Clarke previously was supported by and Dr. Nussenblatt continues to be supported by intramural funds of the National Eye Institute. Dr Suhler also received support from the Veterans' Administration, Washington, DC. None of the sponsors had any role in the design and conduct of the report; collection, management, analysis, and interpretation of the data; nor in the preparation, review, and approval of this manuscript. NR 65 TC 52 Z9 53 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0161-6420 J9 OPHTHALMOLOGY JI Ophthalmology PD FEB PY 2010 VL 117 IS 2 BP 356 EP 365 DI 10.1016/j.ophtha.2009.06.060 PG 10 WC Ophthalmology SC Ophthalmology GA 555RB UT WOS:000274530300024 PM 19969366 ER PT J AU Zaidi, AA Ying, GS Daniel, E Gangaputra, S Rosenbaum, JT Suhler, EB Thorne, JE Foster, CS Jabs, DA Levy-Clarke, GA Nussenblatt, RB Kempen, JH AF Zaidi, Ali A. Ying, Gui-Shuang Daniel, Ebenezer Gangaputra, Sapna Rosenbaum, James T. Suhler, Eric B. Thorne, Jennifer E. Foster, C. Stephen Jabs, Douglas A. Levy-Clarke, Grace A. Nussenblatt, Robert B. Kempen, John H. CA Systemic Immunosuppressive Therapy TI Hypopyon in Patients with Uveitis SO OPHTHALMOLOGY LA English DT Article ID BEHCETS-DISEASE AB Purpose: To evaluate the risk of and risk factors for hypopyon among patients with uveitis and to evaluate the risk of visual changes and complications after hypopyon. Design: Retrospective cohort study. Participants: Patients with uveitis at 4 academic ocular inflammation subspecialty practices. Methods: Data were ascertained by standardized chart review. Main Outcome Measures: Prevalence and incidence of hypopyon, risk factors for hypopyon, and incidence of visual acuity changes and ocular complications after hypopyon. Results: Among 4911 patients with uveitis, 41 (8.3/1000) cases of hypopyon were identified at the time of cohort entry. Of these, 2885 initially free of hypopyon were followed over 9451 person-years, during which 81 patients (2.8%) developed hypopyon (8.57/1000 person-years). Risk factors for incident hypopyon included Behcet's disease (adjusted relative risk [RR] = 5.30; 95% confidence interval [CI], 2.76-10.2), spondyloarthropathy (adjusted RR = 2.86; 95% CI, 1.48-5.52), and human leukocyte antigen (HLA)-B27 positivity (adjusted RR = 2.04; 95% CI, 1.17-3.56). Patients with both a spondyloarthropathy and HLA-B27 had a higher risk than either factor alone (crude RR = 4.39; 95% CI, 2.26-8.51). Diagnosis of intermediate uveitis (+/- anterior uveitis) was associated with a lower risk of hypopyon (with respect to anterior uveitis only, adjusted RR = 0.35; 95% CI, 0.15-0.85). Hypopyon incidence tended to be lower among patients with sarcoidosis (crude RR = 0.22; 95% CI, 0.06-0.90; adjusted RR = -0.28; 95% CI, 0.07-1.15). Post-hypopyon eyes and eyes not developing hypopyon had a similar incidence of band keratopathy, posterior synechiae, ocular hypertension, hypotony, macular edema, epiretinal membrane, cataract surgery, or glaucoma surgery. Post-hypopyon eyes were more likely than eyes not developing hypopyon to gain 3 lines of vision (crude RR = 1.54; 95% CI, 1.05-2.24) and were less likely to develop 20/200 or worse visual acuity (crude RR = 0.41; 95% CI, 0.17-0.99); otherwise, visual outcomes were similar in these groups. Conclusions: Hypopyon is an uncommon occurrence in patients with uveitis. Risk factors included Behcet's disease, HLA-B27 positivity, and spondyloarthropathy. Intermediate uveitis cases (+/- anterior uveitis) had a lower risk of hypopyon. On average, post-hypopyon eyes were no more likely than other eyes with uveitis to develop structural ocular complications or lose visual acuity. Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. Ophthalmology 2010; 117: 366-372 (C) 2010 by the American Academy of Ophthalmology. C1 [Zaidi, Ali A.; Ying, Gui-Shuang; Daniel, Ebenezer; Kempen, John H.] Univ Penn, Dept Ophthalmol, Ctr Prevent Ophthalmol & Biostat, Philadelphia, PA 19104 USA. [Zaidi, Ali A.; Ying, Gui-Shuang; Daniel, Ebenezer; Kempen, John H.] Univ Penn, Ocular Inflammat Serv, Philadelphia, PA 19104 USA. [Ying, Gui-Shuang; Kempen, John H.] Univ Penn, Ctr Clin Epidemiol & Biostat, Dept Biostat, Philadelphia, PA 19104 USA. [Ying, Gui-Shuang; Kempen, John H.] Univ Penn, Ctr Clin Epidemiol & Biostat, Dept Epidemiol, Philadelphia, PA 19104 USA. [Daniel, Ebenezer; Gangaputra, Sapna; Thorne, Jennifer E.; Jabs, Douglas A.] Johns Hopkins Univ, Dept Ophthalmol, Baltimore, MD USA. [Thorne, Jennifer E.; Jabs, Douglas A.] Johns Hopkins Univ, Dept Epidemiol, Baltimore, MD USA. [Gangaputra, Sapna] Univ Wisconsin, Dept Ophthalmol, Fundus Photograph Reading Ctr, Madison, WI USA. [Rosenbaum, James T.; Suhler, Eric B.] Oregon Hlth & Sci Univ, Dept Ophthalmol, Portland, OR 97201 USA. [Rosenbaum, James T.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA. [Suhler, Eric B.] Portland VA Med Ctr, Portland, OR USA. [Foster, C. Stephen] Massachusetts Eye Res & Surg Inst, Cambridge, MA USA. [Foster, C. Stephen] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA. [Jabs, Douglas A.] Mt Sinai Sch Med, Dept Ophthalmol, New York, NY USA. [Jabs, Douglas A.] Mt Sinai Sch Med, Dept Med, New York, NY USA. [Levy-Clarke, Grace A.] St Lukes Cataract & Laser Inst, Tarpon Springs, FL USA. [Levy-Clarke, Grace A.; Nussenblatt, Robert B.] NEI, Immunol Lab, Bethesda, MD 20892 USA. RP Kempen, JH (reprint author), Univ Penn, Dept Ophthalmol, Ctr Prevent Ophthalmol & Biostat, 3535 Market St,Suite 700, Philadelphia, PA 19104 USA. EM john.kempen@uphs.upenn.edu OI Daniel, Ebenezer/0000-0002-2027-2316 FU National Eye Institute [EY014943]; Research to Prevent Blindness; Paul and Evanina Mackall Foundation; Prevent Blindness James S. Adams Special Scholar Award; National Eye Institute FX Supported primarily by National Eye Institute Grant EY014943 (Dr. Kempen). Additional support was provided by Research to Prevent Blindness and the Paul and Evanina Mackall Foundation. Dr Kempen is a Research to Prevent Blindness James S. Adams Special Scholar Award recipient. Drs. Jabs and Rosenbaum are Research to Prevent Blindness Senior Scientific Investigator Award recipients. Dr. Thorne is a Research to Prevent Blindness Harrington Special Scholar Award recipient. Dr. Suhler also received support from the Veteran's Affairs Administration. Dr. Levy-Clarke was previously supported by and Dr. Nussenblatt continues to be supported by intramural funds of the National Eye Institute. NR 12 TC 16 Z9 16 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0161-6420 J9 OPHTHALMOLOGY JI Ophthalmology PD FEB PY 2010 VL 117 IS 2 BP 366 EP 372 DI 10.1016/j.ophtha.2009.07.025 PG 7 WC Ophthalmology SC Ophthalmology GA 555RB UT WOS:000274530300025 PM 20006905 ER PT J AU Fernandez, C Jami, S Loredo, G Ko, F Hahn, T McDougall, S Peters, JH AF Fernandez, C. Jami, S. Loredo, G. Ko, F. Hahn, T. McDougall, S. Peters, J. H. TI Recognition of the alternatively spliced segments of fibronectin by the RCJ 3.1C5.18 chondrocytic rat cell line SO OSTEOARTHRITIS AND CARTILAGE LA English DT Article DE Chondrocyte; Mulipotential stem cell; Differentiation; Fibronectin alternative splicing; Cartilage ID ISOFORM DISTRIBUTION; BINDING PROTEIN-3; PROGENITOR CELLS; MESSENGER-RNA; V-SEGMENT; CARTILAGE; DIFFERENTIATION; EIIIA; IDENTIFICATION; POPULATION AB Objectives. To define, for the C5.18 chondrocyte-restricted rat cell line, (1) the capacities for recognition of alternatively spliced segments of the adhesion protein fibronectin (FN), (2) the integrin subunits required for such recognition, and (3) differences in such FN recognition vs the multipotential chondroprogenitor line, RCJ 3 1 Methods C5 18 and RCJ 3 1 cells were tested for their capacities to adhere to recombinant alternatively spliced segments of rat FN, presented on plastic surfaces either in isolation or in partial FNs spanning the 7th through 15th type III repeats (III7-15 FNs) The effects on such adhesion of cations and integrin subunit-specific antibodies were tested Results Despite significant augmentation in chondrocyte-specific gene expression in C5.18 relative to the RCJ 3 1 cells, the two lines exhibited similar recognition of FN spliced segments and partial isoforms Specifically, both lines adhered to the extra type III repeat A (EIIIA) and V, but not extra type III repeat B (EIIIB), segments There were different cation and integrin subunit requirements for adhesion to EIIIA vs V segments, and only the V segment was recognized in the context of a III7-15 FN Such recognition was mediated via a "second" arginineglycine-aspartic acid (RGD) sequence that is present in the V95 subsegment in rat, but not human, FN Conclusion The chondrocyte lineage-committed C5 18 cell line, similar to its multipotential chondroprogenitor, RCJ 3 1, recognizes the "cartilage-restricted" EIIIA and V segments of FN with cation, integrin, and molecular context requirements that are specific to each of these segments Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International C1 [Peters, J. H.] UC Davis, Med Ctr, Ctr Healthy Aging, Dept Internal Med,Sch Med, Sacramento, CA 95817 USA. [Fernandez, C.; Jami, S.; Loredo, G.; Peters, J. H.] VA No Calif Hlth Care Syst, Sacramento Med Ctr, Mather, CA 95655 USA. [Ko, F.; Hahn, T.; McDougall, S.] Greater Los Angeles VA Healthcare Syst, W LA VA Med Ctr, Los Angeles, CA USA. [Hahn, T.; McDougall, S.] Univ Calif Los Angeles, Sch Med, Dept Internal Med, Div Geriatr Med, Los Angeles, CA 90024 USA. RP Peters, JH (reprint author), UC Davis, Med Ctr, Ctr Healthy Aging, Dept Internal Med,Sch Med, Room 2351,Oak Pk Bldg,2700 StocktonBlvd, Sacramento, CA 95817 USA. OI Jami, Shekib/0000-0001-5478-1963 FU Career Development Award; Department of Veterans Affairs; Charles See Foundation; UC Davis Center for Healthy Aging FX We thank Jane Aubin of the University of Toronto for generously supplying the RCJ 3 1 and RCJ 3 1 C5 18 cell lines, Richard Hynes of M.I.T for providing the cDNA constructs used to produce the III7-15 fusion proteins. J.H.P was supported by a Career Development Award and a Merit Review Award from the Department of Veterans Affairs, a gift from the Charles See Foundation and an intramural grant from the UC Davis Center for Healthy Aging during this study NR 31 TC 1 Z9 1 U1 1 U2 2 PU W B SAUNDERS CO LTD PI LONDON PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND SN 1063-4584 J9 OSTEOARTHR CARTILAGE JI Osteoarthritis Cartilage PD FEB PY 2010 VL 18 IS 2 BP 228 EP 239 DI 10.1016/j.joca.2009.09.005 PG 12 WC Orthopedics; Rheumatology SC Orthopedics; Rheumatology GA 566HK UT WOS:000275360500011 PM 19822234 ER PT J AU Profit, J Petersen, LA McCormick, MC Escobar, GJ Coleman-Phox, K Zheng, Z Pietz, K Zupancic, JAF AF Profit, Jochen Petersen, Laura A. McCormick, Marie C. Escobar, Gabriel J. Coleman-Phox, Kim Zheng, Zheng Pietz, Kenneth Zupancic, John A. F. TI Patient-to-Nurse Ratios and Outcomes of Moderately Preterm Infants SO PEDIATRICS LA English DT Article DE infant; newborn; health services research; nurse-staffing; outcomes ID NEONATAL INTENSIVE-CARE; BIRTH-WEIGHT INFANTS; STAFF RATIOS; MORTALITY; RISK; UNIT; WORKLOAD; QUALITY AB OBJECTIVE: Moderately preterm infants (30-346/7 weeks' gestational age) represent the largest population of NICU residents. Whether their clinical outcomes are associated with differences in NICU nurse-staffing arrangements has not been assessed. The objective of this study was to test the influence of patient-to-nurse ratios (PNRs) on outcomes of care provided to moderately preterm infants. PATIENTS AND METHODS: Using data from a prospective, multicenter, observational cohort study of 850 moderately preterm infants from 10 NICUs in California and Massachusetts, we tested for associations between PNR and several important clinical outcomes by using multivariate random-effects models. To correct for the influence of NICU size, we dichotomized the sample into those with an average daily census of <20 or >= 20 infants. RESULTS: Overall, we found few clinically significant associations between PNR and clinical outcomes of care. Mean PNRs were higher in large compared with small NICUs (2.7 vs 2.1; P < .001). In bivariate analyses, an increase in PNR was associated with a slightly higher daily weight gain (5 g/day), greater gestational age at discharge, any intraventricular hemorrhage, and severe retinopathy of prematurity. After controlling for case mix, NICU size, and site of care, an additional patient per nurse was associated with a decrease in daily weight gain by 24%. Other variables were no longer independently associated with PNR. CONCLUSIONS: In this population of moderately preterm infants, the PNR was associated with a decrease in daily weight gain, but was not associated with other measures of quality. In contrast with findings in the adult intensive care literature, measured clinical outcomes were similar across the range of nurse-staffing arrangements among participating NICUs. We conclude that the PNR is not useful for profiling hospitals' quality of care delivery to moderately preterm infants. Pediatrics 2010; 125: 320-326 C1 [Profit, Jochen] Texas Childrens Hosp, Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA. [Profit, Jochen; Petersen, Laura A.; Pietz, Kenneth] Texas Childrens Hosp, Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA. [Profit, Jochen; Petersen, Laura A.; Pietz, Kenneth] Houston Vet Affairs Hlth Serv, Res & Dev Ctr Excellence, Hlth Policy & Qual Program, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. [McCormick, Marie C.; Zheng, Zheng; Zupancic, John A. F.] Beth Israel Deaconess Med Ctr, Dept Neonatol, Boston, MA 02215 USA. [McCormick, Marie C.; Zupancic, John A. F.] Harvard Univ, Sch Med, Div Newborn Med, Boston, MA USA. [McCormick, Marie C.] Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, Boston, MA 02115 USA. [Escobar, Gabriel J.; Coleman-Phox, Kim] Kaiser Permanente Med Care Program, Perinatal Res Unit, Oakland, CA USA. RP Profit, J (reprint author), Houston Vet Affairs Hlth Serv, Res & Dev Ctr Excellence 152, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM profit@bcm.edu OI Zupancic, John/0000-0003-1734-7193; McCormmick, Marie/0000-0002-3938-1707 FU Agency for Healthcare Research and Quality [5 R01 HS 10131-02, T32 HS 000063]; Eunice Kennedy Shriver National Institute of Child Health and Human Development [K23 HD056298-01]; American Heart Association [0540043N]; Veterans Administration Center [CoE HFP90-20] FX This project was supported by the Agency for Healthcare Research and Quality (grant 5 R01 HS 10131-02, "Unstudied Infants: Low Risk Babies in a High Risk Place" [to Dr McCormick]). Dr Profit's contribution is supported in part by the Agency for Healthcare Research and Quality (grant T32 HS 000063) and Eunice Kennedy Shriver National Institute of Child Health and Human Development grant K23 HD056298-01. Dr Petersen is a recipient of the American Heart Association Established Investigator Award (grant 0540043N). Drs Petersen and Profit also receive support from a Veterans Administration Center grant (Veterans Affairs Health Services Research and Development CoE HFP90-20). NR 18 TC 14 Z9 14 U1 0 U2 4 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 J9 PEDIATRICS JI Pediatrics PD FEB PY 2010 VL 125 IS 2 BP 320 EP 326 DI 10.1542/peds.2008-3140 PG 7 WC Pediatrics SC Pediatrics GA 573VH UT WOS:000275942900017 PM 20064868 ER PT J AU Inhoff, T Stengel, A Peter, L Goebel, M Tache, Y Bannert, N Wiedenmann, B Klapp, BF Monnikes, H Kobelt, P AF Inhoff, Tobias Stengel, Andreas Peter, Lisa Goebel, Miriam Tache, Yvette Bannert, Norbert Wiedenmann, Bertram Klapp, Burghard F. Moennikes, Hubert Kobelt, Peter TI Novel insight in distribution of nesfatin-1 and phospho-mTOR in the arcuate nucleus of the hypothalamus of rats SO PEPTIDES LA English DT Article DE Arcuate nucleus; Rat; Nesfatin-1; Phospho-mTOR; CART; NPY ID AMPHETAMINE-REGULATED TRANSCRIPT; NEUROPEPTIDE-Y; FEEDING-BEHAVIOR; CART NEURONS; SPINAL-CORD; FOOD-INTAKE; PEPTIDE; PROTEIN; GHRELIN; BRAIN AB Recently, two proteins have been localized in the arcuate nucleus (ARC) and implicated in the regulation of food intake: the serine-threonine-kinase mammalian target of rapamycin (mTOR) as part of the TOR signaling complex 1 (TORC1), and nesfatin-1 derived from the precursor protein nucleobindin2. However, the exact cell types are not well described. Therefore, we performed double-labeling studies for NPY, CART, nesfatin-1 and pmTOR in the ARC. In this study, we showed that nesfatin-1 is not only intracellularly co-localized with cocaine- and amphetamine-regulated transcript (CART) peptide as reported before, but also with phospho-mTOR (pmTOR) and neuropeptide Y (NPY) in ARC neurons. Quantification revealed that 59 +/- 5% of the pmTOR-immunoreactive (it) neurons were immunoreactive for nesfatin-1. Moreover, double labeling for nesfatin-1 and NPY exhibited that 19 +/- 5% of the NPY positive cells were also immunoreactive for nesfatin-1. Furthermore, we could also confirm results from previous studies, showing that the majority of nesfatin-1 neurons are also positive for CART peptide, whereas most of the pmTOR is co-localized with NPY and only to a lesser extent with CART. (C) 2009 Elsevier Inc. All rights reserved. C1 [Inhoff, Tobias; Peter, Lisa; Wiedenmann, Bertram; Kobelt, Peter] Univ Med Berlin, Dept Med, Div Hepatol Gastroenterol & Endocrinol, Charite, D-10117 Berlin, Germany. [Klapp, Burghard F.; Kobelt, Peter] Univ Med Berlin, Dept Med, Div Psychosomat Med & Psychotherapy, Charite, D-10117 Berlin, Germany. [Stengel, Andreas; Goebel, Miriam; Tache, Yvette] Univ Calif Los Angeles, Dept Med, Div Digest Dis, CURE Digest Dis Res Ctr, Los Angeles, CA 90024 USA. [Stengel, Andreas; Goebel, Miriam; Tache, Yvette] Univ Calif Los Angeles, Ctr Neurobiol Stress, Los Angeles, CA 90024 USA. [Stengel, Andreas; Goebel, Miriam; Tache, Yvette] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Bannert, Norbert] Robert Koch Inst, D-1000 Berlin, Germany. [Moennikes, Hubert] Martin Luther Hosp, Dept Med, Berlin, Germany. [Moennikes, Hubert] Martin Luther Hosp, Inst Neurogastroenterol, Berlin, Germany. RP Kobelt, P (reprint author), Univ Med Berlin, Dept Med, Div Hepatol Gastroenterol & Endocrinol, Charite, Campus Virchow, D-10117 Berlin, Germany. EM peter.kobelt@charite.de FU German Research Foundation [DFG KO 3864/2-1, DFG STE 1765/1-1, GO 1718/1-1]; Charite-Universitatsmedizin Berlin [UFF 09/41730, 09/42458]; Veterans Administration Research Career Scientist Award; Veterans Administration Merit Award; NIHDK [33061]; [DK-41301] FX This work was supported by grants from the German Research Foundation to PX (DFG KO 3864/2-1), A.S. (DFG STE 1765/1-1), M.G. (GO 1718/1-1), and from Charite-Universitatsmedizin Berlin to PX (UFF 09/41730 and 09/42458) as well as Veterans Administration Research Career Scientist Award (Y.T.), Veterans Administration Merit Award (Y.T.), NIHDK 33061 (Y.T.), Center Grant DK-41301 (Animal Core) (Y.T.). NR 32 TC 40 Z9 44 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-9781 J9 PEPTIDES JI Peptides PD FEB PY 2010 VL 31 IS 2 BP 257 EP 262 DI 10.1016/j.peptides.2009.11.024 PG 6 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy SC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy GA 560BQ UT WOS:000274877200010 PM 19961888 ER PT J AU Yuan, PQ Wu, SV Wang, L Tache, Y AF Yuan, P. -Q Wu, S. V. Wang, L. Tache, Y. TI Corticotropin releasing factor in the rat colon: Expression, localization and upregulation by endotoxin SO PEPTIDES LA English DT Article DE Corticotropin releasing factor; Enterochromaffin cells; Enteric nervous system; Lipopolysaccharide; Colon; Stress; Defecation; Corticosterone ID ENTERIC NERVOUS-SYSTEM; IRRITABLE-BOWEL-SYNDROME; MYENTERIC NEURONS; INTESTINAL INFLAMMATION; CONSCIOUS RATS; MAST-CELLS; TRYPTOPHAN-HYDROXYLASE; ENTEROCHROMAFFIN CELLS; 5-HT3 RECEPTORS; CHALLENGED RATS AB Little is known about CRF expression and regulation in the rat colon compared to the brain. We investigated CRF gene expression, cellular location, and regulation by endotoxin and corticosterone in the male rat colon at 6 h after intraperitoneal (ip) injection. CRF mRNA level, detected by reverse transcription-polymerase chain reaction (RT-PCR) was 1.3-fold higher in the distal than proximal colon and 3.4-fold higher in the proximal colonic submucosa plus muscle layers than in mucosa. CRF immunoreactivity was located in the epithelia, lamina propria and crypts, and co-localized with tryptophan hydroxylase. a marker for enterochromaffin (EC) cells, and in enteric neurons. Lipopolysaccharide (LPS, 100 mu g/kg, ip) increased defecation by 2.9-fold and upregulated CRF mRNA by 2.5-fold in the proximal and 1.1-fold in the distal colon while there was no change induced by corticosterone as monitored by quantitative PCR. LPS-induced increased CRF mRNA expression occurred in the submucosa plus muscle layers (1.5-fold) and the mucosa of proximal colon (0.9-fold). LIPS increased significantly CRF immunoreactivity in the submucosal and myenteric plexuses of proximal and distal colon compared to saline groups. These results indicate that in rats, CRF is expressed in both proximal and distal colon and more prominently in enteric neurons of the submucosa plus muscle layers and subject to upregulation at the gene and protein levels by LPS through corticosteroid independent pathways. These data suggests that colonic CRF may be part of the local effector limb of the CRF, receptor mediated colonic alterations induced by acute stress. (C) 2009 Elsevier Inc. All rights reserved. C1 [Yuan, P. -Q] Univ Calif Los Angeles, CURE, DDRC, VA GLAHS, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Ctr Neurobiol Stress, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Div Digest Dis, Dept Med, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90073 USA. RP Yuan, PQ (reprint author), Univ Calif Los Angeles, CURE, DDRC, VA GLAHS, Bldg 115,Rm 213B,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM pqyuan@mednet.ucla.edu FU National Institute of Diabetes and Digestive and Kidney Diseases [R01 DK-57238]; VA Career Scientist Award and Merit Award [DK-41301]; [P01-DK 33506] FX We thank Drs. Wylie W. Vale and jean Rivier(Salk institute, San Diego, CA) for the generous donation of the rabbit anti-CRF antiserum, and rat CRF, respectively and Ms Honghui Liang for technical assistance. This work was supported by the National Institute of Diabetes and Digestive and Kidney Diseases, grants R01 DK-57238 (YT), VA Career Scientist Award and Merit Award (YT), DK-41301 (Animal Core, YT), P01-DK 33506 (C. Pothoulakis, PI). NR 55 TC 20 Z9 20 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-9781 J9 PEPTIDES JI Peptides PD FEB PY 2010 VL 31 IS 2 BP 322 EP 331 DI 10.1016/j.peptides.2009.11.012 PG 10 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy SC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy GA 560BQ UT WOS:000274877200020 PM 19944726 ER PT J AU Stengel, A Goebel, M Wang, LX Tache, Y AF Stengel, Andreas Goebel, Miriam Wang, Lixin Tache, Yvette TI Ghrelin, des-acyl ghrelin and nesfatin-1 in gastric X/A-like cells: Role as regulators of food intake and body weight SO PEPTIDES LA English DT Review DE Body weight; Endocrine cell; Food intake; Ghrelin; Nesfatin-1; NUCB2; Obesity; Stomach ID GROWTH-HORMONE SECRETAGOGUE; GLUCAGON-LIKE PEPTIDE-1; STIMULATES LOCOMOTOR-ACTIVITY; O-ACYLTRANSFERASE GOAT; COUPLED RECEPTOR GPR39; AGOUTI-RELATED PROTEIN; RAT ARCUATE NUCLEUS; PLASMA GHRELIN; PERIPHERAL GHRELIN; SLEEVE GASTRECTOMY AB Numerous peptides released from endocrine cells in the intestinal mucosa were established early on to be involved in the physiological regulation of food intake with a prominent role in termination of food ingestion when nutrients pass along the intestinal tract. Recently, peptides released from X/A-like endocrine cells of the gastric oxyntic mucosa were recognized as additional key players in the regulation of feeding and energy expenditure. Gastric X/A-like cells release the octanoylated peptide, ghrelin, the only known peripherally produced hormone stimulating food intake through interaction with growth hormone secretagogue I a receptor(GHS-R1a). Additionally, non-octanoylated (des-acyl) ghrelin present in the circulation at higher levels than ghrelin is currently discussed as potential modulator of food intake by opposing ghrelin's action independent from GHS-R1a although the functional significance remains to be established. Obestatin, a ghrelin-associated peptide was initially reported as anorexigenic modulator of ghrelin's orexigenic action. However, subsequent reports did not support this contention. Interesting is the recent identification of nesfatin-1, a peptide derived from the nucleobindin2 gene prominently expressed in gastric X/A-like cells in different vesicles than ghrelin. Circulating nesfatin-1 levels vary with metabolic state and peripheral or central injection inhibits dark phase feeding in rodents. Overall, these data point to an important role of gastric X/A-like cells in food intake regulation through the expression of the orexigenic peptide ghrelin along with des-acyl ghrelin and nesfatin-1 capable of reducing food intake upon exogenous injection although their mechanisms of action and functional significance remain to be established. Published by Elsevier Inc C1 [Tache, Yvette] Univ Calif Los Angeles, Digest Dis Res Ctr, CURE, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Div Digest Dis, David Geffen Sch Med, Los Angeles, CA 90073 USA. RP Tache, Y (reprint author), Univ Calif Los Angeles, Digest Dis Res Ctr, CURE, VA Greater Los Angeles Healthcare Syst, Bldg 115,Room 117,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM astengel@mednet.ucla.edu; ytache@mednet.ucla.edu FU VA Research Career Scientist Award; NIH [DK-33061, DK-57238]; VA Merit Award; German Research Foundation [STE 1765/1-1 and GO 1718/1-1] FX Y.T. is in receipt of VA Research Career Scientist Award and NIH R01 grants DK-33061, DK-57238 and VA Merit Award. A.S. and M.G. are supported by the German Research Foundation grants STE 1765/1-1 and GO 1718/1-1 respectively. We thank Ms. Eugenia Hu for careful reading of the manuscript. NR 170 TC 61 Z9 65 U1 1 U2 13 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-9781 J9 PEPTIDES JI Peptides PD FEB PY 2010 VL 31 IS 2 BP 357 EP 369 DI 10.1016/j.peptides.2009.11.019 PG 13 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy SC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy GA 560BQ UT WOS:000274877200025 PM 19944123 ER PT J AU Evans, CT Li, K Burns, SP Smith, B Lee, TA Weaver, FM AF Evans, Charlesnika T. Li, Keran Burns, Stephen P. Smith, Bridget Lee, Todd A. Weaver, Frances M. TI Antibiotic Prescribing for Acute Respiratory Infection and Subsequent Outpatient and Hospital Utilization in Veterans With Spinal Cord Injury and Disorder SO PM&R LA English DT Article AB Objective: To assess the association between antibiotic prescribing for acute respiratory infection (ARI) and subsequent health-care utilization in veterans with spinal cord injury and disorder (SCI/D). Design: Retrospective cohort of veterans with SCI/D. Setting: Veterans Affairs medical facilities that provide outpatient care. Patients: Veterans with SCI/D with a diagnosis of acute bronchitis or upper respiratory infection during an outpatient visit between fiscal year 2006 and 2007 that did not result in same-clay hospitalization. Independent Variable: Receipt of a new antibiotic prescription occurring within 3 clays before or after an ARI visit. Main Outcome Measure: Subsequent outpatient visit or hospitalization within 30 days of the index ARI visit. Results: A total of 1277 patients were identified with ARI; 53.2% were prescribed an antibiotic. An outpatient clinic visit within 30 days of the index ARI visit occurred in 47.0% of patients. Receipt of an antibiotic prescription was not associated with a subsequent outpatient visit. However, in those with certain chronic respiratory conditions (cough, shortness of breath, bronchitis not specified as acute or chronic, and allergic rhinitis), those prescribed antibiotics were less likely to return for an outpatient visit than those not prescribed antibiotics (adjusted relative risk = 0.77, 95% confidence interval = 0.61-0.97); no association was observed in those patients without these conditions. A total of 7.9% of patients were hospitalized within 30 days and did not differ by prescribing group. The 30-day mortality rate was 0.6%. Conclusions: Certain chronic respiratory conditions in veterans with SCI/D may be risk factors for increased health-care utilization and potentially poor outcomes if a patient is not treated with antibiotics for ARI. However, in those without these conditions, those with ARI who were prescribed antibiotics have similar utilization to those not prescribed antibiotics. These data suggest that in the absence of chronic respiratory conditions, antibiotic use for ARI can be curbed in this population that is at high risk for respiratory complications. PM R 2010;2:101-109 C1 [Evans, Charlesnika T.] Vet Affairs Edward Hines Jr Hosp, Ctr Management Complex Chron Care Spinal Cord Inj, Dept Vet Affairs VA, Hines, IL USA. [Evans, Charlesnika T.; Li, Keran; Smith, Bridget; Weaver, Frances M.] Northwestern Univ, Feinberg Sch Med, Inst Healthcare Studies, Chicago, IL 60611 USA. [Li, Keran] Northwestern Univ, Dept Prevent Med, Chicago, IL 60611 USA. [Burns, Stephen P.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Burns, Stephen P.] Univ Washington, Seattle, WA 98195 USA. [Lee, Todd A.] Univ Illinois, Chicago, IL USA. [Weaver, Frances M.] Northwestern Univ, Sch Med, Dept Neurol, Chicago, IL 60611 USA. RP Evans, CT (reprint author), Vet Affairs Edward Hines Jr Hosp, Ctr Management Complex Chron Care Spinal Cord Inj, Dept Vet Affairs VA, 5th Ave & Roosevelt Rd,POB 5000,Room D302, Hines, IL USA. EM Charlesnika.Evans@va.gov FU Department of Veterans Affairs, Office at Research and Development, Health Services Research and Development Service Locally Initiated Project [LIP 42-503]; Paralyzed Veterans of America Research Foundation [2562] FX Supported by the Department of Veterans Affairs, Office at Research and Development, Health Services Research and Development Service Locally Initiated Project (LIP 42-503), and the Paralyzed Veterans of America Research Foundation (Project #2562). NR 39 TC 3 Z9 4 U1 1 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1934-1482 J9 PM&R JI PM&R PD FEB PY 2010 VL 2 IS 2 BP 101 EP 109 DI 10.1016/j.pmrj.2009.11.002 PG 9 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA V23RY UT WOS:000208361100004 PM 20117971 ER PT J AU Conklin, SM Runyan, CA Leonard, S Reddy, RD Muldoon, MF Yao, JK AF Conklin, Sarah M. Runyan, Caroline A. Leonard, Sherry Reddy, Ravinder D. Muldoon, Matthew F. Yao, Jeffrey K. TI Age-related changes of n-3 and n-6 polyunsaturated fatty acids in the anterior cingulate cortex of individuals with major depressive disorder SO PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS LA English DT Article DE Depression; Anterior cingulate cortex; Postmortem; n-6 fatty acids; Arachidonic acid; n-3 fatty acids; Eicosapentaenoic acid; Docosahexaenoic acid; Age ID OMEGA-3-FATTY-ACID DOCOSAHEXAENOIC ACID; POSTMORTEM ORBITOFRONTAL CORTEX; RANDOMIZED CONTROLLED-TRIAL; PLACEBO-CONTROLLED TRIAL; PRELIMINARY DOUBLE-BLIND; BLOOD-CELL MEMBRANES; ARACHIDONIC-ACID; BIPOLAR DISORDER; FISH CONSUMPTION; FRONTAL-CORTEX AB Accumulating evidence finds a relative deficiency of peripheral membrane fatty acids in persons with affective disorders such as unipolar and bipolar depression. Here we sought to investigate whether postmortem brain fatty acids within the anterior cingulate cortex (BA-24) varied according to the presence of major depression at the time of death. Using capillary gas chromatography we measured fatty acids in a depressed group (n = 12), and in a control group without lifetime history of psychiatric diagnosis (n = 14). Compared to the control group, the depressed group showed significantly lower concentrations of numerous saturated and polyunsaturated fatty acids including both the n-3 and n-6 fatty acids. Additionally, significant correlations between age at death and precursor (or metabolites) in the n-3 fatty acid pathway were demonstrated in the depressed group but not in control subjects. In the n-6 fatty acid family, the ratio of 20:3(n-6)/18:2(n-6) was higher in patients than in control groups, whereas the ratio of 20A(n-6)/20:3(n-6) was relatively decreased in patients. Lastly, a significant negative correlation between age and the ratio of 20:4(n-6) to 22:6(n-3) was found in patients, but not in controls. Taken together, decreases in 22:6(n-3) may be caused, at least in part, by the diminished formation of 20:5(n-3), which is derived from 20:4(n-3) through a Delta 5 desaturase reaction. The present findings from postmortem brain tissue raise the possibility that an increased ratio of 20:4(n-6) to 22:6(n-3) may provide us with a biomarker for depression. Future research should further investigate these relationships. Published by Elsevier Ltd. C1 [Conklin, Sarah M.; Reddy, Ravinder D.; Muldoon, Matthew F.; Yao, Jeffrey K.] VA Pittsburgh Healthcare Syst, Med Res Serv, Pittsburgh, PA USA. [Conklin, Sarah M.] Allegheny Coll, Neurosci Program, Meadville, PA 16335 USA. [Conklin, Sarah M.] Allegheny Coll, Dept Psychol, Meadville, PA 16335 USA. [Runyan, Caroline A.] MIT, Dept Brain & Cognit Sci, Picower Inst Learning & Memory, Cambridge, MA 02139 USA. [Leonard, Sherry] Univ Colorado, Hlth Sci Ctr, Denver VA Med Ctr, Denver, CO USA. [Leonard, Sherry] Univ Colorado, Hlth Sci Ctr, Dept Psychiat, Denver, CO 80262 USA. [Leonard, Sherry] Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA. [Reddy, Ravinder D.; Yao, Jeffrey K.] Univ Pittsburgh, Med Ctr, Dept Psychiat, Pittsburgh, PA USA. [Muldoon, Matthew F.] Univ Pittsburgh, Sch Med, Ctr Clin Pharmacol, Pittsburgh, PA USA. [Yao, Jeffrey K.] Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Pittsburgh, PA 15261 USA. RP Yao, JK (reprint author), VA Pittsburgh Healthcare Syst, Med Res Serv, Pittsburgh, PA USA. EM jkyao@pitt.edu FU Office of Research and Development, Department of Veterans Affairs; NIH [T32 HL007560]; Highland Drive VA Pittsburgh Healthcare System FX This study was supported in parts by the Office of Research and Development, Department of Veterans Affairs [Merit Reviews (JKY,SL) and Research Career Scientist Awards (JKY,SL)], NIH T32 HL007560 (SMC, MFM), and the Highland Drive VA Pittsburgh Healthcare System. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The contents of this article do not represent the views of the Department of Veterans Affairs or the United States Government. NR 57 TC 28 Z9 28 U1 6 U2 8 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0952-3278 J9 PROSTAG LEUKOTR ESS JI Prostaglandins Leukot. Essent. Fatty Acids PD FEB-MAR PY 2010 VL 82 IS 2-3 BP 111 EP 119 DI 10.1016/j.plefa.2009.12.002 PG 9 WC Biochemistry & Molecular Biology; Cell Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Cell Biology; Endocrinology & Metabolism GA 569RQ UT WOS:000275617500007 PM 20060277 ER PT J AU Vera, M Perez-Pedrogo, C Huertas, SE Reyes-Rabanillo, ML Juarbe, D Huertas, A Reyes-Rodriguez, ML Chaplin, W AF Vera, Mildred Perez-Pedrogo, Coralee Huertas, Sarah Enid Reyes-Rabanillo, Maria Leticia Juarbe, Deborah Huertas, Aracelis Reyes-Rodriguez, Mae Lynn Chaplin, William TI Collaborative Care for Depressed Patients With Chronic Medical Conditions: A Randomized Trial in Puerto Rico SO PSYCHIATRIC SERVICES LA English DT Article ID COMORBID DEPRESSION; HEALTH-SERVICES; CHRONIC DISEASE; TERM OUTCOMES; MANAGEMENT; METAANALYSIS; POPULATION; VALIDATION; SYMPTOMS; VALIDITY AB Objective: This study examined whether a collaborative care model for depression would improve clinical and functional outcomes for depressed patients with chronic general medical conditions in primary care practices in Puerto Rico. Methods: A total of 179 primary care patients with major depression and chronic general medical conditions were randomly assigned to receive collaborative care or usual care. The collaborative care intervention involved enhanced collaboration among physicians, mental health specialists, and care managers paired with depression-specific treatment guidelines, patient education, and follow-up. In usual care, study personnel informed the patient and provider of the diagnosis and encouraged patients to discuss treatment options with their provider. Depression severity was assessed with the Hopkins Symptom Checklist; social functioning was assessed with the 36-item Short Form. Results: Compared with usual care, collaborative care significantly reduced depressive symptoms and improved social functioning in the six months after randomization. Integration of collaborative care in primary care practices considerably increased depressed patients' use of mental health services. Conclusions: Collaborative care significantly improved clinical symptoms and functional status of depressed patients with coexisting chronic general medical conditions receiving treatment for depression in primary care practices in Puerto Rico. These findings highlight the promise of the collaborative care model for strengthening the relationship between mental health and primary care services in Puerto Rico. (Psychiatric Services 61:144-150, 2010) C1 [Vera, Mildred; Perez-Pedrogo, Coralee; Juarbe, Deborah] Univ Puerto Rico, Ctr Evaluat & Sociomed Res, Grad Sch Publ Hlth, San Juan, PR 00936 USA. [Huertas, Aracelis] Univ Puerto Rico, Sch Hlth Profess, San Juan, PR 00936 USA. [Huertas, Sarah Enid] Univ Puerto Rico, Dept Psychiat, Sch Med, San Juan, PR 00936 USA. [Vera, Mildred] Univ Puerto Rico, Dept Hlth Serv Adm, San Juan, PR 00936 USA. [Reyes-Rabanillo, Maria Leticia] US Dept Vet Affairs, VA Caribbean Healthcare Syst, San Juan, PR USA. [Reyes-Rodriguez, Mae Lynn] Univ N Carolina, Sch Med, Dept Psychiat, Chapel Hill, NC USA. [Chaplin, William] St Johns Univ, Dept Psychol, New York, NY USA. RP Vera, M (reprint author), Univ Puerto Rico, Ctr Evaluat & Sociomed Res, Grad Sch Publ Hlth, Med Sci Campus,POB 365067, San Juan, PR 00936 USA. EM mildred.vera@upr.edu FU National Institute of General Medical Sciences [S06-GM008224]; Pfizer, Inc [WS297211]; National Center for Research Resources [P20-RR11126] FX This project was supported by grant S06-GM008224 from the National Institute of General Medical Sciences, grant WS297211 from Pfizer, Inc., and grant P20-RR11126 from the National Center for Research Resources. NR 36 TC 19 Z9 20 U1 2 U2 2 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD FEB PY 2010 VL 61 IS 2 BP 144 EP 150 PG 7 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 550VN UT WOS:000274160300008 PM 20123819 ER PT J AU Joo, MJ Au, DH Fitzgibbon, ML Lee, TA AF Joo, Min J. Au, David H. Fitzgibbon, Marian L. Lee, Todd A. TI Inhaled corticosteroids and risk of pneumonia in newly diagnosed COPD SO RESPIRATORY MEDICINE LA English DT Article DE Chronic obstructive pulmonary disease; Pneumonia; Corticosteroids; Drug therapy; Case-control studies ID OBSTRUCTIVE PULMONARY-DISEASE; SALMETEROL/FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE; THERAPEUTIC TRIALS; EXACERBATIONS; METAANALYSIS; SALMETEROL AB Introduction: The use of inhaled corticosteroids (ICS) in COPD may be associated with an increased risk of pneumonia. Little is known of this risk in newly diagnosed COPD patients. The objective of this study was to determine if the use of ICS among newly diagnosed COPD patients is associated with an increased risk of pneumonia hospitalizations. Methods: Using data from the Department of Veterans Affairs and Centers for Medicare and Medicaid Services, a nested case-control study was performed. We identified patients 65 years of age or older with a new diagnosis of COPD from 1998 to 2002. A total of 145,586 patients were identified. Cases were defined based on hospitalization for pneumonia and exposure was prior use of ICS. Up to 10 controls were matched for each case based on age, sex, month and year of the case. The association between ICS use and pneumonia was evaluated with conditional logistic regression controlling for age, comorbidities, medication classes associated with the risk of pneumonia, and markers of COPD severity. Results: There were 13,995 cases of pneumonia. The cohort was predominantly mate with an average age of 75.1 (SD = 5.4) years. The rate of pneumonia was 6.4 per 100 person-years. After adjustment for covariates, patients with current use of ICS were 1.38 (95% CI, 1.31-1.45) times more likely to have a hospitalization for pneumonia than those without current use of ICS. Conclusions: The use of ICS among patients with newly diagnosed COPD is associated with an increased risk of hospitalization for pneumonia. Published by Elsevier Ltd. C1 [Joo, Min J.] Univ Illinois, Dept Med, Sect Pulm Crit Care & Sleep Med, Chicago, IL USA. [Joo, Min J.; Lee, Todd A.] Hines VA Hosp, Ctr Management Complex Chron Care CMC3, Hines, IL USA. [Joo, Min J.; Fitzgibbon, Marian L.] Jesse Brown VA Med Ctr, CMC3, Chicago, IL USA. [Au, David H.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA. [Au, David H.] Univ Washington, Div Pulm & Crit Care Med, Seattle, WA 98195 USA. [Lee, Todd A.] Univ Illinois, Dept Pharm, Chicago, IL USA. RP Joo, MJ (reprint author), 840 S Wood St,M-C 719, Chicago, IL 60612 USA. EM joo@uic.edu FU Health Services Research & Development Service, Center for Management of Complex Chronic Care, Center of Excellence, Hines VA Hospital FX This research was supported in part by the Health Services Research & Development Service, Center for Management of Complex Chronic Care, Center of Excellence, Hines VA Hospital. The views expressed in this manuscript reflect those of the authors and not necessarily those of the Department of Veterans Affairs. NR 23 TC 32 Z9 32 U1 0 U2 0 PU W B SAUNDERS CO LTD PI LONDON PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND SN 0954-6111 J9 RESP MED JI Respir. Med. PD FEB PY 2010 VL 104 IS 2 BP 246 EP 252 DI 10.1016/j.rmed.2009.10.002 PG 7 WC Cardiac & Cardiovascular Systems; Respiratory System SC Cardiovascular System & Cardiology; Respiratory System GA 558QJ UT WOS:000274759400013 PM 19879745 ER PT J AU Klein, RS Morganroth, PA Werth, VP AF Klein, Rachel S. Morganroth, Pamela A. Werth, Victoria P. TI Cutaneous Lupus and the Cutaneous Lupus Erythematosus Disease Area and Severity Index Instrument SO RHEUMATIC DISEASE CLINICS OF NORTH AMERICA LA English DT Article DE Cutaneous lupus erythematosus; Disease classification; Rowell syndrome; CLASI; Clinical outcome instrument ID EPIDERMOLYSIS-BULLOSA-ACQUISITA; QUALITY-OF-LIFE; SYSTEMIC-LUPUS; CLINICAL-MANIFESTATIONS; OUTCOME INSTRUMENT; ATOPIC-DERMATITIS; REVISED CRITERIA; ROWELLS-SYNDROME; SURFACE-AREA; INVOLVEMENT AB This article provides an overview of cutaneous lupus erythematosus, including classification schemes, disease subtypes, and therapy. It also describes the Cutaneous Lupus Erythematosus Disease Area and Severity Index, a novel clinical outcome instrument that quantifies cutaneous activity and damage in cutaneous lupus erythematosus. C1 [Klein, Rachel S.; Morganroth, Pamela A.; Werth, Victoria P.] Univ Penn, Dept Dermatol, Sch Med, Philadelphia, PA 19104 USA. [Klein, Rachel S.; Morganroth, Pamela A.; Werth, Victoria P.] Philadelphia VA Med Ctr, Philadelphia, PA USA. RP Werth, VP (reprint author), Univ Penn, Dept Dermatol, Sch Med, Suite 1-330A,3400 Civ Ctr Blvd, Philadelphia, PA 19104 USA. EM werth@mail.med.upenn.edu FU National Institutes of Health; NIH [K24-AR 02207, T32-AR007465-25]; Department of Veterans Affairs; Veterans Health Administration; Office of Research and Development; Biomedical Laboratory Research and Development FX This material is based upon work supported by the National Institutes of Health, including NIH grant K24-AR 02207 (Werth) and NIH training grant T32-AR007465-25 (Klein). This work was also partially supported by a Merit Review Grant from the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development. NR 78 TC 12 Z9 13 U1 1 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0889-857X J9 RHEUM DIS CLIN N AM JI Rheum. Dis. Clin. North Am. PD FEB PY 2010 VL 36 IS 1 BP 33 EP + DI 10.1016/j.rdc.2009.12.001 PG 20 WC Rheumatology SC Rheumatology GA 576OE UT WOS:000276153400004 PM 20202590 ER PT J AU Perlick, DA Rosenheck, RA Kaczynski, R Swartz, MS Canive, JM Lieberman, JA AF Perlick, Deborah A. Rosenheck, Robert A. Kaczynski, Richard Swartz, Marvin S. Canive, Jose M. Lieberman, Jeffrey A. TI Impact of antipsychotic medication on family burden in schizophrenia: Longitudinal results of CATIE trial SO SCHIZOPHRENIA RESEARCH LA English DT Article DE Schizophrenia; Family burden; Second-generation antipsychotics ID BIPOLAR DISORDER; MENTAL-HEALTH; OLANZAPINE; CAREGIVERS; HALOPERIDOL; SCALE; DRUGS AB Background: This study evaluated the effectiveness of first- and second-generation antipsychotics in reducing family burden associated with schizophrenia. Methods: The family caregivers of 623 SCID-diagnosed patients enrolled in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) randomly assigned to a first-generation antipsychotic (perphenazine) or one of four second-generation drugs (olanzapine, quetiapine, risperidone or ziprasidone) were interviewed about resources provided and stresses experienced at baseline and followed for 18 months. Patient symptoms, side effects and service use were assessed as well. Hierarchical regression analyses evaluated the effect of treatment assignment on four burden factors: problem behavior, resource demands and disruption, impairment in activities of daily living and patient helpfulness. Intention-to-treat analyses with all available observations classified based on initial treatment assignment, including observations after medications changed were followed by secondary analyses excluding observations after the first medication change, i.e. only considering initial medication. Results: Despite significant reductions on the problem behavior and resource demands/disruption factors, there were no significant differences between perphenazine and any of the second-generation medications. When only initial treatment period observations were included, patients were perceived as more helpful when medicated with perphenazine as compared to risperidone. in comparisons between second-generation drugs, patients on quetiapine were perceived as more helpful than those on risperidone (p = 0.004). Conclusion: In this 18-month randomized trial. there was no evidence of superiority of second-generation antipsychotics in relieving family burden. (C) 2009 Published by Elsevier B.V. C1 [Perlick, Deborah A.] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. [Perlick, Deborah A.] James J Peters VA Med Ctr, Mental Illness Res Educ & Clin Ctr, Bronx, NY 10468 USA. [Rosenheck, Robert A.] VA Connecticut Hlth Care Syst, New England Mental Illness, Res Educ & Clin Ctr, West Haven, CT 06516 USA. [Rosenheck, Robert A.; Kaczynski, Richard] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06510 USA. [Rosenheck, Robert A.; Kaczynski, Richard] Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06510 USA. [Swartz, Marvin S.] Duke Univ, Dept Psychiat & Behav Sci, Durham, NC 27708 USA. [Canive, Jose M.] Univ New Mexico, Dept Psychiat, VA Med Ctr, Albuquerque, NM 87108 USA. [Canive, Jose M.] Univ New Mexico, New Mexico VA Hlth Care Syst, VA Med Ctr, Albuquerque, NM 87108 USA. [Lieberman, Jeffrey A.] Columbia Univ Coll Phys & Surg, Dept Psychiat, New York, NY 10032 USA. RP Perlick, DA (reprint author), Mt Sinai Sch Med, Dept Psychiat, 1 Gustave L Levy Pl,Box 1230, New York, NY 10029 USA. EM debbieperlick@aol.com; robert.rosenheck@yale.edu; richard.kaczynski@yale.edu; Marvin.swartz@duke.edu; jose.canive@va.gov; jlieberman@pi.cpmc.Columbia.edu FU NIMH NIH HHS [N01 MH90001] NR 27 TC 6 Z9 8 U1 0 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD FEB PY 2010 VL 116 IS 2-3 BP 118 EP 125 DI 10.1016/j.schres.2009.09.026 PG 8 WC Psychiatry SC Psychiatry GA 561AB UT WOS:000274946000003 PM 19864114 ER PT J AU Cryder, CE London, AJ Volpp, KG Loewenstein, G AF Cryder, Cynthia E. London, Alex John Volpp, Kevin G. Loewenstein, George TI Informative inducement: Study payment as a signal of risk SO SOCIAL SCIENCE & MEDICINE LA English DT Article DE Risk; Incentives; Ethics; Participant payments; Human Participants research; USA, informed consent ID RESEARCH PARTICIPATION; UNDUE; ETHICS AB In research involving human subjects, large participation payments often are deemed undesirable because they may provide 'undue inducement' for potential participants to expose themselves to risk. However, although large incentives may encourage participation, they also may signal the riskiness of a study's procedures. In three experiments, we measured people's interest in participating in potentially risky research studies, and their perception of the risk associated with those studies, as functions of participation payment amounts. All experiments took place 2007-2008 with an on-line nationwide sample or a sample from a northeastern U.S. city. We tested whether people judge studies that offer higher participation payments to be riskier, and, if so, whether this increased perception of risk increases time and effort spent learning about the risks. We found that high participation payments increased willingness to participate, but, consistent with the idea that people infer riskiness from payment amount, high payments also increased perceived risk and time spent viewing risk information. Moreover, when a link between payment amount and risk level was made explicit in Experiment 3, the relationship between high payments and perceived risk strengthened. Research guidelines usually prohibit studies from offering participation incentives that compensate for risks, yet these experiments' results indicate that potential participants naturally assume that the magnitude of risks and incentives are related. This discrepancy between research guidelines and participants' assumptions about those guidelines has implications for informed consent in human subjects research. (C) 2009 Elsevier Ltd. All rights reserved. C1 [Cryder, Cynthia E.] Washington Univ, John M Olin Sch Business, St Louis, MO 63130 USA. [London, Alex John; Loewenstein, George] Carnegie Mellon Univ, Pittsburgh, PA 15213 USA. [Volpp, Kevin G.] Univ Penn, Sch Med, Philadelphia VA Med Ctr, CHERP, Philadelphia, PA 19104 USA. RP Cryder, CE (reprint author), Washington Univ, John M Olin Sch Business, CB 1133,1 Brookings Dr, St Louis, MO 63130 USA. EM cryder@wustl.edu OI London, Alex/0000-0002-6450-0309 NR 17 TC 30 Z9 30 U1 1 U2 7 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0277-9536 J9 SOC SCI MED JI Soc. Sci. Med. PD FEB PY 2010 VL 70 IS 3 BP 455 EP 464 DI 10.1016/j.socscimed.2009.10.047 PG 10 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA 552VK UT WOS:000274321500015 PM 19926187 ER PT J AU Tennis, MA Vanscoyk, M Keith, RL Winn, RA AF Tennis, Meredith A. Vanscoyk, Michelle Keith, Robert L. Winn, Robert A. TI The role of prostacyclin in lung cancer SO TRANSLATIONAL RESEARCH LA English DT Article ID VASCULAR SMOOTH-MUSCLE; ACTIVATED RECEPTOR-GAMMA; CELL-LINES; GENE-EXPRESSION; CARCINOMA-CELLS; MURINE MODEL; PROSTAGLANDIN; SYNTHASE; ANALOGS; GROWTH AB Prostanoids are bioactive lipids that interact with 7-membrane-spanning G-protein-coupled receptors on target cells to impart their biologic effects.(1) They include prostaglandins, prostacyclin, and thromboxane. Prostanoids are widely distributed; mediate several diverse biologic effects like platelet aggregation and smooth-muscle contraction; and are known to be involved in allergies, acquired immunity, and cancer metastasis.(2) Prostanoids have also been associated with breast and endometrial cancer promotion, and with the inhibition of melanoma. The role of prostanoids in the development of lung disease has been poorly understood. In particular, prostacyclin possesses significant anti-inflammatory and antimetastatic properties and is the main product of cyclooxygenase-2 activity in the lung. In fact, the balance of the various members of the prostanoids family, specifically the prosoglandins PGE(2) and prostacyclin (PGI(2)), seems to play an increasingly important role in the development of lung cancer. Gaining a better understanding of prostanoids and their associated pathways is critical to the future development of molecular-based and pharmaceutical treatments of lung disease. (Translational Research 2010;155:57-61) C1 [Winn, Robert A.] Univ Colorado Denver, Hlth Sci Ctr, Dept Med, Div Pulm & Crit Care Med, Aurora, CO 80045 USA. Denver VA Med Ctr, Dept Med, Div Pulm Sci & Crit Care Med, Denver, CO USA. RP Winn, RA (reprint author), Univ Colorado Denver, Hlth Sci Ctr, Dept Med, Div Pulm & Crit Care Med, 12700 E 19th Ave, Aurora, CO 80045 USA. EM robert.winn@ucdenver.edu NR 53 TC 6 Z9 7 U1 1 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1931-5244 J9 TRANSL RES JI Transl. Res. PD FEB PY 2010 VL 155 IS 2 BP 57 EP 61 DI 10.1016/j.trsl.2009.06.010 PG 5 WC Medical Laboratory Technology; Medicine, General & Internal; Medicine, Research & Experimental SC Medical Laboratory Technology; General & Internal Medicine; Research & Experimental Medicine GA 593GH UT WOS:000277440500002 PM 20129485 ER PT J AU Gerton, BK Theeler, B Samii, A AF Gerton, Brooke K. Theeler, Brett Samii, Ali TI Backpack Treatment for Camptocormia SO MOVEMENT DISORDERS LA English DT Letter ID PARKINSONS-DISEASE; PATHOGENESIS C1 [Gerton, Brooke K.; Samii, Ali] Vet Affairs Puget Sound Hlth Care Syst, Parkinsons Dis Res Educ Ctr, Dept Neurol, Seattle, WA USA. [Gerton, Brooke K.; Samii, Ali] Vet Affairs Puget Sound Hlth Care Syst, Ctr Clin, Seattle, WA USA. [Gerton, Brooke K.; Samii, Ali] Univ Washington, Seattle, WA 98195 USA. [Theeler, Brett] Madigan Army Med Ctr, Dept Med, Neurol Serv, Tacoma, WA 98431 USA. RP Gerton, BK (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Parkinsons Dis Res Educ Ctr, Dept Neurol, Seattle, WA USA. EM bgerton@u.washington.edu NR 6 TC 18 Z9 18 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0885-3185 J9 MOVEMENT DISORD JI Mov. Disord. PD JAN 30 PY 2010 VL 25 IS 2 BP 247 EP 248 DI 10.1002/mds.22909 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA 586TY UT WOS:000276937600018 PM 20077473 ER PT J AU Lin, HZ Liu, DP Zhou, XH AF Lin, Huazhen Liu, Danping Zhou, Xiao-Hua TI A correlated random-effects model for normal longitudinal data with nonignorable missingness SO STATISTICS IN MEDICINE LA English DT Article DE nonignorable missing; correlated random effects; Laplace approximation; longitudinal data ID DROP-OUT; INFORMATIVE DROPOUT; DATA SUBJECT; BINARY DATA; NONRESPONSE; REGRESSION; TIME; INFERENCE; OUTCOMES; COUNT AB The missing data problem is common in longitudinal or hierarchical structure studies. In this paper, we propose a correlated random-effects model to fit normal longitudinal or cluster data when the missingness mechanism is nonignorable. Computational challenges arise in the model fitting due to intractable numerical integrations. We obtain the estimates of the parameters based on an accurate approximation of the log likelihood, which has higher-order accuracy but with less computational burden than the existing approximation. We apply the proposed method to a real data set arising from an autism study. Copyright (C) 2009 John Wiley & Sons, Ltd. C1 [Liu, Danping; Zhou, Xiao-Hua] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Lin, Huazhen] Sichuan Univ, Sch Math, Chengdu 610064, Sichuan, Peoples R China. [Zhou, Xiao-Hua] VA Puget Sound Hlth Care Syst, HSR&D Ctr Excellence, Seattle, WA 98108 USA. RP Zhou, XH (reprint author), Univ Washington, Dept Biostat, Seattle, WA 98195 USA. EM azhou@u.washington.edu RI Liu, Danping/D-2544-2013 FU National Natural Science Foundation of China [10771148]; AHRQ [R01HS013105]; U.S. Department of Veterans Affairs, Veterans Affairs Health Administration, HSRD [ECI-03-206]; National Science Foundation of China [30728019] FX Contract/grant sponsor: National Natural Science Foundation of China; contract/grant number: 10771148; Contract/grant sponsor: AHRQ contract/grant number: R01HS013105; Contract/grant sponsor: U.S. Department of Veterans Affairs, Veterans Affairs Health Administration, HSR&D, contract/grant number. ECI-03-206; Contract/grant sponsor: National Science Foundation of China; contract/grant number: 30728019 NR 23 TC 4 Z9 4 U1 1 U2 9 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 0277-6715 J9 STAT MED JI Stat. Med. PD JAN 30 PY 2010 VL 29 IS 2 BP 236 EP 247 DI 10.1002/sim.3760 PG 12 WC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Medicine, Research & Experimental; Statistics & Probability SC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Research & Experimental Medicine; Mathematics GA 544OD UT WOS:000273666600007 PM 19941316 ER PT J AU Fujikawa, DG Zhao, S Ke, XR Shinmei, SS Allen, SG AF Fujikawa, Denson G. Zhao, Shuangping Ke, Xingrao Shinmei, Steve S. Allen, Suni G. TI Mild as well as severe insults produce necrotic, not apoptotic, cells: Evidence from 60-min seizures SO NEUROSCIENCE LETTERS LA English DT Article DE Apoptosis; Caspase-3; Excitotoxicity; Necrosis; Programmed cell death; Status epilepticus ID INTERNUCLEOSOMAL DNA CLEAVAGE; INDUCED STATUS EPILEPTICUS; ACID-INDUCED SEIZURES; NEURONAL DAMAGE; KAINIC ACID; TEMPORAL EVOLUTION; CEREBRAL-CORTEX; BRAIN-DAMAGE; RAT-BRAIN; NECROSIS AB We tested the hypothesis that mild insults produce apoptotic, and severe insults necrotic, cells by subjecting adult Wistar rats to 60-min instead of 3-h generalized seizures. Rats' brains were evaluated 6 and 24 h later for evidence of neuronal necrosis by light and electron microscopy, the presence of TUNEL staining and active caspase-3 immunoreactivity, and for evidence of DNA laddering 24 h after seizures. Apoptotic neurons from the retrosplenial cortex of postnatal day 8 rat pups served as positive controls. Six and 24 h after seizures, 16 and 15 brain regions respectively out of 24 showed significant numbers of acidophilic neurons by hematoxylin and eosin stain. Three brain regions had significant numbers of TUNEL-positive neurons 24 h after seizures. No neurons showed active caspase-3 immunoreactivity. Acidophilic neurons were necrotic by electron-microscopic examination. Ultrastructurally, they were shrunken and electron-dense, with shrunken, pyknotic nuclei and swollen mitochondria with disrupted cristae. Nuclei did not contain the irregular chromatin clumps found after 3-h seizures. None of the six brain regions studied ultrastructurally that show DNA laddering 24 h after 3-h seizures showed DNA laddering 24 h after 60-min seizures, probably because there were too few damaged neurons, although the lack of chromatin clumping might have been a contributing factor. Following seizures, a mild as well as a severe insult produces caspase-3-negative necrotic neurons. These results do not support the hypothesis that mild insults produce apoptotic, and severe insults, necrotic, cells. Published by Elsevier Ireland Ltd. C1 [Fujikawa, Denson G.; Zhao, Shuangping; Allen, Suni G.] VA Greater Los Angeles Healthcare Syst, Expt Neurol Lab, North Hills, CA 91343 USA. [Fujikawa, Denson G.] Univ Calif Los Angeles, Dept Neurol, David Geffen Sch Med, Los Angeles, CA 90024 USA. [Fujikawa, Denson G.] Univ Calif Los Angeles, Brain Res Inst, David Geffen Sch Med, Los Angeles, CA 90024 USA. [Ke, Xingrao] Univ Utah, Sch Med, Dept Pediat, Salt Lake City, UT USA. [Shinmei, Steve S.] Univ Calif Davis, Adm Univ Extens, Davis, CA 95616 USA. RP Fujikawa, DG (reprint author), VA Greater Los Angeles Healthcare Syst, Expt Neurol Lab, Mail Code 151B4,16111 Plummer St, North Hills, CA 91343 USA. EM dfujikaw@ucla.edu FU Office of Research and Development, Department of Veterans Affairs FX This study was funded by the Office of Research and Development, Department of Veterans Affairs. Dr. Jeffrey A. Gornbein, a UCLA biomathematician, provided expert assistance in the statistical analysis of data. NR 24 TC 9 Z9 11 U1 1 U2 2 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0304-3940 J9 NEUROSCI LETT JI Neurosci. Lett. PD JAN 29 PY 2010 VL 469 IS 3 BP 333 EP 337 DI 10.1016/j.neulet.2009.12.022 PG 5 WC Neurosciences SC Neurosciences & Neurology GA 558DX UT WOS:000274722100011 PM 20026247 ER PT J AU Ecker, AS Berens, P Keliris, GA Bethge, M Logothetis, NK Tolias, AS AF Ecker, Alexander S. Berens, Philipp Keliris, Georgios A. Bethge, Matthias Logothetis, Nikos K. Tolias, Andreas S. TI Decorrelated Neuronal Firing in Cortical Microcircuits SO SCIENCE LA English DT Article ID PRIMARY VISUAL-CORTEX; AREA MT; NOISE CORRELATIONS; INFORMATION; VARIABILITY; DISCHARGE; ACCURACY; MACAQUE; CONNECTIVITY; SYNAPSES AB Correlated trial-to-trial variability in the activity of cortical neurons is thought to reflect the functional connectivity of the circuit. Many cortical areas are organized into functional columns, in which neurons are believed to be densely connected and to share common input. Numerous studies report a high degree of correlated variability between nearby cells. We developed chronically implanted multitetrode arrays offering unprecedented recording quality to reexamine this question in the primary visual cortex of awake macaques. We found that even nearby neurons with similar orientation tuning show virtually no correlated variability. Our findings suggest a refinement of current models of cortical microcircuit architecture and function: Either adjacent neurons share only a few percent of their inputs or, alternatively, their activity is actively decorrelated. C1 [Ecker, Alexander S.; Berens, Philipp; Tolias, Andreas S.] Baylor Coll Med, Dept Neurosci, Houston, TX 77030 USA. [Ecker, Alexander S.; Berens, Philipp; Keliris, Georgios A.; Bethge, Matthias; Logothetis, Nikos K.] Max Planck Inst Biol Cybernet, D-72076 Tubingen, Germany. [Ecker, Alexander S.; Berens, Philipp; Bethge, Matthias] Univ Tubingen, Inst Theoret Phys, D-72076 Tubingen, Germany. [Ecker, Alexander S.; Berens, Philipp; Bethge, Matthias] Univ Tubingen, Ctr Integrat Neurosci, D-72076 Tubingen, Germany. [Logothetis, Nikos K.] Univ Manchester, Div Imaging Sci & Biomed Engn, Manchester M1 7HL, Lancs, England. [Tolias, Andreas S.] Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Tolias, Andreas S.] Rice Univ, Dept Computat & Appl Math, Houston, TX 77005 USA. RP Tolias, AS (reprint author), Baylor Coll Med, Dept Neurosci, Houston, TX 77030 USA. EM atolias@cns.bcm.edu RI Ecker, Alexander/A-5184-2010; Berens, Philipp/A-5653-2009; Bethge, Matthias/B-1554-2008; Keliris, Georgios A/B-6692-2008 OI Ecker, Alexander/0000-0003-2392-5105; Keliris, Georgios A/0000-0001-6732-1261; Berens, Philipp/0000-0002-0199-4727 FU National Eye Institute, NIH [R01 EY018847]; Max Planck Society; U.S. Department of Defense [W81XWH-08-2-0147]; Department of Veterans Affairs; Arnold and Mabel Beckman Foundation; German Federal Ministry of Education and Research (BMBF) [FKZ:01GQ0601] FX We thank M. Subramanian, A. Hoenselaar, T. J. Williford, and D. Murray for help with experiments; R. J. Cotton for his contribution in setting up recording equipment; and the Siapas laboratory at Caltech for providing the recording software. We thank R. J. Cotton, P. Dayan, S. Deneve, K. D. Harris, E. V. Lubenov, W. J. Ma, J. H. Macke, A. Renart, J. de la Rocha, A. G. Siapas, and S. M. Smirnakis for comments on the manuscript and discussions. This work was supported by the National Eye Institute, NIH (R01 EY018847), the Max Planck Society, the U.S. Department of Defense (W81XWH-08-2-0147), a VA Merit Award from the Department of Veterans Affairs, and an Arnold and Mabel Beckman Foundation Young Investigator Award to A. S. T., and by the German Federal Ministry of Education and Research (BMBF) through the Bernstein award to M. B. (FKZ:01GQ0601). NR 31 TC 282 Z9 286 U1 1 U2 24 PU AMER ASSOC ADVANCEMENT SCIENCE PI WASHINGTON PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA SN 0036-8075 J9 SCIENCE JI Science PD JAN 29 PY 2010 VL 327 IS 5965 BP 584 EP 587 DI 10.1126/science.1179867 PG 4 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 549CT UT WOS:000274020500039 PM 20110506 ER PT J AU Andrews, S Burgess, SJ Skaalrud, D Kelly, JX Peyton, DH AF Andrews, Simeon Burgess, Steven J. Skaalrud, Deborah Kelly, Jane Xu Peyton, David H. TI Reversal Agent and Linker Variants of Reversed Chloroquines: Activities against Plasmodium falciparum SO JOURNAL OF MEDICINAL CHEMISTRY LA English DT Article ID BETA-HEMATIN INHIBITION; DRUG-RESISTANCE; MALARIA; ANTIMALARIAL; COMBINATIONS; TRANSPORTER AB We have shown that "reversed chloroquine molecules" constructed from chloroquine-like and resistance "reversal-agent"-like cores can be powerful drugs against malaria (J. Med. Chem. 2006, 49, 5623-5625). Several reversed chloroquines are now presented that probe parameters governing the activities against chloroquine-resistant and chloroquine-sensitive malaria strains. The design is tolerant to linker and reversal agent changes, but it piperazinyl group adjacent to the quinoline, at least for the group Of Compounds studied here, may be detrimental. C1 [Andrews, Simeon; Burgess, Steven J.; Skaalrud, Deborah; Kelly, Jane Xu; Peyton, David H.] Portland State Univ, Dept Chem, Portland, OR 97207 USA. [Burgess, Steven J.; Kelly, Jane Xu] DesignMedix Inc, Portland, OR 97201 USA. [Kelly, Jane Xu] Portland VA Med Ctr, Portland, OR 97239 USA. RP Peyton, DH (reprint author), Portland State Univ, Dept Chem, POB 751, Portland, OR 97207 USA. EM peytond@pdx.edu FU Medical Research Foundation of Oregon [0530]; National Institutes of Health [AI067837, AI072923]; Murdock Charitable Trust FX The authors thank the following for supporting this research: the Medical Research Foundation of Oregon (Grant 0530), the National Institutes of Health (Grants AI067837 and AI072923) to DHP, and a grant from the Murdock Charitable Trust for the NMR instruments. NR 19 TC 55 Z9 55 U1 0 U2 4 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0022-2623 J9 J MED CHEM JI J. Med. Chem. PD JAN 28 PY 2010 VL 53 IS 2 BP 916 EP 919 DI 10.1021/jm900972u PG 4 WC Chemistry, Medicinal SC Pharmacology & Pharmacy GA 544PX UT WOS:000273672100037 PM 20088608 ER PT J AU Ix, JH Katz, R Peralta, CA de Boer, IH Allison, MA Bluemke, DA Siscovick, DS Lima, JAC Criqui, MH AF Ix, Joachim H. Katz, Ronit Peralta, Carmen A. de Boer, Ian H. Allison, Matthew A. Bluemke, David A. Siscovick, David S. Lima, Joao A. C. Criqui, Michael H. TI A High Ankle Brachial Index Is Associated With Greater Left Ventricular Mass MESA (Multi-Ethnic Study of Atherosclerosis) SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Article DE cardiovascular disease; heart failure; left ventricular mass; medial arterial calcification; vascular stiffness ID PERIPHERAL ARTERIAL-DISEASE; CARDIOVASCULAR HEALTH; RISK-FACTORS; CALCIFICATION; PRESSURES; PREVALENCE; MORTALITY; EVENTS; ADULTS AB Objectives This study sought to determine the association of high ankle brachial index (ABI) measurements with left ventricular (LV) mass, and to compare its strength with that of low ABI with LV mass. Background Arterial stiffness leads to LV mass through nonatherosclerotic pathways in mice. In humans, a high ABI indicates stiff peripheral arteries and is associated with cardiovascular disease (CVD) events. Whether high ABI is associated with LV mass in humans and whether this might reflect consequences of arterial stiffness, atherosclerosis, or both is unknown. Methods Among 4,972 MESA (Multi-Ethnic Study of Atherosclerosis) participants without clinical CVD, we used linear regression to evaluate the association of low (<0.90) and high (>1.40 or incompressible) ABI with LV mass by cardiac magnetic resonance imaging (MRI). Intermediate ABIs served as the reference category. To determine the effect of subclinical atherosclerosis, models were adjusted for common and internal carotid intima media thickness (cIMT) and natural log-transformed coronary artery calcification. Results Compared with subjects with intermediate ABI, LV mass was higher with either low (2.70 g/m(2) higher, 95% confidence interval: 0.65 to 4.75) or high ABI (6.84 g/m2 higher, 95% confidence interval: 3.2 to 10.47) after adjustment for traditional CVD risk factors, kidney function, and C-reactive protein. However, further adjustment for cIMT and CAC substantially attenuated the association of low ABI with LV mass index (1.24 g/m(2) higher, 95% confidence interval: -0.84 to 3.33), whereas the association of high ABI was minimally altered (6.01 g/m(2) higher, 95% confidence interval: 2.36 to 9.67). Conclusions High ABI is associated with greater LV mass; an association that is not attenuated with adjustment for subclinical atherosclerosis in nonperipheral arterial beds. High ABI might lead to greater LV mass through nonatherosclerotic pathways. (J Am Coll Cardiol 2010; 55: 342-9) (C) 2010 by the American College of Cardiology Foundation C1 [Ix, Joachim H.] Univ Calif San Diego, Div Nephrol & Hypertens, Dept Med, San Diego VA Healthcare Syst, San Diego, CA 92161 USA. [Ix, Joachim H.; Allison, Matthew A.; Criqui, Michael H.] Univ Calif San Diego, Div Prevent Med, Dept Family & Prevent, San Diego, CA 92161 USA. [Ix, Joachim H.] Vet Affairs San Diego Healthcare Syst, Nephrol Sect, San Diego, CA USA. [Katz, Ronit] Univ Washington, Dept Biostat, Collaborat Hlth Studies Coordinating Ctr, Seattle, WA 98195 USA. [de Boer, Ian H.] Univ Washington, Dept Med, Div Nephrol, Seattle, WA 98195 USA. [Siscovick, David S.] Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA USA. [Siscovick, David S.] Univ Washington, Dept Epidemiol, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA. [Peralta, Carmen A.] Univ Calif San Diego, Div Nephrol, Dept Med, San Diego, CA 92161 USA. [Peralta, Carmen A.] San Francisco VA Med Ctr, San Francisco, CA USA. [Bluemke, David A.] Natl Inst Hlth Clin Ctr, Bethesda, MD USA. [Lima, Joao A. C.] Johns Hopkins Univ, Dept Med, Div Cardiol, Baltimore, MD USA. RP Ix, JH (reprint author), Univ Calif San Diego, Div Nephrol & Hypertens, Dept Med, San Diego VA Healthcare Syst, 3350 La Jolla Village Dr,Mail Code 111-H, San Diego, CA 92161 USA. EM joeix@ucsd.edu OI Bluemke, David/0000-0002-8323-8086; Allison, Matthew/0000-0003-0777-8272 FU National Heart, Lung, and Blood Institute (NHLBI) [R21HL091217, N01-HC-95159, N01-HC-95169]; American Heart Association Fellow to Faculty Transition Award FX From the *Division of Nephrology and Hypertension, Department of Medicine, and the dagger Division of Preventive Medicine, Department of Family and Preventive Medicine, University of California San Diego, San Diego, California; Nephrology Section, Veterans Affairs San Diego Healthcare System, San Diego, California; Collaborative Health Studies Coordinating Center, Department of Biostatistics, ||Division of Nephrology, Department of Medicine, and the Cardiovascular Health Research Unit, Departments of Medicine and Epidemiology, University of Washington, Seattle, Washington; #Division of Nephrology, Department of Medicine, University of California San Francisco, San Francisco, California; **San Francisco Veterans Affairs Medical Center, San Francisco, California; dagger dagger Radiology and Imaging Sciences, National Institutes of Health Clinical Center, Bethesda, Maryland; and the Division of Cardiology, Department of Medicine, Johns Hopkins University, Baltimore, Maryland. This study was supported by the National Heart, Lung, and Blood Institute (NHLBI) grant R21HL091217 (to Dr. Ix), an American Heart Association Fellow to Faculty Transition Award, and contracts N01-HC-95159 through N01-HC-95169 from the NHLBI. Michael R. Jaff, MD, served as Guest Editor for this article. NR 28 TC 40 Z9 41 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD JAN 26 PY 2010 VL 55 IS 4 BP 342 EP 349 DI 10.1016/j.jacc.2009.11.010 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 546HP UT WOS:000273802200011 PM 20117440 ER PT J AU Clough-Gorr, KM Stuck, AE Thwin, SS Silliman, RA AF Clough-Gorr, Kerri M. Stuck, Andreas E. Thwin, Soe Soe Silliman, Rebecca A. TI Older Breast Cancer Survivors: Geriatric Assessment Domains Are Associated With Poor Tolerance of Treatment Adverse Effects and Predict Mortality Over 7 Years of Follow-Up SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID QUALITY-OF-LIFE; FUNCTIONAL ASSESSMENT; ADJUVANT TAMOXIFEN; CONTROLLED-TRIALS; SOCIAL SUPPORT; AGE; CHEMOTHERAPY; ONCOLOGY; WOMEN; CARE AB Purpose To evaluate geriatric assessment (GA) domains in relation to clinically important outcomes in older breast cancer survivors. Methods Six hundred sixty women diagnosed with primary breast cancer in four US geographic regions (Los Angeles, CA; Minnesota; North Carolina; and Rhode Island) were selected with disease stage I to IIIA, age >= 65 years at date of diagnosis, and permission from attending physician to contact. Data were collected over 7 years of follow-up from consenting patients' medical records, telephone interviews, physician questionnaires, and the National Death Index. Outcomes included self-reported treatment tolerance and all-cause mortality. Four GA domains were described by six individual measures, as follows: sociodemographic by adequate finances; clinical by Charlson comorbidity index (CCI) and body mass index; function by number of physical function limitations; and psychosocial by the five-item Mental Health Index (MHI5) and Medical Outcomes Study Social Support Survey (MOS-SSS). Associations were evaluated using t tests, chi(2) tests, and regression analyses. Results In multivariable regression including age and stage, three measures from two domains (clinical and psychosocial) were associated with poor treatment tolerance; these were CCI >= 1 (odds ratio [OR] = 2.49; 95% CI, 1.18 to 5.25), MHI5 score less than 80 (OR = 2.36; 95% CI, 1.15 to 4.86), and MOS-SSS score less than 80 (OR = 3.32; 95% CI, 1.44 to 7.66). Four measures representing all four GA domains predicted mortality; these were inadequate finances (hazard ratio [HR] = 1.89; 95% CI, 1.24 to 2.88; CCI >= 1 (HR = 1.38; 95% CI, 1.01 to 1.88), functional limitation (HR = 1.40; 95% CI, 1.01 to 1.93), and MHI5 score less than 80 (HR = 1.34; 95% CI, 1.01 to 1.85). In addition, the proportion of women with these outcomes incrementally increased as the number of GA deficits increased. Conclusion This study provides longitudinal evidence that GA domains are associated with poor treatment tolerance and predict mortality at 7 years of follow-up, independent of age and stage of disease. C1 [Clough-Gorr, Kerri M.] Boston Univ, Med Ctr, Sch Med, Sect Geriatr, Boston, MA 02118 USA. Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02118 USA. US Dept Vet Affairs, Massachusetts Vet Epidemiol Res & Informat Ctr, Boston, MA USA. Univ Bern, ISPM, CH-3012 Bern, Switzerland. Univ Hosp Bern, Inselspital, Dept Geriatr, CH-3010 Bern, Switzerland. RP Clough-Gorr, KM (reprint author), Boston Univ, Med Ctr, Sch Med, Sect Geriatr, 88 E Newton St,Robinson 2, Boston, MA 02118 USA. EM kmclough@bu.edu FU National Cancer Institute, Bethesda, MD [CA106979, CA/AG 70818, CA84506] FX Supported by Grants No. CA106979, CA/AG 70818, and CA84506 from the National Cancer Institute, Bethesda, MD. NR 67 TC 46 Z9 47 U1 1 U2 3 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD JAN 20 PY 2010 VL 28 IS 3 BP 380 EP 386 DI 10.1200/JCO.2009.23.5440 PG 7 WC Oncology SC Oncology GA 544MY UT WOS:000273662700005 PM 20008637 ER PT J AU Santillan, AA Messina, JL Marzban, SS Crespo, G Sondak, VK Zager, JS AF Santillan, Alfredo A. Messina, Jane L. Marzban, Suroosh S. Crespo, Gema Sondak, Vernon K. Zager, Jonathan S. TI Pathology Review of Thin Melanoma and Melanoma in Situ in a Multidisciplinary Melanoma Clinic: Impact on Treatment Decisions SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID AMERICAN-JOINT-COMMITTEE; PRIMARY CUTANEOUS MELANOMA; MANDATORY 2ND OPINION; LYMPH-NODE POSITIVITY; MALIGNANT-MELANOMA; STAGING SYSTEM; MITOTIC RATE; INTEROBSERVER VARIABILITY; BRESLOW DEPTH; CLARK LEVEL AB Purpose Patients with thin melanoma (<= 1.0 mm) and melanoma in situ (MIS) represent the majority of newly diagnosed melanoma. We estimated the impact of expert review of outside pathology material on the staging and thus treatment decisions affecting patients referred to a multidisciplinary clinic with early-stage melanoma. Patients and Methods We studied patients with a diagnosis of thin melanoma or MIS referred to H. Lee Moffitt Cancer Center from 2006 to 2009. After comparing the referring laboratory and in-house dermatopathologic interpretations, we calculated any differences in diagnosis and tumor staging and the potential impact of differences in diagnosis and staging on prognosis and surgical treatment using the National Comprehensive Cancer Network clinical guidelines. Results The overall pathologic discordance rate in diagnosis was 4% (15 of 420 patients; 95% CI, 2% to 6%). The overall change in tumor staging rate was 24% (97 of 405 patients; 95% CI, 20% to 28%). Pathology review led to changes in surgical excision margins in 12% of patients (52 of 420 patients; 95% CI, 9% to 16%) and in the decision about whether to perform a sentinel lymph node biopsy in 16% of patients (67 of 420 patients; 95% CI, 13% to 20%). Key pathologic factors, particularly mitotic rate, were frequently missing from outside pathology reports. Conclusion Our data suggest that review of thin melanoma or MIS by an expert dermatopathologist results in frequent, clinically meaningful alterations in diagnosis, staging, prognosis, and surgical treatment. Referral of these patients to a multidisciplinary melanoma clinic is appropriate, and management of such patients should include review of the biopsy whenever feasible. C1 Univ Texas Hlth Sci Ctr San Antonio, Dept Surg, Sect Surg Oncol, San Antonio, TX USA. Audie L Murphy Vet Affairs Hosp, Sect Surg Oncol, San Antonio, TX USA. Univ S Florida, Coll Med, Dept Oncol Sci, Tampa, FL USA. Univ S Florida, Coll Med, Dept Dermatol, Tampa, FL USA. Univ S Florida, Coll Med, Dept Surg, Tampa, FL 33612 USA. RP Zager, JS (reprint author), 12902 Magnolia Dr,SRB4-24012, Tampa, FL 33602 USA. EM jonathan.zager@moffitt.org NR 29 TC 26 Z9 26 U1 0 U2 3 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD JAN 20 PY 2010 VL 28 IS 3 BP 481 EP 486 DI 10.1200/JCO.2009.24.7734 PG 6 WC Oncology SC Oncology GA 544MY UT WOS:000273662700020 PM 20008627 ER PT J AU Graham, DP Savas, L White, D El-Serag, R Laday-Smith, S Tan, G El-Serag, HB AF Graham, D. P. Savas, L. White, D. El-Serag, R. Laday-Smith, S. Tan, G. El-Serag, H. B. TI Irritable bowel syndrome symptoms and health related quality of life in female veterans SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS LA English DT Article ID FUNCTIONAL GASTROINTESTINAL DISORDERS; POSTTRAUMATIC-STRESS-DISORDER; GENERALIZED ANXIETY DISORDER; GULF-WAR VETERANS; WOMEN VETERANS; PSYCHOMETRIC PROPERTIES; MEDICAL PATIENTS; SURVEY SF-36; PREVALENCE; INVENTORY AB P>Background The status and determinants of health-related quality of life (HRQOL) in female veterans with and without irritable bowel syndrome (IBS) are unknown. Aim To compare HRQOL in female veterans with and without IBS symptoms and examine the contribution of post-traumatic stress disorder, depression and anxiety to HRQOL. Methods A cross-sectional study of 339 female veterans. Self-report questionnaires were used to evaluate IBS symptoms, post-traumatic stress disorder, depression, anxiety and HRQOL. Results Symptoms consistent with IBS were present in 33.5% of participants. Female veterans with IBS symptoms had significant reductions in physical component score and 5 of 8 Health Related Quality of Life subscales and on 7 of 8 Irritable Bowel Syndrome Quality Of Life subscales than female veterans without IBS symptoms. Compared with the US general female population, female veterans had significantly lower Health Related Quality of Life physical component score and mental component scores (MCS) irrespective of IBS symptom status. Differences in the MCS score were most explained by depression, while those in the physical component score were most explained by anxiety. Conclusions Irritable bowel syndrome symptoms in female veterans are associated with considerable reduction in HRQOL. However, female veterans, regardless of IBS symptom status, have lower HRQOL compared with the general US female population. Aliment Pharmacol Ther 31, 261-273. C1 [Graham, D. P.; White, D.; El-Serag, H. B.] Michael E DeBakey Dept Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Hlth Serv Res & Dev Serv, Houston, TX USA. [Graham, D. P.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA. [Savas, L.] Baylor Coll Med, Sect Hlth Serv Res, Houston, TX 77030 USA. [Savas, L.] Baylor Coll Med, Dept Family & Community Med, Houston, TX 77030 USA. [White, D.; El-Serag, H. B.] Michael E DeBakey Dept Vet Affairs Med Ctr, Gastroenterol Sect, Houston, TX USA. [White, D.; El-Serag, H. B.] Baylor Coll Med, Gastroenterol Sect, Houston, TX 77030 USA. [El-Serag, R.; Laday-Smith, S.] Michael E DeBakey Dept Vet Affairs Med Ctr, Womens Hlth Ctr, Houston, TX USA. [Tan, G.] Baylor Coll Med, Dept Anesthesiol & Phys Med & Rehabil, Houston, TX 77030 USA. RP Graham, DP (reprint author), Houston VA Med Ctr 152, Houston Ctr Qual Care & Utilizat Studies, Houston, TX 77030 USA. EM david.graham@med.va.gov RI Graham, David /J-1158-2014 FU Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service [H-17978]; Novartis pharmaceuticals; Public Health Service [DK56338]; National Institute of Health [K-24 DK078154-03]; National Research Service [5 T32 HP10031-09] FX Disclosure of personal interests: Hashem El-Serag has served as a consultant and an advisory board member for Novartis Pharmaceuticals. None of the authors is an employee, owns stocks or shares, or has patents that constitute a conflict of interest. Hashem B. ElSerag was responsible for the study design. Hashem B. El-Serag and David P. Graham were responsible for the interpretation of results and manuscript. Data analysis was done by David P. Graham. All authors reviewed and revised the manuscript of the paper and approved its final version. All analyses and writing was conducted solely by the listed authors. There are no conflicts of interest. The views expressed in this article are those of the author(s) and do not necessarily represent the views of the Department of Veterans Affairs. Declaration of funding interests: The research reported/outlined here was supported by the Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service (HSR&D, project H-17978). This work was also supported in part by a grant from Novartis pharmaceuticals to Dr El-Serag, and by a Public Health Service Grant DK56338 which funds the Texas Medical Center Digestive Disease Center. Dr El-Serag was supported by National Institute of Health grant K-24 DK078154-03. Dr Savas was supported by the National Research Service Award 5 T32 HP10031-09 funded by the Health Resources and Services. NR 59 TC 8 Z9 8 U1 0 U2 1 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0269-2813 J9 ALIMENT PHARM THER JI Aliment. Pharmacol. Ther. PD JAN 15 PY 2010 VL 31 IS 2 BP 261 EP 273 DI 10.1111/j.1365-2036.2009.04159.x PG 13 WC Gastroenterology & Hepatology; Pharmacology & Pharmacy SC Gastroenterology & Hepatology; Pharmacology & Pharmacy GA 533ZH UT WOS:000272864600011 PM 19814746 ER PT J AU Hage, FG Agel, R Aljaroudi, WL Heo, J Pothineni, K Hansalia, S Lawson, D Dubovsky, E Iskandrian, AE AF Hage, Fadi G. Agel, Raed Aljaroudi, Wad L. Heo, Jaekyeong Pothineni, Koteswara Hansalia, Sachin Lawson, David Dubovsky, Eva Iskandrian, Ami E. TI Correlation Between Serum Cardiac Markers and Myocardial Infarct Size Quantified by Myocardial Perfusion Imaging in Patients With Hypertrophic Cardiomyopathy After Alcohol Septal Ablation SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Article ID BRAIN NATRIURETIC PEPTIDE; PHOTON-EMISSION-TOMOGRAPHY; TROPONIN-T; EJECTION FRACTION; CREATINE-KINASE; TC-99M-SESTAMIBI; REPERFUSION; EXPRESSION; BIOMARKERS; SERIAL AB Myocardial infarct (MI) size is a well-established prognostic marker but the association of serum markers with MI size, as measured by myocardial perfusion imaging (MPI), has not been well studied in patients with hypertrophic cardiomyopathy (NC) after alcohol septal ablation (ASA). Creatine kinase (CK), CK-MB, troponin I, and brain natriuretic peptide were measured before and at multiple points after ASA in patients with HC and were correlated with MI size measured by MPI. MPI at rest was performed in 54 patients with HC at a median of 2 days after ASA. CK, CK-MB, and troponin I increased after ASA to peak levels at 12 hours and their cumulative levels (area under the curve) showed significant correlation with size of MI by MPI (r = 0.544, 0.408, and 0.477, p <0.001, 0.003, and 0.001, respectively). The best marker was level of CK at 12 hours (r = 0.609, p <0.0001) after ASA. Brain natriuretic peptide level did not change significantly after ASA (p = 1.0) and only weakly correlated with MI size by MPI (r = 0.130, p = 0.007). In conclusion, CK, CK-MB, and troponin I measured at 12 hours, at peak, and as the area under the curve correlated well with infarct size, but CK level at 12 hours was the best marker. CK continues to be a useful marker of MI size despite the introduction of newer, more specific markers, especially when infarct onset is known with certainty as in patients with HC undergoing ASA. (C) 2010 Elsevier Inc. All rights reserved. (Am J Cardiol 2010;105:261-266) C1 [Hage, Fadi G.; Agel, Raed; Aljaroudi, Wad L.; Heo, Jaekyeong; Pothineni, Koteswara; Hansalia, Sachin; Lawson, David; Dubovsky, Eva; Iskandrian, Ami E.] Univ Alabama, Div Cardiovasc Dis, Birmingham, AL 35294 USA. [Hage, Fadi G.; Agel, Raed] Birmingham Vet Affairs Med Ctr, Div Cardiol, Birmingham, AL USA. RP Hage, FG (reprint author), Univ Alabama, Div Cardiovasc Dis, Birmingham, AL 35294 USA. EM fadihage@uab.edu OI Hage, Fadi/0000-0002-1397-4942 NR 25 TC 7 Z9 8 U1 0 U2 1 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9149 J9 AM J CARDIOL JI Am. J. Cardiol. PD JAN 15 PY 2010 VL 105 IS 2 BP 261 EP 266 DI 10.1016/j.amjcard.2009.08.680 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 602JW UT WOS:000278136400023 PM 20102929 ER PT J AU Nahas, Z Anderson, BS Borckardt, J Arana, AB George, MS Reeves, ST Takacs, I AF Nahas, Ziad Anderson, Berry S. Borckardt, Jeff Arana, Ashley B. George, Mark S. Reeves, Scott T. Takacs, Istvan TI Bilateral Epidural Prefrontal Cortical Stimulation for Treatment-Resistant Depression SO BIOLOGICAL PSYCHIATRY LA English DT Article DE Anterior poles; brain stimulation; cingulate; depression; epidural cortical stimulation; frontal lobes; medial prefrontal cortex ID VAGUS NERVE-STIMULATION; DEEP BRAIN-STIMULATION; TRANSCRANIAL MAGNETIC STIMULATION; MOTOR CORTEX STIMULATION; MAJOR DEPRESSION; NEUROPATHIC PAIN; RATING-SCALE; OUTCOMES; BURDEN; VNS AB Background: Treatment-resistant depression presents a serious challenge to both patients and clinicians. The anterior and midlateral prefrontal cortices play complementary roles in integrating emotional and cognitive experiences and in modulating subcortical regions. Both regions offer a distinct opportunity for targeted antidepressant treatments. We chose to pilot the safety and therapeutic benefits of chronic and intermittent epidural prefrontal cortical stimulation (EpCS) in patients with treatment-resistant depression. Methods: We enrolled five adults with an average of 5.8 failed antidepressant treatments in their current depressive episode. All subjects underwent comprehensive clinical assessments, detailed neuropsychological testing, and presurgical magnetic resonance imaging. Four cortical stimulation paddle leads were stereotactically placed bilaterally over the anterior frontal poles and midlateral prefrontal cortex. We also acquired a postsurgical computed tomography scan and repeatedly assessed clinical outcomes over time of EpCS as an adjunctive treatment to constant medications. Results: All patients tolerated the therapy. At 7-month follow-up, the average improvement from preimplant baseline on the Hamilton Rating Scale for Depression and the Inventory of Depressive Symptoms-Self-Report were 54.9% (+/- 37.7) and 60.1% (+/- 34.1), respectively. Three implanted subjects reached remission. One patient's left hemisphere leads were explanted 12 weeks postsurgery because of a scalp infection. Conclusions: Bilateral EpCS over anterior and mid lateral frontal cortex is a promising new technology for treatment-resistant depression. Future double-blind studies are warranted. C1 [Nahas, Ziad; Anderson, Berry S.; Borckardt, Jeff; Arana, Ashley B.; George, Mark S.] Med Univ S Carolina, Dept Psychiat, Mood Disorders Program & Brain Stimulat Lab, Charleston, SC 29425 USA. [Nahas, Ziad; George, Mark S.; Takacs, Istvan] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA. [Borckardt, Jeff; Reeves, Scott T.] Med Univ S Carolina, Dept Anesthesia & Perioperat Med, Charleston, SC 29425 USA. [George, Mark S.] Med Univ S Carolina, Dept Radiol, Charleston, SC 29425 USA. [Takacs, Istvan] Med Univ S Carolina, Dept Neurosurg, Charleston, SC 29425 USA. [George, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Nahas, Z (reprint author), Inst Psychiat, 67 President St, Charleston, SC 29425 USA. EM nahasz@musc.edu FU National Alliance of Research for Depression and Schizophrenia (NARSAD) Independent Investigator Award; Mood Disorders Program; The Brain Stimulation Laboratory; General Clinical Research Center; Center for Advanced Imaging Research at the Medical University of South Carolina; Medtronic, Inc.; The National Institute of Mental Health (NIMH); National Alliance Research for Schizophrenia and Depression; Hope for Depression Research, Neuronetics, Inc.; Cyberonics, Inc.; GlaxoSmithKline; Jazz Pharmaceuticals; National Institute on Drug Abuse; National Institute of Neurological Disorders and Stroke; Ralph H. Johnson VA Medical Center FX This study was funded primarily by a National Alliance of Research for Depression and Schizophrenia (NARSAD) Independent Investigator Award to ZN. It was also made possible with general funds from the Mood Disorders Program, The Brain Stimulation Laboratory, the General Clinical Research Center, the Center for Advanced Imaging Research at the Medical University of South Carolina, Medtronic, Inc. (Minneapolis, MN donated the devices, but was otherwise not involved in the study particularly data acquisition, analysis, or drafting the article. We thank Mark Rise (Medtronic, Inc.) for technical assistance ill stimulation setups and Sarah Coker (now a postgraduate year I psychiatry resident at Medical University of South Carolina [MUSC]) for assistance in, The accuracy, of lead placement analysis I. S.; Dr. Nahas reports having received consulting fees from Neuronetics, Inc. and Cyberonics, Inc.; research funding from the The National Institute of Mental Health (NIMH), National Alliance Research for Schizophrenia and Depression, Hope for Depression Research, Neuronetics, Inc., Cyberonics, Inc., Medtronic, Inc. (in the form of device donations for this study), Brainsway, and Integra. Dr. George reports research funding from GlaxoSmithKline, Jazz Pharmaceuticals, NIMH, National Institute on Drug Abuse, National Institute of Neurological Disorders and Stroke. and the Ralph H. Johnson VA Medical Center. Dr. George reported consulting for , Bristol-Meyers-Squibb, DarPharma, , Jazz Pharmaceuticals, Parke Davis, Aspect Medical, Brainsway (unpaid) , Cephos (unpaid), Cyberonics, Inc., Dantex, MediPhysics/Amersham, Neuronetics, Inc. (unpaid), and Neuropace. Dr. George also reported that The Medical University of South Carolina has filed eight patents or invention disclosures under his name regarding brain imaging and brain stimulation. Dr, Borckardt receives The National Institute for Neurological Disorders and Stroke and The National Institute of Nursing Research at the National Institutes Health, Cyberonics, Inc., and the Neurosciences Institute at MUSC. Dr. Borckardt is a consultant for Neuropace. Dr. Reeves, Dr. Tackacs, Mr. Anderson, and Ms. Arana reported no biomedical financial interests or potential conflicts of interest. NR 59 TC 42 Z9 43 U1 2 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD JAN 15 PY 2010 VL 67 IS 2 BP 101 EP 109 DI 10.1016/j.biopsych.2009.08.021 PG 9 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 538RN UT WOS:000273201800003 PM 19819427 ER PT J AU Pantuck, AJ An, JB Liu, HR Rettig, MB AF Pantuck, Allan J. An, Jiabin Liu, Huiren Rettig, Matthew B. TI NF-kappa-Dependent Plasticity of the Epithelial to Mesenchymal Transition Induced by Von Hippel-Lindau Inactivation in Renal Cell Carcinomas SO CANCER RESEARCH LA English DT Article ID HYPOXIA-INDUCIBLE FACTOR; TUMOR-SUPPRESSOR GENE; E-CADHERIN; B ACTIVATION; CANCER; VHL; TRANSCRIPTION; EXPRESSION; PROTEIN; HIF-1-ALPHA AB The critical downstream signaling consequences contributing to renal cancer as a result of loss of the tumor suppressor gene von Hippel-Lindau (VHL) have yet to be fully elucidated. Here, we report that VHL loss results in an epithelial to mesenchymal transition (EMT). In studies of paired isogenic cell lines, VHL silencing increased the levels of N-cadherin and vimentin and reduced the levels of E-cadherin relative to the parental VHL(+) cell line, which displayed the opposite profile. VHL(+) cells grew as clusters of cuboidal and rhomboid cells, whereas VHL-silenced cells took on an elongated, fibroblastoid morphology associated with a more highly invasive character in Matrigel chamber assays. Based on earlier evidence that VHL loss can activate NF-kappa B, a known mediator of EMT, we tested whether NF-kappa B contributed to VHL-mediated effects on EMT. On pharmacologic or molecular inhibition of NF-kappa B, VHL-silenced cells regained expression of E-cadherin, lost expression of N-cadherin, and reversed their highly invasive phenotype. Introducing a pVHL-resistant hypoxia-inducible factor 1 alpha (HIF1 alpha) mutant (HIF alpha(M)) into VHL(+) cells heightened NF-kappa B activity, phenocopying EMT effects produced by VHL silencing. Conversely, inhibiting the heightened NF-kappa B activity in this setting reversed the EMT phenotype. Taken together, these results suggest that VHL loss induces an EMT that is largely dependent on HIF alpha-induced NF-kappa B. Our findings rationalize targeting the NF-kappa B pathway as a therapeutic strategy to treat renal tumors characterized by biallelic VHL inactivation. Cancer Res; 70(2); 752-61. (C)2010 AACR. C1 [Pantuck, Allan J.; Rettig, Matthew B.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90095 USA. [Rettig, Matthew B.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [An, Jiabin; Liu, Huiren; Rettig, Matthew B.] Vet Affairs Greater Los Angeles Healthcare Syst W, Dept Med, Los Angeles, CA USA. RP Rettig, MB (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Box 951738, Los Angeles, CA 90095 USA. EM mrettig@mednet.ucla.edu FU Department of Veterans Affairs; Pom Wonderful FX Grant Support; Department of Veterans Affairs Merit Review Program (M. B. Rettig) and Pom Wonderful (A.J. Pantuck). NR 31 TC 42 Z9 46 U1 0 U2 4 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 J9 CANCER RES JI Cancer Res. PD JAN 15 PY 2010 VL 70 IS 2 BP 752 EP 761 DI 10.1158/0008-5472.CAN-09-2211 PG 10 WC Oncology SC Oncology GA 607FW UT WOS:000278485500035 PM 20068166 ER PT J AU Ahuja, SK He, WJ AF Ahuja, Sunil K. He, Weijing TI Double-Edged Genetic Swords and Immunity: Lesson from CCR5 and Beyond SO JOURNAL OF INFECTIOUS DISEASES LA English DT Editorial Material ID WEST-NILE-VIRUS; HUMAN-IMMUNODEFICIENCY-VIRUS; CHEMOKINE RECEPTOR CCR5; MACROPHAGE-TROPIC HIV-1; IN-VITRO; MIP-1 ALPHA; VIRAL ENTRY; INFECTION; DENSITY; SUSCEPTIBILITY C1 [Ahuja, Sunil K.; He, Weijing] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Ahuja, Sunil K.; He, Weijing] Univ Texas Hlth Sci Ctr San Antonio, Vet Adm Res Ctr AIDS & HIV Infect 1, S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. RP Ahuja, SK (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, 7703 Floyd Curl Dr,Rm 5-009R, San Antonio, TX 78229 USA. EM ahujas@uthscsa.edu FU NIAID NIH HHS [R37 AI046326]; PHS HHS [R37046326] NR 43 TC 5 Z9 5 U1 0 U2 0 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD JAN 15 PY 2010 VL 201 IS 2 BP 171 EP 174 DI 10.1086/649427 PG 4 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 536NN UT WOS:000273051200001 PM 20025529 ER PT J AU Malik, S Jiang, SM Garee, JP Verdin, E Lee, AV O'Malley, BW Zhang, M Belaguli, NS Oesterreich, S AF Malik, Simeen Jiang, Shiming Garee, Jason P. Verdin, Eric Lee, Adrian V. O'Malley, Bert W. Zhang, Mao Belaguli, Narasimhaswamy S. Oesterreich, Steffi TI Histone Deacetylase 7 and FoxA1 in Estrogen-Mediated Repression of RPRM SO MOLECULAR AND CELLULAR BIOLOGY LA English DT Article ID BREAST-CANCER CELLS; NUCLEAR RECEPTOR COREPRESSOR; GENOME-WIDE ANALYSIS; NF-KAPPA-B; GENE-EXPRESSION; ANDROGEN-RECEPTOR; TRANSCRIPTION FACTORS; RESPONSE ELEMENTS; DOWN-REGULATION; BINDING-SITES AB Activation of estrogen receptor alpha (ER alpha)results in both induction and repression of gene transcription; while mechanistic details of estrogen induction are well described, details of repression remain largely unknown. We characterized several ER alpha-repressed targets and examined in detail the mechanism for estrogen repression of Reprimo (RPRM), a cell cycle inhibitor. Estrogen repression of RPRM is rapid and robust and requires a tripartite interaction between ER alpha, histone deacetylase 7 (HDAC7), and FoxA1. HDAC7 is the critical HDAC needed for repression of RPRM; it can bind to ER alpha and represses ER alpha's transcriptional activity-this repression does not require HDAC7's deacetylase activity. We further show that the chromatin pioneer factor FoxA1, well known for its role in estrogen induction of genes, is recruited to the RPRM promoter, is necessary for repression of RPRM, and interacts with HDAC7. Like other FoxA1 recruitment sites, the RPRM promoter is characterized by H3K4me1/me2. Estrogen treatment causes decreases in H3K4me1/me2 and release of RNA polymerase II (Pol II) from the RPRM proximal promoter. Overall, these data implicate a novel role for HDAC7 and FoxA1 in estrogen repression of RPRM, a mechanism which could potentially be generalized to many more estrogen-repressed genes and hence be important in both normal physiology and pathological processes. C1 [Malik, Simeen; Jiang, Shiming; Garee, Jason P.; Lee, Adrian V.; Oesterreich, Steffi] Baylor Coll Med, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA. [Malik, Simeen; Garee, Jason P.; Lee, Adrian V.; O'Malley, Bert W.; Oesterreich, Steffi] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA. [Lee, Adrian V.; Oesterreich, Steffi] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Verdin, Eric] Univ Calif San Francisco, Dept Med, San Francisco, CA 94158 USA. [Verdin, Eric] Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94158 USA. [Zhang, Mao; Belaguli, Narasimhaswamy S.] Michael E DeBakey Vet Affairs Med Ctr, Michael E DeBakey Dept Surg, Houston, TX 77030 USA. RP Oesterreich, S (reprint author), 1 Baylor Plaza,MS 600, Houston, TX 77030 USA. EM steffio@breastcenter.tmc.edu OI Verdin, Eric/0000-0003-3703-3183 FU Department of Defense Breast Cancer Research Program [BC043880]; NIH [R01 CA097213, P01030195]; SPORE pilot [CA58183]; Nancy Owen Foundation FX This work was supported by a Department of Defense Breast Cancer Research Program grant (BC043880) ( S. Malik), NIH grants R01 CA097213 and P01030195 ( S. Oesterreich), a SPORE pilot grant (CA58183) ( S. Oesterreich), and a Nancy Owen Foundation grant ( S. Oesterreich). NR 73 TC 31 Z9 32 U1 0 U2 8 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0270-7306 J9 MOL CELL BIOL JI Mol. Cell. Biol. PD JAN 15 PY 2010 VL 30 IS 2 BP 399 EP 412 DI 10.1128/MCB.00907-09 PG 14 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 535GL UT WOS:000272955200004 PM 19917725 ER PT J AU Feliers, D Kasinath, BS AF Feliers, Denis Kasinath, Balakuntalam S. TI Mechanism of VEGF expression by high glucose in proximal tubule epithelial cells SO MOLECULAR AND CELLULAR ENDOCRINOLOGY LA English DT Article DE Renin-angiotensin system; VEGF; Glucose; Epithelial cells; Kidney ID ENDOTHELIAL GROWTH-FACTOR; RENIN-ANGIOTENSIN SYSTEM; MESSENGER-RNA TRANSLATION; RAT MESANGIAL CELLS; DIABETIC-NEPHROPATHY; CONVERTING-ENZYME; CARDIAC-HYPERTROPHY; II PRODUCTION; FACTOR-BETA; ACTIVATION AB Angiotensin II (Ang II) and vascular endothelial growth factor (VEGF) are important mediators of kidney injury in diabetes. VEGF expression is increased in proximal tubules of mice with type 1 diabetes. In mouse proximal tubular epithelial cells (MCT) cultured with 30 mM glucose (HG) for 24 h, VEGF expression is increased at the protein and the mRNA level, suggesting a transcriptional mechanism. HG stimulation of VEGF synthesis is prevented by captopril, an inhibitor of angiotensin-converting enzyme, and, by losartan, a specific antagonist of angiotensin type 1 receptor (AT1), suggesting that VEGF synthesis is mediated by Ang II. Synthesis of angiotensinogen (AGT), a precursor of angiotensin II, is increased in MCTs cultured in HG. Although synthesis of renin and ACE is not affected by HG, their activity, is increased in the conditioned medium. Concentrations of Ang I and Ang II are also increased in conditioned medium from HG-treated MCTs and captopril prevents increased Ang II, but not Ang 1, synthesis. Finally, AT1 is activated in MCTs treated with HG, and its activation is prevented by captopril and losartan. The ERK pathway is activated by HG within minutes of stimulation and lasting for up to 24 h. The initial phase of ERK activation is due to HG itself and leads to AGT upregulation and the sustained phase is mediated for the most part by Ang II-activated AT1 receptor and leads to increased VEGF synthesis. These data show that: (1) HG increases AGT synthesis and activation of renin and ACE by MCTs, leading to local production of Ang I and Ang II. (2) Ang II activates endogenous AT1 and stimulates synthesis of VEGF. (3) HG activation of ERK starts within minutes and lasts for up to 24h. Early ERK activation is involved in AGT upregulation and sustained ERK activation, mediated via AT1, is responsible for VEGF synthesis. In conclusion, our study shows that MCTs express an endogenous renin-angiotensin system that is activated by high glucose to stimulate the synthesis of VEGF, through activation of the ERK pathway. (C) 2009 Elsevier Ireland Ltd. All rights reserved. C1 [Feliers, Denis; Kasinath, Balakuntalam S.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med Nephrol, OBrien Kidney Res Ctr, San Antonio, TX 78229 USA. [Kasinath, Balakuntalam S.] S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. RP Feliers, D (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med Nephrol, OBrien Kidney Res Ctr, Mail Code 7882,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM feliers@uthscsa.edu FU American Heart Association [RO1 DK077295]; VA Research Service Merit Review FX This work was supported by grants from the American Heart Association (DF), RO1 DK077295 (BSK), and VA Research Service Merit Review Grant (BSK). We thank Dr. E. Neilson for mouse proximal tubular epithelial cells. NR 69 TC 11 Z9 14 U1 0 U2 2 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0303-7207 J9 MOL CELL ENDOCRINOL JI Mol. Cell. Endocrinol. PD JAN 15 PY 2010 VL 314 IS 1 BP 136 EP 142 DI 10.1016/j.mce.2009.09.009 PG 7 WC Cell Biology; Endocrinology & Metabolism SC Cell Biology; Endocrinology & Metabolism GA 523VC UT WOS:000272101700016 PM 19765632 ER PT J AU Bader, B Walker, RH Vogel, M Prosiegel, M McIntosh, J Danek, A AF Bader, Benedikt Walker, Ruth H. Vogel, Mathias Prosiegel, Mario McIntosh, Jacqueline Danek, Adrian TI Tongue Protrusion and Feeding Dystonia: A Hallmark of Chorea-Acanthocytosis SO MOVEMENT DISORDERS LA English DT Letter C1 [Bader, Benedikt; Danek, Adrian] Univ Munich, Neurol Klin & Poliklin, Munich, Germany. [Walker, Ruth H.] Mt Sinai Sch Med, New York, NY USA. [Walker, Ruth H.] James J Peters Vet Affairs Med Ctr, Dept Neurol, Bronx, NY USA. [Vogel, Mathias] Klinikum Bogenhausen, Clin Neuropsychol, Munich, Germany. [Prosiegel, Mario] Ctr Dysphagia, Fachklin Bad Heilbiunn, Bad Heilbrunn, Germany. [McIntosh, Jacqueline] Wolfson Neurorehabil Ctr, London, England. RP Bader, B (reprint author), Univ Munich, Neurol Klin & Poliklin, Munich, Germany. RI Danek, Adrian/G-7339-2011 OI Danek, Adrian/0000-0001-8857-5383 NR 7 TC 19 Z9 24 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0885-3185 J9 MOVEMENT DISORD JI Mov. Disord. PD JAN 15 PY 2010 VL 25 IS 1 BP 127 EP 129 DI 10.1002/mds.22863 PG 3 WC Clinical Neurology SC Neurosciences & Neurology GA 554HD UT WOS:000274425200024 PM 19938148 ER PT J AU Osawa, R Alexander, BD Lortholary, O Dromer, F Forrest, GN Lyon, GM Somani, J Gupta, KL del Busto, R Pruett, TL Sifri, CD Limaye, AP John, GT Klintmalm, GB Pursell, K Stosor, V Morris, MI Dowdy, LA Munoz, P Kalil, AC Garcia-Diaz, J Orloff, S House, AA Houston, S Wray, D Huprikar, S Johnson, LB Humar, A Razonable, RR Fisher, RA Husain, S Wagener, MM Singh, N AF Osawa, Ryosuke Alexander, Barbara D. Lortholary, Olivier Dromer, Francoise Forrest, Graeme N. Lyon, G. Marshall Somani, Jyoti Gupta, Krishan L. del Busto, Ramon Pruett, Timothy L. Sifri, Costi D. Limaye, Ajit P. John, George T. Klintmalm, Goran B. Pursell, Kenneth Stosor, Valentina Morris, Michele I. Dowdy, Lorraine A. Munoz, Patricia Kalil, Andre C. Garcia-Diaz, Julia Orloff, Susan House, Andrew A. Houston, Sally Wray, Dannah Huprikar, Shirish Johnson, Leonard B. Humar, Atul Razonable, Raymund R. Fisher, Robert A. Husain, Shahid Wagener, Marilyn M. Singh, Nina TI Identifying Predictors of Central Nervous System Disease in Solid Organ Transplant Recipients With Cryptococcosis SO TRANSPLANTATION LA English DT Article DE Cryptococcosis; Solid organ transplant; Central nervous system disease ID HEMATOPOIETIC STEM-CELL; NEOFORMANS INFECTION; PRACTICE GUIDELINES; MENINGITIS; MANAGEMENT AB Background. Cerebrospinal fluid (CSF) analysis is often deferred in patients with cryptococcal disease, particularly in the absence of neurologic manifestations. We sought to determine whether a subset of solid organ transplant (SOT) recipients with high likelihood of central nervous system (CNS) disease could be identified in whom CSF analysis must be performed. Methods. Patients comprised a multicenter cohort of SOT recipients with cryptococcosis. Results. Of 129 (88%) of 146 SOT recipients with cryptococcosis who underwent CSF analysis, 80 (62%) had CNS disease. In the overall study population, abnormal mental status, time to onset of cryptococcosis more than 24 months posttransplantation (late-onset disease), serum cryptococcal antigen titer more than 1:64, and fungemia were independently associated with an increased risk of CNS disease. Of patients with abnormal mental status, 95% had CNS cryptococcosis. When only patients with normal mental status were considered, three predictors (serum antigen titer >1:64, fungemia, and late-onset disease) independently identified patients with CNS cryptococcosis; the risk of CNS disease was 14% if none, 39% if one, and 94% if two of the aforementioned predictors existed (chi(2) for trend P<0.001). Conclusions. CSF analysis should be strongly considered in SOT recipients with cryptococcosis who have late-onset disease, fungemia, or serum cryptococcal antigen titer more than 1:64 even in the presence of normal mental status. C1 [Osawa, Ryosuke; Singh, Nina] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Osawa, Ryosuke; Husain, Shahid; Wagener, Marilyn M.; Singh, Nina] Univ Pittsburgh, Pittsburgh, PA USA. [Alexander, Barbara D.] Duke Univ, Med Ctr, Durham, NC USA. [Lortholary, Olivier] Hop Necker Enfants Malad, Fac Med Paris Descartes, Paris, France. [Lortholary, Olivier; Dromer, Francoise] Inst Pasteur, Paris, France. [Lyon, G. Marshall; Somani, Jyoti] Emory Univ, Atlanta, GA 30322 USA. [Gupta, Krishan L.] Postgrad Inst Med Educ & Res, Chandigarh 160012, Punjab, India. [del Busto, Ramon] Henry Ford Hosp, Detroit, MI 48202 USA. [Pruett, Timothy L.; Sifri, Costi D.] Univ Virginia, Charlottesville, VA USA. [Pruett, Timothy L.; Sifri, Costi D.] Univ Minnesota, Minneapolis, MN USA. [Limaye, Ajit P.] Univ Washington, Seattle, WA 98195 USA. [John, George T.] Christian Med Coll & Hosp, Vellore, Tamil Nadu, India. [Klintmalm, Goran B.] Baylor Univ, Med Ctr, Dallas, TX USA. [Pursell, Kenneth] Univ Chicago, Chicago, IL 60637 USA. [Stosor, Valentina] Northwestern Univ, Chicago, IL 60611 USA. [Morris, Michele I.; Dowdy, Lorraine A.] Univ Miami, Miller Sch Med, Miami, FL 33136 USA. [Munoz, Patricia] Hosp Gen Univ Gregorio Maranon, CIBER Enfermedades Resp CIBERES, Madrid, Spain. [Kalil, Andre C.] Univ Nebraska, Omaha, NE 68182 USA. [Garcia-Diaz, Julia] Ochsner Clin & Alton Ochsner Med Fdn, New Orleans, LA USA. [Orloff, Susan] Oregon Hlth & Sci Univ, Portland, OR USA. [House, Andrew A.] Univ Western Ontario, London, ON, Canada. [Houston, Sally] Tampa Gen Hosp, Tampa, FL 33606 USA. [Wray, Dannah] Med Univ S Carolina, Charleston, SC 29425 USA. [Huprikar, Shirish] Mt Sinai Med Ctr, New York, NY 10029 USA. [Johnson, Leonard B.] St Johns Hosp, Detroit, MI USA. [Humar, Atul] Toronto Gen Hosp, Univ Hlth Network, Toronto, ON, Canada. [Forrest, Graeme N.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA. [Razonable, Raymund R.] Mayo Clin, Rochester, MN USA. [Fisher, Robert A.] Virginia Commonwealth Univ, Richmond, VA USA. RP Singh, N (reprint author), Vet Adm Med Ctr, Infect Dis Sect, Univ Dr C, Pittsburgh, PA 15240 USA. EM nis5@pitt.edu RI Garcia-Diaz, Julia/D-3555-2011 OI Munoz Garcia, Patricia Carmen/0000-0001-5706-5583 FU National Institutes of Health, National Institute of Allergy and Infectious Diseases [R01 AI 054719-01]; Astellas; Enzon; Pfizer; Merck; Basilea; Schering-Plough FX This work was Supported by National Institutes of Health, National Institute of Allergy and infectious Diseases (R01 AI 054719-01; N.S.).; B.D.A. has served on advisory board for Enzon, Basilea, Abbott, and Schering-Plough, served on the speaker's bureau of Astellas and Pfizer, and received grant from Astellas, Enzon, and Pfizer; G.N.F. has received grant from Astellas. G.M.L. has served on advisory board for and received grant front Merck and Astellas and served on speaker's bureau of Astellas, Schering-Plough, and Wyeth; K.P. has served on speaker's bureau of Merck; M.I.M. has served on advisory board for Astellas, Pfizer, and Merck, received grant from Astellas, Basilea, and Pfizer, and served on speaker's bureau of Astellas and Pfizer; P.M. has served on the speaker's bureau of Merck and Novartis and served on advisory board for Pfizer; L.B.J. has served on speaker's bureau of Pfizer; and S. Husain has served on consultant board for and received grant from Pfizer, Astellas, and Schering-Plough; N.S. has received grant from Pfizer; and the other authors have no conflict of interests. NR 22 TC 6 Z9 6 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0041-1337 J9 TRANSPLANTATION JI Transplantation PD JAN 15 PY 2010 VL 89 IS 1 BP 69 EP 74 DI 10.1097/TP.0b013e3181bcda41 PG 6 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA 543DQ UT WOS:000273551000009 PM 20061921 ER PT J AU Kajiwara, Y Franciosi, S Takahashi, N Krug, L Schmeidler, J Taddei, K Haroutunian, V Fried, U Ehrlich, M Martins, RN Gandy, S Buxbaum, JD AF Kajiwara, Yuji Franciosi, Sonia Takahashi, Nagahide Krug, Lisa Schmeidler, James Taddei, Kevin Haroutunian, Vahram Fried, Ulrik Ehrlich, Michelle Martins, Ralph N. Gandy, Samuel Buxbaum, Joseph D. TI Extensive proteomic screening identifies the obesity-related NYGGF4 protein as a novel LRP1-interactor, showing reduced expression in early Alzheimer's disease SO MOLECULAR NEURODEGENERATION LA English DT Article ID RECEPTOR-RELATED PROTEIN; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN-E RECEPTOR; ISOFORM-SPECIFIC MANNER; CYTOPLASMIC DOMAIN; E GENE; LIPOPROTEIN; LRP; BINDING; MICE AB Background: The low-density lipoprotein receptor related protein 1 (LRP1) has been implicated in Alzheimer's disease (AD) but its signalling has not been fully evaluated. There is good evidence that the cytoplasmic domain of LRP1 is involved in protein-protein interactions, important in the cell biology of LRP1. Results: We carried out three yeast two-hybrid screens to identify proteins that interact with the cytoplasmic domain of LRP1. The screens included both conventional screens as well as a novel, split-ubiquitin-based screen in which an LRP1 construct was expressed and screened as a transmembrane protein. The split-ubiquitin screen was validated in a screen using full-length amyloid protein precursor (APP), which successfully identified FE65 and FE65L2, as well as novel interactors (Rab3a, Napg, and ubiquitin b). Using both a conventional screen as well as the split-ubiquitin screen, we identified NYGGF4 as a novel LRP1 interactor. The interaction between LRP1 and NYGGF4 was validated using two-hybrid assays, coprecipitation and colocalization in mammalian cells. Mutation analysis demonstrated a specific interaction of NYGGF4 with an NPXY motif that required an intact tyrosine residue. Interestingly, while we confirmed that other LRP1 interactors we identified, including JIP1B and EB-1, were also able to bind to APP, NYGGF4 was unique in that it showed specific binding with LRP1. Expression of NYGGF4 decreased significantly in patients with AD as compared to age-matched controls, and showed decreasing expression with AD disease progression. Examination of Nyggf4 expression in mice with different alleles of the human APOE4 gene showed significant differences in Nyggf4 expression. Conclusions: These results implicate NYGGF4 as a novel and specific interactor of LRP1. Decreased expression of LRP1 and NYGGF4 over disease, evident with the presence of even moderate numbers of neuritic plaques, suggests that LRP1-NYGGF4 is a system altered early in disease. Genetic and functional studies have implicated both LRP1 and NYGGF4 in obesity and cardiovascular disease and the physical association of these proteins may reflect a common mechanism. This is particularly interesting in light of the dual role of ApoE in both cardiovascular risk and AD. The results support further studies on the functional relationship between NYGGF4 and LRP1. C1 [Kajiwara, Yuji; Franciosi, Sonia; Takahashi, Nagahide; Krug, Lisa; Fried, Ulrik; Buxbaum, Joseph D.] Mt Sinai Sch Med, Lab Mol Neuropsychiat, New York, NY 10029 USA. [Kajiwara, Yuji; Franciosi, Sonia; Takahashi, Nagahide; Krug, Lisa; Schmeidler, James; Haroutunian, Vahram; Fried, Ulrik; Gandy, Samuel; Buxbaum, Joseph D.] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. [Kajiwara, Yuji; Buxbaum, Joseph D.] Mt Sinai Sch Med, Dept Neurosci, New York, NY 10029 USA. [Taddei, Kevin; Martins, Ralph N.] Edith Cowan Univ, Sch Exercise Biomed & Hlth Sci, Ctr Excellence Alzheimers Dis Res Care, Joondalup, WA, Australia. [Taddei, Kevin] Hollywood Private Hosp, Sir James McCusker Alzheimers Dis Res Unit, Perth, WA, Australia. [Haroutunian, Vahram] James J Peters Vet Affairs Med Ctr, Bronx, NY 10468 USA. [Ehrlich, Michelle; Gandy, Samuel] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA. [Buxbaum, Joseph D.] Mt Sinai Sch Med, Dept Genet & Genom Sci, New York, NY 10029 USA. RP Buxbaum, JD (reprint author), Mt Sinai Sch Med, Lab Mol Neuropsychiat, 1 Gustave L Levy Pl, New York, NY 10029 USA. EM joseph.buxbaum@mssm.edu OI Buxbaum, Joseph/0000-0001-8898-8313 FU National Institute of Aging of the National Institutes of Health [AG010491, AG005138, AG002219, AG21792] FX A part of this work was carried out at the Marine Biological Laboratory, Woods Hole, MA. We thank Dr. Guojun Bu for the mLRP4 construct, Dr. Eddie Koo for anti-LRP1, and Rebecca Vitale for her help with this study. This work was supported by grants from the National Institute of Aging of the National Institutes of Health [AG010491 (SEG, PI; JDB, PL), AG005138 (Mary Sano, PI; JDB, PL), AG002219 (VH, PI; JDB, PL), and AG21792 (JDB, PI)]. JDB is the G. Harold and Leila Y. Mathers Professor of Geriatrics and Adult Development. NR 51 TC 8 Z9 9 U1 0 U2 7 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1750-1326 J9 MOL NEURODEGENER JI Mol. Neurodegener. PD JAN 14 PY 2010 VL 5 AR 1 DI 10.1186/1750-1326-5-1 PG 11 WC Neurosciences SC Neurosciences & Neurology GA 559QA UT WOS:000274839800001 PM 20205790 ER PT J AU VanCott, AC Cramer, JA Copeland, LA Zeber, JE Steinman, MA Dersh, JJ Glickman, ME Mortensen, EM Amuan, ME Pugh, MJ AF VanCott, Anne C. Cramer, Joyce A. Copeland, Laurel A. Zeber, John E. Steinman, Michael A. Dersh, Jeffrey J. Glickman, Mark E. Mortensen, Eric M. Amuan, Megan E. Pugh, Mary Jo TI Suicide-related behaviors in older patients with new anti-epileptic drug use: data from the VA hospital system SO BMC MEDICINE LA English DT Article ID LEVETIRACETAM THERAPY; CLINICAL-TRIALS; RISK-FACTORS; FOLLOW-UP; EPILEPSY; DEPRESSION; VETERANS; AGE; DISORDERS; DEMENTIA AB Background: The U. S. Food and Drug Administration (FDA) recently linked antiepileptic drug (AED) exposure to suicide-related behaviors based on meta-analysis of randomized clinical trials. We examined the relationship between suicide-related behaviors and different AEDs in older veterans receiving new AED monotherapy from the Veterans Health Administration (VA), controlling for potential confounders. Methods: VA and Medicare databases were used to identify veterans 66 years and older, who received a) care from the VA between 1999 and 2004, and b) an incident AED ( monotherapy) prescription. Previously validated ICD-9-CM codes were used to identify suicidal ideation or behavior (suicide-related behaviors cases), epilepsy, and other conditions previously associated with suicide-related behaviors. Each case was matched to controls based on prior history of suicide-related behaviors, year of AED prescription, and epilepsy status. Results: The strongest predictor of suicide-related behaviors (N = 64; Controls N = 768) based on conditional logistic regression analysis was affective disorder ( depression, anxiety, or post-traumatic stress disorder (PTSD); Odds Ratio 4.42, 95% CI 2.30 to 8.49) diagnosed before AED treatment. Increased suicide-related behaviors were not associated with individual AEDs, including the most commonly prescribed AED in the US - phenytoin. Conclusion: Our extensive diagnostic and treatment data demonstrated that the strongest predictor of suicide-related behaviors for older patients newly treated with AED monotherapy was a previous diagnosis of affective disorder. Additional, research using a larger sample is needed to clearly determine the risk of suicide-related behaviors among less commonly used AEDs. C1 [VanCott, Anne C.] VA Pittsburgh Healthcare Syst, Div Neurol, Pittsburgh, PA USA. [VanCott, Anne C.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA. [Cramer, Joyce A.] Yale Univ, Dept Psychiat, New Haven, CT 06520 USA. [Cramer, Joyce A.] Epilepsy Therapy Project, Orange, CT USA. [Copeland, Laurel A.; Zeber, John E.; Dersh, Jeffrey J.; Mortensen, Eric M.; Pugh, Mary Jo] S Texas Vet Hlth Care Syst VERDICT, Vet Affairs HSR&D, San Antonio, TX USA. [Copeland, Laurel A.; Zeber, John E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Steinman, Michael A.] San Francisco VA Med Ctr, San Francisco, CA USA. [Steinman, Michael A.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. [Glickman, Mark E.; Amuan, Megan E.] Edith Nourse Rogers Mem Hosp, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA. [Glickman, Mark E.] Boston Univ, Sch Publ Hlth, Boston, MA USA. [Pugh, Mary Jo] Univ Texas Hlth Sci Ctr San Antonio, Dept Gen Med, San Antonio, TX 78229 USA. RP VanCott, AC (reprint author), VA Pittsburgh Healthcare Syst, Div Neurol, Pittsburgh, PA USA. EM Anne.VanCott@va.gov OI Glickman, Mark/0000-0003-3993-2801; Pugh, Mary Jo/0000-0003-4196-7763; Mortensen, Eric/0000-0002-3880-5563; Copeland, Laurel/0000-0002-9478-0209 FU Department of Veterans Affairs, Health Services Research and Development Service [IIR-02-274]; VA Health Services Research and Development Service Merit Review Entry [MRP-05-145]; South Texas Veterans Healthcare System/Audie L. Murphy Division; VERDICT FX This study was funded by the Department of Veterans Affairs, Health Services Research and Development Service (IIR-02-274). Dr. Copeland received funding from VA Health Services Research and Development Service Merit Review Entry Program Award (MRP-05-145). The authors acknowledge and appreciate support from the South Texas Veterans Healthcare System/Audie L. Murphy Division and the VERDICT research program. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. We thank Alan Ettinger, MD for reviewing and providing comments regarding this manuscript. We also acknowledge contributions of other members of the TIGER research team: Dan R. Berlowitz MD, MPH, Janice E. Knoefel MD, Jeffrey Tabares BA, Francesca Cunningham PharmD, Omotola Hope MD, Nancy Kressin PhD, Barbara Bokhour PhD, and Marcos Restrepo MD. NR 31 TC 40 Z9 41 U1 3 U2 7 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1741-7015 J9 BMC MED JI BMC Med. PD JAN 11 PY 2010 VL 8 AR 4 DI 10.1186/1741-7015-8-4 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 557OG UT WOS:000274678200001 PM 20064226 ER PT J AU Darouiche, RO Wall, MJ Itani, KMF Otterson, MF Webb, AL Carrick, MM Miller, HJ Awad, SS Crosby, CT Mosier, MC AlSharif, A Berger, DH AF Darouiche, Rabih O. Wall, Matthew J., Jr. Itani, Kamal M. F. Otterson, Mary F. Webb, Alexandra L. Carrick, Matthew M. Miller, Harold J. Awad, Samir S. Crosby, Cynthia T. Mosier, Michael C. AlSharif, Atef Berger, David H. TI Chlorhexidine-Alcohol versus Povidone-Iodine for Surgical-Site Antisepsis SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID ELECTIVE COLORECTAL SURGERY; SUPPLEMENTAL PERIOPERATIVE OXYGEN; WOUND-INFECTION; ANTIMICROBIAL PROPHYLAXIS; PREVENTION; TRIAL; CEFOTETAN; HOSPITALIZATION; ANTIBIOTICS; MULTICENTER AB BACKGROUND Since the patient's skin is a major source of pathogens that cause surgical-site infection, optimization of preoperative skin antisepsis may decrease postoperative infections. We hypothesized that preoperative skin cleansing with chlorhexidine-alcohol is more protective against infection than is povidone-iodine. METHODS We randomly assigned adults undergoing clean-contaminated surgery in six hospitals to preoperative skin preparation with either chlorhexidine-alcohol scrub or povidone-iodine scrub and paint. The primary outcome was any surgical-site infection within 30 days after surgery. Secondary outcomes included individual types of surgical-site infections. RESULTS A total of 849 subjects (409 in the chlorhexidine-alcohol group and 440 in the povidone-iodine group) qualified for the intention-to-treat analysis. The overall rate of surgical-site infection was significantly lower in the chlorhexidine-alcohol group than in the povidone-iodine group (9.5% vs. 16.1%; P = 0.004; relative risk, 0.59; 95% confidence interval, 0.41 to 0.85). Chlorhexidine-alcohol was significantly more protective than povidone-iodine against both superficial incisional infections (4.2% vs. 8.6%, P = 0.008) and deep incisional infections (1% vs. 3%, P = 0.05) but not against organ-space infections (4.4% vs. 4.5%). Similar results were observed in the per-protocol analysis of the 813 patients who remained in the study during the 30-day follow-up period. Adverse events were similar in the two study groups. CONCLUSIONS Preoperative cleansing of the patient's skin with chlorhexidine-alcohol is superior to cleansing with povidone-iodine for preventing surgical-site infection after clean-contaminated surgery. (ClinicalTrials.gov number, NCT00290290.) C1 [Darouiche, Rabih O.] Baylor Coll Med, Ctr Prostheses Infect, Houston, TX 77030 USA. [Darouiche, Rabih O.; Awad, Samir S.; AlSharif, Atef; Berger, David H.] Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. [Wall, Matthew J., Jr.; Carrick, Matthew M.; Miller, Harold J.] Ben Taub Gen Hosp, Houston, TX 77030 USA. [Itani, Kamal M. F.] Vet Affairs Boston Healthcare Syst, Boston, MA USA. [Itani, Kamal M. F.] Boston Univ, Sch Med, Boston, MA 02118 USA. [Otterson, Mary F.] Vet Affairs Med Ctr, Milwaukee, WI USA. [Otterson, Mary F.] Med Coll Wisconsin, Milwaukee, WI 53226 USA. [Webb, Alexandra L.] Vet Affairs Med Ctr, Atlanta, GA 30033 USA. [Crosby, Cynthia T.] Cardinal Hlth, Leawood, KS USA. [Mosier, Michael C.] Washburn Univ, Topeka, KS 66621 USA. RP Darouiche, RO (reprint author), Baylor Coll Med, Ctr Prostheses Infect, 1333 Moursund Ave,Suite A221, Houston, TX 77030 USA. EM rdarouiche@aol.com NR 27 TC 421 Z9 435 U1 0 U2 46 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD JAN 7 PY 2010 VL 362 IS 1 BP 18 EP 26 DI 10.1056/NEJMoa0810988 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA 540PA UT WOS:000273345500005 PM 20054046 ER PT J AU Zuckerbraun, BS Shiva, S Ifedigbo, E Mathier, MA Mollen, KP Rao, J Bauer, PM Choi, JJW Curtis, E Choi, AMK Gladwin, MT AF Zuckerbraun, Brian S. Shiva, Sruti Ifedigbo, Emeka Mathier, Michael A. Mollen, Kevin P. Rao, Jayashree Bauer, Philip M. Choi, Justin J. W. Curtis, Erin Choi, Augustine M. K. Gladwin, Mark T. TI Nitrite Potently Inhibits Hypoxic and Inflammatory Pulmonary Arterial Hypertension and Smooth Muscle Proliferation via Xanthine Oxidoreductase-Dependent Nitric Oxide Generation SO CIRCULATION LA English DT Article DE hypoxia; nitric oxide; monocrotaline sodium; pulmonary artery smooth muscle cells; xanthine oxidoreductase ID ACTIVATED-PROTEIN-KINASE; L-ARGININE; CELL-PROLIFERATION; ISCHEMIA/REPERFUSION INJURY; ISCHEMIA-REPERFUSION; EXERCISE CAPACITY; ORGANIC NITRATES; IN-VIVO; EXPRESSION; SYNTHASE AB Background-Pulmonary arterial hypertension is a progressive proliferative vasculopathy of the small pulmonary arteries that is characterized by a primary failure of the endothelial nitric oxide and prostacyclin vasodilator pathways, coupled with dysregulated cellular proliferation. We have recently discovered that the endogenous anion salt nitrite is converted to nitric oxide in the setting of physiological and pathological hypoxia. Considering the fact that nitric oxide exhibits vasoprotective properties, we examined the effects of nitrite on experimental pulmonary arterial hypertension. Methods and Results-We exposed mice and rats with hypoxia or monocrotaline-induced pulmonary arterial hypertension to low doses of nebulized nitrite (1.5 mg/min) 1 or 3 times a week. This dose minimally increased plasma and lung nitrite levels yet completely prevented or reversed pulmonary arterial hypertension and pathological right ventricular hypertrophy and failure. In vitro and in vivo studies revealed that nitrite in the lung was metabolized directly to nitric oxide in a process significantly enhanced under hypoxia and found to be dependent on the enzymatic action of xanthine oxidoreductase. Additionally, physiological levels of nitrite inhibited hypoxia-induced proliferation of cultured pulmonary artery smooth muscle cells via the nitric oxide-dependent induction of the cyclin-dependent kinase inhibitor p21Waf1/Cip1. The therapeutic effect of nitrite on hypoxia-induced pulmonary hypertension was significantly reduced in the p21-knockout mouse; however, nitrite still reduced pressures and right ventricular pathological remodeling, indicating the existence of p21-independent effects as well. Conclusion-These studies reveal a potent effect of inhaled nitrite that limits pathological pulmonary arterial hypertrophy and cellular proliferation in the setting of experimental pulmonary arterial hypertension. (Circulation. 2010; 121: 98-109.) C1 [Ifedigbo, Emeka; Choi, Augustine M. K.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. [Zuckerbraun, Brian S.; Mollen, Kevin P.; Rao, Jayashree; Bauer, Philip M.] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA USA. [Shiva, Sruti] Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Pittsburgh, PA USA. [Ifedigbo, Emeka; Choi, Justin J. W.; Choi, Augustine M. K.; Gladwin, Mark T.] Univ Pittsburgh, Sch Med, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA USA. [Mathier, Michael A.] Univ Pittsburgh, Sch Med, Div Cardiol, Pittsburgh, PA USA. [Zuckerbraun, Brian S.] VA Pittsburgh Hlth Care Syst, Pittsburgh, PA USA. [Shiva, Sruti; Choi, Justin J. W.; Curtis, Erin; Gladwin, Mark T.] NHLBI, Pulm & Vasc Med Branch, NIH, Bethesda, MD 20892 USA. RP Choi, AMK (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, 75 Francis St, Boston, MA 02115 USA. EM amchoi@rics.bwh.harvard.edu; gladwinmt@upmc.edu FU American Heart Association [0535203N] FX This work was supported by the American Heart Association, Scientist Development Grant 0535203N (B.S.Z.). NR 49 TC 99 Z9 104 U1 0 U2 13 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD JAN 5 PY 2010 VL 121 IS 1 BP 98 EP 109 DI 10.1161/CIRCULATIONAHA.109.891077 PG 12 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 539PH UT WOS:000273267700014 PM 20026772 ER PT J AU Mendez, MF AF Mendez, Mario F. TI What progressive aphasia says about its neuropathology SO NEUROLOGY LA English DT Editorial Material ID FRONTOTEMPORAL LOBAR DEGENERATION; PATHOLOGY; ALZHEIMER; VARIANTS; PATTERNS; DISEASE C1 [Mendez, Mario F.] Univ Calif Los Angeles, David Geffen Sch Med, Neurobehav Unit, VA Greater Los Angeles Healthcare Syst & Neurol &, Los Angeles, CA 90095 USA. RP Mendez, MF (reprint author), VA Greater Los Angeles Healthcare, Neurobehav Unit, 116AF,Bldg 500,3S,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM mmendez@ucla.edu FU NIA NIH HHS [R01 AG034499] NR 10 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD JAN 5 PY 2010 VL 74 IS 1 BP 16 EP 17 DI 10.1212/WNL.0b013e3181c719b3 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA 537GE UT WOS:000273100400003 PM 19940268 ER PT S AU Hayes, TL Riley, T Pavel, M Kaye, JA AF Hayes, Tamara L. Riley, Thomas Pavel, Misha Kaye, Jeffrey A. GP IEEE TI Estimation of Rest-Activity Patterns using Motion Sensors SO 2010 ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY (EMBC) SE IEEE Engineering in Medicine and Biology Society Conference Proceedings LA English DT Proceedings Paper CT 32nd Annual International Conference of the IEEE Engineering-in-Medicine-and-Biology-Society (EMBC 10) CY AUG 30-SEP 04, 2010 CL Buenos Aires, ARGENTINA SP IEEE Engn Med & Biol Soc (EMBS) ID SLEEP; ACTIGRAPHY; BED AB Disrupted sleep patterns are a significant problem in the elderly, leading to increased cognitive dysfunction and risk of nursing home placement. A cost-effective and unobtrusive way to remotely monitor changing sleep patterns over time would enable improved management of this important health problem. We have developed an algorithm to derive sleep parameters such as bed time, rise time, sleep latency, and nap time from passive infrared sensors distributed around the home. We evaluated this algorithm using 404 days of data collected in the homes of 8 elderly community-dwelling elders. Data from this algorithm were highly correlated to ground truth measures (bed mats) and were surprisingly robust to variability in sensor layout and sleep habits. C1 [Hayes, Tamara L.; Riley, Thomas] Oregon Hlth & Sci Univ OHSU, Biomed Engn Dept BME, 3303 SW Bond Ave, Portland, OR 97239 USA. [Kaye, Jeffrey A.] ORCATECH, OHSU, Dept Neurol, Portland, OR 97239 USA. [Kaye, Jeffrey A.] Portland VA Med Ctr, Portland, OR 97239 USA. [Pavel, Misha] ORCATECH OHSU, BME Dept, Portland, OR 97239 USA. RP Hayes, TL (reprint author), Oregon Hlth & Sci Univ OHSU, Biomed Engn Dept BME, 3303 SW Bond Ave, Portland, OR 97239 USA. EM hayest@bme.ogi.edu; rileyt@bme.ogi.edu; pavel@bme.ogi.edu; kaye@ohsu.edu OI Kaye, Jeffrey/0000-0002-9971-3478 FU Intel Corporation; NIH [P30 AG024978] FX This study was funded by Intel Corporation and by NIH grant P30 AG024978. Dr. Hayes has a significant financial interest in Intel Corporation, a company that may have a commercial interest in the results of this research and technology. This potential conflict has been reviewed and managed by OHSU. NR 9 TC 7 Z9 7 U1 0 U2 0 PU IEEE PI NEW YORK PA 345 E 47TH ST, NEW YORK, NY 10017 USA SN 1557-170X BN 978-1-4244-4124-2 J9 IEEE ENG MED BIO PY 2010 BP 2147 EP 2150 DI 10.1109/IEMBS.2010.5628022 PG 4 WC Engineering, Biomedical; Engineering, Electrical & Electronic SC Engineering GA BTS36 UT WOS:000287964002136 ER PT S AU Sundara-Rajan, K Bestick, A Rowe, GI Klute, GK Ledoux, WR Mamishev, AV AF Sundara-Rajan, Kishore Bestick, Aaron Rowe, Gabriel I. Klute, Glenn K. Ledoux, William R. Mamishev, Alexander V. GP IEEE TI Capacitive Sensing of Interfacial Stresses SO 2010 IEEE SENSORS SE IEEE Sensors LA English DT Proceedings Paper CT 2010 IEEE Sensors Conference CY NOV 01-04, 2010 CL Kona, HI SP IEEE ID PROSTHETIC SOCKET INTERFACE; TIBIAL AMPUTEE SUBJECTS; SHEAR STRESSES; PRESSURES; SUCTION AB Studying interfacial stresses is an important step towards understanding load distributions in mechanical, biomedical, and industrial systems. This paper presents a capacitive sensor that is capable of simultaneously measuring compressive and shear stresses. The sensor consists of two electrode layers separated by a set of flexible and compressible polymer pillars. The sensor's response to compressive and shear stresses was tested and characterized up to 320 kPa and 70 kPa respectively. An algorithm to estimate the applied stresses based on sensor output was developed and validated. The applied compressive stresses were estimated with an accuracy of 95.04 % and shear stress with an accuracy of 89.45 %. C1 [Sundara-Rajan, Kishore; Bestick, Aaron; Rowe, Gabriel I.; Mamishev, Alexander V.] Univ Washington, Dept Elect Engn, Sensors Energy & Automat Lab, Seattle, WA 98195 USA. [Klute, Glenn K.; Ledoux, William R.] Ctr Excellence Limb Loss Prevent & Prosthet Engn, VA Puget Sound Hlth Care Syst, Seattle, WA USA. RP Sundara-Rajan, K (reprint author), Univ Washington, Dept Elect Engn, Sensors Energy & Automat Lab, Seattle, WA 98195 USA. EM kishore@u.washington.edu FU U.S. National Institute of Health [R21HD052109-02]; Department of Veterans Affairs [A4843C]; Washington NASA Space FX This work was supported in part by the U.S. National Institute of Health under Grant R21HD052109-02, the Department of Veterans Affairs Grant A4843C, and the Washington NASA Space Grant scholarships. NR 20 TC 2 Z9 2 U1 0 U2 1 PU IEEE PI NEW YORK PA 345 E 47TH ST, NEW YORK, NY 10017 USA SN 1930-0395 BN 978-1-4244-8168-2 J9 IEEE SENSOR PY 2010 BP 2569 EP 2572 DI 10.1109/ICSENS.2010.5690146 PG 4 WC Engineering, Electrical & Electronic; Instruments & Instrumentation SC Engineering; Instruments & Instrumentation GA BTS59 UT WOS:000287982100569 ER PT S AU Efthimiadis, EN Hammond, KW Laundry, R Thielke, SM AF Efthimiadis, Efthimis N. Hammond, Kenric W. Laundry, Ryan Thielke, Stephen M. GP IEEE TI Developing an EMR Simulator to Assess Users' Perception of Document Quality SO 43RD HAWAII INTERNATIONAL CONFERENCE ON SYSTEMS SCIENCES VOLS 1-5 (HICSS 2010) SE Proceedings of the Annual Hawaii International Conference on System Sciences LA English DT Proceedings Paper CT 43rd Hawaii International Conference on Systems Sciences (HICSS 2010) CY JAN 05-08, 2010 CL Honolulu, HI SP Univ Hawaii, Shidler Coll Business ID PHYSICIAN ORDER ENTRY; ERRORS; SYSTEM; RECORD AB Simulators are used in research and training because they provide a realistic and safe environment for participants In the course of conducting a comprehensive study of patient care documentation in electronic medical record (EMR) systems we found that use of a simulated EMR system could address logistic and conceptual barriers encountered in deploying a research instrument to assess user perceptions of patient care document quality Designed for use by practitioners, nurses, and administrators at four VA hospital sites, the web-based EMR simulator presents clinical documents as they appear in VA's CPRS production EMR, and administers a document quality assessment questionnaire The EMR simulator was developed to overcome the contradiction of studying computerized documents with a paper instrument, to permit self-administration at multiple sites and to manage data collection This paper discusses the motivation to evaluate EMR document quality, development of the quality questionnaire, and how the design of the simulator evolved and was pilot tested C1 [Efthimiadis, Efthimis N.; Laundry, Ryan] Univ Washington, Informat Sch, Seattle, WA 98195 USA. [Hammond, Kenric W.; Thielke, Stephen M.] VA Puget Sound Hlth Care Syst, Tacoma, WA 98498 USA. [Hammond, Kenric W.; Thielke, Stephen M.] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. RP Efthimiadis, EN (reprint author), Univ Washington, Informat Sch, Seattle, WA 98195 USA. NR 26 TC 0 Z9 0 U1 2 U2 2 PU IEEE COMPUTER SOC PI LOS ALAMITOS PA 10662 LOS VAQUEROS CIRCLE, PO BOX 3014, LOS ALAMITOS, CA 90720-1264 USA SN 1060-3425 BN 978-1-4244-5509-6 J9 P ANN HICSS PY 2010 BP 2491 EP + PG 3 WC Computer Science, Theory & Methods; Engineering, Electrical & Electronic SC Computer Science; Engineering GA BRD18 UT WOS:000282391802072 ER PT J AU Steinman, MA Boscardin, CK Aguayo, L Baron, RB AF Steinman, Michael A. Boscardin, Christy K. Aguayo, Leslie Baron, Robert B. TI Commercial Influence and Learner-Perceived Bias in Continuing Medical Education SO ACADEMIC MEDICINE LA English DT Article ID INDUSTRY SUPPORT; PHYSICIANS; PROMOTION; DOCTORS; GIFTS; TOOL; CME AB Purpose To directly examine the relationship between commercial support of continuing medical education (CME) and perceived bias in the content of these activities. Method Cross-sectional study of 213 accredited live educational programs organized by a university provider of CME from 2005 to 2007. A standard question from course evaluations was used to determine the degree to which attendees believed commercial bias was present. Binomial regression models were used to determine the association between course features that may introduce commercial bias and the extent of perceived bias at those CME activities. Results Mean response rate for attendee evaluations was 56% (SD 15%). Commercial support covered 20%-49% of costs for 45 (21%) educational activities, and >= 50% of costs for 46 activities (22%). Few course participants perceived commercial bias, with a median of 97% (interquartile range 95%-99%) of respondents stating that the activity they attended was free of commercial bias. There was no association between extent of commercial support and the degree of perceived bias in CME activities. Similarly, perceived bias did not vary for 11 of 12 event characteristics evaluated as potential sources of commercial bias, or by score on a risk index designed to prospectively assess risk of commercial bias. Conclusions Rates of perceived bias were low for the vast majority of CME activities in the sample and did not differ by the degree of industry support or other event characteristics. Further study is needed to determine whether commercial influence persisted in more subtle forms that were difficult for participants to detect. C1 [Steinman, Michael A.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Steinman, Michael A.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. [Boscardin, Christy K.] Univ Calif San Francisco, Div Gen Internal Med, San Francisco, CA 94143 USA. [Boscardin, Christy K.; Aguayo, Leslie] Univ Calif San Francisco, Off Med Educ, San Francisco, CA 94143 USA. RP Steinman, MA (reprint author), San Francisco VA Med Ctr, Box 181-G,4150 Clement St, San Francisco, CA 94121 USA. EM mike.steinman@ucsf.edu OI Boscardin, Christy/0000-0002-9070-8859 FU VA Health Services Research and Development Service [CDTA 01-013]; National Institute on Aging [K23 AG030999] FX Funding for this work was provided by VA Health Services Research and Development Service (CDTA 01-013) and by the National Institute on Aging (K23 AG030999) (both for Dr. Steinman). NR 35 TC 14 Z9 14 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1040-2446 J9 ACAD MED JI Acad. Med. PD JAN PY 2010 VL 85 IS 1 BP 74 EP 79 DI 10.1097/ACM.0b013e3181c51d3f PG 6 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA 576GC UT WOS:000276131300020 PM 20042828 ER PT B AU Fujikawa, DG AF Fujikawa, Denson G. BE Fujikawa, DG TI Acute Neuronal Injury The Role of Excitotoxic Programmed Cell Death Mechanisms Introduction SO ACUTE NEURONAL INJURY: THE ROLE OF EXCITOTOXIC PROGRAMMED CELL DEATH MECHANISMS LA English DT Editorial Material; Book Chapter ID ELECTRON-MICROSCOPIC FINDINGS; HYPOGLYCEMIC BRAIN-DAMAGE; INTERNUCLEOSOMAL DNA CLEAVAGE; POLY(ADP-RIBOSE) PAR POLYMER; INDUCED STATUS EPILEPTICUS; APOPTOSIS-INDUCING FACTOR; CEREBRAL-ISCHEMIA; GLUTAMATE NEUROTOXICITY; TEMPORAL EVOLUTION; GLOBAL-ISCHEMIA C1 [Fujikawa, Denson G.] VA Greater Los Angeles Healthcare Syst, Dept Neurol, North Hills, CA 91343 USA. [Fujikawa, Denson G.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Fujikawa, Denson G.] Univ Calif Los Angeles, David Geffen Sch Med, Brain Res Inst, Los Angeles, CA 90095 USA. RP Fujikawa, DG (reprint author), VA Greater Los Angeles Healthcare Syst, Dept Neurol, North Hills, CA 91343 USA. EM dfujikaw@ucla.edu; dfujikaw@ucla.edu NR 63 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES BN 978-0-387-73225-1 PY 2010 BP 1 EP 6 DI 10.1007/978-0-387-73226-8_1 D2 10.1007/978-0-387-73226-8 PG 6 WC Cell Biology; Neurosciences SC Cell Biology; Neurosciences & Neurology GA BMT69 UT WOS:000273556000001 ER PT B AU Fujikawa, DG AF Fujikawa, Denson G. BE Fujikawa, DG TI Age-Dependence of Neuronal Apoptosis and of Caspase Activation SO ACUTE NEURONAL INJURY: THE ROLE OF EXCITOTOXIC PROGRAMMED CELL DEATH MECHANISMS LA English DT Article; Book Chapter ID PROGRAMMED CELL-DEATH; INTERNUCLEOSOMAL DNA CLEAVAGE; ELECTRON-MICROSCOPIC FINDINGS; POLY(ADP-RIBOSE) PAR POLYMER; INDUCED STATUS EPILEPTICUS; HYPOGLYCEMIC BRAIN-DAMAGE; CYTOCHROME-C; TEMPORAL EVOLUTION; CALPAIN ACTIVATION; CEREBRAL-ISCHEMIA C1 [Fujikawa, Denson G.] VA Greater Los Angeles Healthcare Syst, Dept Neurol, North Hills, CA 91343 USA. [Fujikawa, Denson G.] Univ Calif Los Angeles, David Geffen Sch Med, Brain Res Inst, Los Angeles, CA 90095 USA. [Fujikawa, Denson G.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. RP Fujikawa, DG (reprint author), VA Greater Los Angeles Healthcare Syst, Dept Neurol, North Hills, CA 91343 USA. EM dfujikaw@ucla.edu; dfujikaw@ucla.edu NR 58 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES BN 978-0-387-73225-1 PY 2010 BP 67 EP 77 DI 10.1007/978-0-387-73226-8_4 D2 10.1007/978-0-387-73226-8 PG 11 WC Cell Biology; Neurosciences SC Cell Biology; Neurosciences & Neurology GA BMT69 UT WOS:000273556000004 ER PT B AU Liu, C Signore, AP Cao, GD Chen, J AF Liu, Can Signore, Armando P. Cao, Guodong Chen, Jun BE Fujikawa, DG TI Apoptosis-Inducing Factor Translocation to Nuclei After Transient Global Ischemia SO ACUTE NEURONAL INJURY: THE ROLE OF EXCITOTOXIC PROGRAMMED CELL DEATH MECHANISMS LA English DT Article; Book Chapter ID FOCAL CEREBRAL-ISCHEMIA; NEURONAL CELL-DEATH; SUBSEQUENT DNA FRAGMENTATION; OXYGEN-GLUCOSE DEPRIVATION; NEONATAL HYPOXIA-ISCHEMIA; X-LINKED INHIBITOR; POLY(ADP-RIBOSE) POLYMERASE; CYTOCHROME-C; MITOCHONDRIAL RELEASE; CALPAIN INHIBITOR C1 [Liu, Can; Signore, Armando P.; Cao, Guodong; Chen, Jun] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA. [Liu, Can; Chen, Jun] Fudan Univ, Sch Med, State Key Lab Med Neurobiol, Shanghai 200032, Peoples R China. [Cao, Guodong; Chen, Jun] Vet Affairs Pittsburgh Hlth Care Syst, Educ & Clin Ctr, Pittsburgh, PA 15261 USA. RP Chen, J (reprint author), Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA. EM chenj2@upmc.edu NR 79 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES BN 978-0-387-73225-1 PY 2010 BP 131 EP 144 DI 10.1007/978-0-387-73226-8_9 D2 10.1007/978-0-387-73226-8 PG 14 WC Cell Biology; Neurosciences SC Cell Biology; Neurosciences & Neurology GA BMT69 UT WOS:000273556000009 ER PT B AU Fujikawa, DG AF Fujikawa, Denson G. BE Fujikawa, DG TI Activation of Caspase-Independent Programmed Pathways in Seizure-Induced Neuronal Necrosis SO ACUTE NEURONAL INJURY: THE ROLE OF EXCITOTOXIC PROGRAMMED CELL DEATH MECHANISMS LA English DT Article; Book Chapter ID INDUCED STATUS EPILEPTICUS; EXTRACELLULAR AMINO-ACIDS; CELL-DEATH MECHANISMS; INTERNUCLEOSOMAL DNA CLEAVAGE; ELECTRON-MICROSCOPIC FINDINGS; POLY(ADP-RIBOSE) PAR POLYMER; PILOCARPINE-INDUCED SEIZURES; HYPOGLYCEMIC BRAIN-DAMAGE; NMDA RECEPTOR ANTAGONIST; FREELY MOVING RATS C1 [Fujikawa, Denson G.] VA Greater Los Angeles Healthcare Syst, Dept Neurol, North Hills, CA 91343 USA. [Fujikawa, Denson G.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Fujikawa, Denson G.] Univ Calif Los Angeles, David Geffen Sch Med, Brain Res Inst, Los Angeles, CA 90095 USA. RP Fujikawa, DG (reprint author), VA Greater Los Angeles Healthcare Syst, Dept Neurol, North Hills, CA 91343 USA. EM dfujikaw@ucla.edu; dfujikaw@ucla.edu NR 85 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES BN 978-0-387-73225-1 PY 2010 BP 277 EP 293 DI 10.1007/978-0-387-73226-8_17 D2 10.1007/978-0-387-73226-8 PG 17 WC Cell Biology; Neurosciences SC Cell Biology; Neurosciences & Neurology GA BMT69 UT WOS:000273556000017 ER PT B AU Fujikawa, DG AF Fujikawa, Denson G. BE Fujikawa, DG TI Acute Neuronal Injury The Role of Excitotoxic Programmed Cell Death Mechanisms Concluding Remarks SO ACUTE NEURONAL INJURY: THE ROLE OF EXCITOTOXIC PROGRAMMED CELL DEATH MECHANISMS LA English DT Editorial Material; Book Chapter ID DNA FRAGMENTATION; APOPTOSIS; NECROSIS; PRIMATES; CALPAIN; ACTIVATION; INHIBITOR; CATHEPSIN; CASPASE; GOLGI C1 [Fujikawa, Denson G.] VA Greater Los Angeles Healthcare Syst, Dept Neurol, North Hills, CA 91343 USA. [Fujikawa, Denson G.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Fujikawa, Denson G.] Univ Calif Los Angeles, David Geffen Sch Med, Brain Res Inst, Los Angeles, CA 90095 USA. RP Fujikawa, DG (reprint author), VA Greater Los Angeles Healthcare Syst, Dept Neurol, North Hills, CA 91343 USA. NR 18 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES BN 978-0-387-73225-1 PY 2010 BP 295 EP 298 D2 10.1007/978-0-387-73226-8 PG 4 WC Cell Biology; Neurosciences SC Cell Biology; Neurosciences & Neurology GA BMT69 UT WOS:000273556000018 ER PT S AU Frascella, J Potenza, MN Brown, LL Childress, AR AF Frascella, Joseph Potenza, Marc N. Brown, Lucy L. Childress, Anna Rose BE Uhl, GR TI Shared brain vulnerabilities open the way for nonsubstance addictions: Carving addiction at a new joint? SO ADDICTION REVIEWS 2 SE Annals of the New York Academy of Sciences LA English DT Article; Book Chapter DE nonsubstance addiction; DSM-V; brain imaging; nosology ID BODY-MASS INDEX; HUMAN ORBITOFRONTAL CORTEX; INCREASE EXTRACELLULAR DOPAMINE; SUBSTANCE USE DISORDERS; VENTRAL TEGMENTAL AREA; POSITRON-EMISSION-TOMOGRAPHY; COCAINE-DEPENDENT SUBJECTS; IMPULSE CONTROL DISORDERS; GRAY-MATTER VOLUME; EVENT-RELATED FMRI AB For more than half a century, since the beginning of formal diagnostics, our psychiatric nosology has compartmentalized the compulsive pursuit of substance (e.g., alcohol, cocaine, heroin, nicotine) from nonsubstance (e.g., gambling, food, sex) rewards. Emerging brain, behavioral, and genetic findings challenge this diagnostic boundary, pointing to shared vulnerabilities underlying the pathological pursuit of substance and nonsubstance rewards. Working groups for the fifth revision of the Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-V), are thus considering whether the nosologic boundaries of addiction should be redrawn to include nonsubstance disorders, such as gambling. This review discusses how neurobiological data from problem gambling, obesity, and "normal" states of attachment (romantic infatuation, sexual attraction, maternal bonds) may help us in the task of carving addictions "at a new joint." Diagnostic recarving may have a positive effect on addiction research, stimulating discovery of "crossover" pharmacotherapies with benefit for both substance and nonsubstance addictions. C1 [Childress, Anna Rose] Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. [Frascella, Joseph] Natl Inst Drug Abuse, Div Clin Neurosci & Behav Res, Rockville, MD USA. [Potenza, Marc N.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. [Potenza, Marc N.] Yale Univ, Sch Med, Ctr Child Study, New Haven, CT 06510 USA. [Brown, Lucy L.] Albert Einstein Coll Med, Saul R Korey Dept Neurol, New York, NY USA. [Brown, Lucy L.] Albert Einstein Coll Med, Dominick P Purpura Dept Neurosci, New York, NY USA. [Childress, Anna Rose] Dept Vet Affairs Med Ctr, VISN MIRECC 4, Philadelphia, PA 19104 USA. RP Childress, AR (reprint author), Univ Penn, Sch Med, Dept Psychiat, 3900 Chestnut St, Philadelphia, PA 19104 USA. EM childress_a@mail.trc.upenn.edu FU NIAAA NIH HHS [RL1 AA017539, RL1 AA017539-01]; NIDA NIH HHS [R01 DA019039-05, R01 DA019039] NR 254 TC 84 Z9 87 U1 9 U2 29 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN STREET, MALDEN 02148, MA USA SN 0077-8923 BN 978-1-57331-767-2 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2010 VL 1187 BP 294 EP 315 DI 10.1111/j.1749-6632.2009.05420.x PG 22 WC Substance Abuse; Multidisciplinary Sciences SC Substance Abuse; Science & Technology - Other Topics GA BOV89 UT WOS:000277795700015 PM 20201859 ER PT J AU Kaufman, L Collins, SE Klotman, PE AF Kaufman, Lewis Collins, Susan E. Klotman, Paul E. TI The Pathogenesis of HIV-Associated Nephropathy SO ADVANCES IN CHRONIC KIDNEY DISEASE LA English DT Article DE HIV-associated nephropathy; Podocyte; MYH9; Glomerulosclerosis AB HIV-associated nephropathy (HIVAN) is one of the leading causes of ESRD in HIV-1-seropositive patients. Patients typically present with heavy proteinuria and chronic renal failure with pathologic findings of collapsing focal segmental glomerulosclerosis (FSGS). The disease is caused by direct infection of renal epithelial cells by HIV-1 in a genetically susceptible host. The genetic factors responsible for the susceptibility to HIVAN among blacks include a noncoding variant in the podocyte-expressed gene nonmuscle myosin, heavy chain 9 (MYH9) as well as other genes yet to be identified. Podocyte and tubular dysfunction results from the expression of viral genes, in particular nef and vpr, and the subsequent dysregulation of numerous host factors, including critical signaling pathways, inflammatory mediators, and others. The identification of these factors has the potential to provide novel therapeutic targets to prevent and treat this important disease. (C) 2010 by the National Kidney Foundation, Inc. All rights reserved. C1 [Kaufman, Lewis] Mt Sinai Sch Med, Div Nephrol, New York, NY 10029 USA. James J Peters VA Med Ctr, Div Nephrol, Bronx, NY USA. RP Kaufman, L (reprint author), Mt Sinai Sch Med, Div Nephrol, 1 Gustave L Levy Pl,Box 1243, New York, NY 10029 USA. EM lewis.kaufman@mssm.edu NR 47 TC 9 Z9 11 U1 0 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1548-5595 J9 ADV CHRONIC KIDNEY D JI Adv. Chronic Kidney Dis. PD JAN PY 2010 VL 17 IS 1 BP 36 EP 43 DI 10.1053/j.ackd.2009.08.012 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA V24KD UT WOS:000208408400006 PM 20005487 ER PT B AU Moinuddin, I Leehey, DJ AF Moinuddin, Irfan Leehey, David J. BE Lieberman, DC TI Aerobic Exercise in Patients with Chronic Kidney Disease SO AEROBIC EXERCISE AND ATHLETIC PERFORMANCE: TYPES, DURATION AND HEALTH BENEFITS SE Sports and Athletics Preparation Performance and Psychology LA English DT Article; Book Chapter ID STAGE RENAL-DISEASE; C-REACTIVE PROTEIN; MAINTENANCE HEMODIALYSIS-PATIENTS; INFLAMMATION COMPLEX SYNDROME; QUALITY-OF-LIFE; DIALYSIS PATIENTS; PHYSICAL-ACTIVITY; TRANSPLANT RECIPIENTS; OXIDATIVE STRESS; CARDIOVASCULAR RISK AB Patients with chronic kidney disease (CKD) have increased cardiovascular morbidity and mortality. They are frequently deconditioned as a result of inactivity, malnutrition, and abnormal muscle function In advanced CKD, hyperparathyroidism, acidosis, and severe catabolism/malnutrition contribute to debility. Patients with CKD often have cardiovascular risk factors such as inadequate blood pressure control, impaired fasting glucose (or overt diabetes), impaired insulin secretion and/or insulin resistance, abnormal lipid profiles, decreased testosterone and/or estrogen levels, and poor quality of life. Other non-traditional risk factors, such as sympathoactivation, inflammation, oxidative stress, and endothelial dysfunction, are also thought to increase cardiovascular morbidity and mortality. In addition to physical disease, CKD is associated with abnormal mental health, including depression, anxiety, and a feeling of helplessness and lack of wellbeing. Aerobic exercise has been proposed to have beneficial effects in CKD. This chapter seeks to define the mechanisms whereby aerobic exercise may benefit such patients. The type, duration, and recommended intensity of exercise will be discussed. While aerobic exercise is relatively safe for most CKD patients, the potential pitfalls of aerobic exercise and concerns about its safety will be addressed. The effects of exercise in the adult non-dialysis CKD population and end-stage renal disease (ESRD) population on dialysis will be clarified. Home exercise, and interdialytic versus intradialytic aerobic exercise will be discussed. Children with CKD are also susceptible to muscle weakness, low aerobic capacity, and abnormal fat composition; the impact of aerobic exercise in the pediatric CKD population will also be discussed. The effect of aerobic exercise on muscle weakness, weight loss, graft loss, and mortality in CKD patients post-transplantation will be illuminated. Finally, emphasis will be placed on areas novel to aerobic exercise and CKD requiring further research. C1 [Moinuddin, Irfan] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA. Loyola Univ, Sch Med, Maywood, IL 60153 USA. RP Moinuddin, I (reprint author), US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Roosevelt Rd & 5th Ave, Hines, IL 60141 USA. NR 114 TC 0 Z9 0 U1 2 U2 5 PU NOVA SCIENCE PUBLISHERS, INC PI HAUPPAUGE PA 400 OSER AVE, STE 1600, HAUPPAUGE, NY 11788-3635 USA BN 978-1-60876-217-0 J9 SPORTS ATHL PREP PER PY 2010 BP 323 EP 340 PG 18 WC Psychology; Sport Sciences SC Psychology; Sport Sciences GA BPL92 UT WOS:000279187300014 ER PT J AU Tang, XN Yenari, MA AF Tang, Xian N. Yenari, Midori A. TI Hypothermia as a cytoprotective strategy in ischemic tissue injury SO AGEING RESEARCH REVIEWS LA English DT Review DE Hypothermia; Ischemia; Injury; Cytoprotection ID TRAUMATIC BRAIN-INJURY; ACUTE LIVER-FAILURE; CEREBRAL HYPOXIA-ISCHEMIA; ACUTE MYOCARDIAL-INFARCTION; TRANSIENT FOCAL ISCHEMIA; COMBINATION-DRUG THERAPY; SPINAL-CORD-INJURY; DELAYED POSTISCHEMIC HYPOTHERMIA; GLOBAL FOREBRAIN ISCHEMIA; MILD SYSTEMIC HYPOTHERMIA AB Hypothermia is a well established cytoprotectant, with remarkable and consistent effects demonstrated across multiple laboratories. At the clinical level, it has recently been shown to improve neurological outcome following cardiac arrest and neonatal hypoxia-ischemia. It is increasingly being embraced by the medical community, and could be considered an effective neuroprotectant. Conditions such as brain injury, hepatic encephalopathy and cardiopulmonary bypass seem to benefit from this intervention. It's role in direct myocardial protection is also being explored. A review of the literature has demonstrated that in order to appreciate the maximum benefits of hypothermia, cooling needs to begin soon after the insult, and maintained for relatively long period periods of time. In the case of ischemic stroke, cooling should ideally be applied in conjunction with the re-establishment of cerebral perfusion. Translating this to the clinical arena can be challenging, given the technical challenges of rapidly and stably cooling patients. This review will discuss the application of hypothermia especially as it pertains to its effects neurological outcome, cooling methods, and important parameters in optimizing hypothermic protection. Published by Elsevier Ireland Ltd. C1 [Yenari, Midori A.] Univ Calif San Francisco, Dept Neurol, VAMC, San Francisco, CA 94121 USA. [Tang, Xian N.; Yenari, Midori A.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Tang, Xian N.] Stanford Univ, Sch Med, Dept Anesthesia, Stanford, CA 94305 USA. RP Yenari, MA (reprint author), Univ Calif San Francisco, Dept Neurol, VAMC, Neurol 127,4150 Clement St, San Francisco, CA 94121 USA. EM yenari@alum.mit.edu FU National Institutes of Health NINDS [R01 NS40516, P50 NS014543]; American Heart Association; Department of Defense FX This work was supported by: The National Institutes of Health NINDS, R01 NS40516, P50 NS014543 (MAY), American Heart Association Established Investigator Award and the Department of Defense (MAY). NR 141 TC 28 Z9 33 U1 3 U2 10 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 1568-1637 J9 AGEING RES REV JI Ageing Res. Rev. PD JAN PY 2010 VL 9 IS 1 SI SI BP 61 EP 68 DI 10.1016/j.arr.2009.10.002 PG 8 WC Cell Biology; Geriatrics & Gerontology SC Cell Biology; Geriatrics & Gerontology GA 556TT UT WOS:000274616100006 PM 19833233 ER PT J AU Rafi, A Do, LT Katz, R Sheinkopf, LE Simons, CW Klaustermeyer, W AF Rafi, Asif Do, LanAnh T. Katz, Roger Sheinkopf, Lee E. Simons, Caroline Watson Klaustermeyer, William TI Effects of omalizumab in patients with food allergy SO ALLERGY AND ASTHMA PROCEEDINGS LA English DT Article; Proceedings Paper CT 64th Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology CY MAR 14-18, 2008 CL Philadelphia, PA SP Amer Acad Allergy, Asthma & Immunol DE Anti-IgE; asthma; biologic therapeutic; food allergy; IgE; omalizumab; peanut; prospective; treatment ID CHRONIC URTICARIA; ASTHMA AB Omalizumab is a novel therapy approved for treating patients with moderate to severe persistent allergic asthma with a serum IgE ranging from 30 to 700 IU/mL. We examined the efficacy of omalizumab as a treatment for IgE-mediated food allergy. An Institutional Review Board-approved prospective pilot study was performed to assess the efficacy of omalizumab in 22 patients with persistent asthma and concomitant IgE-mediated food allergy. All patients showed skin test positivity to foods and experienced allergic food reactions based on history. Patients were interviewed on unintentional and/or unauthorized exposures to sensitized foods, Thirteen female and nine male patients (range, 4-66 years: old; mean, 38 years) were evaluated in a private practice setting. Mean IgE level was 1120.74 IU/mL. Sensitized allergens included fish, shellfish, peanuts, tree nuts, egg, soybean, and wheat. All 22 (100%) patients maintained significant improvement as shown by a decrease/lack of clinical symptoms on reexposure to sensitized foods. Clinical improvement by the sixth dosage of omalizumab (150-300 mg q. 2-4 weeks) was noted by history and physical examination. Eight patients noted a decrease in their food-induced atopic dermatitis, 13 patients noted a decrease in their food-induced asthma symptoms, 3 patients noted a decrease in their food-induced urticaria, 6 patients noted a decrease in their food-induced rhinosinusitis symptoms, and 9 patients showed efficacy for angioedema and/or anaphylaxis. While treating asthma patients with omalizumab, patients subjectively observed a reduction in their concomitant IgE-mediated food allergy symptoms. (Allergy Asthma Proc 31:76-83, 2010; doi: 10.2500/aap.2010.31.3304) C1 [Rafi, Asif; Simons, Caroline Watson; Klaustermeyer, William] Univ Calif Los Angeles, VA Greater Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Do, LanAnh T.; Katz, Roger; Sheinkopf, Lee E.] Allergy Asthma Care Ctr Inc, Los Angeles, CA USA. RP Rafi, A (reprint author), Univ Calif Los Angeles, VA Greater Angeles Healthcare Syst, 11301 Wilshire Blvd,111R, Los Angeles, CA 90073 USA. EM asifrafi1@yahoo.com NR 13 TC 23 Z9 24 U1 1 U2 4 PU OCEAN SIDE PUBLICATIONS INC PI PROVIDENCE PA 95 PITMAN ST, PROVIDENCE, RI 02906 USA SN 1088-5412 J9 ALLERGY ASTHMA PROC JI Allergy Asthma Proc. PD JAN-FEB PY 2010 VL 31 IS 1 BP 76 EP 83 DI 10.2500/aap.2010.31.3304 PG 8 WC Allergy SC Allergy GA 564CG UT WOS:000275188800010 PM 20167148 ER PT J AU Chao, LL Buckley, ST Kornak, J Schuff, N Madison, C Yaffe, K Miller, BL Kramer, JH Weiner, MW AF Chao, Linda L. Buckley, Shannon T. Kornak, John Schuff, Norbert Madison, Catherine Yaffe, Kristine Miller, Bruce L. Kramer, Joel H. Weiner, Michael W. TI ASL Perfusion MRI Predicts Cognitive Decline and Conversion From MCI to Dementia SO ALZHEIMER DISEASE & ASSOCIATED DISORDERS LA English DT Article DE mild cognitive impairment; dementia; cognitive and functional decline; ASL perfusion MRI; hippocampal volume ID CEREBRAL-BLOOD-FLOW; EARLY ALZHEIMERS-DISEASE; POSITRON-EMISSION-TOMOGRAPHY; EPISODIC MEMORY DEFICIT; CLINICAL DEMENTIA; RECOGNITION MEMORY; FUNCTIONAL STATUS; FDG-PET; IMPAIRMENT; BRAIN AB We compared the predictive value of cerebral perfusion as measured by arterial-spin labeling magnetic resonance imaging (ASL-MRI) with MRI-derived hippocampal volume for determining future cognitive and functional decline and subsequent conversion from mild cognitive impairment to dementia. Forty-eight mild cognitive impairment subjects received structural and ASL-MRI scans at baseline and clinical and neuropsychologic assessments annually. Thirteen subjects became demented during the period of longitudinal observation (2.7 +/- 1.0 y). Cox regression analyses suggest that baseline hippocampal volume [relative risk (RR) = 0.99, P = 0.004], baseline right inferior parietal (RR = 0.64, P = 0.01) and right middle frontal (RR = 0.73, P = 0.01) perfusion were associated with conversion to dementia. Results from linear mixed effects modeling suggest that baseline perfusion from the right precuneus predicted subsequent declines in Clinical Dementia Rating Sum of Boxes (P = 0.002), Functional Activates Questionnaire (P = 0.01), and selective attention (ie, Stroop switching, P = 0.009) whereas baseline perfusion from the right middle frontal cortex predicted subsequent episodic memory decline (ie, total recognition discriminability score from the California Verbal Learning Test, P = 0.03). These results suggest that hypoperfusion as detected by ASL-MRI can predict subsequent clinical, functional, and cognitive decline and may be useful for identifying candidates for future Alzheimer disease treatment trials. C1 [Chao, Linda L.; Buckley, Shannon T.; Schuff, Norbert; Weiner, Michael W.] San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis, San Francisco, CA USA. [Chao, Linda L.; Kornak, John; Schuff, Norbert; Weiner, Michael W.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA. [Chao, Linda L.; Yaffe, Kristine; Weiner, Michael W.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Kornak, John; Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Yaffe, Kristine; Miller, Bruce L.; Kramer, Joel H.; Weiner, Michael W.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [Madison, Catherine] Calif Pacific Med Ctr, Dept Neurol, San Francisco, CA USA. RP Chao, LL (reprint author), 4150 Clement St 114M, San Francisco, CA 94121 USA. EM linda.chao@ucsf.edu FU NIH NIA [NIA R01 AG010897] FX Supported by NIH NIA R01 AG010897. NR 66 TC 68 Z9 70 U1 3 U2 15 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0893-0341 J9 ALZ DIS ASSOC DIS JI Alzheimer Dis. Assoc. Dis. PD JAN-MAR PY 2010 VL 24 IS 1 BP 19 EP 27 DI 10.1097/WAD.0b013e3181b4f736 PG 9 WC Clinical Neurology; Pathology SC Neurosciences & Neurology; Pathology GA 564FC UT WOS:000275197700003 PM 20220321 ER PT J AU Steinman, MA Schillinger, D AF Steinman, Michael A. Schillinger, Dean TI Drug Detailing in Academic Medical Centers: Regulating for the Right Reasons, with the Right Evidence, at the Right Time SO AMERICAN JOURNAL OF BIOETHICS LA English DT Editorial Material ID PROMOTION; INDUSTRY C1 [Steinman, Michael A.; Schillinger, Dean] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Steinman, Michael A.] San Francisco VA Med Ctr, San Francisco, CA USA. [Schillinger, Dean] San Francisco Gen Hosp, San Francisco, CA USA. RP Steinman, MA (reprint author), 4150 Clement St,Box 181G, San Francisco, CA 94121 USA. EM mike.steinman@ucsf.edu FU NCRR NIH HHS [UL1 RR024131]; NIA NIH HHS [K23 AG030999] NR 11 TC 3 Z9 3 U1 0 U2 2 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1526-5161 J9 AM J BIOETHICS JI Am. J. Bioeth. PY 2010 VL 10 IS 1 BP 21 EP 23 PG 4 WC Ethics; Medical Ethics; Social Issues; Social Sciences, Biomedical SC Social Sciences - Other Topics; Medical Ethics; Social Issues; Biomedical Social Sciences GA 543WX UT WOS:000273611700008 PM 20077331 ER PT J AU Gabayan, GZ Derose, SF Asch, SM Chiu, VY Glenn, SC Mangione, CM Sun, BC AF Gabayan, Gelareh Z. Derose, Stephen F. Asch, Steven M. Chiu, Vicki Y. Glenn, Sungching C. Mangione, Carol M. Sun, Benjamin C. TI Predictors of Short-Term (Seven-Day) Cardiac Outcomes After Emergency Department Visit for Syncope SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Article ID RISK STRATIFICATION; PROSPECTIVE VALIDATION; EXTERNAL VALIDATION; RULE; SCORE; PROGNOSIS; ADMISSION AB Syncope is a common reason for emergency department (ED) visits, and patients are often admitted to exclude syncope of cardiovascular origin. Population-based data on patterns and predictors of cardiac outcomes may improve decision-making. Our objective was to identify patterns and predictors of short-term cardiac outcomes in ED patients with syncope. Administrative data from an integrated health system of 11 Southern California EDs were used to identify cardiac outcomes after ED presentation for syncope from January 1, 2002, to December 31, 2005. Syncope and cause of death were identified by codes from the International Classification of Disease, Ninth Revision. Cardiac outcomes included cardiac death and hospitalization or procedure consistent with ischemic heart disease, valvular disease, or arrhythmia. Predictors of cardiac outcomes were identified through multivariate logistic regression. There were 35,330 adult subjects who accounted for 39,943 ED visits for syncope. Risk of cardiac outcome sharply decreased following the 7 days after syncope. A 7-day cardiac outcome occurred in 893 cases (3%). Positive predictors of 7-day cardiac outcomes included age >= 60 years, male gender, congestive heart failure, ischemic heart disease, cardiac arrhythmia, and valvular heart disease. Negative predictors included dementia, pacemaker, coronary revascularization, and cerebrovascular disease. There was an age-dependent relation between 7-day cardiac outcomes and arrhythmia and valvular disease, with younger patients (<60 years of age) having greater risk of an event compared to their same-age counterparts. In conclusion, ED decision-making should focus on risk of cardiac event in the first 7 days after syncope and special attention should be given to younger patients with cardiac co-morbidities. Published by Elsevier Inc. (Am J Cardiol 2010;105:82-86) C1 [Gabayan, Gelareh Z.; Asch, Steven M.; Sun, Benjamin C.] Univ Calif Los Angeles, Dept Med, Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA 90024 USA. [Derose, Stephen F.; Chiu, Vicki Y.; Glenn, Sungching C.] Kasier Permanente So Calif, Dept Res & Evaluat, Pasadena, CA USA. RP Gabayan, GZ (reprint author), Univ Calif Los Angeles, Dept Med, Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA 90024 USA. EM Gelareh@gabayan.com RI Max, Mad/E-5238-2010 OI Max, Mad/0000-0001-6966-6829 FU Greater Los Angeles Veteran's Affairs Health Services Research and Development Fellowship, Los Angeles, California; American Geriatrics Society New York [20051687]; New York Dennis Jahnigen Career Development Award; University of California, Los Angeles [AG 01-004]; National Institutes of Aging [K12]; UCLA Older Americans Independence Center, NIH/NIA [P30-AG028748] FX Dr. Gabayan is supported by a Greater Los Angeles Veteran's Affairs Health Services Research and Development Fellowship, Los Angeles, California. This research was also supported by Grant 20051687 to Dr. Sun from the American Geriatrics Society New York, New York Dennis Jahnigen Career Development Award and Grant AG 01-004 to Dr. Sun from the University of California, Los Angeles, National Institutes of Aging K12 Mentored Clinical Scientist Development Program in Geriatrics. Los Angeles, California. Dr. Sun also received support from the UCLA Older Americans Independence Center, NIH/NIA Grant P30-AG028748, and the content does not necessarily represent the official views of the National Institute on Aging or the National Institutes of Health. NR 18 TC 9 Z9 9 U1 0 U2 1 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9149 J9 AM J CARDIOL JI Am. J. Cardiol. PD JAN 1 PY 2010 VL 105 IS 1 BP 82 EP 86 DI 10.1016/j.amjcard.2009.08.654 PG 5 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 602JU UT WOS:000278136200014 PM 20102895 ER PT J AU Aljaroudi, W Hermann, D Hage, F Heo, J Iskandrian, AE AF Aljaroudi, Wael Hermann, Daniel Hage, Fadi Heo, Jaekyeong Iskandrian, Ami E. TI Safety of Regadenoson in Patients with End-Stage Renal Disease SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Article ID ADENOSINE; AGONIST; SPECT AB Regadenoson is a selective A(2A) receptor agonist that was recently approved by the Food and Drug Administration for vasodilator stress myocardial perfusion imaging. Because the drug is cleared by renal excretion, its safety in patients with end-stage renal disease (ESRD) needs to be determined. We studied 277 consecutive patients with ESRD who had undergone regadenoson stress gated single photon emission computed tomography myocardial perfusion imaging and compared their side effect profile and safety outcome to those of 134 patients with normal kidney function. The ESRD group included 164 men (59%) and the control group included 73 men (54%; p = NS). The patients with ESRD were younger than the controls (52 11 years vs 61 +/- 12 years; p <0.001). The myocardial perfusion imaging findings were abnormal in 53 patients (19%) with ESRD and in 24 patients in the control group (18%; p = NS). The left ventricular ejection fraction was 57 +/- 12% in the ESRD group and 64 +/- 12% in the control group (p <0.001). The changes in heart rate and systolic blood pressure (from baseline to peak stress) were 20 +/- 12 beats/min versus 22 +/- 13 beats/min and -11 +/- 24 mm Hg versus 12 +/- 23 mm Hg in the ESRD and control groups, respectively (p = NS for both). Very few patients in either group reported symptoms during the stress test. No medication-related hospitalizations, serious events, or death occurred in either group within 30 days of the study. In conclusion, this is the first study to document the safety of regadenoson in a large number of patients with ESRD. The drug was well tolerated, and the hemodynamic and side effect profiles were similar to those of patients with normal renal function. (C) 2010 Elsevier Inc. All rights reserved. (Am J Cardiol 2010; 105:133-135) C1 [Aljaroudi, Wael; Hage, Fadi; Heo, Jaekyeong; Iskandrian, Ami E.] Univ Alabama, Div Cardiovasc Dis, Birmingham, AL 35294 USA. [Hermann, Daniel] Univ Alabama, Dept Med, Birmingham, AL 35294 USA. [Hage, Fadi] Birmingham Vet Affairs Med Ctr, Cardiol Sect, Birmingham, AL USA. RP Aljaroudi, W (reprint author), Univ Alabama, Div Cardiovasc Dis, Birmingham, AL 35294 USA. EM waljaroudi@cardmail.dom.uab.edu OI Hage, Fadi/0000-0002-1397-4942 NR 14 TC 23 Z9 23 U1 1 U2 1 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9149 J9 AM J CARDIOL JI Am. J. Cardiol. PD JAN 1 PY 2010 VL 105 IS 1 BP 133 EP 135 DI 10.1016/j.amjcard.2009.08.663 PG 3 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 602JU UT WOS:000278136200024 PM 20102905 ER PT J AU Peralta, CA Adeney, KL Shlipak, MG Jacobs, D Duprez, D Bluemke, D Polak, J Psaty, B Kestenbaum, BR AF Peralta, Carmen A. Adeney, Kathryn L. Shlipak, Michael G. Jacobs, David, Jr. Duprez, Daniel Bluemke, David Polak, Joseph Psaty, Bruce Kestenbaum, Bryan R. TI Structural and Functional Vascular Alterations and Incident Hypertension in Normotensive Adults SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Article DE arteries; elasticity; hypertension ID INTIMA-MEDIA THICKNESS; PULSE CONTOUR ANALYSIS; ARTERIAL COMPLIANCE; BLOOD-PRESSURE; INDEPENDENT PREDICTOR; SERUM CREATININE; WAVE VELOCITY; NORMAL VALUES; ATHEROSCLEROSIS; DISEASE AB Vascular abnormalities may exist before clinical hypertension. Using Poisson regression, the authors studied the association of coronary artery calcium (CAC), common carotid intima-media thickness (CIMT), aortic distensibility, and large and small arterial elasticity with incident hypertension among 2,512 normotensive US adults free of cardiovascular disease. Incidence rate ratios for incident hypertension (blood pressure >= 140/90 mm Hg or new antihypertensive medication) were calculated. Increased CAC was associated with incident hypertension in demographics-adjusted models (incidence rate ratio (IRR) = 1.35, 95% confidence interval (CI): 1.04, 1.75; IRR = 1.35, 95% CI: 1.02, 1.78; and IRR = 1.59, 95% CI: 1.12, 2.25 for CAC scores of 30-99, 100-399, and >= 400, respectively) but was attenuated after further adjustment. Increased common CIMT was associated with incident hypertension (IRR = 1.77, 95% CI: 1.28, 2.46 for quintile 4; IRR = 1.80, 95% CI: 1.28, 2.53 for quintile 5). Participants with the lowest, compared with the highest, aortic distensibility had an increased risk of hypertension (IRR = 1.75, 95% CI: 1.10, 2.79), as did those with the lowest large arterial elasticity (IRR = 1.49, 95% CI: 1.11, 1.99). Lower small arterial elasticity was incrementally associated with incident hypertension starting at quintile 2 (IRR = 2.01, 95% CI: 1.39, 2.91; IRR = 2.47, 95% CI: 1.71, 3.57; IRR = 2.73, 95% CI: 1.88, 3.95; and IRR = 2.85, 95% CI: 1.95, 4.16). Structural and functional vascular abnormalities are independent predictors of incident hypertension. These findings are important for understanding the pathogenesis of hypertension. C1 [Peralta, Carmen A.; Shlipak, Michael G.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Peralta, Carmen A.; Shlipak, Michael G.] San Francisco VA Med Ctr, Gen Internal Med Sect, San Francisco, CA USA. [Adeney, Kathryn L.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Jacobs, David, Jr.] Univ Minnesota, Sch Publ Hlth, Minneapolis, MN USA. [Duprez, Daniel] Univ Minnesota, Div Cardiovasc, Sch Med, Minneapolis, MN 55455 USA. [Bluemke, David] NIH, Bethesda, MD 20892 USA. [Polak, Joseph] Tufts Univ, Dept Radiol, Boston, MA 02111 USA. [Psaty, Bruce] Univ Washington, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA. Univ Washington, Dept Med, Seattle, WA 98195 USA. Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Psaty, Bruce] Grp Hlth, Ctr Hlth Studies, Seattle, WA USA. [Kestenbaum, Bryan R.] Univ Washington, Div Nephrol, Seattle, WA 98195 USA. RP Peralta, CA (reprint author), VA Med Ctr, Gen Internal Med Sect 111A1, 4150 Clement St, San Francisco, CA 94124 USA. EM carmenalicia.peralta@ucsf.edu OI Bluemke, David/0000-0002-8323-8086 FU National Heart, Lung, and Blood Institute [N01-HC-95159, N01-HC-95165, N01-HC-95169]; National Center for Research Resources [KL2 RR024130] FX This work was supported by contracts (N01-HC-95159 through N01-HC-95165 and N01-HC-95169) from the National Heart, Lung, and Blood Institute. This work was also funded by the National Center for Research Resources (KL2 RR024130 to C. A. P.). NR 28 TC 48 Z9 51 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD JAN 1 PY 2010 VL 171 IS 1 BP 63 EP 71 DI 10.1093/aje/kwp319 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 537KT UT WOS:000273112500008 PM 19951938 ER PT J AU Cole, SR Jacobson, LP Tien, PC Kingsley, L Chmiel, JS Anastos, K AF Cole, Stephen R. Jacobson, Lisa P. Tien, Phyllis C. Kingsley, Lawrence Chmiel, Joan S. Anastos, Kathryn TI Using Marginal Structural Measurement-Error Models to Estimate the Long-term Effect of Antiretroviral Therapy on Incident AIDS or Death SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Article DE acquired immunodeficiency syndrome; bias (epidemiology); cohort studies; confounding factors (epidemiology); epidemiologic measurements; HIV; pharmacoepidemiology; selection bias ID HUMAN-IMMUNODEFICIENCY-VIRUS; LOGISTIC-REGRESSION; CLINICAL-COHORT; EPIDEMIOLOGIC RESEARCH; BAYESIAN PERSPECTIVES; SURVIVAL ANALYSIS; CAUSAL INFERENCE; CONTROLLED-TRIAL; VIRAL LOAD; HIV AB To estimate the net effect of imperfectly measured highly active antiretroviral therapy on incident acquired immunodeficiency syndrome or death, the authors combined inverse probability-of-treatment-and-censoring weighted estimation of a marginal structural Cox model with regression-calibration methods. Between 1995 and 2007, 950 human immunodeficiency virus-positive men and women were followed in 2 US cohort studies. During 4,054 person-years, 374 initiated highly active antiretroviral therapy, 211 developed acquired immunodeficiency syndrome or died, and 173 dropped out. Accounting for measured confounders and determinants of dropout, the weighted hazard ratio for acquired immunodeficiency syndrome or death comparing use of highly active antiretroviral therapy in the prior 2 years with no therapy was 0.36 (95% confidence limits: 0.21, 0.61). This association was relatively constant over follow-up (P = 0.19) and stronger than crude or adjusted hazard ratios of 0.75 and 0.95, respectively. Accounting for measurement error in reported exposure using external validation data on 331 men and women provided a hazard ratio of 0.17, with bias shifted from the hazard ratio to the estimate of precision as seen by the 2.5-fold wider confidence limits (95% confidence limits: 0.06, 0.43). Marginal structural measurement-error models can simultaneously account for 3 major sources of bias in epidemiologic research: validated exposure measurement error, measured selection bias, and measured time-fixed and time-varying confounding. C1 [Cole, Stephen R.] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Epidemiol, Chapel Hill, NC 27599 USA. [Jacobson, Lisa P.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Tien, Phyllis C.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Tien, Phyllis C.] San Francisco VA Med Ctr, San Francisco, CA USA. [Kingsley, Lawrence] Univ Pittsburgh, Dept Infect Dis & Microbiol, Pittsburgh, PA USA. [Chmiel, Joan S.] Northwestern Univ, Dept Prevent Med, Feinberg Sch Med, Chicago, IL 60611 USA. [Anastos, Kathryn] Montefiore Med Ctr, Bronx, NY 10467 USA. [Anastos, Kathryn] Albert Einstein Coll Med, Bronx, NY 10467 USA. RP Cole, SR (reprint author), Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Epidemiol, MacGavran Greenberg Hall,CB 7435, Chapel Hill, NC 27599 USA. EM cole@unc.edu FU National Institutes of Health [R03-AI-071763, R01-AA-017594, P30-AI-50410]; National Institute of Allergy and Infectious Diseases [UO1-AI-35004, UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UO1-AI-34993, UO1-AI-42590]; National Institute of Child Health and Human Development [UO1-HD-32632]; National Cancer Institute; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Center for Research Resources [UL1 RR024131]; MACS [UO1-AI-35042, 5-MO1-RR-00722, UO1-AI-35043, UO1-AI-37984, UO1-AI-35039, UO1-AI-35040, UO1-AI-37613, UO1-AI-35041] FX Dr. Stephen Cole's work was partially supported by National Institutes of Health grants R03-AI-071763, R01-AA-017594, and P30-AI-50410. The Women's Interagency HIV Study is funded by the National Institute of Allergy and Infectious Diseases (grants UO1-AI-35004, UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UO1-AI-34993, and UO1-AI-42590) and by the National Institute of Child Health and Human Development (grant UO1-HD-32632). The study is cofunded by the National Cancer Institute, the National Institute on Drug Abuse, and the National Institute on Deafness and Other Communication Disorders. Funding is also provided by the National Center for Research Resources (UCSF-CTSI grant UL1 RR024131). MACS is funded by grants UO1-AI-35042, 5-MO1-RR-00722 (GCRC), UO1-AI-35043, UO1-AI-37984, UO1-AI-35039, UO1-AI-35040, UO1-AI-37613, and UO1-AI-35041 from the National Institutes of Health. NR 59 TC 11 Z9 11 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD JAN 1 PY 2010 VL 171 IS 1 BP 113 EP 122 DI 10.1093/aje/kwp329 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 537KT UT WOS:000273112500013 PM 19934191 ER PT J AU Axon, RN Zhao, YM Egede, LE AF Axon, R. Neal Zhao, Yumin Egede, Leonard E. TI Association of Depressive Symptoms With All-Cause and Ischemic Heart Disease Mortality in Adults With Self-Reported Hypertension SO AMERICAN JOURNAL OF HYPERTENSION LA English DT Article DE blood pressure; depression; epidemiology; hypertension; mortality ID NATIONAL DEATH INDEX; MAJOR DEPRESSION; UNITED-STATES; OLDER-ADULTS; RISK-FACTOR; CARDIOVASCULAR HEALTH; BLOOD-PRESSURE; FOLLOW-UP; PREVALENCE; TRIAL AB BACKGROUND Hypertension (HTN) is a prevalent and important risk factor for both cardiovascular and all-cause mortality. Depression is often present in hypertensive patients and has also been associated with increased mortality risk. The aim of this study was to evaluate the association of depressive symptoms with all-cause mortality and ischemic heart disease (IHD) mortality among adults with self-reported HTN. METHODS We studied 10,025 participants in the National Health and Nutrition Epidemiologic Follow-up Study (NHANES 1) who were alive and interviewed in 1982 and had complete data for the Center for Epidemiologic Studies Depression Scale (CES-D). Four groups were identified based screening status at initial interview: (i) no HTN, no depression (reference group); (ii) HTN, no depression; (iii) no HTN, depression; and (iv) both HTN and depression. Cox proportional hazards regression was used to calculate multivariate-adjusted hazard ratios (HRs) of death for each group. RESULTS Over an average of 8 years (83,943 person-years) of follow-up, patients with both self-reported HTN and depressive symptoms had the highest multivariate-adjusted HR for all-cause mortality at 1.39 (95% confidence interval (CI) 1.14,1.69) as well as for IHD mortality at 1.59 (95% CI 1.08, 2.34). In post hoc analysis, nondepressed hypertensive patients had significantly lower adjusted HR for all-cause mortality compared to depressed hypertensive patients (HR 0.85; 95% CI 0.73-1.00), but the HR for IHD mortality was not significant (HR 0.87,95% CI 0.63-1.20). CONCLUSION Comorbid depressive symptoms are associated with increased all-cause mortality in patients with self-reported HTN. C1 [Axon, R. Neal; Zhao, Yumin; Egede, Leonard E.] Med Univ S Carolina, Dept Med, Div Gen Internal Med & Geriatr, Charleston, SC 29425 USA. [Axon, R. Neal; Egede, Leonard E.] Ralph Johnson Vet Adm Med Ctr, Charleston, SC USA. RP Axon, RN (reprint author), Med Univ S Carolina, Dept Med, Div Gen Internal Med & Geriatr, Charleston, SC 29425 USA. EM axon@musc.edu FU Department of Veterans Affairs Research Enhancement FX Dr Axon and Dr Egede receive funding support from the Department of Veterans Affairs Research Enhancement Award Program. NR 45 TC 20 Z9 21 U1 1 U2 6 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0895-7061 J9 AM J HYPERTENS JI Am. J. Hypertens. PD JAN PY 2010 VL 23 IS 1 BP 30 EP 37 DI 10.1038/ajh.2009.199 PG 8 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 533NS UT WOS:000272831400006 PM 19893497 ER PT J AU Maciejewski, ML Bryson, CL Perkins, M Blough, DK Cunningham, FE Fortney, JC Krein, SL Stroupe, KT Sharp, ND Liu, CF AF Maciejewski, Matthew L. Bryson, Chris L. Perkins, Mark Blough, David K. Cunningham, Francesca E. Fortney, John C. Krein, Sarah L. Stroupe, Kevin T. Sharp, Nancy D. Liu, Chuan-Fen TI Increasing Copayments and Adherence to Diabetes, Hypertension, and Hyperlipidemic Medications SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Article ID INCENTIVE-BASED FORMULARIES; OF-VETERANS-AFFAIRS; PRESCRIPTION DRUGS; MANAGED CARE; LONG-TERM; ANTIHYPERTENSIVE MEDICATION; PHARMACY BENEFITS; LONGITUDINAL DATA; RISK ADJUSTMENT; STATIN THERAPY AB Objective: To examine the impact of a medication copayment increase on adherence to diabetes, hypertension, and hyperlipidemic medications. Study Design: Retrospective pre-post observational study. Methods: This study compared medication adherence at 4 Veterans Affairs medical centers between veterans who were exempt from copayments and propensity-matched veterans who were not exempt. The diabetes sample included 1069 exempt veterans and 1069 nonexempt veterans, the hypertension sample included 3545 exempt veterans and 3545 nonexempt veterans, and the sample of veterans taking statins included 2029 exempt veterans and 2029 nonexempt veterans. The main outcome measure was medication adherence 12 months before and 23 months after the copayment increase. Adherence differences were assessed in a difference-in-difference approach by using generalized estimating equations that controlled for time, copayment exemption, an interaction between time and copayment exemption, and patient demographics, site, and other factors. Results: Adherence to all medications increased in the short term for all veterans, but then declined in the longer term (February-December 2003). The change in adherence between the preperiod and the postperiod was significantly different for exempt and nonexempt veterans in all 3 cohorts, and nonadherence increased over time for veterans required to pay copayments. The impact of the copayment increase was particularly adverse for veterans with diabetes who were required to pay copayments. Conclusion: A $5 copayment increase (from $2 to $7) adversely impacted medication adherence for veterans subject to copayments taking oral hypoglycemic agents, antihypertensive medications, or statins. (Am J Manag Care. 2010; 16(1): e20-e34) C1 [Maciejewski, Matthew L.] Durham VA Med Ctr, Ctr Hlth Serv Res Primary Care 152, Durham, NC 27705 USA. [Maciejewski, Matthew L.] Duke Univ, Div Gen Internal Med, Durham, NC USA. [Bryson, Chris L.; Perkins, Mark; Sharp, Nancy D.; Liu, Chuan-Fen] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA. [Bryson, Chris L.] Univ Washington, Div Gen Internal Med, Seattle, WA 98195 USA. [Blough, David K.] Univ Washington, Pharmaceut Outcomes Res & Policy Program, Seattle, WA 98195 USA. [Sharp, Nancy D.; Liu, Chuan-Fen] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Cunningham, Francesca E.] Dept Vet Affairs, Pharm Benefits Management Strateg Healthcare Grp, Hines, IL USA. [Cunningham, Francesca E.] Univ Illinois, Dept Pharm Practice, Chicago, IL USA. [Fortney, John C.] Cent Arkansas Vet Healthcare Syst, Ctr Mental Healthcare & Outcomes Res, Little Rock, AR USA. [Fortney, John C.] Univ Arkansas, Dept Psychiat & Behav Sci, Little Rock, AR 72204 USA. [Fortney, John C.] Univ Arkansas, Dept Hlth Policy & Management, Little Rock, AR 72204 USA. [Krein, Sarah L.] VA Ann Arbor Healthcare Syst, Ctr Clin Management Res, Ann Arbor, MI USA. [Krein, Sarah L.] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA. [Stroupe, Kevin T.] Hines VA Hosp, Ctr Management Complex Chron Care, Hines, IL USA. [Stroupe, Kevin T.] Northwestern Univ, Inst Healthcare Studies, Evanston, IL USA. RP Maciejewski, ML (reprint author), Durham VA Med Ctr, Ctr Hlth Serv Res Primary Care 152, 508 Fulton St, Durham, NC 27705 USA. EM matthew.maciejewski@va.gov RI Krein, Sarah/E-2742-2014 OI Krein, Sarah/0000-0003-2111-8131 FU Office of Research and Development, Health Services Research and Development Service, Department of Veterans Affairs [HR 03-200] FX This work was supported by the Office of Research and Development, Health Services Research and Development Service, Department of Veterans Affairs, project number HR 03-200. The views expressed are those of the authors and do not reflect the views of the Department of Veterans Affairs. NR 56 TC 37 Z9 38 U1 1 U2 5 PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC PI PLAINSBORO PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD JAN PY 2010 VL 16 IS 1 BP E20 EP E34 PG 15 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 549TQ UT WOS:000274077600011 PM 20059288 ER PT J AU Hare, E Glahn, DC Dassori, A Raventos, H Nicolini, H Ontiveros, A Medina, R Mendoza, R Jerez, A Munoz, R Almasy, L Escamilla, MA AF Hare, Elizabeth Glahn, David C. Dassori, Albana Raventos, Henriette Nicolini, Humberto Ontiveros, Alfonso Medina, Rolando Mendoza, Rick Jerez, Alvaro Munoz, Rodrigo Almasy, Laura Escamilla, Michael A. TI Heritability of Age of Onset of Psychosis in Schizophrenia SO AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS LA English DT Article DE schizophrenia; psychosis; heritability; age of onset ID FACTOR A61G POLYMORPHISM; GENOME-WIDE SCAN; GENDER-DIFFERENCES; SCHIZOAFFECTIVE DISORDER; NEUROTROPHIC FACTOR; CHINESE POPULATION; ASCERTAINMENT BIAS; LINKAGE ANALYSIS; SIBLING PAIRS; ANTICIPATION AB Schizophrenia is a genetically complex illness with heterogeneous clinical presentation, including variable age of onset. In this study, the heritability, or proportion of variation in age of onset of psychotic symptoms due to genetic factors, was estimated using a maximum likelihood method. The subjects were 717 members of families with more than one member affected with schizophrenia from Mexican and Central American populations. Age of onset of psychosis was determined by best-estimate consensus diagnosis based on the Diagnostic Interview for Genetic Studies, Family Interview for Genetic Studies, and each subject's medical records. Mean age of onset was 21.44 years (SD 8.07); 20.55 years for males (SD 6.90), and 22.67 for females (SD 9.34). Variance components were estimated using a polygenic model in the SOLAR software package. The sex of the participant was a significant covariate (P = 0.010) accounting for 0.02 of the total variance in age of onset. The heritability of age of onset of psychosis was 0.33 (SE = 0.09; P = 0.00004). These findings suggest that genetic factors significantly contribute to the age of onset of psychotic symptoms in individuals with schizophrenia and that sex influences this trait as well. (C) 2009 Wiley-Liss, Inc. C1 [Hare, Elizabeth; Dassori, Albana; Medina, Rolando; Escamilla, Michael A.] UT Hlth Sci Ctr, S Texas Psychiat Genet Res Ctr, San Antonio, TX USA. [Glahn, David C.] Yale Univ, Sch Med, Inst Living, Olin Neuropsychiat Res Ctr, Hartford, CT USA. [Raventos, Henriette] Univ Costa Rica, Ctr Res Mol Biol, San Jose, Costa Rica. [Nicolini, Humberto] Carracci SC, Med & Family Res Grp, Mexico City, DF, Mexico. [Ontiveros, Alfonso] Inst Informac Invest Salud Mental, Monterrey, Mexico. [Medina, Rolando] S Texas Vet Healthcare Syst, San Antonio, TX USA. [Mendoza, Rick] Univ Calif Los Angeles Harbor, Los Angeles, CA USA. [Jerez, Alvaro] CITACA, Guatemala City, Guatemala. [Munoz, Rodrigo] Family Hlth Ctr San Diego, San Diego, CA USA. [Munoz, Rodrigo; Almasy, Laura] SW Fdn Biomed Res, San Antonio, TX 78284 USA. [Escamilla, Michael A.] Univ Texas Hlth Sci Ctr San Antonio, Reg Acad Hlth Ctr, S Texas Med Genet Res Grp, Edinburg, TX USA. RP Hare, E (reprint author), 454 Soledad St,Suite 200, San Antonio, TX 78205 USA. EM hare@uthscsa.edu OI Nicolini, Humberto/0000-0003-2494-0067; Raventos, Henriette/0000-0001-9423-8308; Jerez Magana, Alvaro Antonio/0000-0002-1208-3769 NR 55 TC 21 Z9 23 U1 2 U2 3 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1552-4841 J9 AM J MED GENET B JI Am. J. Med. Genet. B PD JAN PY 2010 VL 153B IS 1 BP 298 EP 302 DI 10.1002/ajmg.b.30959 PG 5 WC Genetics & Heredity; Psychiatry SC Genetics & Heredity; Psychiatry GA 541SM UT WOS:000273440500036 PM 19350535 ER PT J AU Tsai, HT Caroff, SN Miller, DD McEvoy, J Lieberman, JA North, KE Stroup, TS Sullivan, PF AF Tsai, Huei-Ting Caroff, Stanley N. Miller, Del D. McEvoy, Joseph Lieberman, Jeffrey A. North, Kari E. Stroup, T. Scott Sullivan, Patrick F. TI A Candidate Gene Study of Tardive Dyskinesia in the CATIE Schizophrenia Trial SO AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS LA English DT Article DE schizophrenia; tardive dyskinesia; antipsychotic medication; adverse drug reaction; genetic; candidate gene association ID RECEPTOR GENE; GENOMEWIDE ASSOCIATION; METAANALYSIS; ANTIPSYCHOTICS; POLYMORPHISMS; METABOLISM; RISK; SET AB Tardive dyskinesia (TD) is a movement disorder characterized by involuntary oro-facial, limb, and truncal movements. As a genetic basis for inter-individual variation is assumed, there have been a sizeable number of candidate gene studies. All subjects met diagnostic criteria for schizophrenia and were randomized to receive antipsychotic medications as participants in the Clinical Antipsychotic Trials of Intervention Effectiveness project (CATIE). TD was assessed via the Abnormal Involuntary Movement Scale at regular intervals. Probable TD was defined as meeting Schooler-Kane criteria at any scheduled CATIE visit (207/710 subjects, 29.2%). A total of 128 candidate genes were studied in 710 subjects-2,580 SNPs in 118 candidate genes selected from the literature (e.g., dopamine, serotonin, glutamate, and GABA pathways) and composite genotypes for 10 drug-metabolizing enzymes. No single marker or haplotype association reached statistical significance after adjustment for multiple comparisons. Thus, we found no support for either novel or prior associations from the literature. (C) 2009 Wiley-Liss, Inc. C1 [Sullivan, Patrick F.] Univ N Carolina, Dept Genet, Chapel Hill, NC 27599 USA. [Tsai, Huei-Ting; North, Kari E.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27599 USA. [Tsai, Huei-Ting] NCI, US Natl Inst Hlth, Bethesda, MD 20892 USA. [Caroff, Stanley N.] Univ Penn, Dept Psychiat, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. [Miller, Del D.] Univ Iowa, Dept Psychiat, Carver Coll Med, Iowa City, IA 52242 USA. [McEvoy, Joseph] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC USA. [Lieberman, Jeffrey A.] Columbia Univ, Dept Psychiat, New York, NY USA. [Stroup, T. Scott; Sullivan, Patrick F.] Univ N Carolina, Dept Psychiat, Chapel Hill, NC 27599 USA. RP Sullivan, PF (reprint author), Univ N Carolina, Dept Genet, CB 7264,4109D Neurosci Res Bldg, Chapel Hill, NC 27599 USA. EM pfsulliv@med.unc.edu RI Stroup, Thomas/F-9188-2014 OI Stroup, Thomas/0000-0002-3123-0672 FU NIMH [N01 MH90001]; [R01s MH074027]; [R01s MH077139]; [R01s MH080403] FX Dr. Sullivan was supported by R01s MH074027, MH077139, and MH080403. The CATIE project was funded by NIMH contract N01 MH90001. We thank Dr. David Goldstein of Duke University for providing genotypes. NR 29 TC 27 Z9 30 U1 0 U2 1 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1552-4841 J9 AM J MED GENET B JI Am. J. Med. Genet. B PD JAN PY 2010 VL 153B IS 1 BP 336 EP 340 DI 10.1002/ajmg.b.30981 PG 5 WC Genetics & Heredity; Psychiatry SC Genetics & Heredity; Psychiatry GA 541SM UT WOS:000273440500043 PM 19475583 ER PT J AU Mortensen, EM Copeland, LA Pugh, MJ Fine, MJ Nakashima, B Restrepo, MI de Molina, RM Anzueto, A AF Mortensen, Eric M. Copeland, Laurel A. Pugh, Mary Jo Fine, Michael J. Nakashima, Brandy Restrepo, Marcos I. de Molina, Rosa Malo Anzueto, Antonio TI Diagnosis of Pulmonary Malignancy after Hospitalization for Pneumonia SO AMERICAN JOURNAL OF MEDICINE LA English DT Article DE Cancer; Incidence; Pneumonia ID LUNG-CANCER; COMORBIDITY INDEX; VALIDATION; QUALITY; STAGE AB BACKGROUND: Many physicians recommend that patients receive follow-up chest imaging after the diagnosis of pneumonia to ensure that a pulmonary malignancy is not missed. However, there is little research evidence to support this practice. Our aims were to assess the frequency of the diagnosis of Pulmonary malignancy, and to identify risk factors for pulmonary malignancy following hospitalization for pneumonia. METHODS: By excluding patients with a prior diagnosis of pulmonary malignancy, we examined the incidence of a new pulmonary malignancy diagnosis in inpatients aged >= 65 years with a discharge diagnosis of pneumonia in fiscal years 2002-2007, and at least 1 year of Department of Veterans Affairs outpatient care before the index admission. RESULTS: Of 40,744 patients hospitalized with pneumonia, 3760 (9.2%) patients were diagnosed with pulmonary malignancy after their index pneumonia admission. Median time to diagnosis was 297 days, with only 27% diagnosed within 90 days of admission. Factors significantly associated with a new diagnosis of pulmonary malignancy included history of chronic pulmonary disease, any prior malignancy, white race, being married, and tobacco use. Increasing age, Hispanic ethnicity, need for intensive care unit admission, and a history of congestive heart failure, stroke, dementia, or diabetes with complications were associated with a lower incidence of pulmonary malignancy. CONCLUSION: A small, but clinically important, proportion of patients are diagnosed with pulmonary malignancy posthospitalization for pneumonia. Additional research is needed to examine whether previously undiagnosed pulmonary malignancies might be detected at admission, or soon after, for those hospitalized with pneumonia. Published by Elsevier Inc. The American Journal of Medicine (2010) 123, 66-71 C1 [Mortensen, Eric M.; Copeland, Laurel A.; Pugh, Mary Jo; Nakashima, Brandy; Restrepo, Marcos I.; de Molina, Rosa Malo; Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, ALMD, VERDICT Res Program, San Antonio, TX 78229 USA. [Mortensen, Eric M.; Copeland, Laurel A.; Pugh, Mary Jo; Nakashima, Brandy; Restrepo, Marcos I.; de Molina, Rosa Malo; Anzueto, Antonio] S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. [Mortensen, Eric M.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Copeland, Laurel A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Pugh, Mary Jo] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA. [Fine, Michael J.] VA Pittsburg Healthcare Syst, VA Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Fine, Michael J.] Univ Pittsburgh, Dept Med, Div Gen Internal Med, Pittsburgh, PA 15260 USA. [Restrepo, Marcos I.; de Molina, Rosa Malo; Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, Div Pulm Crit Care Med, San Antonio, TX 78229 USA. RP Mortensen, EM (reprint author), Univ Texas Hlth Sci Ctr San Antonio, ALMD, VERDICT Res Program, 7400 Merton Minter Blvd 11C6, San Antonio, TX 78229 USA. EM mortensene@uthscsa.edu RI Restrepo, Marcos/H-4442-2014 OI Pugh, Mary Jo/0000-0003-4196-7763; Mortensen, Eric/0000-0002-3880-5563; Copeland, Laurel/0000-0002-9478-0209 FU National Institute of Nursing Research [R01NR010828]; VA Health Services Research and Development program [MRP-05-145]; National Institutes of Health [KL2]; University of Texas Health Science Center at San Antonio FX The project described was supported by Grant Number R01NR010828 from the National Institute of Nursing Research. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Nursing Research or the National Institutes of Health. This material is the result of work supported with resources and the use of facilities at the South Texas Veterans Health Care System. Dr Copeland is funded by Merit Review Entry Program grant MRP-05-145 from the VA Health Services Research and Development program. Dr. Restrepo is funded by a KL2 of the National Institutes of Health and the University of Texas Health Science Center at San Antonio. The funding agencies had no role in conducting the study, or role in the preparation, review, or approval of the manuscript. NR 18 TC 21 Z9 21 U1 1 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9343 J9 AM J MED JI Am. J. Med. PD JAN PY 2010 VL 123 IS 1 BP 66 EP 71 DI 10.1016/j.amjmed.2009.08.009 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA 545HC UT WOS:000273722100016 PM 20102994 ER PT J AU Li, M Khan, AM Maderdrut, JL Simon, EE Batuman, V AF Li, Min Khan, Altaf-M. Maderdrut, Jerome L. Simon, Eric E. Batuman, Vecihi TI The Effect of PACAP38 on MyD88-Mediated Signal Transduction in Ischemia-/Hypoxia-Induced Acute Kidney Injury SO AMERICAN JOURNAL OF NEPHROLOGY LA English DT Article DE Acute kidney injury; Innate immunity; Pituitary adenylate cyclase-activating polypeptide; Proximal tubule cells; Toll-like receptors ID TOLL-LIKE RECEPTORS; ACUTE-RENAL-FAILURE; INNATE IMMUNE-RESPONSE; ISCHEMIA/REPERFUSION INJURY; MACROPHAGES CONTRIBUTE; TUBULAR CELLS; UP-REGULATION; BRAIN-INJURY; PATHWAYS; INFLAMMATION AB Background/Aims: Toll-like receptor 4 (TLR4) and its adaptor protein MyD88 play an important role in ischemia/reperfusion (I/R) injury in the kidney, and pituitary adenylate cyclase-activating polypeptide (PACAP) could ameliorate renal I/R injury. Methods: Primary cultures of proximal tubule epithelial cells (PTEC) were prepared from wild-type and MyD88(-/-) mice, and subjected to hypoxia in vitro. Acute kidney injury (AKI) was induced by I/R in vivo in wild-type mice only. Results: Hypoxia resulted in significant increases in cytokine production and apoptosis/necrosis in wild-type PTEC, but these responses were markedly blunted in MyD88(-/-) PTEC. Treatment with PACAP38 before or after hypoxia further suppressed the hypoxia-induced cytokine responses and apoptosis in both MyD88(+/+) and MyD88(-/-)PTEC cultures. PACAP38 significantly inhibited TLR4/MyD88/TRAF6 as well as TRIF and IRF3 expression in mouse kidney and PTEC, and inhibited the secretion and mRNA expression of cytokines in kidneys from mice after I/R, paralleling the cytokine responses in vitro. Moreover, treatment with PACAP38 protected mice from renal failure, histological damage, neutrophil influx and tubule cell apoptosis after I/R. Conclusion: Our data reveal that the TLR4-mediated cytokine responses to hypoxia are primarily dependent on MyD88 signaling and highlight the pivotal role of MyD88-dependent mechanisms in the coordination of the innate immune responses to ischemic/hypoxic acute renal tubular injury. The renoprotective effect of PACAP in AKI involves both MyD88-dependent and -independent pathways. Copyright (C) 2010 S. Karger AG, Basel C1 [Li, Min; Khan, Altaf-M.; Simon, Eric E.; Batuman, Vecihi] Tulane Univ, Sch Med, Dept Med, Sect Nephrol & Hypertens, New Orleans, LA 70112 USA. [Maderdrut, Jerome L.] Tulane Univ, Sch Med, Dept Med, Peptide Res Lab, New Orleans, LA 70112 USA. [Simon, Eric E.; Batuman, Vecihi] SE Louisiana Vet Hlth Care Syst, US Dept Vet Affairs, New Orleans, LA USA. RP Li, M (reprint author), Tulane Univ, Sch Med, Dept Med, Sect Nephrol & Hypertens, 1430 Tulane Ave,SL-45, New Orleans, LA 70112 USA. EM minlee@tulane.edu OI Batuman, Vecihi/0000-0002-1800-9009 FU Louisiana Board of Regent [013RCEEP-07]; Rudolph Matas Memorial Fund; Dialysis Clinic Inc. FX M.L., J.L.M. and V.B. were supported by the Research Commercialization and Educational Enhancement Program of the Louisiana Board of Regents (013RCEEP-07). V.B. and M.L. were also supported by the Rudolph Matas Memorial Fund and the Dialysis Clinic Inc., and M.L. received additional support from the Arimura Foundation. The authors would like to thank Dr. Eduardo Davila (Louisiana State University Health Sciences Center in New Orleans, La., USA) for providing kidneys from MyD88-/-mice. Data from this research was presented in part at the Annual Meeting of American Society of Nephrology, October 27 to November 1, 2009, in San Diego, Calif., USA. NR 40 TC 11 Z9 12 U1 0 U2 2 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0250-8095 J9 AM J NEPHROL JI Am. J. Nephrol. PY 2010 VL 32 IS 6 BP 522 EP 532 DI 10.1159/000321491 PG 11 WC Urology & Nephrology SC Urology & Nephrology GA 699OU UT WOS:000285673500002 PM 20980738 ER PT J AU Peralta, CA Risch, N Lin, F Shlipak, MG Reiner, A Ziv, E Tang, H Siscovick, D Bibbins-Domingo, K AF Peralta, Carmen A. Risch, Neil Lin, Feng Shlipak, Michael G. Reiner, Alex Ziv, Elad Tang, Hua Siscovick, David Bibbins-Domingo, Kirsten TI The Association of African Ancestry and Elevated Creatinine in the Coronary Artery Risk Development in Young Adults (CARDIA) Study SO AMERICAN JOURNAL OF NEPHROLOGY LA English DT Article DE Ancestry; Creatinine; Race; Kidney ID STAGE RENAL-DISEASE; CHRONIC KIDNEY-DISEASE; 9 GENE MYH9; POPULATION-STRUCTURE; RACIAL-DIFFERENCES; SERUM CREATININE; BLOOD-PRESSURE; UNITED-STATES; AMERICANS; ADMIXTURE AB Whether genetic factors account for differences in early kidney disease among blacks in a young healthy population is not well known. We evaluated the association of self-reported race and genetic African ancestry with elevated creatinine (>= 1.3 mg/dl for men, >= 1.1 mg/dl for women) among 3,113 black and white participants in the Coronary Artery Risk Development in Young Adults (CARDIA) study, ages 38-50 years. We estimated individual African ancestry using 42 ancestry informative markers. Blacks were more likely to have elevated creatinine than whites, and this effect was more pronounced in men: adjusted odds ratio (AOR) for black versus white men = 7.03, 4.15-11.91; AOR for women = 2.40, 1.15-5.02. Higher African ancestry was independently associated with elevated creatinine among black men (AOR = 1.53,1.08-2.16 per SD increase in African ancestry), but not women. A graded increase in odds of elevated creatinine by African Ancestry was observed among black men compared with white men: AOR = 4.27 (2.26-10.06) for black men with 40-70% African ancestry; AOR = 8.09 (4.19-15.61) for black men with 70-80% African ancestry; AOR = 9.05 (4.81-17.02) for black men with >80% African ancestry. Genetic factors common to African ancestry may be associated with increased risk of early kidney dysfunction in a young, healthy population, particularly among black men. Copyright (C) 2009 S. Karger AG, Basel C1 [Peralta, Carmen A.; Shlipak, Michael G.; Ziv, Elad; Bibbins-Domingo, Kirsten] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Peralta, Carmen A.; Shlipak, Michael G.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA. [Risch, Neil; Lin, Feng; Shlipak, Michael G.; Ziv, Elad; Bibbins-Domingo, Kirsten] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Risch, Neil] Univ Calif San Francisco, Inst Human Genet, San Francisco, CA 94143 USA. [Reiner, Alex; Siscovick, David] Univ Washington, Dept Med, Seattle, WA USA. [Reiner, Alex; Siscovick, David] Univ Washington, Dept Epidemiol, Seattle, WA USA. [Tang, Hua] Stanford Univ, Palo Alto, CA 94304 USA. [Bibbins-Domingo, Kirsten] San Francisco Gen Hosp, Div Gen Internal Med, San Francisco, CA 94110 USA. [Bibbins-Domingo, Kirsten] Univ Calif San Francisco, San Francisco Gen Hosp, Ctr Vulnerable Populat, San Francisco, CA USA. RP Peralta, CA (reprint author), 4150 Clement St,111A1, San Francisco, CA 94121 USA. EM carmenalicia.peralta@ucsf.edu RI Ziv, Elad/L-5396-2014 NR 40 TC 8 Z9 8 U1 1 U2 1 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0250-8095 J9 AM J NEPHROL JI Am. J. Nephrol. PY 2010 VL 31 IS 3 BP 202 EP 208 DI 10.1159/000268955 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA 570LE UT WOS:000275678400002 PM 20029176 ER PT J AU Shields, AM LaRue, EM AF Shields, Anne-Marie LaRue, Elizabeth M. TI Transitioning from clinician to clinical research coordinator SO AMERICAN JOURNAL OF NURSING LA English DT Article C1 [Shields, Anne-Marie] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [LaRue, Elizabeth M.] Univ Pittsburgh, Sch Nursing, Pittsburgh, PA 15261 USA. RP Shields, AM (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. NR 6 TC 1 Z9 1 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0002-936X J9 AM J NURS JI Am. J. Nurs. PY 2010 SU S BP 26 EP 27 PG 2 WC Nursing SC Nursing GA 549PH UT WOS:000274065600009 ER PT J AU Sosa, MAG De Gasperi, R Rocher, AB Wang, ACJ Janssen, WGM Flores, T Perez, GM Schmeidler, J Dickstein, DL Hof, PR Elder, GA AF Sosa, Miguel A. Gama De Gasperi, Rita Rocher, Anne B. Wang, Athena Ching-Jung Janssen, William G. M. Flores, Tony Perez, Gissel M. Schmeidler, James Dickstein, Dara L. Hof, Patrick R. Elder, Gregory A. TI Age-Related Vascular Pathology in Transgenic Mice Expressing Presenilin 1-Associated Familial Alzheimer's Disease Mutations SO AMERICAN JOURNAL OF PATHOLOGY LA English DT Article ID CEREBRAL AMYLOID ANGIOPATHY; BLOOD-VESSELS; MUTANT PRESENILIN-1; NEURONAL EXPRESSION; MOUSE-BRAIN; ADULT MICE; A-BETA; PLAQUES; PROTEIN; GENE AB Mutations in the presenilin 1 (PS1) gene are the most commonly recognized cause of familial Alzheimer's disease (FAD). Besides senile plaques, neurofibrillary tangles, and neuronal loss, Alzheimer's disease (AD) is also accompanied by vascular pathology. Here we describe an age-related vascular pathology in two lines of PS1 FAD-mutant transgenic mice that mimics many features of the vascular pathology seen in AD. The pathology was especially prominent in the microvasculature whose vessels became thinned and irregular with the appearance of many abnormally looped vessels as well as string vessels. Stereologic assessments revealed a reduction of the microvasculature in the hippocampus that was accompanied by hippocampal atrophy. The vascular changes were not congophilic. Yet, despite the lack of congophilia, penetrating vessels at the cortical surface were often abnormal morphologically and microhemorrhages; sometimes occurred. Altered immunostaining of blood vessels with basement membrane-associated antigens was an early feature of the microangiopathy and was associated with thickening of the vascular basal laminae and endothelial cell alterations that were visible ultrastructurally. Interestingly, although the FAD-mutant transgene was expressed in neurons in both lines of mice, there was no detectable expression in vascular endothelial cells or glial cells. These studies thus have implications for the role of neuronal to vascular signaling in the pathogenesis of the vascular pathology associated with AD. (Am J Pathol 2010, 176:353-368; DOI: 10.2353/ajpath.2010.090482) C1 [Elder, Gregory A.] James J Peters VA Med Ctr, Neurol Serv, Bronx, NY 10468 USA. [Sosa, Miguel A. Gama; De Gasperi, Rita; Perez, Gissel M.; Schmeidler, James; Elder, Gregory A.] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Rocher, Anne B.; Wang, Athena Ching-Jung; Janssen, William G. M.; Flores, Tony; Dickstein, Dara L.; Hof, Patrick R.] Mt Sinai Sch Med, Dept Neurosci, New York, NY USA. [Hof, Patrick R.] Mt Sinai Sch Med, Dept Geriatr & Palliat Care, New York, NY USA. [Elder, Gregory A.] Mt Sinai Sch Med, Dept Neurol, New York, NY USA. [Dickstein, Dara L.; Hof, Patrick R.] Mt Sinai Sch Med, Computat Neurobiol & Imaging Ctr, New York, NY USA. [Rocher, Anne B.] Boston Univ, Dept Anat & Neurobiol, Boston, MA 02215 USA. RP Elder, GA (reprint author), James J Peters VA Med Ctr, Neurol Serv 3E 16, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM gregory.elder@mssm.edu RI Dickstein, Dara/F-3036-2013 FU National Institute on Aging [AG20139, AG02219, AG05138, AG010491, AG029361]; Alzheimer's Association [IIRG-07-57318]; Department of Veterans Affairs [5I01BX000342-02] FX Supported by the National Institute on Aging (grants AG20139, AG02219, AG05138, AG010491, and AG029361), the Alzheimer's Association (IIRG-07-57318), and a merit award from the Department of Veterans Affairs (5I01BX000342-02). NR 56 TC 30 Z9 30 U1 1 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9440 J9 AM J PATHOL JI Am. J. Pathol. PD JAN PY 2010 VL 176 IS 1 BP 353 EP 368 DI 10.2353/ajpath.2010.090482 PG 16 WC Pathology SC Pathology GA 550EN UT WOS:000274111200035 ER PT J AU Nakamura, Y Do, JH Yuan, JZ Odinokova, IV Mareninova, O Gukovskaya, AS Pandol, SJ AF Nakamura, Yuji Do, Jae Hyuk Yuan, Jingzhen Odinokova, Irina V. Mareninova, Olga Gukovskaya, Anna S. Pandol, Stephen J. TI Inflammatory cells regulate p53 and caspases in acute pancreatitis SO AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY LA English DT Article DE pancreatitis; p53; caspases-2; Mdm2; apoptosis ID CERULEIN-INDUCED PANCREATITIS; CYTOCHROME-C RELEASE; INDUCED APOPTOSIS; ACINAR-CELLS; T-CELLS; INHIBITOR; DEATH; ACTIVATION; PROTEIN; COMPLEX AB Nakamura Y, Do JH, Yuan J, Odinokova IV, Mareninova O, Gukovskaya AS, Pandol SJ. Inflammatory cells regulate p53 and caspases in acute pancreatitis. Am J Physiol Gastrointest Liver Physiol 298: G92-G100, 2010. First published October 22, 2009; doi:10.1152/ajpgi.00324.2009.-The inflammatory response during pancreatitis regulates necrotic and apoptotic rates of parenchymal cells. Neutrophil depletion by use of anti-polymorphonuclear serum (anti-PMN) increases apoptosis in experimental pancreatitis but the mechanism has not been determined. Our study was designed to investigate signaling mechanisms in pancreatic parenchymal cells regulating death responses with neutrophil depletion. Rats were neutrophil depleted with anti-PMN treatment. Then cerulein pancreatitis was induced, followed by measurements of apoptosis signaling pathways. There was greater activation of executioner caspases-3 in the pancreas with anti-PMN treatment compared with control. There were no differences between these groups of animals in mitochondrial cytochrome c release or in activities of initiator caspase-8 and -9. However, there was greater activation of caspase-2 with anti-PMN treatment during cerulein pancreatitis. The upstream regulation of caspases-2 includes p53, which was increased; the p53 negative regulator, Mdm2, was decreased by anti-PMN treatment during cerulein pancreatitis. In vitro experiments using isolated pancreatic acinar cells a pharmacological inhibitor of Mdm2 increased caspase2/-3 activities, and an inhibitor of p53 decreased these activities during cholecystokinin-8 treatment. Furthermore, experiments using the AR42J cell line Mdm2 small interfering RNA (siRNA) increased caspase-2/-3 activities, and p53 siRNA decreased these activities during cholecystokinin-8 treatment. These results suggest that during acute pancreatitis the inflammatory response inhibits apoptosis. The mechanism of this inhibition involves caspase-2 and its upstream regulation by p53 and Mdm2. Because previous findings indicate that promotion of apoptosis decreases necrosis and severity of pancreatitis, these results suggest that strategies to inhibit Mdm2 or activate p53 will have beneficial effects for treatment of pancreatitis. C1 [Nakamura, Yuji; Do, Jae Hyuk; Yuan, Jingzhen; Odinokova, Irina V.; Mareninova, Olga; Gukovskaya, Anna S.; Pandol, Stephen J.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Nakamura, Yuji; Do, Jae Hyuk; Yuan, Jingzhen; Odinokova, Irina V.; Mareninova, Olga; Gukovskaya, Anna S.; Pandol, Stephen J.] Univ Calif Los Angeles, Los Angeles, CA USA. [Nakamura, Yuji] Keio Univ, Sch Med, Dept Internal Med, Div Gastroenterol & Hepatol, Tokyo, Japan. [Do, Jae Hyuk] Chung Ang Univ, Sch Med, Dept Internal Med, Div Gastroenterol, Seoul 156756, South Korea. [Odinokova, Irina V.] Russian Acad Sci, Inst Theoret & Expt Biophys, Pushchino 142292, Moscow Region, Russia. RP Pandol, SJ (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd,Bldg 258,Rm 340, Los Angeles, CA 90073 USA. EM stephen.pandol@med.va.gov FU National Institutes of Health (NIH) [5P01AT003960, 2P50AA011999] FX This study was supported by the Department of Veterans Affairs, UCLA Center for Excellence in Pancreatic Diseases [National Institutes of Health (NIH) Grant no. 5P01AT003960], and Southern California Research Center for ALPD and Cirrhosis (NIH Grant no. 2P50AA011999). NR 51 TC 10 Z9 11 U1 0 U2 2 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1857 J9 AM J PHYSIOL-GASTR L JI Am. J. Physiol.-Gastroint. Liver Physiol. PD JAN PY 2010 VL 298 IS 1 BP G92 EP G100 DI 10.1152/ajpgi.00324.2009 PG 9 WC Gastroenterology & Hepatology; Physiology SC Gastroenterology & Hepatology; Physiology GA 534VQ UT WOS:000272926000012 PM 19850968 ER PT J AU Ohno, I Eibl, G Odinokova, I Edderkaoui, M Damoiseaux, RD Yazbec, M Abrol, R Goddard, WA Yokosuka, O Pandol, SJ Gukovskaya, AS AF Ohno, Izumi Eibl, Guido Odinokova, Irina Edderkaoui, Mouad Damoiseaux, Robert D. Yazbec, Moussa Abrol, Ravinder Goddard, William A., III Yokosuka, Osamu Pandol, Stephen J. Gukovskaya, Anna S. TI Rottlerin stimulates apoptosis in pancreatic cancer cells through interactions with proteins of the Bcl-2 family SO AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY LA English DT Article DE phytochemical; polyphone; mitochondria; proapoptotic protein ID KINASE-C-DELTA; MITOCHONDRIAL PERMEABILITY TRANSITION; LIGAND-INDUCED APOPTOSIS; CYTOCHROME-C; ACINAR-CELLS; PKC-DELTA; MEMBRANE PERMEABILIZATION; CARCINOMA-CELLS; NADPH OXIDASE; ATP LEVELS AB Ohno I, Eibl G, Odinokova I, Edderkaoui M, Damoiseaux RD, Yazbec M, Abrol R, Goddard WA 3rd, Yokosuka O, Pandol SJ, Gukovskaya AS. Rottlerin stimulates apoptosis in pancreatic cancer cells through interactions with proteins of the Bcl-2 family. Am J Physiol Gastrointest Liver Physiol 298: G63-G73, 2010. First published September 17, 2009; doi:10.1152/ajpgi.00257.2009.-Rottlerin is a polyphenolic compound derived from Mallotus philipinensis. In the present study, we show that rottlerin decreased tumor size and stimulated apoptosis in an orthotopic model of pancreatic cancer with no effect on normal tissues in vivo. Rottlerin also induced apoptosis in pancreatic cancer (PaCa) cell lines by interacting with mitochondria and stimulating cytochrome c release. Immunoprecipitation results indicated that rottlerin disrupts complexes of prosurvival Bcl-xL with Bim and Puma. Furthermore, siRNA knockdown showed that Bim and Puma are necessary for rottlerin to stimulate apoptosis. We also showed that rottlerin and Bcl-2 and Bcl-xL inhibitor BH3I-2' stimulate apoptosis through a common mechanism. They both directly interact with mitochondria, causing increased cytochrome c release and mitochondrial depolarization, and both decrease sequestration of BH3-only proteins by Bcl-xL. However, the effects of rottlerin and BH3I-2' on the complex formation between Bcl-xL and BH3-only proteins are different. BH3I-2' disrupts complexes of Bcl-xL with Bad but not with Bim or Puma, whereas rottlerin had no effect on the Bcl-xL interaction with Bad. Also BH3I-2', but not rottlerin, required Bad to stimulate apoptosis. In conclusion, our results demonstrate that rottlerin has a potent proapoptotic and antitumor activity in pancreatic cancer, which is mediated by disrupting the interaction between prosurvival Bcl-2 proteins and proapoptotic BH3-only proteins. Thus rottlerin represents a promising novel agent for pancreatic cancer treatment. C1 [Gukovskaya, Anna S.] Univ Calif Los Angeles, W Los Angeles VA Healthcare Ctr, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Ohno, Izumi; Odinokova, Irina; Edderkaoui, Mouad; Yazbec, Moussa; Pandol, Stephen J.; Gukovskaya, Anna S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Eibl, Guido] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA. [Odinokova, Irina] Russian Acad Sci, Inst Theoret & Expt Biophys, Pushchino 142292, Russia. [Abrol, Ravinder; Goddard, William A., III] CALTECH, Beckman Inst, Mat & Proc Simulat Ctr, Pasadena, CA 91125 USA. [Ohno, Izumi; Yokosuka, Osamu] Chiba Univ, Grad Sch Med, Dept Med & Clin Oncol, Chiba, Japan. RP Gukovskaya, AS (reprint author), Univ Calif Los Angeles, W Los Angeles VA Healthcare Ctr, VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd,Bldg 258,Rm 340, Los Angeles, CA 90073 USA. EM agukovsk@ucla.edu RI Damoiseaux, Robert/F-1086-2011; Abrol, Ravinder/B-4980-2010 OI Damoiseaux, Robert/0000-0002-7611-7534; FU Hirshberg Foundation for Pancreatic Cancer Research; NIH [CA119025]; NCCAM [AT003960]; Department of Veterans Affairs Merit Award FX This study was supported by the Hirshberg Foundation for Pancreatic Cancer Research, the NIH grants CA119025 (to A. Gukovskaya.), NCCAM AT003960 (to S. Pandol), and the Department of Veterans Affairs Merit Award (to A. Gukovskaya). NR 48 TC 21 Z9 21 U1 0 U2 1 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1857 J9 AM J PHYSIOL-GASTR L JI Am. J. Physiol.-Gastroint. Liver Physiol. PD JAN PY 2010 VL 298 IS 1 BP G63 EP G73 DI 10.1152/ajpgi.00257.2009 PG 11 WC Gastroenterology & Hepatology; Physiology SC Gastroenterology & Hepatology; Physiology GA 534VQ UT WOS:000272926000009 PM 19762431 ER PT J AU Wang, LX Gourcerol, G Yuan, PQ Wu, SV Million, M Larauche, M Tache, Y AF Wang, Lixin Gourcerol, Guillaume Yuan, Pu-Qing Wu, S. Vincent Million, Mulugeta Larauche, Muriel Tache, Yvette TI Peripheral peptide YY inhibits propulsive colonic motor function through Y-2 receptor in conscious mice SO AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY LA English DT Article DE PYY3-36; stress; serotonin; bethanechol ID ENTERIC NERVOUS-SYSTEM; INDUCED ILEAL BRAKE; NEUROPEPTIDE-Y; FOOD-INTAKE; PANCREATIC-POLYPEPTIDE; MYENTERIC NEURONS; FACTOR CRF; RAT COLON; GASTROINTESTINAL-TRACT; INCREASED DEFECATION AB Wang L, Gourcerol G, Yuan P-Q, Wu SV, Million M, Larauche M, Tache Y. Peripheral peptide YY inhibits propulsive colonic motor function through Y-2 receptor in conscious mice. Am J Physiol Gastrointest Liver Physiol 298: G45-G56, 2010. First published November 5, 2009; doi:10.1152/ajpgi.00349.2009.-Peptide YY (PYY) antisecretory effect on intestinal epithelia is well established, whereas less is known about its actions to influence colonic motility in conscious animals. We characterized changes in basal function and stimulated colonic motor function induced by PYY-related peptides in conscious mice. PYY3-36, PYY, and neuropeptide Y (NPY) (8 nmol/kg) injected intraperitoneally inhibited fecal pellet output (FPO) per hour during novel environment stress by 90%, 63%, and 57%, respectively, whereas the Y-1-preferring agonists, [Pro(34)] PYY and [Leu(31), Pro(34)] NPY, had no effect. Corticotrophin-releasing factor 2 receptor antagonist did not alter PYY3-36 inhibitory action. PYY and PYY3-36 significantly reduced restraint-stimulated defecation, and PYY3-36 inhibited high-amplitude distal colonic contractions in restrained conscious mice for 1 h, by intraluminal pressure with the use of a microtransducer. PYY suppression of intraperitoneal 5-hydroxytryptophan induced FPO and diarrhea was blocked by the Y-2 antagonist, BIIE0246, injected intraperitoneally and mimicked by PYY3-36, but not [Leu(31), Pro(34)] NPY. PYY3-36 also inhibited bethanechol-stimulated FPO and diarrhea. PYY3-36 inhibited basal FPO during nocturnal feeding period and light phase in fasted/refed mice for 2-3 h, whereas the reduction of food intake lasted for only 1 h. PYY3-36 delayed gastric emptying after fasting-refeeding by 48% and distal colonic transit time by 104%, whereas [Leu(31), Pro(34)] NPY had no effect. In the proximal and distal colon, higher Y-2 mRNA expression was detected in the mucosa than in muscle layers, and Y-2 immunoreactivity was located in nerve terminals around myenteric neurons. These data established that PYY/PYY3-36 potently inhibits basal and stress/serotonin/cholinergic-stimulated propulsive colonic motor function in conscious mice, likely via Y-2 receptors. C1 Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, CURE Digest Dis Res Ctr, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Ctr Neurobiol Stress,Div Digest Dis, Los Angeles, CA 90095 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Wang, LX (reprint author), Bldg 115,Rm 117B,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM lixinw@ucla.edu OI Larauche, Muriel/0000-0003-3320-3675 FU National Institute of Diabetes and Digestive and Kidney Diseases [DK-57238, DK 41301, DK078676] FX This work was supported by the National Institute of Diabetes and Digestive and Kidney Diseases R01 grant DK-57238 (Y. Tache), Center grant DK 41301 (Peptidomics core and Animal Model core), and DK078676 (M. Million), and VA Senior Career Scientist Award (Y. Tache). NR 69 TC 18 Z9 18 U1 0 U2 2 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1857 J9 AM J PHYSIOL-GASTR L JI Am. J. Physiol.-Gastroint. Liver Physiol. PD JAN PY 2010 VL 298 IS 1 BP G45 EP G56 DI 10.1152/ajpgi.00349.2009 PG 12 WC Gastroenterology & Hepatology; Physiology SC Gastroenterology & Hepatology; Physiology GA 534VQ UT WOS:000272926000007 PM 19892938 ER PT J AU Peterfi, Z McGinty, D Sarai, E Szymusiak, R AF Peterfi, Zoltan McGinty, Dennis Sarai, Erzsebet Szymusiak, Ronald TI Growth hormone-releasing hormone activates sleep regulatory neurons of the rat preoptic hypothalamus SO AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY LA English DT Article DE preoptic area; growth hormone-releasing hormone; somatostatin; octreotide; median preoptic nucleus; ventrolateral preoptic nucleus ID CENTRAL-NERVOUS-SYSTEM; SOMATOSTATIN-CONTAINING NEURONS; WAKING DISCHARGE PATTERNS; SLOW-WAVE SLEEP; MESSENGER-RNA; FACTOR GRF; IMMUNOCYTOCHEMICAL LOCALIZATION; GABAERGIC NEURONS; ULTRADIAN RHYTHM; ARCUATE NUCLEUS AB Peterfi Z, McGinty D, Sarai E, Szymusiak R. Growth hormone-releasing hormone activates sleep regulatory neurons of the rat preoptic hypothalamus. Am J Physiol Regul Integr Comp Physiol 298: R147-R156, 2010. First published November 4, 2009; doi:10.1152/ajpregu.00494.2009.-We examined whether growth hormone-releasing hormone (GHRH) may promote non-rapid eye movement (NREM) sleep via activation of GABAergic neurons in the preoptic area. Male Sprague-Dawley rats were implanted with EEG, EMG electrodes and a unilateral intracerebroventricular cannula. Groups of rats received injections (3 mu l icv) with gonadotropin-releasing hormone (GHRH) (0.1 nmol/100 g body wt) or equal volume of physiological saline at the onset of the dark period and were permitted spontaneous sleep for 90 min. Separate groups of rats were sleep deprived by gentle handling for 90 min, beginning at the time of GHRH or saline injection, at the onset of the dark period. Other groups of rats received intracerebroventricular octreotide (somatostatin analog OCT) injections, intracerebroventricular injection of one of two doses of competitive GHRH antagonist, or intracerebroventricular saline injection at light onset and were then permitted 90 min spontaneous sleep-waking. Rats were killed immediately after the 90-min sleep/wake monitoring period. Brain tissue was processed for immunohistochemistry for c-Fos protein and glutamic acid decarboxylase (GAD). Single c-Fos and dual Fos-GAD cell counts were determined in the median preoptic nucleus (MnPN), and in the core and the extended parts of the ventrolateral preoptic nucleus (cVLPO and exVLPO). Intracerebroventricular GHRH elicited a significant increase in NREM sleep amount. Double-labeled Fos + GAD cell counts were significantly elevated after GHRH injection in the MnPN and VLPO in both undisturbed and sleep-deprived groups. OCT and GHRH antagonist significantly decreased NREM sleep amount compared with control rats. OCT injection increased single c-Fos-labeled cell counts in the MnPN, but not in the VLPO. Double-labeled cell counts were significantly reduced after OCT and the high dose of GHRH antagonist injection in all areas examined. These findings identify GABAergic neurons in the MnPN and VLPO as potential targets of the sleep-regulatory actions of GHRH. C1 [Peterfi, Zoltan; McGinty, Dennis; Sarai, Erzsebet; Szymusiak, Ronald] VA Greater Angeles Healthcare Syst, Res Serv, North Hills, CA 91344 USA. [Peterfi, Zoltan; Szymusiak, Ronald] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Szymusiak, Ronald] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA. RP Szymusiak, R (reprint author), VA Greater Angeles Healthcare Syst, Res Serv 151A3, 16111 Plummer St, North Hills, CA 91344 USA. EM rszym@ucla.edu FU Department of Veterans Affairs; National Institutes of Health [MH63323] FX This study is supported by The Department of Veterans Affairs and National Institutes of Health Grant MH63323. NR 66 TC 15 Z9 16 U1 0 U2 4 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6119 EI 1522-1490 J9 AM J PHYSIOL-REG I JI Am. J. Physiol.-Regul. Integr. Comp. Physiol. PD JAN PY 2010 VL 298 IS 1 BP R147 EP R156 DI 10.1152/ajpregu.00494.2009 PG 10 WC Physiology SC Physiology GA 536VF UT WOS:000273071300018 PM 19889861 ER PT J AU Jaimes, EA Hua, P Tian, RX Raij, L AF Jaimes, Edgar A. Hua, Ping Tian, Run-Xia Raij, Leopoldo TI Human glomerular endothelium: interplay among glucose, free fatty acids, angiotensin II, and oxidative stress SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY LA English DT Article DE diabetes; prostaglandins; reactive oxygen species; nitric oxide ID NITRIC-OXIDE SYNTHASE; SUPEROXIDE ANION PRODUCTION; TYPE-1 DIABETES-MELLITUS; INTIMA-MEDIA THICKNESS; STAGE RENAL-DISEASE; INSULIN-RESISTANCE; METABOLIC SYNDROME; NEPHROPATHY; KIDNEY; PROGRESSION AB Jaimes EA, Hua P, Tian R-X, Raij L. Human glomerular endothelium: interplay among glucose, free fatty acids, angiotensin II, and oxidative stress. Am J Physiol Renal Physiol 298: F125-F132, 2010. First published October 28, 2009; doi:10.1152/ajprenal.00248.2009.-Glomerular endothelial cells (GEC) are strategically situated within the capillary loop and adjacent to the glomerular mesangium. GEC serve as targets of metabolic, biochemical, and hemodynamic signals that regulate the glomerular microcirculation. Unequivocally, hyperglycemia, hypertension, and the local renin-angiotensin system partake in the initiation and progression of diabetic nephropathy (DN). Whether free fatty acids (FFA) and reactive oxygen species (ROS) that have been associated with the endothelial dysfunction of diabetic macrovascular disease also contribute to DN is not known. Since endothelial cells from different organs and from different species may display different phenotypes, we employed human GEC to investigate the effect of high glucose (22.5 mmol/l), FFA (800 mu mol/l), and angiotensin II (ANG II; 10(-7) mol/l) on the genesis of ROS and their effects on endothelial nitric oxide synthase (eNOS), cyclooxygenase-2 (COX-2), and the synthesis of prostaglandins (PGs). We demonstrated that high glucose but not high FFA increased the expression of a dysfunctional eNOS as well as increased ROS from NADPH oxidase (100%) and likely from uncoupled eNOS. ANG II also induced ROS from NADPH oxidase. High glucose and ANG II upregulated (100%) COX-2 via ROS and significantly increased the synthesis of prostacyclin (PGI(2)) by 300%. In contrast, FFA did not upregulate COX-2 but increased PGI(2) (500%). These novel studies are the first in human GEC that characterize the differential role of FFA, hyperglycemia, and ANG II on the genesis of ROS, COX-2, and PGs and their interplay in the early stages of hyperglcyemia. C1 [Jaimes, Edgar A.; Hua, Ping] Univ Alabama Birmingham, Div Renal, Birmingham, AL 35294 USA. [Jaimes, Edgar A.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Tian, Run-Xia; Raij, Leopoldo] Univ Miami, Miller Sch Med, Div Renal, Miami, FL 33136 USA. [Raij, Leopoldo] Miami Vet Affairs Med Ctr, Miami, FL USA. RP Jaimes, EA (reprint author), Univ Alabama Birmingham, Div Renal, 701 19th St S,LHRB 459, Birmingham, AL 35294 USA. EM ejaimes@uab.edu FU Veterans Affairs Merit Review Award; National Institutes of Health Research [DK-063972]; South Florida Veterans Affairs Research Foundation FX These studies were supported by a Veterans Affairs Merit Review Award (E. A. Jaimes), a National Institutes of Health Research Grant (DK-063972 to E. A. Jaimes), and by research funds from the South Florida Veterans Affairs Research Foundation (L. Raij). NR 47 TC 32 Z9 36 U1 0 U2 7 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1931-857X EI 1522-1466 J9 AM J PHYSIOL-RENAL JI Am. J. Physiol.-Renal Physiol. PD JAN PY 2010 VL 298 IS 1 BP F125 EP F132 DI 10.1152/ajprenal.00248.2009 PG 8 WC Physiology; Urology & Nephrology SC Physiology; Urology & Nephrology GA 534VC UT WOS:000272924500016 PM 19864304 ER PT J AU Cheng, EM Cohen, SN Lee, ML Vassar, SD Chen, AY AF Cheng, Eric M. Cohen, Stanley N. Lee, Martin L. Vassar, Stefanie D. Chen, Alex Y. TI Use of Antithrombotic Agents Among US Stroke Survivors, 2000-2006 SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID AMERICAN-HEART-ASSOCIATION; TRANSIENT ISCHEMIC ATTACK; ATHEROSCLEROTIC CARDIOVASCULAR-DISEASE; FACTOR SURVEILLANCE SYSTEM; HEALTH-CARE PROFESSIONALS; ASPIRIN USE; MYOCARDIAL-INFARCTION; SECONDARY PREVENTION; SEX-DIFFERENCES; UNITED-STATES AB Background: Secondary stroke prevention guidelines recommend antithrombotic agents such as over-the-counter aspirin, prescription antiplatelet agents, or anticoagulant agents. Purpose: The study was designed to measure whether use of outpatient antithrombotic agents is increasing among stroke survivors. Methods: The sample consisted of 4168 people who self-reported cerebrovascular disease and who participated in the Medical Expenditure Panel Survey, an annual representative sample of the U.S., during the years 2000-2006. Use of antithrombotic agents was calculated from face-to-face interviews about the use of aspirin and from pharmacies about the use of prescription medications. Cochran-Armitage tests were used to detect temporal trends and multivariate models to identify predictors of use of antithrombotic agents. Results: Pooling results across the 7 years, it was found that 57% were taking aspirin, 66% were using any antiplatelet agent, and 75% were using any antithrombotic agent. After excluding people who said aspirin was unsafe, 81% were using any antithrombotic agent. During the study period, use of prescription antiplatelet agents increased (p<0.001) but there was no temporal change in use of antithrombotic agents overall. In multivariate models, being aged >65 years, male gender, non-Hispanic ethnicity, having a usual source of care, and poor or fair health status were associated with use of an antithrombotic agent (p<0.05). Conclusions: Although a high percentage of stroke survivors appear to use an antithrombotic agent, further research should investigate whether and how to improve care among the remaining 20% of stroke survivors, particularly among younger, female, and Hispanic patients. (Am J Prev Med 2010;38(1):47-53) Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Cheng, Eric M.; Vassar, Stefanie D.] VA Greater Los Angeles Healthcare Syst, Dept Neurol, Los Angeles, CA 90073 USA. [Cheng, Eric M.; Vassar, Stefanie D.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Hlth Serv Res Program, Los Angeles, CA 90095 USA. [Lee, Martin L.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Biostat, Los Angeles, CA 90024 USA. [Chen, Alex Y.] Univ So Calif, Keck Sch Med, Dept Pediat, Los Angeles, CA 90033 USA. [Cheng, Eric M.; Lee, Martin L.] VA Greater Los Angeles Healthcare Syst, HSR&D Ctr Excellence, Sepulveda, CA USA. [Cohen, Stanley N.] Nevada Neurosci Inst Sunrise, Stroke Prevent Program, Las Vegas, NV USA. RP Cheng, EM (reprint author), VA Greater Los Angeles Healthcare Syst, Dept Neurol, 11301 Wilshire Blvd,Bldg 500,ML 127, Los Angeles, CA 90073 USA. EM eric.cheng@va.gov FU NIH/National Institute of Neurological Disorders and Stroke (NINDS) [K23NS058571]; UCLA/DREW Project EXPORT, National Center on Minority Health and Health Disparities (NCMHD) [P20MD000148/P20MD000182-06]; American Heart Association (AHA) through funding for the AHA/Pharmaceutical Roundtable Outcomes Research Center at UCLA; NIH/National Institute of Child Health and Human Development (NICHD) [K23HD047270]; Veterans Administration; Boeringer Ingelheim speakers bureau FX SNC has received speaking fees from the Boeringer Ingelheim speakers bureau. NR 31 TC 4 Z9 4 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD JAN PY 2010 VL 38 IS 1 BP 47 EP 53 DI 10.1016/j.amepre.2009.08.029 PG 7 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 541KL UT WOS:000273413800006 PM 20117556 ER PT J AU Wells, TS LeardMann, CA Fortuna, SO Smith, B Smith, TC Ryan, MAK Boyko, EJ Blazer, D AF Wells, Timothy S. LeardMann, Cynthia A. Fortuna, Sarah O. Smith, Besa Smith, Tyler C. Ryan, Margaret A. K. Boyko, Edward J. Blazer, Dan CA Millennium Cohort Study Team TI A Prospective Study of Depression Following Combat Deployment in Support of the Wars in Iraq and Afghanistan SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH PROBLEMS; PERSIAN-GULF-WAR; MILLENNIUM COHORT; MILITARY SERVICE; PRIMARY-CARE; US MILITARY; MAJOR DEPRESSION; UNITED-STATES; PEACEKEEPING OPERATIONS AB Objective. We investigated relations between deployment and new-onset depression among US service members recently deployed to the wars in Iraq and Afghanistan. Methods. We included 40219 Millennium Cohort Study participants who completed baseline and follow-up questionnaires and met inclusion criteria. Participants were identified with depression if they met the Primary Care Evaluation of Mental Disorders Patient Health Questionnaire criteria for depression at follow-up, but not at baseline. Results. Deployed men and women with combat exposures had the highest onset of depression, followed by those not deployed and those deployed without combat exposures. Combat-deployed men and women were at increased risk for new-onset depression compared with nondeployed men and women (men: adjusted odds ratio [AOR]=1.32; 95% confidence interval [CI]=1.13, 1.54; women: AOR=2.13; 95% CI=1.70, 2.65). Conversely, deployment without combat exposures led to decreased risk for new-onset depression compared with those who did not deploy (men: AOR=0.66; 95% CI=0.53, 0.83; women: AOR = 0.65; 95% CI = 0.47, 0.89). Conclusions. Deployment with combat exposures is a risk factor for new-onset depression among US service members. Post-deployment screening may be beneficial for US service members exposed to combat. (Am J Public Health. 2010;100:90-99. doi:10.2105/AJPH.2008.155432) C1 [Wells, Timothy S.; Fortuna, Sarah O.] USAF, Res Lab, Wright Patterson AFB, OH 45433 USA. [LeardMann, Cynthia A.; Smith, Besa; Smith, Tyler C.; Ryan, Margaret A. K.] USN, US Dept Def, Ctr Deployment Hlth Res, Hlth Res Ctr, San Diego, CA 92152 USA. [Boyko, Edward J.] VA Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA USA. [Blazer, Dan] Duke Univ, Med Ctr, Durham, NC USA. RP Wells, TS (reprint author), 711th HPW RHPA,Bldg 824,Room 206,2800 Q St, Wright Patterson AFB, OH 45433 USA. EM timothy.wells@wpafb.af.mil RI Blazer II, Dan/D-6675-2012 OI Boyko, Edward/0000-0002-3695-192X FU Department of Defense [60002] FX This work represents report 08-06, supported by the Department of Defense, under work unit no. 60002.The views expressed in this article are those of the authors and do not reflect the official policy or position ofthe Department of the Navy, Department of the Army, Department of the Air- Force, Department of Defense, Department of Veterans Affairs, or the US Govemment. NR 82 TC 107 Z9 107 U1 10 U2 17 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD JAN PY 2010 VL 100 IS 1 BP 90 EP 99 DI 10.2105/AJPH.2008.155432 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 538EK UT WOS:000273166800020 PM 19910353 ER PT J AU Dyer, E Pickerodt, PA Zarndt, R Swenson, ER AF Dyer, E. Pickerodt, P. A. Zarndt, R. Swenson, E. R. TI ERYTHROPOIETIN MITIGATES VENTILATOR-INDUCED LUNG INJURY IN RATS SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract C1 [Dyer, E.; Pickerodt, P. A.; Zarndt, R.; Swenson, E. R.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. EM philipp.pickerodt@charite.de NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2010 VL 181 MA A1684 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA V29TP UT WOS:000208771000684 ER PT J AU Glavan, BJ Martin, TR Nickerson, D Holden, TD Black, RA Smith, JD Wurfel, MM Edwards, K AF Glavan, B. J. Martin, T. R. Nickerson, D. Holden, T. D. Black, R. A. Smith, J. D. Wurfel, M. M. Edwards, K. TI Common Genetic Variants In The Fas/FasL Pathway Modify The Risk Of Acute Lung Injury SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract C1 [Glavan, B. J.; Nickerson, D.; Holden, T. D.; Black, R. A.; Smith, J. D.; Edwards, K.] Univ Washington, Seattle, WA 98195 USA. [Martin, T. R.] VA Puget Sound Healthcare Syst, Seattle, WA USA. [Wurfel, M. M.] Univ Washington, Harborview Med Ctr, Seattle, WA 98104 USA. EM bglavan@u.washington.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2010 VL 181 MA A2706 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA V29TP UT WOS:000208771001619 ER PT J AU Herrero, R Kajikawa, O Wang, Y Matute-Bello, G Fu, X Martin, TR AF Herrero, R. Kajikawa, O. Wang, Y. Matute-Bello, G. Fu, X. Martin, T. R. TI Structural Determinants Of The Biological Activity Of Soluble Fas Ligand In The Lungs SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract C1 [Herrero, R.; Kajikawa, O.] VA Puget Sound, Seattle, WA USA. [Herrero, R.; Kajikawa, O.; Wang, Y.; Matute-Bello, G.; Fu, X.] Univ Washington, Seattle, WA 98195 USA. [Wang, Y.; Fu, X.] Puget Sound Blood Ctr, Seattle, WA 98104 USA. [Martin, T. R.] VA Puget Sound Healthcare Syst, Seattle, WA USA. EM rherrero@u.washington.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2010 VL 181 MA A2707 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA V29TP UT WOS:000208771001620 ER PT J AU Huynh, TN Weigt, SS Shapiro, S Kleerup, EC AF Huynh, T. N. Weigt, S. S. Shapiro, S. Kleerup, E. C. TI Characteristics And Prognostic Factors Of Patients With Pulmonary Hypertension Admitted To The Medical ICU SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract C1 [Huynh, T. N.; Kleerup, E. C.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Weigt, S. S.] UCLA Hlth Syst, Los Angeles, CA USA. [Shapiro, S.] VA Greater LA Healthcare, Los Angeles, CA USA. EM thuynh@mednet.ucla.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2010 VL 181 MA A1640 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA V29TP UT WOS:000208771000640 ER PT J AU Junaid, I Hoo, GWS Klaustermeyer, WB AF Junaid, I. Hoo, G. W. Soo Klaustermeyer, W. B. TI Severe Angiotensin Converting Enzyme-Inhibitor (ACEI) Associated Angioedema Admitted To An ICU SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract C1 [Junaid, I.; Klaustermeyer, W. B.] VA Greater Los Angeles Healthcare Syst, West VA, Los Angeles, CA USA. [Hoo, G. W. Soo] West Los Angeles VA, Los Angeles, CA USA. EM imjunaid@gmail.com NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2010 VL 181 MA A1643 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA V29TP UT WOS:000208771000643 ER PT J AU Lipke, AB Matute-Bello, G Martin, TR AF Lipke, A. B. Matute-Bello, G. Martin, T. R. TI Febrile-range Hyperthermia Augments Apoptosis Of Alveolar Epithelial Cells By Suppressing NF-kappa B Activity SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract C1 [Lipke, A. B.; Matute-Bello, G.] Univ Washington, Seattle, WA 98195 USA. [Martin, T. R.] VA Puget Sound Healthcare Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2010 VL 181 MA A1366 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA V29TP UT WOS:000208771000367 ER EF